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Evelyn H. Lauder
(1936–2011)
On hearing of her passing on November 12, 2011, Mike Wigler described her so compellingly: “She
exemplified the best in human nature—grace and passion, intelligence and commitment, com-
passion and effectiveness, humor and seriousness of purpose.” Evelyn H. Lauder was a remarkable
woman.
At the Laboratory, she made her mark funding Mike’s groundbreaking breast cancer research.
Her relationship with him began in 1998, when he received his first grant from the Breast Cancer
Research Foundation (BCRF). It was thanks to Larry Norton, who has directed the BCRF’s sci-
entific activities from the start, that Evelyn’s organization was introduced to Mike and Cold Spring
Harbor Laboratory. Our first BCRF grant was in 1998, including funds toward the purchase of mi-
croarray equipment to support collaboration between CSHL and Memorial Sloan-Kettering Can-
cer Center.
The evening before BCRF’s fall 1998 research symposium, Liz and I were invited along with
Mike and Deedee for dinner at Evelyn and Leonard’s spacious Fifth Avenue apartment, whose more
public walls were dominated by wonderful cubist-period paintings by Pablo Picasso. The next
spring, in May, Evelyn, along with BCRF donor Lillian Goldman, Larry Norton, and BCRF 
Executive Director Susan Hirschorn, visited CSHL to view the equipment. A plaque naming the
Lillian Goldman DNA Microarray Facility was presented. During the last 14 years, CSHL has ben-
efited from nearly $4 million in funding from the BCRF.
At a late November 2002 fundraising evening, Liz and I, charmed by Evelyn’s aerial photos of
green Caribbean hills, quickly chose Flying to Sasua to hang in our recently purchased New York
City apartment. Soon after, Evelyn graciously let us elect her as one of our Honorary Trustees.
When she afterward dined with us, Evelyn saw how well the picture fitted in with the largely Eu-
ropean paintings and drawings that we had collected over the then more than 35 years of our mar-
riage.
When celebrating 50 years (1953−2003) of the Double Helix on DNA Day (April 25), we lit
our 1904 Carnegie Building in pink lights to further raise awareness of breast cancer. After we ini-
tiated the Double Helix Medals, we honored Evelyn at a Mandarin Oriental celebratory dinner in
November 2010 together with Mary-Claire King, who mapped BRCA1, the first human breast
cancer gene. Also honored that evening was John Nash, whose profound idea on game theory re-
vealed his most “beautiful mind.”
Upon the occasion of my receiving the Aspen Institute’s Public Service Award in the summer of
2007, I visited Evelyn and Leonard’s rustic, no-frills home in the center of Aspen. A month before,
I was alarmed to learn that cancer had reentered Evelyn’s life. In her reply to my note of concern,
she wrote back that her doctors had again given her a good prognosis. Battling ovarian cancer, how-
ever, is a much greater challenge than initially overcoming most breast cancers. Although her treat-
ment soon led to her being symptom-free, only four years were to pass before her cancer came back
with such ferocity that she lived only several more months. 
Evelyn’s caring smile and genuine empathy for the less fortunate are already sorely missed. Her
memory will be best honored if the cancer world, today powerfully armed with the many fruits of
the Human Genome Project, moves quickly into high gear against “incurable” late-stage breast and
ovarian cancers. Skilled medicinal chemists need to develop innovative drugs that specifically tar-
get the molecular “Achilles’ heels” of cancers that inevitably arise when normal cells become onco-
genetically programmed for uncontrolled growth and cell division. Once we cross the starting line,
no more than a decade of intelligent passion may be required. The sooner we start, the sooner we
will win!
James D. Watson
Evelyn H. Lauder      ix
Research directions at Cold Spring Harbor Laboratory Cold Spring Harbor Laboratory follow an ever-
changing landscape that is influenced by the intellect of our scientists, by the evolution of scientific prob-
lems that can be addressed by current or newly developed technologies, and by a dynamic institutional
view that promotes collaborative research and a focus on specific problems that are of collective interest.
The neuroscience program at the Laboratory is a prime example of how three different areas of research
have morphed together to contribute to major new insights into cognition and cognitive disorders.
A fall 2011 paper published in the Proceedings of the National Academy of Sciences from the labo-
ratories of Alea Mills and Michael Wigler included Internet links to three rather grainy time-lapse
videos. Each is a few minutes in length and allows us to peer into the cages of several mice simulta-
neously as they go about their activities. These videos demonstrate something potentially significant
about autism genetics. The story behind the research suggests something equally interesting about
the way in which we do science at Cold Spring Harbor Laboratory and about the evolution of our
neuroscience program.
Mills’ team had worked for several years to breed mice with a specific genetic defect that mimics
one seen in certain children with autism. Called a copy-number variation (CNV), the defect is a
deleted region on chromosome 16, referred to as 16p11.2. Its occurrence in autism, reported by Mike
Wigler in 2007, has since been characterized as one of the most common spontaneous genetic alter-
ations, yet it only affects less than 1% of children who have been classified with autism spectrum dis-
order (ASD). But what is its biological significance? CNVs, which are missing or extra segments of
DNA, sometimes occur in regions that encode our genes. The 16p11.2 region contains 27 genes. One
of the questions that the Mills and Wigler teams wanted to answer was if a mouse is missing this seg-
ment of chromosome 16, or has an extra copy of it, is its behavior affected—and if so, how?
The team did indeed observe behavioral changes, most prominently in mice lacking one of two
copies of the 16p11.2 region that are present in most people. A normal mouse—or person—should
have two copies, one inherited from each parent. Importantly, the abnormal mouse behaviors seen
in the videos resemble some behavioral abnormalities seen in children with autism. In one video clip,
a normal mouse quickly learns to climb to the highest point in her cage, while her sibling, bred with
the 16p11.2 deletion, is observed during the same time interval to make almost no progress in her
climbing ability. Another of the videos shows a mouse with the “autism” deletion unable during an
extended interval—unlike her normal sibling—to figure out how to descend from the ceiling of her
cage. A third clip shows a mouse with the 16p11.2 deletion displaying repetitive, stereotypical be-
havior in climbing down from a raised platform, a behavior not observed in healthy mice.
These experiments and others that they have set in motion serve to illustrate the power of a three-
pronged approach to neuroscience that we have taken at the Laboratory. The three prongs, broadly de-
scribed, are human genetics, cognition, and connectivity. For some years, these have tended to run in
parallel. The success in creating an autism mouse model is notable because it demonstrates how the three
areas of concentration are complementary, mutually informing and enabling, and ultimately integrative.
Neuroscience is one of the most dynamic fields in biology today. It has come a long way since one
of its antecedents, called biophysics, was a subject of research at Cold Spring Harbor in the decade
before the Second World War. Our first advanced courses on the subject, which commenced in the
early 1970s with critical support from the Sloan Foundation and advice from John Nicholls, Eric Kan-
del, David Van Essen, Reg Kelly, and others, coincided with the installation of teaching labs in the old
“Animal House” research building, a 1912-built laboratory now named for Barbara McClintock.
Not until the late 1970s did the Laboratory hire its first staff neurobiologists, Birgit Zipser and
Ron McKay, who were joined in 1980 by then University of California at San Francisco postdoc and
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future Massachusetts Institute of Technology (MIT) president Susan Hockfield. Their collaborations
soon generated insights into the development and organization of the mammalian nervous system.
But, alas, these forays into the emerging field of what the 1983 CSHL Symposium called “Molecular
Neurobiology” were not sustained because the Laboratory lacked year-round space for neuroscience
experimentation. It was a missed opportunity, but one decisively addressed by Jim Watson and an
ad hoc committee of the Board of Trustees. In 1985, they set the Laboratory on a course that would
result in a full and lasting commitment to neuroscience and in the construction of a major state-of-
the-art laboratory. Named for Arnold and Mabel Beckman, it would enable CSHL to initiate year-
round neuroscience research in the Laboratory’s centennial year, 1990.
The current era of neuroscience investigation at Cold Spring Harbor dates from this time, over
20 years ago. An early focus on the molecular basis of learning and memory led, in time, to studies
pertaining to neural dysfunction in people—to memory loss and, separately, to neurofibromatosis
(NF), an inherited illness in which tumors form in nerve tissue. These studies, initially focusing on
the fruit fly Drosophila, enabled our new neuroscientists to include a genetic approach to under-
standing the brain, taking advantage of the rich genetics legacy and research at CSHL. Studies were
also begun to address questions pertaining to synaptic development and function.
In 1996, we recognized that still more space was needed to accommodate our growing neuro-
science research effort, and we began to plan construction of a new facility that would be devoted,
in part, to new techniques of imaging neurons and their functions in living animals. The centerpiece
of the Nancy and Edwin Marks Laboratory was the Advanced Neuroscience Imaging Facility, in
which Karel Svoboda collaborated with Roberto Malinow and Zach Mainen to introduce a powerful
new tool called two-photon excitation laser-scanning microscopy to CSHL and, through our ad-
vanced laboratory courses, to the rest of the neuroscience community. This technology enabled our
scientists to obtain images of individual neurons and synapses during sensory processing in live an-
imals, something not possible previously. By October 1999, when the Marks building was dedicated,
our neuroscience program had begun to explore the brain and nervous system in the context of each
of the themes that I have mentioned—human genetics, cognition, and connectivity. For example,
Dimitri (Mitya) Chklovskii studied in the worm Caenorhabditis elegans the reconstructed wiring di-
agram of the 279 nonpharyngeal neurons, a subset of the worm’s 302 neurons, to reveal principles
about how neuronal circuits deviate from optimal wiring and connection solutions. However, with
the departure of a number of our neuroscientists to the newly established Janelia Farm Research
Campus of the Howard Hughes Medical Institute, and elsewhere, we shifted our focus to under-
standing cognition and cognitive dysfunction, linking human genetics to behavioral neuroscience in
a program developed in part by Tony Zador.
Zador, with Adam Kepecs and former colleague Zach Mainen, introduced the study of cognition
in rodents as a powerful system for understanding complex cortical events in the brain. Their studies
enabled them to investigate how rodents, and ultimately humans, use external stimuli to make de-
cisions and pay attention, and use working memory for cognitive tasks. Later joined by Anne Church-
land and Florin Albeanu, they are investigating how external stimuli such as odors and sound work
their way through the initial sensing regions of the brain to be coded in working and long-term
memory that in turn influences behavior. Today, our neuroscientists—who have expanded their ac-
tivities beyond Beckman and Marks to the new Hillside Laboratory buildings—are able to use so-
phisticated techniques called optogenetics, a method invented at Stanford University that enables
individual neurons to be switched on and off with beams of colored laser light delivered painlessly
via fiber-optic threads into the cortex of behaving rodents. Zador, Kepecs, and Albeanu, along with
Stephen Shea and Glenn Turner, have mobilized this and other advanced recording technologies to
explore how incoming sensory signals are processed in successively more complex layers of neural
anatomy, from the sensory epithelia in the nose to the olfactory bulb and olfactory cortex in rodents,
and analogous structures in fruit flies. Shea is studying the way in which the emotional salience of
an experience—say, an encounter with a potential mate—is encoded, along that path leading from
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olfactory receptors to the brain’s olfactory cortex, where decisions are made based on processed signals.
Some decisions, it is believed, are innate, whereas others, such as these, are forged in response to ex-
perience or environmental cues. Tony Zador, who heads our Swartz Center for Computational Neu-
roscience, established computational analysis of brain circuits as an important part of this work.
Zador uses the rodent auditory system as his model in work that seeks to better understand how
neural dysfunction can produce the kinds of deficits in social interaction and attention that we see
in disorders such as autism and schizophrenia.
Bo Li’s research places him at the nexus of behavior and another of the three major themes of
neuroscience at the Laboratory: connectivity. When they study connectivity, our scientists broach
the immense question of the mammalian brain’s architecture and the relationship of structure to
function. This can be studied at multiple levels of detail: from the structure of the synapses at which
individual neurons communicate, to circuits and networks composed of ever-shifting ensembles of
interconnected nerve cells, to entire regions of the brain in which specific kinds of tasks are handled
by the neural network. In 2011, Bo Li and Fritz Henn collaborated to discover that neurons in a
tiny area in the central brain called the lateral habenula (LHb) are hyperactive in depressed rodents.
They found that dysfunction in this one area creates imbalances in other areas of the brain to which
it sends neural projections. Understanding the nature of these interrelationships holds a potential
key to new ways of treating depression, and, as a result of these studies, Fritz Henn has begun to
translate these results into a clinical trial focusing on deep-brain stimulation in the LHb of patients
with otherwise untreatable chronic depression.
Connectivity in its neuroscience context is the theme of many different CSHL studies at the cellular
level. Linda Van Aelst, an expert on signal transduction, has complemented her work on brain cancer
in children with research on how mutations in signaling molecules in the Ras and Rho families of
proteins are implicated in various brain disorders. Linda has extensively studied functional implications
of mutations of the oligophrenin-1 gene in several neuropathologies, including X-chromosome-linked
mental retardation, and has found that the gene is essential in activity-dependent maturation of
synapses and the ability of an existing synapse to change, commonly called plasticity. Linda’s interest
in neurodevelopment is complemented by the work of Grigori Enikolopov and Alex Koulakov, who
study the role played by stem cells during brain development as well as in the adult brain. In 2011,
they found that each adult brain stem cell in mice is used only once to amplify into many neurons
and hence is disposable, as opposed to stem cells in the blood or gut that self-renew many times during
their life span. Whether stem cells that have been expended can be enticed to revert to their former
identity and be recruited back into the stem cell pool is a question that Enikolopov’s team is now pur-
suing. Hiro Furukawa’s research concerns another aspect of nerve cell biology, that of proteins that lie
on the surface of individual nerve cells. He studies the structure of the immense multiunit protein
that forms NMDARs (N-methyl-D-aspartate receptors) that control the strength of connections be-
tween neurons and thereby have a central role in learning and memory. Membrane receptors, the place
where neurotransmitter molecules “dock” with nerve cells, are at the “front end” of cell-signaling net-
works and are of great interest as targets for drug discovery in diseases such as Alzheimer’s and in cog-
nitive disorders such as autism and depression. This year, Hiro’s team discovered and mapped a new
regulatory site in a class of NMDARs, progress that now opens the way to the development of a po-
tentially new class of drugs to modulate the receptor.
By a very rough estimate, the human brain contains 100 billion neurons, but they are certainly
not all the same cell type. Some are excitatory and activate circuits, and others are inhibitory and
modulate neuronal networks. Josh Huang is studying a class of inhibitory neurons that are divided
into about several dozen different types. He is interested in neural development and has invested
much time and effort in creating a powerful new resource for the entire neuroscience community.
His team has developed 20 different mouse lines, each of which is engineered to express markers of
specific cell types. They recently demonstrated the exquisite specificity of this technology by imaging
the main inhibitory nerve cell type in the mammalian brain, so-called GABA cells. In a fascinating
series of images, Josh’s team showed a particular subset of GABA cells as they moved from their place
of birth in the mouse brain through various stages of the developmental process. We can see them
migrate into the cortex and take up positions at which they forge connections with one another and
with excitatory neurons. This type of plasticity underlies much of how our brain develops and re-
sponds to learning and memory of new tasks.
The way in which the brain is wired can be studied at many levels, from how individual neurons
are connected to one another, to how groups of neurons form networks of cells that “compute” in-
formation, to how the small networks are connected to one another to form regions of the brain
that are linked to recognizable tasks such as vision, motor control, and hearing. Finally, our brain is
composed of large functional regions that communicate with one another and coordinate all sensory
input and behavioral responses. Using funding from a National Institutes of Health TR-01 grant
and funds from the Allen Institute for Brain Science, both awarded to advance potentially “trans-
formational science,” Tony Zador is developing a novel, high-throughput method to probe the con-
nectivity of neural circuits at the level of individual neurons in mice—called the “connectome.” He
is collaborating with molecular biologist Greg Hannon to use very innovative technologies that
allow molecular codes to be passed from one neuron to another in the brain, later capturing how
the information is linked using powerful DNA sequencing technologies. The potential for under-
standing how networks of neurons are wired is enormous. Josh Dubnau, another TR-01 grant re-
cipient, is approaching neural connections from an entirely different angle. He seeks to assemble a
comprehensive store of information about how RNAs are translated into proteins needed for the
assembly of synapses. He and his team are focusing initially on spatial and temporal control of trans-
lation in the context of fragile-X syndrome, an autism spectrum disorder in which the process goes
awry.
On a different scale, two exciting imaging technologies have recently been developed at CSHL
and are beginning to yield valuable data regarding brain structure and connectivity. Partha Mitra is
progressing in an effort backed by a third TR-01 grant to map the mouse brain at what he defines as
the “mesoscopic” level. Partha’s project is focused on identifying the nature of the connections within
and between different brain regions and eventually integrating the data with the Allen Brain Atlas,
which has proven to be a valuable map of genes that are expressed in different regions of the mouse
brain. Partha and his team have built a robotic laboratory that enables the analysis of many mouse
brains and the storage of very large data sets for computational analysis.
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An ultimate scale of understanding brain activity and connectivity is at the cellular level. Pavel
Osten and his team have built an impressive automated system dedicated to systematic brain con-
nectivity and functional studies. By automating and standardizing the process by which brain samples
are divided into very thin sections and then imaged sequentially with precise spatial orientation by
high-resolution microscopes, Pavel has opened the door to making whole-brain mapping at the cel-
lular level more routine. In essence, each neuron in the brain has a gene that is turned on when the
neuron has been recently active, expressing a green fluorescent protein (GFP) that can be imaged. It
is possible to image all of the brain cells that “light up” after the mouse has a new experience or re-
ceives a drug that affects brain activity. This technology, along with the technology developed by
Mitra, will enable an analysis of the connectivity and activity within the brains of mice bred with
the autism 16p11.2 CNV. This application of brain imaging of mice with genetic alterations that
mimic those in patients with Alzheimer’s disease, autism, bipolar disorder, depression, and schizo-
phrenia is one aspect of the “integration” of science that is characteristic of research at CSHL. It
makes perfect sense, given a credible animal model of a brain disorder, to explore at the level of both
structure and function how the brain in an abnormal phenotype differs from that in a healthy control.
This should provide unique and, we hope, powerful insights into both disease causation and new
therapeutic approaches.
The integration of connectivity and behavioral studies is only two-thirds of the story of integration.
The final third concerns human genetics but in many ways is a key starting point for understanding how
the brain functions. It is the part with the longest and richest history at Cold Spring Harbor—one that
takes us back to our institutional roots and forward to current and future research. In what I consider a
classic instance of research in the CSHL style, Alea Mills—a geneticist—became involved in an important
neuroscience project because of a technique that she had previously invented called chromosome engi-
neering. Some years ago, she demonstrated its utility in solving a decades-old mystery about a section of
human chromosome 1 that is frequently deleted in neural, epithelial, and hematopoietic cancers.
It had long been clear that this region of the chromosome harbored an important tumor-suppressor
gene. But the region was large and, like the 16p11.2 region in autism, was known to contain many
genes. Which was the tumor suppressor? Mills and colleagues created mice with gains and losses of
genomic regions that corresponded to the deleted region on chromosome 1. They confirmed that
loss of the region predisposes to cancer, whereas gain of the region results in excessive tumor sup-
pression. Ultimately, they identified Chd5 as the tumor suppressor within the region and determined
that the protein that it encoded was a remodeler of chromatin that regulates an extensive tumor-sup-
pressive network. Thus, a technology developed to study cancer genetics made possible the engineer-
ing of the “autism mouse.”
Another thread of current neuroscience research at CSHL can be traced to cancer research and
goes back even further than chromosome engineering. During the 1980s, as Michael Wigler and his
group studied the genetics of breast cancer, Mike became interested in comparing a woman’s normal
DNA to the DNA found in her tumor. In collaboration with former colleague Nikolai Lisitsyn, he
invented a technique called representational difference analysis (RDA), followed by a second-gener-
ation method called representational oligonucleotide microarray analysis (ROMA) developed with
Rob Lucito, to perform such comparisons. This evolved over several years into successive variants of
the technique, including the recently developed ability to sequence the genome of a single cell, en-
abling comparisons to be made on a whole-genome scale. By collecting DNA from hundreds of
women with breast cancer, Wigler and collaborators were able to build an extensive DNA database
that, among other things, also enabled them to compare the DNA readouts of the noncancer, or
normal, DNA from each woman. But unexpectedly, an important discovery followed that revised
our notion of what normal means. Every supposedly normal sample contained a large number of
DNA variations relative to the standard human reference genome. Each person was significantly dif-
ferent because they harbored gene CNVs. This led to the realization that CNVs were not a rare and
exotic form of genome mutation but instead were present in every individual.
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Wigler pursued an inspired hunch that some common genetic disorders—such as autism and
schizophrenia—might be traceable to CNVs that occurred spontaneously, that is, not present in
either parent of an affected individual. In subsequent work, this hypothesis was confirmed for both
disorders. In autism especially, it became clear that spontaneous CNVs accounted for a large fraction
of cases. With generous support from the Simons Foundation, a large sample of families with an
autistic child was assembled. Analysis of the genomes of the affected child compared with that of the
parents and sometimes an unaffected sibling enabled the identification of hundreds of regions in the
human genome associated with autism. The surprising fact that we all have CNVs, coupled with the
Wigler lab’s invention of the technological means to identify them across the genome, was a major
step along the path toward understanding the cause of the disorder and toward the eventual use of
chromosome engineering to create a mouse model of autism.
Mike Wigler continues to explore the genetics of neuro-psychiatric disorders in humans. He and
collaborators have also made a major contribution to describing the role of both spontaneous and in-
herited CNVs in schizophrenia. Another of our senior scientists, W. Richard McCombie, shares this
interest in the human genetics of brain disorders. Dick heads the Laboratory’s Stanley Institute for
Cognitive Genomics and is sequencing patients with schizophrenia, bipolar disorder, and depression.
The collaboration between Wigler and McCombie has enabled the genetic analysis of autism to pro-
ceed to identifying rare single-gene mutations.
The three paths of research in neuroscience—human genetics, connectivity, and the study of cogni-
tion—are rapidly converging. Furthermore, the Laboratory’s recent investment in building a Quanti-
tative Biology program is infusing our neuroscience program with a new source of intellectual vibrancy.
In 2011, Ivan Iossifov, a CSHL Quantitative Biology Fellow, along with Michael Ronemus, Dan Levy,
and Sarah Gilman in the Wigler lab, collaborated with Dennis Vitkup at Columbia University to un-
dertake a novel quantitative study of CNVs in autism spectrum disorder. One of their published papers
addressed a question that is now being asked in the Mills–Wigler collaboration about their autism
mouse model: Which genes within a CNV of interest are actually involved in disease pathology?
Iossifov, Vitkup, and colleagues used a novel form of statistical analysis to identify the large bio-
logical network of genes affected by rare spontaneous CNVs in autism. They found that this network
was strongly related to genes previously implicated in studies of autism and intellectual disability.
And they confirmed that the genes in question relate primarily to the development of synapses as
well as to the targeting of axonal fibers and the ability of young neurons to migrate. All are essential
aspects of brain development. In more recent studies to be published in 2012, Iossifov, Ronemus,
Levy, McCombie, Wigler, and collaborators have sequenced the genomes of families with a child
with autism and have made some remarkable discoveries. First, the age of the father is a significant
contributor to the occurrence of spontaneous gene mutations that are linked to autism. Second, a
large percentage of the genes found to be causative of autism fall into a network of genes whose
RNAs are regulated by fragile-X mental retardation protein (FMRP). Fragile-X syndrome is a disorder
on the spectrum of autism disorders and is caused by a mutation in a single gene. By studying how
the defect in the FMRP gene alters synaptic activity in the brain, Mark Bear and his colleagues at
MIT have developed a drug that targets the neuronal mGluR5 protein that reverses the effect of the
fragile-X syndrome mutation in mice. The drug is now in clinical trials in children with fragile-X
syndrome. The fact that a disorder on the autism spectrum can be reversed is remarkable in itself,
but the observations that genes that cause autism overlap with FMRP and fragile-X syndrome offer
the possibility that more common forms of autism, or at least a subset of autism, might be treatable.
This finding suggests how the fruitful integration of nominally distinct research approaches is pro-
viding major insight into how the brain functions and offers hope that some form of treatment may
be on the horizon. I look forward to further substantial progress in our neuroscience research that is
as exciting as it has been during the past 15 years.
Bruce Stillman, Ph.D., F.R.S.
President
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Research
In summing up the year’s achievements in the annual “State of the Lab” presentation to Laboratory
staff, I characterized 2011 as one in which research productivity was “truly exceptional.” In fact, Cold
Spring Harbor Laboratory remains at the very top of the list of scientific research institutions world-
wide for its impact, as measured by science publisher Thomson Reuters.  During the last decade, re-
search papers in molecular biology and genetics published by CSHL investigators have been cited,
on average, more frequently than those published by scientists in comparable institutions.
    These statistics say something important about CSHL scientists beyond the general reputation
of the institution, which has long been stellar. They tell us that work coming out of their laboratories
is consistently important to their colleagues at other institutions, who trust, cite, and build upon
their data. Notable about research at Cold Spring Harbor Laboratory is the highly collaborative
nature of the research, which is focused on a few areas, including cancer, neuroscience, plant biology,
and quantitative biology. Research results in 2011, highlighted below, indicate how studies in basic
science, when pursued consistently over time, provide the basis for practical advances in medicine.
Here is a sampling of a few of the many important results obtained by CSHL scientists in 2011.
Unconventional Hunt for Cancer Targets Yields a Drug Candidate
of Unusual Potential
Using an unconventional approach to discover new targets for anticancer drugs, a team led
by CSHL Fellow (and now Assistant Professor) Christopher Vakoc along with Professor
Scott Lowe pinpointed a protein called Brd4 as a novel target in the treatment of acute
myeloid leukemia (AML). AML is an aggressive blood cancer that is incurable in about
70% of patients. In an early success for CSHL’s new Cancer Therapeutics Initiative, Vakoc,
Lowe, and their colleagues used a sophisticated screening method based on RNA
interference (RNAi), developed in Greg Hannon’s laboratory, to identify Brd4, a protein
that helps regulate gene expression by reading chemical tags that attach to chromatin, the
material in which the genetic material is bundled. They used short-hairpin RNAs to disable
the gene that encodes Brd4 in mouse models of AML developed by Lowe, halting
progression of the disease and bringing about significant remissions. In collaboration with
physician and chemist Dr. James Bradner at the Dana-Farber Cancer Institute, the team was able
to reproduce these antileukemic effects using a small-molecule drug called JQ1, previously
characterized by Bradner to specifically inhibit the Brd4 protein. That drug is now being optimized
for testing in human patients with AML, in trials that should begin within the next 18 months.
Because Brd4 is a link in an intracellular signaling pathway that includes the major human cancer
gene c-Myc, there is a chance that if successful, JQ1 or its analogs may be effective in treatment of
other human cancer types in which c-Myc activation has an important role.
New Therapeutic Target for Liver Cancer and a Predictive Biomarker
In another research effort that highlights “next-gen” approaches in cancer research, Associate
Professor Scott Powers and colleagues identified a strategy for targeted molecular therapy
in liver cancer, which currently has limited treatment options and one of the worst one-
year survival rates of any cancer type. Their experiments reveal that up to 15% of liver
tumors are driven by the hyperactivity of a gene called FGF19, which is involved in various
normal biological processes such as cell growth and tissue repair. Powers’ collaborator, Dr.
Dorothy French at Genentech, had previously developed a potent antibody that blocks the
activity of the protein produced by the FGF19 gene. Experiments showed that shutting
down its activity with the antibody inhibited tumor growth. This work therefore provides
C. Vakoc
S. Powers
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not only a potential treatment but also a biomarker—FGF19 gene amplification—to predict
whether treatment with the antibody is going to be effective. The research represents a new chapter
in efforts to expand the current goals of large-scale cancer genome projects in which whole-genome
sequencing of cancer genomes is pinpointing new therapeutic strategies and drug targets.
Relationship between Two Genes Mutated in Prostate Cancer Can Dictate
Outcome and Aid Treatment Decisions
Prostate cancer is common, but only about 15% of newly diagnosed cancers progress to a malignant
and lethal form. Identifying those patients who might progress is of high importance. Research by
Associate Professor Lloyd Trotman and colleagues addressed this issue when they set out to
discover what kind of gene deletions work together with the loss of a tumor suppressor gene
called PTEN to trigger prostate cancer. The PTEN protein normally removes phosphate
molecules from its molecular targets and tempers prostate cell proliferation by preventing
activation of a cancer-causing gene called AKT. Focusing on another phosphatase, PHLPP1,
that was recently identified as a deactivator of AKT, Trotman’s team showed that the
PHLPP1 gene also functions as a suppressor of prostate tumors. Mice that lacked both
copies of Phlpp1 developed a premalignant form of prostate cancer. The team found that
monitoring the activity of the two genes—PTEN and PHLPP1—in patients following
prostate surgery can predict whether a patient is on a path to develop dangerous dual
deletions and thus relapse following initial hormone therapy. This information could help
identify the best patients for clinical trials testing a new class of prostate cancer drugs that inhibit
the AKT pathway and could also influence which inhibitors of this type are used and when.
New Method Reveals How Tumors Evolve and Spread
A new analytic method devised by Professor Michael Wigler, Research Professor James Hicks, and
colleagues features a process called single-cell sequencing that enables accurate quantification of gene
copy number within the DNA of a single cell. Gene copy number refers to the number of each gene
in the cell, and normally it should be two (one inherited from each parent). In cancer, portions of
the genome are amplified or deleted, giving rise to extra or missing copies of key genes and interfering
with mechanisms that normally control cell growth and proliferation. Single-cell sequencing, the
latest in a long line of technical innovations by the Wigler team, represents a major advance in our
ability to understand how tumors evolve, uncovering the genetic complexity within a single tumor.
The insights offered by this method have relied heavily on research within the new program of
quantitative biology at CSHL that has expanded in the last several years. The analysis of breast cancers
using single-cell sequencing methods suggests that tumors may not evolve gradually, but rather in
punctuated bursts. It is a finding that has already shed new light on the process of tumor growth and
metastasis and should help in the development of new methods to clinically evaluate tumors.
Powerful Quantitative and Clinical Study on Autism Causation and Gender Skew
Dan Levy, Michael Ronemus, and others investigators in the Wigler lab joined with CSHL
Quantitative Biology Fellow, now Assistant Professor, Ivan Iossifov to complete a clinically extensive
and mathematically powerful study of autism spectrum disorder (ASD). Using a newly
assembled patient and family sample population called the Simons Simplex Collection—
which at the time included about 1000 families comprising both birth parents and in most
cases two children, one with ASD and the other unaffected—the team affirmed prior results
stressing the importance of noninherited, spontaneously occurring copy-number variations
(CNVs) as causal factors in autism. The team was able to consistently resolve much smaller
genomic irregularities than previously possible. This analysis revealed a significantly greater
number of genome areas where spontaneous DNA deletions and duplications affected genes
thought to contribute substantially to ASD. The team estimates a minimum of 250–300
places in the genome harboring CNVs can give rise to ASD. Most of the CNVs detected
L. Trotman
M. Wigler
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were only seen once and are classified as rare gene mutations. This is a potential source of confusion
because these rare events, taken in total, are possibly the source of at least half of all autism and, based
on Wigler’s previous studies, contribute to inherited forms of autism. 
Mice Engineered with Chromosome 16 Deletion Seen in Humans 
Display Autism-Like Behaviors
Professor Alea Mills, together with Mike Wigler and colleagues, achieved an important
milestone in 2011, proving that one of the most common genetic alterations in autism—
deletion of a 27-gene cluster on chromosome 16—causes autism-like features. By generating
mouse models of autism using a technique known as chromosome engineering, the Mills
team provided functional evidence that inheriting fewer copies of these genes leads to features
resembling those commonly used to diagnose children with autism. The behavior of mice
with the deletion contrasted with that of normal mice; they were hyperactive, had difficulty
adapting to a new environment, suffered from sleeping deficits, and displayed restricted,
repetitive behaviors. Mice engineered to bear human gene aberrations associated with autism
will be invaluable in pinpointing the disorder’s genetic basis and elucidating how these
alterations affect the brain. They could also be used for inventing ways to diagnose children
before they develop the full-blown syndrome and for designing clinical interventions.
Overlooked Brain Area Found to Be an Important Locus of Depression
The scientific importance of animal models was also shown in experiments performed by Assistant
Professor Bo Li, Professor Fritz Henn, and colleagues at Brookhaven National Laboratory and the
University of California, San Diego. By implanting electrodes into a tiny area of the rat brain called
the lateral habenula (LHb), they were able to deliver an analog of deep brain stimulation (DBS).
This had the effect of reversing depression-like symptoms in the rats. The team’s results point to
DBS in the LHb as a potential therapy for depression. DBS is already an important treatment
method for Parkinson’s disease. 
Precise Structural Maps of NMDA Receptors Will Aid Drug Discovery 
In the search for the mechanisms that give rise to depression, scientists have a variety of clues, one
of which is dysfunction of receptors in the brain’s neurons called NMDA (N-methyl-D-aspartate)
receptors. These widely expressed receptors are large, multiunit proteins found at the membrane of
a subset of excitatory neurons. The way in which a neurotransmitter binds to the receptor determines
the strength of neuronal electrical excitability. In 2011, Associate Professor Hiro Furukawa and his
team of structural biologists published the results of two important studies. In one, they mapped
the precise shape of the subunit of the NMDA receptor that binds excitatory neurotransmitters
(notably glutamate, the brain’s most prevalent excitatory neurotransmitter). In a second study, they
obtained a precise molecular map of the binding site for an allosteric inhibitor of an NMDA receptor
subtype. This site—a docking port within the receptor—is important because it is a potential target
for drugs that can modulate NMDA receptors. Problems in these receptors have been linked not
A. Mills
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only to depression, but also to a number of other important disorders including schizophrenia,
Parkinson’s, and Alzheimer’s diseases, as well as stroke-related brain injuries.
Stem-Cell-Related Changes that May Contribute to Age-Related Cognitive Decline
Why do our brains produce fewer and fewer neurons as we age—a phenomenon thought to underlie
the process of age-related cognitive decline? Blood stem cells go through many cycles of self-renewal
followed by quiescence, and their numbers do not decline with age. But Associate Professor Grigori
Enikolopov’s group, together with Associate Professor Alex Koulakov, has found, in contrast, that
adult stem cells in the brain remain quiescent for a prolonged time before they are activated. Then,
they undergo a series of rapid divisions, giving rise to progeny that differentiate into neurons. After
that, the stem cells abandon their “stemness” by differentiating into astrocytes, a type of nonneural
“helper” cell. This implies that each adult brain stem cell is used only once and hence is disposable.
This in turns raises a fascinating question: Does activating neuronal production too much—say, with
the use of neurogenesis-enhancing drugs such as the antidepressant Prozac—exhaust the stem cell
pool prematurely? The answer depends on how the production of new neurons has been induced,
according to Enikolopov. Whereas Parkinson’s disease and traumatic brain injury, which activate stem
cells directly, may result in a depletion of the stem cell pool, therapeutic deep brain stimulation of
certain brain areas, as well as Prozac and exercise, stimulates the downstream progeny of stem cells
and increases production of new neurons while keeping the stem cell pool itself safe and intact.
Paths to New Drugs from Basic Research on Protein Tyrosine Phosphatases
Professor Nicholas Tonks and his team have discovered how targeting an enzyme called PTP1B—
which Tonks discovered in 1988—can provide a path to the discovery of new drugs to fight two
major scourges, diabetes and obesity. As the “founding member” of a superfamily of enzymes
called protein tyrosine phosphatases (all of which remove phosphate groups from tyrosine
residues in proteins), PTP1B is known to be an important player in the intracellular
signaling pathway that regulates the response to insulin. In type 2 diabetes, insulin molecules
dock at cells but the cellular mechanism that sends their signal does not work properly. This
year, Tonks and his colleagues found that PTP1B is regulated by hydrogen sulfide (H2S).
Tonks demonstrated reversible control of PTP1B activity by H2S in cells by the addition of
a sulfur molecule to the active-site cysteine residue in the enzyme, thereby inhibiting the
enzyme activity. They also discovered a new allosteric mechanism that regulates PTP1B
activity, offering the possibility of developing small-molecule drugs that could modulate
PTP1B activity. Tonks’ team generated a specific type of antibody that, when expressed in
cells, selectively recognized and stabilized an oxidized state of PTP1B. In that mode, its role in
suppressing insulin signaling is inactivated, resulting in increased insulin signaling. This had the
effect of enabling insulin to transmit its signal in an enhanced and sustained fashion. It suggests a
new way of targeting PTP1B in therapeutic efforts to address insulin resistance that occurs in
diabetes. But this pathway that influences metabolic signaling may also influence how primary
breast cancer cells switch to metastatic tumor cells and invade other parts of the body. In two separate
papers, Tonks’ team identified and characterized a novel allosteric inhibitor of PTP1B that indicates
a unique mode of therapeutic intervention in HER2-positive breast cancers, and, using RNAi
screening to test the role of PTP family members in controlling migration and invasion in mammary
epithelial cell models of breast cancer, they discovered that PTPN23, another phosphatase family
member, is among the regulators of such invasion, exerting its effects by regulating the well-known
tumor-promoting SRC protein. Their research indicates that inhibitors of SRC might be useful in
treating patients with inactivating mutations in the PTPN23 gene. 
How Plants Are Able to Overcome Environmental Challenges in Order to Thrive
If an animal gets too hot or too cold, or feels pangs of hunger or thirst, it tends to relocate—to where
it is cooler or hotter, or to the nearest place where food or water can be found. But what can a plant
N. Tonks
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do under similar circumstances? Plants cannot change the climate and are unable to uproot themselves
to move to a more favorable spot. Yet they do respond successfully to changes in environmental
conditions in diverse ways, many of which involve modifications of the way they grow and develop.
Professor David Jackson and his team at CSHL have now discovered at the genetic level how one
vitally important species of grass plant—maize—responds to the challenge to growth posed by shade.
Central to this work is the team’s identification of the role played by a gene called grassy
tillers1, or gt1, whose expression, they confirmed, is controlled by light signaling. Maize
plants produce very few tillers, or lateral branches, at their base. Plants with profuse tillers
do not tend to grow well in close proximity because their branches and leaves tend to throw
any close neighbors into shade, thus limiting access to sunlight, their common prime energy
source. By severely limiting its lateral branching, maize is able to redirect its energy to the
primary shoot, which grows taller and escapes the shade. A fascinating sidelight: Without
any knowledge of genes or genetics, ancient Mesoamericans domesticated maize by selecting
for genes that suppressed tillering and thus encouraged maize to grow upward to the sky,
rather than outward into the neighboring stalk. We now know one molecular mechanism of
how the corn that was selected by these early Indians grows to yield tall plants.
Cold Spring Harbor Laboratory Board of Trustees
At the core of the success of Cold Spring Harbor Laboratory are the philanthropic organizations
and generous individuals who recognize the significance of our biomedical research and education
programs to the community and society at large. Investments in CSHL are driving scientific and
medical progress as well as economic development. With more than 1100 employees, the Laboratory
is one of the largest employers in the region. Technologies developed at CSHL have sparked new
companies, some of which have grown to be players in the global economy. One example is OSI
Pharmaceuticals, which was acquired by Astellas Pharma, but importantly remains on Long Island
at the Broad Hollow Bioscience Park. CSHL helped found Broad Hollow at SUNY Farmingdale as
an incubator for life science start-ups. More broadly, a new science cluster that includes CSHL,
Brookhaven National Laboratory, Hofstra University, North Shore−LIJ Health System, and Stony
Brook University could become a formidable engine for economic growth. Combined, the institu-
tions represent a major economic force on Long Island and in New York State.
With an eye to the future, CSHL this year became a founding member of the New York Genome
Center (NYGC), a nonprofit organization leveraging the collaborative resources of 11 leading aca-
demic medical centers, research universities, and hospitals in the vicinity of
New York City. This consortium will generate data essential for the advance
of personalized medicine, accelerate the development of new diagnostics
and treatments for human disease, and promote life science commercial-
ization. It will complement the strong genome research center that is cur-
rently the only genome center in New York State and that has contributed
to major genome sequencing projects and investigation of the causes of
human disease and cognitive disorders.
CSHL’s leadership role in developing and using genomic technologies
will provide the NYGC with expertise that will facilitate the genomic analysis of patient samples.
This in turn will expedite the identification of mutations that drive disease processes, as well as crit-
ical prognostic and diagnostic markers for disease.
I am thankful for the active involvement and support that we receive from the Board of Trustees.
In 2011, the Board elected George Sard, President of Sard Verbinnen & Co. The Laboratory com-
munity mourned the loss of Honorary Trustee Evelyn Lauder. Her leadership of the Breast Cancer
Research Foundation, which supports research conducted at the CSHL Cancer Center and numer-
ous breast cancer research centers throughout the world, has been invaluable in raising awareness
and funds for research and treatment.
D. Jackson
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With newly elected president Sandy Tytel, the CSHL Association
is the institution’s grassroots connection to the community. In its
“Science Never Sleeps” campaign, the CSHLA this year helped raise
a record $5.9 million. “Labapalooza” was a unique fundraiser fea-
turing scientist rock bands and tastings from Long Island’s best
restaurants and enabled our talented scientists to display their mu-
sical flair.
The 10th annual “Women's Partnership for Science” event fea-
tured Pulitzer-Prize−winning New York Times journalist Amy Har-
mon, who presented “Targeting Cancer: A Dose of Hope.” During
the last decade, the Partnership has raised almost $700,000. This
year’s luncheon drew nearly 150 women, who gathered on the sce-
nic lawn of Airslie House.
Research Faculty
Howard Hughes Medical Institute (HHMI) Investigator and CSHL Professor Greg Han-
non, Ph.D., was honored on April 15 with the 2011 Northeastern Association of Graduate
School Geoffrey Marshall Mentoring Award. Greg is among the original faculty of CSHL’s
Watson School of Biological Sciences, which opened its doors in 1999. Since then, he has
mentored some 12 postdoctoral fellows and 17 graduate students. The achievements of
his trainees have been outstanding. Four students completed their Ph.D. degrees in less
than 4 years and two were recipients of the prestigious Harold M. Weintraub Graduate
Student Award, which is presented to the top graduate students in life sciences in the
United States.
Every mentee in Greg’s laboratory has had at least one publication in a high-impact
journal, and more than 60% of Greg’s 200-plus scientific publications have had graduate
mentee coauthorship. The training that he provides has resulted in the placement of 10 of his grad-
uate students in prestigious postdoctoral positions, with four already holding independent faculty
positions at Mt. Sinai School of Medicine, the University of Toronto, the Fred Hutchinson Cancer
Research Center, and the Whitehead Institute.
The HHMI and the Gordon and Betty Moore Foundation in 2011 selected CSHL
Professor Rob Martienssen as one of the nation’s 15 most innovative plant scientists to be-
come an HHMI Investigator. The honorees will share $75 million in research funding
over 5 years. Rob is a trailblazer in unraveling epigenetic mechanisms, which help to reg-
ulate how genes work, and is an expert on transposons—sequences of DNA that jump
around the genome, often altering gene activity.
The Brain & Behavior Research Foundation (BBRF) awarded CSHL Professor Josh
Huang a NARSAD Distinguished Investigator grant to study how genetic alterations as-
sociated with behavioral symptoms of schizophrenia disturb the development and func-
tion of neural circuits. Using a genetically engineered mouse strain, Josh will study
chandelier cells, which are key to inhibitory circuits in the brain’s frontal areas. NARSAD
Distinguished Investigators are selected by BBRF’s 124-member Scientific Council.
CSHL Fellow Chris Vakoc was selected by the Burroughs Wellcome Fund to receive a 2011 Ca-
reer Award for Medical Scientists. The 5-year $700,000 award helps M.D.-Ph.D.s—a unique set of
scientists who are experienced in both research and patient care—to bridge postdoctoral training
and the early years of faculty service. This award supports Chris’ work in identifying epigenetic vul-
nerabilities in chemotherapy-resistant leukemia.
Professor W. Richard McCombie was named a Fellow of the American Association for the Ad-
vancement of Science (AAAS) “for distinguished contributions in the areas of molecular biology,
A. Harmon and J.C. Nicholls, CSHL Board of Trustees
Chairperson
G. Hannon
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computational biology, and genomics, including high-throughput genome sequencing, and as di-
rector of the CSHL Genome Center.”
Assistant Professor Hongwu Zheng was selected by the V Foundation for Cancer Research as a
2011 V Scholar. Additionally, his proposal to study the genetic and functional characterization of
epidermal growth factor receptor (EGFR)-targeted therapy resistance in malignant gliomas received
special attention as the winner of the Martin Abeloff award for outstanding project submission.
CSHL and the National Institutes of Health (NIH) cohosted the “NIH New Investigator Re-
gional Conference” on March 14. The brainchild of the head of our Office of Sponsored Research,
Walter Goldschmidts, and supported by The Alfred P. Sloan Foundation, the event, held at Grace
Auditorium, brought key NIH directors and scientific program leaders together with more than
250 new faculty from 56 universities and research centers to discuss national biomedical research
priorities and issues facing new investigators. Despite NIH programs designed to facilitate the tran-
sition of new scientists to independently funded principal investigators, the average age at which an
investigator first obtains an initial independent research grant remains unacceptably high.
CSHL’s National Cancer Institute (NCI)-designated Cancer Center successfully competed for
and secured a renewal of its NCI grant that provides more than $4 million annually for research
during the next 5 years. CSHL has been an NCI-designated Cancer Center since 1987.
Promotions
Alea Mills was promoted to Professor and two of her colleagues, Raffaella Sordella and Hiroyasu
Furukawa, are now Associate Professors. Former CSH Fellow Christopher Vakoc was appointed As-
sistant Professor.
W.R. McCombie
NIH New Investigator Regional Conference
J. Huang C. Vakoc
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Administrative leaders of CSHL were also recognized with promotions. Lari Russo was named
Chief Financial Officer and Damian Desiderio is now the Comptroller. Hans Erik Aronson, who
heads our Information Technology Department, was promoted to Chief Information Officer.
In the Development Department, Diane Fagiola assumed a new role as Senior Director, Philan-
thropy, and Karen Orzel was named Director of Annual Giving and Donor Relations.
Departures
HHMI Investigator Scott Lowe took on a new position at Memorial Sloan-Kettering Cancer Center,
continuing collaboration with CSHL as an Adjunct Professor and active collaborator on a program
project grant from the National Cancer Institute.
Education Programs
The Watson School of Biological Sciences
The School held its eighth graduation in 2011, with Amy R. Rappaport and Claudio Scuoppo join-
ing the ranks of WSBS doctoral degree recipients, now numbering 49. Honorary degrees were be-
stowed on James H. Simons, Ph.D., Board Chair of Renaissance Technologies LLC, and James R.
Lupski, M.D., Ph.D., Professor of Molecular and Human Genetics at Baylor College of Medicine.
Watson School graduates have thrived in the professional world. They publish in top scientific re-
search journals and secure prestigious independent positions, fellowships, and awards. Eleven graduates
to date have secured tenure-track faculty positions and are now receiving federal grants and publishing
papers as independent researchers. At the end of 2011, WSBS students had published more than 185
research papers, a remarkable record since the school only started graduating students 7 years ago.
The 2011 entering class was composed of 10 accomplished students from the United States,
Canada, the United Kingdom, France, Spain, and Switzerland. A significant number of additional
students studying at CSHL are from Stony Brook University, via a program established between
CSHL and Stony Brook more than 30 years ago.
The 10-week CSHL research program for undergraduate students—affectionately called
“URP”—convenes in the summer and provides some of the finest college students in the nation a
priceless opportunity to conduct sophisticated research at the side of a CSHL investigator. In 2011,
URP’s 53rd year, 727 college students competed for 28 slots, a continuing mark of the program’s
relevance and stellar reputation.
(Left to right) CSHL President B. Stillman, honorary degree recipients J.H. Simon and J.R. Lupski, and
2011 Watson School graduates A.R. Rappaport and C. Scuoppo
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The Gavin Borden Visiting Fellow Lecture “Reading the Human Genome” was presented on
April 25 by Nobel laureate and long-time friend of CSHL Sydney Brenner, Ph.D., F.R.S.
Meetings and Courses Program
The world-renowned CSHL Meetings and Courses program attracted record attendance in 2011.
More than 7750 people attended scientific meetings and more than 1300 (trainees, teaching, and
support faculty) took part in courses. The Cold Spring Harbor Asia program based in Suzhou, China,
meanwhile drew some 2700 participants to 13 conferences and a summer school held during 2011.
Our flagship meeting, the Cold Spring Harbor Symposium on Quantitative Biology, which each
year focuses on a different topic, this year integrated classical biochemistry and modern molecular
biology under the theme of Metabolism and Disease. This year’s Symposium, the 76th in the historic
annual series, featured 63 speakers from North America, Europe, and Asia. Steeped in the tradition
of interactions between visiting scientists and the local community, the Dorcas Cummings Lecture
opened the doors of the meeting to members of the local community, who were enthralled by Cyn-
S. Brenner and B. Stillman at the Gavin Borden Lecture
Scene from the 76th CSHL Symposium
16 Highlights of the Year
thia Kenyon’s talk on “The Deadly Sweet Tooth.” Dinner parties at local homes after the Lecture
were the perfect venue to continue discussions of science and society.
New CSHL meetings in 2011 included Stem Cell Engineering and Cell Therapeutics and The Bi-
ology of Cancer: Microenvironment, Metastasis, and Therapeutics, both reflecting the increased interest
in translational science. Basic bioscience meetings, such as those on Eukaryotic Transcription or Neu-
robiology of Drosophila, continued to flourish, whereas the Eukaryotic RNA Processing meeting was
historic not least for beginning with an earthquake and ending with a hurricane.
CSHL offers ~25 high-level courses that attract more than 1000 scientists each year. Directed pri-
marily at predoctoral-, postdoctoral-, and faculty-level scientists, these intensive courses allow practicing
researchers to immerse themselves in new techniques and ideas that they can apply imme-
diately to their own research. The HHMI awarded the Laboratory a new 4-year grant to-
taling $2.475 million to support current courses and to allow CSHL to start new courses.
Banbury Center
In its 34th year of operation, the Banbury Center hosted 24 scientific meetings as well as six lecture
courses, two Watson School courses, and a variety of third-party events in 2011.
The schedule centers around private scientific gatherings, and during the year, these were attended
by ~686 participants from the United States and 25 other nations. Highlights of the science program
included a series of meetings coorganized by James D. Watson. Dr. Watson and Joseph Schlessinger
organized the meeting on Curing Melanoma and Other Cancers by Targeted Therapies that was well
timed, coinciding with reports of exciting results in treatments with vemurafenib, developed by
Plexxicon and Hoffmann La-Roche and now approved by the Food and Drug Administration. While
the meeting was in session, the FDA approved ipilimumab for the treatment of metastatic cancer.
Dr. James Allison, whose work helped lead to the development of the drug, was present at the meet-
ing. Other timely cancer-themed meetings in the series included Myc and the Pathway to Cancer and
Metformin and Neoplasia, both focusing on recent developments in discovering targeted therapies
for cancer and dealing with cancer’s unusual metabolism.
Outside groups use the Center for training young scientists, and we have developed close rela-
tionships in particular with the National Institute of Mental Health (NIMH) and the Boehringer
Ingelheim Foundation. This year’s NIMH “brain camp” was attended in full by the Institute’s di-
rector, Dr. Thomas Insel. Banbury workshops in 2011 focused on areas of intense interest including
autism spectrum disorders and pancreatic cancer.
DNA Learning Center
The DNA Learning Center (DNALC) continues to convey the wonders of molecular biology to
young people, K−12 teachers, college faculty, and members of the general public. To date, the
DNALC has introduced the concepts and technologies central to the field to more than 600,000
people. In 2011, 28,648 local students participated in labs, through field trips to DNALC facilities
in Cold Spring Harbor, Lake Success, and Harlem, New York City, and via in-school instruction
and the use of equipment footlockers.
More than 2800 of these students were from underserved Long Island and Queens school districts,
and 60.2% of Harlem DNA Lab students in upper Manhattan were members of ethnic groups that
are underrepresented in science. Enrollment in the DNALC summer camp programs set a new
record, exceeding 1000, and collaborations with Cold Spring Harbor High School, the Watson
School of Biological Sciences, and Stony Brook University continued.
Educator training was expanded in 2011: More than 1000 educators took part in training work-
shops across the United States, and more than 1600 people attended presentations or short workshops
at professional meetings. In a continuing partnership with the New York City Department of Edu-
cation, funded by the HHMI, the DNALC also provided training at the Harlem DNA Lab to 128
teachers in 44 1-day workshops, plus 2-week leadership training to 18 highly qualified teachers.
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In late 2011, the DNALC portal (www.dnalc.org) was awarded the Science Prize for Online Re-
sources in Education (SPORE). An essay in Science by DNALC founder and executive director
David Micklos and two members of the team, Sue Lauter and Amy Nisselle, described the evolution
and impact of the DNALC’s suite of websites, apps, and YouTube resources that attract more than
7 million visitors annually. In 2011 alone, the DNALC added three more websites, a new “app,”
and an e-book to the portal.
In 2010–2011, studies were undertaken to measure the effects of DNALC programs on students.
When compared with other educational methods and media, use of the two tested DNALC sites,
Inside Cancer and Genes to Cognition (G2C) Online, helped increase student academic performance,
on average, by one letter grade.
CSHL Press
The goal of the Press is to identify important research, technologies, and scientists; amplify their ef-
fectiveness by selecting, aggregating, and curating information research communities can use; and
deliver that information when, where, and how the communities want it.
During 2011, research articles published by the Press’ seven scientific journals continued to have
a high impact in their respective fields; more than 2100 electronic journal subscriptions
were fulfilled at academic institutions in 150 countries, including all leading American
universities, and 39,600 copies of print books were shipped. This reach is comple-
mented by interest from foreign publishers in translating certain books into languages
such as Chinese, Japanese, Arabic, and most recently, Vietnamese.
As measured by impact factor, the best-known metric of worth, all CSHL journals
advanced in 2011. Genes & Development and Genome Research continue to occupy the
first tier of genetics, biotechnology, and developmental biology journals, and of the
8000 most important science journals published in the world, they are within the top
1.2%. All of the journals exceeded financial expectation, and Cold Spring Harbor Pro-
tocols, in its 5th year, had a remarkable increase in subscriptions. A new journal, Cold
Spring Harbor Perspectives in Medicine, was launched on schedule in September, with
papers on AIDS, Alzheimer’s disease, and Parkinson’s syndrome.
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Seventeen new books were published during the year, bringing the number of available titles to
more than 150. Former Trustee James Darnell’s book, RNA: Life’s Indispensable Molecule, published
in July to critical acclaim, was named one of the 25 Outstanding Academic Titles for 2011 by Choice
magazine. The best-selling titles of the year were the classic handbooks At The Bench and At The
Helm, the iconic manual Molecular Cloning, and the magisterial history of molecular biology The
Eighth Day of Creation by Horace Freeland Judson, whose passing at the age of 80 during the year
we noted with great sadness.
The mission of the Press is being profoundly altered by changes in distribution channels. Labo-
ratory protocols and topic-specific review articles are two types of content for which the Press has
been renowned. Five years ago, that content was delivered only in printed books. Now, it comes
also in the much more usable form of online-only, subscription-based review journals made possible
by the reputation of those print books and the strategies used in creating them. Thus the same con-
tent types now have an additional means of delivery and a different, more robust business model,
but the same exceptional quality. E-books and device apps are being explored. All Press journals on-
line are now optimized for reading on mobile phones and tablet devices.
Library and Archives
Part of CSHL’s broad education mission, the Library and Archives continued to promote open access
to science history through grant-supported digitization projects.
Backed with a generous $600,400 grant from the Wellcome Trust and with the assistance
of photographer Ardon Bar-Hama, who has digitized the Dead Sea Scrolls at the Israel Mu-
seum and the archives of the New York Philharmonic, CSHL is now rendering nearly all
of its comprehensive archives of Dr. Watson’s papers, manuscripts, lectures, and many of his pho-
tographs in high-resolution digital format. Altogether, more than 250,000 Watson items will be
digitized, as well as more than 100,000 items from the collection of Sydney Brenner. It is part of
the Wellcome’s 2-year pilot project on the theme of Modern Genetics and its Foundations that seeks
to digitally “reunite” archival collections of the major players in the development of molecular bi-
ology (in addition to Watson and Brenner, these include Francis Crick, Maurice Wilkins, and Ros-
alind Franklin, among others). The collections will be made available through the Wellcome Digital
Library website and our own CSHL Library’s Archives Digital Collections Database.
Through a grant from the New York State Documentary Heritage Program Basic Processing Proj-
ect, CSHL will arrange and describe three collections that represent CSHL’s predecessor institutions,
providing insights into the lives of scientists working at the Lab from 1890 to 1974. This will include
Item from the James D. Watson Archive
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material from the Eugenics Record Office, an organization that also existed in the Cold Spring Har-
bor neighborhood from 1910 to 1939.
Other notable initiatives undertaken by the Archives include a grant from the National Archives
and Records Administration/National Historical Publications and Records Commission Basic Pro-
cessing Project to process 630 linear feet of CSHL archival collections and a Preservation Assistance
Grant for Smaller Institutions from the National Endowment for the Humanities that allowed for
a general preservation assessment of our collections and a preservation workshop attended by insti-
tutional librarians and archivists across the New York metropolitan area.
Development
The Honorable Patrick J. Kennedy, cofounder of “One Mind for Research,” opened
the 27th annual President’s Council on October 14, greeting donors whose $25,000
gifts support CSHL’s most talented young scientists. The retreat focused on “The Sci-
ence of Addiction” and featured Susan Foster, Columbia University; Joanna Fowler,
Brookhaven National Laboratory; Philip Low, Chairman, Neuro Vigil; Eric Nestler,
Friedman Brain Institute and Mount Sinai School of Medicine; and Howard Shaffer,
Harvard Medical School. CSHL Assistant Professor Adam Kepecs discussed his work
on neural circuit principles behind decision making, which he hopes will lead to better
treatments for diseases such as addiction. We thank event chairpersons Howard Mor-
gan, Cynthia R. Stebbins, and Steve Wiggins.
Double Helix Medals Dinner
At our sixth Double Helix Medals dinner, $3.3 million was raised to strengthen and
expand research and education programs.
The Double Helix Medal honors individuals who have positively impacted human
health by raising awareness and funds for biomedical research. Each of this year’s hon-
orees—Temple Grandin, Harold Varmus, and Kareem Abdul-Jabbar—has made extraor-
dinary contributions that have helped to transform the way in which doctors, patients,
and society approach all types of cancer and neurological conditions such as autism.
Infrastructure Projects
The Laboratory received a National Science Foundation Infrastructure Improvement Grant for
greenhouse renovations at Uplands Farm. Growth facilities were renovated and improved, and all
E. Watson, P.J. Kennedy, J.D. Watson, C. Moraetis, G. Echt, and S. Echt, at the President’s Council meeting
P.J. Kennedy, B. Stillman
Double Helix Medal Winners H. Varmus,
K. Abdul-Jabbar, and T. Grandin
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Osterhout Cottage Olney Barn
three greenhouses received lighting, ventilation, and control system upgrades necessary to accom-
modate the evolving plant research program.
The circa 1830 Hooper House received a facelift in 2011. The entire exterior structure was ren-
ovated, with new cedar siding, windows, doors, and trim work. The existing wood and aluminum
windows were replaced with modern equivalents that recall the 1830 originals. The renovation of-
fered the Laboratory the opportunity to restore gable details and a central front porch that had been
lost during earlier renovations.
Originally built as a single-family residence in the late 1960s, Osterhout was renovated to serve
as the new home of the Laboratory’s Public Affairs Department. The structure was gutted, reinforced,
and modernized for current office needs, but its original exterior character was retained.
The Olney Barn, built in the late 19th century as a companion to the nearby Olney House, was
in drastic need of renovation, but a survey of the structure and the site showed that it was impractical
to renovate the existing structure. To provide a suitable workspace for the Laboratory’s groundskeep-
ers, we constructed a new barn at a more suitable location.
Concerned both with the health of its employees and with rising healthcare expenses, the Labo-
ratory contracted North Shore−LIJ Health System (NSLIJ) to operate an on-site wellness center.
The center was constructed in the space formerly occupied by two sleeping rooms in Dolan Hall.
An NSLIJ Nurse Practitioner provides confidential health counseling and wellness services to CSHL
employees and graduate students.
Hooper House
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Great progress was made during the year on construction of the new, nearly 16,000-square-foot
Alfred D. Hershey Building. Construction began in 2010 and is expected to be complete by the
spring of 2012, just in time for summer courses. Funded by the HHMI, the building will also be
home to the Laboratory’s microscopy facilities, the Flow Cytometry shared resource, one course lab-
oratory, and two spacious seminar rooms.
Our Hillside Laboratories, opened in 2009, continue to be recognized for their innovative ar-
chitecture. In 2011, the project (designed by Centerbrook Architects) was recognized by the Amer-
ican Institute of Architects Connecticut Design Award and was a finalist in the World Architecture
News Colour in Architecture competition.
Information Technology
CSHL is committed to staying ahead of the information technology curve and accordingly has made
considerable investments during the last several years. Our plan has been to provide for strong IT
disaster recovery/business continuity preparedness; a unified, redundant high-speed data network;
and highly available, large-scale storage for scientific data.
In 2011, we successfully commissioned our Business Continuity/Disaster Recovery environment,
which maximizes availability of core IT resources through mirroring of data and services and pro-
viding instant, nondisruptive restoration of mission-critical resources. The CSHL campus high-
speed fiber-optic data network was upgraded to provide access to high-bandwidth applications at
additional CSHL facility locations, including the Banbury Conference Center, Uplands Farm, and
the Knight House.
The entire campus now also enjoys fully redundant, dual-path connection to our Internet service
provider (ISP) and a 10-fold increase in bandwidth product, from 100 Mbp to 1 Gbp. Our research
is better protected as a result of an improved data backup system and the expansion of data storage
systems for scientific computing (high-speed sequencing and data analysis). CSHL’s IT department
currently manages more than 3 PBs of research data!
Community Outreach
CSHL’s guided Walking Tour Program was enjoyed by more than 600 visitors in 2011, who came
from nearby communities as well as faraway lands including Singapore, Japan, Korea, Brazil, and
Germany. We thank our team of a dozen graduate students and postdocs who are the docents.
Local families battled the inclement April weather to explore the history of Cold Spring Harbor
Village’s Main Street and DNA on April 16−17 as part of the Lab-sponsored DNA Day Scavenger
Hershey BuildingOpening of the Center for Health and Wellness 
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Hunt. Neighboring educational organizations such as the Cold Spring Harbor Public Library and
Environmental Center, the Cold Spring Harbor Whaling Museum, the Firehouse Museum, and our
own DNA Learning Center all took part.
DNA Day is celebrated across the country, with educational events sponsored by the National
Human Genome Research Institute (NHGRI), a part of the National Institutes of Health.
In Orlando, Florida, visitors to the Orlando Science Center’s DNA Day celebration en-
gaged in Skype video conference sessions with CSHL faculty members Dick McCombie
and Doreen Ware and Research Investigator Emily Hodges. Among the three scientists,
they covered DNA-relevant topics ranging from genome sequencing and plant biology to
Neanderthal bones.
Seventy-five winners from the 2011 Brentwood District Science Fair celebrated DNA
Day by genetically engineering bacteria that glow. Funded by the National Grid Foundation,
the hands-on scientific experiences delivered by the DNALC are just one example of the
ways in which the DNALC partners with school districts to enhance biology curricula.
At the fourth annual World Science Festival in
Manhattan, the DNALC showcased the Urban Bar-
code Project as part of the festival’s lively Street Fair
event. The city-wide barcode project competition,
funded by a grant from the Alfred P. Sloan Founda-
tion, has attracted 103 high school teams and will culminate
in June 2012 with the award of scholarship prizes to students
on winning teams.
DNA Day Scavenger Hunt map
Orlando Science Center poster
announcing Doreen Ware’s talk
Highlights of the Year      23
CSHL continued its partnership with the Long Island 2-Day Walk to Fight Breast Cancer, judging
the annual scholarship essay contest and cheering on walkers during the event. Our faculty, staff, and
students participated in many other fundraising events that benefit our research; they are organized
by disease-based organizations in our local community including Swim Across America, the Don
Monti Memorial Research Foundation, the Joni Gladowsky Breast Cancer Research Foundation, and
the Manhasset Women’s Coalition.
The year 2011 became the year that CSHL broke into the social-media world, launching an in-
stitutional Facebook page, blogging on our own LabDish page, and amassing a significant Twitter
following. Our monthly electronic NetLetter won national acclaim from PR News for its highly in-
teractive and visually appealing platform, which delivers news and information about CSHL that is
both useful and relevant to a diverse and growing audience.
Public Lectures at Cold Spring Harbor Laboratory
April 4—Paul W. Glimcher, Ph.D., Julius Silver Professor of Neural Science, Economics,
and Psychology and Director for the Center for Neuroeconomics, New York University: Neu-
roeconomics and the Biological Basis of Decision-Making.
June 22—Fritz Henn, M.D., Ph.D., CSHL Professor; Husseini Manji, M.D., Global Head
of Neuroscience at Johnson & Johnson Pharmaceutical Research & Development, LLC; New
Approaches to Treatment of Depression and Bipolar Disorder, cosponsored by CSHL, Brain &
Behavior Research Foundation, Bank of America-Merrill Lynch, and St. Johnland Nursing
Center.
July 6—Partha Mitra, Ph.D., CSHL Professor: Mapping the Mouse Brain, hosted by the Secret Sci-
ence Club, Brooklyn, New York.
August 24—Rob Martienssen, Ph.D., CSHL Professor and HHMI Investigator: Send in the
Clones: Superseeds, Superweeds, and Green Energy, hosted by the Secret Science Club, Brooklyn,
New York.
P. Glimcher
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October 23—Anne Churchland, Ph.D., CSHL Assistant Professor; Concetta M. Tomaino, D.A.,
M.T.-B.C., L.C.A.T., Executive Director/Cofounder, Institute for Music and Neurologic Function;
Senior Vice President, Music Therapy Services, Beth Abraham Family of Health Services; Irene
Gubrud, D.F.A.; Soprano, Voice, and Meditation Teacher; Steven Finch, M.M.; Conductor, Choral
Clinician: Music: How It Can Rewire Your Brain, cosponsored by CSHL and St. Johnland Nursing
Center.
CSHL Public Concerts
April 15: Two Plus One, trio
April 29: Jennifer Johnson, soprano
May 6: Hiroko Sasaki, pianist
May 20: Xun Wang, pianist
August 19: Margarita Shevchenko and Lev 
Polyakin, pianist and violinist
September 9: Bella Hristova, violinist
September 23: Natalia Lavrova, pianist
October 14: Yoonie Han, pianist
Looking Forward
As we look ahead, I remain confident that CSHL is well-positioned to fulfill its research and edu-
cation mission, continuing to lead the field of molecular biology and genetics to its next major
achievements. My confidence is based on this institution’s faculty, staff, and students, who make
my job as President such a source of pride. I thank you, our Board of Trustees, and generous donors
for your support.
Bruce Stillman, Ph.D., F.R.S.
President
Had one been told in advance that 2011 would be marked by an extraordinary nat-
ural disaster in Japan, unprecedented political upheaval in northern Africa, a Euro-
pean debt crisis, stubbornly slow economic growth and high unemployment in the
United States, and a downgrade of the U.S. credit rating, one might have predicted
a terrible year for endowment investment returns and an unusually difficult year for
nonprofit institutions that depend on government funding and philanthropy. For-
tunately, this was not the case at Cold Spring Harbor Laboratory. 
The exceptionally high quality of the Laboratory’s research and education pro-
grams allows us to weather challenging economic times more easily than many insti-
tutions. We have a comparatively high federal grant success rate, and we enjoy very
healthy support from private foundations and individuals. The Laboratory has also
established a unique portfolio of assets including an internationally renowned scien-
tific Meetings and Courses program and a prolific, well-respected scientific publish-
ing arm. These activities serve to diversify the institution from both an economic and intellectual
perspective, as do our graduate school and DNA Learning Center programs.
Although spending from the endowment fund represents a relatively small percentage (11%) of
the annual operating budget, endowment is nevertheless critical to the Laboratory’s stability and fu-
ture. The Investment Committee of our Board of Trustees works hard to ensure that the fund is
well-diversified and positioned appropriately for growth and capital preservation.
In preparing the 2011 budget during the fourth quarter of 2010, we were mindful of two con-
secutive years of strong investment returns in 2009 and 2010, and we anticipated volatility in 2011.
Consequently, we forecasted zero percent return for 2011, which is exactly where we finished. While
not a particularly exciting result, we were pleased that the investment strategy successfully preserved
capital in an extraordinarily volatile year. Looking forward, the Board of Trustees has targeted in-
creasing the Laboratory’s endowment fund as its highest priority in this period of flat federal funding
for research. 
For the fiscal year ending 12/31/11, the Laboratory’s operating budget reached approximately
$154 million, an increase of 5% over the prior year. Although top-line growth is good, it is important
to remember that a portion of federal grant revenue still reflects funding made available through
the American Recovery and Reinvestment Act, presumably a nonrecurring phenomenon. With
Washington facing large deficits and election-year politics, we remain concerned about the levels of
federal funding for research. Management’s focus on driving revenue and controlling expenses led
to a satisfactory operating result in 2011. However, in assimilating our recently expanded infrastruc-
ture and new faculty hires, we are drawing, as planned, on the “research start-up” fund raised in our
last fund-raising campaign. This fund is scheduled to be fully spent by 2016−2017; hence, the em-
phasis on raising more endowment. 
Complacency is hardly an option. The costs of doing innovative science continue to rise. Funding
is uncertain. Remaining in the forefront of the field requires investment in equipment, infrastructure,
and personnel. It is critical that we remain diligent about controlling expenses while preserving and
building the resources required to address the world’s most important health problems. 
As always, we are grateful to all who support the Laboratory’s work, and we are inspired by our
talented team of scientists and staff, of whom we ask so much. 
Dill Ayres
Chief Operating Officer
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Long-Term Service
Front row (left to right) Susan Lauter, Delia King, Patricia McAdams, Marlene Rubino, Patricia Wendel, Mary Ann Miceli, Barbara Zane; top row
(left to right) Michael Regulski, Peter Stahl, Philip Renna, John Maroney, Bruce Stillman, Timothy Mulligan, Christopher Hubert, William Keen,
Peter Schwind, Frank Russo
The following employees celebrated milestone anniversaries in 2011:
40 Years Bill Keen, John Maroney
35 Years Peter Stahl, Pat Wendel
30 Years Rodney Chisum, Philip Renna, Marlene Rubino
25 Years Chris Hubert, Adrian Krainer, Susan Lauter, Vincent Meschan, Tim Mulligan
20 Years Kathy Cirone, Delia King, Mary Ann Miceli, Patricia McAdams, Chris Oravitz,
Michael Regulski, Frank Russo, Peter Schwind, Judi Smith, Linda Van Aelst, 
Barbara Zane
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Front row (left to right) Liz Powers, Marcie Siconolfi, Peggy Brock. Top row (left to right) Florecita Chaves, Kaaren
Janssen, Bruce Stillman
Long-Term Service: 15 Years
15 Years Scott Bennett, Peggy Brock, William Carmona, Florecita Chaves, Wendy Crowley, 
Constance Hallaran, Kaaren Janssen, Melissa Kramer, Oscar Lastra, 
Lorraine McInerny, Maureen Morrow, Liz Powers, Marcie Siconolfi
RESEARCH
See previous page for photos of the following scientific staff:
Row 1: O. Anczukow-Camarda (Krainer lab); S. Xu (Zhong lab); M. Cohen (Egeblad lab); 
M. Matlashov, V. Belousov (Enikolopov lab)
Row 2: N. Chatterjee (Dubnau lab); M. Ramesh (Tonks lab); D. Wah (Joshua-Tor lab); 
C. Kuscu (Joshua-Tor lab)
Row 3: K. Jiang (Lippman lab); A. Jespersen (Furukawa lab); E. Lee (Hannon lab); 
M. Penzo (Li lab)
Row 4: C. Carlston (Hammel lab); N. Azamy (McCombie lab); M. Javelle (Timmermans lab);
H. Taniguchi (Huang lab); B. Zhang (Spector lab)
Row 5: T. Hige (Turner lab); B. Xue (Muthuswamy lab); R. Campbell (Turner lab); 
M. Vigliotti (Lucito lab)
Gene expression and cell proliferation focuses on the regulation of gene expression, cell-division cycle
control, and chromosome structure in normal and cancer cells.
Christopher Hammell’s lab is interested in understanding gene regulatory processes that give rise
to robust phenotypes associated with normal development in animals (specifically, how the timing
of developmental processes is controlled) as well as alterations in these pathways that give rise to dis-
eases such as cancer (as in the alterations in mitogenic pathways in melanoma). To address this ele-
mental problem, Hammell and colleagues are using a variety of model organisms and patient-derived
cancer cell lines. To directly identify the components that function in controlling normal develop-
mental timing, they are using forward and reverse genetic approaches with the small nematode
Caenorhabditis elegans. In contrast to the extreme robustness of cell-fate lineage in C. elegans, in
which specification of developmental programs is hard-wired, mutations that alter conserved sig-
naling pathways in melanoma create relatively plastic developmental landscapes that allow these le-
sions to become aggressive tumors. Notably, the gene regulatory architecture of melanoma cells
allows them to acquire resistance to therapeutic agents. Hammell’s team is interested in epigenetic
mechanisms that contribute to resistance, specifically, dramatic changes in gene expression patterns
and intracellular signaling pathways. High-throughput screens are being performed in the Hammell
lab to identify cellular factors that allow these rewiring events to occur, with the idea that these com-
ponents would make ideal therapeutic targets to complement existing clinical strategies.
Leemor Joshua-Tor’s lab studies the molecular basis of nucleic acid regulatory processes by using
the tools of structural biology and biochemistry to examine proteins and protein complexes associ-
ated with these processes. They use X-ray crystallography to obtain three-dimensional (3D) struc-
tures of individual proteins. Biochemistry and molecular biology enable them to study properties
that can be correlated with protein structure and function. It was Joshua-Tor and her team who
first obtained the structure of a full-length Argonaute protein, work that instantly solved a long-
standing puzzle in the RNA interference (RNAi) field. By observing the structure, they realized that
Argonaute was the long-sought Slicer, which performs the critical slicing event in RNAi, cleavage
of messenger RNA. Joshua-Tor is also well known for her work on the E1 helicase enzyme, which
acts to unwind DNA strands during the DNA replication process. This past year, Joshua-Tor and
colleagues determined the 3D structure of a protein complex called RNA-induced initiation of tran-
scriptional gene silencing (RITS), discovering new details of how its various domains contribute to
heterochromatin assembly and gene silencing. Joshua-Tor and colleagues also solved the crystal
structure of the complex of Gal3p–Gal80p in the yeast Saccharomyces cerevisiae, with α-D-galactose
and ATP—a classic transcription complex with its two ligands. This work revealed that the Gal3p
transducer of the GAL regulon interacts with the Gal80p repressor in its ligand-induced closed con-
formation.
Adrian Krainer’s lab studies mechanisms of RNA splicing, ways in which they go awry in disease,
and means by which faulty splicing can be corrected. Their approach has borne fruit in the study of
spinal muscular atrophy (SMA), a neuromuscular disease that is the leading genetic cause of death in
infants. Their ability to correct an mRNA splicing defect in SMA that makes a gene called SMN2 only
partially functional forms the basis of a potentially powerful therapeutic approach. In recent years,
the team identified a compound that stimulates SMN protein production by altering RNA splicing.
By introducing chemically modified pieces of RNA called antisense oligonucleotides (ASOs) into
the spinal cords of mice, they succeeded in reversing symptoms of Type III SMA. This year, the team
was surprised to discover that systemic—as opposed to central nervous system—injection of ASOs
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in mice with severe SMA a day after birth increased their survival 10-fold to 25-fold, depending on
dose. This suggests that correcting SMN2 splicing in tissue other than brain and spinal cord could
significantly improve outcome. The lab’s expertise in splicing has also helped to shed light on the ab-
normal glucose metabolism of cancer cells, sometimes referred to as the Warburg Effect.
David L. Spector’s lab studies the spatial organization and regulation of gene expression. Their in
vivo approach is exemplified in a live cell gene expression system that has made possible the exam-
ination in real time of the recruitment of members of gene expression and silencing machineries. One
of their current research focuses is on understanding nuclear positioning of genes in relation to their
transcriptional activity. Another focus is on the identification and characterization of long nuclear
retained noncoding RNAs (ncRNAs), whose functions are still poorly understood. Using 4D live
cell imaging during the past year, the team discovered that the formation of a type of nuclear sub-
compartment called the paraspeckle is triggered by a pair of ncRNA molecules, which also main-
tain its structural integrity. In additional work published this year, Spector’s team measured the
kinetics of activation of a single gene locus—the specific chromosomal location of a gene—in a cell
before it divided and compared it with the same gene’s reactivation in newly formed daughter cells.
In this way, they determined how “bookmarking” a gene predivision marks it for reactivation post-
division. The bookmark is an acetylated histone that recruits the protein BRD4 to the gene locus
during mitosis. Their findings revealed a function of BRD4 in chromatin decompaction that al-
lowed for the rapid kinetics of gene activation in postdivision cells.
Arne Stenlund and colleagues have obtained a detailed understanding of processes required for
initiation of DNA replication from papillomaviruses, using this system to gain a general biochem-
ical understanding applicable to other systems. Papillomaviruses are a large viral family that induces
cell proliferation at the site of infection, usually giving rise to benign tumors. But certain types of
human papillomaviruses (HPVs) generate tumors that progress toward malignancy. Among these are
HPVs that cause most cervical cancers. Members of the Stenlund lab also pursue studies aimed at
developing an effective small-molecule inhibitor of HPVs that might someday be used by women
who do not receive the preventive anti-HPV vaccine now available, or those already infected with
HPV who would not be helped by the vaccine.
Bruce Stillman’s lab studies the process by which DNA is copied within cells before the cells di-
vide in two. Working with yeast and human cells, Stillman and colleagues have identified many of
the cellular proteins that function at the DNA replication fork during the S phase, the portion of
the cell-division cycle at which DNA synthesis occurs. Among these proteins are those that facili-
tate the assembly of chromatin, the protein−DNA complexes that form the chromosomes. The pri-
mary focus of current research, however, is on the mechanism that initiates the entire process of
DNA replication in eukaryotic cells. At the heart of this mechanism is a protein that binds to “start”
sites on the chromosomes, called the origin recognition complex (ORC). Stillman’s research has
demonstrated that the ORC is also involved in the process of segregating duplicated chromosomes
in mitosis. The team has found ORC at centrosomes and centromeres, structures that orchestrate
chromosome separation in mitosis. This year, Stillman’s team took part in research that demon-
strated the feasibility of using RNAi technology to switch genes on and off in a nonlethal manner,
a boon to disease research in animal models. They “turned off” a gene necessary for DNA replica-
tion in mice until the animals became moribund and then successfully reversed this condition and
rescued the mice by turning this gene back on.
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The temporal regulation of gene expression is an indis-
pensable characteristic of metazoan development and is
the basis for the progressive control of genetic programs
that coordinate animal growth and aging. Caenorhabdi-
tis elegans is an ideal model organism whose invariant,
well-characterized cell lineage can be leveraged to deter-
mine the mechanisms that couple these processes. Genes
that control the patterning of temporal cell fates, in-
cluding microRNAs (miRNAs) and their targets, are ex-
pressed at defined larval stages and are temporally down-
or up-regulated accordingly. How these regulatory
processes are controlled and coordinated during animal
development is a major focus of our laboratory.
Genetic Approaches to Identify 
Components That Modulate the 
Temporal Activity of miRNAs
C. elegans, as a model organism, has provided an unpar-
alleled system in which the principles of temporal cell-
fate specification can be examined. Characterization of
mutants that alter the patterning of cell-fate determina-
tion has revealed two central precepts of developmental
timing that are conserved throughout evolution. The
most fundamental maxim to emerge from these studies
is that the genes which control the patterning of cell fate
operate within defined modular regulatory programs and
each program is limited to a single stage of development.
Importantly, the activity and sequential expression of
these individual modules is integrated into a much larger,
linear gene regulatory network. This larger regulatory
network is punctuated by four molting periods in which
the hypodermal cells synthesize and secrete a new cuticle
and separate from one produced in the prior stage. The
coordination of the molting cycles, the individual cell di-
visions, and the regulation of temporal cell fate specifi-
cation are precisely timed, allowing the events of cell
specification to occur in absolute developmental time (as
measured from hatching) or relative to reiterated patterns
of cuticle formation expressed during the molting peri-
ods. Heterochronic mutants can be classified into two
groups that reflect their distinct effects on the pattern-
ing of temporal cell-fate specification. Precocious mu-
tants execute later stage-specific cell division programs at
earlier times by skipping intermediate stages of develop-
ment and display adult-specific gene expression programs
during larval development. Conversely, retarded hetero-
chronic mutants reiterate individual cell-fate programs
and inappropriately retain larval features in adulthood.
The modular nature of temporal cell-fate specifica-
tion is also underscored by a regulatory strategy that is
used multiple times during development. This strategy
uses variations on the theme of sharp transcriptional in-
duction of specific miRNAs and the rapid reduction of
their target transcripts. This serial and progressive regu-
lation of heterochronic genes limits the activity of indi-
vidual cell-fate specification programs to a single larval
stage. Animals that lack discrete heterochronic miRNAs
continuously reiterate early cell lineage specification pro-
grams as a consequence of continued, inappropriate ex-
pression to the mRNAs normally targeted by each
miRNA (Fig. 1). These mutations result in specific al-
terations of multiple cell lineages during postembryonic
aging and are easily distinguished from wild-type ani-
mals via multiple observable criteria (including stage-spe-
cific reporters, total number of cells, and the presence or
absence of adult structures). The mechanisms and com-
ponents that ensure the temporal precision of miRNA-
mediated expression (and therefore couple development
processes with chronological aging) are unknown.
Our approach to this problem uses a genetic pipeline
that filters multiple candidates through two powerful
genetic screens that are conducted in series. This ap-
proach has enabled us to isolate gene products that
modulate the expression of specific miRNAs (see
below). From candidates identified in primary screens,
components that coordinate general miRNA-mediated
processes can be identified in secondary screens. To
identify these regulatory candidates, we intentionally
focused on finding suppressors of specific miRNA mu-
tants that produce mature 21-nucleotide regulatory
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C.M. Hammell C. Aquirre-Chen A. Levin
C. Carlston A. Turberfield
D.M. King
RNA products yet fail to efficiently down-regulate their
target transcripts. Animals harboring lin-4(ma161) or
let-7(n2853) mutations (which alter a single nucleotide
in the mature “seed sequence” of the miRNA) display
specific retarded cell lineage phenotypes at early and
late stages of development and underaccumulate func-
tional lin-4 and let-7 miRNAs, respectively. Phenotypes
associated with these alleles are indistinguishable from
those displayed in animals harboring null mutations of
these genes. To identify components that control
miRNA-dependent processes during the middle stages
of larval development, we also used a novel antimor-
phic allele of the C. elegans miRNA-specific argonaute
(alg-1(ma192)) that exhibits retarded heterochronic
phenotypes due to the inappropriate perdurance of a
single miRNA target.
Primary screen. At the cellular and molecular levels,
these mutations result in animals that display distinct cell
lineage phenotypes and disrupt defined genetic interac-
tions. Each of these phenotypes is caused by a general in-
ability of animals to efficiently down-regulate specific
miRNA targets, which ultimately prevents the progres-
sion of the normal regulatory cascade that culminates in
adult-specific gene expression. These mutual macroscopic
defects are easily monitored through the use of a reporter
(col-19pro::GFP) that is only expressed during adulthood
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in wild-type animals. Candidate suppressors of these phe-
notypes are identified as genes that, when mutated or de-
pleted via RNA interference (RNAi), recapitulate the
normal temporal expression pattern of col-19::GFP in
mutant animals (primary screens; Fig. 2). This screening
step, by itself, is analogous to previous methods used to
isolate heterochronic genes, which have identified many
important mutants, and yet remain unsaturated.
Secondary screen. Our strategy uses the power of
these unbiased approaches but is distinguished from prior
screens by the application of a refinement procedure that
isolates, from the suppressors identified in primary
screens, those gene products that normally function to
promote the precise expression of multiple temporally
regulated miRNAs. Specifically, suppressors identified in
the primary screens are queried for their ability to correct
additional heterochronic phenotypes associated with par-
ticular developmental programs occurring at different lar-
val stages. This secondary screening process is both
powerful and direct, as the retarded developmental phe-
notypes displayed by each of these genetic contexts result
from a common inability to express an unambiguous re-
porter of adult-specific expression (col-19::GFP). From
the information gained in our pilot screens, this second-
ary genetic application appears to directly enrich for regu-
latory components that control miRNA expression
within the context of the entire regulatory cascade con-
trolling the patterning of postembryonic cell fates.
Identification and Characterization
of Components that Couple
Developmental and Chronological Ages
In the past year, we have completed pilot, EMS-based
primary screens for each of the genetic backgrounds out-
lined above. Our efforts have resulted in the identifica-
tion of 28 novel mutations that suppress at least one of
Figure 1. C. elegans development proceeds through a strict series
of specific cell-fate patterns that are punctuated by molts. (A) At
each larval molt, many somatic cells divide and display distinct
cell fates and gene expression patterns. In normal animals, tem-
poral patterns of cell specification are “hard-wired” and control
heterochronic genes that directly modulate specific developmen-
tal programs as well as genes that demarcate relative develop-
mental time. (B) The patterning of developmental cell-fate
specification is controlled by several miRNAs that accumulate at
distinct stages of development and down-regulate the expression
of other gene products that control larger suites of temporally reg-
ulated genes.
Figure 2. A two-part genetic strategy to identify genes that mod-
ulate the expression or activity of heterochronic miRNAs.
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these genetic contexts. To focus on regulatory compo-
nents of temporal expression, we are currently catego-
rizing the resulting mutations from the primary screen
for their ability to suppress phenotypes associated with
the other hypomorphic miRNA backgrounds (sec-
ondary screens, Fig. 2). These alleles will be character-
ized using standard genetic techniques and whole-
genome sequencing to assign complementation groups
and identify the causative genetic lesions of these alleles,
respectively.
We have already determined the capacity of several of
these mutations to suppress the retarded heterochronic
phenotypes of all three genetic contexts (lin-4, let-7, and
alg-1), therefore establishing the simplicity and utility of
this two-tiered screening strategy. Surprisingly, five alleles
from the pilot EMS-based screens contain genetic lesions
that lie within a single gene, lin-42, encoding the C. ele-
gans homolog of the human and Drosophila Period genes
implicated in circadian timing. Importantly, novel lin-42
alleles were identified as suppressors in each of the above
mutant backgrounds, testifying to the power of this ge-
netic strategy. Although lin-42 function has been impli-
cated in controlling animal behavior, the molting cycle,
and aspects of postembryonic development, we believe
that the identification of lin-42mutations with this two-
tiered approach allows us to directly interpret its function
in the context of normal temporal gene regulation. These
observations, for several reasons, suggest that lin-42 ac-
tivity is essential for the normal temporal coordination of
cell-fate specification events that occur during larval de-
velopment. First, a reduction in lin-42 function sup-
presses the early, middle, and late cell lineage defects of
distinct miRNA mutants, indicating that lin-42 activity
is required throughout larval development. This inter-
pretation is also supported by the observation that lin-42
encodes multiple nuclear proteins that increase in abun-
dance before being cleared from somatic cells once per
larval stage. This recursive, pulsatile protein accumulation
is reminiscent of the periodic expression profiles of the
human and Drosophila Period proteins controlling circa-
dian gene expression. Genetic evidence also suggests that
much of lin-42 activity is mediated by and is dependent
on the ability of animals to express mature lin-4 and let-
7miRNAs. Northern analysis of miRNA expression pat-
terns in lin-42 mutants indicates that the loss of lin-42
activity results in the precocious and overabundant accu-
mulation of specific heterochronic miRNAs (Fig. 3).
Transcriptional green fluorescent protein (GFP) report-
ers, driven by the lin-4 and let-7 promoter sequences, in-
dicate that lin-42-mediated regulation is controlled
primarily at the transcriptional level. Furthermore, the
mild precocious heterochronic phenotypes of lin-42(lf )
animals are dependent on the expression of specific 
miRNAs and are suppressed by reducing their overall lev-
els. Consistent with this genetic dependency and its
mechanistic role in controlling miRNA transcription, lin-
42mutations completely fail to suppress retarded cell lin-
eage defects associated with null alleles of lin-4 or let-7,
but they completely suppress hypomorphic alleles of mul-
tiple miRNAs. These results suggest that lin-42 normally
functions to reduce the steady-state accumulation of het-
erochronic miRNAs in a pulsatile fashion.
We have also screened ~25% of a genomic RNAi li-
brary in the lin-4, let-7, and alg-1mutant backgrounds.
These efforts have identified at least two novel hetero-
chronic genes: pqn-59, encoding a “prion-like” protein,
and E02D9.1b, the C. elegans homolog of human
Sam68, a conserved RNA-binding protein implicated in
alternative splicing. Mutations in these genes recapitu-
late the RNAi-based suppression phenotypes observed
in all three retarded miRNA mutant backgrounds, and
RNAi depletion of E02D9.1b or mutations of pqn-59,
pqn-59(tm2960), in an otherwise wild-type genetic back-
ground, results in the precocious expression of adult-spe-
cific genes.
Characterization of each suppressor identified by this
strategy is being carried out at both the molecular and
genetic levels. As each of the cell lineage defects in lin-4,
let-7, and alg-1mutants are quantifiable, the suppression
of each of these phenotypes (including the correction of
Figure 3. lin-42(lf) suppresses heterochronic phenotypes of de-
velopmental timing mutants that are defective in miRNA func-
tion. (A) In wild-type animals, the adult-specific expression of a
col-19::GFP reporter is only expressed after the larval stages. In
alg-1(ma192) animals, which harbor mutations in the C. elegans
miRNA-specific argonaute protein, the proper expression of col-
19::GFP is defective because the inability of these animals to
down-regulate larval developmental genes is compromised. Re-
moval of lin-42 function in alg-1(ma192) mutants restores the
normal down-regulation of larval gene expression. (B) lin-4
(ma161) mutants reiterate early larval developmental cell fates
and lack vulval structures. Removal of lin-42 function in lin-
4(ma161) animals corrects these temporal cell-fate defects. (C)
Mutations in lin-42 affect miRNA accumulation.
gene expression patterns, presence or absence of adult-
specific cuticle structures, and changes in cell lineage) by
each gene is also being characterized in detail. In addi-
tion, for genes identified through RNAi screening, we
are constructing null and loss-of-function alleles using
standard techniques. These reagents will be used to prop-
erly characterize phenotypes associated with complete
loss-of-function alleles and order gene function (epista-
sis) with regard to the regulation of cell-fate specification
genes and developmental oscillatory components (see
below). In addition, transcriptional and translational re-
porters of these genes have been constructed and trans-
formed into wild-type animals to ascertain the temporal
and spatial expression patterns of these gene products
(Fig. 4) (see GFP reporters for PQN-59 and E02D9.1b).
These reporters will complement efforts using antisera
directed against these proteins that will be used to iden-
tify the additional protein components that physically
associate with these proteins in vivo via immunoprecip-
itation. In addition, for components that bind nucleic
acids (such as E02D9.1b), these reagents can be used to
identify RNA and DNA elements normally bound by
these components in vivo.
Pervasive Levels of Temporal Gene
Expression throughout C. elegans
Development
In an effort to establish the depth and general dynam-
ics of transcription that occurs during development and
aging, mRNA expression profiles were obtained from
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wild-type nematodes at multiple stages throughout
postembryonic growth. The temporal precision of these
experiments revealed that, in addition to the transcrip-
tional changes associated with the genes controlling tem-
poral cell-fate specification, an astonishingly large
portion of the C. elegans transcriptome is temporally reg-
ulated. About 40% of mRNAs exhibit pulsatile expres-
sion patterns and ~2800 mRNAs cycle in abundance
during each larval stage. These findings compelled us to
pose elemental questions about how developmental tim-
ing networks function in a progressive, unidirectional
manner and how these processes are accomplished with
such precision in the context of dramatic genome-wide
cycles of gene expression. The pervasiveness and the pe-
riodicity of transcriptional cycling suggest that this os-
cillatory behavior is a fundamental biological property
and supports the robustness of cell-fate specification.
Although lin-42, pqn-59, and E02D9.1b each encode
unique classes of gene products (a nuclear protein ho-
mologous to components that regulate circadian gene ex-
pression, a “prion-like” protein, and an RNA-binding
protein), each gene is periodically expressed at the protein
and transcriptional levels. Importantly, these genes cycle
in abundance from essentially undetectable levels to in-
tense expression in a pulsatile fashion during each molt-
ing period. This recursive arrangement of expression is
distinct from the essentially binary regulation displayed
by other developmental timing genes. For instance, pre-
viously characterized heterochronic components, such as
the miRNA targets lin-14, hbl-1, and lin-41, function as
genetic “switches” controlling the intricate gene expres-
sion programs specific to a single larval transition (see
Fig. 1). These genes accomplish this task by being ex-
pressed (switched on) at one or more developmental
stages and then switched off. This sequential reduction of
“switch-like” heterochronic gene expression facilitates the
progressive elaboration of later cell fates by limiting the
function of genes that have been utilized in earlier de-
velopmental programs. In contrast, new heterochronic
genes such as lin-42, pqn-59, and E02D9.1b likely func-
tion as molecular clock components that demarcate both
absolute and relative developmental time. Through their
periodic expression patterns and ability to directly regu-
late expression of other “switch-like” heterochronic genes
(such as miRNAs), these components integrate temporal
cell-fate specification with animal growth. Importantly,
these clock proteins cycle out of phase with the larval
molts and retain this periodic behavior in the context of
mutant animals that display alterations in the patterning
of temporal cell fates. While experiments directed to un-
derstanding the molecular activities of each of these genes
Figure 4. The new heterochronic genes pqn-59 and E02D9.1b
are ubiquitously expressed in C. elegans larva.
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are being pursued in a long-term and independent man-
ner, the hypothesis that these genes coordinate the tem-
poral expression of miRNAs and/or mRNAs is also being
directly tested.
Preliminary analyses of temporal expression programs
generated from RNA-Seq assays revealed an astounding
level of phased gene expression throughout the life span
of the worm. At a superficial level, these transcription
phases appear to be directly coupled to the temporally
controlled cell divisions and molting periods of postem-
bryonic development (Fig. 5). Although one may sug-
gest that these expression patterns represent a simple
repeated cascade of derivative transcriptional processes
that are initiated at the beginning of larval development,
a detailed analysis of these expression patterns suggests
that there are two distinct waves of transcriptional acti-
vation that occur during each larval stage. The first of
these waves is initiated in the middle of each larval pe-
riod, whereas the second wave occurs just before the
molt, during cuticle formation and ecdy-sis, as shown for
two examplar genes (Fig. 5). Peak lin-42 expression is
also pulsatile and remarkably occurs in between these two
developmental peaks. This suggests that developmental
clock components, such as lin-42, pqn-59, and
E02D9.1b, may function to delineate this phasing
process.
To directly assay the roles these clock components
have in regulating both mRNA and miRNA temporal
expression patterns, we have developed a dual reporter
system that enables us to simultaneously measure the
transcription of a variety of genes in living animals. The
basis of this strategy has been used to measure the sto-
chasticity of gene expression in single-celled organisms
and is both extremely sensitive and quantitative. This
strategy involves simultaneously monitoring two genes
in each animal, tagged with either GFP or mCherry.
Both of these reporters include a carboxy-terminal PEST
signal that reduces the half-life of each reporter to less
than 1 hour and dramatically improves the temporal res-
olution of these assays, allowing these reporters to serve
as proxies for transcriptional activation. We are focusing
on the characterization of the transcriptional expression
patterns of representative genes that display distinctly
pulsatile expression at each larval stage. These classes in-
clude genes whose transcripts that are dramatically up-
regulated immediately before lin-42 expression.
Figure 5. C. elegans transcription is pervasively regulated at the
temporal level, and many genes display transcriptional profiles
that are anti-phasic to the expression of lin-42. col-149, lin-42,
and col-12 transcripts are expressed once each larval stage. Im-
portantly, the phasing of transcripts relative to each other is main-
tained for each gene every larval period.
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We study the molecular basis of nucleic acid regulatory
processes by using the tools of structural biology and
biochemistry to examine proteins and protein com-
plexes associated with these processes. X-ray crystallog-
raphy enables us to obtain the three-dimensional
structures of these molecular machines. Biochemistry
and molecular biology allow us to study properties that
can be correlated to protein structure and function.
Mechanisms of RNAi
T. Schalch, C. Faehnle, E. Elkayam, C. Kuhn, C. Kuscu, 
J. Ipsaro, C. Ashar, E. Greene [in collaboration with 
G.J. Hannon, R.A. Martienssen, Cold Spring Harbor 
Laboratory; J. Partridge, St. Jude Children’s 
Research Hospital] 
RNA interference (RNAi) has made an enormous im-
pact on biology in a very short period of time. Not only
are we still discovering new cellular pathways for the reg-
ulation of gene expression that use these pathways, but
RNAi has become an extraordinarily useful and simple
tool for gene silencing. Almost from its beginnings, peo-
ple have used genetics, biochemistry, molecular biology,
and bioinformatics to study the mechanism of RNAi and
related pathways. We argued, however, that in order to
obtain a true mechanistic understanding of these path-
ways, we must understand how the components of the
RNAi machinery worked at a molecular level. Therefore,
we embarked on structural and biochemical studies of
key proteins in the RNAi pathway.
During RNAi, long double-stranded RNA (dsRNA)
is processed to yield short (~19−31 nucleotides) dsR-
NAs that trigger the RNAi response. These short RNAs
become incorporated into effector complexes called
RNA-induced silencing complexes (RISCs). In mature
com- plexes of this type, a single-stranded RNA
(ssRNA) that is the antisense strand of the original
dsRNA is retained. This short RNA (a small interfering
RNA [siRNA] or a microRNA [miRNA]) then acts to
guide the RISC to its target through base complemen-
tarity. The best-characterized pathway, and the one that
is predominantly used for gene knockdown technology,
is a posttranscriptional genes silencing (PTGS) pathway
called “slicing.” Here, the RISC is targeted to the
mRNA and produces an endonucleolytic cut in the
mRNA target, thus preventing gene expression from
proceeding. Other RNAi silencing pathways such as
translational inhibition and transcriptional gene silenc-
ing (TGS) are also mediated through RISCs. In all cases,
these complexes contain a small ssRNA and an Arg-
onaute protein, which serve to define the RISC. In the
past few years, we have been studying Argonaute family
proteins, their complexes, and their roles in various
RNAi silencing pathways.
Proper segregation of chromosomes during cell divi-
sion depends on kinetochore assembly, which is, in turn,
dependent on heterochromatin assembly. In the fission
yeast Schizosaccharomyces pombe, assembly of centrometic
heterochromatin requires the RITS complex, a special-
ized RISC that physically anchors small noncoding RNAs
to chromatin. It consists of the Argonaute protein Ago1,
the chromodomain-containing protein Chp1, the novel
protein Tas3, and siRNAs derived from centromeric re-
peats. Our crystal structure of Chp1’s chromodomain in
complex with a peptide corresponding to histone H3 with
a trimethylated lysine 9, a histone mark characteristic of
heterochromatin, revealed extensive sites of contact that
contribute to Chp1’s high-affinity binding. We found that
this high-affinity binding is critical for the efficient es-
tablishment of centromeric heterochromatin, but pre-
assembled heterochromatin can be maintained when
Chp1’s affinity for H3K9me (trimethylated lysine-9 H3
peptide) is greatly reduced. Apart from the chromo-
domain, Chp1 had no recognizable domains. Our struc-
ture of the carboxy-terminal half of Chp1 in complex
with the Tas3 amino-terminal domain reveals Chp1’s
tight embrace of Tas3. It also reveals the presence of a PIN
domain at the carboxyl terminus of Chp1, which con-
tributes to posttranscriptional gene silencing of sub-
telomeric transcripts independently of RNAi. Our studies
suggest that the Chp1-Tas3 complex provides a solid and
versatile platform to recruit both RNAi-dependent and
RNAi-independent gene-silencing pathways for locus-
specific regulation of heterochromatin (Fig. 1).
STRUCTURAL BIOLOGY OF NUCLEIC ACID REGULATORY PROCESSES
L. Joshua-Tor C. Ashar C. Faehnle C. Kuhn S.-J. Lee A. Tocilj
D. Bahel S. Goldsmith C. Kuscu D. Sau D. Wah
E. Elkayam E. Greene T. Lavy T. Schalch J. Walleshauser
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The Different Faces of E1: A Replicative
Hexameric Helicase
S.-J. Lee
During DNA replication, two complementary DNA
strands are separated and each becomes a template for the
synthesis of a new complementary strand. Strand separa-
tion is mediated by a helicase enzyme, a molecular ma-
chine that uses the energy derived from ATP hydrolysis to
separate DNA strands while moving along the DNA. Our
early studies focused on recognition of the DNA replica-
tion origin by the helicase. Our crystal structure of the
replicative helicase E1 from papillomavirus bound to sin-
gle-stranded DNA and nucleotide molecules at the ATP-
binding sites provided a unique look into the mechanism
of translocation of this molecular machine along the DNA.
We continue to study this helicase and the role other
domains of the protein might have in helicase assembly
and activity. We are also using biophysical studies in so-
lution to understand the helicase in mechanistic detail
and to correlate with the structural framework.
A Transcriptional Switch Revisited
T. Lavy, D. Wah [in collaboration with R. Sternglanz, 
Stony Brook University; S.A. Johnston, Arizona State 
University; J. Rabinowitz, Princeton University;  
A. Caudy, University of Toronto]
A wealth of genetic information and some biochemical
analysis have revealed an elegant model for the GAL reg-
ulon of the yeast Saccharomyces cerevisiae, a beautiful
model system to understand transcriptional activation in
eukaryotes. While attempting to place these studies into
a structural and biochemical framework, we discovered
the involvement of a dinucleotide in the induction of this
classical transcriptional switch. Specifically, nicotinomide
adenine dinucleotide phosphate (NADP) appears to
jump-start the switch, which is then sustained by the pre-
viously known transducer-repressor (Gal3p-Gal80p) in-
teraction. This represents a real shift in how we think
about the GAL transcriptional switch and our textbook
view of how these switches work. In light of this discov-
ery, we would like to find the link between galactose in-
duction and the metabolic state of the cell that is sensed
by the repressor Gal80p. Our goal is to further delineate
the molecular interactions and possible enzymatic activ-
ities involved in induction, activation, and repression in
order to provide a mechanistic view of this switch. We are
using a combination of X-ray crystallography, biochem-
istry, genetics, and metabolomics to more fundamentally
understand this biological paradigm.
The most recent addition is our structure of the com-
plex between the Gal80p repressor, the Gal3p transducer,
and the two small-molecule ligands galactose and ATP
(Fig. 2). We have found that the interaction between the
Figure 1. Structure of the Chp1-Tas3 complex. (Top) Structure of
the Chp1-Tas3 core. (Bottom) Domain representation of Chp1 and
Tas3 depicting the carboxy-terminal domain (CTD) of Chp1 de-
fined by limited proteolysis and the amino-terminal domain (NTD)
of Tas3. Also indicated are the chromodomain (CD) of Chp1, the
GW domain, and the carboxy-terminal Tas3 α-helical motif (TAM).
Figure 2. The structure of the Gal80p-Gal3p-ATP-galactose het-
erotetramer complex. (Top) Ribbon diagram of the complex of a
dimer of Gal80p and a dimer of Gal3p is shown with the ATP and
galactose ligands. ATP and galactose are shown in stick repre-
sentations. (Bottom) A schematic representation of the Gal80p-
Gal3p-ATP-galactose heterotetramer complex illustrating the
mode of binding. Gal3p binds Gal80p in a closed conformation
with a b-strand from Gal3p extending the large b-sheet that forms
the Gal80p dimerization interface. 
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proteins occurs only when Gal3p is in a “closed state” in-
duced by ligand binding. Comparison to the free Gal3p
structure that we have also determined, and a previously
determined structure of a galactose and ATP-bound form
of the very similar active galactokinase, Gal1p, clearly
shows that ligand binding induces the closed state of
Gal3p. Furthermore, examination of the sites of Gal3p
constitutive mutations shows that these would favor a
closed state for Gal3p without necessitating ligand bind-
ing. On the other hand, Gal80p superrepressor mutants
appear to result from their inability to form a stable com-
plex with Gal3p, rather than tighter association with the
activator Gal4p.
Tali Lavy
We are now examining possible enzymatic activities
as well as other complexes involved in this classic tran-
scriptional switch. 
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Mechanisms of Constitutive 
and Alternative Pre-mRNA Splicing
RNA splicing is required for expression of most eu-
karyotic protein-coding genes. The spliceosome selects
authentic splice sites with very high fidelity, relying on
limited sequence information present throughout in-
trons and exons. In humans, >90% of genes are ex-
pressed via alternative splicing, giving rise to multiple
protein isoforms. The choice of alternative splice sites is
commonly regulated to alter gene expression, either tis-
sue-specifically or in response to a developmental pro-
gram or to signaling pathways. The fact that multiple
protein isoforms can be expressed from individual genes
demonstrates that the classical “one gene−one enzyme”
paradigm is no longer valid and provides an explana-
tion for the unexpectedly small number of genes un-
covered by genome-sequencing projects.
Both constitutive and alternative splicing mecha-
nisms involve numerous protein components, as well as
five noncoding RNA components that are part of small
nuclear ribonucleoprotein (snRNP) particles. The work
in our lab focuses on the identification and molecular
characterization of protein factors and sequence ele-
ments that are necessary for the catalysis and fidelity of
splicing and/or for the regulation of alternative splice
site selection. We are interested in how the spliceosome
correctly identifies the exons on pre-mRNA, and how
certain point mutations in either exon or intron se-
quences cause aberrant splicing, leading to various
human genetic diseases. Related areas of interest in-
clude the remodeling of mRNP architecture as a con-
sequence of splicing, which influences downstream
events such as nonsense-mediated mRNA decay
(NMD); the various roles of alternative splicing mis-
regulation in cancer; and the development of effective
methods to correct defective splicing or modulate al-
ternative splicing, especially in a disease context. A
summary of some of our recently published studies is
provided below.
Position-Dependent Splicing Activation
and Repression by RBFOX1 and RBFOX2
RBFOX1 and RBFOX2 are alternative splicing factors
that are predominantly expressed in brain and skeletal
muscle. They specifically bind the RNA element 
UGCAUG and regulate alternative splicing positively
or negatively in a position-dependent manner. The mo-
lecular basis for the position dependence of these and
other splicing factors on alternative splicing of their tar-
gets is not known. We explored the mechanisms of
RBFOX splicing activation and repression using a teth-
ering assay via bacteriophage MS2 coat protein. We
found that the Ala/Tyr/Gly-rich carboxy-terminal do-
main of RBFOX1/2 is sufficient for exon activation
when tethered to the downstream intron, whereas both
the carboxy-terminal domain and the central RRM
(RNA-recognition motif ) are required for exon repres-
sion when tethered to the upstream intron, thus reca-
pitulating the position-dependent properties of the
intact protein. Using immunoprecipitation and mass
spectrometry, we identified hnRNP H1, Raly, and
TFG as proteins that specifically interact with the car-
boxy-terminal domain of RBFOX1 and RBFOX2.
RNA interference (RNAi) experiments showed that
hnRNP H1 and TFG modulate the splicing activity of
RBFOX1/2, whereas Raly had no effect. However,
TFG is localized in the cytoplasm and likely modulates
alternative splicing indirectly.
Alternative Splicing and Cancer
Alternative splicing has an important role in cancer,
partly by modulating the expression of many oncogenes
and tumor suppressors and also because inactivating
mutations that affect alternative splicing of various
tumor suppressor genes account for some of the inher-
ited and sporadic susceptibility to cancer. In addition,
alternative splicing controls a metabolic switch charac-
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teristic of all cancer cells, known as the Warburg Effect.
Cancer cells preferentially metabolize glucose by aero-
bic glycolysis, characterized by increased lactate pro-
duction. This distinctive metabolism involves
reexpression of the embryonic M2 isozyme of pyruvate
kinase, in contrast to the M1 isozyme normally ex-
pressed in differentiated cells, and it confers a prolifer-
ative advantage to tumor cells. The M1 and M2
isozymes are expressed from a single PK-M gene
through alternative splicing of a pair of mutually ex-
clusive exons (exons 9 and 10, respectively). In collab-
oration with Lewis Cantley (Harvard Medical School)
and Matthew Vander Heiden (Massachusetts Institute
of Technology), we demonstrated that PK-M is regu-
lated by reciprocal effects on alternative exon use, such
that exon 9 is repressed and exon 10 is activated in can-
cer cells. We further showed that exonic, rather than in-
tronic, cis elements are the key determinants of PK-M
splicing isoform ratios. Using a systematic subexonic
duplication approach, we identified a potent exonic
splicing enhancer in exon 10, which differs from its ho-
mologous counterpart in exon 9 by only two nu-
cleotides. We identified SRSF3 as one of the cognate
factors and showed that this SR protein activates exon
10 and mediates changes in glucose metabolism. These
findings provided mechanistic insights into the com-
plex regulation of alternative splicing of a key regulator
of the Warburg Effect, and they also have implications
for other genes with a similar pattern of alternative
splicing.
SRSF1 (formerly SF2/ASF) is a prototypical serine-
and arginine-rich (SR) protein with important roles in
splicing and other aspects of mRNA metabolism. We
previously determined that SRSF1 is a potent onco-
protein with increased expression in many tumors, in-
cluding breast cancer. In collaboration with Senthil
Muthuswamy (Ontario Cancer Institute) and Rotem
Karni (Hebrew University, Jerusalem), we have investi-
gated SRSF1’s ability to transform human and mouse
mammary epithelial cells in vivo and in vitro. We
showed that SRSF1-overexpressing mouse COMMA-
1D cells form tumors after orthotopic transplantation
to reconstitute the mammary gland. In organotypic
three-dimensional (3D) culture, SRSF1-overexpressing
human MCF-10A cells form larger acini than control
cells, reflecting increased proliferation and delayed
apoptosis during acinar morphogenesis. We found that
these effects require the first RNA-recognition motif
and nuclear functions of SRSF1. SRSF1 overexpression
promotes alternative splicing of BIM and BIN1 iso-
forms that lack proapoptotic functions and contribute
to the acinar phenotype. We also demonstrated that
SRSF1 cooperates specifically with MYC to transform
mammary epithelial cells, in part by potentiating acti-
vation of the translation initiation factor oncoprotein
eIF4E. Furthermore, MYC and SRSF1 show correlated
expression in human breast tumors. 
SRSF1 is also up-regulated in lung carcinomas,
where it also shows significant correlation with MYC
expression. We have now demonstrated that SRSF1 is a
direct transcriptional target of MYC, providing a mech-
anistic basis for their correlated expression in cancer.
MYC knockdown down-regulates SRSF1 expression in
multiple lung cancer cell lines. MYC directly activates
transcription of SRSF1 through two noncanonical E-
boxes in its promoter. The resulting increase in SRSF1
protein is sufficient to modulate alternative splicing of
a subset of its target transcripts. In particular, MYC in-
duction leads to SRSF1-mediated alternative splicing
of the signaling kinase MKNK2. We further showed
that SRSF1 knockdown reduces MYC’s oncogenic ac-
tivity, decreasing proliferation and anchorage-indepen-
dent growth. These results suggest a mechanism for
SRSF1 up-regulation in a subset of tumors with ele-
vated MYC levels and identify SRSF1 as a critical MYC
target that contributes to its oncogenic potential by en-
abling MYC to regulate the expression of specific pro-
tein isoforms through alternative splicing.
Targeted Antisense Modulation
of Alternative Splicing 
for Therapeutic Purposes
Spinal muscular atrophy (SMA) is a common, autoso-
mal-recessive motor neuron degeneration disorder
caused by homozygous deletion or mutation of the sur-
vival-of-motor-neuron gene, SMN1. A closely related
SMN1 paralog, SMN2, is present in all patients and dif-
fers from SMN1 by a C to T transition in exon 7 that
causes substantial skipping of this exon, such that
SMN2 expresses only low levels of functional protein.
SMN2 decreases the severity of SMA in a copy-num-
ber-dependent manner. We have developed an antisense
method to increase the extent of exon 7 inclusion dur-
ing splicing of SMN2 transcripts, for eventual thera-
peutic use in SMA. This translational research is being
done in collaboration with Frank Bennett and col-
leagues (Isis Pharmaceuticals, California).
There is no effective treatment for SMA, but restor-
ing correct SMN expression in spinal cord motor neu-
rons was expected to be necessary and perhaps sufficient.
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However, pathologies outside of the nervous system
(CNS), including cardiovascular defects, were recently
reported in severe SMA mouse models and patients, re-
flecting autonomic dysfunction or direct effects in cardiac
tissues. We compared systemic versus CNS restoration
of SMN in a severe mouse model. We used an antisense
oligonucleotide (ASO), ASO-10-27, that effectively cor-
rects SMN2 splicing and restores SMN expression in
motor neurons after intracerebroventricular injection.
Systemic administration of ASO-10-27 to neonates ro-
bustly rescued severe SMA mice, much more effectively
than intracerebroventricular administration; subcuta-
neous injections extended the median life span by 25-
fold. Furthermore, neonatal SMA mice had decreased
hepatic Igfals expression, leading to a pronounced re-
duction in circulating insulin-like growth factor 1 (IGF-
1), and ASO-10-27 treatment restored IgfalsmRNA and
circulating IGF-1 protein to normal levels. These results
suggest that the liver is important in SMA pathogenesis,
underscoring the importance of SMN in peripheral tis-
sues, and demonstrate the remarkable efficacy of a prom-
ising drug candidate. This antisense compound already
entered Phase I clinical trials in December.
Splice Site Recognition
and Human Genetics
We continued to analyze the relationship between splice
site mutations and genetic diseases. In 1997, we dis-
covered a very rare class of introns with noncanonical
splice sites that are nevertheless recognized by the major
spliceosome, and we characterized one such intron in a
voltage-gated sodium channel gene, SCN4A. Masanori
Takahashi (Osaka University) recently identified an in-
sertion/deletion mutation in this intron in a myotonia
patient, and we collaborated with his group to charac-
terize the nature of the splicing defect responsible for
the phenotype. The mutation prevents correct recogni-
tion of the 5′ splice site, resulting in activation of cryp-
tic splice sites. This gives rise to a 35-amino-acid
insertion in the sodium channel, which functions ab-
normally and causes muscle disease.
Quantifying Alternative Splicing
by Next-Generation Sequencing 
Alternative splicing is a pre-mRNA maturation process
leading to the expression of multiple mRNA variants
from the same primary transcript. More than 90% of
human genes are expressed via alternative splicing.
Therefore, quantifying the inclusion level of every exon
is crucial for generating accurate transcriptomic maps
and studying the regulation of alternative splicing. In
collaboration with Michael Zhang (University of Texas,
Dallas), we developed SpliceTrap, a method to quan-
tify exon inclusion levels using paired-end RNA-Seq
data. Unlike other tools, which focus on full-length
transcript isoforms, SpliceTrap approaches the expres-
sion-level estimation of each exon as an independent
Bayesian inference problem. In addition, SpliceTrap can
identify major classes of alternative splicing events
under a single cellular condition, without requiring a
background set of reads to estimate relative splicing
changes. We tested SpliceTrap both by simulation and
real data analysis and compared it to state-of-the-art
tools for transcript quantification. SpliceTrap demon-
strated improved accuracy, robustness, and reliability in
quantifying exon-inclusion ratios.
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Most cellular processes can trace their beginnings to the
nucleus where a gene is activated, resulting in the pro-
duction of an RNA molecule, some of which encode
for proteins, whereas others are functional in the form
of RNA. Although much biochemical information is
available regarding many of the factors involved in gene
expression, the spatial and temporal parameters that in-
fluence gene expression and the role of noncoding
RNAs in regulating gene expression are just beginning
to be elucidated. During the past year, our research has
focused on two main areas: (1) examining the nuclear
organization of mouse embryonic stem cells and tran-
sitions to neural progenitor cells and (2) developing and
characterizing a loss-of-function mouse model of a long
nuclear-retained noncoding RNA.
Organization and Expression 
of Genes in Embryonic Stem Cells
and Neural Progenitor Cells
M. Eckersley-Maslin, M. Bodnar, J. Bergmann, Z. Lazar
We are interested in developing a complete under-
standing of the spatial and temporal events involved in
the regulation of gene expression in embryonic stem
cells (ESCs) as they transit from the pluripotent state to
the differentiated state. Such an understanding will pro-
vide important insight into the underlying principles
of nuclear organization and gene expression that will
be critical to fully reveal the signals that regulate the
transition from the pluripotent state to the differenti-
ated state. Pluripotent ESCs are characterized by an ex-
tremely dynamic chromatin organization and nuclear
morphology. The irregular nuclear shape of the ESC
contains many invaginations and protrusions, which
are highly dynamic. Upon differentiation, this nuclear
architecture transitions to a smooth and rigid form,
coupled with a decrease in the open chromatin config-
uration, suggesting a tight connection between nuclear
structure and the differentiation program. The major
structural component of the nuclear periphery is the
nuclear lamina that is composed of lamin proteins,
which also have important functions in gene regulation
and chromatin organization. Loss of lamin proteins re-
sults in severe developmental defects, and mutation of
Lamin A/C is associated with premature aging in indi-
viduals with progeria (for review, see Dechat et al., Cold
Spring Harb Perspect Biol 2: a000547 [2010]). Although
ESCs express lamin B1 and B2, lamin A/C has been re-
ported to be completely absent in ESCs, with levels in-
creasing during embryogenesis (Constantinescu et al.,
Stem Cells 24: 177 [2006]). This purported lack of
lamin A/C in ESCs has served as a landmark for mod-
els and hypotheses explaining pluripotency, chromatin
dynamics, and ESC nuclear plasticity (for review, see
Mattout and Meshorer, Curr Opin Cell Biol 22: 1
[2010]).
We sought to systematically reinvestigate whether
ESCs express lamin A/C. Unexpectedly, we found that
both lamin A and lamin C transcripts in ESCs were
readily detected by quantitative reverse transcrip-
tase–polymerase chain reaction (q-RT-PCR) at a level
similar to that of the neural progenitor cells (NPCs).
Examination of whole-genome poly(A)+ RNA-sequenc-
ing data, as well as published data sets from mouse and
human ESCs, confirmed that full-length lamin A/C
mRNA was expressed. Immunoblotting using three in-
dependent antibodies demonstrated that lamin A/C
mRNA transcripts were efficiently translated into both
protein isoforms. As a control, no signal was seen in a
lamin A knockout (lmna–/–) ESC line, confirming an-
tibody specificity and purity of the ESCs from mouse
embryonic fibroblast (MEF) feeder cells. Both AB2.2
and lmna–/– ESCs expressed the pluripotency marker
Oct4. Lamin A/C was also detected in three early-pas-
sage ESC lines, four additional well-established ESC
lines, and an iPS cell line. Finally, expression was vali-
dated in individual cells by immunofluorescence.
Lamin A/C was detected at the nuclear periphery of all
Oct4-positive ESCs but not in lmna–/– ESCs. Correct
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localization was further confirmed in additional ESC
lines and also with an independent antibody. Notably,
ESCs have significantly lower levels of Lamin A/C
when compared to MEFs, which may explain why pre-
vious reports have failed to detect Lamin A/C in ESCs.
In addition to examining the organization of the nu-
clear periphery in ESCs, we have also initiated an analy-
sis of the dynamics of specific genes that change their
expression profile as cells transit from the pluripotent
state to the differentiated state. We have performed
RNA sequencing screens to identify candidate protein-
coding genes and genes encoding noncoding RNAs
(ncRNAs) that change their expression levels upon dif-
ferentiation. We are currently in the process of charac-
terizing and prioritizing these candidates, and during
the next year, we will perform a series of molecular and
cell biological studies to identify interesting mecha-
nisms of gene regulation. 
Generation and Characterization
of a Knockout Mouse Model Lacking 
Malat1, an Abundant Long Noncoding RNA
B. Zhang, G. Arun, Y. Mao, Z. Lazar [in collaboration with 
C. Zhang, The Rockefeller University]
Genome-wide studies during the last 5 years have indi-
cated that the majority of the human and mouse genomes
are transcribed, yielding a complex network of transcripts
that include tens of thousands of ncRNAs with no pro-
tein-coding capacity (for review, see Orom and Shiekhat-
tar, Curr Opin Genet Dev 21: 194 [2011]). Long non-
coding RNAs (lncRNAs), the largest and most complex
class of ncRNAs, are mRNA-like RNA polymerase II
transcripts ranging in size from 200 nucleotides to >100
kb in various cell types (for review, see Wilusz et al., Genes
Dev 23: 1494 [2009]). The majority of lncRNAs are ex-
pressed at very low levels, some as low as one copy per
cell, and these RNAs generally exhibit poor primary se-
quence conservation over evolution. lncRNAs have been
implicated in numerous molecular functions, including
modulating transcriptional patterns, regulating protein
activities, serving structural or organizational roles, alter-
ing RNA processing events, and serving as precursors to
small RNAs (for review, see Wilusz et al., Genes Dev 23:
1494 [2009]).
Malat1 (metastasis-associated lung adenocarcinoma
transcript 1), also known as Neat2 (noncoding nuclear-
enriched abundant transcript 2), is located on mouse
chromosome 19qA (human chromosome 11q13.1), is
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evolutionarily conserved among mammals, and is
highly expressed in many tissues. MALAT1 is also up-
regulated in several human cancers, suggesting that it
may have an important function during development
and cancer progression. Previous studies in cell lines
have indicated proliferative (Yang et al., Cell 147: 773
[2011]) as well as antiproliferative (Tripathi et al., Mol
Cell 39: 925[2010]) functions of MALAT1. However,
the physiological function of Malat1 lncRNA at the tis-
sue and organismal levels has not been investigated.
To assess the in vivo function of mouse Malat1, we
established a loss-of-function mouse genetic model
using homologous recombination in ES cells. We found
the recombination rate at the Malat1 locus to be 43%,
much higher than other loci in the genome. The mu-
tant mice, lacking a 3-kb 5′ region of the Malat1 gene
including its promoter region, were genotyped by
Southern blotting and tail DNA PCR analyses. North-
ern blotting results showed that the Malat1 transcript is
completely depleted in Malat1–/– tissues, indicating that
Malat1– is a null allele. Malat1–/– mice are grossly nor-
mal and fertile. Offspring of heterozygous breedings
follow Mendelian segregation, suggesting that deletion
of Malat1 does not affect mouse prenatal and postna-
tal viability. Breedings between Malat1 homozygotes
and wild type produce normal-sized litters, indicating
that Malat1–/– mice are fertile. Further cell biological
and biochemical analyses indicated that mouse Malat1
is not essential for nuclear speckle assembly, regulating
the level and phosphorylation of SR splicing factors, or
cell proliferation. 
To assess the level of Malat1 lncRNA in mouse liver
and brain cortex, we performed RNA-Seq profiling and
obtained ~300 million paired-end reads for mouse liver
and brain cortex. Reads from protein-coding genes,
known housekeeping regulatory RNAs, small RNA
precursors, and repeats were filtered out to produce
lncRNA profiles. Malat1 comprised ~15% of the
lncRNA sequence reads in liver. The reads per kilobase
million (RPKM) for Malat1 in liver are extremely high
as compared to several housekeeping protein-coding
genes (Malat1, 109 RPKM; b-Actin; 177 RPKM;
Gapdh, 21 RPKM). Genome-wide expression and
splicing profiling demonstrated that Malat1 loss results
in minimal alterations in global gene expression and
pre-mRNA splicing. However, deletion of Malat1 re-
sulted in a nearly twofold up-regulation of a small
group of genes in the mouse brain cortex. Many of
these genes reside within a 230-kb region of the Malat1
gene, indicating a potential cis regulatory role of Malat1
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gene transcription. Ongoing studies will assess the po-
tential role of the Malat1 gene locus in regulating the
expression of these genes.
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The papillomaviruses are a group of viruses that infect
and transform the basal epithelium, inducing prolifer-
ation of the cells at the site of infection. The resulting
tumors (warts) are in most cases benign and will usually
regress after some time, but certain types of human pa-
pillomaviruses (HPVs) give rise to tumors that are
prone to progress toward malignancy, especially fre-
quently cervical carcinoma. Indeed, HPV infection ap-
pears to be a necessary cause of invasive cervical
carcinoma and thus represents one of the few firmly 
established links between viral infections and the de-
velopment of cancer.
An impediment to the study of papillomaviruses has
been the inability to define simple in vitro cell culture
systems for analysis of the viral life cycle. These viruses
normally require specialized differentiating cells that
can be generated in cell culture only with difficulty.
However, for a bovine papillomavirus (BPV-1), a con-
venient cell culture system exists where viral gene ex-
pression, oncogenic transformation, and viral DNA
replication can be studied. Thus, BPV has become a
useful model for these aspects of the viral life cycle. The
DNA replication properties of the papillomaviruses
show some unique and interesting characteristics. As
part of their normal life cycle, these viruses can exist in
a state of latency, which is characterized by maintenance
of the viral DNA as a multicopy plasmid in infected
cells. The copy number of the viral DNA is tightly con-
trolled and the viral DNA is stably inherited under
these conditions. Papillomaviruses therefore provide a
unique opportunity to study plasmid replication in
mammalian cells. In addition, the viral DNA replica-
tion machinery represents one of the most promising
targets for antiviral therapy.
In previous years, we have reported the characteri-
zation of the papillomavirus replicon and the identifi-
cation of the viral components that are required for viral
DNA replication. In recent years, we have directed our
attention toward the biochemical events that are asso-
ciated with initiation of DNA replication. We are
studying the biochemical properties of the viral E1 and
E2 proteins and how these two proteins interact with
the viral origin of DNA replication and with the cellu-
lar replication machinery to generate initiation com-
plexes. Our studies demonstrate that the E1 protein has
all the characteristics of an initiator protein, including
ori recognition, DNA-dependent ATPase activity, and
DNA helicase activity. The transcription factor E2,
whose precise function has remained more elusive, ap-
pears to serve largely as a loading factor for E1.
Through direct physical interactions with both E1 and
the ori, E2 provides sequence specificity for the forma-
tion of the initiation complex.
We are currently attempting to elucidate how the E1
and E2 proteins orchestrate the precise biochemical
events that precede initiation of DNA replication at the
viral ori. These events include binding of the initiator
to the ori, the initial opening of the DNA duplex (melt-
ing), and the assembly and loading of the E1 replicative
helicase at the replication fork. Our studies so far indi-
cate that these activities are generated in an ordered
process that involves the sequential assembly of E1 mol-
ecules on the ori. This sequential assembly generates
different complexes with different properties that in
turn recognize ori, destabilize the double helix, and
function as the replicative DNA helicase.
Phosphorylation by the Protein Kinase
CK2 Regulates the DNA-Binding Activities
of the Papillomavirus E1 and E2 Proteins
The viral E1 and E2 proteins are site-specific DNA-
binding proteins that recognize specific binding sites in
the viral genome and together control viral gene ex-
pression and viral DNA replication. E2 binds to mul-
tiple binding sites in the E2-dependent enhancer and
activates or represses viral gene expression, whereas E1
binds to a small cluster of sites in the origin of DNA
replication (ori) and prepares the ori for initiation of
DNA replication. E1 also functions as the replicative
DNA helicase. The viral life cycle consists of at least
two distinct stages. In the latent stage, the early viral
genes are expressed and the viral DNA is replicated at
a low level. In the vegetative state, the late viral genes
(such as the capsid proteins) are expressed, the viral
DNA is replicated at a very high level, and new virus
particles are assembled. It is believed that the transition
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from the latent stage to the vegetative stage is controlled
by the differentiation of the infected cells and likely in-
volves changes in cellular gene expression. However, the
precise signals that trigger the switch to vegetative repli-
cation are unknown.
We wanted to determine whether phosphorylation
of the viral E1 protein has a role in the viral life cycle.
It is well established that E1 can be phosphorylated by
the protein kinase CK2 in vitro. To determine what ef-
fects CK2 phosphorylation has on E1, we subjected re-
combinant E1, purified from Escherichia coli, to CK2
phosphorylation and tested the protein for various in
vitro assays related to initiation of DNA replication. In-
terestingly, CK2 phosphorylation of E1 resulted in the
loss of site-specific DNA-binding activity. To map the
inactivating phosphorylation sites, we tested the amino-
terminal half of E1 (E11–308), which contains the E1
DNA-binding domain (E1 DBD), for binding with or
without phosphorylation. This fragment was also inac-
tivated for DNA binding, demonstrating that the in-
activating phosphorylation sites were present in the
amino-terminal half of E1. In collaboration with C.
Ruse (CSHL Proteomics Facility), we performed phos-
phorylation analysis of CK2-phosphorylated E1 by
mass spectrometric analysis and identified multiple
phosphorylation sites in the amino-terminal domain,
each of which was individually capable of inactivating
E1 DNA binding. Interestingly, none of these phos-
phorylation sites were present within the E1 DBD, in-
dicating that phosphorylation events outside of the E1
DBD inactivate DNA binding. Consistent with this re-
sult, the isolated E1 DBD (E1142–308) could not be in-
activated by CK2 phosphorylation. The inactivation of
DNA binding by CK2 phosphorylation is conserved
also in the E1 proteins from HPV-11 and HPV-31, in-
dicating that the mechanism is conserved for other pa-
pillomavirus E1 proteins.
Inspired by this result, we next examined the effect
of CK2 on the viral E2 protein. Previous studies have
indicated that CK2 phosphorylation affects the half-
life of E2. Instead, we found that similar to the effect on
E1, CK2 phosphorylation resulted in complete loss of
E2 DNA-binding activity. Also as in E1, the two phos-
phorylation sites responsible for the inactivation of
DNA binding are located outside the E1 DBD,
demonstrating that the inactivation of the DBD likely
involves structural rearrangements.
To determine precisely what role CK2 phosphoryla-
tion of E1 and E2 has in the viral life cycle, we mutated
all of the CK2 sites in the amino terminus of E1 and
the two sites in E2 in the context of the papillomavirus
genome. We then tested the mutant genomes for viral
DNA replication and transformation in a cell culture
system that represents the latent stage of the viral life
cycle. The phosphorylation site mutations in E2 showed
greatly increased levels of viral DNA replication and also
increased the morphological transformation as measured
by focus formation, indicating that phosphorylation at
these sites has an important role in the viral life cycle.
Surprisingly, however, the phosphorylation mutations
in the amino terminus of E1 had no obvious phenotype.
Because the DNA-binding inactivation is conserved, the
lack of a clear phenotype of these E1 mutations likely is
due to the fact that only a part of the viral life cycle (the
latent stage) is reproduced in these assays.
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Our genome contains the genetic information that is
transmitted from one cell to its two daughter cells dur-
ing cell proliferation and development of tissues and
organs. The genetic information in DNA is also copied,
and half of the duplicated information is passed on
from a parent to a child. The process of duplicating the
DNA double helix—the process central to genome in-
heritance—is therefore of fundamental importance and
has been the focus of research in this laboratory for 31
years at Cold Spring Harbor. DNA is wrapped up with
proteins that form chromatin, and chromatin struc-
tures, which happen to be different in the various cell
types in our body, are also inherited by daughter cells as
we grow from a fertilized egg to produce the ~100 tril-
lion cells in our body. Thus, the information transfer
must be accurate and efficient. This year, progress has
been made on understanding how inheritance of ge-
netic information influences the fate of cells during de-
velopment, how the origin recognition complex (ORC)
cooperates with Cdc6 to recognize DNA, and how es-
sential DNA replication proteins can be studied in the
mouse.
Inheritance of Chromatin 
and Gene Silencing
Previous research from this laboratory had uncovered
how the histone proteins are assembled during the
process of DNA replication. Each sister chromatid, the
products of replicating a DNA molecule, must have its
complement of histone proteins copied along with the
DNA. The multisubunit chromatin assembly factor-1
(CAF-1) was shown to bind histones and load a dimer
pair of newly synthesized histones H3/H4 onto DNA
to form a tetramer that then recruits two dimers of the
H2A/H2B histones to form a nucleosome containing
eight histones (H2A, H2B, H3, H4)2 and DNA. This
process occurs immediately after the DNA replication
fork copies the double helix of DNA and de novo nu-
cleosomes can be assembled on both sister chromatids,
although in cells, the parental H3/H4 tetramers are in-
herited. Thus, the two sisters end up with half the
H3/H4 tetramers in new nucleosomes coming from the
parental chromatin and half synthesized de novo. Be-
cause histone modifications can influence gene expres-
sion and chromosome structure, this inheritance may
be important for developmental patterning.
This year, we hosted a graduate student from Robert
Horvitz’s laboratory at the Massachusetts Institute of
Technology to perform some biochemical studies re-
lated to CAF-1-mediated chromatin assembly. Shunji
Nakano had isolated mutants of the worm Caenorhab-
ditis elegans that failed to establish an asymmetric neu-
ronal cell fate during development. Normally during
development, a cell called ABaraap divides four times to
produce 16 cells, two of which die via programmed cell
death and two become bilaterally asymmetric, with one
cell on the left side of the body becoming an epithelial
cell and its symmetrical distant cousin on the right side
of the body becoming an M1 motor neuron. The mu-
tants that failed to establish the motor neuron, and in-
stead produced an additional epithelial cell in its place,
mapped to a defective histone H3 gene, one of 24 genes
encoding histone H3 in the worm genome. Biochemi-
cal characterization of the histone H3 mutant showed
that it was a dominant inhibitor of the CAF-1-medi-
ated DNA replication-dependent chromatin assembly.
Furthermore, Nakano and Horvitz showed that deple-
tion of CAF-1 subunits during worm development
yielded the same defect in bilateral asymmetry of the
M1 motor neuron. These results have significant im-
plications for the mechanism of cell fate determination,
particularly of bilateral asymmetry. Because the known
transcription factors that determine the M1 motor neu-
ron cell fate were not altered by the histone H3 or CAF-
1 mutations, it is likely that a chromatin structure is
established during DNA replication in S phase of the
M1 mother cell so that one sister chromatid is marked
and transmitted to the M1 postmitotic cell, thereby al-
lowing a neuronal fate to be established.
In previous years, we had shown that CAF-1 medi-
ated nucleosome assembly during DNA replication re-
quired an interaction between CAF-1 and the prolifer-
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ating cell nuclear antigen (PCNA), a DNA polymerase
clamp. PCNA is loaded and unloaded onto the DNA
every time a DNA polymerase starts synthesis, and thus,
because of the discontinuous synthesis of Okazaki frag-
ments on the lagging strand versus continuous DNA
synthesis on the leading strand of a DNA replication
fork, the two sister chromatids will have different
amounts of PCNA topologically linked to them before it
is unloaded. The strand bias of PCNA therefore may
translate into a strand bias in the nature of nucleosomes
assembled on the leading- and lagging-strand products.
Such a strand bias could provide asymmetry in the two
sister chromatids that are inherited by the daughter cells,
leading to bilateral asymmetry of cell fate. It is interest-
ing to compare the phenotype in the specific lineage in
C. elegans and the phenotype of CAF-1 mutants in the
plant Arabidopsis that produce plants with highly vari-
able, epigenetically determined cell fates.
Conditional Depletion of Essential
Genes in Mice
During a screen to identify new DNA replication pro-
teins in human cells using Greg Hannon’s (CSHL)
short hairpin RNA (shRNA) library, we identified
genes that when inhibited could completely block the
proliferation of all human cells. Surprisingly, depletion
of substantial amounts of known DNA replication pro-
teins, even in some cases up to 80%−90%, allowed
some cell proliferation of cells in culture. In the unbi-
ased screen using Hannon’s version-3 shRNA library
and some custom-made shRNAs, we identified multi-
ple shRNAs that depleted either subunits of replication
protein A (RPA) or ribonucleotide reductase as being
the most potent in inhibiting cell proliferation. RPA is
a protein that we and other investigators identified in
the late 1980s as an essential DNA replication, repair,
and recombination protein that is also the primary sen-
sor of single-stranded DNA for checkpoint signaling
Thus, depleting this protein compromises multiple
processes in the cell and prevents checkpoint signaling,
blocking progression through mitosis and thereby en-
hancing cell death.
In collaboration with Scott Lowe’s laboratory at
CSHL, we showed that shRNAs directed to the small-
est subunit of RPA, the RPA3 protein, blocked tumor
cell proliferation in vivo. We also made several versions
of mice in which the RPA3 shRNAs were condition-
ally expressed in all tissues from doxycycline-inducible
promoters by feeding the mouse doxycycline in its
drinking water. Thus, mice could be bred and grown
to adulthood before adding doxycycline to allow for
normal development and cell proliferation, but when
the shRNAs were induced in adult mice, they lost
weight rapidly due to loss of cell proliferation in gut ep-
ithelial cells. Removal of the doxycycline turned off the
transgene and the mice could recover the weight loss,
with concomitant proliferation of the gut epithelial
cells. Thus, this inducible genetic system allows for the
conditional expression of any gene and thereby provides
the ability to examine the phenotype of depleting es-
sential proteins in vivo. It also offers the opportunity
to assess the side effects of drug targets in adult mice if
shRNAs directed to the drug target are conditionally
expressed in all tissues.
Origin Recognition Complex
ORC is a key protein that cooperates with Cdc6 and
Cdt1 to load a double hexamer of the MCM2-7 complex
onto origin DNA to form a pre-replicative complex (pre-
RC). Pre-RC assembly happens during mitotic exit or
during G1 phase and is a precursor to the initiation of
DNA replication in S phase. In collaboration with
Huilin Liu at Brookhaven National Laboratory (BNL)
and former postdoctoral fellow Christian Speck at the
MRC Laboratory at Hammersmith Hospital in London,
we have determined the cryo-electron microscopy (cyro-
EM) structure of ORC bound to an origin DNA and of
the ORC-Cdc6 complex bound to origin DNA (see Fig.
1). The ORC-DNA structure shows that ORC is a flat,
crescent-shaped structure that has the Orc1 amino ter-
minus containing the BAH (bromo adjacent homology)
domain located in the center of the crescent. In contrast,
the ORC-Cdc6-DNA structure, obtained at higher res-
olution than the ORC-DNA structure, shows that Cdc6
occupies the position previously occupied by the BAH
domain, pushing it to the back of the structure. The
ORC-Cdc6 on DNA forms a flat ring shape with many
of the subunits visible as taking on the structure of typi-
cal AAA+ proteins. New density, possibly Orc6 that has
moved from the middle of the ORC crescent, is pro-
truding from the front of the ring. Interestingly, Steve
Bell’s laboratory at MIT has shown that Orc6 binds two
molecules of Cdt1, possibly explaining how the pro-
truded Orc6 might recruit two MCM2-7 hexamers. The
ORC-Cdc6 structure of DNA was of sufficient clarity
that we could model into the cryo-EM structure the X-
ray crystal structure of the AAA+ Orc1/Cdc6 protein
from an archaeal species. The Orc1/Cdc6 protein from
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archaea is the primary origin recognition protein and it-
self forms a C-shaped molecule when bound to DNA.
We proposed that five of the six ORC subunits (all but
Orc6) form a C-shaped structure similar to the archaeal
proteins when bound to DNA. Although we could not
see the DNA density in the cryo-EM structure of ORC-
Cdc6, we have a good working model of how ORC and
Cdc6 bind to DNA.
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Figure 1. Model of the yeast origin recognition complex com-
plexed with double-stranded DNA incorporating a sequence that
encodes the replication origin. The 3D structure of the complex
with bound DNA was determined by single-particle cryo-elec-
tron microscopy in collaboration with Dr. Huilin Li at Stonybrook
University and Brookhaven National Laboratory. The surface en-
velope is shown. The locations of the ORC subunits are shown,
and superimposed molecular structures are models of the ORC
AAA+ subunits (determined by X-ray crystallography for a related
archaeal protein). The ORC is a six-protein machine with a
slightly twisted half-ring conformation that is proposed to wrap
around and bend ~70 bp of double-stranded DNA. When a repli-
cation initiator protein Cdc6 (left-hand side) binds ORC, the ring
is now complete and ready to load the MCM2-7 hexamer pro-
tein onto the DNA. The DNA is modeled into the determined
ORC-Cdc6 protein structure.
Cancer genetics focuses on understanding the genetic basis of cancer, cancer progression, and devel-
opment of resistance to chemotherapy.
Gregory Hannon is a pioneer in the study of RNA interference (RNAi), a process by which dou-
ble-stranded RNA molecules induce gene silencing. Hannon and colleagues have elucidated key el-
ements of RNAi machinery and have led the way in using RNAi to study cancer biology and genetics,
generating libraries of short-hairpin RNAs (shRNAs) that have been widely applied in gene silenc-
ing studies. During the past several years, the Hannon lab has focused on roles of small RNAs in
germ cells, which tend to have the most elaborate set of small RNA pathways of any cell type. They
have discovered an essential role for pseudogenes in producing small RNAs that are critical for proper
oocyte development and an elegant small-RNA-based immune system that guards the genome against
transposable elements. The Hannon lab also strives to understand the biology of cancer cells, with a
focus on breast and pancreatic cancer. Hannon lab scientists are exploring the roles of small RNAs as
oncogenes and tumor suppressors and are exploiting the RNAi libraries that they have developed to
identify new therapeutic targets for specific disease subtypes. Additionally, they are taking genetic
approaches to understand the biology of resistance to currently used targeted therapies. Another re-
search thrust of the Hannon team is to exploit the power of next-generation sequencing to understand
the biology of the mammalian genome. Their efforts range from the identification of new classes of
small RNAs to understanding human evolution and diversity. In the last year, they have placed a
major emphasis on the evolution of the epigenome and its role in driving cell-fate specification.
Scott Lowe’s lab studies cancer gene networks and determines how genetic lesions affecting these
networks contribute to tumor development and resistance to therapy. Lowe’s team has adapted RNAi
technology to produce animal models in which genes can be switched on and off in a spatial, tem-
poral, and reversible manner, and they have used this to study the impact of tumor suppressor genes
on tumor development and maintenance. The team has also spearheaded a collaborative effort in-
volving other CSHL labs to identify novel tumor suppressor genes. They combined their earlier in-
tegrated oncogenomics approach to human liver cancers with RNAi-based screening in a mouse
model. Lowe’s lab also studies cellular senescence, a potentially powerful mechanism for suppres-
sing tumor formation. Lowe lab investigators have discovered that the gene-suppressing activity of
the retinoblastoma (RB) gene can be traced to its ability to trigger senescence. The team has also
demonstrated that senescence helps to limit wound-healing responses in liver disease, a finding that
suggests that growth arrest has functional relevance, in addition to its role in cancer, in the mainte-
nance of tissue homeostasis following damage.
Robert Lucito has had an important role along with Michael Wigler in developing innovative
technologies, including RDA, ROMA, MOMA and CGH, which have proven to be valuable to can-
cer researchers worldwide. As an experimentalist, Lucito conducts studies using these techniques to
detect copy-number changes in large sets of human ovarian and pancreatic cancer tissue samples. His
lab also has turned its attention to epigenetics, specifically to the study of methylation throughout
the genome. When methyl groups in sufficient numbers attach to cytosine bases in DNA, the pack-
ing of DNA into the chromosomes can be altered, reducing the levels at which methylated genes are
expressed. Under circumstances that Lucito is exploring, this may be a means by which normally pro-
tective tumor suppressor genes are turned off, rendering cells tumorigenic.
Alea Mills is studying genetic pathways important in cancer, aging, and autism, identifying the
genetic players and determining how aberrations in their functions culminate in human disease.
Through innovative use of a technique called “chromosome engineering,” this year the Mills group
has demonstrated that one of the most common genetic alterations in autism—deletion of a 27-gene
cluster on chromosome 16—causes autism-like features in mice. The mouse models also revealed a
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potential link between the 16p11.2 deletion and survival because about half of the mice died fol-
lowing birth. Previously, Mills used chromosome engineering to identify a tumor suppressor gene
that had eluded investigators for three decades. The gene, called Chd5, was shown by Mills to reg-
ulate an extensive cancer-preventing network. The epigenetic role of Chd5 in development, cancer,
and stem cell maintenance is currently being investigated. The Mills lab is also studying p63 pro-
teins, which regulate development, tumorigenesis, cellular senescence, and aging in vivo. Mills lab
members succeeded in halting the growth of malignant tumors by turning on production of one of
the proteins, called TAp63, that is encoded by the p63 gene. During the last year, they discovered
that a different version of p63, called DNp63, reprograms stem cells of the skin to cause carcinoma
development—the most prevalent form of human cancer. Modulation of these proteins may offer
new methods of treatment for human malignancies.
Scott Powers’ work focuses on gene mutations that cause cancer and factors that influence re-
sponses to specific anticancer drugs. His lab uses technologies that probe the entire genome to iden-
tify candidate cancer genes and evaluate their functional role in cell transformation and tumor
biology. They also use whole-genome technologies to guide development of novel cancer diagnos-
tics and therapeutics. Using DNA copy-number analysis, the Powers group pinpoints novel ampli-
fied oncogenes and then applies functional studies to address the validity of candidate genes and the
mechanisms by which they are implicated in oncogenesis. They have successfully applied this ap-
proach to liver, colon, and lung cancer. This past year, Powers and colleagues identified a strategy
for targeted molecular therapy in liver cancer based on tumor dependency after amplification of the
FGF19 oncogene. Powers has also had an important role in the development of a distinctive CSHL
approach to the functional study of cancer genes. Called integrative oncogenomics, it is a rapid
large-scale screen for genes that are deleted or amplified in human cancers and suspected of being
tumor suppressors, in the case of deletions, or oncogenes, in the case of amplifications.
Michael Wigler, with James Hicks and others, studies human cancer and genetic disorders from
a population genomics perspective. Their cancer effort focuses on breast and prostate cancer (the lat-
ter jointly with Lloyd Trotman) and involves collaborative clinical studies (with local, national, and
international collaborators) to discover mutational patterns predicting treatment response and out-
come. The lab also develops methodology for single-cell genomic and RNA analysis aimed at de-
tecting cancer cells in bodily fluids such as blood and urine. This has led to major potential
applications for the early detection of cancer and to monitoring its recurrence and response to ther-
apy during and after treatment. Single-cell analysis has also led to insights about the clonal evolu-
tion and heterogeneity of cancers and may lead to a better understanding of initiation, progression,
and metastasis, as well as shed light on the stem cell hypothesis of cancer and host responses. The
Wigler lab’s genetic efforts are largely focused on determining the role of de novo mutation in pe-
diatric disorders with a strong genetic contribution. They study autism as part of a large study of sim-
plex families organized by the Simons Foundation, and they also study congenital heart disease and
pediatric cancers with collaborators at, respectively, Columbia University and Memorial Sloan-Ket-
tering Cancer Center. In collaboration with Alea Mills, they helped to create a mouse model for one
of the most common genetic abnormalities contributing to autism. Recent work has confirmed and
extended the team’s previous observations on the role of de novo copy-number variation in autism,
with similar results in the other disorders. In a large-scale exome sequencing project with W. Richard
McCombie here at CSHL and with the Genome Sequencing Center at Washington University in
St. Louis, the team has proven the role of small-scale de novo mutations that disrupt genes in autism.
Results overall confirm their previous genetic models for autism incidence and identify strong can-
didate mutational targets from which biological models of autism can be made and tested. 
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My lab continues to focus on three distinct areas. First,
we study RNA biology, with a focus on noncoding
RNAs. Second, we study the roles of small RNAs in can-
cer, mainly breast cancer, and use small RNAs as tools to
uncover tumor-specific vulnerabilities as potential ther-
apeutic targets. Third, we develop technologies, mainly
in the areas of mammalian genetics and genomics, with
a particular focus on next-generation sequencing.
We said goodbye to a number of labmates this year.
Sihem Cheloufi and Ingrid Ibarra each completed their
Ph.D. degrees and went on to postdoctoral fellowships
at Harvard and Stanford, respectively. Elena Tonin and
Elena Piccinin joined us for a brief period and then re-
turned to Roberta Maestro’s lab at the CRO, and Julia
Hahn spent a time as a diploma student in the lab. Flo-
riane Pelon, Sai Chen, and Thomas Dowling were our
undergraduate summer students. Sung Wook Chi and
Adam Rosebrock each left for independent positions
after remarkably brief stints as postdoctoral fellows.
We were joined by Nik Rozhkov, Elena Rozhkova,
Ilaria Falciatori, Simon Knott, Leah Sabin (aka Sabine),
and Delphine Fagegaltier as postdoctoral fellows and
Myke Malave as a computer scientist.
A selected set of laboratory projects are described in
detail below.
A Genome-Wide RNAi Screen
Reveals Components of the
Somatic piRNA Pathway
P.M. Guzzardo, F. Muerdter
Piwi-interacting RNAs (piRNAs), together with Piwi-
clade Argonaute proteins, constitute an evolutionarily
conserved, germline-specific small RNA silencing sys-
tem. The piRNA pathway is implicated in gene silenc-
ing, particularly of repetitive elements, as well as
germline differentiation, and maintenance of germline
stem cells. Accordingly, mutations in Piwi almost uni-
versally lead to sterility and germ cell loss.
In Drosophila melanogaster, primary piRNA biogen-
esis involves the processing of a primary transcript into
mature small RNAs by factors that remain elusive. To
search for proteins involved in biogenesis or down-
stream effector pathways, we performed a comprehen-
sive genome-wide RNA interference (RNAi) screen of
more than 40,000 double-stranded RNAs (dsRNAs) in
a cell line derived from Drosophila ovaries. This cell line,
the ovarian somatic sheet (OSS) cell line, expresses Piwi
but not Aubergine or Argonaute3. Consequently, these
cells do not show signatures of secondary piRNA bio-
genesis or the ping-pong cycle.
Using a quantitative polymerase chain reaction
(qPCR)-based readout, we identified ~100 genes that
upon knockdown lead to the derepression of a somati-
cally expressed transposon. As part of this list, we con-
firm all known somatic piRNA pathway components.
The newly identified genes fall into a broad range of
biological pathways such as transcriptional regulators,
mediators of protein−protein interactions and phos-
pholipid biosynthesis.
By assaying several independent dsRNAs against
every gene of the fly genome, this comprehensive study
will provide an important foundation for understand-
ing many aspects of piRNA biology.
A Transcriptome-Wide RNAi Screen 
in the Drosophila Ovary Reveals Novel
Factors of the Germline piRNA Pathway
B. Czech, J. Preall
The Drosophila genome is scarred with the ravages of an
ancestral battle being waged in its germline against self-
ish genetic elements. Transposable elements mobilize in
the early stages of gametogenesis, which if left unchecked
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would invade the genome and cause widespread disrup-
tion of essential genes, leading to collapse of the germline
and sterility. The piRNA pathway provides a defense
against selfish genetic elements by mounting a sequence-
specific, RNAi-like nucleolytic surveillance mechanism.
Several key factors of this pathway have been identified,
but accumulating evidence has suggested that the piRNA
pathway is more complex than was first appreciated, with
possible ties into chromatin structure, transcriptional reg-
ulation, RNA localization, and mitotic regulation.
We have undertaken an in vivo, reverse genetic screen
of unprecedented scale in order to fully describe the set of
genes that participate in piRNA-mediated genomic de-
fense. Approximately 8500 genes, spanning the entire
ovarian transcriptome, were targeted by RNAi constructs
driven by a germline-specific promoter. Our preliminary
results have uncovered several dozen novel candidates that
influence transposon levels and fertility in the female
germline, including cohorts of genes belonging to shared
processes such as epigenetic regulation and RNA metab-
olism. Ongoing analysis will serve to validate these candi-
dates and elaborate on our understanding of their impact
on the piRNA pathway, as we currently understand it.
piRNA Biogenesis: “To Cleave or Not
to Cleave RNA”
A.D. Haase [in collaboration with J.J. Ipsaro (Joshua-Tor lab),
Cold Spring Harbor Laboratory]
Piwi proteins and their associated small RNAs (piRNAs)
act in an evolutionarily conserved genome defense path-
way that silences transposons in the germline. This in-
nate immunity system consists of both hard-wired (pri-
mary) and adaptive (secondary) components.
Despite recent progress in our understanding of
piRNA biogenesis, the nucleases processing the 5¢ and
3¢ ends of primary piRNAs remain elusive. Recent work
by our group and other investigators has implicated
Zucchini (zuc) in the initiation phase of piRNA si-
lencing. Specifically, in zuc mutants, primary piRNAs
are depleted and piRNA cluster transcripts accumulate.
This is particularly noteworthy as Zuc belongs to the
phospholipase D family of phosphodiesterases, which
includes phospholipases and bacterial nucleases.
Our current research focuses on detailing Zucchini’s
role in piRNA silencing. To this end, we are investigating
the enzymatic mechanism and substrate specificity of
Zucchini in vitro and characterizing Zuc-containing
complexes in vivo. Taken together, these complementary
approaches should establish the underpinnings of Zuc-
chini’s molecular function in primary piRNA biogenesis.
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Investigating the Role of piRNAs 
during Germ Cell De Novo
Methylation in the Mouse
A. Molaro, E. Hodges, K. Marran [in collaboration with
A. Smith, University of Southern California; A. Aravin,
California Institute of Technology]
During mammalian embryogenesis, germ cells undergo
a genome-wide erasure and reestablishment of methyla-
tion marks. In this process of de novo methylation,
PIWI-associated small RNAs (piRNAs) have been pro-
posed to help the targeting of retrotransposons. To gain
insight into this phenomenon, we performed a detailed
characterization of methylation as well as transcriptional
patterns at several stages of germ cell maturation in wild-
type and piRNA-deficient animals (MILI nulls).
We found that despite the significant number of
retrotransposons potentially targeted by piRNAs, only a
small subset depends on the pathway for proper remeth-
ylation. We observed that the rest of the repeated se-
quences could be separated into two groups, with the
vast majority being methylated and a smaller but subse-
quent fraction escaping remethylation, despite the pres-
ence of piRNAs. Hypomethylated repeats in wild-type
and mutant animals display their lowest methylation lev-
els over their regulatory sequences (e.g., 5¢ repeats of L1
elements) and mimic some of the features of hypometh-
ylated regions (HMRs) found elsewhere in the genome.
We are now looking for the distinctive sequence features
that could explain these various dynamics of de novo
methylation. Our current analysis suggests that transpo-
son copies falling in each group display different rates of
conservation, closeness to consensus and transcription-
factor-binding affinities. Interestingly, transcriptome
analysis of the developing germ cell before, during, and
after the wave of de novo methylation revealed that retro-
transposons undergo a strong transcriptional reactivation
prior to their silencing. By profiling small RNAs at con-
comitant stages, we were able to find that the selectivity
of PIWI proteins for transposon piRNAs is acquired pro-
gressively as germ cells mature and anticorrelate tran-
script abundance. We find that whereas copies relying on
piRNAs for their remethylation are heavily enriched for
piRNA target sites, constitutively hypomethylated trans-
posons lack such enrichment.
We propose that whereas most remethylation is es-
tablished by default in mature germ cells, some retro-
transposons mimic regions normally protected (e.g.,
promoters) and require the piRNA-mediated pathway
to be properly targeted by de novo methylation. On the
other hand, we suggest that thousands of transposons
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are never remethylated and that they might constitute
interesting cases of domestication and could perform a
yet to be characterized regulatory function.
Structural Variation of the Genome
in Breast Cancer
A. Canela
Structural variation including copy-number polymor-
phisms (CNVs), as well as insertions, inversions, and
translocations, has an important role in tumor develop-
ment. Although the mutagenic effects of translocations
have long been seen as critical to the development of
hematological malignancies, only recently have techno-
logical advances allowed genome-scale analysis of re-
arrangements in common solid tumors. We study
structural variation in breast cancer cells at a single-base
resolution level by next-generation sequencing. As a first
approach, we focused on regions previously characterized
by CGH containing CNV as landmarks for identifying
complex chromosomal rearrangements. We purified these
regions in breast cancer cell lines by array-based genomic
capture and deciphered them by sequencing the precise
structure of genomic rearrangements, which led to de-
tection as copy-number loss and gain in the CGH (in
collaboration with the Wigler lab at CSHL). Because not
all the areas of CNV may contain complex chromosomal
rearrangements, we used an unbiased approach with large
fragment genomic libraries as “jumping libraries” to scan
by sequencing the whole genome for structural variation
events. We are using both approaches in a panel of breast
cancer cell lines to characterize the structural variation
and evaluate its role in breast tumorigenesis; this will
allow us to identify driver translocations and characterize
and define tumor-specific structural variation signatures.
The use of genomic capture and focal resequencing for
chromosomal rearrangements will give us information
about differential sequence features in the breakpoints.
This will further our understanding of how certain areas
of the genome act as hot spots of structural variation and
reveal the mechanisms behind it.
Lineage Mapping of Breast Cancer
Cells during Tumor Development
and Metastasis
C. Rebbeck
We have been developing a multicolor tool to investi-
gate tumor growth and metastasis. This year, we over-
came the challenges that come with using multiple
recombining lox P/Cre sites and made progress on virus
infection of breast tumor cells using the 4T1 cell line.
With the help of a fellow lab member, we have designed
programs for cell identification and color assignment,
whereby various “shades” and color combinations re-
sult in a new “color” being assigned. Using a four-color
construct featuring blue, green, orange, and red flores-
cent proteins, we are able to assign a minimum of 15
colors using pictures taken with a high-powered con-
focal microscope. With shading, we will be able to as-
sign more than 100 colors, allowing questions to be
answered on tumor growth and metastatic seeding. The
programing for cellular identification and color assign-
ment is still being optimized, but Figure 1 shows an ex-
ample of cells expressing different color combinations
and the postprocessing (some processed colors/shades
appear similar to the eye, but as can be seen in the orig-
inal, they are different colors).
Figure 1. Example of predigital and postdigital programming to identify cells with different intensities and
combinations of fluorescent color. Postprocessing assigns new colors based on a shade grouping system.
Transcriptional Profiling of Disseminated
and Circulating Tumor Cells in Breast
Cancer Mouse Models
R. Behrens, D. Fagegaltier, E. Wagenblast
The major cause of death for breast cancer patients is
metastasis of the tumor to distant organs such as the lung,
liver, and bone. Our lab is interested in identifying gene
expression signatures of tumor cell populations that con-
tribute to metastasis. For this, we have developed tech-
niques to isolate disseminated and circulating tumor cells
from breast cancer mouse models. We are using murine
cell lines that were derived from a single spontaneously
arising mammary tumor, which have different metastatic
potentials when injected into the mammary gland of
mice. These murine cell lines are tagged with a green fluo-
rescent protein (GFP) fluorophore for identification pur-
poses. Circulating tumor cells are isolated from the blood
using a combination of immunomagentic separation and
fluorescence-activated cell sorting (FACS). Disseminated
tumor cells from various metastatic organs are isolated by
FACS and laser capture microscopy. Upon isolation, gene
expression profiles are characterized using next-genera-
tion sequencing. We are comparing these gene expression
signatures to other less metastatic cells in order to iden-
tify genes that are responsible for metastasis formation.
Subsequently, we will be validating potential metastatic
regulators by conducting knockdown and overexpression
studies in vitro and in vivo.
Genomic and Epigenetic Changes
Occurring during Carcinogenesis:
A Fly Perspective
D. Fagegaltier, E. Wagenblast
Other questions related to carcinogenesis that remain
largely unexplored are how cells become transformed,
which pathways are involved in reaching a transformed
state, and whether each cell takes the same route to reach
such a state. To this end, we are using the Drosophila
model to study the basic mechanisms by which genomes
coordinate their genetic and epigenetic responses toward
a transformed state activated by specific oncogenes or
tumor suppressors. This STARR consortium project has
three major aims: (1) to generate Drosophila cell lines with
cancer-relevant genotypes, (2) to profile the transcrip-
tional and epigenetic changes that occur during the es-
tablishment of these cell lines, and (3) to address whether
cells remain addicted to the presence of the initiating
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oncogene or loss of tumor suppressor and to establish
which factors are required for the cells to proliferate and
maintain a transformed state. We have established various
cell lines expressing an oncogene or depleted for a tumor
suppressor. A pilot array experiment on primary cell lines
derived from ras-oncogene-expressing embryos suggests
that cells undergo major epigenetic changes via the Poly-
comb group of proteins before reaching a transformed
state. To further confirm the role of these proteins during
transformation, we are comparing the transcriptomes of
a larger set of transformed cell lines using next-genera-
tion sequencing. By dissecting the progressive transcrip-
tional changes generated during transformation, these
studies will shed light on the general mechanisms and
pathways leading to tumorigenesis and reveal changes
specific to each oncogenic molecule studied.
Patterns of Aberrant DNA
Methylation in Cancer
F. Rollins
During the past year, I have been working on under-
standing the patterns of DNA methylation in non-
small-cell lung cancer. We have been using cancer cell
lines, and through the combination of bisulfite conver-
sion and high-throughput whole-genome sequencing,
we are unraveling the epigenetic patterns of cancer cells.
We have identified a set of characteristics that not only
are specific to cancer cells, but could also underlie some
of the most basic phenotypes of cancer cells, including
increased rates of mutation and genomic instability.
These insights give us a further understanding of how
cancer cells are different from normal cells and will pro-
vide a foundation for future cancer research.
Role of an X-linked miRNA Cluster
in Mouse Spermatogenesis
I. Falciatori [in collaboration with S. Raffii, Cornell
University]
Spermatogonial stem cells (SSCs) are the stem cells re-
sponsible for the production of sperm in mammals. When
cultured in vitro, they can spontaneously give rise to a dif-
ferent kind of cells. These cells are called mammary gland
stem cells (MaSCs) and they resemble embryonic stem
cells in terms of both phenotype and developmental po-
tential. In an attempt to characterize the difference in the
small RNA profile between SSCs and MaSCs, we identi-
fied an X-linked cluster of microRNAs (miRNAs) that is
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highly expressed in SSCs and is significantly down-regu-
lated after transition to MaSCs. We established that this
cluster is specifically expressed in testis in several stages of
development, but it is nondetectable in other organs. We
therefore became interested in determining the function of
this miRNA cluster during spermatogenesis. To this end,
we decided to ablate this cluster during spermatogenesis in
mice and analyze their phenotype. We prepared a modi-
fied bacterial artificial chromosome (BAC) in which the
miR cluster is flanked by LoxP sites. This will allow us to
generate mice in which this cluster could be selectively ab-
lated at different stages of spermatogenesis. We will then
assess spermatogenesis in these ablated mice looking for
defects that will allow us to infer the function of the clus-
ter. Because miRNAs exert their function by down-regu-
lating their target genes, we are going to overexpress the
entire cluster in embryonic stem cells and look for tran-
scripts that become down-regulated. To achieve this goal,
we have produced a modified BAC in which we added a
TRE promoter to drive the expression of the cluster in
embryonic stem cells under the control of tetracycline. We
are in the process of producing the transgenic embryonic
stem cell lines carrying this BAC. We will then compare
their mRNA profiles in the presence or absence of tetra-
cycline to find potential miRNA targets. These targets will
then be validated in SSCs.
Studies of piRNA Biology 
in Mice and Flies
K. Wasik, V. Vagin
Preliminary evidence suggests that meiosis in RNF17
knockout spermatocytes is disrupted, resulting in fewer
haploid cells in the testes and the absence of elongating
spermatids. Comparison of the small RNAs between
wild-type and RNF17 knockout mice revealed an ~10-
fold reduction in pachytene piRNAs in RNF17 mutants.
However, the expression levels of pachytene piRNA pre-
cursor transcripts were unaffected. Immunofluorescence
of wild-type testes showed partial colocalization of
RNF17 with Miwi in pachytene spermatocytes, but not
in round spermatids. In contrast, in round spermatids,
Miwi is present in the chromatoid body and RNF17 lo-
calizes in uncharacterized granules. Strikingly, in RNF17
KO mice, Miwi does not localize to chromatoid bodies.
We hypothesize that RNF17 participates in the loading
of pachytene piRNAs onto Miwi. This loading happens
either in RNF17 granules or in chromatoid bodies. We
are currently analyzing the RNA and protein content of
chromatoid bodies and RNF17 granules.
We have also been searching for new piRNA biogene-
sis factors in flies. Because of the significant difficulties in
mapping the Dippp mutation, we decided to map another
mutation—Z20529, a Zucker collection mutant. The
Z20529(−/−) fly is defective in primary piRNA biogene-
sis in germline and somatic cells. We have used a recom-
bination mapping strategy based on the same principles as
for Dippp. The result of this recombination mapping
pointed to a 3-Mb region on chromosome 2R. We have
started crosses with flies harboring deletions in the region
of interest. So far, 10 of 11 deletion lines have been nega-
tive for the mutation. In addition, we have also crossed
the Z20529 fly with other mutants in the piRNA pathway
on chromosome 2. All of these mutations complemented
Z20529. In our fly mutant collection, however, two other
mutants (Z20149 and Z26032) did not complement the
Z20529 mutation. We expected these three fly lines to
have a mutation in the same gene. Hence, we decided to
perform genomic sequencing on all three mutants and use
single-nucleotide polymorphism (SNP) calling to find a
gene that is mutated in all three fly lines. The SNP calling
was performed in collaboration with Michael Shatz. We
are currently filtering out our candidates. Additionally, we
performed small RNA cloning and prepared transcrip-
tome libraries from Z20529 heterozygous and homozy-
gous flies to better characterize the phenotype.
Role of Long Noncoding RNAs
in Normal Hematopoiesis 
and Malignant Transformation
L. Sabin
Precise control of gene expression is achieved through mul-
tiple layers of regulation that influence the transcriptional
and epigenetic states of genomic loci. Long noncoding
RNAs (lncRNAs) have recently emerged as a novel class of
molecules with regulatory potential. However, ascribing
clear functional and biological roles to these noncoding
transcripts has been challenging. Although the function of
most lncRNAs remains unknown, many of the lncRNAs
that have been characterized have roles in transcriptional
and epigenetic regulation of gene expression by acting as
molecular scaffolds to recruit epigenetic modifiers and
other protein complexes to target genomic loci.
One developmental process that requires coordinated
regulation of gene expression is hematopoiesis. Impor-
tantly, the malignant transformation of various hemato-
poietic lineages leads to the development of several forms
of leukemia and lymphoma, and the disruption or mis-
regulation of epigenetic modifications is a common fea-
ture of cancer cells. Therefore, we are studying the func-
tion of lncRNAs in the murine hematopoietic system,
with the aim of identifying lncRNAs that have critical
roles in the epigenetic control of gene regulation. In par-
ticular, we hope to uncover lncRNAs responsible for reg-
ulating the genes involved in promoting or suppressing
tumorigenesis.
To this end, we plan to select a set of candidate 
lncRNAs for further studies using an integrated data set
that includes RNA-Seq and chromatin immunoprecipi-
tation (ChIP)-Seq data from normal and transformed
cells. We are using high-throughput sequencing to pro-
file lncRNA expression in various cell types within the
hematopoietic lineage, including progenitor populations
and mature cell types from both myeloid and lymphoid
lineages. We also hope to profile lncRNA expression in
two mouse models of blood cancer: the MLL-AF9 model
of acute myeloid leukemia and the Em-mycmodel of B-
cell lymphoma. We then plan to use short hairpin RNA
(shRNA) knockdown technology to determine which
candidate lncRNAs have important biological roles in
vivo. We will deplete lncRNA candidates from hemato-
poietic stem cells, and use the lncRNA-deficient cells in
bone marrow reconstitution assays to test whether can-
didates are involved in self-renewal, differentiation, or
malignant transformation. We hope that this work will
provide important insights into lncRNA function in the
epigenetic control of gene expression during normal
hematopoiesis and malignant transformation.
miRNA Target Sites in Mouse
Embryonic Stem Cells
M. Kudla
miRNAs together with Argonaute proteins form a ri-
bonucleoprotein complex involved in posttranscrip-
tional silencing of transcripts. Although Argonaute is
the functional partner in this complex, miRNAs are the
specificity factor, determining which transcripts will be
silenced. The foundation of this target recognition
mechanism is sequence complementarity between the
miRNA and part of the mRNA. In plants, the level of
complementarity is high enough to make a bioinfor-
matic prediction of the target sites a straightforward
task. In animals in general, but particularly in mammals,
the complementarity requirement is relaxed to such an
extent that similar predictions are very inaccurate. An
experimental method of discovery and validation of tar-
get sites is required. We have been using the HITS-CLIP
(high-throughput sequencing isolated by cross-linking
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immunoprecipitation) method for characterization of
mouse embryonic stem cells and cells derived from them
through targeted differentiation. We are now able to ob-
tain a map of target sites used by miRNA:Argonaute
complexes on inhibited transcripts. Using statistical
techniques, based on negative binomial distribution, we
are also able to identify target sites that change system-
atically upon transition from one condition to another.
The Origins and Functions of piRNAs
in Caenorhabditis elegans
W.S. Goh
piRNAs are germline-specific small RNAs that load
onto piwi proteins, and their loss leads to sterility in all
piRNA-possessing species. In light of piRNAs’ dicer in-
dependence, genomic cluster arrangement, and strand
bias, a long single-stranded piRNA precursor is hypoth-
esized to be the intermediate molecule in piRNA bio-
genesis. However, a concrete piRNA biogenesis model
has yet to be established in any species.
The nematode C. elegans is a well-established model
organism for performing genetic screens. C. elegans also
possess piRNAs, which are called 21Us, that load onto
the piwi protein PRG-1. However, much less is known
about piRNAs in C. elegans than in other species. To elu-
cidate piRNA biogenesis in C. elegans, I performed a
genome-wide RNAi screen to identify novel 21U factors
that alter 21U levels as measured by quantitative real-
time PCR: ~25 suppressors and ~50 biogenesis factors
were identified, where the strongest characterized factor
is ulp-5, a desumoylating factor. This factor is involved in
the sumo pathway, which among other processes, is
known to regulate protein degradation by the ubiquitin
pathway. Coincidentally, other members of the sumo
pathway were identified in orthogonal screens for piRNA
factors in fly ovarian sheet cell lines and whole flies. Fu-
ture work on this screen will focus on characterizing ulp-
5 and the other hits identified in this screen.
An EMS Screen Revealed a Functional
Link between Phosphatidic Acid
and Protein Phosphatase 1
in the Primary piRNA Pathway
V.V. Vagin, Y. Yang, E. Harrison
In flies, the piRNA pathway silences transposons in the
germline and somatic follicular cells of ovaries. Despite
recent progress in understanding piRNA biogenesis,
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there is still little known about primary piRNA pro-
cessing. To elucidate this mechanism, we conducted an
ethylmethane sulfonate (EMS) screen to identify new
primary piRNA components.
We found that the mitochondrial glycerol-3-phos-
phate O-acyltransferase gene (CG5508) was a primary
piRNA gene. In the CG5508 mutant, PIWI delocalizes
from nucleus to Yb body, and the elimination of mature
primary piRNAs correlates with accumulation of piRNA
precursor transcripts. Overall, the mutant phenotype is
similar to mutations in known primary piRNA genes.
We genetically dissected mitochondrial phospholipid
biogenesis to understand its role in the primary piRNA
pathway. Knocking down of phospholipid genes indi-
cates that phosphatidic acid (PA) is essential for primary
piRNA production. Interestingly, it was shown that PA
regulates activity of protein phosphatase 1 (PP1). RNAi
against PP1 subunits releases transposon silencing.
Scanning the Genome for Potent shRNAs
X. Zhou
The goal of my work is to improve RNAi tools. miRNA-
based shRNA has become a versatile and powerful RNAi
tool that enables stable and tightly regulated expression
of RNAi triggers of any sequence. However, shRNAs
have some limitations. Among all possible sequences that
target a given RNA transcript, very few are efficient. Due
to limited knowledge of miRNA biogenesis and target
interaction, identification of potent RNAi triggers re-
mains difficult. I aim to develop a deep-sequencing-
based high-throughput “molecular sensor assay” that
measures and quantifies shRNA potency by measuring
target RNA cleavage efficiency. The pilot experiment
using previously characterized shRNAs showed a corre-
lation between cleavage efficiency and shRNA potency.
This method is being tested on a larger scale. If success-
ful, we will be able to identify potent shRNAs from a
large number of candidates quickly and quantitatively.
Moreover, the quantitative feature will lead to better un-
derstanding of shRNA biogenesis and target interaction.
Proteomic Approaches to piRNAs
Y. Yu
I have optimized several systems to perform immuno-
precipitation-SILAC (stable isotope labeling by amino
acids in cell culture) experiments to identify piwi-inter-
acting proteins. With help from Vasily Vagin (CSHL), I
have achieved high labeling efficiencies for various sam-
ples including flies and mouse embryonic testis. I am ac-
tively collecting labeled samples from transgenic animals,
and immunoprecipitation-SILAC will be performed once
they are ready. Through piwi/SILAC from OSS (ovary
somatic sheet) cells, I have identified ~190 piwi-interact-
ing candidates. Known partners such as Yb, Armitage are
among the top hits, and some of the new targets have
been verified through RNAi (e.g., ctp). Although many
targets remain interesting, systematic cross-comparison
of the proteomic data with results of RNAi screens for
new piRNA factors has identified a number of candidates
important for the piRNA pathway. Notably, eight of the
overlapping candidates are known to affect sterility. The
plan is to see which of those candidates affect piRNA pro-
cessing or effector steps through small RNA cloning.
To identify piRNA as the 3¢-end processing factor
(the “trimmer”), I have recently generated stable silk-
worm cell lines expressing Halo-tagged proteins such
as siwi, BmAgo3, and dHen1 in the hope of pulling
down relevant nucleases. By taking advantage of the co-
valent binding between the Halo tag and its specific
chloro-alkane ligand, I was able to cross-link protein
partners of Halo fusion proteins and at the same time
wash away any contaminants under denaturing condi-
tions. Currently, I am optimizing the cross-linking and
purification conditions.
Desiging Potent and Specific Tools
to Find New Anticancer Targets
S. Knott
Functional screens, aimed at identifying putative ther-
apeutic agents, have become a powerful weapon in the
“war on cancer.” Our improved understanding of the
biological parameters that determine the efficacy with
which shRNA molecules suppress their intended target
genes is a fundamental reason for this technology’s
movement to the forefront of cancer research. Recently,
the Hannon lab, in collaboration with the Lowe lab
(both at CSHL), has developed a high-throughput
method for identifying what sequence-based parame-
ters drive shRNA efficacy. Using the results of these
methods, we have developed a computational tool
aimed at predicting the optimal shRNA sequence for
any given gene target. Armed with this tool, we have
predicted optimal genome-wide shRNA libraries for the
human, mouse, and rat genomes. These libraries are
currently under construction and should be available
to the scientific community in the summer of 2012.
Argonautes in Gene Regulation
F. Karginov
Argonaute proteins are guided by their miRNA part-
ners to mRNA targets, leading to regulation of the
mRNA in a spatially and temporally controlled manner.
In recent years, it has become more evident that the in-
teractions between Ago/miRNAs and mRNAs are fur-
ther affected by ancillary RNA-binding proteins,
creating a combinatory system of regulation akin to
transcription factors. We are using novel transcriptome-
wide technologies (CLIP) to identify the sites of inter-
action between Argonaute and mRNAs, to dissect the
Ago regulatory networks and their integration with
other RNA-binding proteins. More specifically, I have
looked at the changes in Argonaute occupancy as a re-
sult of acute cellular stress to assess the participation of
Ago in this process. We have identified global changes
in the interactions of Ago with their mRNA targets, as
well as transcript-specific cases of Ago regulation, that
may help the cell adapt to the stress condition.
Genetics Approaches 
to Anticancer Therapy
K. Chang, S. Knott, S. Shaw, S. Fenoglio, A. Valentine,
K. Marran, C. Peterson, Y.J. Yang
The principal goal of our group is to build tools to har-
ness RNAi to perform large-scale loss-of-function stud-
ies in mammals. One of our aims involves a continued
effort to develop and construct shRNA libraries capa-
ble of silencing every gene in the human and mouse
genomes. To date, we have completed construction for
our third-generation mammalian shRNA libraries, and
these new reagents have been made available to the re-
search community as with our previous versions. Each
generation of the shRNA library has been designed
based on our growing knowledge of the biochemical
and molecular basis of RNAi. The most significant ad-
vance of the third-generation RNAi resources is the
functional validation of efficacy for each individual
shRNA design in these libraries. This huge undertaking
was made possible using a highly parallel, large-scale
“sensor” technology we have developed in collaboration
with Dr. Scott Lowe’s lab (of CSHL and Memorial
Sloan-Kettering Cancer Center) to validate pools of
22,000 shRNAs at a time. In total, the final human and
mouse third-version libraries each comprise 80,000 se-
quence-verified shRNAs (four shRNAs per gene). Due
to the considerable undertaking to validate all the
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shRNAs, we have recently developed a new technology
using a “molecular sensor” approach that could measure
efficacies of shRNAs in a fraction of the time (this is
further elaborated in another section of our lab’s annual
report). Furthermore, the algorithm (DSIR) used to
predict shRNA designs for the third-generation libraries
produced more potent shRNAs for each gene than any
of our previous shRNA collections.
Large-scale in vitro RNAi screening in mammalian
cells was developed by our lab in 2008, and since that
time it has become a widely used tool to uncover genetic
dependencies, particularly in cancer cells. The target
genes or the molecular pathways that define the depend-
encies represent essential processes or modifiers of drug
resistance/sensitivity of tumor cells that can be explored
for therapeutic benefit. To facilitate high-throughput
RNAi screens in cell culture, we have optimized and in-
dustrialized our original screening methodology for
genome-wide interrogation. During the past 2 years, we
have been part of the target discovery group for the
Stand-Up to Cancer (SU2C) effort to combat breast can-
cer. This is a very comprehensive and rigorous study of all
subtypes of breast cancer using state-of the-art research
tools and expertise from many accomplished investiga-
tors to yield new clinical impacts within a relatively short
period of time. Our overall objective for SU2C is to apply
genome-wide RNAi screening, using our third-genera-
tion shRNA library, to uncover genetic vulnerabilities and
pathways that can modify currently used targeted thera-
pies (tamoxifen, frastuzumab, and lapatinib) in de novo
and acquired resistance. To date, we have completed 26
genome-wide screens in tumor-derived cell lines repre-
senting all three treatment classes of breast cancer (ER-
positive, Her2-positive, and triple-negative disease).
Another study, ongoing for more than a year and also in-
volving in vitro genome-wide RNAi screening, is through
funding from the Lustgarten Foundation to find targeted
therapeutic approaches against pancreatic cancer. We
have begun screening a panel of 14 pancreatic cancer cell
lines to uncover genetic vulnerabilities and to probe sen-
sitizing targets against gemcitabine (chemotherapy) for
new combinational therapies to treat this highly aggres-
sive disease. To facilitate our large-scale screening studies,
we have now established a core screening group in our
lab to undertake these projects.
Our third objective is to develop new tools for RNAi
screens in animals. Our approach to in vivo RNAi
screens is based not only on the need to overcome the bi-
ological limitations of cell culture, but also on our intent
to directly interrogate human cancer cells that have not
been adapted in vitro. To this end, we will screen cells
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from human primary tumor-derived xenograft models
(PDX) in immunocompromised mice (subcutaneous
and orthotopic sites). Protocols and tools are currently
being developed. This involves testing an array of pro-
moters for optimal expression of shRNAs in vivo. In ad-
dition, we have developed a new, regulatable expression
vector system to facilitate in vivo screening. Our initial
goal is to screen pancreatic cancer PDX models (Dr. Es-
helman’s lab of Johns Hopkins University) as part of the
Lustgarten project and also breast cancer PDX models
(Dr. Alana Welm of University of Utah). Ultimately, we
wish to expand the application of this new in vivo
screening technology for other cancers.
During the past year, we have began collaborating
with Dr. Charles Sawyers’ lab (Memorial Sloan-Ketter-
ing Cancer Center) to apply RNAi screening to under-
stand the genetic alterations that promote tumor
progression and therapy resistance to castration-resis-
tant prostate cancer (CRPC) (funded by the STARR
Cancer Consortium). A considerable difficulty is that
castration-resistance phenotypes can only be effectively
measured in vivo, necessitating the use of in vivo RNAi.
Screening paradigms will be carried out in two models:
the mouse Myc-CaP prostate cancer xenograft and the
LNCaP/AR human prostate xenograft.
Forays into Neuroscience and Beyond
D. Bressan
My research focuses on the development of new mo-
lecular techniques to investigate connectivity and gene
expression in the brain.
My main project is to develop a system to convert
the complexity of the synaptic connections in the brain
into a “genetic” complexity, by appending unique “bar
codes” to every neuron and causing them to fuse at the
synapse, forming a pair that “freezes” the identity of the
connection in a conformation that can be purified and
sequenced using the instruments of genomics.
Because we can now routinely sequence more than
1 billion bar codes in ~2 weeks in a single run of a se-
quencing machine, this technique could allow resolv-
ing an entire connectome (the full map of connections
in a brain) in a really fast and affordable way. We are
currently testing and troubleshooting the protocol in
the worm C. elegans, the only animal for which a refer-
ence connectome exists.
My second project is to develop a way of labeling
and subsequently purifying the entire translatome (the
collection of mRNAs being translated by ribosomes) of
a cell or subcellular compartment with great spatial ac-
curacy, by means of a photoactivable “tag” that binds
to ribosomes in vivo only upon irradiation by a laser.
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Greg Hannon (seated, far right) and lab members
Cancer arises through an evolutionary process whereby
normal cells acquire mutations that erode growth con-
trols, leading to the expansion of aberrantly proliferating
cells. Such mutations activate oncogenes or inactivate
tumor suppressors, each bestowing new capabilities on
developing cancer cells. Our research is based on the
premise that the path of cancer evolution dictates a
tumor’s subsequent response to therapy and creates
unique vulnerabilities that represent therapeutic oppor-
tunities. Hence, we apply mouse models, RNA interfer-
ence (RNAi), and cancer genomics in a coordinated
effort to identify components of tumor suppressor gene
networks and to understand molecular determinants of
treatment response. We also use conditional RNAi tech-
nology to identify tumor maintenance genes and explore
the cell intrinsic and extrinsic mechanisms involved in
tumor regression. Our goal is to gain a more compre-
hensive understanding of tumor suppressor networks and
identify cancer maintenance genes that will be useful
therapeutic targets relevant to specific cancer genotypes.
Accelerating the Pace of Discovery: 
Mosaic Mouse Models and RNAi 
J. Bolden, J. Cappellani, C. Chen, L. Dow, S. Ebbesen, 
C. Fellmann, D. Grace, X. Guo, Y. Liu, K. McJunkin, 
C. Miething, Y. Park, P. Premsrirut, A. Saborowski, 
M. Saborowski, J. Simon, V. Sridhar, V. Thapar, J. White 
[in collaboration with G. Hannon, C. Malone, R. Sordella, 
M. Comilio, S. Kim, Cold Sring Harbor Laboratory; 
S. Elledge, Harvard Medical School; R. Dickins, Walter 
and Eliza Hall Institute]
Genetically engineered mice provide powerful tools to
study cancer, yet their generation and analysis is time-
consuming and expensive. Loss-of-function studies—
essential for characterizing tumor suppressor genes or
candidate drug targets—are laborious and typically re-
quire tissue-specific conditional knockouts harboring
multiple alleles. Moreover, to validate drug targets, genes
must be inactivated in each cell of an established tumor,
a technical challenge that has only been achieved in a
few instances. Even where feasible, conditional gene
deletions are not reversible and hence do not mimic
transient pharmacologic target inhibition. Conse-
quently, traditional mouse-modeling approaches are not
sufficiently fast or flexible to comprehensively model
cancer heterogeneity or evaluate the range of emerging
drug targets (Dow and Lowe 2012).
To address these issues, we developed strategies to ac-
celerate genetic studies in mice. On the one hand, we
have taken a “mosaic” approach, where cancer-predis-
posing alleles or reporters are transduced into stem and
progenitor cells derived from different tissues or mouse
strains; these modified cells are then transplanted or-
thotopically into syngeneic recipients. Because the ge-
netic configuration of the target cells, transduced genes,
and recipients is easily varied, genotypic diversity can be
readily produced. On the other hand, we have created a
“speedy mouse” platform, in which murine embryonic
stem cells (ES cells) can be derived from mice harboring
several cancer-predisposing alleles, enabling the subse-
quent production of large numbers of mice by blastocyst
injection or tetraploid embryo complementation with-
out extensive intercrossing of germline strains (Prem-
srirut et al. 2011; Dow et al. 2012). To date, we have
developed mosaic models of lymphoma and leukemia
(Zuber et al. 2011), as well as carcinomas of the liver,
breast, bile duct, and pancreas. In addition, we have pro-
duced speedy mouse models of lung adenocarcinoma
(Premsrirut et al. 2011), with efforts aimed at produc-
ing models of melanoma and carcinomas of the colon,
breast, liver, and ovary in progress. Armed with these
models, a single investigator can study the impact of
many cancer genotypes on tumor behavior and rapidly
test new hypotheses based on their results.
To facilitate loss-of-gene-function studies, we worked
with Gregory Hannon at CSHL to develop inducible
short hairpin RNA (shRNA) technology as a rapid and
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reversible alternative to conditional gene deletions. This
platform is based on the fact that shRNAs embedded in
a natural microRNA (miRNA) structure are effectively
expressed from polymerase II promoters, thereby en-
abling robust gene knockdown using constitutive and in-
ducible vectors. During the last year, several convergent
efforts came to fruition, enabling the development of bet-
ter vectors and screening methods that should increase
the efficiency and output of negative selection shRNA
screens performed for the purpose of identifying cancer
drug targets (Zuber et al. 2011). In addition, a “sensor”
assay was developed to sort through thousands of shRNA
sequences to identify the most potent. In addition to de-
scribing a general strategy for the production of large-
scale validated shRNA libraries, the data yielded by these
analyses produced new information related to the un-
derlying biology of efficient RNAi (Fellmann et al. 2011). 
We also developed a scalable platform for producing
mice harboring inducible shRNAs with the long-term
goal of producing a general platform that will enable the
spatial, temporal, and reversible suppression of any mam-
malian gene. The system integrates our advances on
shRNA vector design (inducibility via a tet-transactiva-
tion system, enhanced potency, and coupling shRNA ex-
pression to a fluorescent reporter) with a recombina-
tion-mediated cassette exchange approach developed in
the Jaenisch lab that enables rapid and reproducible tar-
geting of the inducible shRNA cassette to a defined ge-
nomic locus in ES cells (McJunkin et al. 2011; Premsrirut
et al. 2011). Mice can then be produced rapidly using
tetraploid embryo complementation. Currently, our lab-
oratory has produced more than 1000 ES cell lines and 75
mouse strains and is using the resulting cells and mice to
study tissue-specific and reversible suppression of tumor
suppressors, miRNAs, drug targets, and essential genes. 
To accelerate the pace at which we can determine how
particular genes modulate disease phenotypes, we devel-
oped “speedy mouse” technology in which ES cells are
rederived from mice harboring a recombination-medi-
ated cassette exchange homing locus with certain cancer-
predisposing alleles (Premsrirut et al. 2011; Dow et al.
2012). With this approach, shRNAs targeting candidate
disease modifiers (new cancer genes, or genes involved
in tumor maintenance) can be introduced into these ES
cells, enabling researchers to study the impact of study-
ing many genes on the progression or regression of dis-
ease simply by controlling the time and length of gene
inhibition by doxycycline addition. Currently, we are
building such platforms for a variety of cancer genotypes
and anticipate that the use of these systems will substan-
tially impact our research in the years to come. 
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Cell Survival and Cell Death
Y. Liu, C. Miething, C. Scuoppo, J. Simon [in collaboration
with J. Reyes, A. Kraznitz, C. Ruse, D. Pappin, Cold Spring
Harbor Laboratory; J. Pelletier and L. Linqvist, McGill 
University] 
Since its inception, our laboratory has studied genes that
modulate cell death and survival. Current work in this
area exploits the Em-myc B-cell lymphoma model,
where disruption of the ARF-p53 pathway, or overex-
pression of the prosurvival genes Bcl-2 or Akt, cooperates
to accelerate lymphomagenesis. Following up “hits”
from in vivo RNAi screens (see below), we are charac-
terizing new tumor suppressors that modulate apopto-
sis. This year, we identified two tumor suppressors
involved in polyamine biology: Amd1, an enzyme that
catalyzes the rate-limiting step in the synthesis of sper-
midine, and eIF5A, the only protein to incorporate hy-
pusine, a modified amino acid derived from spermidine.
Remarkably, this pathway is conserved from archaebac-
teria to humans, involving two enzymes (DHPS,
DOHH) that specifically target the same highly con-
served lysine on—and apparently only on—eIF5A. In-
deed, a secondary RNAi screen identified two other
enzymes (SRM, DHPS) needed for the production of
hypusine as tumor suppressors, further emphasizing the
relevance of the hypusination pathway.
Although the biochemical action of eIF5A in cancer
is not established, our studies suggest that hypusination
of eIF5A potentiates apoptosis through p53-indepen-
dent control of Bax, a proapoptotic member of the Bcl-
2 family known to function as a tumor suppressor in
this system. As a consequence, our study identified a
previously unanticipated tumor suppressor network
that acts by suppressing apoptosis. Moving forward, we
will continue to explore the underlying biological
mechanism of the new tumor suppressor network we
identified, as well as characterize other tumor suppres-
sors that were identified in our screen. Using the in-
ducible shRNA transgenic mice described above, we are
also studying how control of cell survival by eIF4E and
PTEN impact tumor initiation and maintenance. 
Senescence and Self-Renewal
J. Bolden, A. Chicas, O. Mert, C. Scuoppo, J. Simon, N. Tas-
demir [in collaboration with E. Bernstein and A. Kapoor, Mt.
Sinai School of Medicine; V. Krizhanovsky and A. Sagiv,
Weizmann Institute; X. Wang, Tsinghua University] 
Cellular senescence is a stable form of proliferative ar-
rest that acts as a potent barrier to cancer development
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and may contribute to various age-related pathologies.
Initially defined by the phenotype of cultured fibro-
blasts undergoing replicative exhaustion, senescence can
be triggered in many cell types by a range of cellular
stresses including the aberrant expression of mitogenic
oncogenes. The senescence program is controlled by an
interplay between the retinoblastoma (RB) and p53
tumor suppressor networks, and senescent cells typi-
cally display a characteristic transcriptional profile in-
volving down-regulation of growth-promoting genes,
up-regulation of cell cycle inhibitors, and changes in
the expression of secreted molecules involved in extra-
cellular matrix production and immune surveillance.
We continue to search for other pathway compo-
nents that may contribute to senescence. We previously
showed that RB but not p107 or p130 is required for
the establishment of cellular senescence and proposed
that this nonredundant function of RB is one mecha-
nism by which RB exerts its tumor suppressor function.
To explore the mechanistic basis for this effect, we took
a nonbiased approach to identify changes in histone
modification patterns occurring in senescent cells. Our
work showed that RB mediates a senescence-specific loss
of H3K4 methylation on certain E2F target genes by
binding the H3K4 demethylases Jarid1a and Jarid1b. In
a parallel effort, we used gene expression profiling to
identify new senescence regulators, and in doing so, we
identified a poorly characterized E2F family member as
a novel link between the p53 and RB pathways.
In addition to the stable arrest phenotype controlled
by RB and p53, senescent cells display a “senescence-as-
sociated secretory phenotype” (SASP) involving the
production of factors that reinforce the senescence ar-
rest, alter the microenvironment, and trigger immune
surveillance of the senescent cells. Through a pro-
teomics analysis of senescent chromatin, we identified
the nuclear factor-kB (NF-kB) subunit p65 as a major
transcription factor that accumulates on chromatin of
senescent cells (Chien et al. 2011). We found that NF-
kB acts as a master regulator of the SASP, influencing
the expression of more genes than RB and p53 com-
bined. In cultured fibroblasts, disabling the SASP by
NF-kB suppression causes escape from immune recog-
nition by natural killer (NK) cells and cooperates with
p53 inactivation to bypass senescence and, in a mouse
lymphoma model, bypasses treatment-induced senes-
cence producing drug resistance, early relapse, and
 reduced survival. Our results demonstrate that NF-kB-
mediated control of the SASP influences both cell-
 autonomous and non-cell-autonomous aspects of the
senescence program and identify a tumor suppressive
function of NF-kB that contributes to the outcome of
cancer therapy. 
We have also studied mechanisms of immune sur-
veillance of senescent cells. For example, during liver fi-
brosis, hepatic stellate cells initially proliferate and
secrete extracellular matrix components that produce
the characteristic patterns of fibrosis; however, they
eventually undergo senescence and are cleared by NK
cells and other components of the innate immune sys-
tem. This year, we studied how NK cells target senes-
cent cells and examined the impact of disrupting this
process on liver fibrosis in vivo. We showed that the
granule exocytosis pathway, and not the death receptor
pathway, mediates killing of the senescent cells by the
NK cells, and without this pathway, mice are more
prone to fibrosis (Sagiv et al., in press). This pathway
bias is determined by DcR5, a decoy receptor that at-
tenuates signaling through the death receptor pathway
and is up-regulated in senescent cells. Currently, we are
investigating how the disruption of senescence in stel-
late cells ultimately influences the development of liver
cirrhosis and carcinoma development. Early data sug-
gest that the program may suppress the development of
these conditions in a non-cell-autonomous way. 
Identifying Tumor Maintenance Genes
and Therapeutic Targets
I. Appelmann, J. Cappellani, C. Chen, C.-H. Huang, Y. Liu,
A. Lujambio, B. Ma, A. Rappaport, A. Saborowski, A. Shroff,
J. Simon, N. Tasdemir, V. Thapar, S. Weissmueller, J. Zuber 
[in collaboration with G. Hannon, C. Vakoc, J. Shi, 
E. Wang, Cold Spring Harbor Laboratory; S. Kogan, 
University of California, San Francisco; J. Bradner, Dana- 
Farber Cancer Institute]
We are also using RNAi to systematically identify geno-
type-specific drug targets. Although many investigators
focus on human-derived cancer cell lines for these stud-
ies, our efforts heavily use murine model systems because
of the defined nature of the driving genetic events and
our ability to rapidly extend results to in vivo systems.
By combining inducible RNAi systems and linked fluo-
rescent reporters, many candidate tumor maintenance
genes can be identified and rapidly triaged to focus on
those that show the most promise. Although our efforts
to combine technologies for target discovery focus on a
variety of cancers, our initial successes have come largely
from the study of hematopoietic malignancies. 
One area of investigation focuses on the identifica-
tion of tumor maintenance genes in mouse models of
refractory AML. Previous work from our laboratory has
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lung carcinomas leads to tumor regression associated
with enhanced apoptosis (Premsrirut et al. 2011). We
also showed that Apc loss is required to maintain the
proliferation of T-cell acute lymphoid leukemia, thus
validating the Wnt pathway as a therapeutic target
(Premsrirut et al. 2011). Current efforts are studying
the impact of PTEN restoration in aggressive T-cell
lymphomas. Finally, as a proof of principle, we showed
that inhibiting DNA synthesis in vivo through sup-
pression of replication protein A could produce toxic
but reversible effects in mice. 
Integrated Approaches to Cancer
Gene Discovery
C. Chen, X. Guo, T. Kitzing, Y. Liu, A. Lujambio, B. Ma, 
C. Miething, M. Saborowski, C. Scuoppo, A. Shroff, J.
Simon, M. Spector, V. Thapar, S. Weissmueller, Z. Zhao 
[in collaboration with S. Roessler and X. Wang, National 
Institutes of Health; A. Kraznitz, I. Issifov, M. Wigler, 
J. Hicks, G. Hannon, G. Atwal, S. Powers, Cold Spring 
Harbor Laboratory; S. Allen, North Shore/Long Island 
Jewish Hospital]
Cancer genomes are complex and can harbor cancer-
promoting “driver” mutations together with “passen-
ger” mutations that have no biological effect. To
accelerate cancer gene discovery, we use mosaic mouse
models to filter candidates obtained through genomics
to identify genes whose activity contributes to tumori-
genesis. We presume that (1) recurrent amplifications
and deletions in human tumors are enriched for onco-
genes and tumor suppressors, respectively, and (2) le-
sions that give rise to cancer in humans often do so in
mice. This approach has led to the identification and
validation of more than 50 oncogenes and tumor sup-
pressor genes during the last several years. 
We developed strategies to multiplex this approach
by transducing tissue stem and progenitor cells with
pools of cDNAs or shRNAs corresponding to genes
that are amplified or deleted in human tumors, and we
select for those constructs that promote tumorigenesis
following transplantation into recipient mice. Initial ef-
forts surveyed nearly 400 recurrently deleted genes in
human hepatocellular carcinoma (HCC) and identified
12 new tumor suppressor genes. In a conceptually sim-
ilar screen performed by Scott Powers (CSHL) using
full-length cDNAs, we identified 10 new oncogenes in
human HCC, including FGF19 as a therapeutic target
for existing neutralizing antibodies (Sawey et al. 2011).
Ongoing work with Powers and colleagues is perform-
ing similar studies in ovarian cancer. 
developed such models and shown that, for example,
those triggered by mixed lineage leukemia (MLL) fu-
sion oncoproteins are particularly refractory to conven-
tional cancer therapy. By characterizing how MLL
fusion proteins promote self-renewal in a mouse model
of acute myeloid leukemia (AML), we identified the
Myb transcription factor as specifically required for the
maintenance of an aberrant self-renewal program trig-
gered by MLL-fusion proteins and found that inhibi-
tion of Myb at an advanced disease stage could eradicate
leukemia in mice (Zuber et al. 2011). These observa-
tions provide direct evidence that targeting aberrant self-
renewal programs would provide a therapeutic benefit.
With Christopher Vakoc at CSHL, we screened an
shRNA library targeting “epigenetic” regulators and
have identified several histone-modifying activities
whose suppression causes the selective arrest or death of
leukemic cells. One of these, Brd4, is the target of an
available small-molecule inhibitor that we showed is ac-
tive against our AML models, certain human AML
lines, and primary cancer material (Zuber et al. 2011). 
Interestingly, gene expression changes generated fol-
lowing genetic or pharmacologic inhibition of Brd4 are
remarkably similar to those observed upon suppressing
MLL-AF9 or Myb, suggesting that MLL-AF9, Myb,
and Brd4 functionally intersect within a common tran-
scriptional circuit essential for malignant self-renewal.
A key effector of this program is the oncoprotein Myc,
which has been validated as an attractive therapeutic
target but has to date escaped efforts at pharmacologi-
cal inhibition. Although the precise mechanism remains
to be further defined, targeting Brd4 extinguishes Myc
expression and limits self-renewal with selectivity for
the leukemic context, thus averting hematopoietic tox-
icities potentially associated with systemic Myc inhibi-
tion. Thus, our studies identify Brd4 as a promising
therapeutic target in AML and identify a small mole-
cule that efficiently targets Myc. 
We will continue to apply our mouse modeling and
RNAi technologies to identify context-dependent
tumor maintenance genes, particularly in those cancers
that are refractory to current therapies. Accordingly, we
continue to work with Chris Vakoc to characterize the
PRC complex as a therapeutic target in some types of
AML (Shi et al., in press) and are producing optimized
shRNA libraries targeting relevant drug targets and de-
veloping screening strategies in vivo. Beyond mosaic
models, our shRNA transgenic platform provides a
rapid way to validate targets and elucidate the potential
toxic effects of transient target inhibition. For example,
we showed that INK4a/ARF reactivation in aggressive
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This year, we also completed an additional screen
for novel tumor suppressor genes in lymphoma. We
screened an shRNA library targeting genes deleted in
human lymphomas to identify those whose suppression
promotes tumorigenesis in a mouse lymphoma model.
Among the new tumor suppressors we identified were
adenosylmethionine decarboxylase 1 (AMD1) and eu-
karyotic translation initiation factor 5A (eIF5A), two
genes associated with hypusine, a unique amino acid
produced as a product of polyamine metabolism
through a highly conserved pathway (see above).
Through a secondary screen surveying the impact of all
polyamine enzymes on tumorigenesis, we established
the polyamine−hypusine axis as a new tumor suppres-
sor network regulating apoptosis. Unexpectedly, het-
erozygous deletions encompassing AMD1 and eIF5A
often occur together in human lymphomas, and co-
suppression of both genes act to promote lymphoma-
genesis in mice. Thus, some tumor suppressor functions
can be disabled through a two-step process targeting
different genes acting in the same pathway.
Through our own genomics efforts, we also identi-
fied several new candidate cancer genes via next-gener-
ation sequencing. In a collaboration funded by the
Monti Foundation with Dr. Steven Allen at North
Shore/LIJ, we performed whole-exome sequencing on
a unique mast cell leukemia. These studies identified
potential driver mutations in the IgE mast cell receptor
and the kit receptor that have implications for the treat-
ment of patients with this disease. Other studies on
AML have pointed toward new cancer genes that we
are validating using mouse models.
Beyond identifying new activities of cancer relevance,
our approach is revealing unexpected principles about
the nature and organization of cancer genes. As exam-
ples, we were surprised that so many tumor suppressors
are haploinsufficient, encode secreted proteins, or have
pro-oncogenic activities in other contexts. We also did
not expect recurrent amplifications and deletions to con-
tain more than one relevant activity, yet our results imply
this is the rule rather than the exception.  Indeed, in a
systematic study of genes recurrently located on 8p, we
showed that shRNAs targeting multiple genes in this re-
gion could be tumor-promoting and that suppression of
gene combinations showed that cancer-associated dele-
tions contribute to cancer phenotypes in a manner that
is distinct from single-gene mutations and should be con-
sidered and studied as distinct mutational events. We
hope that  further efforts will facilitate the functional an-
notation of the genomic alterations occurring in human
cancers and identify vulnerabilities these lesions create.
Epilog
After 16 productive years at Cold Spring Harbor Labo-
ratory, the Lowe laboratory moved to Memorial Sloan-
Kettering Cancer Center in August 2011. During its
tenure at CSHL, it expanded its research interests from
focused studies on the action of p53 in apoptosis to
more broad-based approaches for identifying cancer
drivers and dependencies, thereby contributing to, and
benefiting from, the great research environment at the
Laboratory. Many students, postdocs, and technicians
who were Lowe lab members throughout this period
created a spirited and collaborative environment that
impacted the social and scientific character of the Lab-
oratory for nearly a decade. Moving forward, the Lowe
laboratory will continue its association with CSHL
through several formal and informal programs that have
great potential to fuel exciting advances in cancer re-
search during the coming years.
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In addition to genetic mutation, such as amplification
and deletion, epigenetic aberrations are frequent events
that can have far-reaching affects in the phenotype of a
cancer cell. A common epigenetic modification is the
methylation of cytosine residues that are next to gua-
nine residues. It has been shown that methylation pres-
ent in the DNA of the transcriptional control region has
been involved in the silencing of gene expression of
tumor suppressors in cancer. We have previously
adapted ROMA (representational oligonucleotide mi-
croarray analysis) to methylation detection oligonu-
cleotide microarray analysis (MOMA). This meth-
odology was useful and allowed us to identify genes that
were methylated in the tumor cells, but it only gave us
a general idea of where in the CpG island the methyla-
tion had occurred. In addition, after performing the
analysis, sequencing validation was required to deter-
mine which of the array measurements accurately iden-
tified methylated fragments. With the development of
next-generation sequencing technologies, it is now pos-
sible to identify the methylation status for the vast ma-
jority of CpG islands. Presently, our approach is to
sequence small MspI fragments of the genome.
We have presently sequenced four tumors and two
normal samples and have more tumors and normal
samples in the queue. We sequenced two of the sam-
ples on two different formats of the Illumina sequencers
and determined the coverage of each; we have switched
to the newest platform. We developed sequencing pipe-
lines for the analysis of the data and determined the
number of reads necessary to account for 85% of the
CpG sequences in the genomic island sequences. We
are presently further analyzing the data with the goal of
identifying new regions that can serve as markers for
diagnosis and also as a discovery tool to identify gene
candidates that are involved in therapy response. To do
so, we have a tumor set that has been stage normalized
to contain stages 3 and 4 tumors with accurate clinical
data for the past 10 years. These 40 samples will be
methyl sequenced and further analyzed.
Genomic Analysis of Ovarian Cancer
K. Wrzeszczynski, M. Vigliotti, E. Lum, N. Cutter, 
N. Dimitrova
In the United States, there will be ~22,000 new cases of
ovarian cancer in 2011. Of those, ~14,000 will succumb
to the disease. To better treat these women, and improve
survival, our goal is to determine the molecular changes
that have occurred in the patients’ tumors and to inter-
pret the significance that these changes have for the growth
and development of the tumor. This aberrant growth is a
result of chromosomal abnormalities and epigenetic vari-
ations. In addition, generally low rates of somatic nu-
cleotide mutation in ovarian cancer as compared to other
solid tumors suggest an increased significance of copy-
number and epigenetic aberrations. This type of regula-
tion has been shown to affect the many tumor suppressors
and oncogenes discovered in ovarian cancer. The identifi-
cation of genetic and epigenetic alterations from primary
tumor cells has become a common method to identify
genes critical to the development and progression of can-
cer. We have performed a bioinformatic analysis of copy-
number variation and DNA methylation covering the
genetic landscape of ovarian cancer tumor cells. We indi-
vidually examined the copy-number variation and DNA
methylation for 42 primary serous ovarian cancer samples
using our MOMA-ROMA technology and 379 tumor
samples analyzed by the Cancer Genome Atlas. We have
identified 346 genes with significant deletions or amplifi-
cations among the tumor samples. Using associated gene
expression data, we predict 156 genes with significantly
altered copy number and correlated changes in expression.
Among these genes, CCNE1, POP4, UQCRB, PHF20L1,
and C19orf2 were identified within both data sets. We
were specifically interested in copy-number variation as
our base genomic property in the prediction of tumor sup-
pressors and oncogenes in the altered ovarian tumor. We
therefore identify changes in DNA methylation and ex-
pression for all amplified and deleted genes. We predicted
615 potential oncogenes and tumor suppressor candidates
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by integrating these multiple genomic and epigenetic data
types. Genes with a strong correlation for methylation-
dependent expression exhibited at varying copy-number
aberrations include CDCA8, ATAD2, CDKN2A, RAB25,
AURKA, BOP1, and EIF2C3.We provide copy-number
variation and DNA methylation analysis for more than
11,500 individual genes covering the genetic landscape of
ovarian cancer tumors. We show the extent of genomic
and epigenetic alterations for known tumor suppressors
and oncogenes and also use these defined features to iden-
tify potential ovarian cancer gene candidates.
Resistance Mechanisms in Ovarian Cancer
N. Cutter, M. Vigliotti, K. Wrzeszczynski
Epithelial ovarian cancer is the leading cause of death
from gynecological malignancies. Currently, platinum-
based chemotherapy (such as cisplatin or carboplatin),
coupled with a taxane-based drug such as paclitaxel, is the
primary treatment for ovarian cancer. Approximately
25% of patients either present with or rapidly develop re-
sistance to chemotherapy, and all recurrent tumors are re-
sistant. Epigenetic modifications have been associated
with tumor formation and progression and may contri-
bute to therapy response. We have screened a number of
genes and family members for methylation in resistant
patients and not in sensitive patients. We show for one
such gene CHD3, a member of the Mi-2 NuRD com-
plex, that loss of expression is linked to chemoresistance.
CHD3 is silenced through an epigenetic mechanism in
both ovarian cancer cell lines and primary ovarian tumors.
Ovarian cell lines transcriptionally silenced for CHD3
have an increased resistance to the chemotherapy drugs
carboplatin and cisplatin. Additionally, these cells are
more invasive, have migratory ability, and display a trans-
formed epithelial-to-mesenchymal (EMT) phenotype.
Taken together, this provides the first evidence for a role
for CHD3 as an important mediator of chemoresistance in
ovarian cancer, and we hypothesize that EMT is one of
the underlying mechanisms. Furthermore, CHD3might
represent a response predictor and potential therapeutic
target for predicting chemoresistance in this disease.
Genomic Alterations of Phosphatases
E. Lum, G. Fan, F. Chaudhary [in collaboration with N. Tonks,
Cold Spring Harbor Laboratory] 
The goal of this collaborative study is to integrate gene
discovery technology with experimental strategies devel-
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oped in Dr. Tonks’ lab for the characterization of the pro-
tein tyrosine phosphatase (PTP) family of enzymes, to
investigate how tyrosine phosphorylation-dependent sig-
naling pathways are disrupted in cancer. We have taken
advantage of several different forms of genomic data to
determine which PTPs are affected in cancer cells.
We have used genomic copy-number data, expres-
sion data, and now epigenetic DNA methylation data
to determine which PTPs are altered in ovarian cancer.
We have also expanded our extension of analysis of
PTPs in cancer into the proteins with which PTPs in-
teract. An interesting gene in this class is the MTSS1
protein that interacts with a PTP, the receptor-like PTP
RPTPd, and regulates cytoskeletal organization. It is
known to be preferentially methylated in several can-
cers, including breast cancer, and its expression is
markedly decreased in ovarian cancer.
We first generated short hairpin RNAs (shRNAs) to
suppress expression of the MTSS1 gene in cell culture as-
says, which would mimic the transcriptional repression
caused by promoter methylation. Because this gene was se-
lected based only on the comparison of tumor to normal,
we did not have a selection for assay development. We sur-
mised that because MTSS1 possessed an actin-binding
domain, the protein might have a role in cytoskeletal re-
arrangement, cell movement, and invasion. Therefore, we
performed an invasion assay with MCF10A mammary
epithelial cells, which are used typically as a normal line.
We observed that very few cells migrate without the ad-
dition of the attractant epidermal growth factor (EGF).
Furthermore, RNA interference (RNAi)-mediated sup-
pression of MTSS1 enhanced migration in the presence of
EGF. There is evidence in the literature that in ERBB2-
positive breast cancer, there is loss of MTSS1 transcrip-
tion. To determine whether ERBB2 overexpression
synergizes with loss of MTSS1, we performed an invasion
assay in MCF10AN cells. These cells express a chimeric
ERBB2 gene in which the activity of the cytoplasmic PTK
domain of ERBB2 is acutely regulated by a small-mole-
cule dimerizing agent. We noted that the level of invasion
is highest in the cells in which MTSS1was suppressed and
ERBB2 activated, demonstrating cooperation between
these two gene products. Our current data indicate that
these effects are mediated via changes in tyrosine phos-
phorylation regulated by RPTPd.
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The overall goal of our research is to understand the ge-
netic basis of human disease. In particular, we have fo-
cused on cancer and autism. We have made a number
of discoveries that have identified key genes that regu-
late these diseases, revealing insight into the mechanism
responsible. These findings have had a major impact in
the scientific community throughout the world, and in
several instances, have affected the way clinicians ana-
lyze and treat these genetic diseases. The following are
our major discoveries:
• Identifying p63 as a gene affecting development,
cancer, and aging.
• Discovering CHD5 as a gene that prevents cancer.
• Revealing the genetic basis of autism.
Identifying p63 as a Gene Affecting
Development, Cancer, and Aging
A number of years ago, we discovered a gene called p63
that no one knew even existed. Although p63 looked
very similar to p53—a well-studied gene that is defec-
tive in over half of all human cancers—it was not at all
clear how p63 really worked. We found that p63 is
needed for development, as mice lacking it have mal-
formations of the limbs, are lacking skin, and have cleft
palate. This work provided a clue to clinicians search-
ing for the cause of a human syndrome in which chil-
dren have birth defects of the hands and feet, abnormal
skin, and severe cleft palate. Our work showing that
p63 is needed for development had a major impact, as
it is now known that defects in the p63 gene are the
cause of seven different human syndromes characterized
by birth defects affecting the limbs, skin, and palate.
These birth defects can be so severe that in utero screen-
ing for p63 mutations is sometimes performed in the
clinic. We are currently analyzing mouse models of
these human syndromes in an effort to define their ge-
netic and molecular basis.
My group also discovered that p63 affects aging. p63
is needed for stem cells to replenish the tissues of our
body; when p63 is depleted, rapid aging ensues. These
features of aging include curvature of the spine, hair
loss, and severe skin lesions, indicating that p63 main-
tains youthfulness. However, there is a fine balance, as
p63 must be controlled at just the right level. Indeed,
during the last year, we discovered that too much of a
certain p63 protein (DNp63a) leads to carcinoma—
the most prevalent type of human cancer (Keyes et al.
2011). Pathologists throughout the world routinely use
DNp63a as a marker for diagnosing human cancers of
the breast, skin, and prostate.
In contrast to the tumor-causing DNp63a men-
tioned above, we discovered that other classes of p63
proteins (TAp63 proteins) function in an opposite way:
They prevent cancer. We showed that TAp63 proteins
are able to shut down the growth of a tumor that has al-
ready developed, causing the tumor to shrink dramati-
cally. Importantly, TAp63 is able to shut down tumor
growth even when its sister protein, p53, is completely
absent. This work stunned the p53 cancer community,
because it had always been assumed that having inef-
fective p53 was a virtual death sentence that would ren-
der any anticancer therapy ineffective. Our work shows
this is not the case, as TAp63 can step in and do the
job. We are currently working on strategies to activate
TAp63 that might be feasible in the clinic.
Discovering CHD5 as a New
Cancer-Preventing Gene
Another major breakthrough in my laboratory was the
discovery of CHD5 as a tumor suppressor mapping to
human 1p36—a region of our genomes that is sabo-
taged with deletions in cancer cells. Indeed, 1p36 dele-
tions occur in many different types of human cancers,
including those of the epithelia and brain, as well as
those of the blood. Although the cancer community
had searched for more than three decades for this tumor
suppressor, identification of this gene presented a major
challenge. My laboratory discovered CHD5 as a 1p36
tumor suppressor. By generating mice with gain and
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loss of the genomic region corresponding to 1p36 using
chromosome engineering technology—a strategy that
allows us to generate precise chromosome rearrange-
ments in the mouse—we pinpointed a region of the
genome with potent tumor suppressive activity. Using
a series of genetic and molecular approaches, we iden-
tified CHD5 as the tumor suppressor gene in the re-
gion and found that its product worked as a “circuit
breaker” for a cancer-preventing network. In addition,
we discovered that CHD5 was frequently deleted in
human glioma. Our work identifying CHD5 as a tu-
mor suppressor has had a major impact in the cancer
field, as it is now known that CHD5 is mutated in
human cancers of the breast, ovary, and prostate, as well
as in melanoma, glioma, and neuroblastoma. Further-
more, recent reports indicate that CHD5 status is a
strong predictor of whether anticancer therapy will be
effective; indeed, patients with high levels of CHD5
have much better overall survival than those with low
levels.
Revealing the Genetic Basis of Autism
Our discovery during the past year was the finding that
one of the most common genetic alterations in au-
tism—deletion of a 27-gene cluster on chromosome
16—causes autism-like features (Horev et al. 2011). By
generating mouse models of autism using chromosome
engineering (the same technology that we had used for
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cancer gene discovery, discussed above), we provided
the first functional evidence that inheriting fewer copies
of these genes leads to features resembling those used
to diagnose children with autism. First, “autism” mice
had behaviors such as higher activity, resistance to
change in environment, sleeping problems, and repet-
itive/restrictive behavior; each of these features is simi-
lar to clinical criteria used to diagnose autism in
humans. Second, these mice had distinctive architec-
tural changes in the brain that were detectable by mag-
netic resonance imaging (MRI). Our work provides
functional evidence for the genetic basis of autism that
was not previously appreciated. We believe that these
mice will be invaluable for pinpointing the genes re-
sponsible for the autism-like features and for elucidat-
ing how these alterations affect the brain. They could
also be used for designing ways to diagnose children
with autism before they develop the full-blown syn-
drome, as well as for designing clinical interventions.
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Alea Mills (center, left) and lab members
Our laboratory is one of the four research laboratories
located further afield at the Woodbury Genome Cen-
ter. This center was opened a little over 10 years ago to
make the most of the inimitable opportunities arising
from completion of the Human Genome Project (HGP)
in 2001. By providing the first complete human genome
sequence, the HGP enabled the development of vastly
superior tools than had previously existed for detecting
changes in the human genome. These superior tools
were rapidly applied to cancer, which has long been
known to be at its most fundamental level a genetic dis-
ease. What these tools have revealed in the last decade is
that individual cancer genomes are disrupted in incred-
ibly diverse and complex ways, essentially meaning that
each tumor has its own unique set of altered genes. This
explains how the behavior of individual tumors—how
they progress and eventually respond to therapy—is so
tremendously varied and difficult to predict. 
Occasionally, cancer genome analyses have stumbled
across previously unrecognized genetic alterations that are
frequently found in the tumors of one particular tumor
type, such as mutational activation of BRAF in most
melanoma patients, that stand as a counter example to
the overall diversity of mutations and that have provided
a foundation for the development of new targeted ther-
apeutics. However, for the most part, the cancer genome
projects modeled after HGP, despite being tremendously
successful at generating large lists of mutant genes and
other alterations in human tumors, have provided very
few new therapeutic strategies. However, the most sur-
prising event of the last decade in cancer genome research
has been the revolution in next-generation sequencing
and the realization that within the next decade, next-gen-
eration sequencing will be routinely performed as part of
cancer diagnosis, fueled by the hope that having the com-
plete cancer genome and transcriptome will help doctors
make the most informed treatment recommendations.
Ironically, this will happen before the cancer genome
projects have provided more than a small handful of new
treatments. There is a tremendous gap that needs to be
filled if cancer genome projects are to fulfill their prom-
ise of transforming cancer treatment.
Our view is that filling this gap will require a syn-
thesis of cancer genome characterization with func-
tional tests derived from the large number of model
systems that have been developed in the past 100 years.
There are so many model systems to test the relevance
of a given genetic alteration to cancer, and there is re-
ally no excuse for not being able to translate genomic
discoveries into new insights into what is biologically
driving cancer progression. With new insights into bi-
ological drivers we can propose new therapeutic targets,
which could in time be translated to cancer medicine.
The cancer models are there, they just have to be cho-
sen carefully and applied systematically. 
Cancer Genome-Focused Screening
During the last seven years, we and our colleagues have
developed an approach to discovering new treatment
strategies that focuses directly on the genes most signifi-
cantly affected by a given type of genetic alteration, e.g.,
gene amplification, in a given cancer type, e.g., liver can-
cer. This focused approach directly tests genes for tumor-
promoting function in an appropriate cell type (Fig. 1).
In a study we published this year, 124 amplified genes in
human hepatocellular carcinoma (HCC) were screened
in pools for oncogenicity by forced overexpression in a
transplantable mouse hepatocyte model. 18 of these am-
plified genes turned out to be tumor-promoting “driver”
genes, whereas the other 106 genes appeared to be inac-
tive passenger genes. Interestingly, the correlation of
mRNA expression with DNA amplification was unable
to distinguish drivers from passengers in this functionally
vetted set, indicating that passengers and drivers are both
overexpressed as a result of DNA amplification; however,
an algorithm that combined a functional interaction net-
work described with a knowledge-based oncogenicity
ranker (http://cbio.mskcc.org/tcga-generanker/) was able
to distinguish drivers from passengers (albeit only par-
tially). Importantly, a follow-up study using RNA inter-
ference (RNAi) established that HCC cells harboring an
11q13.3 amplicon were selectively dependent on the am-
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plified driver gene and FGF19. This selective depend-
ency was also observed using a monoclonal antibody di-
rected against Fgf19, pinpointing a new targeted
therapeutic strategy. 
This approach is readily generalizable. It was modi-
fied to discover driver genes from recurrently deleted re-
gions in human HCC, by screening pools of short
hairpin RNAs (shRNAs) targeting the candidate deleted
tumor suppressor genes, and modifications of the ap-
proach have been used to screen focused libraries in trans-
plantable mouse models of lymphoma and leukemia.
The cancer genome-focused screening approach
draws strength from the simple fact that it was designed
solely to directly address the oncogenic relevance of
human cancer genomic alterations. Another strength of
the cancer genome-guided screening approach is that by
focusing on fewer genes, the depth and strength of the
corresponding RNAi library can be better optimized. 
Our cancer genome-focused screening efforts are part
of the National Cancer Institute (NCI)-sponsored Can-
cer Target Discovery and Development Consortium
(http://ctd2.nci.nih.gov/) that was developed to incor-
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porate cancer genome characterization into molecular
target discovery and validation programs. The Cancer
Target Discovery and Development (CTD2) network is
the first coordinated effort aimed at translating that ther-
apeutic potential for cancer patients. Five projects (http://
ocg.cancer.gov/programs/ctdd.asp) focus on the devel-
opment of novel scientific approaches to accelerate the
translation of the genomic discoveries into new cancer
treatments. The network emphasizes interaction of lab-
oratories with complementary and unique expertise, in-
cluding bioinformatics, genome-wide loss-of-function
screening and targeted gain-of-function candidate gene
validations, intelligent use of mouse-based screens, and
small-molecule high-throughput screens. Within CTD2,
we are currently performing cancer genome-focused
screens in ovarian and other select cancers.
Pooled shRNA Screening for Cancer Targets
Since 2005, our lab has devoted much of its effort to
genome-scale RNAi screening, which holds the promise
of not only finding the best targets for cancer therapeu-
tics, but also systematizing the search for combination
therapeutic strategies. We have performed one screen to
look for targets to inhibit in combination with inhibi-
tion of the mitotic regulator polo-like kinase (PLK1) in
lung cancer, and another screen to find targets to inhibit
in combination with a candidate cancer drug that com-
bines oleic acid with lactalbumin (“Hamlet”); results
from both of these efforts were published this year. We
have also performed an RNAi screen to find targets to
inhibit in combination with temozolomide, an alkylat-
ing agent used to treat glioblastomas and melanomas,
and another screen to find targets to inhibit in combi-
nation with a phosphoinositol-3 kinase (PI3K) in-
hibitor. We have also screened HCC cells to look for
new therapeutic targets under both normal conditions
and the hypoxic conditions that more closely resemble
how tumors grow in patients. Although in each case we
have discovered some interesting “hits,” the problem
that we have been most frustrated with is the false-neg-
ative problem, resulting from ineffective shRNAs that
do not silence their target gene. This prevents one from
being able to use the extensive data sets that are gath-
ered to “dial-in” on the function of individual genes, and
instead limits shRNA screening utility to finding one or
more genes that, once individually validated, can be pur-
sued in detail. Once truly validated shRNA libraries
have been developed, there is no doubt the technology
will be much more broadly useful. 
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Figure 1. Cancer-genome-focused screening directly tests genes
for tumor-promoting function in vivo. In this example, whole-
genome copy-number alteration data obtained from tumor sam-
ples are computationally analyzed to nominate candidate driver
oncogenes within focal amplifications and tumor suppressors
within focal deletions. Next, focused shRNA or cDNA libraries
are constructed from commercially available plasmid collections
in order to overexpress the predicted oncogenes (cDNA library)
or knock down the tumor suppressor genes (shRNA library). Pre-
malignant cells are infected with pools of the focused library,
which are then screened in the mouse for tumor promotion. Ge-
nomic DNA is then isolated from resulting tumors and shRNA or
cDNA sequences are recovered using polymerase chain reaction
(PCR) amplification. DNA sequencing is used to identify indi-
vidual shRNA or cDNAs responsible for tumor promotion by
comparison to the shRNA or cDNA composition of preinjected
control cells.
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able and involves hypermethylation of polycomb target
and developmental genes. This more variable epigenetic
state was found in differentiated tumors expressing ma-
ture hepatocyte markers and containing extensive DNA
copy-number alterations. Thus, destabilization of DNA
copy number and the DNA methylome may both be
necessary to induce tumorigenicity in mature hepato-
cytes. In contrast, stem-like HCCs can emerge from a
fetal-like normal progenitor with both a stable genome
and stable epigenome. 
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Genomic Analysis of Hepatocellular
Carcinoma
With the ascendancy of centrally organized, productive,
and well-funded cancer genome projects, which have al-
ready characterized thousands of cancer genomes, there
corresponds a diminishing rationale for small individual
laboratories to try to do the same. In what is likely to be
our last cancer genome characterization project, we in-
tegrated analyses of the human hepatocellular DNA
methylome with its copy-number alterations and tran-
scriptional changes. We found two types of hepatocel-
lular carcinomas (HCCs). In one case, we found that the
DNA methylome is remarkably invariant and closely re-
sembles normal fetal liver in the hypermethylation and
silencing of liver-differentiation-specific genes. We
showed that this state is associated with stem-like tumors
that harbor few DNA copy-number alterations and that
resemble fetal liver in the coordinated hypermethylation
and silencing of tumor suppressors (e.g., MST1 and
HNF4A) as well as the hypomethylation and expression
of oncogenes (e.g., STAT5A and OPN ). In the other
case, the HCC DNA methylome is markedly more vari-
Scott Powers (standing, right) with lab members
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The Wigler and Hicks group studies human cancer and
genetic disorders from a population genomics perspective.
The cancer effort focuses on breast and prostate cancer
(the latter jointly with Lloyd Trotman) and involves col-
laborative clinical studies (with local, national, and inter-
national collaborators) to discover mutational patterns
predicting treatment response and outcome. We also de-
velop methodology for single-cell genomic and RNA
analyses to detect cancer cells in bodily fluids such as blood
and urine. This last has major potential applications to the
early detection of cancer and monitoring its recurrence
and response to therapy during and after treatment. The
single-cell analysis has also led to insights about the clonal
evolution and heterogeneity of cancers (Navin et al. 2011).
This work may lead to a better understanding of initia-
tion, progression, and metastasis and shed light on the
stem cell hypothesis of cancer and host responses.
Our genetic efforts are largely focused on determining
the role of new (de novo) mutation in pediatric disorders
with a strong genetic contribution. We study autism as
part of a large study of simplex families organized by the
Simons Foundation (Fischbach and Lord 2010), as well
as congenital heart disease with Dorothy Warburton of
Columbia University and pediatric cancers with Ken
Offit of Memorial Sloan-Kettering Cancer Center
(MSKCC). In collaboration with Alea Mills, we helped
create a mouse model for one of the most common ge-
netic abnormalities contributing to autism (Horev et al.
2011). Recent work has confirmed and extended our
previous observations on the role of de novo copy-num-
ber variation (large-scale mutation) in autism (Levy et al.
2011), with similar results in the other disorders. In a
large-scale exome sequencing project in collaboration
with Dick McCombie (at the Genome Center at CSHL)
and the Genome Sequencing Center at Washington Uni-
versity in St. Louis, we have proven the role of small-scale
de novo mutations that disrupt genes in autism (Iossifov
et al. 2012). Overall, our results succeed in confirming
our previous genetic models for autism incidence and
identify strong candidate mutational targets, from which
biological models of autism can be made and tested.
Breaking with tradition, the remainder of this report
contains two position statements on the direction in
which we are taking our science, and why.
Applications of Single-Cell Analysis
to Biological and Medical Problems
For several years, we have explored methods for gathering
and analyzing nucleic acid sequences from single cells.
There are at least five broad areas in which single-cell
methods can be applied: (1) cancer, (2) neurobiology, (3)
disorders of stem cell renewal, (4) detailed dissection of
cell-state transitions, and (5) genome assembly. We are
working on each. All of these applications require im-
provements in the gathering of single-cell data, both its
quality and cost, and developing new processing algo-
rithms. Some of the mathematical challenges are new. To
improve data generation, we make use of DNA barcod-
ing to facilitate massively parallel sample processing, in-
crease the uniformity of data quality, and reduce costs.
The applications of single-cell analysis in cancer are
nearly endless. Single-cell genome analysis can be used for
detecting cancer cells in samples such as blood or urine
obtained by noninvasive or minimally invasive proce-
dures. A more thorough analysis of standard biopsy ma-
terial, such as needle biopsies, can be achieved by
single-cell genome profiling, revealing details of cancer
heterogeneity, subpopulation structure, host reaction, and
the presence of cancer cells in surgical margins and lymph
nodes. Through single-cell RNA expression, the host re-
sponse at the sites of cancer growth can be monitored: the
presence of capillary endothelium, immunocytes of all
types, and reactive stroma. The identity of soluble factors
to which these cells are responding may be inferred by
observing their response signatures. By means of statisti-
cal methods correlating clinical outcomes with single-cell
observation, we shall be able to improve detection, prog-
nosis, therapeutic choice, and monitoring response to
therapy. The most transformative application would be a
blood test for early detection of cancer onset, where the
GENOMIC ANALYSIS OF CANCER AND HUMAN GENETIC DISORDERS
M. Wigler J. Alexander M. Bekritsky I. Hakker J. Kendall B. Ma M. Riggs
J. Hicks P. Andrews H. Cox Q. Huan Y.-H. Lee S. Marks L. Rodgers
T. Auletta D. Esposito J. Huang A. Leotta J. McIndoo M. Ronemus
T. Baslan E. Grabowska R. Kandasamy D. Levy N. Navin
Cancer: Genetics     79
DNA analysis provides evidence for the presence of can-
cer cells and disease stage, and the RNA analysis indicates
the cancer’s tissue origin and subtype. Both together can
aid in prognosis and choice of therapeutic intervention.
Finally, many fundamental questions of cancer biology
can be addressed by single-cell analysis. Among these:
How do cancer populations evolve? Is there in fact a stem
cell population that is genetically distinct from the ma-
jority of the tumor population? From what cell or com-
bination of cells do metastases arise? To what extent and
through what processes do cancer cells cooperate?
Single-cell expression analysis can also be used to de-
velop a deeper understanding of neural and nonneural
subtypes in the nervous system (brain, chord, and gut)
where tissue heterogeneity obscures bulk analysis. The
result can be a better modeling of neuronal networks
through identification of neuronal subtypes and a bet-
ter understanding of the response of neuronal cells to
stimuli. The role of somatic mutation in nervous system
disease can be explored. Finally, these methods can help
refine our knowledge of the fates of pluripotent stem
cells induced to differentiate into neuronal cells. If suc-
cessful, we could explore the functional consequences of
candidate gene mutations.
The identity of stem cells and the role of aberrant
stem cells in medical disorders are still highly unexplored.
By an iterative process coupling cell separation and re-
generative assays, single-cell RNA analysis can help iden-
tify which cells in a tissue or in distant tissues are in fact
the cells with regenerative capacity. Several medical dis-
orders, particularly those of aging, may be the result of
somatic mutation in stem cells causing the replacement
of critical cell types over time with dysfunctional versions.
The types of disorders that might be caused by this
mechanism include a wide variety of neurodegenerative
conditions (e.g., Alzheimer’s), disorders of autoimmu-
nity (e.g., lupus), cardiomyopathies, and a variety of cu-
taneous (e.g., psoriasis) and connective tissue (e.g.,
scleroderma) diseases. The mechanisms underlying these
disease processes might become apparent by combining
DNA and RNA analysis of single cells, looking for aber-
rant genomes or expression patterns in stem cells. The
latter may be identified at the single-cell level in complex
organs, thereby overcoming the problems that beset the
analysis of mixed-cell populations.
Examples of cell-state transitions abound in all living
systems: the progression through the cell cycle, response
to nutrient opportunity, differentiation, responses to
growth factors and other signaling molecules, and even
responses to contact with other cells. Often, these tran-
sitions involve a causal sequence of changes in the ex-
pressive state of the cell, the proteins and RNAs that they
make. Because these changes typically occur in cell pop-
ulations that are not in temporal synchrony, the study of
the sequence of changes often cannot be determined with
precision. Single-cell analysis offers one way around this
problem, as each cell represents a snapshot in time at the
point when it is destroyed and converted to an ensemble
of macromolecules. In principle, the overall series of
changes can then be assembled into a coherent whole
provided that (1) there is some overlapping signature in
the macromolecular composition between time-adjacent
states and (2) the temporal series is relatively similar from
cell to cell.
We can make sequence libraries from a fraction of a
cell genome. Genome analysis itself can be improved
by doing this. If the DNA of a cell is diluted sufficiently
into isolated “packets,” any contiguous region we se-
quence from a given packet is likely to represent only
one of the two parental haplotypes. If the DNA is not
broken into small pieces during dilution, but diluted
in large blocks—even if we subsequently break the
DNA into small pieces when we make libraries—we
can reassemble the short-read sequences into large hap-
lotype blocks. The result, if conducted efficiently using
many cells as a starting point, would ultimately be a
haplotypic assembly of the genome of any organism at
roughly the cost of sequencing the entire organism in
the conventional manner. As a practical matter, this
converts the most efficient sequencing apparatus cur-
rently available, which is a short-read apparatus, into a
long-read single-molecule apparatus.
Genetic Models of Autism
A large proportion of our lab works on autism genetics.
The purpose of these notes is to give some scientific per-
spective to what the group has achieved and the future
direction it will take. The rewards of studying autism
from a genetic point of view are great. The disorder affects
some of the most profoundly human traits. A complete
analysis may reveal new sources of phenotypic variation.
A good set of targets provides guides to therapies. And
there are unmet needs for early detection and counseling
families and individuals coping with the condition.
It was evident to some by as early as the mid 1980s
that autism was likely to be a disorder caused by new
mutation. The disorder was variable, hinting at multi-
ple underlying causes; the incidence was high; the her-
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itable component was appreciable but low; but the con-
cordance in identical twins was higher than in any other
cognitive or behavioral impairment. Human geneticists
had failed repeatedly to produce evidence of heritable
underlying events, except in the limited cases of X-
linked disease. In both of these cases, Fragile-X syn-
drome (FXS) and Rett syndrome, new or recent de
novo mutations were clearly the root cause. Geneticists
using transmission genetics would explain their failure
under the rubric of a “complex” disorder, caused by
subtle interactions of multiple genes that would there-
fore be hard to crack. But what we knew in fact pointed
to the existence of singular events of strong penetrance.
Cytologic analysis had showed that many rare large-
scale chromosomal events could result in developmen-
tal anomalies. Cytology could only scratch the surface
of the richness of the consequences of new mutation.
In the early 2000s, methods for examining copy-
number variation (CNV) developed in our lab (Lucito
et al. 2003) became very powerful when combined with
the data of the human genome sequence assembly
(Healy et al. 2003). This led to the discovery of wide-
spread CNV in the human gene pool (Sebat et al.
2004) and the hope that we could demonstrate autism
was associated with new mutations likely to disrupt the
dosage of functioning genes. Supported by the Simons
Foundation, we succeeded in showing this (Sebat et al.
2007), and our work fed the acceptance of the idea that
disorders associated with drastically reduced fecundity
would be often caused by new mutation through the
action of gene dosage effects. Altering the functional
dosage of certain genes, whether by duplication, dele-
tion, or disruption, would manifest upon transmission
as dominant traits, and we sought evidence for this in
the AGRE data of multiplex families. We found the ev-
idence (Zhao et al. 2007), namely, that boys born to
parents with two previous offspring with autism spec-
trum disorder (ASD) had a 50% chance of being on
the spectrum. These observations were confirmed in in-
dependent studies by ourselves and others.
Mathematical modeling of the family risk function
using the AGRE data, and data from other sources, led
to several predictions (Zhao et al. 2007). Up to half of
autism might be explained by new mutation, and a
large part of the remainder would be due to transmis-
sion of strongly penetrant variants carried by asympto-
matic parents. We speculated that most often the carrier
parent would be the mother.
Subsequent work has focused on defining the list of
autism target genes and developing a more quantitative
genetic model. We seek a list of target genes in the expec-
tation that such a list would provide medical geneticists
with improved tools for diagnosis, especially early diag-
nosis, and also yield insights into physiologic mechanisms
and thus ideas for intervention. Our most recent studies
of autism were based on the Simons Simplex Collection,
an unparalleled sample set, and are published in Neuron
(Gilman et al. 2011; Iossifov et al. 2012; Levy et al. 2011).
These papers provide a leap forward in assembling the list
of gene targets (Gilman et al. 2011), validated the role of
de novo CNV in autism (Levy et al. 2011), and provided
evidence of a roughly equal role of transmission of rare
CNV. Levy et al. (2011) provided evidence that the
autism candidate loci contained a functionally convergent
network of genes, and they extracted a list of the most
likely autism candidate loci from the CNV data. Iossifov
compared sequence data within families to find com-
pelling evidence that de novo mutations which disrupt
genes contribute to autism. Many of the findings of Ios-
sifov are found in three smaller studies published essen-
tially concurrently (Neale et al. 2012; O’Roak et al. 2012;
Sanders et al. 2012). Recurrence analysis confirmed pre-
vious estimates that there are on the order of 200−800
(most likely, 350–400) dosage-sensitive genes that when
disrupted can contribute significantly to autism. Most sig-
nificantly, the list of genes showed a strong overlap with
genes that encode proteins whose translation may be
under the control of FMRP, the product of the gene re-
sponsible for fragile-X syndrome (FXS). Nearly half of
autism dosage-sensitive genes may be so controlled.
FMRP is one of the central regulators of synaptic plastic-
ity, the physiologic mechanism underlying the response of
neural networks to repetitive stimuli.
In addition to producing an extensive list of well-
vetted autism gene targets, we have focused on obtain-
ing a better, more detailed quantitative genetic model
for autism incidence. What answers would such a
model provide, and why would they be useful? A de-
tailed quantitative model would determine with greater
precision the number of dosage-sensitive gene targets
and determine more precisely the overall role of these in
incidence. Without such information, it will be hard to
know how much of causation we are missing, and
whether we need to consider extragenic mechanisms to
explain phenotypic variation. Without such a model,
we would be unaware of whether we were dealing com-
petently with the problem. An adequate model would
explain the role of gender bias in transmission, and
whether certain targets are gender-specific. Properly un-
derstood, gender bias might guide thinking about ther-
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apy. At the present time, there are gaps in the evidence
supporting any model or mixture of models. Filling
those gaps either with further evidence or by correct-
ing the models will be valuable contributions to our un-
derstandings of genetics and cognition.
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Signal transduction focuses on signaling pathways and cell architecture in normal and cancer cells.
Mikala Egeblad and colleagues study tumors and in particular the contributions of the mi-
croenvironment in which the cancer cells arise and live. Solid tumors are abnormally organized tis-
sues that contain not only cancer cells but also various stromal cell types and extracellular matrices,
and these latter components constitute the microenvironment. Communication between the dif-
ferent components of the tumor influences its growth, response to therapy, and ability to metasta-
size. The lab studies the importance of such communications using mouse models of breast cancer
and real-time imaging of cells in tumors in live mice. This enables them to follow the behaviors of
and the interactions between cancer and stromal cells in tumors during progression or treatment.
Among tumor-associated stromal cells, their main focus is on myeloid-derived immune cells, a di-
verse group of cells that can enhance angiogenesis and metastasis and suppress cytotoxic immune
responses against tumors. Egeblad is interested in how different types of myeloid cells are recruited
to tumors and how their behaviors (for example, their physical interactions with cancer cells and
other immune cells) influence cancer progression including metastasis. The lab is also addressing how
therapy affects cancer and stromal cells in different tumor microenvironments, in part by using im-
aging to follow the response to chemotherapy in mice in real time.
Yuri Lazebnik and colleagues study cell fusion in the context of the hypothesis that viruses and
other common human pathogens may cause cancer under certain conditions. They have established
that massive chromosomal instability can be engendered by a transient event causing genomic desta-
bilization without permanently affecting mechanisms such as mitosis or proliferation. The agent, in
this instance, is an otherwise harmless virus that causes chromosomal disruption by fusing cells
whose cell cycle is deregulated by oncogenes. The resulting cells have unique sets of chromosomes,
and some can produce aggressive epithelial cancers in mice. Having developed a method of pro-
ducing hybrid cells more efficiently—a means of isolating viral fusogenic proteins—Lazebnik and
colleagues are attempting to induce fusion under controlled conditions in order to explore the con-
sequences for cell viability and survival.
Changes in tissue architecture are often the first signs of cancer, but very little is known about
the genes, proteins, and pathways that regulate cellular shape and polarity. Senthil Muthuswamy
has developed a novel paradigm for considering this aspect of cancer biology. Using sophisticated
model systems such 3D cell culture platforms and transgenic mice, his team found that a protein
called Scribble normally regulates proper differentiation of breast epithelial cells, coerces them into
the correct organization and shape, and enforces resistance to cancer. They also have found that
deregulation of the Scribble pathway results in the development of undifferentiated tumors in mice.
Muthuswamy’s team determined that Scribble is frequently mislocalized from cell membranes or not
expressed in human breast cancer lesions, which suggests that understanding the pathways regu-
lated by Scribble can identify therapies aimed at preventing precancerous lesions from becoming in-
vasive. This past year, the lab has collaborated with the Tonks lab to develop novel approaches for
treating HER2-positive breast cancers.
Darryl Pappin’s lab develops chemical and computational methods for analysis of proteins and
peptides. These are fundamental tools for proteomics and are vital in many fields of biological in-
vestigation. Proteins and peptides are typically analyzed via mass spectrometry, a method that in-
volves fragmenting samples by colliding them with gas atoms in a vacuum. Masses of the resulting
fragments are measured, and computer algorithms match results with known or predicted molecules
whose amino acid sequences are either known or inferred. Pappin has developed search engines for
mass spectrometry data that enable investigators to sift through hundreds of thousands of experi-
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mental spectra at a time for database matches. He also seeks to reduce sample complexity via an ap-
proach he calls chemical sorting. This includes the use of chelation to enrich phosphopeptides from
the total peptide pool and the use of specific affinity-tagged small-molecule inhibitors to segregate
classes of kinases or phosphatases for more specific mass-spectroscopic analysis.
Despite their large variety of genetic abnormalities, cancer cells have been found to be extremely
sensitive to the reversal of certain mutations. Raffaella Sordella and colleagues study the reasons why
cells in certain cancers are responsive to the inhibition of one particular gene or gene product. For
instance, why do non-small-cell lung cancer (NSCLC) cells that have a particular mutation in the
EGF (epidermal growth factor) receptor respond dramatically to its inhibition by the drug Tarceva
(erlotinib). This occurs in 15%−20% of patients, in whom the great majority, within 1−3 years, de-
velop resistance. Various mutations have been implicated in about half of resistant patients. Sor-
della and colleagues have discovered a new resistance mechanism in a subpopulation of NSCLC
cells that are intrinsically resistant to Tarceva. These tumor cells were observed to secrete elevated
amounts of a growth factor called transforming growth factor-b (TGF-b), which in turn increases
secretion of interleukin-6 (IL-6), an immune signaling molecule. Significantly, these effects were
independent of the EGF receptor pathway. The team therefore hypothesized that inflammation is
one factor that can render a tumor cell resistant to treatment with Tarceva. In other work, Sordella
collaborates with the Krainer lab to study whether alternative splicing has a role in the failure of p53-
mediated senescence to halt oncogenesis in certain lung cancers.
Nicholas Tonks and colleagues study a family of enzymes called protein tyrosine phosphatases,
or PTPs, which remove phosphate groups from proteins and other signaling molecules, such as
lipids, in cells. Disruption of PTP function is a cause of major human diseases, and several of the
PTPs are potential therapeutic targets for such diseases. Tonks’ group seeks to characterize fully the
PTP family, understand how their activity is controlled, how they modify signaling pathways, and
how those pathways are abrogated in serious illnesses, including cancer, diabetes, and Parkinson’s dis-
ease. The overall goal is to identify new targets and strategies for therapeutic intervention in human
disease. This year, Tonks and colleagues have defined new roles for PTPs in regulating signaling
events in breast cancer, identifying three PTPs as novel potential tumor suppressors. They have char-
acterized the regulation of PTP1B by reversible oxidation, demonstrating that it is regulated by 
covalent modification of the active site by hydrogen sulfide (H
2S) under conditions of endoplasmic
reticulum (ER) stress that are linked to protein-folding-related pathologies, such as Parkinson’s and
Alzheimer’s. In addition, they have generated recombinant antibodies that recognize selectively the
oxidized conformation of PTP1B; these antibodies display the ability to promote insulin signaling
in cells and suggest novel approaches to therapy for diabetes. Finally, they have also discovered a novel
mechanism for allosteric regulation of PTP1B activity, offering the possibility of developing small-
molecule drugs that could inhibit the phosphatase and thereby modulate signaling by insulin and
the oncoprotein tyrosine kinase HER2—potentially offering new ways to treat insulin resistance in
type 2 diabetes and breast cancer.
Lloyd Trotman’s recent research path traces to his discovery some years ago that the loss of a sin-
gle copy of a master tumor-suppressing gene called PTEN is sufficient to permit tumors to develop
in animal models of prostate cancer. His team later found that complete loss of PTEN paradoxically
triggers senescence, an arrested state that delays or blocks cancer development in affected cells. These
findings explained why many patients only display partial loss of this tumor suppressor and estab-
lished a novel mechanism of cancer initiation. His lab has recently been expanding these findings
in collaboration with clinicians at Memorial Sloan-Kettering Cancer Center, with the aim of iden-
tifying patients who have developed tumors with metastasis-favoring mutations. Now, the Trotman
lab is generating mouse models that accurately reflect the core genetic changes driving human
metastatic prostate cancer, with the aim of developing novel molecular assays that separate the few
men who are at risk of developing lethal disease from the rest. Last year, Trotman and colleagues iden-
tified a new prostate tumor suppressor gene called PHLPP1 and showed that it acts in concert with
PTEN, a well-studied tumor suppressor that is mutated in roughly half of prostate cancer patients.
The Trotman lab is using these findings to establish prediction methods for disease progression,
based on high-resolution genomic analysis techniques developed at CSHL by Drs. Wigler and Hicks.
The lab is also studying regulation of PTEN stability and nuclear transport, because many patients
have tumors that aberrantly target PTEN for cytoplasmic degradation.
Linda Van Aelst’s lab studies how aberrations in intracellular signaling involving enzymes called
small GTPases can result in disease. They are particularly interested in Ras and Rho GTPases, which
help to control cellular growth, differentiation, and morphogenesis. Alterations affecting Ras and
Rho functions are involved in cancer and various neurodevelopmental disorders. Van Aelst’s team
has extended its prior study of mutations in a Rho-linked gene called oligophrenin-1 (OPHN1), part
of an effort to connect the genetic abnormalities associated with mental retardation to biological
processes that establish and modify the function of neuronal circuits. In addition to a role for
OPHN1 in activity-driven glutamatergic synapse development, they have obtained evidence that
OPHN1 has a critical role in mediating mGluR-LTD, a form of long-term synaptic plasticity, in CA1
hippocampal neurons. Their findings provide novel insight not only into the mechanism and func-
tion of mGluR-dependent LTD, but also in the cellular basis by which mutations in OPHN1 could
contribute to cognitive deficits in patients. In addition, the Van Aelst team has discovered a critical
role for a novel activator of Rho proteins in the genesis of cortical neurons. Defects in cortical neu-
rogenesis have been associated with cerebral malformations and disorders of cortical organization.
The team finds that interfering with the function of the Rho activator in neuronal progenitors in
embryonic cerebral cortices results in an increase in the number of proliferating neuronal progeni-
tors and defects in the genesis of neurons. This provides novel insight into mechanisms that coor-
dinate the maintenance of the neural progenitor pool and neurogenesis.
The research of Hongwu Zheng and colleagues aims to define the complex biology of malignant
glioma pathogenesis, with the ultimate goal of translating the developed knowledge into patient
benefits. Although eerily similar in terms of their self-renewal capacity and distinct phenotypic plas-
ticity, malignant glioma cells conspicuously lack the terminal differentiation traits possessed by their
normal counterparts—neural progenitors. Using multiple approaches combining human cancer ge-
nomics, animal modeling, and stem cell biology, Zheng has unraveled the causal relationship be-
tween aberrant differentiation and ensuing gliomagenesis. Perhaps more importantly, his team has
demonstrated that forced restoration of differentiation capacity within glioma cells can drastically
attenuate their tumorigenic potential. This finding fits well with the team’s overall strategy, which
is to target differentiation control pathways as a novel avenue for malignant glioma treatment. To
this end, they have sought to (1) develop various animal models to recapitulate the human glioma
pathogenesis and use them to trace and investigate in vivo tumor initiation/progression and (2) iden-
tify key pathways/players controlling normal and neoplastic neural progenitor cell renewal and cell-
fate determination.
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Solid tumors are composed of cancer cells and stroma, a
supportive framework that constitutes the tumor mi-
croenvironment. It includes the extracellular matrix
(ECM) and stromal cells such as fibroblasts, adipocytes,
cells of the vascular system, and immune cells. Interac-
tions between epithelium and stroma are essential for
normal organ development. As tumors develop and
progress, they undergo dramatic changes that involve
both the cancer cells and the microenvironment. Stromal
components that have been proposed to have a more
pronounced tumor-promoting function in advanced
stages than in earlier stages include cells of the myeloid
lineage, such as macrophages and dendritic cells.
We have developed an imaging method that permits
real-time spinning-disk confocal microscopy of tumor−
stroma interactions in mouse models of human breast
cancer (Fig. 1). This allows us to follow, for example,
vascular leakage, myeloid cell infiltration, and cancer
cell proliferation and death in real time. We use this
technology to understand how cancer is affected by the
microenvironment. 
Effects of the Tumor Microenvironment
on Response to Cancer Therapy
When tumors do not respond to treatment, patients die.
Understanding the mechanisms of therapy response and
resistance is therefore of vital concern. Surprisingly, little
is known about how cancer cells in intact tumors respond
to classical chemotherapy, although these drugs have
been used for decades. Most knowledge on the responses
has been obtained from cell culture or xenograft animal
experiments, but such experiments are often not predic-
tive of drug responses in patients.
Development of resistance can be caused by cancer
cell intrinsic factors (genetic or epigenetic changes) or
by extrinsic factors such as survival factors secreted from
stromal cells or impairment of drug penetration
through the altered tumor ECM. Certain organs, such
as the bone marrow and the thymus, have been shown
to offer protection from chemotherapy mediated by se-
creted factors from stromal cells (e.g., interleukin 6).
However, it is not known how the evolving microenvi-
ronment of solid tumors shapes drug sensitivity.
We are using in vivo spinning-disk confocal imaging
to study drug sensitivity in the context of evolving
tumor microenvironments. We have treated mouse
models of mammary carcinoma with doxorubicin and
followed drug responses by live imaging. Cell death
started ~24 h after doxorubicin treatment, and cells
died by necrosis and not apoptosis. We further showed
that the microenvironment of different tumor stages
participated in regulating the drug response. Early-stage
lesions responded poorly compared to intermediate-
sized, early carcinoma stage tumors. However, in vitro,
sensitivity to doxorubicin was similar for cancer cells
from different stages. Treatment also led to a new mi-
croenvironment, as dead cells recruited new myeloid-
derived cells, changing the microenvironment of the
responding tumors. Thus, imaging intact tumors
acutely after treatment with chemotherapy revealed a
complex and evolving relationship between microenvi-
ronment and the drug sensitivity of cancer cells.
Effects of Myeloid Cells on Breast
Cancer Metastasis
The prognosis of metastatic breast cancer is poor, and
although genetic changes that facilitate metastasis have
been identified, such information has not yet improved
patient outcomes much. More than a century ago, Dr.
Stephen Paget observed that metastases develop prefer-
entially in certain organs, suggesting that factors exter-
nal to cancer cells influence metastasis. Indeed, it is now
recognized that growth factors and cytokines secreted
by myeloid-derived cells have a role in the formation of
metastases. 
Traditionally, studies on metastases have relied pri-
marily on measurements made at the endpoint of the
process, the establishment of micro- or macrometas-
tases. However, the metastatic process is dynamic and
characterized by the ability of cancer cells to move from
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one part of the body to another: Cells exit the primary
tumor, invade the local tissue, enter blood or lymphatic
vessels, and are transported to a distant site where they
exit the vessels and move into the tissue. Thus, a better
understanding of metastasis requires technologies that
can follow these dynamic processes in vivo.
Our laboratory is using spinning-disk confocal mi-
croscopy to determine how interactions between
myeloid-derived cells and cancer cells influence metasta-
sis. We are comparing the microenvironment of tumors
formed from the metastatic 4T1 and the nonmetastatic
4T07 cell lines, isolated from the same breast tumor. We
have identified significant differences in the types of
chemokines that are secreted by the cancer cells and in
the nature of the myeloid cell infiltrate between the
metastatic and nonmetastatic tumors. Strikingly, tumors
grow more slowly and metastasis is greatly reduced in
mice that lack the receptor for one of the chemokines
that specifically is secreted by metastatic cancer cells. On-
going  studies are addressing how the chemokine-
chemokine  receptor signaling axis between cancer cells
and myeloid-derived cells influences metastasis. 
Using Tumoricidal Activities
of Macrophages 
Tumor-associated macrophages have tumor-supporting
activities, and their infiltration is associated with poor
patient prognosis. However, macrophages are capable
of killing tumor cells (Fig. 2) if they are activated with
interferon-g (IFN-g) and agonists of receptors for
pathogen-associated molecular patterns. We are using
live cell imaging of cocultures between macrophages
and cancer cells to understand the mechanisms re-
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sponsible for the tumoricidal activities. Macrophage-
mediated cancer cell killing is highly effective, specific
for cancer cells, and requires direct cell−cell contact be-
tween macrophages and cancer cells. A potential medi-
ator of the cell killing has been identified and is under
further investigation.
Antigen-Presenting Myeloid Cells
Stably Engage Tumor-Specific T Cells
in the Tumor Microenvironment
This work was done in collaboration with Matthew
Krummel, University of California, San Francisco.
Antigen presentation in the tumor microenvironment
should lead to activation of tumor-specific T cells and
thereby cytotoxic activities against the tumor. Yet, al-
though T cells with specific reactivity have been iso-
lated from many solid tumors, the immune system is
not capable of eradicating most tumors. To determine
the potential inhibitory activities on T-cell responses, a
fluorescent- and antigen-linked transgenic model of
breast cancer was developed. This model enabled live
imaging of antigen presentation in situ. The primary
cells responsible for ingesting tumor antigens and pre-
senting them to T cells were identified as low-motility
myeloid cells, with properties of both dendritic cells
and macrophages. Marker analysis further demon-
strated that these antigen-presenting cells were a subset
of the myeloid cells that previously have been impli-
cated in tumor remodeling. These antigen-presenting
cells localized along tumor margins and engaged in
long-lived interactions with tumor-specific T cells. In
vitro, these myeloid cells could capture cytotoxic T cells
in signaling-competent conjugates, yet, the interaction
Figure 1. Imaging tumor microenvironments in live mice. The image size and the pixel resolution at the image is
demonstrated using spinning-disk confocal microscopy on a live MMTV-PyMT;ACTB-ECFP;Fsp1+/+.EGFP mouse after in-
travenous injection with 70-kDa rhodamine-conjugated dextran. Cancer cells, fibroblasts, and vasculature are la-
beled. The same maximum intensity projection is shown at increasing magnification (A, B, C). Bars, 100 mm. (Adapted
from Ewald et al. 2011.)
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did not support full T-cell activation or sustain cytoly-
sis of cancer cells. Thus, these antigen-presenting cells
fail to stimulate T cells and may serve as a barrier to an
effective T-cell response. This work demonstrated the
behavior of tolerized T cells within tumors and identi-
fied a target for immunotherapies. 
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Figure 2. Tumor-suppressing functions of myeloid-derived cells. Macrophages can be stimulated with lipopolysac-
charide (LPS) and IFN-g to gain tumor-suppressing functions. These functions comprise the direct killing of tumor cells
as well as the release of proinflammatory cytokines that inhibit angiogenesis and lead to the activation of natural
killer (NK) cells, Th1 cells, cytotoxic T cells, and neutrophil granulocytes. Factors released by dying tumor cells, such
as ATP, can further enhance macrophage activation. (From Kees and Egeblad 2011.)
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During the last year, we continued to test a model, which
we proposed previously, that some viruses can contribute
to carcinogenesis and tumor progression by fusing cells.
Two consequences of such fusion are of particular inter-
est. One is an abnormal combination of properties in a
cell that is derived from fusion of cells of different types,
such as a transformed cell and a bone marrow stem cell.
The hypothesis that such an outcome could be conse-
quential to carcinogenesis was supported by recent find-
ings that bone marrow stem cells fuse to differentiated
cells in the body and reprogram the resulting hybrids into
progenitors. Remarkably, it was also found that the rate
of stem cell fusion increases many-fold in animals that
were irradiated or suffered from chronic inflammation.
Another consequence of cell fusion is chromosomal in-
stability (CIN), which is a well-known feature of cell hy-
brids, although the mechanistic link between cell fusion
and CIN is poorly understood. The facts that CIN is also
a common feature of solid cancers and that cells of many
of these tumors have increased ploidy suggested that cell
fusion could be one of the processes that triggers CIN in
premalignant cells. 
During the last year, we worked in three directions:
(1) We explored how oncogenes can regulate expression
of retroviruses, (2) by collaborating with Alex Koulakov,
a theoretical physicist, we set out to understand how
properties of cell hybrids are determined, and (3) by col-
laborating with David Berman and Ming Tseh-Lin at
Johns Hopkins University, we tested whether cell fusion
occurs in human cancers.
Our model implies that deregulation of fusogenic pro-
teins can elicit cell fusion. We noticed that expression of
genes from a retroviral vector is regulated by oncogenes
E1A and HRAS, which is consistent with previous reports
that expression of retroviral proteins is regulated by cel-
lular transcription factors. We decided to explore this ob-
servation because all known human fusogenic proteins
are of retroviral origin. However, this direction was ter-
minated before it came to fruition due to lack of funds. 
Our collaboration with Alex focused on the mecha-
nisms that determine the ability of cell fusion to create
new cell types, both normal and abnormal. How these
properties are determined is largely unknown. Alex pro-
posed that this ability can be better understood by con-
sidering cells as attractor networks, whose basic property
is to adopt a set of distinct, stable, self-maintaining states
called attractors. According to this model, fusion of two
cell types is a collision of two networks that adopted dis-
tinct attractors. To learn how these networks reach a con-
sensus that would define cell type of the hybrid, he
modeled cell fusion computationally. To do so, Alex sim-
ulated patterns of gene activities using a formalism de-
veloped to simulate patterns of memory in neural
networks. We have found that the hybrid networks can
assume attractors that are unrelated to parental attrac-
tors. This observation implies that cell fusion can create
new cell types by nearly instantaneously moving cells be-
tween attractors. We also showed that hybrid networks
are prone to assume spurious attractors, which are emer-
gent and sporadic network states. This finding means
that cell fusion can produce abnormal cell types, includ-
ing cancerous cells, by placing cells into normally inac-
cessible spurious states. Our model can explain previ-
ously puzzling properties of cell hybrids and predicts that
using cell fusion as a therapeutic tool must be done with
an abundance of caution.
A major outstanding question is whether cell fusion
contributes to cancer in humans. The main difficulty with
answering this is the lack of an approach that can distin-
guish a hybrid of two genetically identical cells from a cell
produced by genome duplication. An alternative is to test
whether cancers that arise in transplant patients contain
hybrids between the cells of the recipient and the donor.
Two groups of such patients are of interest: (1) recipients
of bone marrow or circulating hematopoietic stem cells
who subsequently developed cancers of solid organs and
(2) recipients of solid organs who developed cancers in
those organs. If cancers arise from fusion of circulating
cells to cells of solid organs, cells of these cancers would
carry genetic polymorphisms specific to the donor and
the recipient, which can be determined with available
tools. Our collaborator, Dr. David Berman at Johns Hop-
kins University, has located a small set of samples from
cancers arising in the transplanted organs, and Dr. Ming
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Tseh-Lin kindly agreed to analyze them for possible
chimerism. We are awaiting the results of this analysis.
We have been unable to raise funds to support our re-
search to the extent required to definitively test our
model, but we hope that our results and ideas have
helped to raise sufficient interest in testing the possibil-
ity that cell fusion has a role in cancer development and
progression. 
Joseph Milazzo and Yuri Lazebnik
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Cell polarization is a process by which cells establish
and maintain asymmetric distribution of proteins and
organelles. Cell polarity proteins have important roles
in the establishment of cell polarity and regulation of
tissue morphogenesis. Loss of tissue structure is a hall-
mark of cancer; however, the mechanisms by which tis-
sue structure is disrupted and the role it has during
cancer initiation and progression are poorly under-
stood. We investigate the role played by cell polarity
proteins during initiation and progression of carci-
noma.
We have previously shown that the cell polarity com-
plex Par6/aPKC is required for transformation of three-
dimensional epithelial structures. The role played by
Par-3, another member of the Par6/aPKC protein com-
plex, has never been investigated. Recent genomic stud-
ies suggest that Par-3 is deleted in some cancers; however,
the role Par-3 has in cancer is not known. We have dis-
covered that dysregulation of Par-3 promotes metastasis
by activating a Rac-mediated signaling pathway that dis-
rupts cortical actin organization and inhibits E-cadherin
junction maturation, which leads to a decrease in cell−cell
cohesion. In particular, we find that expression of Par-3
in cell membranes is down-regulated both in human
breast cancers and in lung metastasis of ErbB2 transgenic
mice. Down-regulation of Par-3 cooperated with ErbB2
to induce invasion and metastasis in vivo. Interestingly,
the metastatic behavior was not associated with an overt
mesenchymal phenotype. However, loss of Par3 activated
a Tiam1/Rac/GTP/IRSp53/WAVE2/Arp2/3 pathway
that disrupted cortical actin, blocked E-cadherin junc-
tion maturation, and decreased epithelial cell−cell cohe-
sion. Cortical actin and Arp2/3 localization were
disrupted in tumor cells in vivo. Thus, we identify Par-3
as a novel regulator of metastatic behavior in tumor ep-
ithelial cells.
We have also discovered that down-regulation of cell
polarity proteins induces phenotypic plasticity to mam-
mary epithelial cells that allows them to either undergo
normal morphogenesis or display invasive behavior in re-
sponse to intrinsic or extrinsic signals. We found that
dysregulation of polarity proteins can either cooperate
with oncogenes (ErbB2 or KRasv12) or with changes in
microenvironment (IL-6, TNF-a) to acquire the ability
to invade in a bed of Matrigel/Collagen-1 extracellular
matrix. Simultaneous loss of two polarity proteins is suf-
ficient to induce invasive behavior, in the absence of ex-
pression of oncogene. Our results identify an unexpected
and novel role for cell polarity proteins as regulators of
phenotypic plasticity in epithelial cells. In doing so, we
provide an insight into the mechanism by which tumor
cells can acquire invasive potential early during the gen-
esis of carcinoma. We believe that the ability of cells to
acquire phenotypic plasticity complements the identified
role for epithelial-to-mesenchymal transition (EMT) and
mesenchymal-epithelial transition (MET) during metas-
tasis. The plastic state is likely to provide a significant ad-
vantage for migrating/invading epithelial cells because
migrating cells need to reorganize their cytoskeleton and
their vesicle trafficking and vesicle targeting machinery in
order to transit from apical−basal polarity to front−rear
polarity. Thus, changes in polarity proteins may lower
the threshold for epithelial cells to acquire migratory/in-
vasive cell behavior.
We had previously reported that mislocalization of
Scribble phenocopies RNA interference (RNAi) knock-
down of Scribble for cooperation with Myc during trans-
formation of mammary epithelial cells. In our attempt
to understand if mislocalization of Scribble is involved
in cancer, we generated a mouse model overexpressing
Scribble under the control of mouse mammary tumor
virus (MMTV) promoter. We have discovered that trans-
genic mice expressing a Scribble mislocalization mutant
display defects in mammary morphogenesis, followed by
hyperplasia and tumor formation. Surprisingly, the tu-
mors are pleomorphic and highly metastatic to the lung.
We are pursuing these observations to understand how
dysregulation of Scribble initiates metastatic tumors in
mice.
Our studies continue to define a role for cell polar-
ity proteins as regulators of cancer initiation and pro-
gression. A deeper understanding of the role played by
cell polarity proteins is likely to identify a novel class of
targets for controlling cancer.
EPITHELIAL CELL BIOLOGY AND CANCER
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Proteomic Analysis of Proximal Pulmonary
Venous Blood to Identify Biomarkers
for Non-Small-Cell Lung Cancer
This work was done in collaboration with R. Sordella
(CSHL) and B. Stiles and O. Elemento (Cornell University,
New York).
Each year, more than 220,000 patients are diagnosed
with lung cancer in the United States, with an overall 5-
year survival rate of ≤15%. This is due to the advanced
stage at diagnosis and to difficulties in detecting early tu-
mors. As in the case of prostate-specific antigen (PSA)
for prostate cancer, a reliable and easily accessible bio-
marker would prove invaluable in the early identification
of patients with non-small-cell lung cancer (NSCLC). In
fact, a recent randomized study highlighted the impor-
tance and impact of early diagnosis in NSCLC. Investi-
gators from the National Lung Screening Trial reported
that patients screened for NSCLC with computed to-
mography (CT) scans had a 20.3% decrease in mortal-
ity, exceeding the benefit of many therapeutic drug trials.
We are implementing a novel strategy to identify bio-
markers from the serum of NSCLC patients by mass
spectroscopy (MS) using iTRAQ (isobaric tagging for rel-
ative and absolute quantitation) technology. Unlike pre-
vious efforts aimed at identifying serum biomarkers using
peripheral blood from NSCLC patients, the peripheral
blood in our studies will be used only as reference, and
blood draining directly from the tumor (pulmonary vein)
will instead be used for biomarker identification. Because
of its proximity to the cancer, the pulmonary venous
blood (PVB) is highly enriched for tumor proteins, po-
tentially allowing for greater sensitivity of detection of rel-
evant proteins. In addition, each patient will serve as
his/her own control, eliminating many of the sources of
heterogeneity that have plagued the serum proteomic field
and hampered biomarker discovery. The proteomic sig-
nature elaborated from the PVB will then be validated in
the peripheral blood using more sensitive targeted tech-
niques such as single- and multiple-reaction monitoring
(MRM) and the clinical applicability tested in an inde-
pendent set of blood from patients screened for lung can-
cer. We have already analyzed pulmonary venous blood,
nontumor blood, and peripheral blood samples from four
patients using the 8-plex iTRAQ reagent and 17-
step multidimensional protein-identifcation technology
(MudPIT) liquid chromatography−mass spectrometry
(LC-MS). Preliminary data analysis is being performed
now, and we anticipate collection of data from at least 30
additional patients over the next 12 months. 
Proteomic Analysis of Cystic
Fibrosis Sputum
This work was done in collaboration with S. Pattison
(Queen’s University, Belfast).
People with cystic fibrosis (CF) are unusually susceptible
to lung infections, which contribute significantly to a poor
prognosis. The majority of lung damage results from the
abnormal, destructive action of the patient’s immune sys-
tem during times of extreme inflammation (known as pul-
monary exacerbations). Although exacerbations are usually
treatable with antibiotics, permanent lung damage fre-
quently results. Accumulation of lung damage is respon-
sible for the progressive decrease in lung function routinely
associated with CF, a major detriment to patient quality of
life and the most frequent cause of CF-related death. Ex-
acerbations occur periodically, but their cause remains
poorly understood. This research aimed to improve our
knowledge of exacerbations and identify potential triggers.
In particular, the study focuses on patients chronically col-
onized with Pseudomonas aeruginosa, because this is one of
the most common and destructive infecting organisms. 
In-depth proteomic and microbiological compar-
isons have already been made between sputum samples
collected from 12 CF patients in times of relative good
health versus pulmonary exacerbation, both before and
after antibiotic treatment. This involved more than nine
8-plex iTRAQ MudPIT analyses during ~1 month of
instrument time, and preliminary analysis of the col-
lected data is now in progress. The proteomic analysis of
patient sputum is of high clinical relevance because it
effectively studies the interaction between host and
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pathogens in vivo without introducing experimental
bias through in vitro bacterial cultivation or the use of
animal models. In addition, longitudinal sampling of
the same patients allows documentation of changes in
global protein expression in response to antibiotic treat-
ment. Through the use of comparative proteomics to
identify bacterial biomarkers linked to pulmonary exac-
erbation and disease pathogenesis, we hope to provide
new targets for the development of improved preventa-
tive or therapeutic treatments to limit lung damage and
enhance quality and length of life for CF patients.
Quantitation of Alternative Splice
Variants at the Protein Level
This work was done in collaboration with M. Akerman, 
L. Zepeda, A. Krainer, and M. Zhang (CSHL).
The Shared Resource is working with the Krainer and
Zhang laboratories to develop the use of iTRAQ quanti-
tative proteomics to identify and quantify changes in
exon-junction peptides as a measure of changes in alter-
native splicing isoforms of abundant proteins. In multiple
duplex iTRAQ experiments, protein lysates were prepared
from cytoplasmic and nuclear fractions of control HeLa
cells and cells overexpressing the SF2/ASF splicing factor.
The lysates were digested (trypsin) and labeled with two
members of the 4-plex iTRAQ reagent set before mixing.
The pooled, labeled peptides were analyzed by 15−16-salt-
step MudPIT LC-MS or capillary LC-MS following first-
dimension peptide separation by OffGel isoelectric
focusing (24 fraction; pH 3−10). To quantify exon inclu-
sion levels, we designed an exon isoform peptide database
(PepDB). This captured all known transcripts encoded by
every human gene using annotations from Ref-Seq and
the expressed sequence tag (EST)-based alternative splic-
ing database dbCASE. To account for every possible exon-
skipping event, each transcript set was subdivided (i.e.,
encoded in a same gene) into exon trios by sliding a 3-
exon window along the transcripts. The database was then
formatted to allow exon-skipping quantification. By using
this database as a mapping database for proteomic data,
we can approach every human exon as an independent
case and potentially estimate levels of alternative splicing.
Effect of Hypusination on the Tumor-
Suppressive Function of eIF5a
This work was done in collaboration with S. Lowe (CSHL).
Tumor suppressor genes encode a broad class of mole-
cules whose mutational attenuation contributes to ma-
lignant progression. In the canonical situation, the
tumor suppressor is completely inactivated through a
two-hit process involving a point mutation in one allele
and chromosomal deletion of the other. To functionally
identify tumor suppressor genes in lymphoma, the Lowe
laboratory screened a short hairpin RNA (shRNA) li-
brary targeting genes deleted in human lymphomas to
identify those genes whose suppression promotes tu-
morigenesis in a mouse lymphoma model. Among the
new tumor suppressors they identified were adenosyl-
methionine decarboxylase 1 (AMD1) and eukaryotic
translation initiation factor 5A (eIF5A), two genes as-
sociated with hypusine, a unique amino acid produced
as a product of polyamine metabolism through a highly
conserved pathway. Through a secondary screen sur-
veying the impact of all polyamine enzymes on tumori-
genesis, they established the polyamine-hypusine axis as
a new tumor suppressor network regulating apoptosis.
They next determined whether the expression of apop-
totic regulators known to modulate Myc-induced lym-
phomagenesis (e.g., Bax, Bim, Puma, Bcl-2, Bcl-xL, and
Mcl) were altered in premalignant B cells expressing
shRNAs targeting the hypusination biosynthetic path-
way. Bax was shown to be the only protein consistently
underexpressed, and was also found to be reduced in a
nonbiased iTRAQ-based proteomic analysis of prema-
lignant B cells transduced with shRNAs targeting Eif5a
and Amd1. Gene ontology analysis of the 431 differen-
tially expressed proteins identified apoptosis as the most
significantly enriched functional category. Precisely how
Bax is controlled by Eif5a hypusination remains to be
determined; nonetheless, Bax is a known eIF5A target
and is an established suppressor of lymphomagenesis.
Posttranslational Modification
of Papillomavirus Replication
Factor E1
This work was done in collaboration with A. Stenlund
(CSHL).
Papillomaviruses are responsible for a number of
human diseases including genital papillomavirus infec-
tions and cervical cancer. The Stenlund laboratory has
been investigating the biochemical properties of the
viral E1 and E2 proteins, which are required for viral
DNA replication. E1 is the initiator protein, which rec-
ognizes the origin of replication and also has DNA he-
licase activity. E2 regulates viral gene expression but is
also involved in initiation of DNA replication. Recent
studies have shown that phosphorylation of the E1 and
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E2 proteins by the protein kinase CK2 regulates the ac-
tivities of these proteins. We have analyzed the phos-
phorylation sites in the E1 protein after in vitro
phosphorylation of recombinant E1 protein with re-
combinant CK2 enzyme. Briefly, the in-vitro-phos-
phorylated protein was digested with trypsin and with
the nonsequence-specific protease elastase and sub-
jected to MS analysis to identify phosphorylated pep-
tides. In this manner, we were able to identify eight
CK2 phosphorylation sites in the amino-terminus of
the E1 protein. The modification of these sites has since
been verified by mutational analysis.
Identification of Interacting Partners
of LIN42
This work was done in collaboration with C. Hammell
(CSHL).
Through forward genetics approaches directed toward
understanding how aspects of developmental timing are
controlled during animal development, the Hammell
laboratory has identified the Caenorhabditis elegans ho-
molog of the Period gene, LIN42, as a key player in the
regulation of temporal gene expression. Through analy-
sis of wild-type LIN42 expression and phenotypes asso-
ciated with lin-42 mutants, they have determined that
LIN-42 functions to regulate the production and matu-
ration of a large number of microRNAs, including those
involved in development. In an effort to understand how
LIN-42 functions, we have complemented genetic ap-
proaches with a proteomic analysis of LIN-42-associated
proteins via MudPIT. These efforts have identified a va-
riety of chromatin-modulating components consistent
with LIN-42 functioning in the nucleus to control
miRNA expression.
Posttranslational Modifications
of the Splicing Factor SF2/ASF
This work was done in collaboration with Y. Liu, 
R.-Y. Tzeng, and A. Krainer (CSHL).
Continuing from earlier studies, we used a combination
of bottom-up, middle-down, and multiple reaction
monitoring (MRM) approaches to map posttransla-
tional modifications of human SF2/ASF following mag-
netic bead immunoprecipitation of the protein from
HeLa, A549, and 293E cells. For the bottom-up ap-
proach, a triple-digest protocol was used (trypsin, elas-
tase, and subtilisin) followed by two-dimensional
MudPIT LC-MS analysis of the overlapping, nonspe-
cific digest products to increase coverage. For the mid-
dle-down approach, we have used Lys-C to generate
larger fragments, which were analyzed by both collision-
induced dissociated (CID) and electron transfer disso-
ciation (ETD) fragmentation using the Orbitrap Velos
mass spectrometer. In earlier studies, we identified six
sites of SY phosphorylation, six sites of KR monometh-
ylation, and one site of R dimethylation. We have since
characterized the acetylation state of SRSF1. Previous
discovery experiments had identified a few potential
acetylation sites (e.g., K38 and K179). Immunoprecip-
itated SRP55 complexes from both HeLa and A549 cell
lysates were subjected to triplicate MRM analysis, and
we were able to confirm the presence of K(Ac)179-
SRSF1 in both cell lines with almost 100% occupancy.
Further work is in progress to uncover the biological
function of these modifications.
Regulatory Modification of PTP1B
by Persulfation
This work was done in collaboration with N. Krishnan, 
C. Fu, and N. Tonks (CSHL).
Protein tyrosine phosphatases (PTPs) have been estab-
lished as regulators of a wide variety of signal transduc-
tion pathways, and they use an essential, reactive Cys
residue. The Tonks laboratory tested whether H2S may
also target the catalytic Cys residue to regulate PTP
function. Using high-resolution MS, we together iden-
tified a novel covalent modification (persulfation) of
the active site Cys-215 in PTP1B that occurs in re-
sponse to generation of hydrogen sulfide in vivo. This
sulfhydration reaction also inactivates PTP1B, but it is
subject to different mechanisms of reduction and reac-
tivation compared to the reversibly oxidized enzyme.
To understand the relevance of this modification to the
control of cell signaling, the Tonks laboratory used
RNA interference (RNAi) to suppress the critical en-
zyme in H2S production, cystathionine-g-lyase (CSE),
in 293T cells, where they observed sulfhydration of
Cys-215 following ER (endoplasmic reticulum) stress
only in control cells. Using a novel phosphopeptide
trapping mutant, we searched for potential substrates
of PTP1B in the ER stress response, and identified a
tryptic phosphopeptide derived from PERK (protein
kinase-like ER kinase). The phosphorylation of Y619
in PERK has a critical role in the activation of PERK,
which phosphorylates the eukaryotic translational ini-
tiation factor 2 (eIF2a), leading to translational atten-
uation. It has since been demonstrated that PTP1B de-
phosphorylates Y619 PERK and that this event is re-
gulated by H2S production in ER stress. These data
suggest the possibility that different modes of reduc-
tion and reactivation of PTPs in response to distinct ga-
sotransmitters may introduce new levels of control over
signal transduction.
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Lung cancer is one of the leading causes of death world-
wide with mortality rates exceeding those of breast,
prostate, and colon cancers combined. This is in part
due to the lack of effective treatment and to the highly
aggressive nature of non-small-cell lung carcinomas
(NSCLCs), which account for the large majority of all
cases of lung cancer. Thus, there was much excitement
when treatments with erlotinib and gefitinib, two selec-
tive epidermal growth factor receptor (EGFR) in-
hibitors, resulted in dramatic regression of primary
tumors as well as fewer metastases in patients with
widely metastatic NSCLC. Remarkably, retrospective
studies showed a striking correlation between occurrence
of certain EGFR oncogenic mutations and erlotinib/
gefitinib responses. Deletions in exon 19 of EGFR or
EGFR L858R missense substitutions are found in more
than 80% of NSCLC patients who respond to erlotinib
or gefitinib treatment. Unfortunately, in the majority of
cases, these responses are transient, and within a short
period of time, patients who initially responded to treat-
ment relapse. In ~50% of cases of erlotinib-acquired re-
sistance, the acquisition of an additional mutation in
exon 20 of EGFR resulting in a threonine-to-methion-
ine substitution at position 790 (T790M) and/or am-
plification of c-Met accounted for treatment relapse.
Thus, as is the case for other molecularly targeted ther-
apies (e.g., imatimb, cetuximab, and tamoxifen), a bet-
ter understanding of the molecular mechanisms
responsible for resistance to gefitinib and erlotinib is cru-
cial for effective clinical utilization of these drugs. 
A TGF-b IL-6 Axis Mediates Selective
and Adaptive Mechanisms of Resistance
to Molecular-Targeted Therapy
in Lung Cancer
To uncover new molecular mechanisms of gefitinib and
erlotinib resistance in NSCLC, we developed a cell-
based system. We cultured NSCLC-derived cell lines
harboring EGFR oncogenic mutations (i.e., NCI-
H1650 and HCC827 cells) in the presence of increas-
ing erlotinib concentrations and isolated cells capable of
growing in the presence of up to 30 mM of erlotinib.
Among the erlotinib-resistant cell lines examined, we
identified cell lines that had decreased erlotinib sensi-
tivity but did not harbor the above-described mutations
that led to erlotinib/gefitinib resistance. Interestingly,
these erlotinib-resistant cells have morphological fea-
tures of mesenchymal cells and have an increased motil-
ity, invasion, and metastatic potential. We refer to these
cells as EMMs for erlotinib-resistant, mesenchymal,
and metastatic cells. We found that activation of trans-
forming growth factor-b (TGF-b)-mediated signaling
was sufficient to induce these phenotypes. In particular,
we determined that an increased TGF-b–dependent in-
terleukin-6 (IL-6) secretion unleashed previously ad-
dicted lung tumor cells from their EGFR dependency. 
Interestingly, gene expression profile analysis also re-
vealed changes in the expression of the surface markers
CD44 and CD24 (CD44 is high and CD24 is low in
the resistant cells compared to the parental cells). By
using these surface markers, we were able to show that
the parental erlotinib-sensitive cells contained a sub-
population of cells (0.5%) that had features similar to
those of EMM cells even before selection with erlotinib.
Similarly, we identified EMM-like cells in human
NSCLCs of different stages (Stages IA, IB, III) and in
the bone marrow (BM) of patients. Importantly, a
higher representation of EMM-like cells in early-stage
lung tumors correlates with poor prognosis. Our data
thus imply that erlotinib-resistant cells are already pres-
ent in tumors before treatment and that metastatic
spread and dissemination of tumor cells may be an early
event leading to the eventual development of metasta-
tic disease. This hypothesis departs from the long-held
concept of development of resistance and metastasis as
a consequence only of the acquisition of de novo mu-
tations or late properties. 
Because IL-6 and TGF-b are prominently produced
during inflammatory response, we then used a mouse
model system to determine whether inflammation might
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impair erlotinib sensitivity. Indeed, induction of inflam-
mation not only stimulated IL-6 secretion, but was also
sufficient to decrease the tumor response to erlotinib. 
This result argues that both tumor-cell-autonomous
mechanisms and the activation of the tumor micro-
environment could contribute to primary and acquired
erlotinib resistance, and consequently, treatments based
on EGFR inhibition may not be sufficient for the ef-
fective treatment of lung cancer patients harboring mu-
tant EGFR.
Altogether, these studies highlighted potentially cru-
cial aspects of tumor pathogenesis. Therefore, in the
past year, we followed up these initial findings by ac-
tively pursuing a better understanding of the origin of
EMM-like cells, their role in tumorigenesis, and the
unique signaling pathways important for their survival. 
An Epigenetic Switch Reprograms 
Metastasis-Initiating Cells and Their
Pathways of Addiction through the
Down-Regulation of miR-335
Because our initial observations were on in-vitro-based
studies, we hypothesized that a cell-autonomous mech-
anism might account for the ontogeny of EMM-like
cells. In collaboration with Dr. Ingrid Ibarra in Greg
Hannon’s lab at CSHL, we were able to show the pres-
ence of a distinct miRNA signature in the EMM-like
cells compared to parental cells. Interestingly, we found
that decreasing the expression of miR-335 in the parental
cells was sufficient to induce phenotypic changes and a
molecular signature characteristic of EMM-like cells. 
miR-335 resides within the second intron of MEST/
PEG1. As in the case of other intronic microRNAs
(miRNAs), miR-335 expression has been associated
with the expression of its host gene. Importantly, ge-
netic deletion of miR-335 is a common event in human
breast cancer, is enriched for in breast cancer metastases,
and also correlates with ovarian cancer recurrence. In-
terestingly, in all of the cell lines examined and in
NSCLC tumors, we did not find any deletion of the
miR-335 locus; however, we did find a strong correla-
tion between expression of miR-335, MEST, and
methylation of a specific CpG island located in prox-
imity to the MEST promoter region. Importantly, an
overall decreased expression of MEST and miR-335 in
early-stage NSCLC was associated with an increased
probability of tumor relapse. 
Among the direct targets of miR-335 identified by
bioinformatics analysis and subsequent validation, we
found genes involved in epithelial−mesenchymal tran-
sition (EMT), extracellular matrix remodeling, motility,
osteoclast homeostasis, and self-renewal. Interestingly,
miR-335 also regulated the expression of TGF-b indi-
rectly by decreasing the expression of SRF, one of its di-
rect targets. Interestingly, we found that TGF-b also
regulates the expression of the “don’t eat me” signaling
molecule CD47. Our data thus suggest that an epige-
netic switch is sufficient to reprogram tumor cells to-
ward the acquisition of metastatics-initiating-cell-like
features. This is of particular interest when considering
that metastasis is a rate-limiting event. The ability to
control this multistep process (e.g., extracellular re-
modeling, invasion, extravasation, survival in circula-
tion, homing, and self-renewing) by the regulation of a
single event increases the efficiency of metastatic spread
and thus can explain early dissemination of tumor cells.
Yet miR-335 not only increased the metastatic po-
tential of EMM-like cells, but also rewired their path-
ways of addiction. Although the parental cells are
sensitive to phosphoinositol-3 kinase (PI3K) inhibition,
both EMM-like cells and parental cells in which miR-
335 was down-regulated are more resistant to PI3K in-
hibition and exquisitely sensitive to IL-6 axis inhibition.
The fact that cells have become addicted to signaling me-
diated by IL-6 has important therapeutic implications.
IL-6 neutralizing antibodies; JAK and STAT3 inhibitors
have been developed by pharmaceutical companies and
could be exploited to eliminate disseminating tumor
cells (DTCs) and, in the context of erlotinb treatment,
to overcome resistance. In addition, the association of
increased sensitivity to JAK/IL-6 inhibition and a spe-
cific molecular signature could improve patients’ strati-
fication and can be used toward the development of
tailored lung cancer therapies. 
A Neomorphic p53 Isoform Involved
in Injury-Repair Fails to Activate a
Canonical p53 Tumor Suppressor Response
but Confers Metastatic Features on Cells
Among the genes involved in DNA repair, gene ex-
pression profiling of EMM-like cells revealed a sub-
stantial decrease in expression of p53. The p53 tumor
suppressor has a critical role in genome surveillance,
suppression of oncogenic transformation, and regula-
tion of many fundamental aspects of both reversible
and irreversible cellular stress responses. p53 mutations,
through loss of p53 function and putative gain-of-func-
tion activities, disable these effects and are associated
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with aggressive cancers and poor patient prognosis. Al-
though much is known about the underlying mecha-
nisms of p53 regulation and activity, factors that
influence the diversity and duration of p53 responses
are not well understood. 
When we measured p53 mRNA levels using reverse
transcriptase−polymerase chain reaction (RT-PCR), we
observed a less intense and slower migrating band specif-
ically in the EMM cells, which we showed was the result
of a novel alternative splicing event. The use of an alter-
native 3¢ splice site in intron 6 generates a previously un-
characterized p53 isoform that lacks major portions of
the DNA-binding domain, the nuclear-localization se-
quence, and the tetramerization domain. This p53 iso-
form, dubbed p53p, lacks transcriptional activity and
fails to induce a canonical p53 tumor suppressor re-
sponse. Yet, as is the case for certain gain-of-function
p53 mutations, p53p expression is sufficient to decrease
the expression of E-cadherin and to increase the invasive
capability of cells. Importantly, this novel neomorphic
p53 isoform appears to have a role in tissue-damage re-
sponse by preventing premature senescence of cells in-
volved in tissue remodeling and injury resolution in vivo.
Our results thus identify a new mode of p53 regulation
and suggest a physiological origin for gain-of-function
activities of certain p53 mutants.
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Trine Linsted
The phosphorylation of tyrosyl residues in proteins is a
key component of the regulation of signaling pathways
that control many fundamental physiological processes,
including cell proliferation, differentiation, and survival.
Protein phosphorylation is a reversible, dynamic process
in which the net level of phosphate observed in a target
substrate reflects the coordinated activity of the kinases
that phosphorylate it and the protein phosphatases that
catalyze the dephosphorylation reaction. We study the
family of protein tyrosine phosphatases (PTPs), which,
like the kinases, comprise both transmembrane, recep-
tor-linked forms as well as nontransmembrane, cyto-
plasmic species and represent a major family of signaling
enzymes. Overall, the objective of the lab is to develop
tools for analysis of PTP regulation and function and in-
tegrate them with state-of-the-art cell and animal mod-
els, to define critical tyrosine phosphorylation-de-
pendent signaling events in human disease and thereby
identify novel therapeutic targets. Currently, there are
four broad areas of research in the lab covering functional
analysis of members of the PTP family, regulation of
PTP function, in particular by reversible oxidation, de-
velopment of novel approaches to therapeutic interven-
tion in PTP function, and characterization of a knockout
mouse model to define the function of JSP1, a member
of the PTP family that is a novel regulator of mitogen-ac-
tivated protein kinase (MAPK) signaling.
Having successfully defended their Ph.D.s, Guang
Lin and Aftab Haque left the lab during the last year to
take up postdoctoral positions with Hugo Bellen (Bay-
lor) and Susan Lindqvist (MIT), respectively. 
Novel Approaches to Therapeutic
Inhibition of PTP1B
The protein tyrosine phosphatase PTP1B was the first
member of this family of signaling enzymes to be puri-
fied, in work I conducted as a postdoctoral fellow. In-
terest in PTP1B from a therapeutic perspective has its
foundation in diabetes and obesity, which along with the
associated cardiovascular disease, pose a serious threat to
public health in the 21st century. A recent report from
WHO predicts that total prevalence of type 2 diabetes
will rise from 171 million in 2000 to 366 million in
2030. The treatment options for diabetes and obesity
largely remain unchanged since the 1940s, which im-
plies a need for alternative, more effective ways to
counter the disease. Our increased understanding of sig-
nal transduction in normal and pathophysiological con-
ditions has suggested alternative therapeutic strategies in
many major diseases that focus on manipulating signal-
ing pathways. PTP1B plays a well-documented role as a
negative regulator of insulin and leptin signaling. Tar-
geted deletion of the PTP1B gene product in mice re-
sulted in increased insulin sensitivity and resistance to
obesity induced by a high-fat diet. These and other ob-
servations resulted in PTP1B being extensively validated
as a suitable target for therapeutic intervention. 
Apart from metabolic regulation, PTP1B is also im-
plicated in breast tumorigenesis in response to HER2,
the target for Herceptin. The PTP1B gene located at
chromosome 20q13 is frequently amplified in breast can-
cer. In mice expressing HER2, a gene amplified in about
25% of breast cancer, loss of the PTP1B gene caused de-
layed tumorigenesis and the incidence of lung metastasis
was decreased. These observations suggest that in addi-
tion to its role in attenuating insulin signaling, PTP1B
enhances HER2-mediated signaling—it acts as a positive
regulator of HER2 signaling to promote breast tumorige-
nesis. Therefore, inhibition of PTP1B would offer a novel
avenue for therapeutic intervention in both diabetes and
HER2-positive tumors, such as in breast cancer. 
Several potent, small-molecule inhibitors of PTP1B
have been developed; however, these inhibitors, which tar-
get the active site of the enzyme, are highly charged and
consequently have poor bioavailability and limited drug
development potential. Therefore, there is a pressing need
for an alternative approach to generate inhibitors against
PTP1B that do not involve the active site of the protein.
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X. Cheng
We have identified a novel allosteric inhibitor of PTP1B
that binds to the noncatalytic portion of PTP1B and does
not depend on charge for interaction. Several biochemi-
cal tools were used to define a novel mechanism for inhi-
bition of PTP1B by this molecule. Therefore, we were
interested in testing the inhibitor in breast cancer models
where PTP1B may play a signaling function. 
We have succeeded in demonstrating that this PTP1B
inhibitor antagonized HER2-induced cell migration in
MCF10A mammary epithelial cells that express a well-
characterized, inducible chimeric form of HER2. We have
tested analogs of the molecule and observed that the ef-
fects on migration correlated with the potency of PTP1B
inhibition. Furthermore, we tested the inhibitor in mul-
tiple cell lines and observed that it antagonized migration
preferentially in HER2-positive cells. In addition, we have
incorporated data from a three-dimensional (3D) culture
system that recapitulates several aspects of mammary
gland architecture in vivo and has been used as a model to
study the biological activities of cancer genes. In this sys-
tem, activation of HER2 results in the formation of hy-
perplastic structures in 3D culture; this was attenuated by
treatment of the cells with the PTP1B inhibitor. 
The most recent results are the most exciting. We have
tested the inhibitor in a transgenic mouse model, the
NDL2 mouse, which expresses an activated mutant form
of HER2 and develops mammary tumors and lung
metastases that display features of human breast cancer.
In two independent experiments, we allowed these trans-
genic mice to develop palpable tumors before treating
with the inhibitor. Treatment resulted in marked reduc-
tion of tumor growth. Perhaps most importantly, we ob-
served that treatment with the inhibitor of PTP1B was
accompanied by a dramatic attenuation of metastasis to
the lungs. These data reinforce the therapeutic potential
of inhibiting PTP1B by this allosteric mechanism to an-
tagonize HER2-induced signaling and tumorigenesis.
Currently, we are working with scientists at SWOG (one
of the leading National Cancer Institute−supported co-
operative groups) to complete a preclinical data package
and to pursue the testing of this molecule in clinical tri-
als for HER2-positive breast cancer. Ultimately, we plan
to test this inhibitor and derivatives of it in models of
diet-induced obesity and insulin resistance.
Characterization of Novel Cancer
Therapeutics
Avemar® is a proprietary fermented wheat germ extract
(FWGE) that has been shown to have many beneficial
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characteristics, including potent anticancer, anti-in-
flammatory, immune-modulatory, metabolic-regulatory,
cardiovascular-protective, and anti-aging properties.
FWGE impairs critical aspects of the transformed phe-
notype, including aerobic glycolysis, the pentose phos-
phate pathway, and ribonucleotide reductase. It displays
significant antiproliferative effects and triggers tumor
cell death through apoptosis. Clinical data reveal signif-
icant benefits to patients from treatment with FWGE,
including in combination with existing cancer therapies.
FWGE likely comprises thousands of different mole-
cules. In particular, it is known to contain two biologi-
cally active compounds: lectins (WGA, wheat germ
agglutinin) and methoxy-substituted benzoquinones
(DMBQ, 2,6-dimethoxy-p-benzoquinone; MBQ, 2-
methoxybenzoquinone). Nevertheless, neither of these
components are the physiologically significant active
molecules of the extract. Although current data support
the use of FWGE as a nonprescription nutraceutical in
various cancers, it is clear that exploiting its full poten-
tial will require a more precise definition of the active
ingredient core components of the mixture and the bio-
chemical characterization of their mechanism of action.
During the past couple of years, we have made consid-
erable progress in purifying the active components of
Avemar®, using procedures that are readily adaptable to
large-scale production. Various fractions from the ini-
tial purification procedure have been screened in cell vi-
ability assays on a broad panel of tumor cell lines and
animal models, with encouraging results. In an impor-
tant first step, a fraction has been generated, termed
A250, which represents ~3% of the dry weight of Ave-
mar®, yet retains essentially all of the activity, and has
the potential to represent a new product. In collabora-
tion with Darryl Pappin and Jim Watson here at CSHL
and Mate Hidvegi and his colleagues from Budapest, we
are now focusing on producing stable, enriched, and
well-characterized fraction(s) from crude FWGE that
show significant activity in cell and animal models of
cancer, with the goal of developing novel therapeutics.
Other Projects Brought 
to Successful Publications
We published the results of a comprehensive, PTP fam-
ily-wide RNA interference (RNAi) screen to test sys-
tematically the role of PTPs in controlling migration and
invasion in mammary epithelial cell models of breast can-
cer. The analysis revealed many novel insights, including
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the discovery that the phosphatase PTPN23 is a regula-
tor of mammary cell invasion that exerts its effects via
regulation of the protein tyrosine kinase SRC. One of
the important conclusions of this study is that inhibitors
of SRC may offer a novel therapeutic approach to treat-
ing patients with inactivating mutations in PTPN23, the
gene for which is located at chromosome 3p21 in a hot
spot mutated in breast and other cancers. This is now
being tested in animal models. In addition, we have com-
pleted a loss-of-function screen for the effects of the clas-
sical PTPs on growth of MCF10A cells in 3D culture.
This has identified several novel roles for specific PTPs in
the regulation of HER2 signaling, the mechanistic basis
for which are now being pursued.
We published a major paper describing the genera-
tion of conformation-sensor antibodies that recognize
selectively the oxidized form of PTP1B and the demon-
stration that, when expressed in cells, they lead to en-
hanced and sustained insulin signaling. This is important
because it suggests a new paradigm for PTP-directed
drug development, particularly for treatment of diabetes
and obesity.
We published a paper describing the regulation of
PTPs by “gasotransmitters,” which are a class of gaseous
signaling molecules that are freely permeable to mem-
branes and, therefore, unlike classical regulators of signal
transduction, they act independently of transmembrane
receptors. Hydrogen sulfide (H2S) has long been consid-
ered a toxic molecule; however, with the burgeoning in-
terest in gasotransmitter function, it has recently been
implicated in the regulation of several biological pro-
cesses. A major gap in our understanding of the physio-
logical function of H2S, and its potential role in
signaling, is the identity of its cellular targets. We exam-
ined whether H2S regulates PTP function and revealed a
novel tier of control of the unfolded protein response
(UPR) to endoplasmic reticulum (ER) stress.
The ER plays a major role in controlling the folding
and modification of newly synthesized transmembrane
and secreted proteins. The folding capacity of the ER is
modulated in response to the environmental and physio-
logical status of the cell; thus, a cell can match its capac-
ity for protein folding to its physiological requirements.
However, if that capacity is exceeded, resulting in a con-
dition known as ER stress, an integrated set of three sig-
naling pathways, the UPR, is activated. These pathways
are triggered by transmembrane sensor proteins that de-
tect unfolded proteins in the ER and transduce a signal
that initiates a response in the cytosol or nucleus. This al-
lows the cell to fine-tune the rates of protein synthesis and
its folding capacity to maintain homeostasis and, if that is
not successful, to trigger cell death. We demonstrated that
ER stress leads to the production of H2S, which gener-
ates a persulfide modification of the active site Cys of
PTP1B, with concomitant inhibition of phosphatase ac-
tivity. This, in turn, controls the ability of PTP1B to de-
phosphorylate PERK (protein kinase-like ER kinase),
which is one of the transmembrane sensors of unfolded
proteins (Fig. 1). PERK normally phosphorylates the eu-
karyotic translational initiation factor 2 (eIF2a) leading
to translational attenuation, which limits the load of un-
folded protein entering the ER. Thus, the regulation of
PTP1B by H2S is a critical step in controlling the activity
of PERK and, thereby, the ability of a cell to monitor and
regulate its protein folding capacity. This work introduces
a new level of control over signal transduction, which may
provide fundamentally important insights into the etiol-
ogy of diseases associated with aberrant protein folding,
such as Alzheimer’s and Parkinson’s. 
Using an organotypic brain slice culture system, in
conjunction with 2-photon imaging, we have produced
a system in which to examine PTEN function in neu-
rons. Consistent with the increase in spine density that
has been shown to accompany the loss of PTEN in
knockout mouse models, we observed that expression
of wild-type green fluorescent protein (GFP)-PTEN re-
sulted in a dramatic decrease in spine density compared
to control neurons transfected either with GFP alone or
Figure 1. Proposed model for the role of sulfhydration of
PTP1B in regulating the response to ER stress. Induction of
ER stress increases the production of H2S by cystathion-
ine-g-lyase, which leads to sulfhydration of the essential
active site cysteine residue in PTP1B and concomitant in-
activation of the phosphatase. This transiently protects
pTyr 619 of PERK from dephosphorylation, promoting
PERK activation and its ability to inhibit global translation
by phosphorylating eIF2a. Reduction and reactivation of
sulfhydrated PTP1B restores phosphatase activity and its
ability to dephosphorylate and inactivate PERK. (From 
Krishnan et al. 2011.)
with inactive mutants, thus permitting us to use the
density of dendritic spines as a biological read-out of
PTEN function. In vitro, the tumor suppressor PTEN
displays intrinsic phosphatase activity toward both pro-
tein and lipid substrates. In vivo, the lipid phosphatase
activity of PTEN, through which it dephosphorylates
the 3 position in the inositol sugar of phosphatidylino-
sitol derivatives, is important for its tumor suppressor
function; however, the significance of its protein phos-
phatase activity remains unclear and represents a gap in
our understanding of the function of this important reg-
ulator of cell signaling. Using this bioassay, we have
demonstrated that it was the protein phosphatase activ-
ity, but not the lipid phosphatase activity, that was es-
sential for the ability of PTEN to decrease neuronal
spine density. Furthermore, these effects of PTEN de-
pended upon the phosphorylation status of Ser and Thr
residues in its carboxy-terminal segment and the in-
tegrity of the carboxy-terminal PDZ-binding motif.
Overall, our data suggest that PTEN autodephosphor-
ylation may be a critical event in this process, exerting a
direct influence on its interaction with PDZ domain-
containing proteins. The data reveal that in addition to
dephosphorylating the 3 position in phosphatidylinosi-
tol phospholipids, the critical protein substrate of PTEN
may be PTEN itself. Thus, we demonstrate a striking
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parallel with phosphatidylinositol-3 kinase (PI3K),
which phosphorylates exogenous lipid substrates and
displays protein kinase activity through autophosphor-
ylation, illustrating symmetry in the regulation of sig-
naling via phosphorylation and dephosphorylation of
inositol phospholipids.
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PTEN is a tumor suppressor that is among the most fre-
quently lost or mutated genes of human cancer. It is
unique in directly opposing the enzymatic activity of
phosphoinositol-3 kinase (PI3K) and the downstream
proto-oncogene Akt kinase, which promotes cell survival
and proliferation. This signaling pathway is deregulated
in a majority of, for example, breast, prostate, and brain
tumors. By modeling Pten loss in mice, we have discov-
ered how cells in the prostate can sense the complete loss
of Pten and respond to this insult by withdrawing into
cellular senescence, which is now recognized as a cell-in-
trinsic human antitumoral defense mechanism. This
finding defines a clear role for the p53 gene. It is essen-
tial for preventing lethal prostate cancer by mounting the
senescence response after Pten loss, but it does not ini-
tiate tumor growth when lost on its own. Moreover, the
discovery of the senescence response suggests that tumors
should favor retention of some PTEN. Indeed, many
human cancers present with either partial loss of the
PTEN gene or with partial functional impairment. Col-
lectively, these findings have defined PTEN as a hap-
loinsufficient tumor suppressor in several tissues and thus
emphasize the need for understanding its regulation.
The emergence of patient genome data is now en-
abling us to probe for genome-wide changes that are
consistent with the progression features identified in
mouse. Conversely, we also probe the mouse tumor
genome for spontaneous changes that drive tumori-
genesis downstream from their engineered genetic
changes. This two-pronged approach is allowing us to
move from identification and validation of new cancer
genes to connecting the dots by uncovering the princi-
ples that underlie PTEN-mutant cancer progression.
From Indolent Prostate Cancer
to Lethal Disease
M. Chen, C. Pratt, M. Zeeman, A. Naguib, D. Nowak 
[in collaboration with A. Newton, University of San
Diego, California; B. Carver and C. Sawyers, Memorial
Sloan-Kettering Cancer Center, New York]
Understanding the progression from indolent to lethal
prostate cancer remains the major challenge in the field.
Hyperactivation of the PI3K/AKT pathway is common
in many cancer types. Tumorigenesis through this path-
way is prevented by concerted action of multiple tumor
suppressor genes. Most notably, PTEN reverts PI3K ac-
tivity, whereas excessive pathway activation triggers
p53-mediated senescence arrest. However, it has re-
mained unclear if and at what stage this response acts in
human prostate cancer.
We have identified the AKT-inactivating phospha-
tase PHLPP1 as a tumor suppressor and demonstrated
how the senescence response antagonizes codeletion of
Pten and Phlpp1 genes to form a barrier against prostate
cancer progression in mouse. We could show that
Phlpp1 loss causes neoplasia and, upon partial Pten loss,
carcinoma in mouse prostate. This genetic setting trig-
gered growth arrest via protein translation-dependent
activation of p53. Thus, we found that tumor forma-
tion in the mouse required spontaneous inactivation of
the p53 gene. Validating this conditional gene inacti-
vation scheme in a comprehensive genomic patient data
set, we found that codeletion of PTEN and PHLPP1 is
almost exclusively observed in metastatic prostate can-
cer and highly correlated to deletion of TP53. Further-
more, we found that PTEN/PHLPP1 mRNA expres-
sion can be used for outcome prediction in this patient
cohort, thus adding actionable molecular information
on pathway status to the standard histology-based Glea-
son method.
We showed that the Phlpp2 protein compensates
for Pten loss in a pathway feedback, which rational-
izes their codeletion with PTEN in late-stage prostate
cancer. This important feedback response is blocked
by pharmacological pathway inhibition that inhibits
mTORC1. Thus, mTORC1-mediated translation is
important for supporting high levels of p53 and
PHLPP2 when PTEN is lost. Our finding that these
three genes are genetically abolished only in the lethal
disease emphasizes the importance of the feedback
response. Together, our findings can help the devel-
opment of improved molecular tools for prostate can-
cer prognosis and therapy and highlight the value of
our genetically engineered mouse models for the
process.
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In the Brain: PTEN and Stroke
A. Naguib [in collaboration with S.-S. Tan and J. Howitt, The
University of Melbourne, Australia]
PTEN is the major negative regulator of PI3K signal-
ing with cell-specific functions that go beyond tumor
suppression. We have previously shown that nuclear
import of PTEN is essential for tumor suppression. Yet,
it has remained unclear what physiological stimulus de-
termines the variety of nucleo-cytoplasmic distributions
of PTEN that are observed in tissues. In collaboration
with experts in mouse models for stroke, we have
demonstrated that cytoplasmic Pten is translocated into
the nucleus of neurons following cerebral ischemia.
Critically, this transport event is dependent on the surge
in the Ndfip1 protein, as neurons in Ndfip1-deficient
mice fail to import Pten. Ndfip1 binds Pten, resulting
in enhanced ubiquitination by Nedd4 E3 ligases, an
event that we previously showed to control import. In
vitro, Ndfip1 overexpression increases the rate of Pten
nuclear import detected by photobleaching experi-
ments, whereas Ndfip1−/− fibroblasts show very poor im-
port rates. In vivo, Ndfip1-mutant mice suffer larger
infarct sizes associated with suppressed pAkt activation.
These findings have unraveled the first physiological
stimulus to trigger shuttling of Pten into nuclei. More-
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over, they suggest that getting PTEN out of the cyto-
plasm and into the nucleus for a limited time after
stroke is critical for neuronal survival and prevents ir-
reversible brain damage. These findings may thus open
novel avenues for therapeutic intervention after stroke,
centered around ensuring proper trafficking of PTEN.
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Lloyd Trotman (center, back) and lab members
Research in my laboratory focuses on signal transduc-
tion pathways involving Ras and Rho GTPases. Ras
and Rho family members have key roles in cellular ac-
tivities controlling cell growth control, differentiation,
and morphogenesis. Alterations in Ras and Rho func-
tions have been shown to result in several disease
processes, including cancer and neurodevelopmental
disorders. Our ultimate goal is to understand how aber-
rations in Ras and Rho signaling components con-
tribute to the development of these disease processes.
Toward this end, my lab has continued to define the
functions of selected GTPases, their regulators, and ef-
fectors in models of cancer and neurodevelopmental
disorders. Below are highlighted the main projects that
have been carried out during the past year.
Rapid Synthesis of the X-Linked Mental
Retardation Protein OPHN1 Mediates
mGluR-Dependent LTD through
Interaction with the Endocytic Machinery
Mutations in genes encoding regulators and effectors
of Rho GTPases have been found to underlie various
forms of mental retardation (MR). Oligophrenin-1
(OPHN1), which encodes a Rho-GTPase-activating
protein, was the first identified Rho-linked MR gene. It
was initially identified by the analysis of a balanced
translocation t(X;12) observed in a female patient with
mild MR. Subsequent studies have revealed the pres-
ence of OPHN1 mutations in families with MR asso-
ciated with cerebellar hypoplasia and lateral ventricle
enlargement. All OPHN1 mutations identified to date
have been shown, or predicted, to result in OPHN1
loss of function; however, the pathophysiological role
of OPHN1 has remained poorly understood.
We have begun to unveil the function of OPHN1 at
both the presynaptic site and the postsynaptic site of the
hippocampal CA3-CA1 synapse. We previously showed
that during early development, presynaptic OPHN1 is
important for efficient retrieval of synaptic vesicles,
whereas postsynaptic OPHN1 has a key role in activ-
ity-dependent maturation and plasticity of excitatory
synapses, suggesting the involvement of OPHN1 in
normal activity-driven glutamatergic synapse develop-
ment. We have now found that postsynaptic OPHN1
also has a critical role in mediating a form of plasticity
(mGluR-LTD [long-term depression]) that relies on the
activation of group I metabotropic glutamate receptors,
which consist of mGluR1 and mGluR5 in CA1 hip-
pocampal neurons. Alterations in this form of plasticity
have been linked to drug addiction and cognitive disor-
ders. A key characteristic of mGluR-LTD is its depen-
dence on rapid protein synthesis; however, the identities
of the proteins mediating LTD have remained largely
elusive. We obtained evidence that OPHN1 expression
is translationally induced in dendrites of CA1 neurons
within 10 min of mGluR activation and that this re-
sponse is essential for mGluR-dependent LTD. Specif-
ically, acute blockade of new OPHN1 synthesis impedes
mGluR-LTD and the associated long-term decreases in
surface AMPARs (a-amino-3-hydroxy-5-methyl-4-isox-
azolepropionic acid receptors). Interestingly, the rapid
induction of OPHN1 expression is primarily dependent
on mGluR1 activation and is independent of fragile X
mental retardation protein (FMRP). Importantly, we
further demonstrated that OPHN1’s role in mediating
mGluR-LTD is dissociable from its role in basal synap-
tic transmission. Regulation of basal synaptic strength
requires OPHN1’s Rho-GAP activity and association
with Homer 1b/c proteins, whereas mGluR-LTD and
the associated long-term decreases in surface AMPARs
are dependent on OPHN1’s interaction with endophilin
A2/3. Together, these findings point to a multifunc-
tional role for OPHN1 at CA1 synapses. Independent
of its role in activity-driven glutamatergic synapse de-
velopment, regulated OPHN1 synthesis has a critical
role in mGluR-dependent LTD. Thus, it is conceivable
that, on the one hand, OPHN1 might have an impor-
tant role in synapse maturation and circuit wiring dur-
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ing early development; on the other hand, the regulated
OPHN1 synthesis could operate during adulthood to
weaken synapses in response to behaviorally relevant
stimuli.
DOCK180 Family Member DOCK7
Controls Multiple Steps of Neuronal
Development
DOCK7 is a member of the evolutionarily conserved
DOCK180-related protein superfamily, which we ini-
tially identified as a novel activator of Rac GTPases. We
found that DOCK7 is highly expressed in major re-
gions of the brain, including hippocampus and cortex,
during early stages of development and, importantly,
that the protein is asymmetrically distributed in unpo-
larized hippocampal neurons and becomes selectively
expressed in the axon. We then obtained evidence for a
key role of DOCK7 in controlling the early steps of
axon development in cultured hippocampal neurons.
Knockdown of DOCK7 prevents axon formation,
whereas overexpression induces the formation of mul-
tiple axons. We further demonstrated that DOCK7 and
Rac activation leads to phosphorylation and inactiva-
tion of the microtubule destabilizing protein stath-
min/Op18 in the nascent axon and that this event is
important for axon development. Thus, our findings
unveiled a novel pathway linking the Rac activator
DOCK7 to a microtubule regulatory protein and high-
light the contribution of microtubule dynamics to axon
development.
More recently, we uncovered a distinct role for
DOCK7 in the regulation of cortical neurogenesis.
Neurogenesis in the developing neocortex relies on the
ability of radial glial progenitor cells (RGCs) to switch
from proliferative to differentiative neuron-generating
divisions, but the molecular mechanisms that control
this switch in a correct temporal manner are not well
understood. We found that DOCK7 has a key role in
the regulation of RGC proliferation versus differentia-
tion. In particular, silencing of DOCK7 in RGCs of
developing mouse embryos impedes neuronal differen-
tiation and maintains cells as cycling progenitors. In
contrast, DOCK7 overexpression promotes RGC dif-
ferentiation to basal progenitors and neurons. We fur-
ther obtained evidence that DOCK7 influences the
mode of RGC division and thereby neurogenesis by
controlling apically directed interkinetic nuclear mi-
gration (INM) of RGCs. Importantly, DOCK7 exerts
these effects by antagonizing the microtubule growth-
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promoting function of the centrosome-associated pro-
tein TACC3. Thus, DOCK7 interacts with TACC3 to
control INM, thereby governing RGC proliferation
versus differentiation and genesis of neurons during
cortical development—processes associated with nu-
merous neurodevelopmental disorders.
Oncogenic Tyrosine Kinases Target 
Dok-1 for Ubiquitin-Mediated
Proteasomal Degradation to
Promote Cell Transformation
Dok-1 (also called p62dok) was initially identified as a
tyrosine phosphorylated 62-kDa protein associated
with Ras-GAP in Ph+ chronic myeloid leukemia (CML)
blasts and in v-Abl-transformed B cells. This protein
was termed Dok (downstream of kinases), since it was
also found to be a common substrate of many receptor
and cytoplasmic tyrosine kinases. Subsequently, six ad-
ditional Dok family members have been identified,
Dok-1 to Dok-7. Among them, Dok-1 and Dok-2
share the ability to bind to a negative regulator of Ras,
Ras-GAP. We previously showed that Dok-1 attenuates
growth-factor-induced cell proliferation and that Dok-
1 inactivation in mice causes a significant shortening of
the latency of the fatal myeloproliferative disease in-
duced by p210bcr-abl, suggesting that it possesses tumor
suppressive activity in the context of myeloid leukemia.
In support of this, we found in collaboration with Dr.
Pandolfi’s group that mice lacking both Dok-1 and
Dok-2 spontaneously develop a CML-like myeloprolif-
erative disease. Furthermore, more recent studies have
shown that mice with combined Dok-1, Dok-2, and
Dok-3 knockouts also develop lung adenocarcinoma
with penetrance and latency dependent on the number
of lost Dok family members.
These studies thus indicate that the Dok-1 to Dok-
3 proteins possess tumor suppressive activities and that
their inactivation can contribute to disease/tumor pro-
gression associated with deregulated protein kinase sig-
naling, as, for example, in the case of p210bcr-abl-driven
CML-like disease in mice. To date, however, very little
is known about the regulation of Dok proteins by onco-
genic tyrosine kinases (OTKs). We have focused on
Dok-1 and mechanisms of its regulation by p210bcr-abl
and other OTKs. We found that OTKs, including
p210bcr-abl and oncogenic forms of Src, down-regulate
Dok-1 by targeting it for degradation through the ubiq-
uitin-proteasome pathway. This process is dependent
on the tyrosine kinase activity of the oncoproteins and
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is mediated primarily by lysine-dependent polyubiqui-
tination of Dok-1. Importantly, restoration of Dok-1
levels strongly suppresses transformation of cells ex-
pressing OTKs, and this suppression is more pro-
nounced in the context of a Dok-1 mutant that is
largely refractory to OTK-induced degradation. To-
gether, our findings indicate that proteasome-mediated
down-regulation of Dok-1 is a key mechanism by
which OTKs overcome the inhibitory effect of Dok-1
on cellular transformation and tumor progression.
New Functions of Rap1 Signaling 
in Cell−Cell Adhesion and Epithelial
Morphogenesis
The Rap1 protein, a member of the Ras family, was ini-
tially identified as an antagonist of oncogenic Ras pro-
teins; however, more recent studies indicate that Rap1
acts independently of Ras signaling. Rap1 function is
critical for cell adhesion processes during tissue mor-
phogenesis, and recent studies suggest that dysregulated
Rap1 signaling may contribute to malignant manifes-
tations. However, how Rap1 controls cell adhesion in
vivo has remained largely elusive. Using genetic tools
and cell-based interaction assays, we have identified a
signaling module that contains PDZ-GEF, a Rap1-spe-
cific exchange factor, Rap1 itself, and the adaptor pro-
tein AF-6. Our study of this module in Drosophila
demonstrated that productive signal transduction
through DPDZ-GEF, Rap1, and the Drosophila AF-6
ortholog Canoe governs epithelial migration and gas-
trulation events in the embryo at mitotically silent
stages. We found that the activity of this pathway in
part impinges on myosin II as a motor protein that
modulates cell shape in epithelial morphogenetic
processes in close association with cell−cell adhesion
complexes.
Following up on these observations, we identified an
additional role for Canoe/AF-6 as a Rap1 effector in
mitotically active epithelia, such as the highly prolifer-
ative wing imaginal disc. Our experiments showed that
AF-6/Canoe is key to a mechanism that reconstitutes E-
cadherin-based adherens junctions (AJs) at the apical
membrane between sister cells, late in cytokinesis, in
each cell division event. Canoemutant cell populations
display a dramatic loss of cohesion, do not sort to their
proper positions within the epithelium, and become in-
vasive. We searched for genetic modifiers of the partial
AJ loss between canoe mutant cells and discovered a
critical synergism with the Echinoid protein, the
Drosophila homolog of the Nectin family of IgG adhe-
sion proteins. Nectins in mammalian cells were pro-
posed to function by directly interacting with AF-6 in
cultured epithelial cells. Our results, however, support
a model in which Rap1 and Canoe act independently
of, but in synergy with, Echinoid to control the overall
homeostasis of AJs. Importantly, the general and almost
complete inability to form AJs that we observe in cell
populations lacking both Echinoid and Canoe is cou-
pled to a partial breakdown of the apico-basal polarity
machinery. The strong synergism between Echinoid
and Canoe therefore unravels a molecular link between
polarity systems and the establishment of normal AJs.
In light of the conservation of the structure and func-
tion of AJs and the polarity machinery between
Drosophila and mammalian epithelia, our findings have
important implications for mammalian epithelial tis-
sue morphogenesis in vivo.
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Malignant glioma represents the most common and
lethal type of brain tumor and is stratified into distinct
pathologic grades with well-known biological behav-
iors. Clinically, although WHO (World Health Or-
ganization) grade I astrocytomas exhibit defined
margins and may be removed surgically, higher-grade
tumors often disseminate and invade into surrounding
brain parenchyma. The presence of tumor extensions
beyond their visually identifiable borders precludes
complete surgical resection. As a result, postsurgery
tumor recurrence and/or progression to a higher grade
are inexorable. In its most severe manifestation, the
glio- blastoma multiforme (GBM), the median survival
is only ~12−15 months after initial diagnosis with a 5-
year survival rate <3% despite abundant treatment ef-
forts. Unfortunately, in the last several decades, re-
finements of available therapeutic modalities including
microneurosurgery, radiotherapy, and chemotherapy
have so far failed to substantially improve survival.
Thus, new targeted therapeutic approaches based on a
deeper understanding of glioma biology are urgently
needed. Along this line, we have directed our research
around two major areas: (1) We are developing various
animal models to recapitulate human glioma patho-
genesis and are utilizing them as tools to trace and in-
vestigate the in vivo disease initiation/progression, and
(2) we are applying integrated approaches combining
mouse models, stem cell biology, and RNA interference
(RNAi) to identify the molecular and developmental
pathways relevant to glioma pathogenesis and treat-
ment. We are particularly interested in genetic pro-
grams and pathways governing normal and glioma cell
lineage development with an emphasis on the intimate
relationships between cellular renewal and differentia-
tion. We believe that an improved understanding of the
developmental pathways governing the self-renewal and
differentiation processes along the neural progenitor−
glial axis and, by extension, the glioma initiation
cells−progeny axis will be instrumental in guiding fu-
ture development of efficient treatments targeting this
dreadful disease.
Characterization of EGFR-Targeted
Therapeutic Resistance
As a signature genetic event of malignant gliomas, the
epidermal growth factor receptor (EGFR) amplification/
mutation is present in ~40%−50% of human patient
samples, making it a compelling candidate for targeting
therapy. Although countless studies have repeatedly
demonstrated the crucial roles of aberrant EGFR signal-
ing in glioma cell growth and survival in vitro, unex-
pectedly, the promising laboratory experimental results
seen with EGFR inhibitors have thus far not translated
into clinical success. Results from multiple clinical trials
using different EGFR-specific inhibitors or antibodies
indicated that the majority of patients whose tumors ex-
press amplified EGFR and who would be expected to re-
spond, do not. Even in those patients who did show
some clinical or radiological response to EGFR inhibi-
tors, the benefit was not durable and the disease progres-
sed rapidly thereafter. Clinically, this quick acquisition
of resistance to anti-EGFR drugs poses a huge obstacle to
successful therapy. However, due to absence of appro-
priate biological systems to interrogate in vivo disease
progression, the mechanism(s) underlying the EGFR-
targeted therapeutic resistance remains unclear.
Against this backdrop, we have recently generated a
novel tetracycline-inducible glioma mouse model in
which overexpression of a malignant glioma-specific mu-
tant EGFR is engineered with concurrent brain-specific
inactivation of Ink4a/Arf and Pten, recapitulating the ge-
netic abnormality observed in the human patient sam-
ples. Importantly, the tightly tetracycline-controlled
mutant EGFR expression in this case ensures a faithful
model system to mirror EGFR-targeting therapy, there-
fore providing us an opportunity to dissect the resistance
mechanism(s) under in vivo settings. Phenotypic analy-
sis revealed that the compound mice with mutant EGFR
induction developed malignant gliomas with a median
latency of about 35 weeks. Remarkably, although tumor
initiation in these mice was strictly dependent on in-
duced mutant EGFR expression, we found that after a
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short initial response upon doxycycline or EGFR-in-
hibitor treatment, the developed gliomas were able to
rapidly acquire resistance to EGFR inhibition. In addi-
tion, the resistant tumors continued to progress inde-
pendent of aberrant EGFR signaling, a situation
essentially mirroring the EGFR-targeted therapeutic re-
sistance observed in human patients.
EGFR gene amplification in human malignant glioma
occurs invariably as extrachromosomal double-minute
fragments. When devoid of selective pressure, the ampli-
fied EGFR diminishes rapidly upon cycles of cell division.
As a result, heterogeneous intratumoral EGFR amplifica-
tion and gene expression are commonly observed in
human malignant gliomas. This heterogeneous EGFR ex-
pression pattern is also notably recapitulated in our in-
ducible EGFR mouse gliomas, often with the high EGFR
expression cells present in the peripheral invasive edge of
the tumors compared to low EGFR expression subpopu-
lations in the relatively solid tumor center. Although aber-
rant EGFR expression is essential for glioma initiation in
this mouse model, the existence of large subpopulations
of low EGFR expression tumor cells in the developed tu-
mors nevertheless suggests to us that aberrant EGFR sig-
naling is not absolutely required for all tumor cell survival.
And these subpopulations of low EGFR expression tumor
cells may propagate independent of aberrant EGFR sig-
naling and therefore be inherently resistant to EGFR tar-
get therapy. Along this line, our serial in vivo experiments
further indicated that the EGFR-targeted therapeutic re-
sistance in malignant glioma is indeed largely attributable
to the inherent intratumoral heterogeneity and likely sus-
tained by the preexisting tumor cell subpopulation(s) that
engages alternative survival signaling(s) independent of
the EGFR pathway. We are currently applying an inte-
grated approach to investigate the critical signaling mod-
ules that persist within the resistant glioma cells. By
identifying the potential resistance mechanism(s), we
hope to provide the rationale for the future design of new
combinational therapeutic strategies targeting this dread-
ful disease.
Epigenetic Regulation during Glioma
Pathogenesis
Malignant glioma is a genetic disease driven by the accu-
mulation of numerous genetic and genomic alterations.
At the same time, it is also a highly complex develop-
mental disease. A single tumor can act as an evolving bi-
ological system containing a vast heterogeneous cell pop-
ulation, reminiscent of normal tissue renewal with neural
stem/progenitor cells (NPCs) at the apex of the hierarchy.
Pathologically, malignant glioma is well known for its ex-
plicit intratumoral heterogeneity. But unlike the normal
NPCs, the glioma cells are largely devoid of terminal dif-
ferentiation traits and possess aberrant proliferative ca-
pacity. The recent identification of tumor-initiating cells
(TICs) with stem-cell-like properties in malignant glioma
underscores this developmental plasticity and suggests tar-
geting glioma cell lineage differentiation as a promising
avenue for developing effective therapeutics. Previously,
we had established a malignant glioma model driven by
the brain-specific inactivation of p53 and Pten, the two
most common mutational events found in human GBM.
On the basis of this mouse model, we were able to repro-
ducibly isolate and culture the primary glioma cells en-
riched for glioma TICs. These mouse glioma TICs, unlike
the normal NPCs, were resistant to differentiation induc-
tion. Importantly, we found forced restoration of the dif-
ferentiation capacity within these tumor cells could largely
compromise their gliomagenic potential, making them a
great primary cell-based system to study glioma TIC dif-
ferentiation. Epigenetic regulation as the core mechanism
has been implicated in controlling cellular fate determi-
nation, and thus, in collaboration with Scott Lowe and
Chris Vakoc’s groups at CSHL, we set out to identify the
epigenetic networks essential for maintaining glioma TIC
against differentiation. We screened a customized RNAi li-
brary targeting 243 known chromatin regulators against
the mouse glioma TICs developed from our model sys-
tems. The primary short hairpin RNA (shRNA) screen
was performed using a one-by-one approach in three in-
dependent glioma TIC lines. Right now, we have finished
about three-quarters of the primary screen in which a total
of 78 shRNAs targeting 32 candidate genes were identi-
fied. We anticipate that we will be able to finish the pri-
mary screen within the near future. By using a stringently
filtered list of candidates and rigorous functional valida-
tion systems, we hope that this project will elaborate a
spectrum of prime targets that can be enlisted into pro-
ductive drug discovery and development efforts against
malignant gliomas.
Conversely, we have also been probing the same epi-
genetic RNAi library for chromatin modulators whose
suppression may compromise the neural progenitor
cell’s differentiation capacity and therefore act as tumor
suppressor genes to prevent malignant transformation.
We have identified several interesting candidates and
are currently investigating their mechanistic functions
in glioma initiation and progression. 
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CSHL neuroscientists focus on understanding how neural activity and neural circuitry underlie be-
havior, and how disruptions in these circuits lead to neurological and neuropsychiatric disorders
such as Alzheimer’s disease, autism, schizophrenia, and depression. These questions are addressed in
two model systems—rodents and Drosophila—using molecular, cellular, genetic, developmental,
theoretical, physiological, and behavioral approaches. Neuroscience research at CSHL is highly col-
laborative, and it can be divided into three broad themes: sensory processing, cognition, and cog-
nitive disorders. In addition, there is an effort to develop new anatomical methods to improve our
understanding of brain circuits, connectivity, and function. How does the brain encode stimuli from
the outside world, within and across sensory modalities, to generate specific perceptions that, in
turn, trigger complex behaviors? How is the brain shaped by sensory experience and what modifi-
cations occur in neuronal circuits that allow us to learn and remember? These are questions guid-
ing the work of Florin Albeanu, who is using the olfactory bulb and olfactory cortex of mice as the
subject of his current studies. Airborne chemicals, translated into neuronal signals by specific re-
ceptors in the nose, are sent directly to the olfactory bulb. Advances in optical imaging and opto-
genetics, combined with electrophysiological recordings, enable Albeanu and colleagues to monitor
and/or alter patterns of activity at unprecedented synaptic and millisecond resolution, in real time,
as animals engage in various behaviors. For survival, rodents need to identify the smells of objects
of interest such as food, mates, and predators, across their recurring appearances in the surround and
despite apparent variations in their features. By recording neuronal activity in the input and output
layers of the olfactory bulb, as well as from higher olfactory cortical areas, Albeanu and his team aim
to understand computations that the bulb performs and how this information is decoded deeper in
the brain. They have recently published evidence suggesting that the mouse olfactory bulb is not
merely a relay station between the nose and cortex, as many have supposed. Using optogenetic tools
and a novel patterned illumination technique, they discovered that the number of information out-
put channels leaving the olfactory bulb for the cortex greatly exceeds the number of inputs received
from the nose. They are currently investigating how this diversity of bulb outputs is generated and
how the olfactory cortex makes use of such information during behaviors.
The study of decision-making provides a window on the family of brain functions that consti-
tute cognition. Decision intervenes between perception and action and can link one to the other.
Although much is known about sensory processing and motor control, much less is known about
the circuitry connecting them. Some of the most interesting circuits are those that make it possible
to deliberate among different interpretations of sensory information before making a choice about
what to do. Anne Churchland’s lab investigates the neural machinery underlying decision-making.
Her lab uses carefully designed paradigms that encourage experimental subjects, both rodent and
human, to deliberate over incoming sensory evidence before making a decision. To connect this be-
havior to its underlying neural circuitry, they measure electrophysiological responses of cortical neu-
rons in rodents as they perform designated tasks. The lab’s current focus is on parietal cortex, which
appears to be at the midpoint between sensory processing and motor planning. Churchland and col-
leagues also use theoretical models of varying complexity to further constrain how observed neural
responses might drive behavior. This approach generates insights into sensory processing, motor
planning, and complex cognitive function.
Joshua Dubnau and colleagues use the fruit fly to investigate two different questions. First, Dub-
nau and his team are investigating mechanisms of memory. Because biological mechanisms of mem-
ory are highly conserved through evolution, many features of human memory are observed in
simpler organisms such as fruit flies. The lab’s efforts on memory focus on understanding the gene
pathways that are required as well as the neural circuits in the fly brain. They have recently shown
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that short-term memory forms in one set of neurons, but that long-term memories form in a dif-
ferent brain area. A second area of research in the Dubnau group is focused on uncovering mecha-
nisms or neurodegeneration that underlie amyotrophic lateral sclerosis (ALS) and frontotemporal
lobar degeneration (FTLD). Using the fruit fly as an experimental system, together with analyses of
genomic data sets from mouse, rat, and human, the Dubnau group has developed a novel hypoth-
esis to explain several different neurodegenerative disorders. Ongoing work in flies and mice will be
used to investigate this hypothesis with the goal of developing avenues for therapeutic intervention.
Grigori Enikolopov and colleagues study stem cells in the adult brain. They have generated sev-
eral models to account for how stem cells give rise to progenitors and, ultimately, to neurons, and
they are using these models to determine the targets of antidepressant therapies, identify signaling
pathways that control generation of new neurons, and search for neuronal and neuroendocrine cir-
cuits involved in mood regulation. Recent experiments have suggested to the team a new model of
how stem cells are regulated in the adult brain, with a focus on stem cells’ decision on whether to
divide—and embark on a path of differentiation—or remain quiescent. This model explains why
the number of new neurons decreases with advancing age and may lead to impairments in memory
and depressed mood. In other research, the team has identified the elusive target of deep brain stim-
ulation (DBS), a type of precursor cell that matures into adult hippocampal neurons. Enikolopov’s
group is also part of a team that identified and validated the first biomarker that permits neuronal
progenitor cells to be tracked, noninvasively, in the brains of living humans and animals. The lab is
now using these discoveries to reveal how neurogenesis is related to the course of diseases such as de-
pression, bipolar disorder, and Parkinson’s.
Hiro Furukawa’s lab is studying neurotransmission at the molecular level. They focus on structure
and function of NMDA (N-methyl-D-aspartate) receptors, ion channels that mediate excitatory trans-
mission. Dysfunctional NMDA receptors cause neurological disorders and diseases including
Alzheimer’s disease, Parkinson’s disease, schizophrenia, depression, and stroke-related ischemic in-
juries. NMDA receptors are very large molecules whose three-dimensional atomic structure Fu-
rukawa’s group has undertaken to solve by dividing them into several domains. The investigators seek
to understand the pharmacological specificity of neurotransmitter ligands and allosteric modulators
in different subtypes of NMDA receptors at the molecular level. Toward this end, they use cutting-
edge techniques in X-ray crystallography to obtain crystal structures of the NMDA receptor domains
and validate structure-based functional hypotheses by a combination of biophysical techniques in-
cluding electrophysiology, fluorescent analysis, isothermal titration calorimetry, and analytical cen-
trifugation. Crystal structures of NMDA receptors serve as a blueprint for creating and improving the
design of therapeutic compounds with minimal side effects for treating neurological disorders and dis-
eases. This year, the team discovered and mapped a new regulatory site in a class of NMDA recep-
tors, progress that now opens the way to the development of a potentially new class of drugs to
modulate the receptor.
To better understand neuronal circuits, Josh Huang and colleagues have developed novel means
of visualizing the structure and connectivity of different cell types at high resolution in living ani-
mals and of manipulating the function of specific cell types with remarkable precision. Huang is par-
ticularly interested in circuits that use GABA (g-amino-n-butyric acid), the brain’s primary inhibitory
neurotransmitter. The lab’s work has direct implications for neurological and psychiatric illness such
as autism and schizophrenia, which involve altered development and function of GABAergic circuits.
This past year, Huang’s team developed 20 different mouse lines, each of which is engineered to ex-
press markers of specific cell types, and demonstrated the exquisite specificity of this technology by
imaging GABA cells. The team’s work recently has also shed new light on synapse validation, which
is at the heart of the process by which neural circuits self-assemble and is directly implicated in neu-
rodevelopmental pathologies. Huang’s team looked closely at neurexins, proteins that interact with
neuroligins to form the “zipper” that holds synapses together. The team discovered that α and b
neurexins respond in different ways to neural activity—the α molecules searching out compatible
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connection partners and the bmolecules securing preliminary connections that prove to be strong.
This adds to past studies in the lab on the underlying framework of molecular guides called glial cells,
which nudge nerve fibers to grow in the right direction and make the right contacts. The lab has also
made good progress in studying perturbations in the developing GABAergic system in a mouse
model of Rett syndrome, an autism spectrum disorder.
Adam Kepecs and colleagues are interested in identifying the neurobiological principles under-
lying cognition and decision-making. They use a reductionist approach, distilling behavioral ques-
tions to quantitative behavioral tasks for rats and mice that enable the monitoring and manipulation
of neural circuits supporting behavior. Using state-of-the-art electrophysiological techniques, they
first seek to establish the neural correlates of behavior and then use molecular and optogenetic ma-
nipulations to systematically dissect the underlying neural circuits. Given the complexity of animal
behavior and the dynamics of neural networks that produce it, their studies require quantitative
analysis and make regular use of computational models. The team also has begun to incorporate
human psychophysics to validate their behavioral observations in rodents by linking them with anal-
ogous behaviors in human subjects. Currently, the team’s research encompasses study of (1) the roles
of uncertainty in decision-making, (2) the division of labor among cell types in prefrontal cortex, (3)
how the cholinergic system supports learning and attention, and (4) social decisions that rely on
stereotyped circuits. A unifying theme is the use of precisely timed cell-type- and pathway-specific
perturbations to effect gain and loss of function for specific behavioral abilities. Through such ma-
nipulations of genetically and anatomically defined neuronal elements, the team hopes to identify
fundamental principles of neural circuit function that will be useful for developing therapies for
diseases such as schizophrenia, Alzheimer’s disease, and autism spectrum disorder.
Alexei Koulakov and colleagues are trying to determine the mathematical rules by which the brain
assembles itself, with particular focus on the formation of sensory circuits such as those involved in
visual perception and olfaction. The visual system of the mouse was chosen for study in part because
its components, in neuroanatomical terms, are well understood. What is not known is how projec-
tions are generated that lead from the eye through the thalamus and into the visual cortex, how an
individual’s experience influences the configuration of the network, and which parameters for the
process are set by genetic factors. Even less is known about the assembly of the neural net within the
mouse olfactory system, which, in the end, enables the individual to distinguish one smell from an-
other with astonishing specificity and to remember such distinctions over time. These are among the
challenges that engage Koulakov and his team.
Dysfunction of excitatory glutamatergic synapses in the brain is believed to have an important
role in the pathogenesis of major psychiatric disorders, including schizophrenia and depression. But
what are the causes? Where in the brain does this dysfunction occur? How does it result in the be-
havioral symptoms of illness? To address these issues, Bo Li and colleagues, who include Professor
Fritz Henn, are studying normal synaptic plasticity and disease-related synaptic changes in brain cir-
cuits involved in schizophrenia and depression. Their long-term goal is to develop methods allow-
ing the manipulation of activity in specific brain circuits in order to change disease-related behaviors.
They use a variety of methodologies, including patch-clamp recording and calcium imaging of la-
beled neurons, two-photon imaging of spine morphology and tagged receptors, in vivo virus injec-
tion, RNAi-based gene silencing, activation of specific axon terminals using light-gated cation
channels, activation or silencing of specific brain regions using transgenes, and assessment of the be-
havioral consequences of certain manipulations. A project focusing initially on a gene called ErbB4
seeks to determine the genetic causes of NMDA receptor hypofunction, a pathology believed to
contribute to the etiology of schizophrenia. This past year, Li, Henn, and colleagues demonstrated
that neurons in a tiny area of the mammalian brain called the lateral habenula (LHb) are hyperac-
tive. They used an analog of deep-brain stimulation to reverse depression-like symptoms in rats.
Partha Mitra seeks to develop an integrative picture of brain function, incorporating theory, in-
formatics, and experimental work. In the ongoing Mouse Brain Architecture Project, Mitra and col-
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leagues are well on their way to generating the first-ever brainwide mesoscopic-scale circuit map of
the entire mammalian brain. This is a first step toward mapping vertebrate brain architecture across
species and in mouse models of human disease, starting with schizophrenia and autism. These maps
will be cross-referenced to the Allen Brain Atlas of gene expression, a complementary landmark data
set on which the Mitra lab has innovated multiple analyses. These analyses include assessing coex-
pression patterns and networks of disease-related genes, determining evolutionary ages of genes with
respect to their brain region of expression, and correlation with cell-type-specific gene expression.
Related collaborative efforts include characterization of different types of GABAergic neurons in
the mouse brain, optogenetic studies of the rodent brain, and connectivity mapping in marmoset
and zebra finch brains.
Pavel Osten’s lab works on identification and analysis of brain regions, neural circuits, and con-
nectivity pathways that are disrupted in genetic mouse models of autism and schizophrenia. Osten
hypothesizes that (1) systematic comparison of many genetic mouse models will allow determina-
tion of overlaps in pathology—neural circuit endophenotypes—responsible for the manifestation of
neuropsychiatric disorders and (2) neural-circuit-based classification of autism and schizophrenia will
provide key circuit targets for detailed mechanistic studies and therapeutic development. Osten and
colleagues have developed the first systematic approach to the study of neural circuits in mouse
models of psychiatric diseases, based on a pipeline of anatomical and functional methods for analy-
sis of mouse brain circuits. An important part of this pipeline is high-throughput microscopy for
whole mouse-brain imaging, called serial two-photon (STP) tomography. Other methods include
virus-vector-based anatomical tracing, transgenic and knock-in “indicator” mouse lines for moni-
toring expression of activity-regulated genes, and both in vitro and in vivo two-photon imaging and
electrophysiology.
Stephen Shea’s lab studies the neural circuitry underlying social communication and decisions.
He uses natural social communication behavior in mice as a model to understand circuits and
processes that are evolutionarily conserved and therefore shared broadly across species—and that are
likely contributors to disorders such as autism. Shea and colleagues have examined how emotion and
arousal enable mice, via their olfactory systems, to store memories of other individuals and of related
social signals. The team has exploited the intimate relationship between memory and emotion to ef-
fectively create memories in anesthetized mice, allowing them unprecedented access to neurobio-
logical processes that typically only occur during behavior. This year, the lab has been making a
detailed analysis of the changes in neural connections that underlie odor memory. The team is par-
ticularly focused on an enigmatic cell type that has long been hypothesized to be crucial for mem-
ories but has resisted direct study. Team members have developed methods for recording that are
giving them the first glimpse of the dynamics of these cells while the animal is learning an odor. The
results show unexpected complexity that was independently predicted by a model of odor learning
developed in Alexei Koulakov’s lab. In parallel, a member of the lab is using imaging techniques to
determine how memories are stored among broad neuronal ensembles, as opposed to studying one
cell at a time. Also this year, the Shea lab continued a series of studies of a different form of social
recognition: auditory recognition of pup vocalizations by their mothers. Through this research, they
are beginning their first explicit analysis of a mouse model of Rett syndrome, gathering evidence that
these mice exhibit deficits in communication and learning not unlike those in human patients.
What is a memory? When we learn an association, information from two different sensory streams
somehow becomes linked together. What is this link in terms of neural activity? For example, after
a few bad experiences, we learn that the “green” smell of an unripe banana predicts its starchy taste.
How has the neural response to that green smell changed so it becomes linked to that taste? What
are the underlying mechanisms—what synapses change strength and what ion channel properties
change? These are the questions that drive research in Glenn Turner’s lab. His team addresses these
questions by monitoring neural activity using a combination of different techniques. Using elec-
trophysiological methods, Turner’s team can examine individual neurons with very high resolution,
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monitoring synaptic strength and spiking output. The team has also developed functional imag-
ing techniques to monitor the activity of the entire set of cells in the learning and memory center
of the fly brain. This comprehensive view of neural activity patterns enables lab members to actu-
ally predict the accuracy of memory formation in separate behavioral experiments. By examining the
effects of learning-related genes on this process, they can connect their network-level view of mem-
ory formation to the underlying molecular mechanisms that govern the basic cellular and synaptic
changes that drive learning.
Anthony Zador and colleagues study how brain circuitry gives rise to complex behavior. Work
in the lab is focused on two main areas. First, they ask how the cortex processes sound, how that pro-
cessing is modulated by attention, and how it is disrupted in neuropsychiatric disorders such as
autism. Second, they are developing new methods for determining the complete connectivity of the
mouse brain at single-neuron resolution. In contrast to previous methods that make use of mi-
croscopy, these methods exploit high-throughput DNA sequencing. Because the costs of DNA se-
quencing are plummeting so rapidly, these methods have the potential to yield the complete wiring
diagram of an entire brain for mere thousands of dollars. This past year, Zador published results of
research on the influence of expectation on neuronal activity in the rat sensory cortex, suggesting
that improvements in auditory perception that result from valid temporal expectation arise from
changes in sensory representations as early as the first stages of cortical processing.
Yi Zhong’s lab studies the neural basis of learning and memory. The team works with fruit fly
models to study genes involved in human cognitive disorders, including neurofibromatosis, Noo-
nan’s syndrome (NS), and Alzheimer’s disease. Mutations leading to a lack of function of the neu-
rofibromatosis 1 (NF1) gene cause noncancerous tumors of the peripheral nervous system as well
as learning defects. The lab’s analyses of Drosophila NF1 mutants have revealed how expression of
the mutant gene affects a pathway crucial for learning and memory formation. The NF1 gene and
a gene called corkscrew, implicated in NS, share a biochemical pathway. Recently, the lab succeeded
in linking changes in this pathway due to specific genetic defects in NS with long-term memory de-
ficiencies. In fly models, they discovered the molecular underpinnings of the “spacing effect,” the
fact that memory is improved when learning sessions are spaced out between rest intervals. Zhong’s
team has also succeeded in reversing memory deficits in mutant flies—work suggesting that longer
resting intervals for NS patients might reverse their memory deficits. This year, the team identified
a means of reversing memory loss in fruit flies while suppressing brain plaques similar to those im-
plicated in Alzheimer’s disease. Separately, having discovered that memory decay is an active process
regulated by the Rac protein, the team has proposed that Rac’s role in erasing memory is related to
its influence on downstream cytoskeleton remodeling agents.
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The focus of our research group is to understand how
neuronal circuits encode and interpret inputs from the
environment leading to meaningful behaviors. Toward
this end, we are using optogenetic tools (such as two-
photon imaging of genetically encoded neuronal activ-
ity reporters or light-gated neuronal activity switches)
coupled with electrophysiological measurements (ex-
tracellular and intracellular recordings). We want to un-
derstand (1) how inputs get processed at different
synapses of the underlying neuronal circuits, (2) how
these representations change with the state of the sys-
tem and its circuits (awake vs. anesthetized; naïve vs.
learning), and (3) what changes in the activity patterns
of well-defined neuronal circuits contribute to specific
behaviors. The broad scope of this effort is observing
how perceptions arise.
We use the rodent olfactory system as a model and
monitor neuronal inputs and outputs in different lay-
ers of the circuit. We modulate activity of select neu-
ronal populations in a reversible manner in anesthetized
and behaving animals to understand how fundamental
sensory encoding problems are solved by the olfactory
bulb and piriform cortex networks. 
Characterizing the Input-Output
Transform of the Olfactory Bulb
In the olfactory bulb (OB), sensory neurons expressing the
same type of olfactory receptor converge in tight focus,
forming ~2000 clusters of synapses called glomeruli. The
layout of glomeruli on the bulb is highly reproducible
across individuals with a precision of 1 part in 1000. How-
ever, nearby glomeruli are as diverse in their responses to
odors as distant ones, lacking an apparent chemotopic
arrangement (Soucy et al., Nat Neurosci 12: 2 [2009]).
From each glomerulus, a few dozen mitral cells (principal
output neurons of the OB) carry the output farther to the
olfactory cortex and several other brain areas. Such “sis-
ter” mitral cells typically have only one primary dendrite
that projects to a single glomerulus, but they can sample
inputs on their primary and secondary dendrites from
functionally diverse glomeruli via several types of in-
terneurons (Fig. 1). Using optogenetic manipulations and
patterned photostimulation (Fig. 2), we found that sister
cells carry different information to the cortex: average ac-
tivity representing shared glomerular input and phase-spe-
cific information that refines odor representations and is
substantially independent across sister cells (Dhawale et
al., Nat Neurosci 13: 1404 [2010]).
Activity in the bulb is a rich mix of excitation and in-
hibition, via both direct inputs and feedback connections.
Many different classes of interneurons interact with the
sensory afferents and/or the output neurons via both
short- and long-range connections. Their connectivity
patterns and roles in olfactory processing, however, re-
main largely unknown. We use a Cre/loxP approach to
express reporters (i.e., synaptopHluorin, GCAMP3) and
light-gated switches of neuronal activity (Chr2, Halorho-
dopsin, Arch) in different bulbar neuronal types. We
monitor the inputs (glomerular activity patterns) and out-
puts (mitral cell firing) in response to numerous odorants
across a wide range of concentration as we systematically
perturb the activity of specific interneuron types. Pat-
terned photostimulation allows us to bypass odor stimu-
lation and gain precise spatiotemporal control over the
inputs by directly activating glomerular patterns of choice.
We record bulbar outputs via multitetrode recordings and
patch-clamp or use optical imaging readouts via multi-
photon microscopy in vivo. 
We are currently investigating the roles of two classes
of interneurons: short axon (SA) cells that broadcast long-
range signals in the glomerular layer and granule cells
(GCs) that establish reciprocal synapses with mitral/tufted
(M/T) cells and receive rich cortical feedback input.
Short Axon Cells Gain Control
in the Olfactory Bulb
SA cells, in the glomerular layer, receive inputs from ol-
factory sensory neurons and/or external tufted (ET) cells
and release both GABA and dopamine, synapsing onto
juxtaglomerular cells as far as tens of glomeruli away
UNDERSTANDING NEURONAL CIRCUITS 
IN THE MAMMALIAN OLFACTORY BULB
F. Albeanu A. Banerjee P.G. da Silva P. Gupta F. Marbach H. Patel
H. Chae M. Davis M. Koh G. Otazu S. Rengarajan
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(Kiyokage et al., J. Neurosci 30: 1185 [2010]). Compu-
tational models (Cleland et al., Trends Neurosci 33: 130
[2007]) have suggested that SA cells may be involved in
long-range normalization of bulb outputs, but to date,
their function in the intact brain has not been investi-
gated. We imaged GCAMP3 responses by wide-field mi-
croscopy to odor stimulation across a wide range of
concentrations. Odorants induced transient, yet wide-
spread, SA responses, in contrast to focal glomerular pat-
terns observed via intrinsic optical imaging. 
To understand the roles played by the SA network
on the bulb output dynamics, we recorded extracellu-
larly from M/T cells using tetrodes in anesthetized mice.
In conjunction, we selectively activated/inactivated SA
cells by shining blue/yellow light either throughout the
dorsal bulb surface or in specific spatial patterns. Strik-
ingly, pairing odor presentation at various concentra-
tions with light indicates that SA cells provide both
excitatory and inhibitory drive to the M/T cells in a
stimulus-specific fashion (Fig. 3). At low odorant con-
centrations, SA cells provide excitatory input, whereas
in response to stronger stimuli, both excitatory and in-
hibitory drives are present. We are currently performing
pharmacological manipulations to dissect the dual roles
of SA cells.We propose that the SA network regulates
the dynamic range of M/T cell firing by amplifying the
weak inputs and down-scaling the stronger ones.
Dissecting the Spatial and Temporal
Features of the Glomerular Code
in Awake Behaving Animals via
Optogenetics Strategies 
Odorants activate precise spatiotemporal glomerular ac-
tivity patterns on the OB surface. These patterns con-
stitute the first representation of odor input into the
olfactory system and hence must contain all meaning-
ful attributes of the incoming odor stimulus, such as
odor identity, intensity, and temporal dynamics. Dif-
ferent odors activate distinct overlapping and nonover-
lapping glomerular maps. In principle, these odor maps
can vary in several possible features such as number
(how many glomeruli are activated), space (which
glomeruli), intensity (absolute and relative levels of ac-
tivity of individual glomeruli), and timing (onset with
respect to each other and the order of their activation).
Previous experiments suggest that presenting different
odorants (A vs. B) and mixtures (A and B) or different
concentrations of the same odorant (A) may all result in
modulation of odor maps along many of these (if not all
of these) features. It is unknown how the downstream
circuitry (mitral/tufted cells) interprets these variations
and assigns meaning to them, in order to segregate odor
identity from changes in concentration or components
within/from a mixture.
Figure 2. DLP (digital light processing) patterned illumination in
ORC (orchiectomized) mice maps the parent glomeruli of mitral
cells in vivo. (A) (Left) A DLP projector coupled to a system of
three lenses delivered light patterns to activate individual glom-
eruli on the dorsal surface of the bulb. A CCD (charge-coupled
device) camera was used to visualize the bulb surface and record
the position of the light stimulus. (Top, right) Dorsal surface of
the bulb with a tetrode positioned in the mitral cell layer. One
square light spot is projected onto the surface of the bulb. (Inset)
Schematic of glomeruli on the bulb, a subglomerular-size light
spot, and dual tetrodes positioned in the mitral cell layer. (a) DLP
projector with color wheel removed from optical path, (b) focus-
ing lens, (c) excitation filter, (d) dichroic mirror, (e) emission fil-
ter, (f) CCD camera, (g) dual tetrode, (h) olfactory bulb. (B) (Top)
Raw voltage traces corresponding to the four channels of a
tetrode showing light-induced changes in firing patterns of the
units recorded. (Center) Raster plot showing changes in spiking
activity of a single isolated unit across 25 light stimulation trials,
each 200 ms long. Dots mark spike occurrence times. (Bottom)
Peristimulus time histogram (PSTH) with 25-ms time bins, sum-
ming spikes over the trials shown in the center panel.
Figure 1. Main olfactory bulb wiring schematics.
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One way to understand how the circuit makes sense
of changes in the glomerular activity patterns to extract
relevant information is to systematically alter features of
odor maps and study the concurrent changes in neu-
ronal outputs and olfactory behavior. Hitherto, how-
ever, this has not been possible, primarily because of the
inability to activate and modulate individual glomeruli
in a controlled manner using odorants. We are using op-
togenetic tools to bypass odorant stimulation and sim-
ulate odor-like glomerular activity patterns, or alter
them, by directly activating/inhibiting glomeruli using
light in transgenic mice that express Chr2 or Arch in all
olfactory system neurons. Furthermore, using patterned
illumination, we are activating/inhibiting select subsets
of glomeruli with single glomerulus precision in terms of
intensity, onset time, or duration. This approach con-
fers an unprecedented ability to make feature-specific
perturbations in a glomerular pattern of choice. We aim
to understand what features of an odor map are used by
a behaving mouse in naturalistic conditions to identify
odors and their attributes such as concentrations, tem-
poral fluctuations, or spatial location. Furthermore, we
are testing the resolution at which mice can in principle
detect variations within specific features of odor maps
in a strictly controlled artificial regime. While doing so,
we will also monitor neuronal responses at multiple lay-
ers in the olfactory system to compare the behavioral
and neuronal detection thresholds and to understand
the neuronal correlates of olfactory behavior.
Investigating the Roles of Cortical
Feedback in Invariant Odor Perception
Invariant perception refers to the identification of a sen-
sory stimulus or an object of interest in a generalized
fashion across its variable and recurring presentations.
This is a common feature across all sensory modalities
and becomes particularly preeminent in olfaction. Nat-
ural odor scenes are composed of odor plumes originat-
ing from multiple sources and traveling at fluctuating
intensities that span several orders of magnitude. De-
spite this turbulent nature of the stimulus, rodents read-
ily identify odors essential for their survival against
varying odor-rich backgrounds and faithfully track a
fluctuating odor stream to its source. Several models
have attempted to explain invariant perception in dif-
ferent sensory modalities. Some of these models are
based on the conventional view of sensory processing
that relies solely on feed-forward information flow,
whereas others argue that feed-forward mechanisms are
insufficient and suggest the involvement of feedback
between different neuronal layers. Anatomical studies
show massive feedback projections from higher brain
areas to the sensory periphery that often outnumber di-
rect sensory inputs. However, the importance of these
feedback connections remains largely unknown.
We aim to understand the role of cortico-bulbar
feedback (Fig. 4) in the identification of an odor, in-
variant of fluctuations in its concentration and/or tim-
Figure 3. Optogenetic suppression of SA cells reveals both excitatory and inhibitory drive on M/T (mitral/tufted) cell
output. (A) Homogenous expression of DIO-Halorhodopsin-AAV construct injected in DAT-Cre mice. (B) Example of
full-field yellow-light mask designed to avoid the recording tetrode. (C) Spike raster and PSTH of an M/T cell show-
ing inhibition of spontaneous firing after SA inhibition. Line indicates duration of yellow-light presentation. (D) Ex-
ample of M/T cell response to ethyl valerate alone (top row) when paired with full-field yellow light (bottom row). Top
and bottom lines indicate duration of color and yellow-light presentation, respectively. (E) Ratio of firing rate during
“odor” and “odor + light” period for 147 M/T cell-odor pairs across different dilutions. (F) Percentage of M/T cell-odor
pairs at each dilution, which receive excitatory or inhibitory drive from the SA network.
versibly manipulate the activity of cortical feedback
fibers and their targets in awake head-fixed mice as they
learn and perform invariant odor perception tasks. To
mimic naturalistic odor conditions, we are making use
of custom-designed odor-delivery systems that repro-
ducibly deliver arbitrary time-varying patterns of indi-
vidual odors and mixtures. To understand the under-
lying neuronal mechanisms, we are simultaneously
monitoring the activity of feedback inputs and their tar-
gets via high-speed scanning (~100 Hz) multiphoton
microscopy and multitetrode recordings.
Other Collaborative Projects
with CSHL Groups 
We are collaborating with other fellow CSHL scientists
on the following projects: multisensory integration of
olfactory and visual information in the mouse brain (A.
Churchland); bridging the gap between glomerular
odor responses and odor receptor sequences (A. Koula-
kov and G. Hannon); developing light-sheet-based 
approaches for fast optical reconstruction of neuronal
circuits (P. Osten); and optical monitoring of neuronal
activity in genetically and anatomically defined corti-
cal circuits in animal models of cognition (A. Zador).
Figure 4. Odor-evoked responses in corticobulbar feedback fibers.
(A) Corticobulbar feedback fibers labeled with GCAMP3, (B) feed-
back fiber boutons in an optical plane, 230 mm below the sur-
face, (C) example of responses to three different odors (ethyl
tiglate, 2-heptanone, and p-anis aldehyde) for three synaptic bou-
tons from B. Photoionization detector (PID) signals indicate du-
ration of the odor stimulation.
ing and presence of background odors. We are taking
advantage of optogenetic tools and patterned illumina-
tion techniques recently developed in our group to re-
Florin Albeanu
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Making use of sensory information requires more than
simply relaying incoming signals from the sensory or-
gans. It requires interpreting information, classifying it,
drawing inferences, and ultimately using the context of
behavioral goals to make a decision about its meaning.
A decision is a commitment to a particular choice or
proposition at the expense of competing alternatives.
In some situations, decisions involve integration of ev-
idence, i.e., they make use of multiple pieces of infor-
mation from the environment or from memory. These
decisions can provide a framework in which to investi-
gate complex cognitive processes and open a window
into higher brain function in general. 
Although previous experiments have begun to reveal
how neural systems combine evidence to make deci-
sions, they have left a critical gap in our understanding.
Specifically, very little is currently known about the
neural mechanisms that make it possible to combine
information from multiple sensory modalities for deci-
sions. The gap is apparent, although it is clear from be-
havioral observations that neural systems can combine
multisensory information: When parsing speech in a
crowded room, for example, the listener makes use of
both auditory information (the speaker’s vocal sounds)
and visual information (the speaker’s lip movements).
Understanding the neural mechanisms of multisensory
integration is critical for two reasons. First, it is essen-
tial for a complete understanding of sensory perception
because real-world stimuli rarely affect a single sense in
isolation. Therefore, understanding how the brain in-
terprets incoming information requires understanding
how the brain merges information from different
senses. Second, it is likely of clinical importance: Several
developmental abnormalities appear to be related to dif-
ficulties in integrating sensory information. For exam-
ple, abnormalities in multisensory processing are a
hallmark of subjects with autism spectrum disorder
(ASD). Impairments in multisensory processing are also
observed in subjects with a collection of sensory ab-
normalities known together as sensory processing dis-
order, and they may also be evident in patients with
Rett syndrome and dyslexia. Understanding the neural
mechanisms of multisensory integration could inform
treatment of those conditions. 
Our long-term goal is to understand how the brain
can make decisions that integrate inputs from our mul-
tiple senses, stored memories, and innate impulses. Our
current projects, described below, are a first step toward
this complete understanding of perceptual decision-
making. In the past year, we have made tremendous
strides toward achieving this goal. We have successfully
developed a behavioral paradigm for studying decision-
making in rats and humans (Fig. 1) and have also be-
gun to record electrophysiological responses from the
rats while they are engaged in the task. Our first find-
ings with this new paradigm will be published in 2012
in the Journal of Neuroscience. We also received an
award from the John Merck Fund based on the poten-
tial of this research to inform treatment of childhood
disorders. 
NEURAL CIRCUITRY FOR PERCEPTUAL DECISIONS
A. Churchland A. Brown D. Raposo
R. Iscowitz J. Sheppard
Figure 1. The same decision-making task is used
to probe multisensory integration in rats and hu-
mans. (Left) Schematic drawing of rat in operant
conditioning apparatus. Circles are “ports”
where the rat pokes its nose to initiate the pres-
entation of sensory stimuli or to report its deci-
sion about the stimuli. The white rectangle is the
panel of light-emitting diodes that we use to
present visual stimuli. An auditory speaker is po-
sitioned behind them. (Right) Schematic draw-
ing of a human subject seated in front of a
computer that we use to present the same audi-
tory and visual stimuli that we use for the rats.
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Role of the Parietal Cortex in Multisensory
Decision-Making
This work was done in collaboration with David Raposo,
Champalimaud Neuroscience Program, Lisbon, Portugal. 
The goal of this project is to gain a deeper understand-
ing of the neural mechanisms that enable integration of
visual and auditory inputs for decision-making. To this
end, we record from neurons in a multisensory area of
the rat brain, the posterior parietal cortex. Because we
record from neurons during multisensory behavior, we
can draw connections between the animal’s behavior and
the underlying neural mechanism. Although the poste-
rior parietal cortex in rats has previously been explored
in the context of navigation, our study is the first study
to record from this area on a decision-making task. We
use a number of theoretical models to formalize our as-
sumptions about how the neural activity we record
might give rise to the behavior.
Probabilistic Representation in the Brain:
Insights about Neural Mechanisms that
Allow Organisms to Cope with Stimulus
Uncertainty 
This work was done in collaboration with John Sheppard,
Watson School, CSHL. 
The goal of this project is to understand how the brain
estimates the reliability of sensory stimuli. Previous work
in humans has established that they are easily able to es-
timate the reliability of sensory stimuli. Furthermore, hu-
mans use their estimates of reliability to inform the way
they combine sensory inputs across modalities. In fact,
humans have repeatedly been shown to do this in a sta-
tistically optimal way. However, very little is known
about the neural mechanisms that make this combina-
tion possible. For this project, we have developed a par-
adigm that presents subjects, both rats and humans, with
multisensory stimuli of varying reliability. By measuring
subjects’ decisions, we can infer the relative weights they
assign to one sensory modality or the other. In the rats,
we are developing a system to artificially manipulate neu-
ral signals in the brain and we plan to investigate how
these small manipulations impact subsequent behavior. 
Decision-Making in Mice
A. Brown, R. Iscowitz
We are developing a decision-making paradigm using
mice instead of rats. The advantage of mice is that there
are many tools available that allow us to probe the neu-
ral circuitry that underlies decision-making. We have
made progress in developing a task that elicits stable,
reliable behavior from the mice. A summer student,
Ross Iscowitz, began this project and was named an
Intel Talent Search Semifinalist for his work on the
project. It has been taken over by Amanda Brown, a re-
search associate in the laboratory. 
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The two main areas of research in our lab are (1) to in-
vestigate the genetic and neuronal mechanisms of
memory using Drosophila as a model system and (2) to
use the genetics of the fly system to discover the causes
of human neurodegenerative disorders such as amyo-
trophic lateral sclerosis (ALS). 
An understanding of memory, indeed of all behav-
ioral phenotypes, will require a multidisciplinary ap-
proach to forge conceptual links between the relevant
genetic/cell-signaling pathways and neural circuits.
Work in genetic model systems such as Drosophila can
contribute to our understanding in several ways. First,
by enabling discovery of genes and genetic pathways
underlying normal memory as well as pathological or
degenerative cognitive disorders, model systems provide
entry points for dissection of cellular mechanisms that
are often conserved. Second, systematic manipulation
of gene function within relevant anatomical circuits al-
lows a conceptual integration of findings from cellular,
neuroanatomical and behavioral levels. 
Endogenous Transposable Elements 
and Neurodegenerative Disorders
N. Chatterjee, L. Krug, W. Li, L. Prazak, J. Dubnau
Transposable elements (TEs) and endogenous retro-
viruses (ERVs) are mobile genetic elements that pro-
vide a massive reservoir of potential genetic instability
and toxicity. We have advanced the novel hypothesis
that deregulated TE/ERV expression may contribute to
TDP-43-mediated neurodegenerative disorders. We
have found that TE transcripts are derepressed during
the normal aging process. We used mutations in
Drosophila Argonaute 2 (dAgo2) to create a situation
in which TEs are derepressed in the brain. Such mu-
tants exhibit precocious TE elevation in young animals
and exacerbated age-dependent derepression. This is ac-
companied by rapid age-dependent memory impair-
ment and shortened life span. These findings support
the hypothesis that protracted loss of TE silencing con-
tributes to age-dependent decline in neuronal physio-
logical function. 
In order to investigate the hypothesis that TE dere-
pression contributes to neurodegenerative disorders, we
focused on TDP-43, an RNA-binding protein involved
in a broad spectrum of neurodegenerative disorders in-
cluding ALS and frontotemporal lobar degeneration
(FTLD). By mining a series of deep-sequencing data
sets of protein−RNA interactions and of gene expres-
sion profiles, we uncovered broad and extensive bind-
ing of TE transcripts to TDP-43. We found that
association between TDP-43 and many of its TE targets
is reduced in FTLD patients and have discovered that
a large fraction of the TEs to which TDP-43 binds be-
come derepressed in mouse TDP-43 disease models.
We also have demonstrated that transgenic expression
in fly neurons of neurotoxic forms of human TDP-43
causes activation of gypsy, a fly LTR retrotransposon.
We propose the hypothesis that TE misregulation con-
tributes to TDP-43-related neurodegenerative disease.
Our current efforts are focused on dissection of the un-
derlying mechanisms of transposon control in the brain
and the role of unregulated transposon expression in
neurodegenerative disorders. 
Posttranscriptional Regulatory Network
W. Li, L. Prazak, J. Dubnau
A fundamental property of the brain is that perceptual
experiences drive modifications in the number and
strength of synaptic connections among neurons. These
synapse modifications, which are thought to be neural
correlates of memory and cognition, require synthesis
of specific proteins at individual synaptic sites in re-
sponse to neural activity. The mechanisms governing
this local synthesis of synaptic proteins are poorly un-
derstood. We are using the Drosophila model to inves-
tigate neuronal translation in two different ways. First,
we are developing a novel approach to broadly screen
for neuronal translational regulation in terms of both
GENETICS AND NEURAL CIRCUITS UNDERLYING MEMORY
AND MEMORY DECLINE IN DROSOPHILA
J. Dubnau N. Chatterjee W. Li
M. Cressy L. Prazak
L. Krug H. Qin
Neuroscience 123
targets and trans-activators. Second, we are focusing on
the specific regulatory interactions that we discover to
investigate a few translational regulatory pathways in
some detail. These efforts are focused on pumilio, a
translational repressor that we have shown has a role in
memory, as well as on RNA-induced silencing com-
plex-mediated regulation.
A global screen for regulatory interactions.We are
developing a platform to identify the suite of regula-
tory mechanisms and translational targets in the brain.
The approach involves several steps. The first is a high-
throughput method to create in vivo reporters of trans-
lation for each gene. The second is a strategy to identify
the set of genes whose translation is governed by a par-
ticular regulator. As a proof of principle, we will define
the targets of five key translational regulators, including
Fragile-X protein. Fragile-X is the most common in-
herited form of mental retardation. Our method, which
is conceptually similar to enhancer trapping for tran-
scriptional control, takes advantage of the exceptional
genetic manipulability of the Drosophilamodel system.
The high degree of conservation of gene regulatory
mechanisms and function ensures that much of what
we learn will be transferable to humans.
A microRNA−dopamine receptor genetic module in
distinct neural circuits for olfactory arousal and olfac-
tory memory. microRNAs (miRNAs) are ~21–23-nu-
cleotide noncoding RNA transcripts that regulate gene
expression at the posttranscriptional level. miRNAs reg-
ulate gene expression by binding to complementary se-
quences in the 3¢untranslated regions of target mRNAs.
A growing number of studies demonstrate that miRNA
biogenesis and function broadly speaking are important
for virtually all aspects of cell function, including neu-
ronal function. But there still are relatively few examples
where individual miRNA genes have been shown to
function acutely in the brain in the context of behavior.
We have demonstrated that miR276a expression is re-
quired acutely in the Drosophila melanogaster brain
within two different neural cell types. In both circuits,
miR276a appears to target a DA1-type dopamine recep-
tor, but the circuits subserve different aspects of olfactory
behavior. This miR276a−dopamine receptor interaction
is required in mushroom body (MB) neurons to support
long-term olfactory memory and in the ellipsoid body
R4 neurons in the central complex to modulate olfac-
tory arousal. This may reveal a conserved functional dis-
section of memory and arousal in the mushroom body
and central complex. 
g Neurons Are the Gateway for DA
Input to DrosophilaMB for Aversive
Olfactory Memory Formation
M. Cressy, H. Qin J. Dubnau 
MB-dependent olfactory learning in Drosophila pro-
vides a powerful model to investigate memory mecha-
nisms. MBs integrate olfactory (CS) inputs with neuro-
modulatory reinforcement (US), which for aversive
learning is thought to rely on dopaminergic (DA) sig-
naling to DopR, a D1-like dopamine receptor that is
expressed in MBs. A wealth of evidence supports the
conclusion that parallel and independent signaling oc-
curs downstream from DopR within two of the three
major MB neuron cell types, with each supporting ap-
proximately half of memory performance. For instance,
expression of the rutabaga adenylyl cyclase (rut) in g
lobe neurons is sufficient to restore learning levels of
rut mutants, whereas expression of neurofibromatisis I
(NFI) in α/b neurons is sufficient to rescue NFI mu-
tants. Memory consolidation, in contrast, appears to
require CREB (cAMP response element binding) and
rut signaling in α/b neurons. DopR mutations fully
eliminate memory performance, consistent with the hy-
pothesis that DopR receives US inputs for both g lobe
and α/b lobe signaling. We have used spatially re-
stricted expression of the DopR gene to map the neu-
ronal cell types that receive dopaminergic US infor-
mation underlying this learning task. We have shown
that DopR expression in g neurons is sufficient to fully
support short- and long-term memory (Qin et al., in
press). Our findings support a model in which DA-me-
diated CS-US association is formed in g neurons fol-
lowed by communication between g and α/b neurons
to drive consolidation. Current efforts are focused on
investigation of the role of g−α/b neuron signaling in
memory stabilization/consolidation.
Suppressor Screening by Selective
Breeding: The Evolution of 
Adenylyl-Cyclase-Independent
Learning in Drosophila
M. Cressy, J. Dubnau [in collaboration with P. Mitra,
D. Valente, K. Honneger, Cold Spring Harbor Laboratory]
Natural populations of animals exhibit remarkably nar-
row ranges of phenotypic variation relative to the extent
of underlying genetic heterogeneity. The phenotypic ef-
fects of this hidden genetic variation can be revealed,
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however, in response to selective pressure, environmen-
tal stress, or the presence of strong deleterious muta-
tions. The clinical severity of Mendelian genetic
disorders, for example, can be modulated by variation
at additional loci that on their own would have little
clinical consequence. To investigate the modulatory im-
pact of such cryptic genetic variation on a Mendelian
trait, we used selective breeding over the course of more
than 40 generations to evolve nearly normal levels of
Pavlovian learning in fruit flies that carry null mutations
in the rutabaga adenylyl cyclase (M. Cressy et al., in
prep.). We constrained the starting genetic variability to
a set of 23 loci with known impact in the learning assay,
which provided a means to track the underlying geno-
typic response. We identified eight loci that appear to
drive the selection response. By testing the effects of each
of the eight loci and all di-allele combinations among
them, we demonstrated that at least one locus can par-
tially suppress the rutabaga learning defect on its own.
Our findings also support the conclusions that multiple
genetic solutions underlie the selected suppression of
rutabaga and that typical solutions involve interactions
among several genes.
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Nabanita Chatterjee
We study stem cells, their contribution to tissue main-
tenance and regeneration, and signals that control their
division and fate. Our main focus is on neural stem cells:
We are working to understand how stem cells of the
adult brain are regulated during the life span of the or-
ganism and how they affect cognitive function, mood,
and regeneration of the nervous tissue. Furthermore, we
study how other tissue-specific stem cells are regulated,
to find commonalities in the mechanisms by which they
remain quiescent, self-renew, or differentiate, and to de-
termine whether there is coordination between differ-
ent types of stem cells in response to physiological
stimuli, aging, disease, and therapies. We also study how
diffusible signaling molecules affect stem cell differenti-
ation and mediate interactions between stem cells and
their environment. Together, these studies may provide
an entry point for designing therapeutic interventions
to ameliorate the effects of disease or aging, and we are
working to translate the results we generate with animal
models to human physiology and therapy.
Neural Stem Cells and Brain Disorders
New neurons are continuously generated from multi-
potent neural stem and progenitor cells in the brain of
adult animals and humans. Emerging evidence suggests
that adult neurogenesis is important for memory,
mood, repair of the nervous system, and pharmacolog-
ical intervention. Full transformation of a neural stem
cell into a functional new neuron is a prolonged
process; during this transformation, stem cells and their
progeny undergo symmetric and asymmetric divisions,
exit the cell cycle, are attacked and eliminated by mi-
croglia, express a wide range of markers, change their
morphology, and establish connections with other cells.
This transition from stem cells to fully integrated neu-
rons, the neuronal differentiation cascade, proceeds
through defined steps that can be distinguished through
a combination of markers, morphological features, and
mitotic activity. Production of neurons from stem cells
can be modified by a wide range of intrinsic and ex-
trinsic factors that can positively or negatively affect the
outcome.
Our approach to study neural stem cells and their
transformation into neurons and astrocytes is based on
generating mouse lines in which stem and progenitor
cells, as well as their progeny, are highlighted by differ-
ent fluorescent proteins. These reporter lines enabled
us to dissect the differentiation cascade in the adult
brain into distinct steps and to assemble a detailed
scheme of the cascade (with a focus on the hippocam-
pus, a region of the brain crucial for learning and mem-
ory). This scheme provides a conceptual platform upon
which to map the targets of various pro- and antineu-
rogenic stimuli and to compare experimental strategies
to harness stem cells for tissue maintenance and repair.
We used our scheme of the differentiation cascade
to map the cell populations targeted by a number of
stimuli, including antidepressant drugs and treatments,
physical activity, electroconvulsive shock, deep brain
stimulation (DBS), radiation, chemotherapeutic agents,
cortical trauma, ablation of dopaminergic neurons, and
aging. In particular, we analyzed the effect of DBS of
the anterior thalamic nucleus (ATN) and the cingulate
gyrus (CG) on hippocampal neurogenesis. DBS is
being increasingly used to treat neurological and psy-
chiatric disorders; recently, it has been successfully ap-
plied to patients with treatment-resistant depression or
in a minimally conscious state. In addition to its clini-
cal importance, DBS presents a powerful approach to
target specific neural circuits and to determine the func-
tional relationship between the components of these
circuits. We examined the effect of high-frequency
stimulation of crucial components of the limbic cir-
cuitry, the ATN and the CG, on the generation of new
neurons in the dentate gyrus (DG), another compo-
nent of the same circuitry. Using our reporter mouse
lines designed to quantify changes in selected classes of
neural progenitors, we found that high-frequency stim-
ulation of the ATN increases symmetric divisions of
amplifying progenitors, a defined class of neural pro-
genitors in the DG; this effect is later manifested as an
increased number of new neurons. The same class of
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neural progenitors is also affected by the antidepressant
fluoxetine (Prozac) and physical activity (running). This
confirms that neurogenic stimuli of different natures
can converge on the same neurogenic target in the DG.
Our results also suggest that hippocampal neurogenesis
may be used as a sensitive indicator of the limbic cir-
cuitry activation induced by DBS.
Overall, our results demonstrate that various pro- and
antineurogenic stimuli have defined neurogenic targets
that may or may not overlap. Importantly, we found that
most of the treatments used for the therapy of depres-
sion, while increasing adult hippocampal neurogenesis,
do not affect the pool of stem cells, acting instead on the
downstream steps of the cascade (e.g., increasing the
number of divisions of the transiently amplifying pro-
genitor cells). In contrast, trauma and loss of dopamin-
ergic neurons lead to a transient activation of stem cells;
although this effect may reflect a compensatory response
of the damaged brain, it may also lead to a premature ex-
haustion of the stem cell pool.
Our results also helped to elucidate the most basic
mechanism of stem cell control in the adult and aging
brain. It has been known that there is a profound age-
related decline in the number of new neurons; given the
significance of new neurons for cognitive function, it
has been speculated that age-related decrease in hip-
pocampal neurogenesis contributes to age-related cog-
nitive impairment. However, it was not known whether
the reason for the decrease is the diminished efficiency
of stem cells or a decrease in their number. We used re-
porter lines, lineage tracing, new techniques for cell di-
vision kinetics analysis, and computational modeling to
show that age-related decrease in hippocampal neuro-
genesis is driven by the disappearance of neural stem
cells via their conversion into mature astrocytes. We also
found that the astrocytic differentiation (and the loss of
stem cell properties) of neural stem cells is coupled to a
rapid series of their asymmetric divisions. This finding
stands in great contrast to the conventional model of
stem cell maintenance and division, which assumes mul-
tiple cycles of activation and quiescence of stem cells.
We proposed a “disposable stem cell” model which
posits that an adult hippocampal stem cell is quiescent
throughout the entire postnatal life, but, when activated,
undergoes several rapid asymmetric divisions (with the
daughter cells eventually producing neurons) and then
leaves the pool of stem cells by converting into an as-
trocyte. This model describes the life cycle of an adult
neural stem cell and reconciles numerous observations
on the age-related decrease in production of new neu-
rons, the age-related increase in astrocyte number, and
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the disappearance of hippocampal neural stem cells. To-
gether, these continuous changes underlie age-depen-
dent decrease in production of new neurons and may
contribute to age-related cognitive impairment. Inter-
estingly, we found that although the number of hip-
pocampal neural stem cells gradually declines, their
efficiency (their retention rate and production of prog-
eny per cell) gradually increases, possibly reflecting a
strategy of coping with the consequences of aging. 
This model has important implications for under-
standing the mechanisms of stem cell maintenance and
division in the adult brain; furthermore, it may also
shed light on the modes of stem cell maintenance in
other tissues. In particular, the model indicates that ex-
cessive activation of stem cells (rather than their prog-
eny) during multiple brain traumas or Parkinson’s
disease may lead to a premature exhaustion of the stem
cell pool and may eventually impact cognitive abilities. 
Stem Cells in Nonneural Tissues
Tissues and organs undergo continuous remodeling in
response to stress, damage, or physiological demand.
Adult tissue-specific stem cells are located in specialized
niches that restrict their division and support their un-
differentiated status. We found that the same mouse re-
porter lines which we used to identify stem cells of the
nervous system can also identify stem and progenitor
cells in a range of other tissues and organs. This list in-
cludes stem cells of such dissimilar structures as brain
and spinal cord, hair follicles, liver, pancreas, skeletal
muscle, testis, retina, anterior pituitary, skin, and bone
marrow. This provides a means of visualizing stem and
progenitor cells, tracing their lineage, isolating them,
and studying molecular mechanisms that control their
quiescence, division, self-renewal, and differentiation.
Using this reporter-based approach, we performed col-
laborative experiments with Dr. Paul Frenette’s (Albert
Einstein College of Medicine) and Dr. Sean Morrison’s
(University of Texas Southwestern) groups to identify
mesenchymal stem cells in the bone marrow and to
demonstrate that they contribute to the maintenance
of the hematopoietic stem cells niche. These two types
of stem cells are found in close association; furthermore,
depletion of mesenchymal stem cells results in a re-
duced ability of hematopoietic stem cells to home in
on the bone marrow. This is the first example of a part-
nership between two distinct somatic stem cell types.
Such combinations of heterotypic stem cells may exist
in other tissues as well and may help coordinate the re-
Neuroscience     127
modeling of a tissue or an organ; we are currently work-
ing to identify these combinations.
Most recently, to visualize signaling events that con-
trol stem cell maintenance and division, we generated
transgenic mouse lines that express genetically encoded
sensors of redox signaling. When combined with the
reporter lines, the sensor/reporter combinations enable
visualization of specific signaling events in stem and
progenitor cells and their progeny or in the vicinity of
these cells. We work to expand the panel of sensors and
reporters to visualize multiple signaling events control-
ling stem cells.
Nitric Oxide, Development, 
and Differentiation
Much of our research interest is focused on the biolog-
ical role of a versatile signaling molecule: nitric oxide
(NO). During the last few years, we discovered that
NO has an essential role in development and in stem
cell regulation. We found that in diverse settings, rang-
ing from Drosophila larvae to mouse brain, NO acts as
a regulator of the balance between cell quiescence, di-
vision, and differentiation, eventually controlling tissue
formation and remodeling. Furthermore, we found that
NO also regulates vertebrate morphogenesis by linking
together suppression of cell division and facilitation of
cell movements. We also demonstrated that NO con-
trols these two processes through two separate signaling
pathways, helping to ensure that the crucial processes of
cell proliferation and morphogenetic movements are
tightly coordinated during early development.
We continue to discover the diversity of the biologi-
cal functions of NO. In our latest studies, we found that
in such diverse settings as the skin of the frog embryo
and mammalian airways, production of NO in multi-
ciliated cells is crucial for the establishment of the cell-
and tissue-level polarity and cilia growth, and, eventu-
ally, for the generation of the directed flow of fluid across
the tissue. We also found that NO acts upon two dis-
tinct signaling pathways to control the polarity of cilia
distribution and the cilia length, and we identified the
critical targets of NO signaling in both pathways. The
remarkable conservation of the NO role in the function
of cilia in different developmental contexts suggests that
some of the human ciliopathies and related disorders
may be associated with the inadequate activity of NO
synthase and may benefit from NO-based therapies.
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The research program in my group aims at under-
standing the molecular basis for the functions of cell
surface receptors or membrane proteins that initiate cel-
lular signal transductions involved in neurotransmis-
sion in the mammalian brain. We hope that this work
will support the design of compounds with therapeutic
potential in neurological diseases and disorders includ-
ing schizophrenia, depression, stroke, and Alzheimer’s
disease. Toward this end, we are conducting structural
and functional studies on neurotransmitter receptor ion
channels and intramembrane enzymes, two classes of
membrane proteins that regulate the processes of neu-
rotransmission and the dysfunction of which is im-
plicated in neurodegenerative diseases. To achieve our
goals, we use X-ray crystallography to determine the
three-dimensional atomic structures of target proteins
and test structure-based mechanistic hypotheses by site-
directed mutagenesis in combination with biochemical
and biophysical techniques. Our main focus in 2011
was to obtain high-resolution structures of the extra-
cellular domains of a class of ligand-gated ion channels,
N-methyl-D-aspartate receptor (NMDAR), in complex
with lead compounds with the potential to protect
neurons. Based on the structural information obtained,
we have validated our functional hypotheses using a
combination of techniques including electrophysiology,
isothermal titration calorimetry, and analytical ultracen-
trifugation.
Structural Dissection of NMDAR
Pharmacology
NMDARs belong to the family of ionotropic glutamate
receptors (iGluRs) that mediate the majority of excita-
tory synaptic transmissions in the mammalian brain.
They are voltage-sensitive calcium ion channels com-
posed of two copies each of the GluN1 and GluN2
subunits, which bind glycine and glutamate, respec-
tively. Calcium signals facilitated by NMDARs have a
pivotal role in cellular signal transduction resulting in
the neuroplasticity essential for learning and memory
formation. The four distinct GluN2 subunits (A−D)
control the pharmacological properties of NMDAR ion
channels and show different spatial and temporal ex-
pression patterns; thus, there has been a great interest in
creating subtype-specific compounds that can target
specific neuronal circuits.
The NMDAR subunits are modular and are com-
posed of different protein domains, including the amino-
terminal domain (ATD), ligand-binding domain (LBD),
transmembrane domain (TM), and carboxy-terminal do-
main (CTD) (Fig. 1). Our current studies are focused on
ATD and LBD; these domains mediate allosteric regula-
tion and activation in the NMDAR ion channels upon
binding to polyamine-based compounds and neurotrans-
mitters, respectively. Among all of the ATD-targeting
compounds, those that specifically recognize GluN1/
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Figure 1. Domain organization of NMDAR subunits, modular
proteins composed of distinct domains including the amino-ter-
minal domain (ATD), ligand-binding domain (LBD), transmem-
brane domain (TM), and carboxy-terminal domain (CTD). Shown
are schematic presentations of the glycine-binding GluN1 sub-
unit and the L-glutamate-binding GluN2B subunit. Allosteric
modulators such as phenylethanolamine and zinc bind ATD.
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GluN2B NMDARs (e.g., ifenprodil) have drawn sub-
stantial interest because of their therapeutic potential in
stroke-related brain injuries, depression, and Alzheimer’s
disease. Until 2011, the molecular mechanism for ATD-
mediated regulation was not well understood, and struc-
tural information for the NMDAR ATD had been
limited to the GluN2B ATD monomer in complex with
zinc (recently published by my group). Thus, the precise
mapping of the location of the ifenprodil-binding site
Figure 2. Crystal structure of the recently solved GluN1/GluN2B
NMDAR ATD structure. GluN1 (left) and GluN2B (right) ATDs
have bilobed structures composed of R1 and R2 domains and form
heterodimers. Ifenprodil (spheres) bind to the subunit interface be-
tween GluN1 and GluN2B. Sticks indicate glycosylation sites.
Figure 3. Phenylethanolamine-binding site. Binding modes of ifenprodil (a) and Ro-25-6981 (b). Shown in mesh is the
electron density (Fo-Fc omit electron map) contoured at 3s. (c) Comparison of binding sites for ifenprodil and Ro-25-
6981. van der Waal contacts are stronger for binding of Ro-25-6981 than ifenprodil and probably account for the
higher potency of Ro-25-6981.
within GluN1/GluN2B NMDARs has been met with
much enthusiasm. This strategy may provide crucial in-
formation for improving the design of ifenprodil to min-
imize side effects.
We have also completed X-ray crystallographic studies
on the GluN1/GluN2B ATD in complex with ifenprodil;
thus, we are now able to locate the ifenprodil-binding site
for the first time (Fig. 2). The ifenprodil-binding site iden-
tified through this study is distinct from the previously
predicted site that involved only the GluN2B subunit.
Our study shows the first “correct” model of the ifenpro-
dil-binding site.
To further understand the ifenprodil-binding site, we
wanted to identify the structure of the GluN1/GluN2B
in complex with Ro-25-6981, a significantly (~10-fold)
more potent ifenprodil analog that has become commer-
cially available in recent years. Structural comparison re-
vealed the molecular explanation for the higher affinity of
Ro-25-6981 compared to ifenprodil and provided a pos-
sible strategy for improving the design of the ifenprodil-
like compounds for higher specificity and potency. The
binding site of Ro-25-6981 is located at the subunit in-
terface of GluN1/GluN2B ATD and is mediated by
amino acid residues from both GluN1 and GluN2B sub-
units in a manner similar to that of ifenprodil (Fig. 3).
We have conducted structure-based site-directed mu-
tagenesis to validate the physiological relevance of the
binding site by measuring currents elicited by the mu-
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tants. Seven residues around the binding pocket were
mutated to partially disrupt the binding pocket. All such
mutants showed a shift in either potency or efficacy of
ifenprodil inhibition, indicating that the ifenprodil- and
the Ro-25-6981-binding sites are physiologically rele-
vant (Fig. 4).
To understand the molecular mechanism of allosteric
inhibition mediated by ifenprodil, we have conducted
biochemical/electrophysiological experiments on the full-
length GluN1/GluN2BNMDARs. Toward this end, we
have designed cysteine mutants that disulfide-cross-link
GluN1 and GluN2 subunits at the interfaces, thereby
“trapping” the conformation of GluN1 and GluN2B
ATDs (Fig. 5a). The current recording on the mutant
NMDARs by electrophysiology showed that the disul-
fide cross-link that restricts the motion of a portion of
GluN2B called R2 results in locking the NMDAR ion
channels to the “inhibited” state. These experiments led
to a model that the GluN2B ATD is at a conformational
equilibrium between “open-cleft” and “closed-cleft” con-
formations, where the former represents the active state
of the NMDAR channel and the latter represents the in-
active state (Fig. 5).
Structure and Function of g-Secretase
Another major project that we are deeply involved in is
the structural and functional study of a molecular com-
plex called g-secretase, which is implicated in initiation
of Notch signaling critical for cell differentiation and
stem cell maintenance as well as production of b-amy-
loid. Formation of neurotoxic b-amyloid oligomers and
deposition of b-amyloid fibril are hallmarks of Alz-
heimer’s disease. Furthermore, overactivation of Notch
signaling is frequently observed in various types of can-
cers. Thus, fine regulation of g-secretase may be an ef-
fective strategy in the treatment of those major diseases.
g-Secretase is a multimeric protein complex of four
transmembrane proteins including presenilin, nicastrin,
APH-1, and PEN-2 (Fig. 6). Together, the protein com-
plex mediates an unusual molecular event called regu-
lated intramembrane proteolysis, in which the trans-
membrane substrate is proteolysed within the biological
membrane. This multimembrane protein complex
cleaves a number of single transmembrane substrates, in-
cluding the Notch ligand and amyloid precursor protein.
Figure 4.Mutagenesis at phenylethanolamine-binding site. Single
point mutations are incorporated into GluN1 or GluN2B at the
phenylethanolamine-binding site. All of the mutations cause a
change in either potency or efficacy. This indicates that the
phenylethanolamine-binding site observed in the crystal struc-
ture is physiologically relevant.
Figure 5. Engineering intersubunit disulfide bonds trap the NMDAR ion channel in inhibited state. (a) Location of in-
tersubunit disulfide bonds. (b) Macroscopic current recording in the presence (gray) and absence (black) of DTT. (c)
Possible model of ifenprodil binding and the movement of ATDs coupled to allosteric inhibition.
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The mechanistic understanding of intramembrane pro-
teolytic activities in g-secretase is limited due to a lack of
information about its atomic structure. Our research pro-
gram is aimed at obtaining an atomic map of g-secretase
to gain insight into intramembrane proteolysis, substrate
specificity, inhibition, and functional modulation.
Our group is also interested in determining the
atomic structure of g-secretase to gain insight at the mo-
lecular level. Currently, we are working toward under-
standing the mechanism of substrate recognition medi-
ated by one of the g-secretase components, nicastrin.
Structural and functional studies on g-secretase have the
potential of leading to development of compounds that
can be used to lower the level of neurotoxic amyloid
oligomers in Alzheimer’s disease as well as to alleviate
overactive Notch signaling in cancer.
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Figure 6. Components of g-secretase, a protease complex com-
posed of four integral membrane proteins: presenilin (PS), nicas-
trin (NCT), APH-1, and PEN-2. The wild-type PS contains active
site aspartic residues (asterisks) within the transmembrane (TM)
domains (TM6 and TM7) and becomes active only when it forms
a complex with three other components. A single transmembrane
substrate such as amyloid precursor protein (APP) is proteolyti-
cally processed within the membrane. The extracellular and cy-
tosolic domains form neurotoxic b-amyloid oligomers or act as a
transcriptional regulator, respectively. NCT and APH-1 are con-
sidered to be important for substrate recognition, whereas PEN-2
has a critical role in proteolysing PS at the cytosolic loop between
TM6 and TM7, thereby converting PS into the active form. 
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We combine genetic, imaging, and physiology ap-
proaches to study the organization, function, and de-
velopment of neural circuits in cerebral cortex, focusing
on GABAergic inhibitory interneurons.
Genetic Dissection of GABAergic
Circuits in Neocortex
In the mammalian neocortex, the delicate balance and
dynamic assembly of the functional architecture of neu-
ral circuits are achieved through a rich repertoire of in-
hibitory control mechanisms. A key obstacle to under-
standing cortical circuits is the diversity of GABAergic
interneurons, which poses general questions in neural cir-
cuit analysis: How are diverse cell types generated and as-
sembled into stereotyped local circuits? How do they
differentially contribute to circuit operations that under-
lie cortical functions ranging from perception to cogni-
tion? Using genetic engineering and the Cre/LoxP
strategy in mice, we have generated and characterized
more than 20 Cre and Flp knockin driver lines that reli-
ably targeted major classes and lineages of GABAergic
neurons. More distinct populations are captured by in-
tersection of Cre and Flp drivers and by engaging lineage
and birth-timing mechanisms. Genetic targeting allows
reliable identification, monitoring, and manipulation of
GABAergic neurons, thereby enabling systematic and
comprehensive analysis from cell-fate specification to
connectivity and function in networks and behavior.
The Origin and Organization of Chandelier
Cells in Mouse Neocortex
The precise control of action potential initiation at the
axon initial segment (AIS) determines whether and when
a neuron transmits its information and allows highly co-
ordinated output in a neural ensemble. In mammalian
cerebral cortex, AISs of pyramidal neurons are regulated
by GABAergic synapses from a highly distinct class of in-
terneuron, the axon-axonic cells or chandelier cells (ChCs),
which increase their abundance in primates and human. A
single ChC innervates hundreds of pyramidal neurons and
might exert decisive influence in their firing, but the de-
velopmental origin and cortical organization of ChCs re-
main unknown. Previous studies in rodents suggested that
most if not all cortical GABAergic neurons derive from
the medial and caudal ganglionic eminence (MGE and
CGE) of the basal ganglia and the preoptic area, mainly
during midgestation. We discovered that ChCs in the
mouse predominantly arise from progenitors expressing
the homeodomain protein Nkx2.1  located in the ventral
tip of the late embryonic subventricular zone (SVZ), after
the disappearance of MGE. Postmitotic ChCs migrate to
their cortical destination with stereotyped route and sched-
ule, but they do not follow the inside-out (developmental)
sequence of laminar deployment observed by pyramidal
neurons and MGE-derived interneurons. Mature ChCs
show striking laminar enrichment in layers 2 (L2), 5, and
6 and are more abundant in mediofrontal area compared
to sensory cortices. L2 ChCs selectively innervate the dis-
tal portion of pyramidal cell AISs, the exact site of spike
initiation. Nearby L2 ChCs are frequently electrically cou-
pled and can further activate one another through disyn-
aptic excitation, suggesting a coordinated functional
network. Our results demonstrate protracted neurogene-
sis and a novel progenitor source in the Nkx2.1 lineage
that gives rise to a functionally powerful and evolutionar-
ily expanding class of cortical interneuron. Genetic tar-
geting of ChCs provides an entry point to studying cortical
circuit assembly, organization, and dysfunction.
GABA Signaling Promotes Synapse
Elimination and Axon Pruning 
in Developing Inhibitory Neurons
Accumulating evidence indicates that GABA acts  be-
yond inhibitory synaptic transmission and regulates the
development of inhibitory synapses in the vertebrate
brain, but the underlying cellular mechanism is not well
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understood. We have combined live imaging of cortical
GABAergic axons across timescales from minutes to days
with single-cell genetic manipulation of GABA release
to examine its role in distinct steps of inhibitory synapse
formation in the mouse neocortex. We have previously
shown, by genetic knockdown of GABA synthesis in de-
veloping interneurons, that GABA signaling promotes
the maturation of inhibitory synapses and axons. We
found that a complete blockade of GABA release in bas-
ket interneurons resulted in an opposite effect—a cell-
autonomous increase in axon and bouton density with
apparently normal synapse structures. These results not
only demonstrate that GABA is unnecessary for synapse
formation per se, but they also uncover a novel facet of
GABA in regulating synapse elimination and axon prun-
ing. Live imaging revealed that developing GABAergic
axons form a large number of transient boutons, but
only a subset was stabilized. Release blockade led to sig-
nificantly increased bouton stability and filopodia den-
sity, increased axon branch extension, and decreased
branch retraction. Our results suggest that a major com-
ponent of GABA function in synapse development is
transmission-mediated elimination of subsets of nascent
contacts. Therefore, GABA may regulate activity-de-
pendent inhibitory synapse formation by coordinately
eliminating certain nascent contacts while promoting
the maturation of other nascent synapses. 
Presynaptic GABAB Receptor Regulates
Activity-Dependent Maturation
of Inhibitory Synapses 
Accumulating evidence indicates that GABA regulates
activity-dependent development of inhibitory synapses
in the vertebrate brain, but the underlying mechanisms
remain unclear. Here, we combined live imaging of cor-
tical GABAergic axons with single-cell genetic manipu-
lation to dissect the role of presynaptic GABAB receptors
(GABABRs) in inhibitory synapse formation. Developing
GABAergic axons form a significant number of transient
boutons, but only a subset was stabilized. Synaptic vesi-
cles in these nascent boutons are often highly mobile in
the course of tens of minutes. Activation of presynaptic
GABABRs stabilized mobile vesicles in nascent boutons
through the local en hancement of actin polymerization.
Inactivation of GABABRs in developing basket interneu-
rons resulted in an aberrant pattern of bouton size dis-
tribution, reduced bouton density, and reduced axon
branching, as well as reduced frequency of miniature in-
hibitory currents in postsynaptic pyramidal neurons.
These results suggest that GABABRs along developing
inhibitory axons act as a local sensor of GABA release
and promote presynaptic maturation through increased
recruitment of mobile vesicle pools. Such release-depen-
dent validation and maturation of nascent terminals is
well suited to sculpt the pattern of synapse formation and
distribution along axon branches.
Impact of GABAergic Deficiency
in Synaptic Transmission and Behavior 
A highly reproducible observation in schizophrenia (SZ)
is the reduction of mRNA for GAD67, the principle en-
zyme for GABA synthesis in cortex, in certain types of
cortical interneurons, particularly those expressing par-
valbumin (PV). GAD67 expression is regulated by neu-
ral activity, and its reduction in SZ is most likely a
downstream impact of reduced engagement of the PV
cell network. Because PV cells have an important role in
the generation and maintenance of gamma wave activity,
dysfunction in these cells is thought to contribute to cog-
nitive deficits in SZ, such as working memory impair-
ment. To model the cell-type-specific changes observed
in SZ, we used a cre/lox system in mice to conditionally
knock down GAD67 in PV cells. Virus-vector-mediated
green fluorescent protein (GFP) expression was used for
paired recordings from PV to pyramidal cells, and be-
havioral tests, including Y-maze spontaneous alternation,
to assess working memory function. In young mice, re-
duction of GAD67 in PV cells led to weakened synaptic
inhibition. Removal of one allele of Gad1 (heterozygote)
led to a 33% reduction of GAD67 in PV cells and fur-
ther caused a supralinear deficit in synaptic transmission.
Young mutant mice also demonstrated a behavioral phe-
notype featuring reduced spontaneous alternation in the
Y maze. Additionally, pyramidal cells demonstrated hy-
peractive spiking properties in response to current injec-
tion. In adult mice, however, both the synaptic and
behavioral deficits had resolved, leading the mutant mice
to be indistinguishable from controls in all measured pa-
rameters. We therefore have demonstrated that GABA
deficiency does in fact lead to weakened synaptic trans-
mission, with a concurrent behavioral phenotype. How-
ever, weakened inhibition in juvenile mice appears to not
produce any irreversible changes, as homeostatic mech-
anisms were able to fully eliminate the impact of this ar-
tificially induced GAD67 deficit. Our study suggests that
PV-cell function, or possibly GAD67 expression level it-
self, presents a possible treatment target for cognitive dys-
function.
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Distinct DNA Methylation Signatures
in Glutamatergic and GABAergic
Neurons of the Cerebral Cortex 
A critical role for DNA methylation has been implicated
in cell differentiation and development and recently in
behavioral plasticity in postmitotic neurons. A key ob-
stacle in genomic and epigenomic analysis in the brain is
cellular heterogeneity—genomes of distinct yet highly
intermingled cell types are largely inaccessible to se-
quencing technology. To address this issue, we have gen-
erated a set of cell-type-specific Cre knockin lines that
activate a nuclear-GFP reporter. Using FACS (fluores-
cence-activated cell sorting) of dissociated cortices and
whole-genome bisulfite sequencing, we have analyzed the
DNA methylomes of two cardinal neuron types, the glu-
tamatergic and GABAergic neurons. We achieved 10
times whole-genome coverage per cell type, allowing us
to interrogate ~90% of the CpG sites in the mouse ge-
nome. A hidden Markov model allowed us to identify
hypomethylated regions (HMRs) in the two methyl-
omes. Although similar numbers of HMRs were identi-
fied in both cell types in the transcription start sites,
glutamatergic cells had significantly higher HMRs in the
intragenic and intergenic regions. These HMRs encom-
pass previously defined CpG islands, but we also find sig-
nificantly more previously undetected HMRs. To deter-
mine if these are neuron-specific, we are comparing these
methylomes with those of microglia cells, which are de-
rived from a distinct lineage. As intragenic hypomethyl-
ation likely has a role in regulating gene expression, we
are currently analyzing the differential gene expression
patterns of these cell types using strand-specific RNA-
Seq and RT-PCR (reverse transcriptase−polymerase chain
reaction) on select candidate genes. Interestingly, genes in
several prominent neuronal pathways such as axon guid-
ance and signaling (WNT, MAPK) are differentially
methylated between the two cell types. Our approach es-
tablishes a cell-type-based experimental paradigm for
epigenomic analysis in complex tissues and sets the stage
for analysis of neuronal subtypes during both brain de-
velopment and behavioral plasticity.
Cell-Type-Based Analysis of microRNA
Profiles in the Mouse Brain
microRNAs (miRNAs) are implicated in brain devel-
opment and function, but the underlying mechanisms
have been difficult to study in part due to the cellular
heterogeneity in neural circuits. To systematically ana-
lyze miRNA expression in neurons, we have established
an miRNA tagging and affinity purification (miRAP)
method that is targeted to cell types through the Cre-
loxP binary system in mice. Our studies of the neocor-
tex and cerebellum reveal the expression of a large
fraction of known miRNAs with distinct profiles in glu-
tamatergic and GABAergic neurons and subtypes of
GABAergic neurons. We further detected putative novel
miRNAs, tissue- or cell-type-specific strand selection of
miRNAs, and miRNA editing. Our method thus will
facilitate a systematic analysis of miRNA expression and
regulation in specific neuron types in the context of
neuronal development, physiology, plasticity, pathology,
and disease models and is generally applicable to other
cell types and tissues. 
A Novel Function of MeCP2
in mRNA Translation in the Brain
MECP2 was identified as a nuclear methyl-CpG DNA-
binding protein and is best known as a regulator of tran-
scription and chromatin. Mutations in MECP2 are
linked to autism spectrum disorders, especially the Rett
syndrome (RTT), but the pathogenic mechanisms re-
main elusive. Here, we report on a translation regulatory
function of MECP2. MECP2 is detected in discrete
puncta of neuronal cytoplasm, in brain polyribosomes,
and interacts with numerous messenger ribonucleopro-
teins with translation regulatory functions. MECP2 as-
sociates with hundreds of mRNAs, which, in its absence,
show altered translation and encoded protein levels. Im-
portantly, actively translating mRNAs, but not the
steady-state transcript levels, show pronounced changes
in MeCP2-null brain. The MECP2-regulated mRNAs
are involved in synaptic transmission, cell signaling, and
ion homeostasis and likely contribute to a range of neu-
ral and physiological processes deficient in RTT. Our re-
sults reveal a novel biological function of MeCP2 and
implicate translation regulation in RTT pathogenesis. 
GABAergic Interneurons and
Neurodevelopmental Disorders
We are studying alterations of GABAergic inhibitory
circuits in mouse models of RTT, one of the autism
spectrum disorders, caused by mutations in the X-
linked gene MeCP2. Our general hypothesis is that
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MeCP2mutations perturb the postnatal maturation of
connectivity, function, and plasticity in subsets of in-
hibitory interneurons in distributed brain areas, leading
to altered development and maladaptive plasticity of
neural circuits and characteristic behavioral deficits. 
Neuronal circuits in the brain are shaped by experi-
ence during “critical periods” in early postnatal life. In
the cortex, this activity-dependent development is coin-
cident with the functional maturation of parvalbumin
(PV+) GABAergic interneurons, although the underly-
ing mechanisms are unclear. We have obtained substan-
tial evidence that MeCP2 regulates the timing of a critical
period of plasticity in the visual cortex, likely through
the maturation of the GABAergic neurons. We found
that loss of methyl-CpG-binding protein (MECP2) re-
sults in accelerated maturation of PV+ fast-spiking corti-
cal interneurons, likely resulting in a shift in critical
period onset using molecular markers and physiological
parameters. Furthermore, loss of MeCP2 in PV+ in-
terneurons resulted in increased expression of the rate-
limiting enzyme GAD67, which synthesizes GABA, the
major inhibitory neurotransmitter in the brain. Our cur-
rent results indicate a requirement for MeCP2 in regu-
lating the development of activity-dependent maturation
of PV+ GABAergic interneurons via GAD67, which in
turn innervate the perisomatic region of pyramidal neu-
rons and control their output. As MeCP2-null mice serve
as a model for RTT, our findings provide insight into the
inappropriate synaptic plasticity underlying the patho-
genesis of this disease. Altered timing of critical period
might lead to deficits in  experience-dependent associa-
tions in other modes of perception including multisen-
sory integration, social interaction, and language skills, as
seen in RTT and other neurodevelopmental disorders.
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We are interested in identifying the neurobiological
principles underlying cognition and decision-making.
Using a reductionist approach, we translate psycholog-
ical questions into the language of neuroscience by dis-
tilling them into quantitative behavioral tasks for
rodents that enable the monitoring and manipulation
of neural circuits mediating cognitive behaviors. We use
state-of-the-art electrophysiological techniques to es-
tablish the neural correlates of behavior and then use
molecular and optogenetic manipulations to systemat-
ically dissect their underlying neural circuits.
Given the complexity of animal behavior and the dy-
namics of neural networks producing it, our studies re-
quire quantitative analysis and computational models to
guide and sharpen the neurobiological questions. In ad-
dition, we started incorporating human psychophysics
into our research to validate our behavioral observations
in rodents by linking them with analogous behaviors in
human subjects.
In terms of topics, our approach is multifaceted. We
study (1) the roles of uncertainty in decision-making,
(2) the division of labor between different cell types in
prefrontal cortex, (3) how the cholinergic system sup-
ports sustained attention, and (4) social decisions that
rely on shallow, stereotyped circuits. A unifying theme
is the use of cell-type and pathway-specific perturbations
to effect gain and loss of function for specific behavioral
abilities. Through such manipulations of genetically and
anatomically defined neuronal elements, we hope to
identify fundamental principles of neural circuit func-
tion that will be ultimately useful for developing thera-
pies for diseases such as schizophrenia, Alzheimer’s de-
mentia, and autism spectrum disorder. 
Neural Basis of Decision Confidence
J. Sanders, J. Hirokawa [in collaboration with A. Lak,
University of Cambridge; G. Costa and Z.F. Mainen,
Champalimaud Neuroscience Program, Portugal]
If you are asked to evaluate your confidence in your de-
cision—how sure are you that you made the correct
choice—you can readily answer. What is the neural basis
for such judgments? Previously, we discovered neurons in
orbitofrontal cortex (OFC) that signal decision confi-
dence, and we are pursuing these observations by trying
to establish the causal neural circuit for estimating and
acting on decision confidence.
As a first step, we designed a new behavioral task for
rats, in which we could measure confidence behaviorally
on a trial-by-trial basis. Briefly, rats are trained on a simple
olfactory decision task, and by delaying reward, we found
that the time they are willing to wait for an uncertain re-
ward is proportional to decision confidence, as predicted
by theory. To further refine the role of OFC in confidence,
we are trying to “read out” confidence reports, i.e., predict
the timing of leaving decisions on a trial-by-trial basis based
on neural activity (establish correlation). To demonstrate
that OFC is necessary for confidence reports, we used both
excitotoxic lesions and pharmacological inactivation tech-
niques and found that confidence reports were disrupted
without changing decision accuracy. To establish the suf-
ficiency of OFC for confidence reporting, we are prepar-
ing gain-of-function experiments. Because there is no
obvious map in the prefrontal cortex, we cannot use elec-
trical microstimulation. Instead, we will use optogenetic
activation of neurons defined by projection target using
retrograde viruses and attempt to inject extra “uncertainty”
into the brain by activating the appropriate population of
neurons. Our ultimate aim is to define a precise neural cir-
cuit for computing and using decision confidence.
Confidence Judgments in Humans
J. Sanders
In our rodent studies of confidence, we use a computa-
tional framework to interpret behavioral and neural data.
Nevertheless, we are also interested in understanding the
degree to which the theoretical concept of decision confi-
dence corresponds to the human notion of subjective
confidence. Our goal was therefore to develop a new con-
fidence-reporting task that provides both implicit and
explicit measures of decision confidence and is suitable
for both rodents and humans in order to make direct
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comparisons. Therefore, we tested humans in a paradigm
similar to that of rats (using an auditory task) and found
that humans follow the same patterns of waiting time
and their explicit self-reports of confidence (1−5 scale)
correlate with this implicit waiting time measure.
On the basis of these results, we are now in a position
to use these quantitative measures of decision confidence
to study humans, through collaborations, with neuro-
imaging and genetic approaches. Moreover, by showing
that a single confidence measure is applicable to humans
and rodents, our results strengthen the case for using the
rat as a model system for studying decision confidence.
Integration of Decision Confidence 
and Reward Size in Orbitofrontal Cortex
J. Hirokawa
Making optimal decisions requires the integration of
different sources of information. For instance, past ex-
perience with rewards enables animals to make predic-
tions about their quality, size, and predictability. When
the main source of uncertainty is due to a perceptual
decision process, estimating decision confidence pro-
vides a mechanism for predicting reward outcomes.
Can rats combine experienced reward value and deci-
sion uncertainty to make optimal choices? And how
does the brain dynamically compute and integrate these
different estimates to make predictions?
We designed a reward-biased psychometric decision
task to dissociate reward estimates based on decision
uncertainty and reward history and recorded neurons in
the orbitofrontal cortex (OFC). We found that behav-
iorally, rats optimally combined decision confidence
and reward size. In OFC, we observed a heterogeneous
representation: one class of neurons signaled decision
confidence independent of reward, and another class
signaled the integrated negative reward value by com-
bining decision uncertainty with reward size. Therefore,
OFC appears to contain a mixture of representations
about future outcomes, including separate signals for
reward value and decision confidence.
Division of Labor between Distinct
Interneuron Subtypes during Behavior
D. Kvitsiani, S. Ranade, B. Hangya [in collaboration with
Z.J. Huang, Cold Spring Harbor Laboratory]
The medial prefrontal cortex (mPFC) in humans and ro-
dents has been implicated in a variety of goal-directed be-
haviors including working memory, inhibitory response
control, and attentional set switching. Electrophysiolog-
ical recordings from mPFC show a great diversity of neu-
ronal responses to specific behavioral variables. On the
other hand, we know that the mammalian cortex is com-
posed of a variety of cell types among which GABAergic
interneurons exhibit greatest diversity in connectivity,
morphology, and intrinsic physiology. Does the anatom-
ical and molecular variety of interneuron subtypes map
onto the diversity of neuronal responses in behaving an-
imals? To address this issue, we use optogenetics as a
means to identify extracellularly recorded neurons in
freely moving mice, focusing on inhibitory interneurons.
We recorded from the two largest and nonoverlap-
ping populations of interneurons: somatostatin (Som)
and parvalbumin (Pv) neurons, which synapse onto dis-
tal and proximal regions and differentially regulate the
input and output of pyramidal neurons, respectively.
To engage prefrontal ensembles, we trained mice on a
simple reward foraging task in which they ran on a lin-
ear track between two platforms, collecting rewards at
one platform and triggering rewards at the other plat-
form. Mice slowed their speed during reward zone ap-
proach in omission trials, demonstrating that behavioral
performance was goal-directed.
We found that Pv and a subtype of Som neurons
showed distinct and homogeneous responses during spe-
cific behavioral epochs. Furthermore, Pv neurons fired
with millisecond synchrony, resulting in brief and precise
inhibitory control. In contrast, the asynchronous firing
of Som interneurons resulted in weaker and variable in-
hibitory impact. Our results reveal that two prominent
interneuron subtypes previously defined by their connec-
tivity and in vitro physiology comprise complementary
networks for inhibitory control in mPFC and point to
the possibility that functional response diversity during
behavior can in part be explained by cell-type diversity.
Function of VIP Interneurons 
in Cortical Microcircuits
H.J. Pi [in collaboration with Z.J. Huang, Cold Spring
Harbor Laboratory]
We are interested in understanding how the diversity of
cortical inhibitory interneurons underlies distinct neural
circuit dynamics that directs perception and behavior. As
part of this broader project, we have begun to study va-
soactive intestinal peptide (VIP)-expressing interneurons.
Although VIP neurons constitute less than 2% of total
cortical neuronal population, previous studies indicate
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that VIP might have a distinct function in local cortical
computation. VIP neurons are mostly bipolar and their
processes are vertically oriented. Interestingly, these neu-
rons specifically target other inhibitory neurons and
avoid pyramidal cells. On the basis of these ideas, we are
currently testing the hypothesis that VIP inhibitory in-
terneurons provide local excitation to a patch of cortex
via disinhibition of other interneurons.
Neural Representation of Social Decisions
and Rewards 
E. Demir [in collaboration with R. Axel, Columbia Univer-
sity]
Mice, like humans, are social animals. To interact, coop-
erate, and compete with others, mice have to collect in-
formation about each others’ identity, fertility, and likely
intent. We would like to understand how social informa-
tion is represented, computed, and used by mice. In ro-
dents, a main source of information for social decision-
making and reward valuation is the chemosensory system.
The neural circuits supporting these tend to be shallow,
from sensory input to motor actions, and highly stereo-
typed, enabling the systematic dissection of this system.
We have begun our studies by recording from the me-
dial amygdala, the first brain region that combines infor-
mation from the two olfactory systems, the main olfactory
system transducing volatile odors and the vomeronasal
system detecting behaviorally significant chemical cues,
such as pheromones. Currently, we are developing psy-
chophysical social behavior tasks to use for our electro-
physiology studies. To deliver social stimuli and determine
their “value” for a mouse, we began to develop a new be-
havioral setup, the “mouse carousel.” This system im-
proves stimulus delivery precision and repertoire. To
characterize the social cue responses (e.g., urinary pro-
teins) of medial amygdala neurons, we also began to de-
velop protein ports to systematically deliver pheromonal
stimuli. Currently, we are performing optogenetic exper-
iments to map the behavioral relevance of social infor-
mation onto specific medial amygdala neurons.
Paying Attention to Light: Optogenetic
Dissection of the Cholinergic System
during Behavior
B. Hangya, S. Ranade, M. Faleiro
The cholinergic basal forebrain (CBF) is a vitally impor-
tant yet poorly understood neuromodulatory system that
is thought to have significant roles in cognitive functions,
including attention. Projections of CBF innervate the
entire cortical mantle and release acetylcholine, which
enhances cortical processing. Our goal is to understand
the function of the CBF in sustained attention, using a
combination of molecular genetic, electrophysiological,
optogenetic, and psychophysical techniques.
We use a knockin mouse line (Chat-cre) to specifi-
cally target cholinergic neurons in the basal forebrain.
We can express optical activators/inactivators delivered
via viral vectors specifically in these neurons to manipu-
late their activity with high spatiotemporal precision. We
have successfully developed visual and auditory versions
of sustained attention tasks in mice. In these tasks, mice
report target stimuli occurring at uncertain times. Per-
formance and reaction time are used as an indicator of at-
tention. We manipulate temporal expectancy by using
specific distributions for stimulus timing, thus modulat-
ing attention in a temporally precise, graded manner,
which is reflected by the reaction times of the animals.
We are currently testing the causal role of acetylcholine
in this task by transiently inactivating cholinergic neu-
rons with light during behavior. We have also started
recording from identified cholinergic neurons to assess
their role in sustained auditory attention. Using these
tools enables an unprecedented degree of mechanistic in-
vestigation of the behavioral functions of the CBF system
and provides an entry point for future studies of cholin-
ergic degenerative diseases, such as Alzheimer’s disease.
Mechanisms of Cholinergic Modulation in
Auditory Cortex
S. Ranade, T. Hromadka, B. Hangya [in collaboration with
T. Zador, Cold Spring Harbor Laboratory]
Acetylcholine (Ach) has profound physiological effects
on cortical neurons. Cholinergic agonists increase firing
rates, decrease firing correlations between neighboring
neurons, and change the receptive field properties of
cortical neurons. 
What is the physiological mechanism by which Ach
modulates cortical neuronal firing? The goal of this
project is to investigate the cellular and circuit mecha-
nisms of cholinergic modulation of spontaneous and
stimulus-evoked activity of cortical neurons in the au-
ditory cortex (ACx). We targeted the light-activator,
ChR2, to cholinergic neurons projecting to ACx to
evoke light-triggered release of acetylcholine. Using this
technique, we observed the effects of acetylcholine on
auditory responses. A high percentage of neurons in-
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creased their firing rate in response to light activation
and some also showed changes in their auditory tuning
curves. Using cell-attached recordings, we now plan to
investigate the underlying cellular mechanism of
cholinergic modulation. 
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Our laboratory develops mathematical models of neural
processing. We work in parallel on three important top-
ics. First, we are attempting to formulate an accurate
mathematical model for combining genetic information
and experience (nature and nurture) during the forma-
tion of connections between neurons. Our model de-
scribes how genes can help build neural networks and
how neural activity adds a layer of plasticity to the net-
work topology that reflects learning and experience. This
model has been tested on simple circuits that are formed
in the visual system and can be rewired using genetic,
surgical, and pharmacological manipulations. Second,
we have been developing the neural network theory for
olfactory processing. Our theory attempts to describe
the olfactory space, which has been an elusive concept
that excites the imagination of chemists, neuroscientists,
and experimental psychologists alike. Using this theory,
we attempted to link several levels of olfactory percep-
tion: chemical, genetic, neural, and perceptual. Our
main result so far has been the mapping between chem-
ical and perceptual spaces that was established on the
basis of a database of human olfactory responses. We
have developed a robust description of the human per-
ceptual olfactory space. This description is analogous to
understanding the main directions in the human color
space, i.e., red, green, and blue. These main perceptual
dimensions can be understood in terms of properties of
the underlying chemical compounds, at least on the level
of correlation. We also proposed a network theory for
information processing in the olfactory bulb. We sug-
gest that the granule cells, the inhibitory neurons of the
olfactory bulb, form representations of smells using the
network implementation of sparse overcomplete repre-
sentations. Granule cells are remarkable because, unlike
most of the neurons in the adult mammalian nervous
system, they are continuously replaced by the new neu-
rons produced from the neural stem cells. Third, we
have been working on the mathematical description of
adult neural stem cell differentiation and proliferation in
hippocampus. These models describe the evolution in
time of various markers that experimental researchers
use to study the division/differentiation cascade. By
comparing the computational/theoretical models to ex-
perimental data, one can understand changes occurring
in neurogenesis due to aging and antidepressant drug
therapies. 
A Race Model for Singular
Olfactory Receptor 
A.A. Koulakov [in collaboration with I. Iossifov and
B.E. Kolterman, Cold Spring Harbor Laboratory]
In vertebrates, olfactory sensory neurons choose only
one olfactory receptor to produce out of ~2000 possi-
bilities. This feature is important because it lowers the
detection threshold of odorants by olfactory receptors.
The mechanism for this singular receptor expression is
unknown. Here, we study a computational model that
can stochastically select a single gene out of a large
number of possibilities. In this model, receptor genes
compete for a limited pool of transcription factors
(TFs). The gene that recruits a target number of TFs is
selected for expression. To support this mechanism, we
have attempted to detect repeated motifs within known
sequences of mouse olfactory receptor promoters. Mo-
tifs were found that are significantly overrepresented in
olfactory versus other gene promoters. We identified
possible TFs that can target these motifs. Our model
suggests that a small number of TFs can control the se-
lection of a single gene out of ~2000 possibilities.
An Exactly Solvable Model of Stochastic
Cre-Lox Recombinations
A.A. Koulakov [in collaboration with Y. Wei, Cold 
Spring Harbor Laboratory]
The Cre-Lox system is used as a genetic tool to control
site-specific recombination events in genomic DNA. If
multiple recombination sites are organized in a com-
pact cluster within the same genome, a series of sto-
chastic recombination events may generate substantial
cell-specific genomic diversity. This diversity is used,
for example, to distinguish neurons in the brain of the
same multicellular mosaic organism, within the brain-
bow approach to the neuronal connectome. Thus, every
THEORETICAL AND COMPUTATIONAL NEUROSCIENCE
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cell in an organism could be identified on the basis of
a relatively short unique DNA barcode. Here, we study
an exactly solvable statistical model for site-specific re-
combination operating on a cluster of recombination
sites. We consider two types of recombination events:
inversions and excisions. Both of these events are avail-
able in the Cre-Lox system. We derive three properties
of the sequences generated by multiple recombination
events. First, we describe the set of sequences that can
in principle be generated by multiple inversions oper-
ating on the given initial sequence. Second, we demon-
strate that after a large number of stochastic inversions,
every sequence that can be generated is generated with
equal probability. Finally, we derive equations for the
probability of finding a sequence as a function of time
in the limit when excisions are much less frequent than
inversions, such as in shufflon sequences.
Competition Is a Driving Force
in Topographic Mapping
A.A. Koulakov [in collaboration with C. Pfeiffenberger, 
J.W. Triplett, J. Yamada, B.K. Stafford, D. Feldheim,
University of California, Santa Cruz]
Connectivity in the brain is established on the basis of
chemical labels and structured activity. For the two-di-
mensional, topographically organized projection from
the retina to the superior colliculus (SC), the Eph fam-
ily of receptor tyrosine kinases and their ephrin ligands
exert the role of chemical labels. Despite specific effects
of receptor activation on retinal axons, axons respond to
relative rather than absolute levels of chemical labels,
which endows the mapping mechanism with substan-
tial robustness. However, it is not known how axons
compare global levels of chemical labels. Here, we pre-
sent experimental and computational evidence that in-
teraxon competition has a nonredundant role as a
mapping mechanism for the retinocollicular projection.
We investigated topographic maps in the SC of Math5
mutant mice in which the overall number of retinal
axons is severely reduced. We show that topographic
maps are substantially distorted under conditions of re-
duced competition (Fig. 1). RGC axons project almost
entirely to the anteromedial portion of the SC where
repulsion from ephrin-A ligands is minimized and
where their attraction to ephrin-Bs is maximized. We
conclude that chemical labels alone do not instruct the
formation of the map. We provide a mathematical
model for topographic mapping that incorporates mo-
lecular labels, neural activity, and axon competition. 
The Structure of Human Olfactory
Space of Mixtures
A.A. Koulakov [in collaboration with A. Enikolopov, 
D. Rinberg, HHMI Janelia Farm]
We investigated the responses of human observers con-
tained in the atlas of human character profiles (AOCP)
by Andrew Dravnieks. We had shown previously that
146-dimensional (146D) profiles of odorants that rep-
resent the responses of human observers to a variety of
monomolecular odorants can be accurately described by
a two-dimensional (2D) curved manifold. Here, we in-
vestigate the responses of human subjects to the set of 15
mixtures contained in the same database. The particu-
lar question that we address is whether the percepts of
mixtures (the mixture space) reside close to the olfac-
tory space determined from the monomolecular odor-
ants. We show that indeed the mixture space can be
predicted by the percepts of monomolecular odorants
(Fig. 2). The important difference, however, is that the
mixture space contains one extra dimension compared
to monomolecular odorants. Thus, approximating
146D profiles of monomolecular odorants with the 2D
curved manifold allowed us to include 51% of variance
Figure 1. A race model for singular olfactory receptor (OR) expres-
sion. (A−D) Number of TFs bound to each promoter as a function of
time for 80 functional genes and 20 pseudogenes (psGs) with coop-
erative binding of TFs. Each panel shows a simulation for a single neu-
ron. Pseudogenes do not invoke a negative feedback mechanism to
stabilize gene choice, whereas functional genes do. OR expression
occurs when at least four TFs are bound. Singular expression occurs
for functional genes in almost all cases, with occasional coexpression
of pseudogenes (B−D). (E) Table of probabilities for various psG and
functional gene expression level combinations determined from 1000
simulated cells.
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contained in the data. In the case of mixtures, the same
amount of variance can be explained by a 3D curved
space. One extra dimension, however, is predicted by
the small residual fluctuations of monomolecular per-
cepts around the 2D curved monomolecular space. We
conclude that the responses of human observers to mix-
tures can be found to be low dimensional and pre-
dictable from the percepts of monomolecular odorants.
Sparse Incomplete Representations: 
A Novel Role for Olfactory Granule Cells
A.A. Koulakov [in collaboration with D. Rinberg, 
HHMI Janelia Farm]
Mitral cells of the olfactory bulb form sparse represen-
tations of odorants and transmit this information to
the cortex. The olfactory code carried by the mitral cells
is sparser than the inputs that they receive. In this
study, we analyzed the mechanisms and functional sig-
nificance of sparse olfactory codes. We consider a
model of the olfactory bulb containing populations of
excitatory mitral and inhibitory granule cells. It can be
argued that sparse codes may emerge as a result of self
organization in the network leading to the precise bal-
ance between mitral cells’ excitatory inputs and inhi-
bition provided by the granule cells. We propose a
novel role for the olfactory granule cells and show that
these cells can build representations of odorant stimuli
that are not fully accurate. Due to the incompleteness
in granule cell representation, the exact excitation-in-
hibition balance is only established by some mitral
cells, leading to sparse responses. Our model suggests a
functional significance of the dendrodendritic synapses
that mediate interactions between mitral and granule
cells. The model accounts for the sparse olfactory code
in the steady state and predicts that transient dynam-
ics may be less sparse.
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Figure 2. The structure of human olfactory space. The odors (crosses)
cluster around a 2D curved surface in the perceptual space. The 2D
surface exists in a 146D space of various perceptual descriptors. The
parameters defining the positions on the surface (X and Y) are re-
lated to the molecule’s chemical composition and hydrophobicity. 
We are interested in understanding the synaptic mecha-
nisms of behaviors that are related to psychiatric disorders.
Synaptic plasticity is believed to serve as the cellular mech-
anism for learning and memory, and impairments in this
process have been linked to psychiatric disorders, includ-
ing schizophrenia and depression. We use rodent models
of these disorders, as well as a number of complementary
methodologies, including behavioral assays, electrophysi-
ology, two-photon imaging, in vivo circuit tracing, elec-
trical deep brain stimulation, molecular genetics, and
optogenetic techniques, to address questions in three
major areas: (1) the synaptic mechanisms of depression,
(2) the synaptic mechanisms underlying adaptive behav-
iors, such as resilience to depression or behavioral flexibil-
ity, and (3) the synaptic mechanisms of schizophrenia. 
The Synaptic Circuitry of the Lateral
Habenula and Behavioral Depression
The cellular basis of depressive disorders is poorly un-
derstood. Recent studies in monkeys indicate that neu-
rons in the lateral habenula (LHb), a nucleus that
mediates communication between forebrain and mid-
brain structures, can increase their activity when an ani-
mal fails to receive an expected positive reward or receives
a stimulus that predicts aversive conditions (i.e., disap-
pointment or anticipation of a negative outcome). LHb
neurons project to and modulate dopamine-rich regions
such as the ventral-tegmental area (VTA) that control re-
ward-seeking behavior and participate in depressive dis-
orders. Our study shows in two learned helplessness
models of depression that excitatory synapses onto LHb
neurons projecting to the VTA are potentiated. Synaptic
potentiation correlates with an animal’s helplessness be-
havior and is due to an enhanced presynaptic release
probability. Depleting transmitter release by repeated
electrical stimulation of LHb afferents, using a protocol
that can be effective on depressed patients, dramatically
suppresses synaptic drive onto VTA-projecting LHb neu-
rons in brain slices and can significantly reduce learned
helplessness behavior in rats. Our results indicate that in-
creased presynaptic action onto LHb neurons contributes
to the rodent learned helplessness model of depression.
We are currently determining the specific path-
ways/mechanisms that can mediate the behavioral ef-
fects of DBS (deep brain stimulation) in LHb. We are
also using optogenetic methods to either manipulate
LHb cellular activity or modulate the monoaminergic
inputs to LHb, and to determine the behavioral effects.
Depression and Resilience: Role
of the Medial Prefrontal Cortex 
We are testing the hypothesis that normal synaptic plas-
ticity in neurons of the medial prefrontal cortex (mPFC)
has an important role in behavioral flexibility and re-
silience to depression, whereas its impairments lead to be-
havioral depression. The mPFC has been implicated in
executive function and behavioral flexibility. Recent stud-
ies suggest that mPFC is critical in the determination of
whether an organism has control over a stressor. Rats with
inactivated mPFC are prone to behavioral depression in-
duced by stressors (Amat et al., Nat Neurosci 45: 365
[2005]). Aberrant activity of the mPFC also accompanies
clinical depression, and DBS in mPFC leads to remission
of treatment-resistant depression (Mayberg et al., Neuron
45: 651 [2005]). However, the cellular processes in mPFC
accompanying behavioral depression are not clear. The
cellular mechanisms in mPFC that underlie controllabil-
ity, therefore affording resilience to behavioral depression,
are also unknown. 
To determine cellular activity in the mPFC in differ-
ent groups of animals, we measured c-Fos expression in
the infralimbic (IL) and prelimbic (PL) regions of the
mPFC. We found that in the learned helplessness (LH)
model of depression, neurons in the mPFC were acti-
vated. After the LH procedure, animal behavior diverged
to become either depressed or resilient to depression. In-
terestingly, the resilient animals had significantly en-
hanced neuronal activation compared with the depressed
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THE FUNCTION AND PLASTICITY OF CENTRAL SYNAPSES
IN ANIMAL MODELS OF PSYCHIATRIC DISORDERS
B. Li S. Ahrens S. Ghosh M. Penzo
H. Chae H. Li Z. Perova
K. Delevich R. Paik M. Wang
animals, indicating an active coping process. We are cur-
rently examining whether deferential plastic changes in
the synapses onto mPFC neurons in response to stress are
critical in determining an animal’s susceptibility or re-
silience to behavioral depression. 
The mPFC and LHb are synaptically connected and
belong to a synaptic circuitry strongly implicated in de-
pression. The first and second projects are integral com-
ponents of a synergistic effort aimed at attaining  a more
complete understanding of the synaptic and circuitry
mechanisms underlying depression. 
Genetic Deficiency, Dysfunction
of the Thalamic Reticular Nucleus,
and Schizophrenia 
The thalamic reticular nucleus (TRN) integrates exci-
tatory inputs from the cortex and thalamus, and sends
inhibitory outputs to control thalamic function. This
cortico-TRN-thalamic circuitry is thought to modulate
the processing of sensory stimuli and to have an im-
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portant role in cognitive functions such as attention.
Dysfunction of TRN has been implicated in schizo-
phrenia, a complex mental disorder in which impair-
ments in cognitive functions, including attention, are
core symptoms; however, the molecular and cellular
mechanisms underlying TRN circuit dysfunction in
schizophrenia are not well understood. 
Recent studies indicate that molecules linked to schiz-
ophrenia are enriched in TRN neurons. These include
ErbB4 and its ligand neuregulin-1 (NRG1). The NRG1/
ErbB4 signaling pathway has been implicated in many bi-
ological processes, including the development and func-
tion of synapses in the central nervous system. A plausible
hypothesis, therefore, is that deficits in NRG1/ErbB4
function can alter the formation or function of synapses
that assemble the TRN circuitry, leading to circuit dys-
function and cognitive impairments associated with schiz-
ophrenia. Consistent with this idea, recent results from my
lab indicate that reducing ErbB4 protein levels in TRN
neurons causes alterations in attention in mice (Fig. 1).
We focus on a class of TRN neurons that express so-
matostatin (SOM+) and constitute a major cell popu-
Figure 1. Deletion of ErbB4 in SOM+ TRN neurons altered attention. We first trained mice in the auditory or visual two-
alternative choice task (2-AC). In the auditory 2-AC, mice were rewarded for correctly discriminating a target sound.
The tone frequency indicated the location of reward (right or left). Animals were further trained in a visual 2-AC, in
which a left or right light signaled reward in the left or right, respectively. Having learned these basic 2-AC tasks, mice
were tested in a “distractor” task and a “rule-selection” task to examine goal-directed attention. (a) Schematic diagram
of the “distractor” task, in which the target tone (gray “~”) is embedded in a stream of distractor tones (black lines). (b)
Schematic diagram of the “rule-selection” task, in which the mice were presented with both the sound and light. How-
ever, only one of the stimuli predicted reward. For example, in a “light-ignore-sound” session (as shown), only sound
predicts reward, whereas light is random to reward. (c) All groups can learn the basic auditory (left) or visual (right) 2-
AC task. (d) SOM/ErbB4+/– (Het) and SOM/ErbB4–/– (KO) mice had enhanced performance in the “distractor” task. (e)
KO mice had impaired performance in the “rule-selection” task. Data are presented as mean ± S.E.M.; ***p < 0.001;
numbers in the bar indicate N. 
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lation in the TRN. Our preliminary results indicate
that ErbB4 is enriched in SOM+ neurons in the TRN
and that it has a rather unexpected role: It suppresses
glutamatergic synaptic transmission, an effect that de-
viates from its role in other brain areas, where ErbB4
positively regulates synaptic function (Fig. 2). We are
capitalizing on these exciting preliminary findings and
are determining whether and how ErbB4 controls the
synaptic connectivity of SOM+ TRN neurons, thereby
regulating the cortico-TRN-thalamic circuitry func-
tion. To achieve these goals, we use a combination of
genetic, molecular, optogenetic, and electrophysiolog-
ical methodologies. Results from this research will shed
light on the cellular mechanisms underlying TRN cir-
cuit dysfunction in major psychiatric disorders.
PUBLICATION 
Li B, Piriz J, Mirrione M, Chung C, Proulx C, Schulz D, Henn F, Ma-
linow R. 2011. Synaptic potentiation onto habenula neurons in the
learned helplessness model of depression. Nature 470: 535−539. 
Figure 2. Regulation of excitatory synapse in SOM+ TRN neurons by ErbB4. (a) A schematic diagram of the recording
configuration. (Right) A SOM+ neuron. (b, Left) Sample EPSC traces recorded at +40 and −70 mV holding potentials,
from ErbB4 wild-type (WT), SOM/ErbB4+/– (HET), and SOM/ErbB4–/– (KO) mice (calibrations: 20 pA and 50 msec). (b,
Right) Quantification of AMPA and NMDA EPSC amplitude normalized to the mean of SOM− neurons (*p < 0.05; **p
< 0.001; ***p < 0.0001).
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Our research is aimed at understanding the neural basis
of psychiatric disease, with an emphasis on depression.
The focus of our current work involves the use of a
unique animal model of depression that we have de-
veloped over the last decade to understand the anatomy
and pathophysiology of depression. We use a model in-
volving uncontrollable and unpredictable stress, which
leads to “learned helplessness” in ~15%–20% of ani-
mals. We conducted outbreeding studies using the
most helpless animals to form one strain and the ani-
mals most resistant to this stressor to form the other
strain. A comparison of these two strains using positron
emission tomography (PET) carried out at Brookhaven
National Laboratory suggested to us that the largest dif-
ference in activity in the brains of the two strains was
in a small structure, the lateral habenula that sits be-
tween the cortex and the midbrain aminergic nuclei
(see Fig. 1).
Working with Bo Li at CSHL, we were able to show
that the l. habenula is overactive in helpless animals,
leading to an inhibition of dopamine release in reward
centers. In addition, our PET data suggest that the l.
habenula also leads to serotonin decreases in the help-
less state, which fits with the idea behind most antide-
pressant medications that attempt to increase serotonin.
The driver of this activity appears to be the medial pre-
frontal cortex (mPFC), which also seems to be abnor-
mal in the helpless animals. Thus, we looked at the
mPFC in our helpless animals in collaboration with a
group at the University of California, Irvine, headed by
Gary Lynch and found that there are 40% fewer
synapses in the helpless cortex than in the resilient an-
imals, a result that is consistent with the functional be-
havior of the strains and appears to reflect pathology
due to increased glutamate extracellularly leading to
synaptic damage. This is consistent with the result in
patients, where ketamine, which restores glutaminergic
synapses, reverses many cases of treatment-resistant de-
pression. Unpublished work, done at our suggestion,
shows down-regulation of habenular activity in patients
following ketamine administration. Our earlier data
suggest that this decrease in synaptic boutons is due to
decreased glutamate transporters in astrocytes in the
helpless animals. We just received a patent for a class of
drugs that up-regulate the astrocytic glutamate trans-
porter as possible antidepressants, and we are arranging
to test this idea at the National Institutes of Health
(NIH) clinical center in the coming year.
MECHANISMS OF DEPRESSION
F. Henn M. Mirrione
N. Ruth
Figure 1. PET scans of helpless and nonhelpless lines versus naïve rat brains.
Note habenula activation (Hb) in helpless line but not in resistant line.
Neuroscience 147
We are continuing to look at the details of the
anatomy between the two strains using c-fos to mark ac-
tivated neurons and specific stains to identify the trans-
mitters used by these cells. Under the direction of Dr.
Mirrione, we are developing a whole-brain atlas of both
the helpless line and resilient lines to determine the
transmitters and circuits that underlie the differences. 
We are also looking at the whole genome sequences
of the two lines in collaboration with Professor McCom-
bie at CSHL to get an idea of the genetic differences in
the lines as a clue to genetic factors in human depres-
sion.
Much of the work in the past 2 years was aimed at
defining the circuit that mediates depression; one test of
the central hypothesis that the l. habenula is a key struc-
ture mediating this circuit is to use deep-brain stimula-
tion to inhibit the overactive l. habenula in treatment-
resistant cases of depression. One trial case, done a few
years ago in Europe at my former institute, resulted in
the total cure of the patient. We have applied to the
Food and Drug Administration (FDA) in the United
States to carry out a large trial of this procedure.We
have worked with a neurosurgeon and psychiatrists at
Mount Sinai Medical Center to develop a team to
carry out these studies and have submitted a request to
the FDA.We should be able to begin in the next year
to definitively test this hypothesis. 
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Our basic research philosophy is to combine theoreti-
cal, computational, and experimental approaches for the
study of complex biological systems, with a particular
focus on neurobiological questions. Efforts in our group
fall into three main areas: informatics, theory, and ex-
perimental work. 
Our neuroinformatics research involves the applica-
tion of analytical tools to large volumes of neurobiolog-
ical data, as well as the development of informatics
infrastructures for data and knowledge integration. Our
study in the area of theoretical engineering applies the-
ories developed in human-engineered systems to study
the theoretical principles underlying biological systems.
The final area of our research is experimental and has
previously consisted of collaborative studies in multiple
species including Drosophila, zebra finch, macaque mon-
key, and human infants. We are now undertaking a
major in-house experimental project to generate the first
brainwide mesoscale connectivity map in the mouse.
Continuing in the Mitra laboratory in 2011 are Pas-
cal Grange and Swagatam Mukhopadhyay (postdoctoral
fellows), Jamie Jones, Alex Tolpygo, and Joshua Novy
(laboratory technicians), Sandra Michelsen (administra-
tor), Vadim Pinskiy and Zhen Gong (graduate students),
Gregor Havkin (informatics manager), Linzie Wood
(project assistant), and Caizhi Wu (research associate).
Kevin Weber, Neil Franciotti, and Caitlin Powell (labo-
ratory technicians) and Noah Jakimo (informatics ana-
lyst) joined this past year. 
We also have close collaborative ties with multiple re-
search groups at CSHL and other institutions, which cur-
rently include Dr. Nicholas D. Schiff at the Weill Medical
School of Cornell University, where Dr. Mitra is an ad-
junct associate professor; a laboratory evolution study in
Drosophilawith Josh Dubnau at CSHL; the Brain Archi-
tecture Project, with collaborators at multiple institutions,
notably Harvey Karten (University of California, San
Diego), Kathy Rockland (Massachusetts Institute of Tech-
nology), Michael Hawrylycz (Allen Institute of Brain Re-
search), and Jin Hyung Lee (University of California, Los
Angeles); a collaboration with Josh Huang at CSHL on
GABAergic interneuron expression in ASD mouse mod-
els; and a collaboration with Gregory Hannon at CSHL
on analysis of a small hairpin RNA (shRNA) screen. 
Mouse Brain Architecture Project
V. Pinskiy, A. Tolpygo, C. Wu, N. Jakimo, J. Jones,
K. Weber, J. Novy, G. Havkin, P. Grange
Brain function is determined by its circuitry, but our
knowledge of mammalian brain connectivity is highly
incomplete. We have set out to address this problem in
the Mouse Brain Architecture Project, in which we are
comprehensively determining the patterns of neural
connectivity between brain regions.
Following initial funding by the Keck foundation and
support from CSHL, we obtained two National Insti-
tutes of Health (NIH) grants (a Transformative-R01 and
RC1 Challenge Grant) to produce the connectivity map
of C57BL/6J mice and to align these results to the Allen
Brain Atlas. Our plan involves injecting anterograde
(BDA, AAV) and retrograde (CTB, Rabies) tracers sys-
tematically on a grid of locations distributed through-
out the brain. Each injection site yields information
about the other regions of the brain projecting to and
from the injected region. This project is now in full pro-
duction phase. The pipeline to process tissue from tracer-
injected mice through to image analysis is fully
functional and all equipment has been integrated into a
laboratory information management system (LIMS). 
We have already injected more than 800 production
animals at ~200 different sites. We are currently per-
forming cortical injections in columnar fashion. For
adeno-associated virus (AAV) injections, we aim to simul-
taneously label superficial (layers 1−3) and deep layers
(1−4), in two colors, green fluorescent protein (GFP) and
red (TdTomato). These injections are more elaborate
than single-point injections (used to target subcortical
structures), but we are able to perform them at the same
INTEGRATIVE SYSTEMS NEUROBIOLOGY
P. Mitra N. Franciotti J. Jones A. Tolpygo
P. Grange S. Mukhopadhyay K. Weber
G. Havkin J. Novy L. Wood
N. Jakimo V. Pinskiy C. Wu
D. Johnston C. Powell
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throughput and at the same quality, due to the versatility
of the stereotaxic method, designed the previous year.
Computer-guided injections are the standard in the lab-
oratory and are being used for all cortical injections. Fig-
ures 1A,B are examples of cortical injections. Figures
1C,D show the computational processing of the image
data registration of the sections onto the Allen Reference
Atlas (ARA) and the automatic detection of labeled cells.
During the last year, we have begun the process of
analyzing the collected data and making it available on
the MBA portal. We have developed an interactive data
browser that allows for high-resolution viewing of the
data in a neuroanatomical context. The user is able to
view all sections of a given brain, adjust individual view-
ing parameters (color channels for fluorescence), zoom
and pan throughout the section, provide regional an-
notations, and link to appropriate neuroanatomical ref-
erences, such as ARA and BAMS (Brain Architecture
Management System, University of California, Los An-
geles). We have worked extensively to improve the per-
formance of this server, such that many users can
simultaneously access the data without delay. Figure 2
shows the graphical user interface of the portal. 
In the last year, we have also begun collecting auxil-
iary data sets for the portal, using the MBA pipeline.
These data sets include a complete set of nissl-stained
brains (sectioned in the coronal, sagittal, and transverse
planes), immunohistochemical staining of various com-
mon neuronal markers (lectin, TH, PV, etc.), and
myelin. Myelin has been one of the most challenging to
gather; results are shown in Figure 3. 
Finally, this project has also benefited from a sum-
mer course that Dr. Mitra cofounded at CSHL in 2010
and held again in 2011. 
Through this project, Cold Spring Harbor Labora-
tory has become a leading center for filling the critical
knowledge gap urged by Dr. Crick and championed by
Jim Watson. For more information, see the Brain Archi-
tecture Project website at http://brainarchitecture.org.
Alterations in Brain-Wide GABAergic 
Neuroanatomy in ASD Mouse Models
S. Mukhopadhyay, V. Pinskiy, A. Tolpygo, J. Jones, 
N. Franciotti, K. Weber, J. Novy, Z. Collins 
In collaborative work with Josh Huang at CSHL, we have
received funding from the Simons Foundation Autism
Figure 1. MBA pipeline output and examples of data generated from the MBA pipeline. (A) Cortical AAV fluorescent
injections performed at adjacent sites. Contralateral labeling via callosal projections is evident. (Inset) Thalamic pro-
jections observed in the same brain. (B) Cortical BDA injection showing contralateral projection through the corpus
callosum. (Inset) Close-up of contralateral projection area. (C) Images containing labeled cells are registered with the
Allen Reference Atlas. (D) Specially designed software automatically determines the locations of labeled cells and plots
them in three-dimensional space.
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Research Initiative (SFARI) to generate brain-wide maps
of inhibitory neuron subpopulations and inhibitory long-
range projections in both wild-type (WT) mice and
autism spectrum disorder (ASD) model mice to deter-
mine the neuroanatomy of dysfunctional inhibition rele-
vant to autism. This project uses the MBA pipeline to
process the mouse models developed by Josh Huang’s
group. The project focuses on four GABAergic neuron
subtypes: PV (parvalbumin), SOM (somatostatin), CRH
(corticotrophin releasing hormone), and VIP (vasoin-
testinal peptide). The project was started in the summer of
2011. Since then, we have processed an N = 2 of each sub-
type for 56-day-old animals. As part of the grant, we are
also studying the development of these mouse models, by
processing animals at p14 and p36. As part of this project,
we have developed an algorithm to allow for the auto-
mated counting of cells across the whole brain. An exam-
ple of the cell-counting algorithm is shown in Figure 4. 
Mapping Long-Range Neuronal Circuits 
in the Postmortem Human Brain
V. Pinskiy, C. Powell
Our goal is to develop a practical method of studying
long-range connectivity in postmortem human tissue.
Figure 3.Whole brain myelin staining. As part of the MBA project,
we have initiated an effort to collect auxiliary data sets of common
biomarkers, including myelin. We have successfully modified the
MBA pipeline to produce high-quality myelin staining of 20-mm
mouse brain sections. Bars, 2 mm and 500 mm (B–D).
Figure 4. To allow for an efficient and reliable means of counting la-
beled neurons throughout the large data stacks, we developed an al-
gorithm that takes advantage of the approximate symmetries of
objects and uses multiple features of the objects to determine their
centers in an iterative method. In the specific implementation, we
used the edge-detected-image pixels (A) and the gradient of intensi-
ties on these pixels as the features. Intensity gradient direction of edge
pixels, weighted by the angle between points, is used to determine
the approximate center of each cell (B). After further iteration of the
algorithm (sharpening) and thresholding, the center of the cells is de-
tected (C,D). This algorithm is appropriate for cell counting even in
seemingly dense regions and in regions where the cells have uneven
intensities (a different vertical position within the 20-mm section).
Figure 2. Project website interactive interface. Data
sets generated by the MBA pipeline are  included in
an interactive database. The web-based interface al-
lows for viewing of high- resolution images of brain
slices as well as an information panel that  includes
metadata and links to related resources.
Neuroscience 151
To this end, we continue to work on a method that al-
lows for the accelerated transport of DiI through post-
mortem tissue while maintaining tissue integrity. We
have also been exploring methods of imaging whole
human brains and are in the process of purchasing a
large-format, whole-slide imaging scanner. 
We have verified that an electrical field of adequate
strength can be applied and sustained across a tissue sam-
ple using our current “tractophoresis” prototype. We have
been reengineering the current apparatus to allow for
prolonged electrical field applications while minimizing
damage to the tissue over time. The use of a dual-phase
gel construct has allowed for extended runs at relatively
stable sustained currents, as compared to our previous
all-agarose design. Originally, we were only able to run
the system for a maximum of 6−7 h at ~10 V/cm before
contact between tissue and gel eroded at the positive ter-
minal to the point that the gel needed to be recast. With
the addition of a polyacrylamide layer, samples can be
run routinely under a similar electrical field magnitude
for 24−48 h with little change in sustained current
through the system being observed; we have even
achieved a run of more than 100 h with this design. 
Maintaining tissue integrity remains as the main lim-
iting factor in long-term sustained electrical field appli-
cation. We are testing the use of different mineral oil
formulations to mitigate dehydration of the sample dur-
ing the application of the electrical field. We are contin-
uing to test and perfect our methodology using sheep
brains.
We have also begun the process of developing prac-
tical methods of sectioning and imaging whole human
brains. We are running initial trials with whole sheep
brains. Although we optimize our methods for DiI
propagation, we intend to proceed with traditional his-
tochemical processing of whole brain slides, beginning
with myelin-staining studies. We also plan to configure
the soon-to-be acquired TISSUEscope large-format slide
scanner for the imaging of existing neuroanatomical
samples from the collection of Dr. Patrick Hof. This
project is supported by the G. Harold and Leila Y.
Mathers Charitable Foundation.
Analysis of Gene Expression
in the Mouse Brain
P. Grange
Statistical analysis of coexpression of genes. Large sets
of genes related to addiction have been compiled in pub-
lic databases. It is desirable to establish the coexpression
properties of such sets of genes in order to prioritize fur-
ther studies. We developed probabilistic techniques to
compare the coexpression properties of sets of genes to
those of random sets of genes. These techniques were
applied to extract highly coexpressed genes from a set of
288 genes from the NICSNP database (single-nu-
cleotide polymorphisms [SNPs] associated with nico-
tine addiction), using the Allen Gene Expression Atlas
(AGEA) of the mouse brain. This research was sup-
ported by NIDA (National Institute on Drug Abuse).
The application of these methods to the human data re-
leased by the Allen Institute is in progress. We estab-
lished a collaboration with Sharmila Basu (MindSpec)
and analyzed a set of 26 genes related to autism, which
was found to have higher coexpression compared to a
random set of genes. These studies indicate that the
AGEA coexpression data can be useful in prioritizing
gene lists obtained from human genetic studies and hav-
ing insight into intervening phenotypic variables. 
Brainwide distribution of cell types. The AGEA cor-
responds to the gene-based approach to the study of gene
expression in the brain: Expression of a single gene is
measured using in situ hybridization in the whole brain.
The results cover the whole brain, but they have no cell-
type specificity. In contrast, a cell-based approach in-
volves the isolation of homogeneous neuronal
populations or even single cells. This approach is cell-
type-specific but does not cover the whole brain. We ob-
tained microarray data for 64 different cell types from
Sacha Nelson (Brandeis University). We proposed a lin-
ear model decomposing the gene expression in the
AGEA as a sum over cell-type data. This allowed us to
estimate the spatial density of cells of a given type, thus
combining the complete brain coverage of the AGEA
and the cell-type specificity of microarray data. 
Evolutionary ages of genes and neuroanatomy.We
used the OMA ortholog data set to infer the evolution
of mouse−brain neuroanatomy from the standpoint of
the evolution of genes. For each gene in the AGEA Atlas,
using the phylogenetic tree for all fully sequenced species
and the presence of orthologs of the gene in these
species, we constructed a discrete measure of “evolu-
tionary age.” We found sets of genes appearing at 12
major branching points in the phylogenetic tree. We
studied the deviation of these dated sets of genes from
the average expression across the whole AGEA. Some of
these deviations are statistically significant and region-
specific: For instance, the genes dated to the appearance
of vertebrates are overly expressed in the cerebellum.
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shRNA Library Analysis
S. Mukhopadhyay 
In collaboration with Greg Hannon at CSHL, we have
been developing machine learning tools and models in-
spired by population genetics to study an experimental
selection process: a massively parallel sensor assay to ex-
tract potent shRNA. The observed success of shRNAs in
this selection process was used to construct a machine
learning tool (Random Forest and Boosted Trees) to pre-
dict shRNAs that are potent in vivo. The predictions are
being tested in the lab. 
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Serial Two-Photon Tomography: 
An Automated Brain-Wide Screening 
of Neural Circuits in Wild-Type Mice
and Genetic Mouse Models 
of Autism and Schizophrenia
Our laboratory is focused on the study of brain circuits
mediating complex behaviors, such as different forms of
social behaviors, and how these circuits may be disrupted
in genetic mouse models of autism and schizophrenia.
The use of serial two-photon (STP) tomography, a novel
whole-brain microscopy method (Ragan et al. 2012), al-
lows us, for the first time, to perform brain-wide and cel-
lular resolution screening of neural activation evoked
during behavioral tasks (Fig. 1). The STP technology is
matched by a pipeline of custom-built computational and
image-processing methods that serve to reconstruct the
brain-wide data sets and statistically compare the detected
brain-activation patterns within a standard mouse brain
atlas. The identified brain regions of activation are inter-
preted as candidate “nodes” of the brain circuit mediating
the behavior being investigated, and the mean number of
activated cells per node is taken as a measure of the
strength of brain activation. The validity of the circuit
nodes in mediating the behavior is tested by pharmaco-
logically “removing” one or more nodes (e.g., by using
stereotaxic viral vector-based delivery of DREADD mol-
ecules) and measuring the effect of the manipulation on
the animal’s behavioral performance. Finally, the connec-
tivity between the nodes is determined by retro- and an-
terograde tracing in order to generate complete diagrams
of mouse brain circuits mediating specific behaviors. 
The Application of STP Tomography
to the Study of Autism and Schizophrenia
in Genetic Mouse Models 
The goal of this work is to identify brain-circuit-based
endophenotypes related to autism and schizophrenia in
genetic mouse models, which could be used in preclin-
ical research in the future. The use of STP tomography
allows us to rapidly screen neural activation in the whole
mouse brain at cellular resolution in order to identify
anatomical regions with altered functions. Such regions
are interpreted as “nodes” of candidate brain circuits af-
fected in the mouse model, and the cellular and molec-
ular pathophysiologies underlying the region-specific
changes are studied by traditional methods of experi-
mental neuroscience. These follow-up studies aim to
generate hypotheses for the development of therapeutic
agents that could eliminate the abnormality and restore
normal circuit functions in the mouse model. Our ap-
proach thus aims to provide a comprehensive platform
of quantitative and standardized brain-circuit-based as-
says that could be used to identify autism-related patho-
physiologies and test novel treatments in animal models.
We currently focus on five mouse models of autism:
16p11.2 deletion and duplication mice, which replicate
one of the most frequent and penetrant mutations asso-
ciated with autism (the 16p11.2 copy-number variation
in autism was identified by Mike Wigler’s lab and the
mice were generated by Alea Mills’ lab, both at CSHL),
and Neuroligin R451C, Neuroligin 4 knockout, and
CNTNAP2/Caspr2 knockout mice, which carry muta-
tions in genes with synaptic functions. 
The Application of STP Tomography
to the Study of GABAergic Neurons
in the Mouse Brain
The goal of this work is to generate a quantitative atlas of
GABAergic neurons, the most diverse class of cells in the
mammalian brain, which would provide the first com-
prehensive model of brainwide GABAergic circuitry and
its role in brain function (Fig. 2) (this work is a collabo-
ration with Josh Huang’s lab at CSHL). GABAergic neu-
rons maintain the delicate excitatory-inhibitory balance
in the brain, which enables persistent activity while
avoiding seizures, control synaptic integration and spik-
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IDENTIFICATION OF DISRUPTED BRAIN CIRCUITS IN MOUSE
MODELS OF AUTISM AND SCHIZOPHRENIA
P. Osten Y. Bao N. Takada
Y. Kim J. Taranda
R. Palaniswamy K.U. Venkataraju
ing of excitatory neurons, and generate network oscilla-
tions that serve as temporal structures for orchestrating
brain-wide neural ensembles. It is therefore not surpris-
ing that disruptions in GABAergic circuits are leading
risk factors for many cognitive disorders. The atlas and
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methods we are generating will thus also serve as a refer-
ence data set and standard technology for determining
the GABAergic circuit defects in mouse models of hu-
man disorders, including epilepsy, schizophrenia, autism,
depression, and attention deficits.
Summary
We hope that our work will lead to a better under-
standing of how neural circuits generate complex be-
haviors and how such circuits are disrupted in autism
and schizophrenia. 
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Figure 2. Reconstruction of GABAergic neurons in the mouse
brain by STP tomography, using GAD-Cre knock-in mice gener-
ated by Josh Huang’s lab at CSHL. (Top panels) Imaged GABAer-
gic neurons, (bottom panels) anatomical segmentation into spe-
cific brain regions.
Figure 1. Brain-wide screen of behavior-evoked neural activation. (A−D) At the end of a behavioral task, the brain of a
transgenic c-Fos-GFP (green fluorescent protein) mouse is imaged by STP tomography. (E−F) c-Fos-GFP-positive cells are
computationally detected and reconstructed. (G) The data sets are warped onto a standard “reference” brain (top pan-
els) and voxelized for statistical comparisons (bottom panels). (H) c-Fos-GFP distribution in control and experimental
brains is compared by series of negative binomial regressions, with a false discovery rate of 0.01. The arrows point to an
example of a strong, behavior-evoked activation in the medial prefrontal cortex. 
The overarching research goal in our laboratory is to un-
derstand how processing in specific brain circuits works
to support natural communication behaviors. We aim
to reveal neural mechanisms that allow organisms to de-
tect and recognize familiar individuals, to gather infor-
mation about their identity and social status, and to
select appropriate behaviors. Mice are capable of acquir-
ing detailed profiles on one another from the smells and
sounds experienced during their social encounters. These
dossiers may include information on a mouse’s sex, ge-
netic identity, reproductive state, levels of distress or sex-
ual interest, or even recently consumed foods, details that
are indispensable for survival and mating success. Ini-
tially, we are working to understand the neuronal activ-
ities and mechanisms in primary sensory brain areas that
support these forms of communication. In the future,
we anticipate moving deeper into the brain to ascertain
where the sensory data from those regions are collected
and integrated into hormonal and electrical signals that
promote appropriate behavioral choices.
The scientific benefit of this approach is twofold.
First, we want to identify fundamental principles for
how the brain controls complex behavior. To this end,
it is our belief that the nervous system’s function is best
interpreted in the context of the behaviors it was evo-
lutionarily designed to perform. Thus, it is advanta-
geous to use natural behaviors such as intraspecific
communication. Second, impairment of social percep-
tion and cognition is a core feature of the autism spec-
trum disorders (ASDs); for example, patients may have
difficulty perceiving and interpreting communication
gestures such as speech, facial expressions, and “body
language.” This broad feature is recapitulated in many
mouse models of ASD that carry genetic variants iden-
tified in human ASD populations. Therefore, if we can
ascertain the neural circuit substrates of social behavior
in normal mice, we can make and test predictions for
how the circuitry is affected in the mouse models. The
results are likely to tell us more about the synaptic mod-
ifications that occur in human autism.
There are three broad areas of research in the lab.
One concerns olfactory communication and memories
for familiar individuals. Another direction is an exam-
ination of vocal (auditory) communication between
mother mice and their pups. Our final avenue of study
involves recording from neurons in awake, behaving an-
imals to reveal the neural encoding of social cues dur-
ing a live encounter with another mouse.
Noradrenaline and Memories 
for Familiar Individuals
H. Demmer, D. Eckmeier, G. Ewall
How do we remember individuals that we have previ-
ously encountered? Substantial evidence indicates that
many animals remember each other based on olfactory
cues. Memories are especially strong for individuals en-
countered during key life events such as mating with a
new partner or the birth of a litter of young. These im-
portant events typically evoke massive release of the neu-
rochemical noradrenaline (NA), initiating a heightened
state of emotion and arousal. This surge appears to cause
long-lasting modifications to the responses to odorants
in the olfactory bulb, which is the first processing sta-
tion for scent in the mammalian brain. Indeed, it was
hypothesized that the coincidence of an odor stimulus
with a surge of NA is minimally sufficient to store a
memory. We exploited the intimate relationship between
NA, olfactory bulb activity, and behavior to create and
study olfactory memories in the anesthetized mouse. We
discovered that, indeed, when NA release is evoked by
stimulating the locus coeruleus (LC), the source of most
NA, while the sleeping mouse sniffed an odorant, neu-
ral responses to that odor underwent specific long-term
alterations. Remarkably, once awake, the mouse’s subse-
quent behavior toward the odorant was also changed. In
other words, the mouse seemed to remember the odor
and treat it as though it were familiar.
The ability to induce ethologically relevant memo-
ries under anesthesia opens up exciting possibilities for
observing the synaptic mechanisms underpinning such
memories using advanced techniques that are currently
impossible in behaving animals. For example, we are be-
ginning to use a variety of imaging approaches in ge-
netically modified mice during memory formation.
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S. Shea H. Demmer G. Ewall
D. Eckmeier M. Manglani
These experiments will allow us to separately visualize
olfactory bulb input and output as well as wide-scale
neuronal populations to ascertain how and where NA-
dependent plasticity is coordinated and interacts among
neuronal populations. We are also beginning to use
high-resolution electrophysiological techniques, targeted
to specific cell types, in order to build a circuit picture
of how different olfactory bulb cell types adapt their fir-
ing to result in long-term changes to circuit output. 
How are olfactory memories for individuals stored
mechanistically among the specific synaptic connections
of the various neuronal types in the olfactory bulb? To
answer this question, one of our group, Heike Demmer,
developed techniques for making technically challenging
targeted recordings from a specific type of inhibitory neu-
ron (granule cells) whose function remains mysterious.
She then made these recordings during the induction of
NA-dependent plasticity to examine how they contribute
to memories. The data suggest that these cells not only
participate in storing olfactory memories, but do so in
surprising and complex ways. Although we anticipated
that the granule cells might increase their activity to sup-
press responses to remembered odors, we found the op-
posite was true. One interpretation is that NA input
uncouples granule cells’ synaptic output from their ac-
tion potential firing. This unique property could be an
important factor in maintaining memory specificity. 
This year, in addition to solidifying the above findings,
Heike has begun making even more challenging and sen-
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sitive recordings from granule and mitral cells. The data
provide the first compelling evidence that naturalistic
stimulation of NA release in vivo suppresses granule cells
and alters the temporal pattern of their firing (Fig. 1), thus
relieving mitral cells from their inhibition. We believe
these findings are important clues to the fundamental
mechanisms by which NA stores memories in the olfac-
tory bulb. Disinhibition of mitral cells may be a key trig-
ger for the synaptic plasticity that likely underlies memory.
We have been testing this model using cutting-edge
optogenetics techniques to activate and inactivate iso-
lated circuit elements with light in order to establish
their causal role in the general phenomenon. We have
shown that the basic features of NA-dependent plastic-
ity can be recapitulated using light-mediated neural
stimulation to replace sensory stimulation. To follow
up, we have shown that by isolating different parts of
the olfactory bulb circuit, we can constrain the key neu-
ral activities that alter behavior. For example, we are
planning to use disinhibition of mitral cells by optoge-
netics techniques to recreate the neural dynamics that
we now know are set up by NA and assess its sufficiency
for plastic changes.
Dennis Eckmeier has been taking a different ap-
proach to observe NA-dependent memory formation
with functional neural imaging. Figure 2A shows a sam-
ple odor response image taken from the left and right
olfactory bulbs of a mouse. The dark spots show parts
of the brain that are activated by the odor. By plotting
Figure 1. LC stimulation acutely suppresses glucocorticoids (GCs). (A, Top) Average median filtered (5 ms) trace taken
from 22 stim trials of a GC recorded in the “whole cell” configuration. Stimuli were five 20-Hz bursts of five pulses
delivered at 1 Hz to LC. (A, bottom) PSTH (poststimulus time histogram) of spiking taken from the same trials. Bins =
100 ms. (B) LC stimulation acutely suppresses spontaneous firing in many GCs. Mean spontaneous firing rate in each
30-s trial is plotted for 100 trials. LC stim during the shaded period is a 5-s, 5-Hz, 50-mA train once per trial. (C) LC
stimulation acutely disrupts the phase of firing relative to inspiration in many GCs. Mean phase angle of spiking, cal-
culated as the angle of the vector sum of all spikes recorded on each 30-s trial, is plotted for 120 trials. Inspiration =
0°. LC stimulation during the shaded period is a 5-s, 5-Hz, 50-mA train once per trial. Trials that are missing a data-
point were trials that did not exhibit enough spiking activity to accurately measure phase.
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the response strength of each of these spots before and
after NA release, Dennis has shown that NA weakens
the response to paired odors. This effect is only ob-
served in the stimulated bulb (Fig. 2B). These prelimi-
nary data open the door to observing the encoding of
memories at the neural population level.
How are changes in the firing rate of olfactory bulb
neurons read out by deeper stations in the brain? It has
been hypothesized that NA may modulate behavior by
suppressing input to downstream targets that mediate
innate behavioral responses. To begin testing this hy-
pothesis, we have made recordings from some of these
deep-brain structures, including the bed nucleus of the
stria terminalis and the medial amygdala. We were able
to demonstrate that these regions respond robustly to
biologically important stimuli such as urine from the
opposite sex and predator odors. This work sets the
stage for examining how NA shapes these responses and
relating these effects to different behaviors.
Vocal Communication 
between Mothers and Pups
M. Manglani
Far outside the range of our hearing, in the ultrasound
range, mice are constantly holding conversations with
one another in a language that is poorly understood at
best. Many types of vocalizations are emitted by males
and females, juveniles and adults, in a variety of behav-
ioral contexts. We would like to better understand the
perceptual significance of these calls to the mice and
how they are used to guide behavioral choices.
One form of vocalization that is actually reasonably
well understood is the ultrasonic distress vocalization
(USV). Young mice prior to vision and full mobility
will occasionally become separated from the nest. This
is stressful for them and they will therefore call out to
their mother with a very high frequency peep. New
mothers develop sensitivity to these cries and respond
by moving toward their source (phonotaxis) to retrieve
the pup. Mothers will also approach a speaker emitting
playback of synthetic calls, providing a simple assay for
their perception of manipulated calls. Such experiments
suggest that there are sharp limits to the types of sounds
that will elicit phonotaxis, possibly implying a neural
selectivity mechanism that creates a perceptual bound-
ary between pup distress cries and other sounds and vo-
calizations. Moreover, nulliparous females who have
never given birth do not show approach responses to
pups or their calls, suggesting that the underlying neu-
ral responses may also differ.
Evidence suggests that vocal selectivity and the
changes in behavior between mothers and nulliparous
females may be related to inhibition in the auditory
cortex. We are using optogenetic inactivation of in-
hibitory cortical interneurons to test this hypothesis.
Our summer URP Monica Manglani began these ex-
periments this year and was able to show that our viral
strategy for expression of optogenetic tools is effective
and allows us to disinhibit cortical neurons, thus af-
fecting their selectivity (Fig. 3).
Neural Activity during Social Encounters
D. Eckmeier
We have begun experiments that are ultimately aimed
at recording individual neurons during social encoun-
ters and other behavioral assays involving the perception
Figure 2. LC stimulation suppresses population responses to paired odors. (A) A typical ISI (intersymbol interference)
response to cineole in the MOB (main olfactory bulb). Dark spots indicate active glomeruli. (B) Scatterplot of the re-
sponse of 83 glomeruli from seven mice, plotting post-LC stimulation response strength over pre-LC stimulation re-
sponse strength. (Black circles) From the contralateral bulb, (gray circles) from the ipsilateral bulb.
of social and nonsocial information. There are two broad
related goals to this approach. The first goal is to exam-
ine the encoding of social information such as body
odors and vocalizations in primary sensory structures of
awake animals. We hypothesize that activity in response
to these signals may be labile to associative learning, at-
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tention, and arousal, which we may be able to manipu-
late in the context of social encounters. The second goal
is to record from neurons in deep-brain neuromodula-
tory centers during these encounters as well. Neurons
that release noradrenaline and dopamine are likely re-
sponsive to social signals and may modulate encoding of
sensory data and associative plasticity. Understanding the
context-dependent activity patterns of these neurotrans-
mitters is therefore critical to developing models for how
they affect behavior.
Critical to this approach is the development of tech-
niques for observing neural activity with implantable
probes that are sufficiently lightweight and low profile
to not interfere with normal social behaviors, yet are
also stable enough to allow steady, low-noise recordings
during highly interactive behaviors such as mating. Our
initial experiments make use of fixed silicon probes
etched with a high-density array of electrical contacts.
The data show that these probes can be used to record
multiple isolated neurons in the socially significant
modulatory nucleus locus coeruleus. We are now using
these probes in awake animals to assess the structure of
LC output during social learning with high temporal
resolution.
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Figure 3. Inhibition shapes auditory cortical tuning. (Top panel)
Response of an auditory cortical neuron in a mouse in which au-
ditory cortical interneurons are expressing an optogenetic tool
that allows them to be inactivated by light. Depicted beneath are
peristimulus time histograms and tuning curves showing how
light inactivation of inhibitory neurons affects the mean response
and frequency tuning.
Heike Demmer and Steve Shea
The brain has a tremendous capacity to form different
memories. These memories are, under normal circum-
stances, highly accurate for particular stimuli and situ-
ations. This is precisely the facility that is lost in diseases
such as Alzheimer’s and other dementias. Our overall
goal is to understand how the brain forms such precise
memories: How does the specificity arise, and how does
the brain derive such tremendous capacity for forming
different memories?
We address these questions by studying olfactory
memory formation in Drosophila. Just like Pavlov’s
dogs, Drosophila learn to form associations between
smells and reward or punishment. A specific area of
the fly brain, known as the mushroom body (MB), is
essential for the flies to form olfactory memories. We
are investigating how the neural activity patterns in this
brain area are used to form specific olfactory memo-
ries. To achieve this, we monitor activity using both
electrophysiological and functional imaging tech-
niques. We have found that MB neurons exhibit highly
odor-specific responses and that activity patterns are
relatively sparse across the population of MB neurons.
This specificity is thought to underlie the accuracy of
memory because modifying the synapses of highly
odor-specific neurons would lead to relatively precise
memories. Sparse representations by highly stimulus-
specific neurons are a general feature of brain areas in-
volved in learning and memory, including hippocam-
pus and cerebellum.
Using the simplicity and genetic manipulability of
Drosophila, our goal is to understand several funda-
mental properties of neural responses in learning- and
memory-related brain areas: What mechanisms give rise
to the stimulus specificity? What exactly is meaningful
about the activity patterns: Is it simply which cells re-
spond or does the precise timing of activity matter?
How are these response patterns modified by learning?
And ultimately, what is the role of the many genes im-
plicated in learning with respect to network-level ac-
tivity in the brain?
Robust Sparse Coding in the MB 
K. Honegger, R. Campbell 
Theoretical studies indicate that sparse representations
are useful for learning and memory. However, it is cru-
cial to distinguish between truly sparse representations
and simply weak responses observed because the stim-
uli tested are suboptimal (i.e., not those the system
evolved to detect) or because strongly responsive cells
are spatially segregated. In this study, we used imaging
to establish that odor representations are genuinely
sparse in the MB. We showed that natural stimuli that
have intrinsic meaning to the fly do not elicit qualita-
tively distinct responses from artificial, monomolecu-
lar odors. Additionally, there is no evident spatial
segregation of responses which would suggest that ol-
factory information is channeled into distinct anatom-
ical pathways. Rather, odors evoke responses in a small
fraction of the MB population, with cells randomly dis-
tributed throughout the MB. 
This format is likely to be useful for memory storage
and recall. It is a simple way to minimize the overlap be-
tween representations of different stimuli: If each odor
evokes a response in 10% of the MB neurons, and for
each odor, the 10% are randomly distributed across the
population, the representation of any two odors will
overlap by only 1%. Consequently, any changes in the
properties of neurons that respond to one of the odors
should only have a tiny effect on the representations of
other odors. Overall, this format optimizes the circuit
to form accurate memories with specific odors. We ex-
amined this explicitly in the next project. 
MB Population Responses Predict
the Specificity of Olfactory Learning
R. Campbell, K. Honegger, E. Demir, H. Qin, W. Li
Do the neuronal response patterns in the MB convey
the specificity of memory formation? If so, what  fea-
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G. Turner R. Campbell T. Hige
E. Gruntman K. Honegger
tures of neural activity underlie that specificity? To ad-
dress these fundamental questions, we tested whether
we could use the activity patterns we measure in the
MB to predict the odor specificity of flies’ memories.
We examined this in two contexts: when flies learn 
(1) fine discriminations between highly similar odors
and (2) an association with one odor and then they 
generalize that association to a different but related
odor. 
To assess the odor specificity of the memories, we
used the standard Pavlovian conditioning protocol,
training flies to form an association with one odor
and testing the specificity of those memories by giv-
ing flies a choice between that odor and a second,
similar but distinct, odor. We compared this behav-
ioral measure with the specificity of the response pat-
tern of ~150 MB neurons to these odors. We found
that the MB activity patterns accurately predict the
specificity of memory formation. This prediction held
true even as we approached the limit of how accu-
rately flies learn. 
To evaluate the features of neural activity that un-
derlie accurate memory formation, we developed tech-
niques to track activity of ~80% of the 2000 neurons
in the MB. The unprecedented scope of these experi-
ments enabled us to find the small differences between
different odor representations. We found that, even
when flies are forced to choose between two odors that
are near the limit of their discrimination ability, there
are neurons that respond to only one odor of the pair,
so that binary differences are present between the two
odor representations. These differences are sufficient
to train a biologically realistic model network to re-
spond specifically to different odors. Two important
conclusions from this study are that (1) although re-
sponse patterns in the olfactory receptor neurons
(ORNs) differ in the relative levels of activity across
different ORNs (analog coding), these differences are
converted into simple on/off (binary) differences in re-
sponse patterns at the MB and (2) a simple learning
scheme of changing synaptic strength of all neurons
that respond to an odor is sufficient to accurately de-
termine odor identity.
These results show how a simple coding scheme can
enable accurate but generalizable memory formation.
They also suggest that it may be possible to restore
memories with coarse interventions that simply drive
neurons to respond and that precise control of spike
timing may not be needed. 
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Integrating the Olfactory Combinatorial
Code at the Dendrites of MB Neurons
E. Gruntman
How is it possible to recognize an odor as a unified
smell (e.g., coffee) when it is composed of so many dif-
ferent components? One idea is that ORNs in the nose
(fly’s antennae) each recognize a particular feature of an
odor, and the overall combination of activated ORNs
conveys the identity of the odor. For this combinator-
ial coding scheme to work, there must be neurons at
deeper layers of the brain that respond to specific com-
binations of coactive inputs. In this work, we show it is
the MB neurons that read the combinatorial code of
the earlier layers of the system. 
We addressed this issue by examining odor responses
of individual dendritic input sites on the MB neurons,
making this one of only a handful of studies to exam-
ine sensory responses of dendrites in vivo. To achieve
this, we expressed a calcium-sensitive fluorescent pro-
tein in single MB neurons and then used two-photon
imaging to examine the responses of each dendritic site
to a panel of different odors. Using this approach, we
could construct an odor-tuning curve for each dendritic
input site. By comparing tuning curves for different
dendritic sites, we directly showed that some MB neu-
rons integrate combinations of different inputs. We also
find evidence that, for a small fraction of MB neurons,
all of the inputs are identical. These neurons may act as
amplifiers, summing up weak but identical signals from
multiple synaptic contact sites. 
We have also devised an approach to test whether
multiple different inputs must be active in order to
drive the MB neuron to spike. Our early results here
suggest an elegant explanation for why MB neurons are
so odor-selective: They not only receive different types
of inputs, but they require those different inputs to be
coactive in order for the MB neuron to spike. 
Decoding Sparse Representations
T. Hige 
Sparse representations are useful for learning and mem-
ory, but how do downstream neurons integrate this in-
formation? Ultimately, the information in layers with
sparse representations must be converted into a behav-
ioral response. How does this process occur, and how
do neurons downstream from a sparsely responding
brain area integrate that information? 
In Drosophila, this process appears to occur imme-
diately after the MB, as the 2000 MB neurons con-
verge onto an estimated 75 output neurons. Individual
members of this output population can be labeled with
green fluorescent protein (GFP) using the genetic tools
available in Drosophila, making this an excellent sys-
tem to determine the basic principles of information
processing downstream from sparse representations.
Using GFP-targeted intracellular recordings, we have
characterized the odor responses of one of these MB
output neurons. In contrast to the highly odor-specific
tuning of MB neurons, this output cell responds to a
broad array of different odors. These functional prop-
erties are reflected in the cell’s anatomy: It has very ex-
tensive dendritic processes within the output lobes of
the MB, suggesting that it receives highly convergent
input from many MB neurons. Although the neuron
responds to almost all tested odors, it nevertheless re-
sponds distinctly to different odors, suggesting that
this neuron is capable of carrying odor-specific infor-
mation. However, the odor-tuning properties of this
neuron vary  between individual flies; the same neuron
has very different tuning curve shapes in different an-
imals. One explanation for this variability is that it re-
flects synaptic plasticity operating on a developmental
timescale. Our working hypothesis is that the tuning
curves of the MB output neurons are a product of the
prior olfactory experience of the individual fly. We are
currently testing this by examining the role of olfac-
tory experience in shaping the response properties of
these neurons. 
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My laboratory is interested in how neural circuits un-
derlie normal processing and attention in the auditory
cortex, and how this processing is disrupted in cognitive
disorders such as autism. To address these questions, we
use a combination of computational, electrophysiolog-
ical, and imaging techniques at the molecular, synap-
tic, cellular, circuit, and behavioral levels.
Sequencing the Connectome
G. Cao, H. Oyibo, S. Peikon, H. Zhan [in collaboration
with J. Dubnau and L. Enquist, Cold Spring Harbor
Laboratory]
The brain is a complex network, consisting of billions of
neurons connected by trillions of synapses. The details
of these connections—which neurons form synaptic
connections with which other neurons—are crucial in
determining brain function. Malformation of connec-
tions during prenatal and early postnatal development
can lead to mental retardation, autism, or schizophre-
nia; loss of specific connections later in life is associated
with neurodegenerative diseases such as Alzheimer’s. An
efficient method for determining the brain’s wiring dia-
gram would transform neuroscience research. 
Inspired in part by the success of the Allen Brain
Atlas, the human genome project and other major ef-
forts, there is growing excitement in neuroscience to de-
termine the complete connectivity diagram—the
“connectome”—of the brain. So far, the complete con-
nectome has been established for only one organism, the
tiny worm Caenorhabditis elegans, with 302 neurons
connected by ~7000 synapses. However, determining
the connectome of even this simple nervous system was
a heroic task, requiring more than 50 person-years of
labor to collect and analyze the electron micrographs.
All current approaches to determining the connectome
are based on microscopy. Unfortunately, microscopy is
poorly suited to the study of neural connectivity because
brains are macroscopic structures, whereas the synaptic
connections between neurons require electron micros-
copy. Reconstructing the complete wiring diagram of
such a brain is akin to piecing together the complete road-
map of the United States from a collection of postage-
stamp-sized photographs. 
To circumvent the considerable challenges associated
with determining the connectome based on microscopy,
we are developing an entirely novel approach based on
high-throughput DNA sequencing technology. Se-
quencing technology has not previously been applied in
the context of neural connectivity. The appeal of using se-
quencing is that it is already fast—sequencing hundreds
of millions of individual pieces of DNA in a single day
is now routine—and, like microprocessor technology,
getting faster exponentially. Moreover, the cost of se-
quencing is plummeting: Predictions are that it will be
possible to sequence an entire human genome (~3B nu-
cleotides) for $1000 within a few years. Thus, by con-
verting brain connectivity from a problem of microscopy
to a problem of sequencing, we render it tractable using
current techniques.
An inexpensive and rapid method for deciphering
the wiring diagram of a neural circuit of an entire brain
would have a profound impact on neuroscience re-
search. Knowing the neuronal wiring diagram would
provide a foundation for understanding neuronal func-
tion and development, in the same way that knowing
the complete genomic sequence provides the starting
point for much of modern biological research in the
postgenomic era. Moreover, many neuropsychiatric
diseases such as autism and schizophrenia are thought
to result from disrupted neuronal connectivity, but
identifying the disruptions even in mouse models is a
major challenge given current technology. Our ap-
proach may help to usher in an era when understand-
ing the connectivity of a new mouse model of neuro-
psychiatric disease is the routine first step to analyzing
its deficits. 
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Disruption of Auditory Cortical Circuits
by Autism Candidate Genes
Q. Xiong, H. Oviedo
Autism is a highly heritable disorder thought to arise
through disruption of neural circuits. Many candidate
genes have been implicated, but how these genes lead to
the autistic phenotype remains unclear. We hypothe-
size that the circuit defect underlying autism involves an
imbalance between excitatory and inhibitory neural ac-
tivity. To test this hypothesis, we are using in vitro and
in vivo methods to assess circuit dysfunction in the au-
ditory cortex. We recently found that the autism can-
didate gene PTEN disrupts local and long-range con-
nections (Xiong et al. 2012). 
Role of Interneurons in Auditory
Cortex Function
A. Reid, T. Hromadka
Fast synaptic inputs to neurons in the auditory cortex are
either inhibitory or excitatory. Cortical interneurons are
tremendously diverse. One interneuron subclass, defined
molecularly by the expression of parvalbumin (“PV+”),
seems ideally positioned to mediate the fast component
of the characteristic barrage of inhibition elicited by a
sound. We are testing the hypothesis that PV+ inhibitory
interneurons mediate fast sound-evoked inhibitory
synaptic currents in the auditory cortex. 
Our proposal seeks to establish a causal link between
a physiological property—the fast sound-evoked inhibi-
tion that contributes to receptive field dynamics—and a
component of the underlying cortical circuitry. We ap-
proach the problem at three different levels, from brain
slices through in vivo physiology to behavior. Although
we are currently focusing on the role of one particular
interneuron subclass (PV+), our approach combining
electrophysiological and molecular tools can readily be
generalized to other subclasses and can be extended to
probe the circuitry underlying other sensory and behav-
iorally elicited neuronal responses.
Processing of Spatial Information
in the Auditory Cortex
S. Koh
In vision and somatosensation, spatial information is
already present at the receptor level. In audition, spatial
information is not available at the cochlear level and
must be computed using information from both hemi-
spheres. A subpopulation of neurons in the primary au-
ditory cortex conveys sound location and sound mo-
tion information, but little is known at the neural
circuit level because of technical difficulties of identify-
ing neurons during in vivo recordings.
We have previously developed a technique called
PINP (photostimulation-assisted identification of neu-
ronal populations) which allows us to “tag” subpopula-
tions of neurons based on their axonal projections. The
tag is a light-gated ion channel, channelrhodopsin-2
(ChR2), that can be triggered by a brief flash of blue
laser with millisecond precision. We inject herpes sim-
plex virus (HSV), which can be taken up by axons and
travels in a retrograde fashion, in order to deliver ChR2
specifically to the neurons projecting to the infected
area. ChR2-tagged neurons can be identified during in
vivo recording by responsiveness to a flash of blue light.
We are using PINP to test the hypothesis that layer-
3 ACx neurons projecting to the contralateral ACx are
more sensitive to auditory spatial information than
other subpopulations in ACx. Layer-3 neurons seem to
be ideal candidates, deduced from the facts that (1)
many layer-3 ACx cells project to contralateral ACx,
unlike visual and somatosensory cortex where layer-3
cells predominantly project to ipsilateral cortical areas,
and (2) processing of spatial information requires in-
puts from both hemispheres.
Circuits Underlying Auditory
Representations and Decisions
S. Jaramillo, P. Znamenskiy, K. Borges
We are studying the circuits underlying auditory repre-
sentations and how these representations give rise to deci-
sions. We train rats and mice to perform well-controlled
auditory tasks and then use electrical and optogenetic
methods to monitor and perturb neural activity. Using this
approach, we recently found that the auditory cortex me-
diates the perceptual effects of acoustic temporal expecta-
tion (Jaramillo and Zador 2011). We are now extending
this approach to study the role of the auditory thalamus,
cortex, and striatum in these behavioral processes.
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Olfactory Trace Conditioning
in the Fruit Fly
Y. Shuai
Trace conditioning is a simple experimental model to
assess how the brain associates events that are discrete
in time. To study trace conditioning in the fruit fly, we
trained the animals to avoid an odor that is followed
by foot shock many seconds later. The molecular mech-
anisms of this form of learning are surprisingly distinct
from the well-characterized simultaneous condition-
ing, where odor and punishment temporally overlap.
First, rutabaga adenylylcyclase (Rut-AC), a putative
molecular coincidence detector vital for simultaneous
conditioning, is dispensable in trace conditioning. Sec-
ond, dominant-negative Rac expression, thought to
sustain early labile memory, significantly enhances
learning of trace conditioning, but it leaves simultane-
ous conditioning unaffected. Targeting Rac inhibition
to the mushroom body (MB) suffices to achieve the en-
hancement effect, which suggests the MB as a crucial
neuroanatomical locus for trace conditioning. We show
in a working model that the MB may harbor a Rac ac-
tivity-sensitive olfactory “sensory buffer,” which bridges
the temporal gap between odor and foot shock in trace
conditioning. Live animal imaging is now being ap-
plied to characterize the nature of this putative sensory
memory.
Value Coding in the Drosophila
Brain
J. Beshel
Odors are highly evocative, yet how and where in the
brain odors derive meaning remains unknown. We first
established Drosophila’s partiality for differing food
odors and then showed that odor-evoked activity of neu-
rons located outside of the canonical olfactory system
precisely determines odor value. In vivo two-photon cal-
cium imaging of the fly brain revealed that the respon-
siveness of Drosophila neuropeptide F (dNPF), the
neuropeptide Y homolog, was much greater to food
odors than to nonfood odors, including food-odor com-
ponents. Moreover, hunger similarly elevates neural and
behavioral food-odor responses. Remarkably, these neu-
rons are not only necessary, sufficient, and specific to
food-odor attraction, but the amount of activity exactly
defines attraction level to, and even preference between,
individual food odors. We thus demonstrated the exis-
tence of a motivationally scaled neural “value signal” ac-
cessible from uniquely identifiable cells. Responses are
graded within a specific class of stimuli and stable across
individuals, making precise predictions about behavior
possible.
NF1 and Memory in Drosophila
C. Xu
The ras/mek/MAPK (mitogen-activated protein kinase)
pathway has been implicated as an important pathway
for cognitive function by linkage mapping studies. Neu-
rofibromatosis type 1 (NF1) is a single-gene disorder
caused by mutations in the gene neurofibromin (NF1).
NF1 encodes the GAP domain and thus functions as a
negative regulator of the ras pathway. Drosophila melano-
gaster has an NF1 gene that shares high similarity with
the human NF1 gene. NF1-null mutant flies have both
short- and long-term memory defects, and the defects
can be rescued by reexpressing the NF1 gene construct
specifically in the MB—the memory center for flies.
Overexpression of dominant-negative ras postdevelop-
mentally in the MB also severely affects long-term mem-
ory, suggesting that the manner in which NF1 has been
involved in the long-term memory process is ras-path-
way dependent. MAPK has been shown to have a criti-
cal role in LTP (long-term potentiation) formation and
memory processes. NF1-null mutants have abnormally
high MAPK activity, which suggests that the long-term
memory defects in NF1 mutant flies is probably caused
by MAPK disregulation. We are currently investigating
how MAPK is regulated during memory processes and
the role of NF1 in the long-term memory process.
NEURAL BASIS OF LEARNING AND MEMORY IN DROSOPHILA
Y. Zhong J. Beshel A. Sodsiri
Y. Shuai C. Xu
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Drosophila as a Model to Study
Nonsyndromic Mental Retardation
A. Sodsiri
ARHGEF6 is one of the genes that have been linked to
nonsyndromic mental retardation. It encodes Rho-type
guanine nucleotide exchange factor (Rho-GEF), which
can switch on Rho GTPases by mediating the exchange of
GDP for GTP. A Drosophila homolog of this gene, dPix,
has been shown to regulate postsynaptic structure and
protein localization at the Drosophila neuromuscular junc-
tion. We set out to study the role of Rho-GEF in learn-
ing and memory in Drosophila and to characterize the
regions in the fly brain whereby dPix functions. In our
preliminary study, we found that mutation in dPix or
knocking down of dPix by RNA interference (RNAi) pro-
duces learning deficits in Drosophila. Moreover, knocking
down of dPix in the MB throughout development causes
the fly to have a significantly smaller MB, which might ex-
plain the observed learning deficit because the MB is the
central site for associative learning. Investigation into these
behavioral and anatomical phenotypes will give insight
into mechanisms underlying learning disabilities seen in
patients with nonsyndromic mental retardation.
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Uncovering the molecular processes governing how plants grow and develop is of fundamental bi-
ological interest and importance, with vital implications both for agriculture and human health.
Plant genetics has had a major role in the advance of all areas of research at CSHL almost since the
Laboratory’s inception and is epitomized by the work of Nobel laureate Barbara McClintock, who
discovered transposable genetic elements in her work on maize in the 1940s. Plant geneticists at
CSHL have been among the leaders of efforts to sequence the first plant genomes, and they con-
tinue to be at the center of sequencing and genome-annotation projects involving a wide range of
cereal crops that feed the planet’s growing population. CSHL plant geneticists also have been pio-
neers in the study of RNA interference, stem cell research, and, most recently, efforts to spur the de-
velopment of next-generation biofuels and related alternative energy sources.
David Jackson and colleagues study genes and signals that regulate plant growth and architecture.
They are investigating a unique way in which plant cells communicate, by transporting regulatory
proteins via small channels called plasmodesmata. These channels, which direct the flow of nutri-
ents and signals through growing tissues, are regulated during development. The team discovered a
chaperone protein-encoding gene, CCT8, that controls the transport of a transcription factor,
KNOTTED1, between cells in the plant stem cell niche, or meristem. KNOTTED1 is critical for
stem cell maintenance, and studies of the CCT8 gene indicate that movement of KNOTTED1 be-
tween cells is required for this function. The lab also continues to identify other genes that control
plant architecture through effects on stem cell maintenance and identity. Recent examples include
discovery of a subunit of a heterotrimeric G protein that is conserved throughout animals and plants,
and these studies indicate that this gene controls stem cell proliferation. A second example is the
identification of the gene GRASSY TILLERS1 that appears to have been instrumental in the do-
mestication of the corn plant, a process that led to the development of agriculture almost 10,000
years ago. This past year, the Jackson team demonstrated that gt1 expression is associated with the
suppression of tiller growth and amassed evidence indicating that gt1 was specifically (if unwit-
tingly) selected by ancient agriculturalists in their attempts to domesticate teosinte. Separately, the
lab has characterized system-wide networks of gene expression in inflorescence development, using
“next-gen” profiling methods, and is developing a collection of maize lines that can drive expression
of any reporter or experimental gene in any tissue type. These tools are of great interest to maize re-
searchers and are being made available to the broader scientific community, enabling experiments
never before possible in crop plants.
Zach Lippman’s research focuses on identifying genes that cause tomato plants to produce their
flowers in an elegant repetitive zigzag arrangement on a branching structure called an “inflores-
cence.” Proceeding from a base of knowledge that they have built regarding a universal growth habit
represented by tomato, called sympodial growth, Lippman’s lab is addressing the question of zigzag
flower patterning by focusing on the fundamental question of how plants are able to stop making
leaves and start making flowers. Of particular interest is how these “reproductive phase transitions”
have contributed to the evolution of diverse inflorescence branching patterns in the tomato’s larger
Solanaceae family, which includes plants that make just one flower in each inflorescence, to plants
whose inflorescences produce dozens of branches and hundreds of flowers. Using classical and mod-
ern genetic techniques, Lippman is dissecting the gene networks that are responsible for the varia-
tion in inflorescence branching found in nature. He hopes to leverage these discoveries to improve
crop yields in several solanaceous plants such as pepper, eggplant, and potato. Already, a collabora-
tion between Lippman’s group and scientists at Hebrew University has identified a gene called flori-
gen that is responsible for making flowers in plants and can be altered using simple genetic tricks to
push hybrid tomato plants to increase their yield by as much as 60%. This past year, the lab used a
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systems biology approach and next-generation sequencing technology to capture the transcriptome
of stem cells at five different stages of maturation, which enabled the team to identify nearly 4000
genes that represent the “maturation clock” in tomato plants.
Epigenetic mechanisms of gene regulation—chemical and conformational changes to DNA and
the chromatin that bundles it—have important impacts on genome organization and inheritance as
well as on cell fate. These mechanisms are conserved in eukaryotes and provide an additional layer
of information superimposed on the genetic code. Robert Martienssen, a pioneer in the study of epi-
genetics, investigates mechanisms involved in gene regulation and stem cell fate in yeast and model
plants including Arabidopsis and maize. He and colleagues have shed light on a phenomenon called
position-effect variegation, caused by inactivation of a gene positioned near densely packed chro-
mosomal material called heterochromatin. They have found that heterochromatin is programmed
by small RNA molecules arising from repeating genetic sequences. Recently, Martienssen and col-
leagues described a remarkable process by which “companion cells” to sperm in plant pollen grains
provide them with instructions that protect sperm DNA from transposon damage. With collabo-
rators in Mexico, Martienssen has also coaxed Arabidopsis, a flowering plant, to produce egg cells
without meiosis, an important step toward a long-time goal of plant breeding: generating clonal off-
spring to perpetuate hybrid vigor. This past year, the lab published research revealing that when
RNA polymerase II has transcribed a stretch of DNA, the RNAi mechanism causes the enzyme to
release its hold on the DNA and fall away. This allows the replication fork to progress smoothly and
the DNA strands to be copied; histone-modifying proteins, which follow right along, establish het-
erochromatin. Martienssen’s group also continues to work on problems related to the creation of
plant-based biofuels.
The growing tips of plants, called meristems, contain a population of stem cells that serve as a per-
sistent source of daughter cells from which new organs arise. They also produce signals important
for the determination and patterning of lateral organs. Marja Timmermans and colleagues are using
a genomic approach to study genes active in the meristem. They have also used mutational analyses
to unravel the mechanism that suppresses stem cell fate during organ development. They have shown
that this process requires a highly conserved epigenetic mechanism. In particular, they have found
that the chromatin-remodeling factor HIRA, through interaction with specific DNA-binding pro-
teins, mediates the recruitment of Polycomb repressive complexes to stem cell factors, an action that
stably represses their expression in differentiating organs. The lab has also identified regulatory mech-
anisms that allow for the precise spatial accumulation of developmentally important small RNAs in
plants. This work has revealed that polarity in leaves is established via opposing gradients of mobile
small RNAs that act as morphogen-like signals. The lab’s most recent findings identified a third small
RNA gradient involved in maintenance of organ polarity, illustrating the complexity with which
small RNAs generate developmental patterns. Mathematical modeling suggests that such opposing
small RNA gradients might serve to generate robustness during development.
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Our research aims to identify genes, signals, and path-
ways that regulate plant growth and development. All or-
ganisms develop by carefully controlling the flow of
information (“signals”) that passes between cells and tis-
sues. We are particularly interested in discovering these
signals and finding out how they are transmitted and
how they function. As an example, we have identified
genes that control how plant cells communicate with
each other through small channels, called plasmodes-
mata. These channels were described in plants more than
100 years ago, but their central importance and how they
are regulated are just beginning to emerge. Plasmo des-
mata are critical for plant growth because they allow the
passage of nutrients and signals through growing tissues.
We have elucidated an important mechanism by which
transport through these channels is controlled via a chap-
eronin gene that regulates the specific transport of a tran-
scription factor, KNOTTED1 (KN1). This factor is a
homeodomain protein that is expressed in the plant stem
cells and is necessary to keep these cells in a pluripotent
state. We found that KN1 function depends on chaper-
onin activity, highlighting the importance of cell-to-cell
trafficking in plant stem cell function.
We also continue to identify maize genes with novel
roles in shoot development and plant architecture. We
have recently identified genes that control branching,
stem cell proliferation, and leaf growth. One of these,
compact plant2 (CT2), encodes a subunit of a het-
erotrimeric G protein that has previously not been
linked with stem cell proliferation in plants. Studies of
CT2 have identified a novel signaling pathway that con-
trols stem cell proliferation. Other newly identified
genes include those controlling maize branching in re-
sponse to light signals and maize ear size. Finally, we
continue to develop a collection of fluorescent-protein-
tagged maize lines that are an essential resource for all
maize researchers. This is the first collection of its kind
and promises to enhance maize genetics research
through characterization of developmental gene path-
ways and identification of maize promoters that can be
used in crop improvement.
Characterization of a Dominant
Phyllotaxy Mutant, Abphyl2,
in Maize
F. Yang, A. Kolbe, D. Jackson [in collaboration with 
D.V. Llaca and H. Sakai, DuPont Crop Genetics, 
Wilmington, Delaware]
Plant morphology and diversity are largely dependent on
phyllotaxy, which is the geometric arrangement of new
primordia formed by the shoot apical meristem (SAM).
Biologists and mathematicians have wondered for cen-
turies how these patterns, such as the beautiful sunflower
head spirals, are generated. Recent studies found that a
plant hormone, auxin, and its polar transport by PIN-
FORMED1 (PIN1) proteins, is crucial for controlling
phyllotactic patterns. Recently, our studies on ABPHYL1
in maize have shown that cytokinin hormone signaling,
as well as its cross-talk with auxin, have an important role
in this process. abphyl1 (abph1) mutations change maize
phyllotaxy from alternate to decussate. Here, we describe
a similar phyllotaxy mutant, Abph2. Abph2 is dominant,
and it originated from a Chinese inbred line and has a
decussate leaf pattern that becomes visible at the four-
to-five leaf stage. Map-based cloning located the Abph2
locus to a region of ~ 20 kb on chromosome 7, contain-
ing five predicted genes in the reference B73 genome.
However, sequencing of the open reading frames (ORFs)
of these five genes, as well as their transcript level analy-
sis by RT-PCR (reverse transcriptase−polymerase chain
 reaction), did not give any obvious clues as to the iden-
tity of the Abph2 gene. Given the dynamic nature of the
maize genome, we hypothesized that a gene not present
in the reference B73 genome could be responsible for the
Abph2 phenotype. We therefore made a bacterial artifi-
cial chromosome (BAC) library from the Abph2mutant
and screened it using probes located within the 20-kb
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 mapping interval. We identified a positive clone that cov-
ered the entire interval, and BAC sequencing revealed a
4.5-kb fragment inserted into the mapping interval rel-
ative to the B73 reference genome. This inserted frag-
ment contained a predicted glutaredoxin (GRX) gene that
was identical to a gene located ~800 kb distal in the B73
genome. To determine whether the transposed 4.5-kb
fragment was responsible for the Abph2 phenotype, we
made maize transgenic lines containing this 4.5-kb re-
gion with yellow fluorescent protein (YFP) fused to the
GRX-coding sequence. These transgenic lines pheno-
copied the Abph2 phyllotaxy phenotypes, demonstrat-
ing that this GRX gene is the cause of the decussate leaf
phenotype. Meanwhile, knockout lines of the dominant
Abph2 mutation were generated by EMS (ethyl-
methanesulfonate) mutagenesis. Sequencing the GRX
gene in these knockout lines found point mutations lead-
ing to conserved amino acid changes in two independ-
ent lines, further supporting the idea that the transposed
GRX gene is responsible for the Abph2 phenotype. 
RNA in situ hybridization was used to localize Abph2
transcripts, which accumulate in the P zero (P0) leaf ini-
tiation site and vasculature in vegetative meristems (Fig.
1). More careful investigation showed that Abph2 is ex-
pressed first in the leaf vasculature at 20 days after polli-
nation, and later on, it becomes localized to the P0.
Further analysis will focus on how this transposed GRX
gene changes the leaf pattern as well as the meristem size.
Finally, informed by the fact that auxin patterning and
PIN1 maxima in the leaf initiation site are diminished
in abph1, we are currently analyzing auxin distribution in
Abph2 meristems, using PIN1-YFP and DR5-RFP (red
fluorescent protein) as markers. Preliminary analysis re-
vealed that the expression of PIN1 in the Abph2 SAM
appears to be decreased, suggesting a common mecha-
nism by which these mutants control phyllotaxy. 
Regulation of the Cell-to-Cell
Trafficking of the Transcription
Factor KNOTTED1
X.M. Xu, R.T. Morales, V. Galvan
Cell-to-cell communication functions in specifying cell
fate and coordinating development in all multicellular
organisms. A special paradigm for such communication
in plants is the selective trafficking of signaling macro-
molecules, e.g., transcription factors and small RNAs
through plasmodesmata (PDs), channels that traverse the
cell wall and connect all plant cells. In addition to cell-
fate specification, PDs are also involved in viral move-
ment, transport of metabolites, and cell-to-cell spread of
RNA interference (RNAi), which points to their funda-
mental importance in coordinating plant defense, me-
tabolism, and development. Despite the discovery of PD
more than 100 years ago, and our increasing recognition
of their functional significance, the underlying compo-
nents and mechanisms of PD trafficking remain poorly
understood. Hence, we are taking an unbiased genetic
strategy to dissect these molecular components and
mechanisms, using a transgenic reporter system. We used
this system to identify mutants that affect KN1 trans-
port. One mutant that we have identified encodes a
chaperonin. Genetic interaction data provide evidence
that the endogenous function of KN1-related genes in
Arabidopsis requires chaperonin, clearly supporting the
functional relevance of chaperonin-mediated trafficking
through PD (Fig. 2). Our results suggest that chaperonin
dependency is a general mechanism for protein traffick-
ing and highlight the importance of conformational
changes for PD trafficking. Current efforts are focused
on isolation of additional mutants and their identifica-
tion by next-generation sequencing. 
Figure 1. Highly localized expression of ABPHYL2 in “P zero”
domains of the shoot apical meristem.
Figure 2.An Arabidopsis double mutant, between a weak shoot-
meristemless allele and the cct8 mutant, shows enhanced stem
cell defects.
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Illuminating Maize Biology: Using
Fluorescent Proteins for High-
Throughput Analysis of Protein
Localization and Function in Maize
S. DeBlasio, A. Goldschmidt, T. Zadrozny, J. Wang
[in collaboration with A. Chan, J. Craig Venter Institute; 
A. Sylvester, University of Wyoming]
Recent advances in sequencing technology have gener-
ated thousands of publicly available genome sequences
from nearly all groups of organisms. These massive data
sets have revolutionized the types of biological ques-
tions that can now be addressed. A continued challenge
is to ascribe function to the high percentages of pre-
dicted proteins and proteins of unknown function. De-
spite the ability to predict the function of some proteins
by comparative bioinformatics, experimental validation
remains necessary to assign function definitively. One
of the most effective approaches to validate gene func-
tion is to develop visualization and biochemical tools
associated with fluorescent protein (FP) technology. 
When exposed to light, FPs fused to a protein or reg-
ulatory element fluoresce, making the attached normally
invisible protein visible and easy to track under a micro-
scope. Because of their relatively small size, FP fusions
rarely interfere with native protein targeting, function,
and trafficking. Thus, FP technology is a powerful tool
that can be used to noninvasively mark protein expres-
sion and localization to study various subcellular
processes, in vivo in real time. We have successfully op-
timized this technology for maize and have created a
public resource of cellular biomarkers that we and other
members of the plant community use both for small-
scale analysis of individual genes and for global expres-
sion and functional profiling. To date, we have generated
more than 100 stable, natively expressed, maize FP fusion
lines that highlight most subcellular compartments and
allow us to study various cellular pathways including hor-
mone signaling, cytoskeletal behavior, vesicle trafficking,
and stem cell maintenance and differentiation. We are
also using these lines to immunoprecipitate tagged pro-
teins to identify previously uncharacterized components
of these important pathways. In the case of FP-tagged
transcriptional regulators, chromatin immunoprecipita-
tion (ChIP) is being used to identify putative DNA-
binding sites and/or to confirm gene targets that have
been detected by transcriptional profiling of the respec-
tive mutant. 
To study maize development on a broader scale, we
are optimizing the LhG4 two-component trans-activa-
tion expression system for use in maize. This system
 relies on the transcription factor LhG4 being expressed
by a cell or tissue-specific promoter to drive the expres-
sion of a reporter in trans, via the pOp-binding sites.
The reporter can be any gene, such as GUS, FPs, an FP
fusion protein, a gene of interest for tissue-specific ex-
pression, a silencing construct for transcriptional knock-
downs, or a gene encoding a toxin for tissue ablation
experiments. We have already generated an overexpres-
sion promoter construct and are currently working to
create several meristem- and leaf-specific LhG4 drivers,
including pRAMOSA3, pWUSCHEL, and pYABBY14.
Our goal is to produce an array of cell- and tissue-specific
LhG4 lines, which we will use to (1) isolate specific cell
types by fluorescence-activated cell sorting (FACS) for
transcriptional profiling and (2) drive the misexpression
of developmentally regulated genes such as RAMOSA3 in
order to better understand the changes that occur within
stem cell niches during differentiation and development.
Data on the characterization of our FP and LhG4 trans-
genic lines, including confocal  micrographs, movies, and
recent publications, can be found on our website, http://
maize.jcvi.org/cellgenomics/index.shtml.
Quantitative Variation in Maize
Kernel Row Number Is Controlled
by the FASCIATED EAR2
Locus of Maize 
P. Bommert [in collaboration with M. Komatsu and
H. Sakai, DuPont Crop Genetics]
Plant growth and development are dependent on meri-
stems, stem cell populations that serve to maintain inde-
terminate stem cells for organ initation throughout the
life cycle. Although we know a lot about the pathways
that control stem cell maintenance and proliferation, lit-
tle is known about how variation in these pathways
might contribute to quantitative variation in plant
growth or yield. The variation in kernel rows in maize is
controlled by the number of axillary meristems that are
formed on the flanks of the inflorescence meri stem (IM),
which is located at the tip of the developing ear primor-
dia. Many studies have identified small regions in the
genome for maize kernel row number (KRN), but the
genes within those regions and the molecular mechanism
underlying this variation are largely unknown. Kernels
are initiated following initiation and development of ax-
illary spikelet pair meristems (SPMs), which divide once
to form two spikelet meristems (SMs), each of which
gives rise to floral meristems that will produce a single
kernel after pollination. A simple hypothesis is that an
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increase in the size of the IM would provide more avail-
able space for SPM initiation, and hence a higher KRN.
Indeed, when we compared two standard inbred lines of
maize, B73 and Mo17, we found that B73, which has a
higher KRN, also has a larger IM. To further test our hy-
pothesis, we dissected immature ear primordia from a
number of maize inbred lines and measured IM diame-
ter. The mean IM diameter varied between lines from
~170 mm to ~340 mm, and mean KRN varied from 10
to 20 rows. We found a significant positive correlation
between IM diameter and KRN, in which variation in
IM diameter explained ~60% of the variation in kernel
row number. To understand the genetic contribution to
the variation in maize KRN, we performed quantitative
trait locus (QTL) mapping. We grew the intermated
B73xMo17 (IBM) population in 3 successive years.
KRN was counted from ears from ~200 recombinant in-
bred lines per year. The mean KRN for the parental lines
was 16 for B73 and 12 for Mo17, and in the RILs, the
mean KRN was 14. QTL positions were mapped using
composite interval mapping. One QTL on chromosome
4 was found in each year and explained ~6%−8.5% of
the KRN variation, with a positive effect from the B73
allele. Interestingly, this region contains a candidate gene,
FASCIATED EAR2 (FEA2). fea2 null mutants have a sig-
nificant impact on the kernel row number; the ears are
highly disorganized with a massively overproliferated IM
and up to 40 or more irregular kernel rows. FEA2 en-
codes the maize ortholog of CLAVATA2 (CLV2), a
leucine-rich repeat receptor-like protein that is involved
in regulation of stem cell number by transmitting signals
from the CLAVATA3 peptide ligand to repress the tran-
scription of the WUSCHEL homeodomain transcrip-
tion factor. We further substantiated these findings by
isolating new, weak alleles of fea2 that would allow us to
ask if subtle variation in FEA2 might affect KRN. Each
of the newly identified alleles was predicted to be weak,
and indeed, the plants homozygous for these alleles did
not show ear fasciation. However, careful analysis of row
number in plants homozygous for those alleles revealed
subtle changes. Whereas the majority of W22 inbred ears
had 14 or 16 rows, three of the weak allele populations
had a significant number of homozygous mutant plants
developing ears with 18–20 kernel rows. These results
confirm that a weak allele of fea2 can enhance KRN
without leading to a strong fasciated phenotype that
would normally be deleterious to yield. In collaboration
with Dupont Pioneer, we are in the process of introduc-
ing our weak fea2 alleles into commercial elite hybrid
lines to ask whether the observed increase in KRN can be
maintained and used to increase yield.
The Regulation of Meristem
Size in Maize
P. Bommert, M. Pautler, B.I. Je, H. Szilagyi, L. Marshall,
A. Eveland [in collaboration with M. Komatsu and
H. Sakai, DuPont Crop Genetics] 
All plant organs derive from populations of stem cells
called meristems. These stem cells have two purposes:
to divide to replace themselves and to give rise to daugh-
ter cells, which will differentiate into lateral organs.
Consequently, plant meristems must precisely control
the size of the stem cell niche via a network of positive
and negative feedback signals. A loss of function in a
negative regulator of stem cell fate can result in an en-
larged or fasciated meristem phenotype and a dramatic
alteration in the morphology of the maize ear and tassel.
Maize is an excellent genetic model system because
of a large collection of developmental mutants and a
sequenced reference genome. Our lab has undertaken a
forward genetic approach to identify key regulators of
stem cell homeostasis and meristem size. Two previ-
ously cloned mutants, fasicated ear2 and thick-tassel
dwarf1, encode orthologs of the Arabidopsis thaliana
genes CLAVATA1 and CLAVATA2, suggesting that the
well-known CLAVATA-WUSCHEL regulatory feed-
back loop is conserved from dicots to monocots. How-
ever, little else is known about the control of this
important developmental process in maize. Here, we
describe our progress in identifying additional genes
contributing to stem cell niche homeostasis. 
Compact plant2 (ct2) is a classical mutant of maize
that exhibits a fasciated inflorescence phenotype as well
as semidwarfism. We discovered via a map-based
cloning approach that ct2 encodes the a subunit of a
heterotrimeric GTPase, a membrane-associated protein
involved in the transduction of extracellular signals to
induce specific cellular responses by activating down-
stream effectors. To identify CT2-interacting proteins,
we pursued immunochemistry approaches using trans-
genic maize lines expressing a translational fusion of
CT2 and YFP under control of the endogenous CT2
promoter. In coimmunoprecipation experiments (Co-
IPs), using a custom-made peptide antibody raised
against FEA2 and a commercial YFP antibody, we
found that FEA2 and CT2 interact, implicating het-
erotrimeric G-protein signaling in the CLAVATA sig-
naling pathway. 
Another fasciated ear mutant that we recently cloned
is fasciated ear3 (fea3), which was derived from a  radi-
ation mutagenesis screen in Russia. fea3 shows an over-
proliferation of the inflorescence meristem. We cloned
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the fea3 gene using map-based cloning, and the mutant
results from the insertion of a partial retrotransposon
into an exon of the FEA3 locus. We confirmed this
identity by isolation of new alleles of fea3 from an
EMS-targeted mutagenesis. FEA3 encodes a leucine-
rich repeat (LRR) receptor-like protein similar to FEA2;
however, double mutants of fea2 and fea3 have an ad-
ditive fasciated phenotype in ear and tassel, indicating
that they act in independent pathways. To further clar-
ify these pathways, we have adopted a CLV3 peptide
assay first used in Arabidopsis. In this assay, CLV3 pep-
tide inhibits root growth in a CLV2-dependent path-
way. Interestingly, even though FEA3 is expressed in the
root, like FEA2, the fea3 mutant responds like wild-
type seedlings to CLV3 peptide treatment, whereas fea2
mutants are insensitive to CLV3 peptide. These data
suggest that the regulation of stem cell proliferation in
the maize CLAVATA pathway is not limited to a CLV3
peptide-dependent pathway and that the function of
FEA3 as an LRR receptor-like protein is distinct from
that of FEA2. Future work will include characterizing
the spatial expression of fea3 and profiling the tran-
scriptome to understand which pathways with which
it interacts.
An additional similar mutant, fea4, is a semidwarfed
maize mutant with thickened, or fasciated, ears and tas-
sel. These phenotypes are caused by enlarged vegetative
and inflorescence meristems, which have lost control of
the pathways normally regulating meristem size. We
had previously mapped fea4 to a small region of chro-
mosome 6 containing 30 genes. Sequencing of candi-
date genes in the reference allele revealed a bZIP (basic
leucine zipper) transcription factor with an EMS-in-
duced GÆA transition causing a premature stop
codon. Two additional alleles also contained mutations
in the gene consistent with EMS mutagenesis. We sub-
sequently obtained a series of transposon insertional
mutants through a collaboration with DuPont-Pioneer.
We have thus identified a novel gene required for the
control of meristem size in maize. 
We are characterizing the function of this bZIP tran-
scription factor through several parallel approaches. We
have generated YFP-FEA4 transgenic constructs under
the native promoter and will analyze the transgenic
plants in the coming months. In situ hybridization will
also be used to visualize the spatial expression pattern of
the gene. We will obtain a global picture of transcrip-
tional changes in the mutant by constructing mRNA-
Seq libraries. Additional approaches include making
double-mutant combinations between fea4 and other
meristem regulation mutants. So far, these analyses have
suggested that FEA4 acts outside of the canonical
meristem size regulation pathways, consistent with a
role in buffering the balance between division and dif-
ferentiation. Double mutants between fea4 and the
ramosa branching mutants suggest an interesting con-
nection between meristem size regulation and meris-
tem determinacy that will be further explored.
In addition, we are in the process of mapping ~50
fasciated ear mutants from nontargeted EMS muta ge-
nesis screens. Our current approach involves creating
F2 mapping populations and rough mapping by bulked
segregant analysis. We take advantage of the precise
quantitative genotyping capability of the Sequenom
MassArray system to look for areas of the genome that
are linked to the phenotype. We have determined rough
positions for several of these mutants and are proceed-
ing with fine mapping and molecular cloning.
A Systems Approach to Elucidate
Developmental Networks
Controlling Inflorescence Architecture 
A.L. Eveland, A. Goldschmidt, M. Pautler [in collaboration
with D. Ware, Cold Spring Harbor Laboratory; 
E. Vollbrecht, Iowa State University; K. Morohashi 
and E. Grotewold, The Ohio State University]
Inflorescences bear the fruits and grains that we eat, and
thus understanding the genetic and regulatory basis for
how these structures are formed has clear relevance to
important agronomic traits such as grain yield and har-
vesting ability. Inflorescence architecture among cereal
crops is diverse, yet characterized by a unique morphol-
ogy where florets are borne on short, determinate
branches called spikelets. In maize, these spikelets are
paired, an exclusive feature of the Andropogoneae tribe,
which also includes important cereals and energy crops
such as sorghum and sugarcane. Variations in inflores-
cence branching patterns arise from position and devel-
opmental fate of differentiating stem cell populations
called meristems. The spatiotemporal actions of key de-
velopmental regulators, as well as genetic interactions
between them, modulate meristem initiation and deter-
minacy. Our goal is to understand the mechanisms by
which these regulators act in our model system, maize,
which will provide a knowledge base for the genetic con-
trol of branching and ultimately translation to other im-
portant crop species.
The primary objective of this work is to integrate var-
ious large-scale genomics data sets and to expand existing
knowledge of genetic interactions that regulate branching
during maize inflorescence development. Our data sets
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represent maize male and female inflorescence primor-
dia, tassels and ears, respectively, sampled during key de-
velopmental transitions and in perturbed genetic
backgrounds. The latter includes loss-of-function mu-
tants in three important regulators of the RAMOSA (RA)
pathway, which controls stem-cell-fate decisions and the
decision to branch. Using these data sets, we have estab-
lished a robust system to investigate the networks that
modulate branching, including characterization of pre-
cise timing of developmental events and associated spa-
tiotemporal changes in gene expression. We integrated
genome-wide mRNA-Seq data to resolve coexpression
networks during key stages of maize inflorescence devel-
opment and are working to expand these networks by in-
corporating additional data sets, such as genome-wide
transcription factor (TF) occupancy profiles and cis-reg-
ulatory information. We use these approaches to priori-
tize candidate genes as potential regulators of important
events in spikelet development, such as axillary meristem
initiation and determinacy. 
To establish a framework for studying coexpression
networks, we characterized genome-wide expression sig-
natures that coincided with specific morphological tran-
sitions during inflorescence development. We made use
of known developmental marker genes and their spa-
tiotemporal transcriptional responses to genetic pertur-
bation to test our experimental system and establish a
proxy for developmental staging. A k-means clustering
approach revealed predicted expression patterns for pre-
viously characterized marker genes. For example, we
showed that RA1 and RA3were coexpressed during nor-
mal ear and tassel development, as predicted by their
colocalized expression pattern at the base of the spikelet
pair meristem (SPM). We then used this approach to
identify candidate genes in SPM determinacy and
spikelet meristem (SM) initiation networks, by integrat-
ing differential expression signatures from developmen-
tally staged ramosa mutants. One interesting candidate
for modulating SPM determinacy, ZMM18, an ortholog
of the floral homeotic gene PISTILLATA, was localized
to the SPM by in situ hybridization, an unexpected ex-
pression pattern given its previously described role in the
later stages of flower development. We continue to mine
coexpression clusters for enrichment of cis-regulatory el-
ements and modules to computationally predict classes
of TFs that regulate coexpressed genes. Work is currently
under way to analyze loss-of-function mutations in new
candidate regulators identified by profiling, as well as
crosses to the ramosamutants to study potential genetic
interactions. In addition, we have generated mRNA-Seq
data sets representing comparable inflorescence stages in
sorghum and will use these data in comparative genomics
analyses.
To further expand our coexpression network, we
identified putative targets of the RA1TF on a genome-
wide scale by chromatin immunoprecipitation followed
by high-throughput sequencing (ChIP-Seq) using
maize transgenic RA1-tagged lines. Of ~1000 high-con-
fidence targets, one-third were differentially expressed
in ra1 mutants based on our mRNA-Seq analysis.
These putative targets were significantly enriched for
TFs, and they included genes that confer inflorescence
phenotypes when mutated. Our data also suggested
that RA1 is both an activator and repressor of gene
 expression, as groups of TFs were either up- or down-
regulated. We continue to expand this network by in-
te grating additional ChIP-Seq data sets. For example,
analysis of ChIP-Seq data for KNOTTED1 (KN1), a
master regulator of meristem maintenance, revealed the
potential for combinatorial binding with RA1 at mul-
tiple loci in the maize genome. We are investigating en-
richment of cis-regulatory elements within these regions
to identify conserved binding sites and computation-
ally predict additional TFs that may be interacting at
these loci. Future work will investigate whether such
binding is developmentally regulated.
Control of Branching
and Determinacy in Plants
Y.G. Wolfenson, S. Goldschmidt 
The RAMOSA (RA) genes in maize function to impose
determinacy on axillary meristem growth; conse-
quently, ra loss-of-function mutants (ra1, ra2, and ra3)
have more highly branched inflorescences. RA1 encodes
a C2H2 putative transcription factor that appears to
have had a key role in maize domestication and grass
evolution. RA2 also encodes a putative transcription
factor, a LOB domain protein, whereas RA3 encodes a
predicted metabolic enzyme, a trehalose phosphate
phosphatase. The disaccharide trehalose is not abun-
dant in plant tissues and may have a regulatory role be-
cause it has been implicated in stress protection, control
of sugar signaling, and regulation of photosynthetic
rates. This is the first indication that trehalose has a spe-
cific developmental function. RA3 is expressed in a lo-
calized domain at the base of axillary inflorescence
meristems, and it localizes to nuclear and cytoplasmic
compartments, suggesting that its effect on develop-
ment is not simply metabolic. Interestingly, genetic and
molecular studies suggest that both RA2 and RA3 are
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required for proper RA1 expression and act upstream
of RA1. All three genes are expressed in overlapping do-
mains; RA2 is expressed in the axillary inflorescence
meristems themselves, whereas RA1 and RA3 expres-
sion is only at the base of the axillary inflorescence meri -
stems, suggesting that they may control a mobile signal
that regulates meristem determinacy. The RAMOSA
(RA) genes therefore define a boundary domain that
surrounds the developing branch meristem, rather than
being deployed in the meristem itself. These data sup-
port the hypothesis that RA genes may serve as media-
tors of signals, maybe a sugar signal, originated at the
boundary domain and regulating determinacy. RA3 it-
self may have a transcriptional regulatory function be-
cause it affects the expression of specific genes.
To find specific genes that are differentially expressed in
the RA-specific domain, we are using FACS followed by
mRNA-Seq. pWUSCHEL::RFP:NLS and pRA3::RFP:
NLS reporter lines crossed to ramutants are used for this
purpose. The pWUSCHEL reporter is a marker for cells of
the organizing center of the meristem. We expect that cell-
specific profiling will enable identification of genes that
act directly in the RAMOSA signaling pathway.
In another approach, we will use yeast one-hybrid
analysis to identify transcription factors that regulate
RA3 gene transcription. The RA3 putative promoter is
cloned into a reporter vector and is integrated into the
yeast genome. This strain provides a host for library
screening. A cDNA library of DNA-binding pro-
teins, which are expressed as fusions to the yeast GAL4
transcription activation domain (GAL4 AD prey pro-
teins) will then be screened, in collaboration with Li-
fang Zhang (Ware lab at CSHL). After screening,
further analysis of identified transcription factors will be
done in order to learn more about their role in deter-
minacy. Furthermore, testing whether RA3 gene tran-
scription is affected by other factors, such as sugars,
could be performed in the yeast reporter system. These
studies will therefore contribute additional information
about RAMOSA-mediated determinacy pathways.
The A. thaliana genome contains a family of 10
genes related to RA3. Null mutants of all AtTPPs were
tested and only one has an interesting phenotype that
is connected to development and determinacy. Its late-
flowering phenotype is accompanied with reduced size
and shorter roots, and fusion of cauline leaves to the
main stem. In addition, double mutants with superman,
an ra1 homolog, show increased indeterminacy, sug-
gesting conservation of this developmental module. Ac-
cording to these findings, we have identified a  potential
ortholog of RA3 in Arabidopsis, and we are characteriz-
ing additional alleles and double mutant combinations. 
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Plant architecture and reproductive success is driven pre-
dominantly by the number and arrangement of branches
and flowers on structures called inflorescences. Inflores-
cences develop from small groups of pluripotent cells in
growing tips called shoot apical meristems (SAMs).
SAMs first give rise to leaves before transitioning to in-
florescence meristems (IMs), which can produce lateral
(axillary) meristems that either transition into flower-
bearing shoots or differentiate directly into flowers. In-
florescences can be simple, producing only a single
flower, or they can be highly complex, producing dozens
of branches and hundreds of flowers. Our research fo-
cuses on deciphering the genetic and molecular programs
that control the rates at which SAMs transition from a
leaf-producing vegetative state to a flower-producing re-
productive state. We are working under the hypothesis
that evolutionary differences in the rate at which meri-
stems transition to a reproductive state modulate inflo-
rescence architecture and flower production, providing
a basis for natural selection and the improvement of crop
yields. Diversity in inflorescence architecture is based on
two major growth habits. In “monopodial” plants, such
as Arabidopsis, IMs grow continuously and initiate axil-
lary flowers laterally. In contrast, in “sympodial” plants,
IMs terminate in flowers and growth continues from a
variable number of new axillary (sympodial) IMs that re-
peat this process to form compound inflorescence shoots.
Sympodial plants produce a remarkable range of inflo-
rescence architectures, but the basis for this diversity is
unknown. We are uniting genetics with quantitative ge-
nomics to discover the genes and networks that control
sympodial growth, which is found in half of all flowering
plants, including most trees. We are taking advantage of
tools in tomato (Solanum lycopersicum) to understand
how meristem maturation and sympodial growth are
modulated to give rise to compound, multiflowered in-
florescences. Through knowledge gained in tomato, we
are exploring mechanisms underlying variation in inflo-
rescence branching in the larger nightshade (Solanaceae)
family. Importantly, the Solanaceae comprise several crop
and ornamental species, including potato, pepper, egg-
plant, petunia, and tobacco, as well as many edible wild
species. Our research is therefore pertinent to both evo-
lution and agriculture.
Sympodial Growth in Tomato
Tomato is a powerful model to study mechanisms of
meristem maturation and sympodial growth because it
produces several types of meristems, each of which un-
dergoes a different rate of maturation (Fig. 1). Most im-
portantly, tomato meristems are large, and easily dis-
sected from surrounding leaves. The primary shoot
meristem (PSM) originates from the embryo and pro-
duces eight leaves before switching to reproductive
growth and terminating in an inflorescence. Upright
growth continues from the reiteration of a specialized
axillary meristem called a sympodial shoot meristem
(SYM) that forms in the axil of the last leaf on the PSM
and terminates after producing only three leaves. A new
SYM then forms in the axil of the last leaf of the previ-
ous SYM, and all subsequent SYMs develop three leaves,
a terminal inflorescence, and the next SYM to produce
a compound vegetative shoot. Inflorescences are also
compound, resulting from the zigzag reiteration of sym-
podial inflorescence meristems (SIMs), each of which
gives rise to another SIM before terminating in a flower
meristem (FM). Finally, each canonical axillary meri-
stem produces primary, sympodial and axillary shoots,
and inflorescences. Thus, tomato growth is modular,
and numerous reproductive transitions throughout life
give rise to a plant with hundreds of branches, inflores-
cences, and flowers (Fig. 2).
Tomato Inflorescence Architecture 
and the “Meristem Maturation Clock”
S.-J. Park, K. Jiang
Using a systems genetics approach, we have addressed
two fascinating questions in plant biology: (1) What are
the molecular dynamics underlying how SAMs switch
from a leaf-producing vegetative state to a flower-pro-
ducing reproductive state, and (2) what is the basis for
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Z. Lippman K. Jiang C. MacAlister
K. Liberatore S. Park
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Figure 1. Sympodial growth in tomato and inflorescence archi-
tecture variation. (A) A tomato scanning electron microscope
(SEM) image reflecting the meristems that give rise to the vegeta-
tive sympodial shoot of tomato (right arrow) and the multiflow-
ered sympodial inflorescence (left arrow). (B) Schematic of
tomato sympodial growth. (C,D) Stereoscope images of tomato
meristems as they reach the reproductive state to produce a flo-
ral meristem (FM) and a sympodial inflorescence meristem (SIM).
(E) Mature tomato inflorescence producing six to nine flowers in
a zigzag pattern. (F) Model for inflorescence branching in the
Solanaceae family based on delayed meristem maturation and
termination. (G) Inflorescence mutant compound inflorescence.
(H) Weakly branched wild tomato species, Solanum peruvianum.
the evolutionary diversity in inflorescence branching pat-
terns among plants showing the widespread, yet poorly
understood, “sympodial” growth habit? In the last
decade, individual genes controlling inflorescence archi-
tecture have been identified; yet, the molecular programs
underlying inflorescence diversity remain a mystery. By
taking advantage of the large and exposed meristem of
tomato, we have captured age-dependent gene expres-
sion dynamics that define the maturation of a single
meristem gradually transitioning from a vegetative state
to a flower. We developed a simple two-step acetone fix-
ation technique for dissecting and collecting abundant
amounts of high-quality RNA from tomato meristems.
By performing deep RNA sequencing (RNA-Seq) on five
stages of meristem maturation, we have revealed that
thousands of genes show dynamic, age-dependent ex-
pression changes. Using these data, we applied algo-
rithms to formulate a high-resolution quantitative
“meristem maturation clock,” which revealed that sym-
podial growth is based on primary shoot meristem mat-
uration causing uppermost axillary meristems to adopt
advanced states of maturation and terminate after brief
(SYM) or no (SIM) vegetative growth.
By profiling meristems from a highly branched mu-
tant called compound inflorescence (s), we further discov-
ered that the primary inflorescence of s branches in two
stages: In the first stage, multiple SIMs develop on the
primary shoot due to a delay in PSM termination, and in
the second stage, branching continues through delays in
SIMs. In another major advance, we profile transcrip-
tomes of meristems from a related tomato species (S. pe-
ruvianum), which consistently develops between two to
four branches, but whose morphological variation can-
not be dissected genetically. Using the meristem matura-
tion clock, we showed that S. peruvianum branching is
due to a surprisingly early delay in the maturation of the
primary branch meristem, but a normal maturation of
the SIM, thereby explaining why no more than two to
four branches develop on each wild tomato species inflo-
rescence. These findings reveal that the program for in-
florescence branching is initiated surprisingly early during
meristem maturation, and shows that evolutionary di-
versity in inflorescence architecture is modulated by het-
erochronic shifts in the acquisition of floral fate (Fig. 3).
Novel Inflorescence Architecture Mutants
C. MacAlister
Sympodial growth is characterized by the coordinated
termination and replacement of meristems to form
compound shoots. The transition from a single primary
meristem to this dynamic turnover of meristems occurs
at the onset of flowering, but how termination is coor-
dinated with the formation of new meristems is not un-
derstood. By cloning genes with novel floral transition
and inflorescence architecture defects, we have uncov-
ered new pathways controlling flowering and the tran-
sition to sympodial growth.  
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The classic terminating flower (tmf ) mutant exhibits
an accelerated transition to flowering and termination of
the primary meristem in a single flower without pro-
ducing any sympodial meristems to continue growth. We
have cloned TMF and found that it encodes a protein of
unknown function belonging to a small, plant-specific
but deeply conserved, gene family. Furthermore, we have
shown that the TMF-encoded protein is localized to the
nucleus, and RNA-Seq and in situ hybridization reveal
that the gene is expressed in the vegetative meristem be-
fore the floral transition. Using RNA-Seq, we have com-
pared the vegetative stage meristem transcriptome of tmf
to that of wild type. Leveraging the dynamic meristem
transcriptome data generated in the lab, we have found
that the genes up-regulated in tmf are significantly en-
riched for those that are most highly expressed as the
meristem approaches termination, for example, the
known floral meristem identity genes FALSIFLORA and
ANANTHA (the tomato orthologs of the Arabidopsis
LEAFY and UNUSUAL FLORAL ORGANS). Both fal-
siflora and ananthamutants exhibit reduced determinacy
in the inflorescence and are completely epistatic to tmf,
whereas precocious meristem expression of these genes
leads to single-flowered inflorescences, as observed in tmf.
We therefore hypothesize that TMF acts in the vegetative
meristem to repress flowering by blocking precocious ac-
tivation of the floral meristem identity program, thereby
allowing sufficient time for the primary meristem to
form the sympodial meristems before terminating. 
Mutants in fasciated inflorescence (fin) also exhibit dis-
ruptions in inflorescence structure, but unlike tmf, fin
mutants produce a highly branched inflorescence with
greatly enlarged flowers and fruits due to a progressive
expansion of the meristem over time. The fin pheno-
type is reminiscent of the Arabidopsis clavatamutants; in
conjunction with WUSCHEL, the CLAVATA signaling
cascade forms a feedback loop to maintain meristem
size. By combining map-based cloning and RNA-Seq,
we have cloned fin and found that it encodes a protein
of unknown function, lacking any known protein mo-
tifs, demonstrating that additional, novel factors are in-
volved in meristem homeostasis beyond the classic
WUS-CLV feedback network.
Our identification of new genes controlling tomato
inflorescence architecture highlights that novel mecha-
nisms regulate determinate sympodial growth. We are
now working to generate new mutants through several
mutagenesis programs, as well as exploiting the pheno-
typic diversity found in the domesticated tomato germ
plasm to identify additional players in sympodial growth.
Genetic and Molecular Characterization
of Moderately Branched Inflorescence
Mutants
K. Liberatore
A number of tomato accessions have strong branching
inflorescences and most of this natural variation is due
to mutations in the homeobox transcription factor en-
coded by S. However, the molecular basis for hundreds
of weaker branching tomato variants is still unknown.
To broaden our understanding of the genes and mo-
lecular networks involved in controlling inflorescence
architecture, we have focused recent efforts on the map-
ping and characterization of several of these variants.
Figure 2. Transient dynamic expression of three tomato meristem maturation genes. (A–C) In situ hybridization of
TMF (A), S (B), and AN (C). (D) RNA-Seq data of TMF, S, and AN revealing temporal dynamic expression. (E) Depic-
tion of sequential transient expression of TMF, S, and AN. The VM expresses TMF, followed by S in the SIM, and AN
in the FM. TMF expression drops as S is activated, and S drops as AN is activated in the FM. S followed by AN reit-
erates in subsequent SIMs to form a multiflowered zigzag inflorescence.
One group of moderately branched lines called bifur-
cating inflorescence (bif ) branch in a manner reminis-
cent of s mutants, and preliminary allelism tests have
suggested that bif might be a weak allele of s. However,
because no mutations were identified in the S-coding
region, mapping populations of three bif lines were
generated to identify quantitative trait loci (QTL) for
inflorescence branching. Interestingly, our preliminary
QTL analysis on two bif populations revealed only a
single significant QTL in the region of the S gene on
chromosome 2, but this QTL only accounts for 25% of
branching variation. These data suggest that improve-
ment of our mapping resolution should reveal addi-
tional QTL residing elsewhere on the 12 tomato
chromosomes. Further genetic and molecular charac-
terization is necessary to determine if S is responsible
for the chromosome 2 QTL.
We have also begun characterizing another inflores-
cence branching mutant called fasciated and branched
(fab), which exhibits both branching and fasciation (en-
largement) of the flowers and fruits. We have cloned
the FAB gene and have found that it encodes the
tomato ortholog of Arabidopsis CLAVATA1 (CLV1), a
well-characterized LRR receptor-like protein kinase that
is involved in meristem (stem cell) maintenance. In ad-
dition to standard developmental analysis, we will fur-
ther our understanding of fab by (1) mRNA-Seq
expression profiling in fab mutants during the transi-
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tion to flowering and (2) double-mutant analysis with
other inflorescence mutants including fin and s. In par-
ticular, we are intrigued by the similar phenotypes seen
in both fab and finmutants, especially because FIN en-
codes a protein of unknown function with putative
transmembrane domains, suggesting that it may also act
in a receptor complex. Interestingly, the fab:fin double
mutants result in an extremely enlarged meristem that
fails to transition to flowering (sterile plants). This syn-
ergistic enhancement in the double mutant suggests
that fab and fin may work in parallel pathways. We are
carrying out further genetic and molecular analyses to
better understand the roles of both these genes in meris-
tem maintenance and inflorescence architecture in
tomato.
Single-Gene Heterosis, Flowering,
and Tomato Yield
K. Jiang
Previous studies identified a remarkable example of
heterosis in domesticated tomato plants, in which het-
erozygosity of a single gene causes greater inflorescence
production and fruit yield over both parents. Surpris-
ingly, this “single-gene heterosis” was discovered in hy-
brids between homozygous mutants and nonmutant
wild-type parents, suggesting that mutations can cause
Figure 3. Characterization of tomato meristem maturation and underlying transcriptome dynamics. (A) Microdissec-
tion and collection of five sequential stages of the tomato primary meristem for Illumina RNA-Seq transcriptome pro-
filing. (Dashed lines) Dissected tissue line, (arrowheads) dissected meristem, (DAG) days after germination, (L) leaf
number. Shown below each image are clusters (C) of stage-enriched marker genes. (B) Microdissection and profiling
of the uppermost axillary meristem of the primary shoot (i.e., the SIM) (top) and digital differentiation index (DDI)
analysis predicting the maturation states of the SIM from wild-type tomato and s mutants. (For details, see text and
Park et al. 2012.)
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overdominance. Two of the mutated genes were iden-
tified as SFT and S, which are the tomato orthologs
of Arabidopsis FT and WOX9, respectively. Both genes
encode key signal integrators in the pathways control-
ling flowering time and inflorescence architecture in
plants. The nature of this single-gene heterosis led to
the hypothesis that transient, semidominant expres-
sion of SFT and S in developing tomato meristems re-
sults in semidominant effects on component traits for
yield, which are amplified over time due to the itera-
tive sympodial growth pattern of tomato. We are test-
ing this hypothesis with meristem RNA-Seq using our
streamlined workflow to collect and harvest multiple
meristem stages for expression profiling. Currently, for
S heterozygous plants, RNA-Seq libraries of three key
stages when semidominant expression of S is first evi-
dent are being profiled. These stages include transition
meristems, when vegetative meristems just begin the
process of committing to reproductive organ produc-
tion, sympodial inflorescence meristems, a unique
stage between transition and floral meristems to create
the compound inflorescence of tomato, and floral
meristems, which will ultimately become flowers. Pre-
liminary analyses by semiquantitative reverse tran-
scriptase−polymerase chain reaction (RT-PCR) have
already revealed that S is expressed in a semidominant
manner. Similar experiments are under way for SFT
heterozygous plants, and together, these experiments
should reveal the molecular basis for how mutations
in flowering genes cause pleiotropic dosage effects on
plant development, leading to transgressive phenotypic
variation.
Interestingly, sft mutants may have a wild-species
counterpart; the species Solanum cheesmanii from the
Galápagos Islands is very late flowering and generates an
excessive number of leaves in sympodial shoots, highly
reminiscent of sft mutants. The excessive vegetative
growth in both primary and sympodial shoots, as well as
inflorescences, suggested that S. cheesmanii might con-
tain loss-of-function genetic variation in the SFT gene or
related genes in the SFT family. Preliminary analysis of an
F2 QTL mapping population involving S. cheesmanii as
a parent revealed a strong correlation among all the veg-
etative traits such as number of leaves in primary and
sympodial shoots, and a large portion of the phenotypic
variance of the population seems to be segregating in a
Mendelian fashion, suggesting a single gene might con-
trol these phenotypes. Current work on this front in-
cludes characterizing the SFT gene family members in
the S. cheesmanii genome, and the future construction of
genetic markers to conduct an association study in the
larger S. cheesmanii germ plasm to assess if late flowering
is based on natural variation at the SFT locus.
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Plants and fission yeast provide excellent model or-
ganisms to address the question of how epigenetic in-
formation is propagated to daughter cells, including
transposon regulation, heterochromatic silencing, and
gene imprinting, important both for plant breeding
and for human health. We are investigating the inher-
itance of heterochromatic silencing and the role of
RNA interference (RNAi) in the fission yeast Schizo-
saccharomyces pombe and the plant Arabidopsis
thaliana, as well as continuing our work on Zea mays
and the Lemnaceae (duckweed). In the past year, we
have found that RNAi is important in determining
germ cell fate as well as transposon activation in Ara-
bidopsis, whereas in fission yeast, transposable elements
(TEs) control DNA replication via the highly con-
served centromere-binding protein B (CENP-B). Im-
portantly, we have shown that RNA and DNA poly-
merase collide during replication of heterochromatin
and that RNAi helps resolve this collision by releasing
RNA polymerase II (pol II). Release prevents DNA
damage signaling and promotes spreading of histone
modification, which may provide an explanation for
transcription of some noncoding RNA in higher or-
ganisms. 
This year, we welcomed postdocs Almudena Molla-
Morales and Benjamin Roche, graduate student Steph-
ane Castel, and computational biologist Mark Donoghue.
Graduate student Patrick Finigan obtained his Ph.D.
from the Watson School of Biological Sciences, and Pierre
Baduel (from Polytechnique in Paris) performed his hon-
ors research project in the lab. 
We said farewell to two senior postdoctoral fellows
after many enjoyable and productive years: Milos 
Tanurd z˘i ¢c accepted a faculty position at the Univer-
sity of Queensland, and Mikel Zaratiegui became as-
sistant professor at Rutgers, the State University of
New Jersey. 
RNAi Coordinates DNA Replication 
and Epigenetic Modification 
in Heterochromatin through 
the Release of RNA Pol II
M. Zaratiegui, S. Castel, J. Ren, B. Roche [in 
collaboration with Z. Cande, University of 
California, Berkeley; F. Antequera, University 
of Salamanca, Spain; B. Arcangioli, Institut 
Pasteur, Paris]
One defining characteristic of epigenetic modifications
is their heritability. The pericentromeres of the fission
yeast S. pombe are composed of repressive heterochro-
matin and repetitive noncoding RNAs whose processing
by RNAi is required for histone modification. We have
previously shown that these otherwise silenced noncod-
ing RNAs are expressed specifically during S phase, the
same time at which histone marks are deposited and
DNA replication occurs. To further study the role of
RNAi in regulating transcription, chromatin immuno-
precipitation was used to interrogate RNA pol II accu-
mulation genome wide in wild-type and RNAi-
deficient S. pombe throughout the cell cycle. In the ab-
sence of RNAi, pol II stalling and DNA damage occur
at centromeres during DNA replication, and they re-
quire repair by homologous recombination to proceed
(Fig. 1). RNAi is therefore required to coordinate DNA
replication and epigenetic modification in centromeric
heterochromatin. We propose that transcription of non-
coding RNAs during S phase leads to the collision of
RNA pol II with nearby replication forks that is resolved
by processing of nascent RNAs by RNAi. This process-
ing releases pol II and allows DNA replication to pro-
ceed, but it also functions to localize the repressive
histone-modifying complex to replicating heterochro-
matin. The RNAi-mediated release of pol II in the con-
text of replication may occur at euchromatic loci ge-
EPIGENETIC INHERITANCE AND REPROGRAMMING
IN PLANTS AND FISSION YEAST 
R. Martienssen J. Calarco Y. Jacob J. Simorowski
S. Castel C. LeBlanc C. Tang
A.-Y. Chang A. Molla-Morales M. Tanurdz˘i ¢c
K. Creasey M. Regulski U. Umamaheswari
E. Ernst J. Ren F. Van Ex
P. Finigan B. Roche M. Zaratiegui
J.-J. Han A. Schorn
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nome wide and could function analogously in higher
organisms. The coupling of histone modification to
DNA replication may also account for the spreading of
gene silencing in position-effect variegation.
CENP-B Preserves Genome Integrity
at Replication Forks Paused 
by Retrotransposon LTR
M. Zaratiegui [in collaboration with J. Bähler, University
College London; B. Arcangioli, Institut Pasteur, Paris]
CENP-B is a widely conserved DNA-binding factor as-
sociated with heterochromatin and centromeric satellite
repeats. In fission yeast, CENP-B homologs have been
shown to silence long terminal repeat (LTR) retrotrans-
posons by recruiting histone deacetylases. However,
CENP-B factors also have unexplained roles in DNA
replication. We have shown that a molecular function of
CENP-B is to promote replication fork progression
through the LTR. Mutants have increased genomic in-
stability caused by replication fork blockage that depends
on the DNA-binding factor switch-activating protein 1
(Sap1), which is directly recruited by the LTR. The loss
of Sap1-dependent barrier activity allows the unhindered
progression of the replication fork, but it results in re-
arrangements deleterious to the retrotransposon. We
conclude that retrotransposons influence replication po-
larity through recruitment of Sap1 and transposition
near replication fork blocks, whereas CENP-B counter-
acts this activity and promotes fork stability. Our results
may account for the role of LTR in fragile sites and for
the association of CENP-B with pericentromeric hetero-
chromatin and tandem satellite repeats. 
DNA Methylation Dynamics through
Pollen Development Involves Two
Distinct Mechanisms to Control
Epigenetic Reprogramming and
Genomic Imprinting
J. Calarco, Y. Jacob, J. Simorowski, F. Van Ex [in 
collaboration with J. Feijo and J. Becker, Gulbenkian
Institute, Lisbon; F. Berger, Temasek Institute, 
Singapore]
The male gametophyte of higher plants encloses two dif-
ferentiated cells called the sperm cells and vegetative cell.
Although separated by only two cell divisions, the cell
types have very different chromatin architecture. We
profiled DNA methylation of the three different types of
nuclei observed through pollen maturation, from the
postmeiotic precursor cell to the mature pollen grain, in
an attempt to understand epigenetic reprogramming
during plant germline development. CG and CHG
methylation is reduced in the vegetative cell compared
with that of sperm and microspore, but only at specific
loci, which tend to mark transposable elements sur-
rounding some noted imprinted genes. This indicates
that symmetric methylation in the microspore is main-
tained during DNA replication in the first pollen divi-
sion and actively lost at imprinted loci. In contrast,
CHH methylation, which is tied to RNA-directed
DNA methylation (RdDM), is much lower in sperm
cells than in the companion cell, overlapping with the
accumulation of corresponding small interfering RNAs
(siRNAs) and preferential expression of DRM2. All of
this suggests two distinct and antagonistic mechanisms:
one through targeted active demethylation and another
with targeted reestablishment of methylation, combined
with the surprising observation that unlike mammals,
the Arabidopsismale germline never undergoes genome-
wide erasure of DNA methylation.
Figure 1. RNAi protects cells from spontaneous DNA damage.
Rad22-YFP foci were scored under fluorescence microscopy in
unsynchronized dcr1D cells, which were assessed for cell cycle
stage by differential interference contrast (DIC). S phase (binu-
cleate septated cells) could be readily distinguished from G2
(mononuclear cells). Double foci in cells in G2 and single foci in
S-phase cells are shown (J. Ren).
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Multiple Roles for Small RNAs
during Plant Reproduction
F. Van Ex, K. Creasey, Y. Jacob [in collaboration with
F. Berger, Temasek, Singapore; J.-P. Vielle Calzada,
LANGEBIO CINVESTAV, Mexico]
Germline development and early embryogenesis in eu-
karyotes are characterized by large-scale genome repro-
gramming events. In companion cells of the Arabidopsis
male gametophyte, epigenome reorganization leads to
loss of heterochromatin and production of a distinct
small RNA (sRNA) population. A specific class of sRNAs
derived from transposons appears to be mobile and can
accumulate in germ cells. In the germline of maize, rice,
and Arabidopsis, specific ARGONAUTE−sRNA silenc-
ing complexes appear to have key roles in reproductive
development, including meiosis and regulation of germ
cell fate. These results reveal new roles for sRNAs during
plant reproduction and suggest that mobility of sRNAs
could be critical for some of these functions. In the ovule,
ARGONAUTE 9 (AGO9) has a role not only in silenc-
ing TE in the egg cell, but also in preventing the forma-
tion of multiple asexual gametophytes (Olmedo-Monfil
et al., Nature 464: 628 [2010]). We propose that repro-
gramming of heterochromatin in germline companion
cells reveals TE in a controlled manner to expose them
within the germline and, by the production of siRNA,
ensures TE silencing in the next generation. We also pro-
pose that the mechanisms evolved to silence TE may ac-
tually promote sexual reproduction by inhibiting the
formation of asexual gametes.
A Functional Phylogenomic View
of the Seed Plants
F. Van Ex [in collaboration with D. Stevenson, New York
Botanical Garden; W.R. McCombie, Cold Spring Harbor
Laboratory; G. Coruzzi, New York University; R. Desalle,
American Museum of Natural History, New York]
We have used 22,833 sets of orthologs from expressed
sequence tag (EST) and genome sequences from 101
genera across land plants to reconstruct their phyloge-
netic relationships. In using this novel phylogenomic
approach, we were able to identify overrepresented func-
tional gene ontology categories in genes that provide
positive branch support for major nodes, prompting
new hypotheses for genes associated with the diversifi-
cation of angiosperms. RNAi has had a significant role
in the divergence of monocots from other angiosperms,
which has experimental support in Arabidopsis and rice.
This analysis also implied that the second largest sub-
unit of RNA polymerase IV and V (NRPD2) had a
prominent role in the divergence of gymnosperms. This
hypothesis is supported by the lack of the 24-nucleotide
siRNA in conifers, the maternal control of small RNA
in the seeds of flowering plants, and the emergence of
double fertilization in angiosperms. Our approach takes
advantage of genomic data to define orthologs, recon-
struct relationships, and narrow down candidate genes
involved in plant evolution within a phylogenomic view
of species’ diversification.
Transposon Instability in Interspecies
Hybrids Is Mediated by RNAi
M. Tanurdz˘i ¢c, P. Finigan, E. Ernst [in collaboration 
with L. Comai, University of California, Davis; 
B.C. Meyers, University of Delaware; R.W. Doerge, 
Purdue University]
Silencing of transposable elements ensures genome sta-
bility and lowers the mutagenic effects of transposition.
We have used statistical analysis of small RNA popula-
tions to demonstrate that COPIA retrotransposons from
the pollen parent are activated in Arabidopsis interspecific
hybrids, but only when matching siRNA are absent from
the seed parent. EASY RIDER elements lose DNA
methylation, and hybrid leaves accumulate the 21-nu-
cleotide “epigenetically activated siRNA” (easiRNA) nor-
mally found in pollen, along with RNA and extra-
chromosomal cDNA transposition intermediates. Our
results indicate that small RNA provides a general recog-
nition mechanism for transposons in interspecific hy-
brids, reminiscent of hybrid dysgenesis and hybrid
lethality in Drosophila, and may contribute to postfertil-
ization hybridization barriers in a similar way.
cis- and trans-Regulation of 
Nonadditive Gene Expression 
in Arabidopsis Allopolyploids
P. Finigan, M.Tanurdz˘i ¢c [in collaboration with 
M. Vaughn, Cold Spring Harbor Laboratory; 
R.W. Doerge, Purdue University]
Allopolyploids are hybrid species that contain two or
more complete chromosome sets derived from cross-
fertilization of distinct species and exhibit novel phe-
notypic variation. This novel variation is accompanied
by nonadditive gene expression whereby homologous
genes (homeoalleles) are expressed at levels that differ
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from the average level in the progenitor species. We
have used transcriptome sequencing and high-through-
put single-nucleotide polymorphism (SNP) genotyp-
ing in Arabidopsis allopolyploids to determine the
contribution of homeoallele bias to nonadditive gene
expression. We have found that homologous genes with
a biased transcript accumulation in favor of one homeo-
allele are no more likely to be nonadditively expressed
than those genes without such a bias. Furthermore,
chromatin immunoprecipitation followed by high-
throughput sequencing (ChIP-Seq) indicates that
homeoallele-specific expression is not associated with
methylation of histone H3 at lysine-4 (H3K4me2)
within exons, a euchromatic mark associated with gene
expression. Although some parental bias is inherited in
cis, we conclude that nonadditive gene expression in
Arabidopsis allopolyploids is largely a trans effect, con-
sistent with the Bateson−Dobzhansky−Muller hypoth-
esis of gene interaction in hybrids.
Role of RDR6 in the Origin
of Epialleles in Arabidopsis 
K. Creasey [in collaboration with V. Colot, Ecole 
Normale Superieur, Paris; T. Kakutani, National 
Institute of Genetics, Japan] 
The origin of epialleles by ectopic loss or gain of DNA
methylation can result in epigenetically heritable gene
silencing and is widespread in plants as well as in
human cancer. In A. thaliana, rare epialleles emerge in
mutants with decreased DNA methylation (ddm1 and
met1). We have previously reported the loss of methyl-
ation at centromeric repeats in ddm1 and met1 mu-
tants, as well as the activation of all classes of TEs. Yet,
ddm1 mutants only begin to display developmental
phenotypic abnormalities after several generations of
inbreeding. Following the discovery of a novel class of
21-nucleotide siRNA, known as epigenetically activated
siRNA (easiRNA), corresponding to pericentromeric
ATHILA retrotransposons in ddm1 mutants, we went
on to create double mutants with members of the
RNA-silencing pathways. We have found that devel-
opmental phenotypes are exacerbated in ddm1 RNA-
dependent RNA polymerase 6 (rdr6) double mutants.
We have also found that the loss of RDR6 in ddm1
leads to the loss of easiRNA. But, like in ddm1 single
mutants, transcriptome analysis reveals the activation
of the same classes of TEs in ddm1 rdr6 double mu-
tants. We have also found an accumulation of ectopic
24-nucleotide small RNA and hypermethylation at spe-
cific loci in ddm1 rdr6. We conclude that the loss of
ddm1 provides an epigenetically compromised situation
whereby the activation of TEs, along with the sporadic
accumulation of siRNA within the genome, can result
in aberrant methylation and epiallele formation.
Transposon Small RNA Expression
in the Embryonic and Trophectoderm
Lineage
A. Schorn [in collaboration with W. Reik, Babraham 
Institute, Cambridge, United Kingdom; R.W. Doerge, 
Purdue University]
Epigenetic reprogramming is essential to regain pluri-
potency during mammalian reproduction, but it also
results in transient release of TEs from heterochromatin
repression. In plants, transposon release in neighboring
tissues triggers the production of mobile small RNAs
that are capable of inducing silencing in the generative
cells (Slotkin et al., Cell 136: 461 [2009]). We won-
dered if, similarly, nurse tissues in mammals express
transposon-targeting small RNAs that could ensure
genome integrity in the offspring. We profiled small
RNA expression from mouse embryonic stem (ES) and
trophectoderm stem (TS) cells to assess the potential
contribution of nurse tissues to transposon silencing in
the embryonic lineage in mice. We found TEs that pro-
duce small RNAs in ES or TS cells are on average
younger than the mean transposon age genome-wide.
In addition, endogenous retrovirus (ERV) small RNA
is particularly overexpressed in TS cells. Interestingly,
ERV elements are still active in mice and have con-
tributed to placenta evolution. Therefore, small RNA
expression in the trophectoderm lineage might reflect a
trade-off between the benefits of transposon domesti-
cation during eutherian evolution and the necessity of
protecting the embryo from active transposition. We
propose an in vivo model to test for small RNA signal-
ing between placenta tissues and the embryo proper.
The Maize Methylome: Function, 
Diversity, and Inheritance
M. Regulski [in collaboration with D. Ware, J. Hicks, 
and W.R. McCombie, Cold Spring Harbor Laboratory; 
S. Tingey and A. Rafalski, Pioneer-DuPont]
The maize genome has undergone dramatic changes in
sequence and organization following domestication and
improvement and is one of the most diverse crop
genomes. We have mapped the cytosine methylation of
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two maize inbred lines, B73 and Mo17, at single-nu-
cleotide resolution. Methylation is highest in symmet-
ric CG (65%) and CHG (50%), rather than non-
symmetric CHH (5%) contexts, and is highly enriched
in transposons, repeats, and intergenic regions but not
in centromeric repeats. Within genes, symmetric CG
methylation (8%) and CHG methylation (5%) are
found in some exons, whereas CHH methylation is
found at splice sites within introns. Alignment with
RNA sequences indicates that some of these patterns
are correlated with small RNA, gene expression, and al-
ternate splicing. Diversity in cytosine methylation pat-
terns was observed in TEs and especially in genes and
was found to be largely heritable in recombinant inbred
lines (RILs). However, significant deviations from her-
itability were observed, many of which were conserved
in different RILs. We conclude that directed changes
in DNA methylation, resembling paramutation, are fre-
quent events and may account for at least some of the
“hidden” variation in maize breeding programs.
The Maize Mutant Tunicate1 Is Caused
by Ectopic Expression of a MADS-Box
Transcription Factor, Zmm19,
in a Dosage-Dependent Manner
J.-J. Han [in collaboration with D. Jackson, Cold Spring
Harbor Laboratory]
Pod corn was once regarded as the ancestral form of cul-
tivated corn due to its characteristic of enclosing the
kernel in glumes or chaff and was prized by pre-
Columbian peoples for its magical properties. The Tu-
nicate1 (Tu1) mutant of maize is a naturally occurring
dominant mutation, resulting in a striking pod corn
phenotype that may be present in the ancestors of
maize. In a dosage-dependent manner, we could ob-
serve not only the elongation of outer glumes, but also
sex determination and branching defects in tassel and
ear. We cloned Tu1 and found that it encodes a maize
MADS-box gene Zmm19, whose 5¢ untranslated region
(5¢UTR) region is invaded by an unknown mutator-like
DNA transposon. We have shown that yellow fluores-
cent protein (YFP)- and red fluorescent protein (RFP)-
tagged Tu1 transgenic maize plants phenocopy Tu1. In
addition, YFP- and RFP-fused Tu1 proteins are local-
ized to the nucleus in immature reproductive organs
and glumes, suggesting that Tu1 participates in speci-
fying a floral organ identity. Moreover, misexpression
of miR172 is detected in Tu1, suggesting that the
Zmm19 transcription factor may target the miR172
gene in a direct or indirect way. Interestingly, the 22-
Mb region surrounding the tu1 locus in inbred B73 was
selected for finishing during the maize genome se-
quencing project, and we have found that insertion of
the mutator-like element resulted in a 1.8-Mb inversion
immediately upstream. This rearrangement prohibits
recombination and, thus, likely accompanied the ori-
gin of this ancient gene. 
Biological Design of Lemnaceae 
Aquatic Plants (Duckweed) for 
Alkane and Biodiesel Production
E. Ernst, A. Molla-Morales [in collaboration with 
J. Shanklin and H. Schwender, Brookhaven National 
Laboratory, New York; V. Citovsky, SUNY Stony Brook]
Lemnaceae species (including Lemna gibba, Lemna per-
pusilla, and Spirodela polyrhyza) are the world’s smallest
aquatic flowering plants, and although they are true
monocotyledonous angiosperms, they have a much re-
duced morphology comprising growing fronds, resting
fronds, simple roots, and two “pockets” of meristematic
stem cells. Lemnaceae, under optimal conditions, have
an exponential growth rate that can double the number
of fronds in 30 hours and produce 64 g of biomass per
gram starting weight in 1 week, which is far beyond the
fastest growing corn rates (2.3 g/g/week) and unencum-
bered by secondary products such as lignin. Lemnaceae
offer an attractive alternative to algae as biofuel feed-
stocks, because of their robust growth in marginal aquatic
environments and excellent metabolic characteristics. Ex-
isting strains of Lemna are already in commercial use, but
they have been optimized for environmental sensing and
wastewater remediation. We propose to redesign these
strains for biofuel production. Our goal is to divert a sub-
stantial portion of accumulated carbon from starch to oil
or alkane metabolism in Lemna, using resting fronds and
primitive roots as the storage tissue. Clonal propagation,
limited seed set, and variable chromosome number are
shared with sugar cane and Miscanthus gigantea, and
many of the technologies that we develop will have ap-
plications in other energy crops. 
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Specification of adaxial−abaxial (upper/lower) polarity
in the developing leaf drives the flattened outgrowth
of the leaf blade and directs the differentiation of dis-
tinct cell types within the leaf ’s adaxial/top and abax-
ial/bottom domains. Both are important innovations
in the evolution of land plants that maximize photo-
synthesis while minimizing water loss to the envi-
ronment. In addition to being a key developmental
process, adaxial−abaxial patterning is of particular in-
terest from a mechanistic point of view and has proven
to be an excellent model to study small RNA-medi-
ated gene regulation. We previously showed that pat-
terning of this developmental axis involves a cascade
of opposing small RNAs, in which microRNA
miR390 triggers the biogenesis of the TAS3-derived
21-nucleotide tasiR-ARF on the adaxial side of devel-
oping leaves. These confine the accumulation of abax-
ial determinants, including AUXIN RESPONSE
FACTOR3 (ARF3) and miR166, to the lower side of
leaves. miR166, in turn, demarcates the abaxial side by
repressing expression of class III homeodomain leucine
zipper (HD-ZIPIII) transcription factors that specify
adaxial fate.
Importantly, our analysis of the TAS3 trans-acting
small interfering RNA (tasiRNA) pathway in Arabidop-
sis demonstrated that tasiR-ARF functions as a mobile
positional signal in adaxial−abaxial patterning. Move-
ment of this small RNA from its defined source of bio-
genesis in the two uppermost cell layers of leaves creates
a gradient of accumulation that dissipates abaxially. The
tasiR-ARF gradient generates a sharply defined expres-
sion domain of the abaxial determinant ARF3 on the
bottom side of leaf primordia, suggesting that small
RNAs can establish pattern through a morphogen-like
activity.
This work provided the first direct evidence that
small RNAs are mobile and can function as instructive
signals in development, thereby revealing a novel pat-
terning activity of small RNAs.
The START Domain Regulates HD-ZIPIII
Activity and Organ Polarity
A. Husbands [in collaboration with V. Yong and
H. Djaballah, Memorial Sloan-Kettering Cancer
Center, New York]
On the basis of our previous observations regarding the
expression and function of miR166 and tasiR-ARF, it is
evident that adaxial−abaxial patterning involves a cas-
cade of positional signals. The mobile signals that pat-
tern the newly formed leaf are distinct from those that
maintain polarity during subsequent development. We
have recently started a new project to identify addi-
tional signals in adaxial−abaxial patterning. Defining
the identity of mobile positional signals remains not
only a pressing question in the field of organ polarity,
but also one of the main challenges in contemporary
plant development.
The adaxial promoting HD-ZIPIII transcription fac-
tors contain a predicted START lipid-binding domain.
Modeling of the START domain of the HD-ZIPIII
member PHABULOSA (PHB) suggests structural sim-
ilarity to human PC-TP, a phosphatidylcholine-binding
START domain. This model and sequence conservation
with other START domains was used to predict amino
acids in PHB critical for START domain ligand bind-
ing. To assess the importance of the START domain to
PHB function, we generated transgenic Arabidopsis lines
that express START domain variants of a PHB-YFP fu-
sion protein. These PHB-YFP reporters also carry silent
mutations in the miR166 target site, which normally
leads to the formation of severely adaxialized leaves.
Lines expressing a PHB-YFP variant in which several
residues lining the ligand-binding pocket of the START
domain are mutated show a wild-type phenotype, as do
lines that express a variant in which the START domain
is deleted entirely. These findings reveal positive regula-
tion of HD-ZIPIII activity by an unknown ligand and
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show that the START domain is required for proper
function of HD-ZIPIII proteins.
Experiments to determine the mechanism through
which the START domain controls HD-ZIPIII function
are ongoing. Ligand binding does not appear to affect
the subcellular localization of these transcription factors,
as confocal imaging showed that the PHB-YFP deriva-
tives correctly localize to the nucleus. We are currently
investigating whether ligand binding affects PHB’s abil-
ity to bind DNA, to activate transcription, or to interact
with required protein partners. We have also developed
a yeast-based assay that allows the high-throughput
screening of chemical libraries for compounds that are
bound by the HD-ZIPIII START domain and modu-
late protein activity. Compounds identified in this screen
may not only provide critical insight into the nature of
the HD-ZIPIII ligand, but also identify agonists/antag-
onists of the START domain that enable innovative 
experimentation into the mechanism via which HD-
ZIPIII proteins regulate diverse aspects of plant devel-
opment, including stem cell activity and organ polarity.
The screen is scheduled to start early in 2012.
Dissecting Small RNA Mobility in Plants
D. Skopelitis, C. Fernandez-Marco
Given the scope of miRNA-regulated gene networks,
the cell-to-cell movement of small RNAs has important
implications with respect to their potential as instruc-
tive signals in development or in response to physiolog-
ical and stress stimuli. We are using artificial miRNAs
targeting easy-to-score reporter genes to study parame-
ters of miRNA movement, such as tissue-specificity, di-
rectionality, dose-dependence, and the kinetics of
movement. Previous work provided evidence for move-
ment of small RNAs from the epidermis into underly-
ing cells. To further investigate miRNA mobility in
multiple distinct developmental contexts, we are ex-
pressing miRNAs targeting cell-autonomous GUS and
GFP reporters from a number of promoters that drive
expression in various spatiotemporal patterns. A first
analysis showed that miRNAs expressed from the vas-
cular-specific SUC2 promoter lead to miRNA-medi-
ated gene silencing in the mesophyll, consistent with
the idea that miRNAs can traffic from the vasculature
into adjacent mesophyll cells. Expression of artificial
miRNAs from the mesophyll-specific RBCS promoter
leads to silencing in the pavement cells of the epidermis,
indicating that miRNA mobility between the meso-
phyll and epidermis is bidirectional. Interestingly, no
reporter silencing was observed in the stomata of the
epidermis, which are symplastically isolated. This sug-
gests that miRNAs likely traffic via plasmodesmata,
channels that connect most plant cells. Analyses of
miRNA mobility in other developmental contexts are
still ongoing. In addition, with the knowledge that
miRNAs can traffic from the epidermis into underlying
tissue layers, we are carrying out forward genetic screens
to identify factors influencing this process.
Additional experiments are ongoing to decipher the
biological significance of small RNA mobility, particu-
larly with respect to their role in developmental pat-
terning. Mathematical models describing the interaction
between tasiR-ARF and ARF3 predict that small RNA
gradients resulting from mobility are uniquely suited to
establish discreet domains of target gene expression. To
test this, we are expressing a modified form of miR166
(miR166*) from promoters with distinct expression pat-
terns in a background carrying a miR166 insensitive
PHB-YFP transgene (PHB*-YFP). The miR166* se-
quence specifically cleaves the PHB*-YFP transcripts.
We are analyzing these lines by in situ hybridization to
monitor the miR166* accumulation pattern and by con-
focal microscopy to monitor PHB*-YFP accumulation.
The outcome of these experiments will reveal whether
gradients of miRNAs can sharpen target gene expression
domains, which presents a novel role for miRNA mo-
bility in pattern formation.
Characterization of Novel tasiRNA
Loci in Maize
M. Dotto [in collaboration with M. Hammell, Cold
Spring Harbor Laboratory; M. Aukerman, M. Beatty,
and R. Meeley, DuPont-Pioneer]
tasiRNAs are processed from noncoding TAS precursor
transcripts. Following cleavage by miRNA-loaded ARG-
ONAUTE (AGO) complex, one of the cleavage products
is converted into double-stranded RNA (dsRNA) through
the activities of RNA-DEPENDENT RNA POLY-
MERASE6 (RDR6) and LEAF BLADELESS1 (LBL1/
SGS3) and subsequently processed by DICER-LIKE4
(DCL4) into phased 21-nucleotide siRNAs. Arabidopsis
contains four characterized TAS gene families. AGO1 is
required for the biogenesis of tasiRNAs from the TAS1,
TAS2, and TAS4 loci, whereas miR390-loaded AGO7
triggers the biogenesis of TAS3 tasiRNAs. We previously
identified four TAS3 loci in the maize genome; however,
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the TAS1, TAS2, and TAS4 loci are not conserved be-
tween Arabidopsis and maize. To identify potential novel
TAS loci in maize, we used a deep-sequencing approach to
compare the small RNA content between wild-type and
lbl1mutant apices. This identified four novel TAS candi-
dates, all of which are targeted by miR390 and generate
tasiRNAs closely related to the known tasiR-ARFs. We
are currently using bioinformatics approaches to identify
additional phased small RNA clusters in an attempt to de-
termine whether these TAS3 loci are the only phased
siRNA generating loci in the maize genome.
In a separate approach, we are characterizing small
RNAs that associate with specific AGO proteins. We are
generating transgenic maize plants expressing FLAG-
tagged versions of ZmAGO7 and ZmAGO1b to isolate
associated small RNAs via immunoprecipitation. We ex-
pect to identify novel tasiRNAs, miRNAs, and possibly
the transcripts that are the targets of these small RNAs.
For additional information regarding the small RNA
pathways in maize, we are also characterizing small RNAs
that associate with ZmAGO10. This AGO protein has
been implicated in the miRNA- and tasiRNA-mediated
regulation of meristem maintenance and leaf develop-
ment in Arabidopsis. Phylogenetic analysis showed that
the maize genome contains two close homologs of
AtAGO10. We analyzed the small RNAs associated with
ZmAGO10 by deep sequencing the small RNAs present
in immunoprecipitates with a ZmAGO10-specific pep-
tide antibody. We found that ZmAGO10 proteins pref-
erentially bind 21-nucleotide small RNAs containing a
5¢-U, which are features common to nearly all plant 
miRNAs. However, the immunoprecipitation fraction
was enriched for just a subset of known miRNAs and
tasiRNAs, and these include miR166 and tasiR-ARF,
which we had previously shown to function in the spec-
ification of maize leaf polarity. A previously uncharacter-
ized miRNA was most enriched in the immunoprecipi-
tation fraction. In situ hybridization showed that this
miRNA also accumulates in a polar pattern, establishing
a gradient on the adaxial side of developing leaves, pre-
senting the possibility that organ polarity is regulated also
by a fourth small RNA signal. Screens for mutations af-
fecting this miRNA and its targets are ongoing.
Small RNA-Regulated Gene Networks
in Adaxial−Abaxial Patterning
K. Petsch
Mutants that disrupt tasiRNA biogenesis exhibit defects
in leaf polarity, which are characterized by sectors of
abaxial identity on the adaxial leaf surface and/or by ra-
dialization of the leaves. Interestingly, in maize, the
severity of these phenotypes is greatly dependent on the
inbred background. tasiRNA pathway mutants, as well
as other small RNA biogenesis mutants, typically exhibit
weaker phenotypes when introgressed into B73 as op-
posed to other inbred backgrounds, such as Mo17,
A619, and W22. The strongest mutant phenotypes are
frequently observed in W22, where severe alleles of
many of the tasiRNA mutants fail to produce a shoot
apical meristem. To understand how inbred background
influences mutant phenotype expressivity with respect
to the tasiRNA pathway, we are using the ragged1 allele
of leafbladeless1 (lbl1-rgd1). Taking advantage of the dif-
ferent lbl1-rgd1 phenotypes in B73 and W22, we are
using an F2 mapping population to fine-map modifiers
of the pathway that either enhance the phenotype in
W22 or suppress it in B73. Additionally, we have per-
formed a transcriptome analysis of lbl1-rgd1mutant em-
bryos and nonmutant siblings in B73 and W22 back-
grounds. This identified 214 genes that are differentially
expressed between lbl1-rgd1 and nonmutant embryos in
both backgrounds. These include known tasiRNA tar-
gets and genes showing differential expression across the
adaxial−abaxial axis, as well as genes predicted to func-
tion in the embryonic shoot meristem. We are currently
characterizing a select subset of differential expressed
genes by in situ hybridization and reverse genetics. By
combining these approaches, we hope to gain a better
understanding of the factors contributing to natural vari-
ation in the tasiRNA pathway.
Adaxial−Abaxial Patterning 
by the AS1-AS2 Complex
A. Husbands, A. Benkovics
Our findings indicate that establishment of organ polar-
ity requires the precise spatiotemporal accumulation and
relative efficacy of tasiR-ARF and miR166. We are using
genetic and biochemical approaches to identify genes
that regulate the accumulation and activities of these po-
larizing small RNAs. We have previously shown that the
Arabidopsis DNA-binding proteins ASYMMETRIC
LEAVES1 (AS1) and AS2 form a complex that contri-
butes to organ polarity. Using chromatin immunopre-
cipitation (ChIP), we have identified several polarity
determinants that are direct targets of the AS1-AS2 com-
plex. These include selected MIR166 precursors as well as
components of the TAS3 tasiRNA pathway. Our ChIP
results have been verified using reporter constructs and
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reverse transcriptase−polymerase chain reaction (RT-
PCR) analysis, and we are currently using ChIP-Seq to
examine AS1-AS2 targets in a genome-wide context. 
The abaxial determinants ARF3 and ARF4 are targets
of the TAS3-derived tasiR-ARFs. We have shown that
transcript levels for both ARF genes are up-regulated in
as2. Considering that tasiRNA pathway components are
direct targets of AS1-AS2, these transcription factors may
control ARF3 and ARF4 expression through regulation of
tasiR-ARF accumulation. To test the interaction between
the AS1/AS2 and tasiR-ARF pathways, we generated as2
plants expressing a tasiR-ARF-insensitive allele of ARF3
(ARF3-D). Interestingly, double mutants develop highly
serrated leaves with ectopic leaf-like outgrowths at the
proximal margins. Removal of ARF3 activity results in
complete suppression of leaflet formation, as does the
chemical disruption of polar auxin transport. These and
other data led us to propose that leaflet formation occurs
at auxin maxima in response to ARF3 activity. Con-
firming this, as2 ARF3-D plants expressing the PIN1:
GFP polar auxin transport reporter show colocalization
of auxin maxima with sites of incipient leaflet formation
and prolonged activity of this reporter. We are currently
examining the putative connection between the tasiR-
ARF pathway, auxin transport and the production of
compound leaf architecture.
The Ancestral Role
of the tasiRNA Pathway
E. Plavskin [in collaboration with R. Quatrano,
Washington University, St. Louis, Missouri; M. Hasebe,
National Institute for Basic Biology, Okazaki, Japan]
The diversity of multicellular organisms raises the ques-
tion of how so many varied morphologies evolved. A
number of studies have demonstrated that novel struc-
tures often arise through the hijacking of existing de-
velopmental pathways for new functions. The pathways
controlling leaf development seem to be no exception,
as many of these have been shown to be conserved in
the moss Physcomitrella patens, whose ancestors di-
verged from the lineage of flowering plants ~100 mil-
lion years before leaves first evolved in the latter. Thus,
studying the role of leaf polarity pathways in moss pro-
vides a unique opportunity to explore the evolution of
complex novel structures.
We are focusing on the miR390-dependent tasiRNA
pathway, which regulates expression of the abaxial de-
terminants ARF3 and ARF4.The genes involved in bio-
genesis of tasiRNAs, including SGS3, RDR6, and DCL4,
and the tasiRNA targets are conserved between maize,
Arabidopsis, and P. patens. Elucidating the function of
this pathway in Physcomitrella may lead to an under-
standing of its ancestral role in plant development. To
dissect the developmental processes in P. patens regulated
by tasiR-ARFs, we are taking advantage of the unique
ability of this moss to be transformed by homologous
recombination and are characterizing knockouts of genes
involved in tasiRNA biogenesis, as well as the targets of
the moss tasiR-ARFs. Our preliminary results indicate a
role for tasiRNA regulation in filamentous stem cell di-
vision in moss. sgs3 loss-of-function mutants display in-
creased branching in the filamentous stage of growth,
and mutants of some tasiRNA targets are lethal, poten-
tially reflecting a defect in the ability of filamentous stem
cells to divide. These results are further supported by a
transcriptional reporter of miR390 in moss, which shows
expression in dividing cells. Because the miR390-de-
pendent tasiRNA pathway is also involved in meristem
maintenance, our preliminary results suggest a conserved
role for the pathway in plant stem cell function. We are
continuing to explore the function of miR390-depen-
dent tasiRNA biogenesis in moss through the genera-
tion of additional knockouts and expression reporters.
We have also begun exploring the function of a miRNA
regulatory site in tasiRNA targets, which presents the
unique opportunity to study the coregulation of a gene
by a tasiRNA and miRNA.
Establishment of Determinacy 
during Lateral Organ Development
M. Lodha
Plants have the distinctive ability to form new organs
throughout their lifetime, which can span hundreds or
even thousands of years. The growing tip of a plant con-
tains a population of stem cells that are located within
a specialized niche, termed the shoot apical meristem
(SAM). These stem cells divide to maintain the SAM
and to generate daughter cells from which lateral or-
gans, such as leaves and flowers, arise. This project aims
to dissect the genetic networks that regulate stem cell
homeostasis and that distinguish indeterminate stem
cells from their differentiating derivatives.
Stem cell activity in the SAM is maintained in part by
the class I KNOX homeobox genes. To give rise to dif-
ferentiating structures, such as leaves, KNOX gene ex-
pression needs to be maintained in a stable “off” state
throughout lateral organ development. We have previ-
ously shown that this process is mediated by the tran-
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scription factors AS1 and AS2, which form hetero-
dimers that bind specific sites in the KNOX promoters.
We have now identified a role for a Polycomb repressive
complex 2 (PRC2) in the stable silencing of KNOX
genes during leaf development. PRC2 complexes have
histone H3K27 trimethylation (H3K27me3) activity,
and we have identified this repressive mark on nucleo-
somes at the BP and KNAT2 loci in leaves of Arabidop-
sis. Mutations in the PRC2 component CURLY LEAF
(CLF) lead to reduced levels of this repressive
H3K27me3 chromatin mark at the KNOX loci and to
ectopic expression of KNOX genes in developing leaves.
Likewise, H3K27me3 levels at the KNOX loci are dra-
matically reduced in the as1 and as2 mutants, identify-
ing these DNA-binding proteins as upstream com-
ponents in the KNOX silencing pathway and possible
recruitment factors for the PRC2 complex. We have
used bimolecular fluorescence complementation (BiFC),
yeast two-hybrid and protein immunoprecipitation as-
says to study possible direct and indirect interactions be-
tween AS1, AS2, and PRC2 subunits. These experi-
ments revealed multiple direct interactions between the
transcription factors, AS1 and AS2, and various PRC2
subunits.
We have also established a role for the Polycomb re-
pressive complex 1 (PRC1) in the stable silencing of
KNOX genes during leaf development. PRC1 is a
downstream component in the Polycomb pathway that
maintains long-term silencing. In plants, this complex
contains LIKE HETEROCHROMATIN PROTEIN1
(LHP1), which recognizes the H3K27me3 signature
deposited by PRC2. We found that LHP1 directly
binds silenced KNOX loci, and as expected, this bind-
ing is partially lost in an as2 mutant. These data
demonstrate that cellular differentiation is achieved via
an epigenetic mechanism in which the AS1-AS2 com-
plex serves to recruit Polycomb group proteins to
pluripotency factors to suppress their expression dur-
ing organ differentiation.
A High-Resolution Gene Expression Atlas
for the Maize Shoot Apex
M. Javelle [in collaboration with M. Scanlon, Cornell 
University, Ithaca, New York; G. Muehlbauer, 
University of Minnesota, Minneapolis; 
J. Yu, Kansas State University, Manhattan; 
P. Schnable, Iowa State University, Ames]
The gene regulatory networks controlling meristem in-
determinacy and organogenesis remain largely obscure.
To gain insight into the gene networks involved in these
distinct aspects of meristem function, we generated a
high-resolution gene expression map for the maize shoot
apex. Functional domains of the meristem were isolated
by laser microdissection and analyzed by RNA deep se-
quencing. The tissues sampled are as follows: the whole
meristem; the stem-cell-containing SAM tip; the newly
initiating leaf (P0); the epidermal layer of the SAM
(L1); the subepidermal region (L2); and vasculature
within the stem. Because gene networks controlling
meristem maintenance and leaf development are largely
interconnected, we further compared expression pro-
files in an ontogenic series of leaf primordia, P1, P2,
and P3, as well as between the adaxial and abaxial sides
of developing leaves. We identified 757 genes that
showed strong differential expression between the stem-
cell-containing SAM tip and the P0 and found 502
genes that were differentially regulated between the L1
and the L2. Using unsupervised K-means clustering, we
were able to identify genes that specifically mark the
meristem, its stem cell domain, the P0, or developing
leaf primordia (Fig. 1). This comprehensive data set al-
lows us to precisely predict genes involved in meristem
maintenance, leaf initiation, and/or leaf patterning, and
to assess the distinct contributions of the L1 and L2 to
these processes. In situ hybridization experiments are
ongoing to verify the predicted tissue specificity of se-
lected genes. 
Several known regulators of meristem indeterminacy
and organ initiation are under the control of miRNAs.
To gain insight into small RNA-controlled gene net-
works required for SAM function, we optimized the in
situ hybridization protocol for detection of small RNAs.
Using this protocol, we characterized the precise ex-
pression patterns of selected mature miRNAs. Each
shows a distinct expression pattern, suggesting diverse
contributions of small RNAs and the pathways they tar-
get to the regulation of SAM function. miRNAs appear
to function predominantly during leaf initiation and
leaf development, and only one miRNA has been iden-
tified to function in the stem cell region of the SAM.
The annotation of miRNA families is still ongoing. This
will allow us to assess expression of individual precursor
genes using the gene expression atlas. These data can
highlight instances of regulated miRNA biogenesis, sta-
bility, and mobility and will allow us to gain insight into
nonredundant roles in meristem function. Finally, this
rich resource will be used to guide functional genomics
experiments to address the role of new candidate genes
in meristem function. 
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Characterization of chups, an
Embryonic Patterning Mutant
in Arabidopsis
C. Fernandez-Marco
Embryogenesis in Arabidopsis proceeds through a se-
ries of highly stereotyped divisions and gives rise to a
structure that contains two stem cell niches: the shoot
apical meristem and the root apical meristem, which
are the sources of all cells for postembryonic develop-
ment. An asymmetric division of the zygote gives rise
to the apical embryonic lineage and the basal extraem-
bryonic suspensor. After several more rounds of cell di-
vision, the upper tier of the embryo generates the shoot
apical meristem, whereas the upper cell of the suspen-
sor undergoes two successive asymmetric divisions to
give rise to the root apical meristem. We have identi-
fied a mutant that delays embryonic development. At
the time that wild-type embryos have reached matu-
rity, mutant embryos show globular or heart-shaped
morphologies. We have called this mutant chupa chups
(chups), which means lollipop in Spanish, as a reminder
of the globular shape of mutant embryos. Despite the
delay in embryogenesis, patterning of the shoot apical
meristem is unaffected in chups mutants. In contrast,
cell division of the hypophysis, the specialized cell of
the suspensor that ultimately gives rise to the quiescent
center of the root stem cell niche, is perturbed in chups.
Auxin transport and signaling are key to the specifica-
tion of the hypophysis and patterning of the root stem
cell niche. Preliminary data show that expression of
markers for auxin transport and signaling are altered
in chups and that an auxin maxima is no longer estab-
lished at the boundary between the proembryo and
suspensor, which affects specification of the hypo-
physal cell. Although chups mutant embryos are not
normally viable, mutants can be rescued by transfer-
ring fertilized ovules onto culture medium. Consistent
with the above-mentioned defects, rescued mutant
seedlings lack a root. chups maps to the top arm of
chromosome IV. We are currently determining the un-
derlying mutation. The outcome of these experiments
will allow us to characterize and position CHUPA
CHUPS in the genetic network that patterns the root
stem cell niche during embryogenesis.
Figure 1. A high-resolution gene expression atlas for the maize shoot apex identifies genes that function in specific
domains of the meristem associated with stem cell maintenance and organogenesis. Of the 18,280 genes expressed
at levels above 2RPM in the whole SAM, SAM tip, and/or P0–P3 leaf primordia, 9267 are dynamically expressed,
showing differential expression (≥2-fold, q < 0.05) in at least one of the domains analyzed. Unsupervised K-means
clustering sorted these dynamically expressed genes into 74 clusters, including clusters of genes showing strong
preferential expression in the meristem or in developing leaf primordia, as well as gene clusters that show a strong
enrichment in the SAM tip, the P0, or specific stages of primordium development. In situ hybridization was used to
validate the expression patterns of genes that, based on unsupervised K-means clustering, are predicted to localize
preferentially to the SAM tip (top right) or P0 (bottom right). The arrow points to the position of the P0 leaf pri-
mordium.
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Marie Javelle
Cold Spring Harbor Laboratory is at the leading edge of efforts to manage and interpret the mas-
sive amounts of information generated by contemporary biological experiments, across diverse areas
of specialization. The Laboratory’s commitment is seen in its ongoing participation in multinational
efforts to sequence and annotate genomes of importance and in the recently established Simons
Center for Quantitative Biology. The new center reflects the importance of math and statistics in
the forging of new approaches to problems and new ways of understanding the results of biological
experiments.
Thomas Gingeras and colleagues study where and how functional information is stored in genomes.
These efforts help to explain the biological and clinical effects of disease-causing gene mutations in
humans and other organisms. Gingeras is a leader of ENCODE (ENCyclopedia of DNA Elements),
the mouseENCODE, and modENCODE (model genome ENCODE) projects of the National In-
stitutes of Health. His research has altered our understanding of the traditional boundaries of genes,
revealing that almost the entire lengths of genomes in organisms ranging from bacteria to humans can
be transcribed into RNA (pervasive transcription) and that most RNA products made by a cell are
not destined to be translated into proteins (noncoding, or ncRNAs). In fact, ncRNAs are proving to
be involved in a variety of other important biological functions. Some have been shown to be criti-
cal components in the pretranscriptional, posttranscriptional, and translational processes. Others
serve as scaffolds upon which large protein complexes are assembled.
The insights of W. Richard McCombie and colleagues have led to the introduction and opti-
mization of novel methods of high-throughput genome sequencing. His team has made it possible
to catalog variation among individual organisms in a way that would have been unthinkable a decade
ago. They have brought online a new generation of Solexa sequencers and optimized their function
to a level at which 10 billion DNA bases can be sequenced in a typical day, and on some days as many
as 20 billion. McCombie’s team has been involved in international efforts culminating in genome
sequences for maize and rice, two of the world’s most important food crops. The lab has also had
an important role in projects to sequence the flowering plant Arabidopsis thaliana and the fission
yeast Schizosaccharomyces pombe, as well as Homo sapiens and other important genomes. McCom-
bie’s group is currently involved in several important projects to sequence genes of special interest
to human health, including DISC1, a strong candidate gene for schizophrenia, as well as genomic
regions likely implicated in bipolar illness. With the Memorial Sloan-Kettering Cancer Center, they
are using a method called hybrid resequencing, developed with Greg Hannon, to look at mutations
in samples collected from patients with prostate cancer.
Using multidisciplinary approaches that combine computational analysis, modeling, and pre-
diction with experimental verification, Doreen Ware’s lab seeks a deeper understanding of the evo-
lution of genome sequences in plants and their implications for agricultural improvement. By
looking comparatively across the genomes of plants in the same lineage, Ware’s team seeks answers
to such questions as How are genes conserved and lost over time? What are the fates of duplicated
genes? The team also studies gene regulation in plants, looking at cis-regulatory elements and char-
acterizing transcription factors and microRNA genes and their respective targets, with the objective
of understanding how these parts of the plant genome work together in determining spatial and
temporal expression of genes. The Ware lab has also had an important role in the project to produce
a reference genome of maize, providing annotations and helping to generate a draft haplotype map,
a gauge of maize’s genetic diversity. They have devoted special attention to examining diversity
within maize and grape, aiming to accelerate the development of strategies to introduce new
germplasm that are needed to meet demands of an increasing population and a changing environ-
ment. The lab also has brought fully sequenced genomes into an integrated data framework to en-
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hance the power of its comparative studies. This framework now includes 13 genomes of model
plants such as Arabidopsis and important agricultural species including maize, rice, sorghum, grape,
and poplar. This past year, Ware, as principal investigator for plants, helped lead an effort funded
by the Department of Energy to create, out of many separate streams of biological information, a
single, integrated cyber-“knowledgebase” for plants and microbial life.
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Human/ENCODE Project 
K. Bell, S. Chakrabortty, C. Davis, A. Dobin, J. Drenkow,
M. Fastuca, S. Jha, W. Lin, J. Schlesinger, L.-H. See,
H. Wang, C. Xue, C. Zalenski
Eukaryotic cells make many types of RNAs. As the tech-
nologies for RNA profiling and for cell-type isolation and
culture continue to improve, the catalog of RNA types
has grown—leading to an increased appreciation for the
numerous biological roles played by RNA and arguably
putting them on par with the functional importance of
proteins. The Encyclopedia of DNA Elements (EN-
CODE) project endeavors to identify the functional ele-
ments present in the human genome sequence. One
result of the pilot phase of the ENCODE project, which
examined ~1% of the human genome, was the pervasive
extent of transcription observed in both gene-rich and
gene-poor regions, confirming some prior studies. Dur-
ing the second phase of the ENCODE project, the scope
of examination has broadened to the complete human
genome (The ENCODE Project Consortium). In this
phase of ENCODE, we have sought both to provide a
comprehensive genome-wide catalog of human tran-
scripts and to identify the subcellular context for distinct
RNAs and their classes. This goal was approached by
identifying and characterizing annotated and novel RNAs
that are enriched in either of the two major cellular sub-
compartments (nucleus and cytosol) for all 15 cell lines
studied and, for one cell line, three additional subnuclear
compartments (chromatin, nucleoplasm, and nucleoli).
In addition, we have sought to determine if identified
transcripts are modified at their 5¢ and 3¢ termini by the
presence of a cap or polyadenylation and to determine as
many precursor-product relationships for the identified
RNAs as was possible. The long and short RNA-Seq li-
braries were each sequenced to an average depth of 100
million (76-mer mate-pairs) and 30 million (single-end
36-mers) reads per library, respectively. A total of 20 and
2 billion reads were mapped with splice transcript and
reconstruction (STAR), a novel split read mapping algo-
rithm or TopHat for the long and short RNA libraries, re-
spectively. Cap analysis of gene expression (CAGE) 
(Djebali et al. 2012) was used to identify the 5¢ end of
posttranscriptionally modified transcripts and to mark
transcriptional start sites (TSSs). CAGE libraries were se-
quenced to an average depth of ~16 million (single-end
36-mers) reads per library totaling 1.1 billion reads and
were mapped with DELVE. PET (paired end tags) was
used to identify 5¢ ends of capped RNAs to their 3¢ ends.
PET libraries were sequenced to an average depth of 11.7
million (paired-end 36-mer) reads totaling ~47 million
reads. These data were mapped using the TopHat algo-
rithm. The majority of the data sets were generated in bi-
ological replicate. The raw data, mapped data, and ele-
ments are then made available by the ENCODE Data
Coordination Center (DCC; http://genome.ucsc.edu/
ENCODE/dataSummary.html). These data, as well as
additional data on all intermediate processing steps, are
available on the RNA Dashboard: http://genome.crg.
cat/encode_RNA_dashboard/. This genome-wide com-
pilation of subcellular localized and product-precursor-
related RNAs serves as a public resource and reveals new
and detailed facets of the RNA landscape that include the
following:
• Cumulatively, a total of 62.1% and 74.7% of the
human genome were observed to be covered by ei-
ther processed (contigs and Gencode exons) and pri-
mary transcripts (contigs, junctions, and Gencode
genes), respectively, with no cell line showing more
than 56.7% of the union of the expressed transcrip-
tome across all cells (Fig. 1).
• A consequence of the increased proportion of the
human genome being transcribed is that the inter-
genic regions of the human genome are shrinking in
size (most being <10,000 bp), having notable im-
plications on the classic definition of a genic region.
• The current genome-wide annotated catalog of long
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T.R. Gingeras P. Batut M. Fastuca H. Wang
S. Chakrabortty S. Jha D. Wu
C. Davis W. Lin C. Xue
A. Dobin J. Schlesinger C. Zaleski
J. Drenkow L.-H. See
polyadenlyated and short RNAs currently cataloged by
the Gencode annotation group can be increased by
94,800 exons (19%), 69,052 splice sites (22%), 73,325
transcripts (45%), and 41,204 genic regions (80%).
• Isoform expression by genes was observed not to fol-
low a minimalistic expression strategy, resulting in
genes tending to express many isoforms simultane-
ously, and appears to plateau at ~10−12 expressed
isoforms per gene per cell line.
• Cell-type-specific enhancers are promoters that are
differentiable from other regulatory regions by the
presence of novel RNA transcripts, chromatin
marks, and DNase-l-hypersensitive sites.
A full description of this work embodied in five
manuscripts was submitted for publication recently.
Mod/ENCODE Project 
C. Davis, A. Dobin, S. Jha, C. Xue 
To comprehensively characterize transcribed sequences
in the genome, members of my laboratory have collabo-
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rated with many other institutions, and these are sum-
marized in the publications listed below (Cherbas et al.
2011; Graveley et al. 2011; The medENCODE Project
Consortium, Science 330: 1787 [2010]). RNA-Seq was
performed using poly(A)+ and total RNA. We found that
94% of the FlyBase (FB) 5.12 genes, and 91% of exons,
showed expression in at least one of 30 developmental
samples or four cell lines. The RNA-Seq data confirmed
45,153 (93%) of the 51,385 annotated FB5.12 splice
junctions and identified 22,965 new splice junctions.
Data from cDNA sequences, RT-PCR (reverse transcrip-
tase−polymerase chain reaction) products, and long
poly(A)+ RNA-Seq support 8012 (35%) of novel splice
junctions. cDNA sequences also support 236 FB5.12
gene merges and validate 485 of 1938 new predicted
genes (25%). A total of 20 million CAGE tags, 1.2 mil-
lion RACE (rapid amplification of cDNA ends) reads,
and 50,000 expressed sequence tags (ESTs) determine
embryonic transcription start sites and their distribu-
tions. A total of 12,454 promoters of 8433 genes were
identified. This corresponds to 70% of the genes ex-
pressed in the embryo and 56% of the genes in FB5.12
Figure 1. Nucleotide coverage of Gencode exonic, intronic, and intergenic regions. Within each cell of the plot, three
different types of coverage are depicted: (1) Total nucleotide coverage of the genome (black), (2) proportion of a certain
genomic domain covered by RNA-Seq reads, and (3) proportion of mapped bases that fall into a genomic domain. The
box plots are generated from values across all cell lines, the largest point showing the cumulative value. These plots rep-
resent the number of nucleotides detected by RNA-Seq during the analysis of total, polyadenylated and nonpolyadenyl-
ated RNAs isolated from total cell extract and from the nucleus cytosol of the same cells. These RNAs are mapped to
exonic, intronic, and intergenic regions of hg19 assembly and using the gene annotations found in Gencode v7. The last
column is a cumulative summary of all coverage observed in each compartment and for each RNA subtype. 
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annotations. We find that 74% of the promoters have a
broad TSS distribution and 26% have a peaked TSS dis-
tribution. A total of 2075 new promoters were discovered
and validated, of which 310 of the 427 promoters adja-
cent to active transcripts in S2 cells (72.5%) are addi-
tionally supported by promoter-associated chromatin
marks discussed below, suggesting that these genes have
a higher potential for alternative TSS regulation. In sum-
mary, compiling these data expanded FB5.12 by 1938
novel genes, 14,016 alternate transcripts of known genes,
and 52,914 new or modified exons, of which 34,505
(65%) have been confirmed by cDNA sequencing. Fur-
thermore, 89% of the 21,071 new exons that are ex-
pressed in S2 cells are independently supported by
promoter- and transcript-associated chromatin signa-
tures. Overall, 74% of FlyBase genes show at least one
new or modified exon or alternative splice form, illus-
trating the importance of systematic transcriptome
probing in numerous cell types, even for a species as well-
studied as Drosophila melanogaster. These and other sig-
nificant findings were recently published (Cherbas et al.
2011; Graveley et al. 2011; The medENCODE Project
Consortium, Science 330: 1787 [2010]). 
Mouse/ENCODE Project
C. Davis, A. Dobin, S. Jha, C. Xue
This year, my laboratory joined the effort to develop a
comprehensive transcription map of the mouse genome
as part of the expanded ENCODE project. The work
this year has focused on carrying out RNA-Seq on
rRNA-depleted total RNA from 30 different mouse tis-
sues in replicate. These data are currently being ana-
lyzed to produce mapped exon, splice site, transcript,
and gene elements. Summary statistics are being com-
piled and cross-sample comparisons are now in prepa-
ration. The goal will be to use these mapped and
summarized data in a comparative analysis with tran-
scriptome data collected from human, fly, and worm.
Software and Database Development
A. Dobin, S. Jha, C. Xue, C. Zaleski
We currently maintain a database of sequenced libraries,
including raw “fastq” data and extensive metadata. The
files maintained in this database currently total more than
7 TB of storage space. The entire data set is managed by
a software system constructed internally. A collection of
software tools was assembled by members of our labora-
tory. Genomics Data Manager (GDM) is composed of a
MySQL database, PHP business layer, and a web-based
front end that is accessible from any browser. In addition
to 7 TB of data directly managed by the database, we also
maintain more than 14 TB of processed/analyzed data.
An extensive software pipeline has been created to process
the data through the many stages of transformation—
mapping, formatting, contig generation, FPKM genera-
tion, QC stats, etc. The pipeline consists of many scripted
modules, written in BASH and PYTHON, which in
turn call to external analysis tools. These tools combine
both internally developed and third party software. The
analysis pipeline also integrates with an SGE (sun grid
engine) system, using many disparate servers that range
from 4 cores and 4 GB of memory up to 24 cores and
144 GB of memory.
A large proportion of these data is also sent to the
CRG (Center for Genomic Regulation) in Barcelona for
later submission as part of the ENCODE project. We
have sent 288 libraries to the CRG comprising human
long RNA (>200 nucleotides), human short RNA (<200
nucleotides), and mouse long RNA (>200 nucleotides).
Each library submission contains both raw and processed
data files. The CRG aggregates many varieties of data for
the ENCODE Project, including CAGE, PET, Mi-
croArray, and RNA-Seq. To date, our laboratory RNA-
Seq submissions constitute the greatest proportion of
submitted libraries. A timely updated status of all data
comanaged by the CRG and ourselves can be found on
a dashboard established by the Guigo laboratory (http://
genome.crg.cat/encode_RNA_dashboard/).
Finally, recent advances in sequencing technologies
have made transcriptome analyses at the single-nu-
cleotide level almost routine. However, hundreds of mil-
lions of short (36-mer) to medium (100-mer) length
sequences (reads) generated from such high-throughput
sequencing experiments present unique challenges to the
detection and characterization of spliced transcripts. Two
key tasks make these analyses extremely computation-
ally intensive. The first is the accurate alignment of reads
that may contain mismatches caused by sequencing
and mapping errors, as well as the presence of single-
 nucleotide polymorphisms (SNPs) and short insertion/
deletions in the genome. The second task involves the
mapping of reads derived from the noncontiguous re-
gions of the genomes comprising the spliced sequence
modules that are joined together to form the spliced
RNAs. Although the first task is shared with DNA rese-
quencing efforts, the second one is specific and crucial to
the RNA  sequencing (RNA-Seq),  because it provides the
connectivity information for the sequenced RNA mol-
ecules that is needed to reconstruct the full length of
spliced RNA transcripts. These alignment challenges are
further compounded by the presence of multiple copies
of identical or related genomic sequences that are them-
selves transcribed, making precise mapping difficult.
An important and novel algorithm entitled STAR (a
spliced transcripts alignment to the reference), which was
designed to specifically address many of the challenges of
RNA-Seq data mapping, was developed by Alex Dobin in
our laboratory this year. This algorithm uses a novel strat-
egy for the spliced reads alignment. STAR was designed
for accurate de novo detection of the canonical splice junc-
tions, as well as noncanonical junctions and nonlinear
chimeric transcripts resulting from genomic rearrange-
ments or trans-splicing. Unlike many other RNA-Seq
mappers, STAR is not an extension of a short-read DNA
mapper, but was developed as a stand-alone C++ code.
STAR does not use any temporary files and hence occupies
a moderate disk footprint; however, it requires a relatively
large amount of RAM, ~10* (genome length) bytes, which
is ~27 GB for the human genome. STAR is capable of run-
ning parallel threads on multicore systems with almost lin-
ear scaling of productivity up to 12 cores. STAR is very
fast: On a modern but not overly expensive server, it can
align to the human genome 36 million of 2 x 76-mer reads
per hour per core, outperforming all other existing RNA-
Seq aligners by more than an order of magnitude. STAR
was used to map a large ENCODE transcriptome data set
(>42 billion Illumina reads), and its accuracy for predict-
ing novel splice junctions was corroborated in several high-
throughput validation experiments. Approximately 82%−
89% (H1ES) and 84%− 95% (HUVEC) of all the tested
novel intergenic/antisense junctions supported by at least
five RNA-Seq reads were corroborated by at least two am-
plicons sequenced by 454. 
STAR was designed primarily as a tool to map shot-
gun RNA-Seq data to a reference genome. In certain
cases, it is possible to solve the problem at hand by tweak-
ing the alignment parameters (e.g., for mapping short
RNAs or mapping long Roche 454 reads); in other cases,
profound changes of the algorithm are required (e.g., for
mapping Pacific Biosciences reads with high indel rate).
We demonstrated STAR’s ability to align long reads con-
taining a large number of splice junction mismatches and
indels by mapping the simulated Pacific Biosciences data.
We have also performed successful alignments of the data
from the other technologies (Ion Torrent, Roche 454,
and Sanger sequencing), demonstrating that STAR can
serve as a universal tool across a broad spectrum of se-
quencing platforms. A full description of this work has
been submitted for publication recently.
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Novel Exon Detection by
Hierarchical RNA-Seq Clustering 
K. Schlesinger, C. Davis
In part, the goals of the ENCODE transcriptome proj-
ect required that we perform a large number of RNA-
Seq experiments on diverse RNA samples. Integrative
analysis of these experiments requires methods to nor-
malize the data and account for varying noise levels and
sensitivity. This is of special importance when trying to
confidently identify novel or poorly understood classes
of transcripts without much prior knowledge. We used a
newly developed pool of 96 synthetic RNAs with various
features covering a 220 concentration range as spike-in
controls to measure sensitivity, accuracy, and biases in
RNA-Seq experiments as well as to derive standard
curves for quantifying the abundance of transcripts. We
observed linearity between read density and RNA input
over the entire detection range and excellent agreement
between replicates, but we observed significantly larger
imprecision than expected under pure Poisson sampling
errors. We use the control RNAs to directly measure re-
producible protocol-dependent biases due to GC con-
tent and transcript length, as well as stereotypic
heterogeneity in coverage across transcripts correlated
with a position relative to RNA termini and priming se-
quence bias. These effects lead to biased quantification
for short transcripts and individual exons, which is a se-
rious problem for measurements of isoform abundances,
but which can partially be corrected using appropriate
models of bias. By using the control RNAs, we derive
limits for the discovery and detection of rare transcripts
in RNA-Seq experiments. Using the ENCODE data, we
demonstrate that external RNA controls are a useful re-
source for evaluating sensitivity and accuracy of RNA-
Seq experiments for transcriptome discovery and quanti-
fication. These quality metrics facilitate comparable
analysis across different samples, protocols, and platforms
(Jiang et al. 2011). 
We also used a collection of quantified ENCODE
transcriptome data to estimate the expression levels of
genes on the autosomes compared to genes on the X
chromosome in several male and female human cell
lines. We demonstrated that the typical expression from
a single active allele on an X-linked gene is identical to
the typical expression from two alleles for autosomal
genes for all tested classes of genes and cell lines. In col-
laboration with researchers at the University of Wash-
ington School of Medicine, we used these and other
data to argue for “Ohno’s Hypothesis” of X-chromo-
some dosage compensation (Deng et al. 2011). 
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Finally, as described previously in our work on the
STAR algorithm, current high-throughput sequencing
strategies rely on short reads, which represent only frag-
ments of cDNAs. Because it is not possible to know if
two different fragments came from the same transcript
isoform, ab initio assembly of full-length transcripts is a
complicated task with significant errors possible. This can
be especially problematic in interesting loci with many
different isoforms spanning a wide range of expression
levels. The task is further complicated by widespread al-
ternative splicing and many novel, poorly understood
types of noncoding RNAs in complex genomes. These
problems could be solved with full-length cDNA se-
quences from individual transcripts. Classic approaches
for cDNA sequencing, however, do not provide sufficient
throughput to analyze whole transcriptomes including
low-abundance isoforms. We have begun to use a new
approach, sequencing full-length human cDNA libraries
using real-time, single-molecule, long reads from a Pa-
cific Biosciences RS sequencer. We developed methods
for library preparation, target enrichment, primary se-
quence analysis, and a transcript mapping pipeline. We
currently can achieve about 1 million reads with average
read length of more than 2500 bp, allowing us to cap-
ture many complete transcripts, including novel isoforms
and non coding RNAs, without using previous annota-
tion or assembling across different molecules.
Transposons and Evolution
of Transcriptional Regulation
in the Drosophila Clade 
P. Batut, A. Dobin
Promoters and their associated transcription start sites
(TSSs) harbor the core genomic elements determining
transcription. Yet their locations, features, and evolution
are poorly characterized, even in well-studied model or-
ganisms, prompting large-scale efforts targeted at these
critical sites. TSS discovery strategies based on 5¢-com-
plete cDNA sequencing, such as cap analysis of gene
 expression (CAGE), have paved the road for such
 endeavors, but they still suffer from very cumbersome
protocols, difficult multiplexing, limited specificity for
TSSs, and the acquisition of single, short sequence tags.
This last point is a major limitation in two respects: It
prevents the identification of the transcripts driven by a
given TSS, and it precludes the study of massive regions
of highly repetitive eukaryotic genomes. We developed a
technology that would offer high-throughput and easy
parallelization, significantly increased specificity for TSSs,
and tunable sequencing read length and would allow for
paired-end sequencing of 5¢-complete cDNAs on the Il-
lumina platform. We termed this technique RAMPAGE
(RNA annotation and mapping of promoters for the
analysis of gene expression). Benchmarking against ex-
isting techniques supports the high performance of our
approach in terms of specificity for TSSs, single-base res-
olution, and gene expression quantification. We have de-
signed a dedicated analysis pipeline to take full advantage
of the unique features of these data. This approach was
applied in a study of the dynamics of promoter activity
throughout the life cycle of D. melanogaster. We showed
that alternative promoter usage is extremely common in
D. melanogaster, with more than 40% of genes having at
least two TSSs. Alternative promoters tend to drive ex-
pression in uncorrelated patterns, suggesting that they
implement different regulatory programs. Furthermore,
we discovered that transposable elements harbor TSSs
driving hundreds of annotated genes and often impart
their own expression specificity on the genes that they
regulate. In agreement with long-standing theories, our
work suggests that transposons contribute significantly
to the generation of standing variation and to the evolu-
tion of gene regulatory networks by distributing stereo-
typed regulatory modules throughout the genome. We
are now applying our approach to investigate the evolu-
tionary dynamics of promoters and their regulation
throughout the Drosophila clade, and the role of trans-
posons in shaping these dynamics, by conducting the
same studies in other species. A complete description of
this work has been recently submitted for publication.
RNA-Mediated Intercellular Signaling 
S. Chakrabortty, A. Dobin
The potential role of RNAs as signaling molecules has, in
part, been better understood based on studies involving
cell-released exosomes. Exosomes are small 40−100-nm
vesicles of endocytic origin that are secreted into the ex-
tracellular milieu on fusion of intracellular multivesicular
bodies (MVBs) to the plasma membrane. Using electron
microscopy, we characterized the exosomes by a cup-
shaped morphology. Because of their  endocytic origin,
exosomes often contain both cell- surface and cytosolic
proteins involved in membrane transport and fusion and
MVB biogenesis. Although the mechanisms for both in-
clusion and uptake of  exosomes containing both proteins
and nucleic acids are largely undefined, extracellular ex-
osomes are known to be enriched in raft lipids such as
cholesterol, sphingolipids, and glycerophospholipids, and
the endosomal sorting complex required for trafficking
(ESCRT) complex members has been implicated in sort-
ing of the proteins to exosomes. Intriguingly, the RNA
content of exosomes and their potential functional sig-
nificance remain unexplored as yet. The goals of this proj-
ect are to evaluate the RNA components found in
mouse-tumor-derived exosomes and evaluate whether ex-
osome delivery of these RNAs is involved in specific in-
tercellular transference of functional long and/or short
RNAs between cells. During the course of this year, sev-
eral parts of this project have been addressed, including
the development of an efficient and quantitative exosome
isolation procedure, the validation of the purity of the
isolated exosomes, RNA isolation, sequencing, charac-
terization, and comparison of exosomal RNA and RNA
from their source cells. Work has been initiated in the de-
termination of whether exosomal-mediated transfer of
the encapsulated RNA can be demonstrated and evalua-
tion of any phenotypes associated with this transfer. 
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Thomas Gingeras (standing, center) and lab members
In 2011, we continued to build genomic capability,
which we used both for our own lab’s projects and for
collaborations with other labs on campus. We produced
a dramatic increase in overall sequencing capacity,
shown in Figure 1. This data output increase, as well as
the reduction in the cost per base that accompanies it,
has been enabling for a number of projects.
In the cognitive genomics area, we have finished or
are nearing completion of several projects described
below, and those projects will be moving into the analy-
sis phase. We have also optimized multiplexed exome
capture and subsequent analysis for a project to study
bipolar disorder and have expanded our effort to per-
form whole-genome sequencing (WGS) with extended
families that have a high burden of psychiatric disor-
ders as described below. Of particular interest for fu-
ture progress is that we have succeeded in initial
attempts to perform “microtargeting” for capturing and
sequencing small regions (~0.5 million bases) from very
large numbers of samples. We believe that advances in
this area will be a long-term component in our studies
of cognitive genomics.
In the cancer genomics field, we moved forward on
two main projects. The first is a study on Barrett’s
esophagus and esophageal cancer in collaboration with
a group at Johns Hopkins. The second is our ongoing
collaboration with Memorial Sloan-Kettering Cancer
Center on prostate cancer.
Lastly, we have continued our work on developing
new sequencing technologies in plant genomics. This
is an exciting area in which we are trying to adapt next-
generation sequencing methodologies to de novo se-
quencing of plant genomes (Fig.1).
Targeted Resequencing of the Human
DISC1 Gene Using Long-Range PCR
and Illumina Sequencing
This work was done in collaboration with D. Blackwood,
D. Porteous, P. Thompson, I. Deary, University of Edinburgh;
P. Visscher and A. McRae, University of Queensland.
Disrupted-In-Schizophrenia 1 (DISC1) is a strong can-
didate gene for bipolar disorder, schizophrenia, and cog-
nitive disorders. A translocation disrupting this gene was
first described by our collaborators in Edinburgh, who
showed that it segregated significantly with psychiatric
disorder in a Scottish pedigree. In conjunction with our
collaborators, we initiated a pilot project to resequence
~523 kb on chromosome 1 containing DISC1 using
long-range polymerase chain reaction (PCR). The
planned sequencing of the DISC1 region on chromo-
some 1 in 2088 samples was completed previously and
putative single-nucleotide polymorphisms (SNPs) were
identified using the program MAQ (Li, Genome Res 18:
1851 [2008]).
After rigorous quality control, the final sample set of
1542 comprised 221 bipolar disorder, 240 schizophre-
nia, 192 major depression, and 889 control individuals
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Figure 1. Comparison of total bases generated versus total high-
quality bases for monthly Illumina sequencing runs from De-
cember 2010 through December 2011. We use Q30 bases as a
metric to ensure very high-quality data.
Table 1. Overview of DISC1 Mutation Analysis
(the majority of controls are samples from the Lothian
Birth Cohort). In 2010 and early 2011, we performed
validation and initial analysis of the resulting large num-
ber of novel variants. We were able to validate 2718 rare
variants by Sanger sequencing. Variants were screened
to exclude repeat regions (RepeatMasker), primer re-
gions, and triallelic regions (Table 1).
Although previous work focused on single-nucleotide
variants (SNVs), in 2011 we included analysis of small
insertions and deletions. The Genome Analysis Toolkit
(GATK) (DePristo MA, et al. 2011) was used to gener-
ate SNPs and small insertion-deletion (indel) calls for
the data. GATK was used for local read realignment
around indels and for base quality score recalibration
using corrections for base position within the Illumina
read, sequence context, and platform-reported quality.
The recalibration was followed by SNP/indel calling.
Variants were filtered for a confidence score of 50, and
SNP clusters (>3 SNPs per 10 bp) were excluded. Ap-
proximately 80%–90% of the SNPs called by MAQ
were also called by GATK, showing a high level of con-
cordance for the methods. With our collaborators, we
will complete the analysis and validation of potentially
interesting indels for this study in early 2012.
During 2011, our collaborators also performed sta-
tistical analysis of the validated SNPs, testing for asso-
ciation of both specific DISC1 variants and overall
burden of variants. This study uncovered a large num-
ber of novel rare variants; however, we also identified
several previously reported rare coding SNPs, includ-
ing R37W, which was initially reported in a patient
with schizophrenia (Song et al., Biochem Biophys Res
Commun 367: 700 [2008]). The results of the analysis
indicate a possible association of noncoding SNPs with
recurrent major depressive disorder. In early 2012, we
will use Sanger sequencing and TaqMan assays to check
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for segregation of interesting rare SNVs in extended
family members. We will complete final analysis of the
data in 2012 and publish our findings. This study high-
lights rare mutations in DISCI that appear to con-
tribute to psychiatric disorders.
Targeted Resequencing of the DISC1
Interactome Using Solution-Based
Hybrid Selection and Illumina 
Sequencing
S. McCarthy, W.R. McCombie [in collaboration with D.
Blackwood, D. Porteous, I. Deary, University of Edinburgh;
P. Visscher, A. McRae, University of Queensland]
The DISC1 interactome is a network of genes that in-
teract with DISC1. These genes have been implicated in
psychiatric and cognitive disorders, and together with
DISC1, they converge on pathways critical for neuronal
signaling and those important in the treatment of schiz-
ophrenia, bipolar disorder, and major depression. Sim-
ilar to DISC1, it is possible that mutations in genes
constituting the DISC1 interactome may also be of
large effect and significantly increase the risk of psychi-
atric disorders. In collaboration with the University of
Edinburgh, we are isolating and sequencing the exons,
promoters, and conserved regions of 250 genes that are
known to directly interact with DISC1 or that are part
of functional biological pathways related to DISC1 in-
teractome activity.
To overcome several technical difficulties and in-
consistent data using hybrid capture arrays targeting
400 genes, and the uneven distribution of data from se-
quencing RainDance Technologies microdroplet PCR
products spanning seven genes (AKT1, GSK3B, NDE1,
NDEL1, PDE4B, PDE4D, and TNIK), we developed
a custom solution capture probe set, in collaboration
with Roche NimbleGen, to specifically enrich ~250
genes of the DISC1 interactome. This design took ad-
vantage of progress made by Roche NimbleGen to bal-
ance probe-target selection in solution, permitting
efficient custom capture of each exon, promoter, and
conserved region that is 20 kb proximal and distal of
all genes. Taking every isoform into account, exons of
the DISC1 interactome were obtained from RefSeq and
the University of California, Santa Cruz (UCSC) gene
list. Promoters were defined as those that were 2 kb up-
stream of each gene, whereas conserved regions were
defined as runs of 10 bp or greater, with an average
score equal to or greater than 0.3 based on phast-
Cons44way nucleotide-wise conservation values.
*The stop mutation is only found in the short isoform of DISC1.
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Approximately 13 Mb (0.4%) of the human genome
is selectively targeted by the custom solution capture de-
sign for the DISC1 interactome. With such a target size,
it is theoretically possible to sequence between 16 and 24
samples per HiSeq2000 lane in pools of barcoded li-
braries. However, we spent significant effort in testing and
optimizing a pooling strategy and highlighted a number
of inefficiencies with the sequence capture of whole-
genome-amplified (WGA) material. Following evaluation
of several pooling schemes, we determined that the most
optimal strategy was to sequence 16 barcoded samples
across three lanes of a HiSeq2000 flow cell.
Making use of this threefold increase in our sequence
requirement, we have begun targeting the DISC1 inter-
actome in 1407 individuals, comprising 207 individu-
als with a diagnosis of bipolar disorder (BP), 225 with a
diagnosis of schizophrenia (SCZ), 172 with unipolar de-
pression (UP), 793 from the Lothian Birth Cohort
(LBC), and 10 additional controls (CTRL). At the time
of writing, the DISC1 interactome had been captured
in ~97% (1357/1407) of all samples WGA to preserve
limited genomic DNA stocks. The remaining 3% rep-
resent samples with insufficient WGA DNA quantity
or quality for capture. To date, 37.7% of the total sam-
ple (531/1407: 91 BP, 142 SCZ, 74 UP, 220 LBC, 4
CTRL) have been sequenced at a minimum depth of
20x spanning >80% of the DISC1 interactome target.
We expect to complete sequencing of all samples, ana-
lyze, and publish our results in 2012.
Sequencing of Barrett’s Esophagus 
and Matched Adenocarcinoma Genomes
M. Streppel, S. Lata, M. Kramer, E. Antoniou, A. Maitra (Johns
Hopkins Medical Institute, Maryland); W.R. McCombie
Barrett’s esophagus (BE)-associated esophagus adeno-
carcinoma (EAC) is an aggressive tumor increasingly di-
agnosed in Caucasian males. The genetic basis of EAC
is largely unknown. The aims of this study were to dis-
cover novel mutations during neoplastic progression of
BE-EAC. Normal squamous epithelium (NSE) of the
esophagus, BE, and EAC frozen biopsies were obtained
from a single EAC patient and were whole-genome se-
quenced using Illumina next-generation sequencing in
the latter half of 2010; analysis was performed in 2011.
SNVs were retrieved in coding regions of annotated
exons and splice sites and in regulatory and nonregula-
tory regions located within 2000 bp of known exons.
To identify mutations that are unique to or enriched
in EAC or BE or are shared between the EAC and BE,
we compared the list of EAC SNVs and BE SNVs. We
identified 46 EAC-specific somatic SNVs (7 missense,
4 UTR3, 2 UTR5, 33 near gene), 50 BE-specific so-
matic SNVs (11 missense, 1 frame shift, 5 UTR3, 4
UTR5, 29 near gene), and 410 somatic SNVs shared
between EAC and BE (64 missense, 3 nonsense, 1
splice5, 498 UTR3, 21 UTR5, and 272 near gene).
SNVs were categorized into four tiers. Tier 1 con-
tained all SNVs in coding regions of annotated exons
and splice sites, and these SNVs were validated by
Sanger sequencing (n = 38). Tier 2 SNVs were located
in regulatory genomic regions, tier 3 SNVs in non-re-
peat-masked and nonregulatory regions, and tier 4 con-
tained all remaining SNVs. Among tier 1 SNVs, one is
only present in EAC, two only in BE, and 35 in both
EAC and BE. Twenty-two genes previously associated
with cancer, cell cycle, and differentiation have tier 1
mutations likely to affect their function. Twenty genes
with tier 1 mutations are part of a cancer-related gene
network centered on TP53 and ITGB3, with both genes
containing mutations shared between BE and EAC.
On the basis of a mutation in one gene, our collab-
orators discovered that the protein from that gene is
missing in 14.3% (14/98) of EAC patients. They
demonstrated that this protein is involved in cellular
growth and invasion of esophageal adenocarcinoma
cells and that this gene regulates expression of other
genes involved in regulation of cell proliferation, apop-
tosis, and invasion.
We are currently working to validate newly discov-
ered short indels and structural variants and character-
ize their potential effects on gene function and the
initiation and progression of disease.
Family-Based Analysis of Bipolar
Disorder by Whole-Genome
Sequencing and Target Sequencing
This work was done in collaboration with D. Blackwood, K.
Evans, D. Porteous, University of Edinburgh.
A genetic study of a large Scottish pedigree by our col-
laborators at the University of Edinburgh suggested that
a 20-Mb haplotype on chromosome 4 has significant
linkage to BP (Blackwood et al., Nat Genet 12: 427
[1996]). We described sequencing the complete ge-
nomes of three affected and two unaffected members in
a previous annual report. This work identified a small
number of possible variants that segregated with the dis-
order. An additional 12 families, identified by our col-
laborators, showed linkage to the chr4 20-Mb haplotype
(Le Hellard et al., Biol Psychiatry 61: 797 [2007]). We se-
quenced the chr4 linkage region plus some of the sur-
rounding region to allow for mapping error (36 Mb
total) from multiple members of these 12 families.
We performed hybrid selection and sequencing on a
36-Mb region from 36 members of the 12 families and
obtained >200x coverage on each captured individual.
Reads from all flow cells for each individual sample
were aligned to UCSC hg19 using Burroughs-Wheeler
alignment (BWA) (Li and Durbin, Bioinformatics 25:
1754 [2009]). We then used PICARD (http://pi-
card.sourceforge.net) to evaluate the quality of each li-
brary by determining the percentage of above-quality
reads, mapped reads, nucleotides, paired reads, strand
balance, chimeras, duplicated reads, and library com-
plexity. SNVs/indels were called using GATK
(McKenna et al., Genome Res 20: 1297 [2010]). The
variants that we considered in analysis were restricted to
those that pass GATK standard filers, and only those
with at least 10-fold coverage were used in the down-
stream analysis. The unique SNV distribution on the
chr4 36-Mb region for each of the 13 families (includ-
ing the previously whole-genome-sequenced F22 fam-
ily) can be found in Table 2.
We then performed a VAAST candidate-gene prior-
itization analysis (Yandell et al. 2011) and in-house
scripts with a likelihood ratio test under the dominant-
inheritance model on the basis of SNV position. Table
3 shows the VAAST candidate genes as top hits in more
than one family.
We are currently selecting SNVs of potential inter-
est from the 36-Mb region of the whole-genome se-
quenced  family for genotyping the large cohort of case
and control samples. We are also analyzing the addi-
tional 12 families to refine possible candidates.
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Discovering Genomic Alterations
in Circulating Prostate Cancer Cells
Using Whole-Exome Sequencing
This work was done in collaboration with D. Danilla, 
C. Sawyer, H. Scher, Memorial Sloan-Kettering 
Cancer Center.
Prostate cancer is the second leading cause of male can-
cer deaths in the United States, and most patients with
metastatic castration-resistant prostate cancer (CRPC)
die of their disease. Recent advances in the ability to
isolate and characterize circulating tumor cells (CTCs)
from the blood of CRPC patients have overcome the
difficulty in obtaining sufficient metastatic CRPC
tumor for genetic study. The goal of this project is to
provide a comprehensive evaluation of somatic genomic
alterations in circulating tumor cells in patients with
CRPC.
SNV type A B C D E F G H I J K L M
nonsyn 18 26 25 38 14 16 20 22 12 21 9 48 74
silent 19 30 32 26 19 11 21 26 14 11 12 66 49
stopgain 0 0 0 1 0 0 0 0 0 0 0 0 0
stoplost 1 0 0 0 0 0 0 0 0 0 1 0 1
5¢ UTR 6 10 17 10 12 12 14 9 6 6 1 33 26
3¢ UTR 65 56 76 50 48 41 66 44 50 42 36 102 114
splicing 0 1 1 1 0 1 1 0 0 0 0 0 0
upstream 20 46 41 50 40 18 51 58 41 12 16 131 121
downstream 47 46 58 28 38 31 46 44 35 24 18 140 128
intronic 2,559 3,934 4,284 3,446 2,878 1,958 2,945 3,736 2,203 1,918 1,863 7,865 6,151
intergenic 5,597 7,434 7,040 6,167 7,340 3,364 8,553 7,448 5,399 5,094 3,567 17,330 14,773
Ts/Tv 2.09 2.00 1.95 1.49 1.90 2.15 1.95 1.96 1.91 1.90 2.10 1.98 1.96
Her/Hom 3.21 2.74 3.85 3.73 4.59 33.37 3.38 4.44 1.60 2.39 313.39 1.41 1.16
Table 2. Unique SNV Distribution on the chr4 36-Mb Region for Each of 13 Families
These unique SNVs are present in the affected individuals but absent in the corresponding unaffected individuals.
Table 3. VAAST Candidate Genes Shown in More Than One Family
Gene P value
HTT 1.01E-06
HAUS3 1.01E-06
CRIPAK 1.01E-06
SORCS2 1.01E-06
CPEB2 1.01E-06
ACOX3 1.85E-06
LGI2 3.99E-06
WFS1 2.79E-05
EVC 3.52E-05
CRIPAK 6.14E-05
C4orf48 6.14E-05
RNF212 6.14E-05
HTT 6.14E-05
OTOP1 6.14E-05
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We performed WGS on 31 CTC samples and 30
paired white blood cell (WBC) samples collected from 15
CRPC patients using NimbleGen exome capture (version
2). Each exome capture was sequenced in a multiplexed
fashion (4-plex) in a HiSeq 2000 flow cell using paired-end
101-cycle sequencing chemistry. Before studying somatic
genomic alterations in the CTC samples, we performed
coverage analysis to evaluate the representation of the
whole exome in each CTC/WBC sample. Only ~50% of
bases on the exome were covered at 20x or greater for most
of the samples. The percentage of base coverage of these
exome captures can be found in Figure 2.
Figure 2. Percentage of base coverage on the exome for each CTC
and paired WBC sample collected from 15 CRPC patients.
We then calculated the average coverage across all of
the bases in each targeted region for each CTC/WBC
sample and found that some regions were consistently
covered at low coverage for most of the samples. For ex-
ample, as shown in Figure 3, region 24830 was covered
much less when compared to other regions for all of the
four CTC/WBC samples obtained from one patient. This
is considerably less than we see for non-CTC samples,
leading us to hypothesize that the process of starting from
a small number of circulating cells and greatly amplifying
their DNA was causing misrepresentation in the result-
ing sequencing. To test this hypothesis and eliminate the
possibility that the hybrid capture of the amplified DNA
was introducing the bias, we performed low-pass WGS
on a number of samples. WGS showed a similar pattern
of uneven representation, indicating that the recovered
DNA did not represent the original genome in complex-
ity. This suggests that the exome of the sequenced
CTC/WBC samples may be underrepresented.
We are now optimizing the representation of the
whole exome in the CTC/WBC sample by performing
a cell-number titration experiment. We are also exam-
ining the possibility of optimizing the cell-sorted and
whole-genome amplification assays used for generating
the CTC/WBC samples. We will continue to sequence
and analyze the optimized CTC/WBC samples from
additional CRPC patients to identify somatic genomic
alterations. In an additional pilot study, as part of our
ongoing prostate cancer project with Memorial Sloan-
Kettering Cancer Center (MSKCC), we generated low-
pass WGS from several tumor samples (not CTC
samples). These were analyzed by MSKCC bioinfor-
maticians and found to provide useful information
about structural rearrangements, which are a common
driving force in these tumors. We have started an ex-
pansion of this facet of the project with MSKCC.
Investigation of Bipolar Disorder
Genetics Using Exome Capture
and Resequencing
This work was done in collaboration with J. Potash (Univer-
sity of Iowa); P. Zandi, F. Goes, R. Karchin, A. Chakravarty
(Johns Hopkins School of Medicine).
Bipolar disorder I (BPI) is a major mental illness with
a significant genetic component, as demonstrated by
family, twin, and adoption studies (Smoller and Finn,
Am J Med Genet C Semin Med Genet 123c: 48 [2003]).
Molecular investigation into the genetics of BPI has in-
cluded linkage analyses and, more recently, several large
genome-wide association studies (GWAS) (Wendland,
Behavioral Neurobiology of Bipolar Disorder and Its Treat-
ment, 1st ed., 19 [2010]). Although GWAS have yielded
a small number of genome-wide significant results, the
apparent “missing heritability” problem suggests that
there should be rare variants contributing to BPI. Thus,
approaches that are capable of effectively identifying
and studying rare variants associated with BPI are nec-
essary. We are applying exome capture and massively
parallel sequencing toward finding rare genetic variants
that contribute to BPI.
Our work in 2011 focused on implementing opti-
mized lab workflows and analytical pipelines before a
scale-up scheduled for 2012. To do this, we performed
a pilot study of exome capture and resequencing of 201
samples, comprising 116 BPI case samples, 56 control
samples, and 29 family samples (Fig. 4A). The exome
capture design that we used was either the standard
commercial EZ Exome version 2.0 (36-Mb genomic
target) or a custom exome-plus version from Nimble-
Gen. The custom capture product consisted of the full
EZ Exome version 2.0 probes plus an additional ~6 Mb
of probes to capture synaptome-specific genes and their
promoters that were not already on the standard exome
product. Each genomic DNA sample was prepared for
capture and sequencing using Illumina TruSeq adapters
that feature unique barcode bases that are sequenced in-
dependently of the library inserts, and the samples were
then captured in pairs. Each captured pair was se-
quenced in one lane of a HiSeq 2000 PE 76 cycle run
with a seven-base index read. Illumina analysis software
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Figure 3. Average coverage across all of the bases in each targeted region for two CTC samples and two WBC sam-
ples obtained from one patient. The x-axis represents target regions in NimbleGen exome capture (version 2) and the
y-axis represents the average coverage across all of the bases in each targeted region.
CASAVA (version 1.7 or 1.8) was used to produce de-
multiplexed pass-filter sequence data, and these data
were then analyzed for target coverage and SNV and
indel variants using a GATK-centered pipeline estab-
lished in our lab. The target coverage and library qual-
ity statistics produced from our pipeline were used to
evaluate the success of the captures, for which we used
a minimum threshold of 80% target coverage at ≥20x
sequencing depth for a sample to successfully complete
capture and sequencing (Fig. 4B). We had established
this threshold in a previous study, in which we found
such a criterion effective for predicting the extent of
high-quality data that we should expect from a sample,
but not so restrictive as to significantly limit our data or
require expensive sample oversequencing to yield only
small coverage benefits.
Having established a harmonized sequence data
analysis pipeline between CSHL and collaborating in-
stitutions, we are finalizing a data quality control
pipeline involving gender testing, principal component
analysis, and Mendelian testing to evaluate the quality
of our data and properly track our samples. Genetic
analyses to evaluate the relationship between SNVs and
indels that we identify and bipolar disorder will involve
the subclassification of coding variants based on the
predicted effects of the mutations on proteins, burden
testing of mutation incidence in genes between cases
and controls, and network- or pathway-based analyses
of variants identified in cases. We also plan to complete
the capture and sequencing of 1800 additional samples
(predominantly cases and controls) during 2012.
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Highly Multiplexed Targeted Resequencing
of Submillion Base Genomic Targets
J.S. Parla, P. Deshpande, J. Marchica, M. Kramer, E. Ghiban,
S. Muller, W.R. McCombie
We and other investigators are finding potentially impor-
tant candidate genes for complex traits such as psychi-
atric disorders through genome and exome sequencing
projects. However, there is a great remaining challenge
in the field to demonstrate the significance of variants in
these genes or regions of the genome in very large num-
bers of individuals. As of now, technology does not exist
that allows the sequencing of a small part of the genome
(0.5–5 million bases) in large numbers of individuals
(1000–10,000). We are making a focused effort to de-
velop this capability.
To address the apparent incompatibility between ge-
netic discovery study phases and large-scale population
study phases, we have been developing a method that
adapts the highly successful solution exome capture
methodology to significantly smaller genomic targets.
Our goals for developing our microtargeting technique
include the minimal modification of existing commer-
cial solution exome capture techniques and the estab-
lishment of maximal sample multiplexing capability at
the capture level, which should support a straightfor-
ward experimental design and candidate validation
strategy. We have initiated the development of our
method with the commercial capture platform with
which we have had the most success, namely, SeqCap
EZ from Roche NimbleGen, and a selection of five
human genes that were identified in a preliminary
analysis of pilot exome data that we produced for one
of our bipolar disorder projects. The final approved
probe design targeted a cumulative 637,760 bp of the
five full-length genes and was predicted to capture
92.6% of the target given a 100-base offset window ac-
counting for library insert length.
In 2011, we initiated capture level multiplexing at
three samples per capture and were able to effectively
multiplex up to 15 samples per capture, based on the
breadth of target coverage at ≥20x sequencing depth
per sample (Fig. 5A). We empirically determined that
high-quality genomic DNA input, highly sensitive dou-
ble-stranded DNA–specific quantitation of the precap-
ture library material, and the use of well-designed
blocking oligos against the low-complexity sequencing-
specific library adapters are important parameters for
successful high-order multiplexing at the capture level.
High-quality genomic DNA starting material supports
the production of complex libraries that are represen-
tative of the genome, stringent DNA quantification of
precapture libraries improves the distribution of sam-
ples in a capture pool (Fig. 5B), and well-designed
blocking oligos significantly improve the specificity of
the capture. Further development of our microtargeting
method will involve increasing the sample multiplex-
ing during capture to at least 96, improving the distri-
bution of samples during pooling and evaluating
alternative methods for precapture library preparation
or target capture to improve capture performance and
overall sample processing capability.
Family-Based Analysis of Schizophrenia
Using Whole-Genome Sequencing
S. McCarthy, J. Badner, W.R. McCombie, W. Byerley
Interest in the contribution of rare genetic variation to
the risk of psychiatric disorders has been revitalized by
Figure 4. (A) Pie chart illustrating the distribution of case, control,
and family samples captured and sequenced during 2011 for the
bipolar disorder exome project. (B) Plot of percent of exome or
custom exome + synaptome target covered at ≥20x sequencing
depth per sample processed during 2011. Captures were per-
formed with NimbleGen SeqCap EZ Exome version 2.0 library
or NimbleGen SeqCap EZ Choice Plus custom library and se-
quenced using Illumina HiSeq MPE 76 x 7 x 76-cycle runs. De-
multiplexed pass-filter data were analyzed for target coverage
and library characteristics using a GATK-centered pipeline.
recent GWAS, copy-number variation (CNV) surveys
of the human genome, and rapid progress in next-gen-
eration sequencing technologies. Together with Drs.
William Byerley (University of California, San Fran-
cisco) and Judith Badner (University of Chicago), we
have been combining the power of WGS with the
strengths of family-based analysis to uncover the genetic
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risk factors that potentially increase the risk of schizo-
phrenia in two extended pedigrees. Our objective is to
take advantage of WGS to catalog the genetic landscape
of at least three affected individuals from two extended
pedigrees with schizophrenia and prioritize genes or
functional loci with rare (<1%), potentially private,
high-impact variants that are shared between the af-
fected members within each family for high throughput
targeted sequencing in larger case control cohorts.
As of December 2011, we had completed WGS of
10 individuals from two extended pedigrees, K1546
and K1527. From family K1546, we sequenced an af-
fected mother, her two affected children, her affected
brother, her affected half sibling, and her unaffected
husband. From family K1527, we sequenced an af-
fected grandfather, his affected grandchild (the off-
spring of one of the affected children), a very distantly
affected relative, and his unaffected wife. For each in-
dividual, we produced a minimum of 1.5 billion reads,
of which ~90% aligned to the human hg19 reference,
ensuring that more than 80% of the genome was cov-
ered at a depth of at least 30x. On average, 3.3 million
SNVs and 350,000 indels were detected in each
genome. Respectively, ~1% and ~5% of SNVs and in-
dels called through our pipeline were absent from
dbSNP135 and considered to be potentially novel.
Approximately 47,131 SNVs and 99,675 indels,
with frequencies of <1% in the EUR population of the
1000 Genomes Project, were shared genome-wide
among the affected individuals of K1546. Initially, 
we focused our attention on nonsynonymous SNVs
(nsSNVs) in regions of linkage identified in previous
genotyping scans of K1546. No nsSNVs were found
within 15 Mb distal or proximal of the marker with the
strongest linkage peak (2.39) on chromosome 4. How-
ever, three nsSNVs were found on chromosome 21
under a linkage peak with a LOD score of 1.34. These
nsSNVs are located in three genes: ACACB (acetyl-
coenzymeA carboxylase b), CCDC42B (coiled-coil do-
main containing 42B), and SCARB1 (scavenger recep-
tor class B isoform 1). The role of these genes is not
clear in the neuropathology of schizophrenia, although
SCARB1 appears to be expressed in the brain, develop-
mentally regulated, and found to be weakly associated
with cognitive function in schizophrenia.
Expanding the analysis of shared nsSNVs genome-
wide in K1546, ~126 variants are present, which may
increase the risk of schizophrenia or diminish cognitive
function in the family. One of these nsSNVs is located
in the gene DCDC2 (double cortin domain containing
2) on chromosome 6. The resulting proline-to-serine
Figure 5. Multiplex capture results from a single hybridization
with 15 human genomic DNA libraries and custom NimbleGen
capture probes targeting five full-length genes or 637,760 bp of
genomic space. Barcoded precapture libraries were prepared
using NEXTflex DNA sequencing kits (Bioo Scientific) and cap-
tured according to the NimbleGen protocol, with a mixture of
barcode-specific blocking oligos. The completed multiplex cap-
ture library was sequenced on one MiSeq PE 101-cycle library
quality control run, which generated a total of 1.1 Gb of pass-fil-
ter sequence data. (A) 14 of the 15 samples produced >80% of the
637,760-bp target at ≥20x sequencing depth. Additional 15-plex
captures using the same set of precapture libraries confirmed that
the one sample that produced <10% target coverage at ≥20x was
a result of low sequence data generated for that sample due to
uneven sample distribution in the capture pool (B). (B) Perfect
matches to the expected barcode sequences were required during
sequence read demultiplexing, and the percent of reads matched
per barcode ranged from 0.8% to 19.4%, with an average of 6.7%
and a standard deviation of 4.6%. A perfect distribution would
have produced 6.7% of reads per barcode. The last data point on
the right (U) is the percent of reads that could not be perfectly
matched to any barcode (1.6%).
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substitution is predicted both by PolyPhen2 and
VAAST to impact protein function based on nucleotide
conservation and protein biochemistry. Notably,
DCDC2 was first predicted to have a role in develop-
mental dyslexia, and in vitro and in vivo functional
analyses of the gene have shown that it binds to micro-
tubules and is involved in neuronal migration. These
previous findings, coupled with the global privacy of the
variant in this family, specifically in its affected mem-
bers, makes DCDC2 a strong candidate gene for follow-
up analysis in larger cohorts. At present, we are
validating this variant plus 231 other shared variants in-
cluding splice donor and acceptor variants in all 18
members of K1546 with available DNA.
In family K1527, ~36,000 SNVs and 56,000 indels
were shared among the genomes of the three affected
members. However, none of the 118 nsSNVs genome-
wide were in genes located under linkage peaks identi-
fied in previous linkage scans, nor were any of the
nsSNVs predicted to have significant impact on gene
function. It is possible that the distant relative is in fact
a sporadic case of schizophrenia and consequently does
not share the same risk variants as the other closer rel-
atives. Therefore, during 2012 we shall sequence an ad-
ditional relative to enrich for shared variants among
relatives in family K1527 and will begin sequencing
two more families with Mendelian-like patterns of in-
heritance of schizophrenia.
Whole-Genome Sequencing
of a Consanguineous Pedigree
with Bipolar Disorder and
Major Depression
S. McCarthy, W.R. McCombie [in collaboration with 
M. Ayub (Durham University) and D. Blackwood 
(University of Edinburgh)] 
In collaboration with Drs. Muhammad Ayub and Dou-
glas Blackwood of the University of Edinburgh, Scot-
land, we are also combining the powers of WGS and
family-based analysis to determine the genetic under-
pinnings of bipolar disorder and major depression. In
contrast to ongoing family-based sequencing studies
using outbred families to reduce the genetic hetero-
geneity of bipolar disorder and major depression, we
are using a large consanguineous pedigree from the
Punjab region of Pakistan to enrich for rare recessive or
compound heterozygous variation of potentially large
genetic effect. To achieve this goal, we generated at least
1.3 billion sequence reads for each of six individuals
representing three subset inbred families of the larger
consanguineous pedigree. More than 80% of each ge-
nome was covered at 30x or higher. Sequencing com-
pleted toward the end of 2011 and annotation of SNVs
and indels is under way in 2012. On average, 3.4 mil-
lion SNVs and 440,000 indels were found in each in-
dividual, with a slightly higher novel variation rate due
to the lack of Punjab genetic variation in dbSNP135.
Although our aim is to examine variants genome-wide
and remain agnostic to the biology of the disorder, we
will initially focus our attention on variants identified
through orthogonal linkage analysis within each family
and all families combined. The strongest LOD score
(>10) is found on chromosome 21 and spans just 10
kb. The region was identified using FESTIM, a soft-
ware package designed specifically to examine inbred
pedigrees; however, prior resequencing of the region re-
vealed little or no sequence variation. Our evaluation
of the chromosome 21 region will also take the latest
ENCODE data into account so that it will not be lim-
ited to just nonsynonymous or frame shift indels. In
addition, we will explore the region for CNV that could
also explain the desertion of SNVs previously found.
In parallel to this analysis, we will examine the entire
genome for shared recessive and or codominant het-
erozygous mutations. Such analyses, to the best of our
knowledge, have not yet been explored and should
make a significant contribution to our understanding of
the neuropathology of bipolar and major depression.
Plant Genomics
S. Pasternak, M. Wright, C.-W. Tung, C. Jer-Ming, 
Y. Berstein, E. Ghiban, M. Kramer, E. Antoniou, 
R. Martienssen [in collaboration with S. McCouch (Cornell
University)]; D. Ware, M. Schatz, W.R. McCombie
We generated several different types of sequencing li-
braries for several species of rice and wheat to test var-
ious ways to assemble these complex genomes.
We obtained high-level sequence coverage from
three varieties of rice (Nipponbare, IR64, and DJ123)
from standard Illumina libraries (300-bp insert). We
also sequenced 180-bp insert libraries designed to work
with the ALLPATHS software (Gnerre 2010), at 150x
for Nipponbare, 130x for IR64, and 105x for DJ1232.
To complement these libraries, we made Illumina
mate-pair libraries and sequenced them at the follow-
ing depth of coverage: 235x for Nipponbare (2-kbp in-
sert), 180x and 145x for IR64 (2- and 5-kbp inserts),
and 180x and 160x for DJ123 (2- and 5-kbp inserts).
We also used the recently released Illumina MiSeq se-
quencer to generate longer 250-bp pair reads to study
the potential advantage of using these reads in the as-
sembly process, to about 8x coverage of the three rice
genomes.
We used the Pacific Biosciences (PacBio) RS se-
quencers to obtain 5.7x genomic coverage of long sin-
gle-molecule sequencing reads for the Nipponbare
genome. These data are being used to evaluate the effi-
cacy of combining PacBio and Illumina sequencing
reads for genome assembly.
We sequenced two wheat genomes, Ae. taushii and
Triticum monococcum, using ALLPATHS 180-bp insert
libraries and paired-end 100-bp reads, at up to 69x and
71x genomic coverage, respectively. We supplemented
210 Research
these data with 2- and 5-kbp mate-pair libraries se-
quenced at 77x and 6.5x genomic coverage for Ae.
taushii and at 66x and 9x genomic coverage for T. mono-
coccum. We are currently testing, in collaboration with
Mike Schatz, the assembly of these different data sets.
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W.R. McCombie (top row, fifth from right) and lab members.
Our lab has dual goals of conducting plant genomics re-
search and developing genomics resources and discovery
tools for use by the broader research community. Re-
search includes a broad range of activities in physical, sta-
tistical, and functional genomics in both model systems
and crop plants, with applications in agriculture. Dur-
ing the past year, we were joined by scientist Marcela
Karey Monaco and postdoctoral researcher Young Koung
Lee, and we said goodbye to Aaron Chuah, Will
Spooner, and Zhijie Liu.
Plant Genome Research
In the last decade, the decoding of complete plant
genomes has borne fruit for scientists who seek to un-
derstand the complexities of plant function and evolu-
tion and to affect economically important traits. The
generation of reference genomes spans many disci-
plines, starting in the laboratory with scientists who
generate the raw sequence data. From there, it is the re-
sponsibility of computational biologists and bioinfor-
maticians, such as those in the Ware lab, to help inter-
pret the output. This includes assembly of raw sequence
reads into overlapping segments, or contigs, and scaf-
folding these to properly represent their order and ori-
entation within chromosomes. Another step is annota-
tion—the discovery and description of genes and other
functional elements, as well homologies to other ge-
nomes. In addition, this information must be faithfully
communicated and visualized, for example, in web-
based platforms such as Gramene.
All of these activities are rapidly evolving with the ad-
vent of new sequencing technologies, algorithms, and
data-handling requirements. For example, high-depth
sequencing of RNA transcripts at low cost is providing
new evidence that informs genome annotation, and it is
spurring the development of new software to model and
perform this task. Low-cost sequencing is also trans-
forming the types of questions that can be asked, mov-
ing beyond the generation of a single reference for a
given species. Ongoing projects within the maize, rice,
and Arabidopsis research communities are now sequenc-
ing hundreds and even thousands of genotypic back-
grounds within species, gathered from carefully con-
structed populations, wild populations, and breeding
germplasms. Information on genetic variation is helping
scientists to understand the genetic basis of phenotypic
traits and questions about the origins of domesticated
crop species. New technologies are also driving research
in epigenetics, the study of heritable traits that are not
caused by changes in the underlying genome sequence.
Epigenetic mechanisms include modification of DNA
by methylation and various forms of histone modifica-
tions, which can cause changes in gene expression and
other phenotypes. Both of these modification types can
be studied with new sequence technologies and analysis
methods. Our lab is engaged in many of these areas of
inquiry. For some species such as maize, we are begin-
ning to see how the provision of genome sequence, an-
notation, genetic variation, epigenetic variation, and
transcript expression is converging to bring about a
deeper understanding of genome function.
Gramene
A. Chuah, M.K. Monaco, S. Pasternak, W. Spooner, J. Stein,
J. Thomason, S. Wei, K. Youens-Clark, S. Kumari [in 
collaboration with E. Buckler, USDA, Cornell University; 
S. McCouch, Cornell University; P. Jaiswal, Oregon State
University; P. Kersey, European Bioinformatics Institute]
Gramene is a collaborative project that leverages se-
quence and functional information from plant reference
genomes to promote research and translational ge-
nomics in agriculture and its various applications in-
cluding food and biofuel production. The Gramene
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PLANT GENOME ORGANIZATION, EVOLUTION, AND FUNCTION
D. Ware J.-M. Chia Z. Lu J. Stein
A. Chuah M.K. Monaco J. Thomason
A. Eveland C. Noutsos P. Van Buren
S. Kumari A. Olson S. Wei
Y.K. Lee S. Pasternak K. Youens-Clark
Z. Liu W. Spooner L. Zhang
website (http://www.gramene.org) serves as a portal to
multiple genome browsers and manually curated data-
bases of genes, proteins, biochemical pathways, quanti-
tative trait loci (QTL), ontologies, germplasm, and
genetic diversity data. In the last year, our group com-
pleted several milestones on the Gramene project, in-
cluding its 33rd and 34th releases since 2000. Of the
many improvements made, we increased the number of
partial and complete sequenced genomes in our En-
sembl genome browser to 22 scientifically and econom-
ically important species including rice, corn, sorghum,
soybean, poplar, grape, and the unicellular green alga
Chlamydomonas reinhardtii. Gramene is also home to
reference sequences for three cultivated and eight wild
species of rice, making it the single most comprehensive
genus level (Oryza) resource in plants. During 2011, we
released pathway databases for maize (MaizeCyc) and
Brachypodium (BrachyCyc), complementing existing
pathway databases for rice, sorghum, and other plants. 
Gramene is also positioning itself as a principal re-
source for conducting population-based genetics re-
search. We added several new diversity/phenotype data
sets covering Arabidopsis, rice, and maize and have added
new tools for querying single-nucleotide polymorphisms
(SNPs) and visualizing genome-wide association stud-
ies. In addition, we used the Ensembl 64 infrastructure
to include multispecies views from whole-genome align-
ments, synteny maps, browsable phylogenetic gene trees,
and SNP views that display diversity data in the context
of functional impacts on gene structure. All of this work
has contributed to a 38% increase of traffic on the
Gramene website during the last 2 years from users all
over the world. Our databases are created in partnership
with the European Bioinformatics Institute (EBI) and
are now also available through the Ensembl Plant por-
tal. During the next year, we will continue to add new
reference genomes, data sets, and functionalities to this
resource.
Updating the Maize Reference Genome
and Annotation
A. Olson, S. Pasternak, J. Stein [in collaboration with
J. Glaubitz and  E. Buckler, Cornell University; R. Fulton and
R. Wilson, Washington University; The Maize Genome 
Sequencing Consortium]
Work continues on refining the assembly and annota-
tion of the maize cv. B73 reference sequence. The pri-
mary objective is to place genes that are currently missing
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or incomplete. A whole-genome shotgun library was se-
quenced to 14× coverage using the 454 Titanium
method, and resulting reads were assembled using Abyss.
To define genes, we used the FLcDNA collection, align-
ing both contig and RefGen_v2 sequences. A graph-
based algorithm was developed to construct novel gene
scaffolds having complete coding sequence coverage. The
gene scaffolds were genetically mapped by a previously
described genotype-by-sequencing (GBS) method,
which was applied both to the 454 contigs and the
FLcDNA sequences. Final incorporation of gene scaf-
folds into the reference sequence was refined using DNA-
and gene-based synteny to rice and sorghum. The re-
sulting new assembly contains an additional ~1.3 Mb of 
sequence. Approximately 500 genes were added or im-
proved with new annotation. The GBS results, along
with synteny, were also used to anchor a number of un-
known (chr0) physical map contigs. Release of the new
reference assembly will proceed following acceptance by
GenBank.
Tackling Wheat
J. Stein, S. Pasternak, A. Olson [in collaboration
with J. Dvorak and M.C. Luo, University of California,
Davis; O. Anderson, University of California, 
Davis/USDA-ARS, Albany; B.S. Gill, Kansas State 
University; W.R. McCombie and M. Schatz, Cold Spring
Harbor Laboratory]
One of the great frontiers in plant genomics is to deter-
mine the complete sequence of the bread wheat Triticum
aestivum. From its early domestication in the Fertile
Crescent, large-scale cultivation of wheat enabled the
rise of human civilization and the formation of city-
based societies. Today, it remains one of the most im-
portant food crops worldwide, grown on more land area
than any other crop, and is a leading source of calories
and protein in the human diet. Better understanding of
the wheat genome will enhance future breeding efforts
to perpetuate its critical role in feeding the world. Con-
sistent with its superlative nature, wheat also represents
the most challenging plant genome to be attempted to
date by scientists. At 16,000 million base pairs, its nu-
clear genome is five times the size of human, eight times
the size of maize, and 40 times the size of rice. One ex-
planation for its imposing size is that wheat is hexaploid,
i.e., it contains not one but three genomes, termed A, B,
and D, that were brought together through hybridiza-
tion of closely related diploid species during domestica-
tion. Because the three genomes are actually quite closely
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related, it is difficult to assign genes to their appropriate
genome. Making matters more complex, the wheat
genome is also one of the most repetitive, with ~90% of
its content bloated with transposable elements that ob-
scure the discovery of functioning genes.
These facts have necessitated multiple international
initiatives to sequence wheat, overseen by the Inter-
national Wheat Genome Sequencing Consortium
(IWGSC), wherein individual chromosomes have been
divvied up for work by individual labs. Our lab is a col-
laborator on the National Science Foundation (NSF)-
funded project to physically map chromosomes 1D, 4D,
and 6D of bread wheat (cultivar Chinese Spring) and all
seven chromosomes of the closely related species Aegilops
tauschii. This latter species is highly informative because
it is the diploid progenitor of the wheat D genome.
Nearing completion, the project has produced physical
maps containing almost three-quarters of a million bac-
terial artificial chromosomes (BACs), positioned relative
to one another by a restriction enzyme fingerprinting
method. The project has also produced the first high-
resolution genetic map of Ae. tauschii, with more than
7000 sequenced markers that are anchored to the phys-
ical map. These maps are scheduled for public release
this year via the Gramene web portal. Gramene will also
display comparative maps between the D genome and
other grass reference genomes to enable study of gene
function and evolution. Together, the information and
physical reagents produced by this project will help lead
the way for future research in wheat genomics.
Funded by a second NSF grant, CSHL is pioneering
the discovery of wheat genes by using ultra-high-
throughput sequencing technologies and rapidly releas-
ing these data to the scientific community. In this
whole-genome shotgun approach, enormous quantities
of sequence data can be generated in a cost-effective
manner. To date, the McCombie lab has deposited more
than 850 Gb (~200-fold coverage) of Ae. tauschii to the
NCBI Sequence Read Archive (SRA). Similar numbers
have been deposited for Triticum monococcum, the
diploid progenitor of the wheat AA genome. Efforts are
under way in our lab to assemble these sequences and
build scaffolds to describe the gene content of these
genomes. Using physical/genetic maps such as those de-
scribed above, and by comparative mapping to other
grass species, we plan to position many of the genes to
their location in the genome. Results will be released via
a browser within Gramene. Work by CSHL comple-
ments extensive research efforts taking place worldwide
that together will ultimately tackle the wheat genome.
The Maize Methylome
Z. Lu, A. Olsen, S. Pasternak [in collaboration with 
R. Martienssen, J. Hicks, W.R. McCombie, M. Regulski, 
and J. Kendall, Cold Spring Harbor Laboratory; S. Tingey
and A. Rafalski, Pioneer/DuPont]
DNA methylation has an important role in the regula-
tion of gene expression and control of transposable el-
ements. The patterns of DNA methylation, referred to
as the methylome, must be faithfully propagated for
proper development in plants and animals. We are col-
laborating with the Martienssen lab and DuPont to se-
quence the methylome of two maize inbred lines, B73
and Mo17 (Fig. 1). The genomic DNA is treated with
bisulfite, which will convert unmethylated cytosine to
thymine. Sequencing using next-generation Illumina
GA2 paired-end reads, followed by mapping back to
the maize genome, resulted in identification of a methy-
lome in single-base resolution. We have generated 20×–
30× coverage over the mappable portion of the maize
genome. Alignment with RNA sequences indicates that
the methylation patterns are correlated with gene ex-
pression, small RNA, and alternate splicing. Diversity
in cytosine methylation patterns was observed in trans-
posable elements and especially in genes and was found
Figure 1. Distribution of methylated sites within the maize nu-
clear genome. Feature density is given in 1-Mb bins. (Coverage
tracks) Average read depth, (CpG/CHG/CHH tracks) average
methylation level, (MF track) methylation filtration density, (re-
peats track) repeat density, (gene track) gene density.
to be largely heritable in recombinant inbred lines
(RILs). However, significant deviations from heritabil-
ity were observed, many of which were conserved in
different RILs. This will help us to reveal the roles of
DNA methylation in gene regulation and other bio-
logical functions in the future.
Maize HapMap
J.-M. Chia [in collaboration with E. Buckler, USDA, Cornell
University; M. McMullen, USDA, University of Missouri, 
Columbia]
Maize breeders have long exploited the diversity in
maize for improving its yield through selective breeding
programs, contributing to its current position at the
apex of the production crop list. We are in an era in
which traditional crop-breeding techniques are being
supplemented, and in some cases supplanted, by mo-
lecular breeding approaches that speed up the breeding
process. Understanding the diversity in maize and how
it impacts agronomic traits is crucial in implementing
these new approaches and will be an important plat-
form for sustainable agriculture in the future. 
In the previous year, we sequenced more than 100
inbred lines of the Zea mays genus. The volume of se-
quences generated per inbred line is approximately five
times the size of the genome, and from these sequences,
we can identify variant loci. Given the complexity of
the genome, these variations were scored using carefully
designed population-genetics-based filters that leverage
the carefully constructed maize breeding populations.
In total, more than 55 million SNPs were identified.
We are currently extending our sampling across di-
verse maize landraces with a target of an additional 40
samples, including 15 at high depth (20×). This will
allow us to assemble these genomes and identify novel
genes that are not present in the elite breeding lines
used commercially.
Tracking the Wild Tomato
J.-M. Chia, S. Pasternak [in collaboration with Z. Lippman,
Cold Spring Harbor Laboratory]
This work also contributed to the Tomato Genome Se-
quencing Project (principal investigator, G. Giuliano,
ENEA CR Casaccia, Italy), which included multiple
coprincipal investigators and researchers from the
United States and internationally.
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To explore variation between tomato and its nearest
red-fruited relative, together with the Lippman lab, we
sequenced, analyzed, and assembled a Solanum pimpinel-
lifolium genome using Illumina short reads. We focused
on identifying SNP and insertion/deletion (InDel) vari-
ation by aligning the quality-trimmed reads to the
pseudomolecule reference of the cultivated tomato, S. ly-
copersicum cv. Heinz. This revealed surprisingly low
genome-wide diversity, supporting an extremely close
evolutionary relationship with Heinz that is consistent
with S. pimpinellifolium serving as the foundation for
tomato domestication. Assembling the reads into se-
quence contigs, we did not see any large structural vari-
ations between the two genomes. This extensive
molecular marker database that is now available makes it
possible to access S. pimpinellifolium variation for crop
improvement. In particular, the diversity in the undo-
mesticated species for adaptation and disease resistance
will be particularly valuable.
The iPlant Collaborative
Z. Lu, C. Noutsos, S. Pasternak, J. Stein
This project employs more than 100 staff and is head-
quartered at the University of Arizona (principal inves-
tigator is Stephen Goff ). Dozens of collaborators are
located at more than 20 institutions.
Driven by the large-scale generation of data, ranging
from genomics to imaging, research in biology is be-
coming increasingly information based. Lagging behind
is the ability of individuals to make efficient use of this
information due to limitations in data access and storage,
computational infrastructure, and available tools. To
tackle big questions in biology, researchers also need ef-
fective ways to collaborate that reach across institutional
and disciplinary lines. The iPlant Collaborative (http://
iplantcollaborative.org) is an NSF-funded cyberinfra-
structure project that provides public access to high-per-
formance computing, data storage, and tools via custo-
mized web-based interfaces. Having completed year 4 of
this 5-year grant, the iPlant Collaborative has made ex-
tensive progress toward meeting these goals. Work in the
last year has culminated in the development of multiple
platforms that are now being used by the research and
educational communities. Staff at CSHL directly con-
tributed to some of these cyberinfrastructure platforms
or have built upon them to provide ready access to
needed software and analysis tools by plant scientists and
educators. Within our lab, these platforms include the
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Discovery Environment (DE), Atmosphere, and Taxo-
nomic Name Resolution Service (TNRS).
The DE is perhaps the most visible portal to iPlant
tools and services. This web-based platform supports
an “app store” model of user-extensible tools, work-
flows, and data storage. Users can take advantage of ex-
isting tools contributed by the iPlant staff and user
community or develop their own tools to use privately
or share. Although users may not be aware, the under-
lying infrastructure provides access to iPlant’s massive
data store, and in the case of computer-intensive tasks
are using advanced computing services such as the Ex-
treme Science and Engineering Discovery Environment
(XSEDE) through the Texas Advanced Computing
Center (TACC). So far, well over 100 tools have been
integrated into the DE that enable a broad range of re-
search activities, including genome/transcriptome as-
sembly, RNA-Seq quantification, variant detection,
GWAS, and phylogenetics. Members of our lab have
had important roles in contributing to workflow de-
sign, tool integration, validation, and documentation.
Atmosphere is iPlant’s cloud infrastructure platform
that addresses the growing need for configurable and
cloud-enabled computational resources by the plant re-
search community. From Atmosphere’s web interface,
users can launch a virtual machine (VM) with precon-
figured working environments and ready-to-use soft-
ware. Users can also create their own applications and
environments and post their VM in Atmosphere for
others to use. As with the DE, Atmosphere is a gate-
way to access iPlant’s core infrastructure resources, such
as the high-performance and grid-computing environ-
ment and big data storage system. Using the Atmos-
phere platform, we created a VM to be used in the fields
of ecological and functional genomics. The VM in-
cludes 19 R statistics packages used in ecology and ge-
netics research and for plotting complex data in graphs.
Our lab contributed directly to the development of
the Taxonomic Name Resolution Service (TNRS), a plat-
form to help standardize taxonomic names for all plant
species—a nontrivial task. Erroneous and synonymous
taxonomic names are a major challenge for virtually every
field of plant biology. Large organismal databases (GBIF,
SpeciesLink, VegBank, SALVIAS, TraitNet, GenBank,
TreeBASE) are plagued by taxonomic error and uncer-
tainty. In some databases, up to 30% of names do not
match to any published name. Furthermore, 5%−20%
of published names may be synonymous. Currently, cor-
recting and harmonizing taxonomy is the time-consum-
ing and ad hoc responsibility of the individual researcher.
The TNRS tool overcomes this barrier, enabling higher-
quality comparative biodiversity science. TNRS is avail-
able to other investigators who wish to perform similar
taxonomic name resolutions on their data sets, enabling
a wider community to expand the public scientific know-
ledge base. The TNRS is currently available at http://tnrs.
iplantcollaborative.org.
A major mission of iPlant is to promote adoption of
the cyberinfrastructure through training workshops and
outreach. In November 2011, members of our lab and
the DNA Learning Center organized the iPlant Tools
and Services Workshop at CSHL to coincide with the
Plant Genomes and Biotechnology meeting. This 1-day
workshop focused on training in the Discovery Envi-
ronment for RNA transcript abundance and phyloge-
netics analysis and touched on additional topics such as
genome-wide association study (GWAS), Atmosphere,
and the iPlant Data Store. The workshop was attended
by nearly 40 lab heads, research staff, postdocs, and grad-
uate students hailing from institutions around the world,
including Argentina, Germany, India, South Korea, and
Singapore. The workshop was a success not only in terms
of training, but also in receiving valuable feedback that
will further strengthen iPlant in the future.
Plant Systems Biology: Exploration of Gene
Regulatory Network Guiding Arabidopsis
Stele miRNA Expression
L. Zhang, S. Kumari, Y.K. Lee [in collaboration with S. Brady,
University of California, Davis]
The gene regulatory network (GRN), comprising both
transcriptional and posttranscriptional pathways, governs
many processes of development and response to environ-
mental stress. A GRN is composed of several types of 
interactions that regulate gene expression, including pro-
tein−DNA, protein−protein, and microRNA (miRNA)−
mRNA interactions. To map protein−DNA interactions,
a gene-centered yeast one-hybrid (Y1H) method enables
systematic and comprehensive identification of upstream-
bound transcription factors (TFs) that regulate expression
of certain genes and miRNAs. To characterize TF inter-
actions in the root stele, we first developed a resource in
Arabidopsis based on the Y1H method. It consists of 653
full-length TFs, which represent 92% of root stele-ex-
pressed TFs and 74.5% of root-expressed TFs (Fig. 2).
We also improved our screening protocol to replace the
labor-intensive direct transformation method with the
more rapid mating-based assay and also used a high-copy
activation domain vector. The process has been auto-
mated with robotics and includes four technical replicates
(Brady et al. 2011). We tested our resource using 13 stele-
expressed TF promoters, which revealed 158 interactions,
many of which have been demonstrated to occur physi-
cally in planta or are associated with altered molecular
phenotypes in response to genetic perturbation. 
Using this resource, we have focused our effort to
map a comprehensive GRN that integrates miRNA-
based posttranscriptional regulation with TF-based tran-
scriptional regulation within root stele in Arabidopsis.
Approximately 60 miRNA promoters have been
screened together with promoters from portions of
miRNA targets and promoters of highly connected TFs.
To validate in vivo the protein and DNA interactions
that resulted from the Y1H data set, we recently char-
acterized homozygous knockout lines in Arabidopsis for
74 candidate TFs by quantitative polymerase chain re-
action (Q-PCR) and 20 TFs by Taqman miRNA assays.
Here, we characterized molecular expression phenotypes
for TFs and their miRNA targets. These data showed
that plants mutant in ~80% of the TFs and 70% of the
miRNAs tested display molecular phenotypes.
We continue to use this resource to investigate key
regulatory interactions specific to the Arabidopsis root
stele, as well as how this GRN overlaps with other reg-
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ulatory networks. Additionally, we are extending our
findings to maize in cross-species comparisons and de-
veloping an analogous Y1H resource for maize based
on orthologous TFs and conserved promoter sequences.
Therefore, this work represents a useful resource for elu-
cidating gene regulatory mechanisms at the tissue-spe-
cific level with strong potential for translation to impor-
tant crop species. 
Characterization of miRNAs in Response
to Short-Term Waterlogging in Three
Inbred Lines of Zea mays
Z. Liu, S. Kumari [in collaboration with Y. Zheng, Huazhong
Agricultural University, China]
Waterlogging of plants leads to low oxygen levels (hy-
poxia) in the roots and causes a metabolic switch from
aerobic respiration to anaerobic fermentation that re-
sults in rapid changes in gene transcription and protein
synthesis. Our research seeks to characterize the gene
regulatory networks associated with short-term water-
logging. In addition to characterizing the involvement of
miRNAs and their targets in response to short-term hy-
poxia conditions, a quantitative reverse transcriptase–
PCR (qRT-PCR) assay was used to quantify the expres-
Figure 2. An Arabidopsis eY1H transcription factor resource. (a) Schematic of root stele cell types. (b) Stele cell-type
expression profiles of the transcription factors present in our collection. Shading is as in a. (c) Family categorization
of transcription factors within the resource. “Other” represents families with fewer than eight members. (GRAS) Gib-
berellic acid–insensitive, repressor of GA1 and scarecrow, (DOF) DNA binding with one finger, (GATA) GATA DNA
motif, (HSF) heat shock factor, (CO-like) Constans-like, (ARF) auxin response factor, (MADS) MCM1, Agamous, De-
ficiens, and SRF box, (HB) homeobox, (BZIP) basic leucine zipper. (From Gaudinier et al. 2011.)
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sion of the 22 candidate mature miRNA signatures (rep-
resenting 64 miRNA loci) and their 84 predicted tar-
gets in three inbred Zea mays lines (Mo17, B73, Hz32)
that showed different tolerance to waterlogging. Study
results suggest that miR159, miR164, miR167,
miR393, miR408, and miR528, already known to have
roles in root development and stress responses, also have
roles in regulating responses to short-term waterlogging
conditions. Furthermore, computational approaches
were used to predict the stress- and development-related
cis-regulatory elements within the promoters of these
miRNAs using the B73 reference genome and to con-
struct a probable miRNA-mediated gene regulatory net-
work in response to short-term waterlogging stress. The
differential expression patterns of miRNAs and their tar-
gets in these three inbred lines suggest that candidate
miRNAs are active participants in signal transduction
at the early stage of hypoxia conditions via a gene regu-
latory network. We also hypothesize that cross-talk takes
place between different biochemical pathways.
Developmental Networks Controlling
Inflorescence Architecture in Maize
A. Eveland [in collaboration with D. Jackson, Cold Spring
Harbor Laboratory]
The goal of this work is to integrate genetics and ge-
nomics data sets to elucidate molecular networks that de-
termine the morphology (architecture) of maize inflores-
cences. Because inflorescences bear the fruits and grains
that we eat, understanding the genetic and regulatory
basis for how these structures are formed has clear rele-
vance to important agronomic traits such as grain yield
and harvesting ability. Our data sets represent maize in-
florescence primordia sampled during key developmen-
tal transitions and in perturbed genetic backgrounds. The
latter includes loss-of-function mutants in three impor-
tant regulators of the RAMOSA (RA) pathway, which
controls stem-cell-fate decisions and ultimately the deci-
sion to branch. We have established a robust system to
investigate the networks that modulate branching, in-
cluding characterization of the precise timing of devel-
opmental events and associated spatiotemporal changes
in gene expression. We integrated genome-wide mRNA-
Seq data to resolve coexpression networks during key
stages of maize inflorescence development, and we are
working to expand these networks by incorporating ad-
ditional data sets, such as genome-wide TF occupancy
profiles and cis-regulatory information.
Primary objectives for this project completed in 2011
were as follows: (1) Establish a comprehensive pipeline
for mRNA-Seq and chromatin immunoprecipitation
(ChIP)-Seq data analysis in maize by evaluating and op-
timizing available software for mapping and quantifica-
tion, as well as testing various statistical methods to ex-
tract biological relevance. (2) Characterize genome-wide
expression signatures specific to a given developmental
event or branching phenotype. We made use of known
developmental marker genes and their spatiotemporal
transcriptional responses to genetic perturbation in order
to test our experimental system and establish a proxy for
developmental staging. (3) Evaluate and implement clus-
tering approaches to identify candidate genes that are 
coexpressed with key regulators and/or coincide with spe-
cific developmental events. Our results included identi-
fication of candidate genes, specifically developmentally
regulated TFs, and novel genes of unknown function,
which are potentially involved in stem cell maintenance
and determinacy. We continue to interrogate coexpres-
sion clusters for enrichment of functional processes and
cis-regulatory motifs that are proximal to the transcrip-
tional start site of coexpressed genes (with Sunita Ku-
mari). (4) Identify targets of the RA1TF using ChIP-Seq
and integrate results with data from parallel mRNA-Seq
experiments. On the basis of this approach, we showed
that one-third of the genes with altered expression levels
in the ra1 mutant are also bound by RA1. We are incor-
porating additional ChIP-Seq data sets as they become
available to investigate combinatorial binding of TFs as-
sociated with the branching pathway. The ChIP-Seq data
also provide in vivo confirmation for binding sites of de-
velopmental regulators in maize, information that is be-
ing leveraged in efforts to resolve cis-regulatory modules
across the maize genome.
In the next phase, we will further prioritize candi-
dates from this work by overlaying the Arabidopsis reg-
ulatory network information (see previous section).
Resulting hypotheses can be tested in Arabidopsis (e.g.,
responses to stress) and ultimately translated to agro-
nomic systems. Additionally, candidate genes that are
maize- and/or grass-specific are of high priority because
they may contribute to the unique morphology of
maize inflorescences and/or features shared among
other grasses. We will further use comparative genomics
approaches, including both computational methods
and integration of analogous RNA-Seq data sets from
closely related grasses such as sorghum, to identify can-
didate genes that may contribute to grass-specific as-
pects of inflorescence architecture.
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Doreen Ware (bottom, second from left) and lab members
Gurinder S. “Mickey” Atwal and colleagues are applying insights from the physical and computa-
tional sciences to the study of population genetics and human disease. In collaborations with col-
leagues at the Institute for Advanced Study in Princeton, Atwal has modeled the process by which
genetic variants, or alleles, have evolved in the last 100,000 years of human history. This has re-
cently led to surprising insights about the role in female fertility played by p53, a master tumor sup-
pressor gene, and furthered our understanding of how complex gene networks evolve. Recently,
Atwal has analyzed the physical organization of the cancer genome and its role in mediating tu-
morigenesis across numerous tissue types.
Alexander Krasnitz and colleagues use mathematical and statistical tools to discover key genetic
elements involved in cancer and to understand how cancer cells evolve. Array-based comparative
genome hybridization, a technique honed in the Wigler lab, and, more recently, sequencing exper-
iments, have revealed subtle patterns of frequent and widespread aberration in cancer genomes.
Krasnitz hypothesizes that aberrant genomic loci observed to recur in a range of cancer types are
under selection and therefore are enriched in important cancer genes. He has developed a novel
comprehensive methodology to study such “epicenters” and has used it to analyze multiple-genome
data sets in breast, lung, colon, and liver cancer. The results have been shared with cancer biology
labs across CSHL, and they have been a key enabling agent of functional studies using mouse mod-
els and RNA interference. Krasnitz has begun to apply advanced statistical methods to the latest gen-
eration of experimental data, which have characterized tumor samples down to the level of single
cells. With such data, Krasnitz and colleagues seek to learn how specific cancer types evolve and
how cancer cells migrate in metastasis. 
Michael Schatz is a computational biologist and an expert on large-scale computational examina-
tion of DNA sequencing data, including the alignment, assembly, and analysis of next-generation se-
quencing reads. These methods have been used to reconstruct the genomes of previously unsequenced
organisms, to probe sequence variations, and to explore a host of biological features across the tree of
life. Recent improvements in sequencing technologies are challenging our capacity to store and ana-
lyze the huge volume of DNA sequence data being generated. In view of this, Schatz is particularly
interested in capitalizing on the latest advances in distributed and parallel computing, especially cloud
computing technologies, to advance the state of the art in bioinformatics and genomics.
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Fueled by data generated from recent technological de-
velopments in DNA sequencing, our lab is currently
focused on population genetics, cancer biology, and
high-performance computing. We often tackle scien-
tific questions computationally by invoking theoretical
concepts from statistical physics and machine learning. 
Suyash Shringapure, a graduate student in the com-
puter science department at Carnegie Mellon Univer-
sity, continues to collaborate with us and Bud Mishra
(New York University). Ying Cai is a graduate student
from the Applied Mathematics and Statistics depart-
ment at Stony Brook University and Bernard Fendler is
a postdoctoral associate with training in theoretical
physics. Willey Liao and Yifan Mo are graduate stu-
dents from Michael Zhang’s group and have continued
to work with him since his departure to the University
of Texas at Dallas. Chengyu Liu was an URP student
during the summer of 2011. Robert Aboukhalil worked
for a week in the summer before entering the Watson
School as a graduate student.
Identification of PHLPP1 as a Tumor 
Suppressor Reveals the Role of
Feedback Activation in PTEN-Mutant
Prostate Cancer Progression
In collaboration with the Trotman Lab at CSHL, we
investigated the synergistic co-deletion of PTEN,
TP53, PHLPP1, and PHLPP2 in metastatic human
cancer samples. Specifically, we analyzed the gene copy-
number profiles of patient data and carried out a
genome-wide analysis of the pairwise mutual informa-
tion between gene mutational events. A false discovery
rate analysis, based on an adaptive Monte Carlo statis-
tical testing procedure, demonstrated that PTEN and
PHLPP1 were significantly co-deleted in metastatic
samples and tightly correlated to deletion of TP53 and
PHLPP2. These data establish a conceptual framework
for progression of PTEN-mutant prostate cancer to life-
threatening disease. 
Regulation of Human Fertility by
Single-Nucleotide Polymorphisms
in the P53 Pathway
We continued our work in collaboration with Cornell
Medical School and the Cancer Institute of New Jersey,
investigating the association of human fertility and ge-
netic polymorphisms in the p53 pathway. The tumor
suppressor protein p53 has an important role in mater-
nal reproduction in mice through transcriptional regula-
tion of leukemia inhibitory factor (LIF), a cytokine cru-
cial for blastocyst implantation. To determine whether
these observations could be extended to humans, a list
of single-nucleotide polymorphisms (SNPs) in the p53
pathway that can modify the function of p53 were as-
sembled and used to study their impact on human fer-
tility. Selected alleles in SNPs in LIF, Mdm2, Mdm4, and
Hausp genes, each of which regulates p53 levels in cells,
were found to be enriched in IVF (in vitro fertilization)
patients. More recently, we have begun to investigate the
association of SNPs in p63 and p73. Initial results are
encouraging, although we await an increase in sample
numbers before the results can be deemed to be statisti-
cally significant.
Localization of Tumor
Suppressor Genes
In collaboration with the Lowe Lab (now at Memorial
Sloan-Kettering Cancer Center), we have carried out a
systematic analysis of the spatial distribution of known
tumor suppressor genes (TSGs) to test the hypothesis
that there exists an evolutionary selection pressure to
cluster TSGs throughout the genome. To this end, we
developed a computational and analytical model to de-
termine the extent to which we expect to find adjacent
TSGs under no selection. Preliminary results show a
strong tendency for TSGs to cluster, and this cluster-
ing occurs across many species. The conservation of
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TSG clusters across species, despite significant chro-
mosomal rearrangements between species, suggests nat-
ural selection has acted to preserve the relative TSG
order. Ongoing investigations are focused on under-
standing the implications of this spatial distribution of
TSGs for the risk and development of human cancer.
Furthermore, we are now investigating the spatial dis-
tribution of known oncogenes. 
Cell-Type-Specific Spatiotemporal
Gene Expression Dynamics
Reflects Cerebellar GABAergic
Circuit Development
In collaboration with the Huang Lab at CSHL, we have
analyzed the temporal gene-expression dynamics of two
GABAergic neuron subtypes in developing mice. The
objective was to unravel the cell-type-specific molecu-
lar correlates of a developing circuit, in contradistinc-
tion to the prevailing wisdom that the expression
landscape remains relatively static throughout postna-
tal development. We developed methods based on a
random matrix theory to determine the significance of
principal component analyses of temporal expression
profiles. A number of distinct temporal patterns, from
day 0 to day 56, were found for a large subset of genes
corresponding to distinct biological pathways. In addi-
tion, the research (1) uncovered groups of novel cell-
type-specific genes, (2) captured the phasic expression
 dynamics of ion channels, receptors, cell adhesion mol-
ecules, gap junction proteins, and transcription factors,
(3) revealed the active developmental modulation of
different molecular pathways involved in circuit for-
mation, and (4) showed evidence of hundreds of ge-
nomically clustered and developmentally coexpressed
transcripts, suggesting the involvement of chromatin
regulatory forces in early postnatal development as well
as maintenance of cell-type identity in the adult stages.
Recent Coselection in Human Populations
In collaboration with Suyash Shringapure from Car -
negie Mellon University and Bud Mishra from New
York University, we have devised a method of detect-
ing recent molecular coselection where the selected al-
leles have not yet reached fixation. A variety of selective
forces, including diverse habitats and diseases, have
been acting on human populations since their earliest
migration out of Africa. Studying recent natural selec-
tion through statistical analysis of human genetic poly-
morphisms is therefore an important way of illu-
minating this recent human history. In the last few
years, a number of methods have been proposed for de-
tecting recent natural selection. These methods have
found a large number of genes in human populations
showing strong signals of recent natural selection, but
they have not been able to find groups of genes (not
necessarily syntenic) that might have responded to
shared selective forces. For instance, because many of
these genes are involved in various common biological
pathways and networks, we hypothesize that selection
pressure on one gene in a network will result in a si-
multaneous selection pressure on other genes in the net-
work. We have analyzed SNP data from the HapMap
project to find candidates for recent coselection in
human populations.
PUBLICATIONS
Chen M, Pratt CP, Zeeman ME, Schultz N, Taylor BS, O’Neill A,
Castillo-Martin M, Nowak DG, Naguib A, Navin N, et al. 2011.
Identification of PHLPP1 as a tumor suppressor reveals the role of
feedback compensation in PTEN-mutant prostate cancer progres-
sion and therapy. Cancer Cell 20: 173−186.
In Press
Hainaut P, Olivier M, Wiman KG (eds.). 2012. The inheritance of p53.
In p53 in the clinics. Springer, New York (in press).
222
Research in our group is focused on in silico cancer ge-
nomics. In the last 5 years, there has been explosive
growth in the volume as well as quality and detail of
cancer-related genomic data available for analysis. This
development came about through rapid accumulation
of public data sets generated by individual laboratories
worldwide, through large-scale cancer genome projects
such as The Cancer Genome Atlas (TCGA) and the In-
ternational Cancer Genome Consortium (ICGC), and
with the advent of new experimental methodologies,
especially the next-generation sequencing. We see our
goal in channeling this flood of data into a number of
clinically relevant applications, including pinpointing
and prioritizing targets for functional analysis, discov-
ery of genomic markers for clinical outcome, and mo-
lecular classification of cancer. All our work is done in
close coordination with experimental studies performed
by M. Wigler, J. Hicks, S. Powers, S. Lowe (presently at
Memorial Sloan-Kettering Cancer Center), and B. Still-
man laboratories at CSHL.
Recurrence in Cancer Genomes
Large collections of intervals are a common form of data
in high-throughput genomics. In the context of chro-
matin immunoprecipitation−high-throughput sequenc-
ing (ChIP-Seq) or cross-linking immunoprecipita-
tion−high-throughput sequencing (CLIP-Seq) analyses,
these intervals represent fragments of DNA or RNA.
DNA copy-number analysis yields intervals of the ge-
nome corresponding to gains or losses of copy number.
In all cases, a common goal is inference of contiguous
genomic regions covered by the intervals with a high de-
gree of recurrence. We call such regions cores. In cancer,
genomes display complex patterns of DNA copy-num-
ber alteration, but recurrent aberrations are observed
within a given cancer type. Detection and quantitative
characterization of the cores in a given malignancy are
potentially beneficial in two ways. First, it is plausible
that at least some of the recurrence owes to selective pres-
sure on regions harboring cancer-related genes. Focus-
ing on these regions may therefore facilitate cancer gene
discovery. Second, once the cores are known, the genome
of a tumor can be described in a drastically simplified
fashion by indicating the presence or absence of copy-
number alteration in any given core. This simplified
form of the data is better suited for further analysis, such
as finding subtypes in a given type of cancer or discov-
ering associations between genomic properties and clin-
ical parameters.
We designed and implemented a method for identi-
fying cores in large surveys of genomic interval data. A
descriptive name for the method is explanation of re-
current intervals by cores (ERIC). Central to ERIC is
the notion of explanatory power. We say that a core ex-
plains an event and quantify the explanation provided
as a number between 0 and 1. The explanation is a
measure of how closely the event is matched by the
core. We then seek a set of cores that jointly provide the
best possible explanation of the data, subject to addi-
tional criteria of statistical significance and robustness
under resampling of the input.
In the course of 2011, we used ERIC to process a
number of massive collections of cancer genomes. In ap-
plication to two sets of genomic profiles derived from
frozen breast tumor tissues, ERIC revealed cores that are
significantly correlated with key histological and clinical
parameters, including tumor grade, cell ploidy, presence
of TP53 mutations, and expression-based molecular sub-
type. Armed with this experience, we applied ERIC to a
more challenging set of genomic profiles, generated by
Dr. James Hicks at CSHL from formalin-fixed breast
tumor tissues of patients with advanced breast cancer
who were in two CALGB (cancer and leukemia group
B) clinical trials. In this case, we also found highly sig-
nificant associations between cores and the molecular
subtypes. In particular, a core corresponding to amplifi-
cation of a narrow genomic region harboring the ERBB2
gene is strongly associated with the ERBB2 subtype. We
also detected cores associated with elevated proliferation
of tumor cells. These findings are evidence of a measur-
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able impact of such genomic alterations on the disease
phenotype. Furthermore, our analysis suggests prognos-
tic utility of the cores. Although trastuzumab is routinely
prescribed to patients with an amplification of the
ERBB2 gene or with overabundance of its protein prod-
uct, we identified two cores as potential markers for ben-
efit from trastuzumab in patients who do not meet these
criteria. This finding suggests the possibility of signifi-
cantly improving the overall survival in ~15% of ad-
vanced breast cancer cases.
Genomic Subtypes of Ovarian Cancer
We used ERIC to analyze a massive (516 profiles) high-
resolution (Agilent 1.1 million probe CGH platform)
DNA copy-number data set accumulated by TCGA for
serous ovarian cancer and used the resulting set of cores
for genomic subtyping of the disease. With the help of
a statistically supported hierarchical clustering tech-
nique developed in our lab, we partitioned the set of
tumors into four subtypes (a−d) exhibiting strikingly
different patterns of copy-number alterations (CNAs).
In particular, CNAs are relatively infrequent in subtype
a. In contrast, copy-number gains are extremely fre-
quent and present across the entire genome in subtype
b. Importantly, the four subtypes differ in additional
genomic and epigenomic properties that are not di-
rectly related to DNA copy number. Examining se-
quence-based exon somatic mutation data, we found
that somatic point mutation counts per tumor differ
significantly (p = 0.0005) from subtype to subtype.
Next, we compared the subtypes in terms of DNA
methylation. Genome-wide microarray-based methyl-
ation profiles were available from TCGA for all tumors.
We detected significant differences among the subtypes
in the degree of methylation for a number of chromo-
somes, but most dramatically (p = 2.8 x 10−10) for chro-
mosome X.
Furthermore, we observed significant phenotypic dif-
ferences between the subtypes. Performing multiclass
gene set analysis, we found that 26 KEGG pathways are
differentially regulated among the subtypes (q < 0.05).
Most of these pathways fall into functional categories
related to cell cycle, DNA-damage repair, immune re-
sponse, and apoptosis-inducing signaling. Moreover,
nearly 100 genes in differentially affected pathways were
also differentially expressed individually among the sub-
types. This property holds for a number of known key
cancer genes whose differential expression patterns help
shed light on the phenotypic differences between the
subtypes. We consistently find that genes with known
oncogenic properties are expressed at elevated levels in
subtype b, whereas genes with tumor suppressive prop-
erties exhibit reduced expression in that subtype. An in-
verse pattern is observed for subtype a.
Taken together, these findings suggest that subtype
b is associated with a more aggressive form of the dis-
ease. We find further support for this expectation when
we consider the subtype effect on patient survival. Clin-
ical prognosis is significantly more adverse for patients
with subtype-b tumors: Their median overall survival
and disease-free survival was shorter by 11 months and
6.5 months, respectively, than those of the remainder of
the cohort. A similar shortening in disease-free survival
time (by 7.5 mo) is found for patients in the narrower
category of complete responders to the initial combined
surgical and chemotherapeutic treatment.
Evolutionary Analysis of Single-Cell
Sequencing Data in Breast Cancer
Single-cell sequencing is a promising technology for re-
vealing properties of single cells that are missed by se-
quencing DNA from macroscopic amounts of tissue.
A recent study by the Wigler lab at CSHL using this
technology accurately determined DNA copy-number
profiles of 100 cells in breast cancer tissue of an indi-
vidual. Subsequent phylogenetic analysis identified sev-
eral distinct subpopulations of cells and pointed to a
possibility of punctuated evolution profiles.
To further characterize cancer cell evolution, we an-
alyzed the 100-cell sequencing data in the framework of
population genetics. In this framework, we viewed can-
cer cells as individuals of a nonsexual species and DNA
copy-number losses as a form of mutation. Applying
this concept, we found that most losses were selectively
neutral but that some were exposed to natural selection.
Tumor suppressor genes appear to be involved not only
in positive selection, but also in balancing selection. We
also estimated population genetic parameters such as
growth rates and mutation rates from the combination
of the copy-number data and data from flow cytome-
try. Our framework will shed light on cancer as an evo-
lutionary process and will help to screen for genomic
regions that are important for cancer cells from the
viewpoint of evolution.
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Our lab develops novel computational analysis methods
to study the information content in biological se-
quences and the dynamics of biological processes. These
include methods for assembling next-generation se-
quence data into complete genomes, aligning sequences
to discover variations or measure transcription levels,
and mining these data to discover relationships between
an organism’s genome and its traits. We then apply
these methods to study several biological systems, for
example, to discover mutations associated with human
diseases such as cancer and autism or to reconstruct the
genomes of important agricultural crops and biofuels.
In the past year, our lab has grown by several new
members. Hayan Lee joined in January, and over the
summer, she has become a candidate in the computer sci-
ence Ph.D. program at Stony Brook University. She is de-
veloping novel machine-learning algorithms to study the
limits of variation detection and to improve genome-wide
association studies. During the summer, Paul Baranay vis-
ited the lab from the University of Notre Dame in the
CSHL undergraduate research program. He is developing
new computational methods for improving genome as-
sembly, which he applied to the assembly of the cichlid
fish in the international Assemblathon-2 competition. In
November, James Gurtowski and Giuseppe Narzisi joined
our lab as informatics developers. James was previously
an analyst at the Mount Sinai School of Medicine, and he
is now working on developing analysis tools for optimiz-
ing the growth of plants as biofuels. Giuseppe recently
completed his Ph.D. in computer science at New York
University and is now developing novel computational
methods for studying the molecular basis of autism. 
CSHL Adjunct Associate Professor D. Ware and I
were awarded a 5-year, $5 million grant from the De-
partment of Energy to study and optimize the growth
of plants as biofuels through the development of a
Knowledgebase in Systems Biology. I have also formal-
ized this collaboration with CSHL Professor M. Wigler
to continue studying the molecular basis of autism, and
with Johns Hopkins University Professor S. Salzberg to
develop large-scale computational sequence analysis
methods for human and plant genomics. In May, I was
awarded the CSHL Winship Herr Award for Excellence
in Teaching for contributions to the new CSHL course
in Quantitative Biology, co-taught by M. Atwal. In the
last year, I have also been interviewed by editors of the
journal Science, the trade publication Genome Technol-
ogy, Reuters, and The New York Times, especially to de-
scribe my work with applying cloud-computing
technologies to help address the data deluge in genomics. 
Competitive Genome Assembly
and Analysis
A major research focus of our lab is developing enhanced
methods for de novo genome assembly, which aims to
reconstruct the genome of an organism from billions of
short DNA sequences. We apply these methods to re-
construct the genomes of previously unsequenced or-
ganisms, including several plant and animal species.
Current sequencing technology can now be used to se-
quence the equivalent of an entire human genome in a
matter of days and at low cost. Sequence read lengths,
initially very short, have rapidly increased since the tech-
nology first appeared, and we now are seeing a growing
number of efforts to sequence large genomes de novo
from these short reads such as the Genome 10k project
that aims to sequence 10,000 vertebrate genomes.
The past year saw two major efforts to benchmark the
state of the art in genome assembly. The first such effort,
the Assemblathon, was organized by researchers at the
University of California, Santa Cruz. In a collaborative
effort, teams were asked to assemble a simulated Illumina
HiSeq data set of an unknown, simulated diploid
genome. A total of 41 assemblies from 17 different groups
were received, including two constructed by our labora-
tory. Novel haplotype aware assessments of coverage, con-
tiguity, structure, base calling, and copy number were
made and established that (1) it is possible to assemble
the genome to a high level of coverage and accuracy and
(2) large differences exist between the assemblies, sug-
gesting room for further improvements in current meth-
ods. The simulated benchmark, including the correct
answer, the assemblies, and the code that was used to eval-
uate the assemblies, is now public and freely available.
In a second project called the Genome Assembly Gold
Standard Evaluations (GAGE) project, organized by re-
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searchers at Johns Hopkins University, we evaluated sev-
eral of the leading de novo assembly algorithms on four
different short-read data sets, all generated by Illumina
sequencers. Our results describe the relative performance
of the different assemblers as well as other significant dif-
ferences in assembly difficulty that appear to be inherent
in the genomes themselves. Three overarching conclu-
sions are apparent: (1) data quality, rather than the as-
sembler itself, has a dramatic effect on the quality of an
assembled genome, (2) the degree of contiguity of an as-
sembly varies enormously among different assemblers
and different genomes, and (3) the correctness of an as-
sembly also varies widely and is not well correlated with
statistics on contiguity. To enable others to replicate our
results, all of our data and methods are freely available, as
are all assemblers used in this study.
These two studies were important for benchmarking
the state of the art in assembly. However, unlike these
studies working from a known reference sequence, it re-
mains an open problem for analyzing an assembly of an
unknown genome to identify any errors. Along these lines,
members of our lab published a revision to the AMOS
project with improved methods for visualizing and assess-
ing the quality of a genome assembly. Since its launch in
2004, the open-source AMOS project has released several
innovative DNA sequence analysis applications including
Hawkeye, a visual analytics tool for inspecting the struc-
ture of genome assemblies; the Assembly Forensics and
FRCurve pipelines for systematically evaluating the qual-
ity of a genome assembly; and AMOScmp, the first com-
parative genome assembler. These applications have been
used to assemble and analyze dozens of genomes ranging
in complexity from simple microbial species through
mammalian genomes. Recent efforts have been focused
on enhancing support for new data characteristics brought
on by second- and now third-generation sequencing. The
revised software emphasized the methods for assessing as-
sembly quality and the visual analytics capabilities of
Hawkeye. These interactive graphical aspects are essential
for navigating and understanding the complexities of a
genome assembly, from the overall genome structure
down to individual bases. Hawkeye and AMOS are freely
available and open-source software.
Ultra-Large-Scale Biological
Sequence Analysis
In the race between DNA-sequencing throughput and
computer speed, sequencing is winning by a mile. Se-
quencing throughput is currently about 500−600 bil-
lions of bases per run on a single sequencing machine,
and it is improving at a rate of about fivefold per year.
In comparison, computer performance generally follows
“Moore’s Law,” doubling only every 18 or 24 months.
As the gap in performance widens, the question of how
to design higher-throughput analysis pipelines becomes
crucial. One option is to enhance and refine the algo-
rithms to make better use of a fixed amount of com-
puting power. Unfortunately, algorithmic breakthroughs
of this kind, like scientific breakthroughs, are difficult
to plan or foresee. The most practical option is to de-
velop methods that make better use of multiple com-
puters and processors in parallel.
Parallel computing systems have existed for decades
in different forms, but a system called MapReduce is es-
pecially promising for accelerating data-intensive ge-
nomics research. MapReduce was developed at Google
for their large data analysis, especially for scanning across
billions of webpages to find the most relevant pages for
a search query. The power of MapReduce is that it can
intelligently distribute computation across a cluster with
hundreds or thousands of computers, each analyzing a
portion of the data set. The system was originally devel-
oped for text and web processing at Google, but an open-
source implementation called Hadoop is now available to
install on any cluster for any application domain.
The first ever application of this technology to ge-
nomics (which I published in 2009) was to accelerate
the short-read mapping algorithm CloudBurst. In
CloudBurst, many computers work together using
Hadoop to map reads to a reference genome, allowing
for any number of differences to determine from where
each read originated and if any variations are present. In
experiments with 96 cores, the mapping algorithm was
~100 times faster than using a single core, thus reducing
the run time from several weeks to a few hours. The
compute cluster used for these experiments was com-
pletely virtual and was leased from the Amazon Elastic
Compute Cloud (EC2), which offers computing time in
their cloud at a small fee per node per hour used.
These pioneering efforts have allowed numerous ap-
plications to be developed to leverage Hadoop and cloud
computing for genomics. Several of these applications
have focused on accelerating sequence alignment, be-
cause it is one of the most important applications in
computational biology, and it is used for such diverse
tasks as identifying homologous proteins, analyzing gene
expression, mapping variations between individuals, or
assembling de novo the genome of an organism. Except
for trivial cases involving just a small number of short se-
quences, virtually all other sequence alignment tasks rely
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on a precomputed index of the sequence to accelerate the
alignment. Two of the most important index structures
are the suffix array, which consists of the lexicographi-
cally sorted list of suffixes of a genome, and the closely re-
lated Burrows-Wheeler Transform (BWT), which is a
permutation of the genome based on the suffix array.
Constructing these structures on large sequences, such
as the human genome, requires several hours of serial
computation and must be performed for each genome,
or genome assembly, to be analyzed. In May, I, along
with two master’s students whom I was supervising in
the computer science department at Stony Brook Uni-
versity, published the first algorithm for constructing the
suffix array and the BWT of a sequence leveraging the
unique features of MapReduce. We demonstrated the
performance of the algorithm by greatly accelerating the
suffix array and BWT construction on five significant
genomes using as many as 120 cores leased from the
EC2, reducing the end-to-end run time from hours to
mere minutes. 
Rate of Meristem Maturation
Determines Inflorescence
Architecture in Tomato
This work was done in collaboration with the Lippman lab
at CSHL.
Flower production and crop yields are highly influenced
by the architectures of inflorescences. In the compound
inflorescences of tomato and related nightshades
(Solanaceae), new lateral inflorescence branches develop
on the flanks of older branches that have terminated in
flowers through a program of plant growth known as
“sympodial.” Variability in the number and organiza-
tion of sympodial branches produces a remarkable array
of inflorescence architectures, but little is known about
the mechanisms underlying sympodial growth and
branching diversity. One hypothesis is that the rate of
termination modulates branching. By performing deep
sequencing of transcriptomes, we have captured gene
expression dynamics from individual shoot meristems
in tomato as they gradually transition from a vegetative
state to a terminal flower. Surprisingly, we find thou-
sands of age-dependent expression changes, even when
there is little change in meristem morphology. From
these data, we reveal that meristem maturation is an ex-
tremely gradual process defined molecularly by a
“meristem maturation clock.” Using hundreds of stage-
enriched marker genes that constitute this clock, we
show that extreme branching, conditioned by loss of
expression of the COMPOUND INFLORESCENCE
gene, is driven by delaying the maturation of both api-
cal and lateral meristems. In contrast, we find that wild
tomato species display a delayed maturation only in
apical meristems, which leads to modest branching.
Our systems genetics approach reveals that the program
for inflorescence branching is initiated surprisingly early
during meristem maturation and that evolutionary di-
versity in inflorescence architecture is modulated by
heterochronic shifts in the acquisition of floral fate.
Two New Complete Genome
Sequences Offer Insight into Host
and Tissue Specificity of Plant
Pathogenic Xanthomonas spp.
This work was done in collaboration with A. Bogdanove,
Iowa State University. 
Xanthomonas is a large genus of bacteria that collec-
tively cause disease in more than 300 plant species. The
broad host range of the genus contrasts with stringent
host and tissue specificity for individual species and
pathovars. Whole-genome sequences of X. campestris pv.
raphani strain 756C and X. oryzae pv. oryzicola strain
BLS256, pathogens that infect the mesophyll tissue of
the leading models for plant biology, Arabidopsis
thaliana and rice, respectively, were determined that pro-
vided insight into the genetic determinants of host and
tissue specificity. Comparisons were made with the
genomes of, respectively, closely related strains that in-
fect the vascular tissue of the same hosts, and across a
larger collection of complete Xanthomonas genomes.
The results suggest a model in which complex sets of
adaptations at the level of gene content account for host
specificity, as well as subtler adaptations at the level of
amino acid or noncoding regulatory nucleotide se-
quence that determine tissue specificity.
Complex Microbiome Underlying
Secondary and Primary Metabolism
in the Tunicate−Prochloron Symbiosis
This work was done in collaboration with M. Donia, 
University of Utah.
The relationship between tunicates and the uncultivated
cyanobacterium Prochloron didemni has long provided a
model symbiosis. P. didemni is required for survival of
animals such as Lissoclinum patella and also makes sec-
ondary metabolites of pharmaceutical interest. Here, we
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studied the metagenomes, chemistry, and microbiomes
of four related L. patella tunicate samples from a wide
geographical range of the tropical Pacific. The remark-
ably similar P. didemni genomes are the most complex so
far assembled from uncultivated organisms. 
Although P. didemni has not been stably cultivated and
comprises a single strain in each sample, a complete set of
metabolic genes indicates that the bacteria are likely ca-
pable of reproducing outside the host. The sequences re-
veal notable peculiarities of the photosynthetic apparatus
and explain the basis of nutrient exchange underlying the
symbiosis. P. didemni likely profoundly influences the
lipid composition of the animals by synthesizing sterols
and an unusual lipid with biofuel potential. In addition,
L. patella also harbors a great variety of other bacterial
groups that contribute nutritional and secondary meta-
bolic products to the symbiosis. These bacteria possess an
enormous genetic potential to synthesize new secondary
metabolites. For example, an antitumor candidate mole-
cule, patellazole, is not encoded in the genome of
Prochloron and was linked to other bacteria from the mi-
crobiome. This study unveils the complex L. patella mi-
crobiome and its impact on primary and secondary
metabolism, revealing a remarkable versatility in creating
and exchanging small molecules.
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Network Analysis of the Genes Affected
by De Novo Copy-Number Variants
Identified in 1000 Families with One 
Autistic Child from the Simons
Simplex Collection 
I. Iossifov
I am studying the genetics of common diseases in hu-
mans using two main tools: next-generation sequencing
and molecular networks representing functional relation-
ships among genetic loci. In combination, these tools en-
able large-scale studies necessary for furthering our un-
derstanding of the complex etiology of disorders such as
autism, bipolar disorder, and cancer. I focus both on the
development of new methods—for sequence analysis, for
building, and for using molecular networks—and on
their applications for specific biomedical problems.
The latest study from Mike Wigler’s group at CSHL
of the genomic copy-number variation in a large cohort
of families with a single child with autism confirmed
the role of de novo deletions and duplications in the
etiology of autism (Levy et al. 2011). The group iden-
tified 75 de novo copy-number events in 68 of the 889
analyzed affected children, whereas only 19 events were
observed in 17 of the 895 unaffected siblings. The sig-
nificantly increased frequency of de novo events argued
for their causative role. 
The limited recurrence within the 75 events in the
autistic children, together with the large number of
genes affected by some of the events, led to a list of
more than 900 perturbed genes. It is natural to expect
that only a small subset of these genes (i.e., one or two
per copy-number event) would be related to autism.
We assumed that the subset will be composed of genes
that are functionally related, and thus, we developed a
novel method, network-based analysis of genetic asso-
ciations (NETBAG) to search for subsets (clusters) of
interconnected genes within the context of a functional
network (Gilman et al. 2011).
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Quantitative biology fellows are independent researchers who enter this position immediately after
receiving a Ph.D. They come from the fields of mathematics, physics, engineering, or computer sci-
ence and will spend 3–5 years at CSHL applying these disciplines to biological questions of present
and future interest to researchers at the Lab.
Ivan Iossifov focuses on the development of new methods and tools for genomic sequence analysis
and for building and using molecular networks, and he applies them to specific biomedical problems.
Iossifov studies the genetics of common diseases in humans using two main tools: next-generation
sequencing and molecular networks representing functional relationships among genetic loci. These
approaches in combination enable the kind of large-scale studies necessary for furthering our un-
derstanding of the complex etiology of disorders such as autism, bipolar disorder, and cancer.
Justin Kinney’s research combines theory, computation, and experiment in an effort to better
understand the relationship between sequence and function in molecular biology. The use of mi-
croarray and ultra-high-throughput sequencing technologies has a central role in this work, making
possible assays on the activities of tens of thousands to millions of different biological sequences in
simple, small-scale experiments. The resulting data can then be used to infer precise quantitative
models for how biological sequence dictates function. Kinney has used ChIP-chip and protein-
binding microarray data to infer models for the DNA sequence specificities of transcription factors.
The same principle can be used to fit models to any data set comprising a list of sequences and cor-
responding measurements for whatever biological activity in which one is interested. He has also
demonstrated that fluorescence-activated cell sorting and 454 pyrosequencing can be used to meas-
ure the transcriptional activities resulting from hundreds of thousands of slightly mutated versions
of the Escherichia coli lac promoter. Measuring the in vivo activity of a large number of slightly mu-
tated regulatory sequences provides a new way of interrogating the transcriptional regulatory code
and may be applicable to a wide range of regulatory sequences in a variety of single-celled organisms
as well as in cell culture.
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When applied to the 75 copy-number events in
autistic children, the NETBAG method did identify a
statistically significant gene cluster. The implications of
this finding are potentially profound. It complements
and strengthens the importance of the de novo copy-
number variants identified by Levy et al. (2011), de-
monstrating the connection between what looked like
disparate events. Moreover, the knowledge that the ob-
served diverse genetic alterations affect a compact func-
tional module opens up more concrete avenues for
research into early diagnosis: We can analyze genetic
variants and judge if they are related to the disease based
on the extent to which they perturb the identified clus-
ter. A close inspection of the genes forming the cluster
revealed that they were primarily related to synapse de-
velopment, axon targeting, and neuron motility.
Next-Generation Sequencing 
for Identifying Genetic Variants
Recent advances in sequencing technology made prac-
tical the identification of the genetic variants at a nu-
cleotide level in whole exomes (i.e., all coding exons)
of large numbers of individuals. This creates exciting
opportunities for studying Mendelian and complex
human phenotypes. There are serious problems associ-
ated with managing the huge amounts of data, dealing
with the substantial levels of noise and biases, and with
the interpretation of the identified variants. In collab-
oration with several groups at CSHL, I tried to address
some of these problems by building a whole exome se-
quence analysis pipeline. 
The pipeline is flexible, easy to run, and provides
structured internal information that greatly facilitates
the interpretation of results. It is almost fully automated,
it efficiently utilizes the computational resources at
CSHL, it produces detailed statistics that help in mon-
itoring the sequencing process and in optimizing the
sample preparation protocols, it handles multiple sam-
ples per lane and multiple lanes per sample designs, it
produces lists of annotated single-nucleotide polymor-
phisms (SNPs) and indel variants for every analyzed
sample, and it can identify the de novo mutations in
families and somatic mutations when given two differ-
ent tissue samples from the same individual.
The pipeline has been adopted in several projects at
CSHL, and two papers whose results were obtained
with its help have already been accepted. In collabora-
tion with Jennifer Parla and Dick McCombie, I system-
atically compared the performance of two leading ex-
ome capture kits to that of the whole-genome sequenc-
ing approach (Parla et al. 2011). Our analysis indicates
that both kits are roughly equal, but stresses some lim-
itations of the exon capture approach, suggesting that
with the rapidly decreasing prices, whole-genome se-
quencing is likely to become the preferred choice. In
collaboration with Mona Spector and Scott Lowe, I an-
alyzed the somatic mutations in the whole exome of
mast cell leukemia cells from one patient. Among the
few identified mutations were an atypical nonsynony-
mous mutation in the KIT receptor and a nonsynony-
mous mutation in the β chain of the IgE mast cell
receptor (Spector et al. 2011). Had these mutations
been known, the course of treatment for the particular
patient would have been different.
Ongoing Projects
• Whole-exome sequencing of the Simons Simplex
Collection (SSC). The SSC is expected to grow to
4000 families, with one child with autism spectrum
disorder diagnosis and with at least one unaffected
child. Such a collection is ideally suited for identifi-
cation of de novo mutations with a strong effect on
the disorder. The recent improvements of the tech-
niques for enrichment of coding genomic sequence
and of the new generation sequencing technology
made whole-exome sequencing for a large number
of samples feasible. The generated data are of high
quality and can be used to identify de novo single-
nucleotide, short-indel, and copy-number muta-
tions. This project is being done in collaboration
with Michael Wigler and Richard McCombie.
• Analysis of the overall sharing of the parental
genome by concordant and discordant autistic sib-
lings. The goal is to test the hypothesis that a sub-
stantial proportion of the inherited autism is caused
by a dominant mutation inherited from the mother,
with different mothers having different affected loci.
So far, we see a suggestive increase of sharing of the
mothers’ genome in a cohort of ~300 multiplex fam-
ilies from the AGRE collection with microsatellite
markers. The next step is to see if the signal is pre-
served and hopefully statistically significant in a
larger set of 700 families genotyped with a 10K SNP
array. This project is being done in collaboration
with Michael Wigler and Kenny Ye.
• Sequencing of treatment-related acute myeloid
leukemia (tAML) 5q and 7q chromosomes. A large
proportion of tAML cases present with hemizygous
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7q or 5q chromosomes. In collaboration with Mona
Spector, we are sequencing 50 samples with the hope
of identifying a gene within the 5q and 7q regions
with recurrent variants affecting protein sequence.
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Dissecting, Decoding, and Reprogramming
Multiprotein−DNA Complexes
J.B. Kinney
Multiprotein−DNA complexes regulate a variety of cel-
lular processes. These large assemblies of protein and
DNA act as discrete information processing units: They
sense protein concentrations and other cellular signals,
perform a computation, and generate an output impor-
tant for cellular physiology. The DNA that scaffolds
each complex contains, within its sequence, instruc-
tions for how that complex functions. However, our
ability to understand such DNA-encoded regulatory
programs, and to reprogram multiprotein–DNA com-
plexes by altering this DNA sequence, remains limited. 
Prior to coming to CSHL, I proposed a combined
experimental and computational method for dissecting
and decoding specific multiprotein−DNA complexes
using flow cytometry and ultra-high-throughput DNA
sequencing. This method, called Sort-Seq, was first
demonstrated in the context of transcriptional regula-
tion with experiments on the Escherichia coli lac pro-
moter. Using Sort-Seq, my colleagues and I were able,
in living cells, to identify protein binding sites, model
the sequence-dependent binding energy of the protein
cognate to each site, and even measure the interaction
energy between such DNA-bound proteins. 
I believe that Sort-Seq and similar techniques have
the potential to open up a new area of high-precision,
data-intensive biochemistry. My laboratory’s efforts are
focused on developing both the experimental and com-
putational aspects of these methods and applying them
to critical problems in molecular and synthetic biology. 
Biophysical Basis of Transcriptional
Regulation in E. coli
Transcriptional regulation in E. coli continues to serve
as the primary development platform for Sort-Seq. In
particular, the extensive biochemical literature on E. coli
RNA polymerase and its interactions with transcription
factors allows us to interpret Sort-Seq data in this con-
text with much more clarity than in other systems. This
work is being pursued in collaboration with Tiberiu
Tesileanu (Institute for Advanced Study) and the labo-
ratories of Curtis Callan (Princeton University) and
Rob Phillips (California Institute of Technology). 
Daniel Jones, a graduate student in the lab of Rob
Phillips, visited my laboratory for 2 months in the sum-
mer of 2011. During this time, he and I performed
Sort-Seq experiments on the E. coli lac and mscL pro-
moters. Tiberiu Tesileanu and the Callan lab are assist-
ing in the analysis of these data. 
The E. coli lac promoter is one of the best-studied
regulatory systems in all of biology. Still, the quantita-
tive biophysical basis for transcriptional regulation at
this promoter remains incompletely understood. Our
goal for this system is to build a full biophysical model
for how this promoter works in vivo, and to use this
system as the primary context in which to investigate
the transcriptional regulatory code of E. coli more gen-
erally. In contrast, the functional structure of the mscL
promoter has, to our knowledge, never been studied.
We are therefore using the mscL promoter to test the
ability of Sort-Seq to decipher the biophysical basis of
a transcriptional regulatory system de novo. 
High-Resolution Characterization of DNA
Replication Origins in Budding Yeast
My laboratory is also using Sort-Seq-like experiments
to elucidate the fine structure of DNA replication ori-
gins in the yeast Saccharomyces cerevisiae. This work is
being pursued in collaboration with the laboratories of
Bruce Stillman, Mike Schatz, and Leemor Joshua-Tor
(CSHL). 
In the summer of 2011, I performed preliminary
experiments on two well-studied yeast replication ori-
gins, ARS1 and HMR-E. An initial analysis of these
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data has already revealed new information about poorly
understood sequence elements within these origins.
Hayan Lee, a graduate student in the Schatz lab, is as-
sisting in the analysis of these data. Ante Tocilj, a post-
doc in the Joshua-Tor lab, is using these results to aid
structural studies and is also helping to apply Sort-Seq-
like techniques in vitro to study prereplication complex
assembly. 
Rapid Dissection and Model-Based
Optimization of Inducible Enhancers
in Human Cells
I am also engaged in an exciting collaboration with Tar-
jei Mikkelsen (Harvard Stem Cell Institute and Broad
Institute). The Mikkelsen lab has developed a massively
parallel reporter assay (MPRA) that produces Sort-Seq-
like data on transcriptional enhancers in mammalian
cell culture. During the last year, I have been working
in collaboration with Tiberiu Tesileanu and the Callan
lab to analyze the sequence data produced by MPRA. 
MPRA was demonstrated on two mammalian en-
hancers: a cAMP-responsive enhancer (CRE) and the
human interferon beta enhancer (IFNβ). By modeling
the sequence-dependent activity of these enhancers
under both inducing and noninducing conditions, we
were able to design new enhancers that have increased
inducibility. We expect this work will pave the way for
reliable model-based construction of novel human en-
hancers, expanding the possibilities for synthetic biology.
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Mechanistic Studies of the Chromatin
Regulatory Machinery in the
Hematopoietic System
C.R. Vakoc, J. Lee, J. Molazzo, S. Shareef, J. Shi, M. Taylor,
E. Wang
Chromatin, composed of DNA in complex with protein,
is the fundamental packaging system for eukaryotic
genomes. The basic organizational unit of chromatin is
the nucleosome, composed of an octamer of core histones
(H2A, H2B, H3, and H4) wrapped by 147 bp of DNA.
In addition to protecting the genetic code from genotoxic
insult, the structure of chromatin has a profound impact
on effectively all DNA-templated processes, including
gene transcription, DNA replication, and recombination.
Hence, an elaborate regulatory system has evolved to an-
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imate chromatin structure so as to facilitate such funda-
mental cellular activities. Two principal categories of
chromatin regulators are the enzymes (e.g., acetyltrans-
ferases, deacetylases, methyltransferases, and demethyl-
ases) and the reader domain-containing proteins (e.g.,
bromodomains, chromodomains, and PHD domains).
The central long-term goal of research performed in our
lab is to explore the mechanistic basis of chromatin reg-
ulation and how it relates to the control of gene transcrip-
tion. We have had a long-standing interest in the rela-
tionship between DNA-binding “master-regulatory”
transcription factors and the chromatin regulatory ma-
chinery, and how this interplay governs cell-fate pro-
grams. The biological context in which we study
chromatin is in the hematopoietic system, where a hier-
archically organized cell lineage program is specified in
large part by transcriptional regulators. In addition,
studying the hematopoietic systems affords a number of
powerful biochemical, as well as genetic, tools for evalu-
ating chromatin and transcription in vivo and ex vivo.
An approach taken by our laboratory for studying
transcriptional/chromatin regulators has been to com-
pare their action under normal physiologic settings with
their role in pathologic conditions, which can deviate
demonstrably from the cellular context under which
these components evolved. As an example, normal tis-
sues in vivo generally possess robust gene regulatory net-
works, such that profound redundancy in gene function
can exist under laboratory conditions, which can often
obscure studies of molecular mechanisms. In contrast,
in aberrant disease states that deviate from normal
homeostasis, the nonredundant function of specific reg-
ulators can often emerge, thus enabling unique insight
into gene function. In addition, studying the action of
chromatin regulators in the pathophysiology of disease
affords opportunities to translate laboratory observations
into biomedical applications, as will be illustrated below.
To this end, we have spent the last several years working
in close collaboration with Scott Lowe’s laboratory at
CSHL to investigate the function of chromatin regula-
tors in the setting of hematopoietic cancer—specifically,
the disease acute myeloid leukemia (AML). Interest-
ingly, the hematopoietic cell-lineage transcriptional pro-
gram is often corrupted during leukemogenesis,
frequently by direct somatic mutation of transcription
factors and chromatin components. The result of this
deregulation is an acquired inability of myeloid progen-
itor cells (a type of white blood cell) to complete termi-
nal differentiation into macrophages and neutrophils,
thereby gaining the capability of infinite self-renewal
normally seen only in stem cells. We seek to understand
how chromatin regulators directly participate in this
unique pathophysiology of AML. 
Our initial work in this area has focused on two spe-
cific chromatin regulators: DOT1L and MLL (mixed-
lineage leukemia). DOT1L encodes a histone H3K79
methyltransferase and MLL encodes a histone H3K4
methyltransferase. We have previously published the first
epigenomic analysis of DOT1L and H3K79 methylation
in mammalian cells, identifying this regulator as a per-
vasive component of recently initiated transcription elon-
gation complexes. More recently, we also identified and
published a novel role for MLL in the epigenetic inher-
itance of gene expression states during mitosis through a
“bookmarking” mechanism. Both MLL and DOT1L
have important roles during normal hematopoiesis, but
they are also intimately connected to the initiation of
AML. As a leukemia proto-oncogene, MLL is frequently
mutated via chromosomal translocation to generate
oncogenic fusion proteins. Interestingly, MLL−fusion
proteins lack their native H3K4 methyltransferase do-
main and instead directly recruit DOT1L via the car-
boxy-terminal fusion partner. Hence, MLL fusions lead
to the aberrant hypermethylation of H3K79 at many ge-
nomic sites, resulting in deregulated transcription pro-
grams. MLL fusion leukemia is a widely used experi-
mental model system for studying leukemogenesis as a
consequence of epigenetic deregulation.
Using a genetically engineered mouse model of MLL
as well as a collection of human leukemia lines, we have
sought to identify the essential chromatin regulators nec-
essary to implement the unique hematopoietic phenotype
seen in this disease, i.e., the aberrant self-renewal har-
bored by committed myeloid progenitors. Importantly,
the MLL−leukemia mouse model recapitulates many of
the aggressive features of the human disease, including
resistance to cytotoxic chemotherapy. Hence, identifying
chromatin regulators as dependencies in this model can
be used as preclinical proof-of-concept for discovering
and validating novel drug targets for the human disease. 
Identification of the Bromodomain Protein
BRD4 as a Leukemia Maintenance Gene,
Upstream Regulator of MYC Expression,
and Drug Target in AML
In an initial effort to systematically identify chromatin
regulatory, or “epigenetic,” dependencies in MLL, we
conducted a short hairpin RNA (shRNA) screen target-
ing ~250 of the most well-documented chromatin ma-
chineries, including most known writers, readers, and
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erasers of chromatin modifications. All chromatin regu-
lators were systematically suppressed and scored for their
impact on growth of MLL cultures ex vivo. Among the
genes identified in the screen, BRD4 was among the
most striking, based on the overall strength of the
growth-inhibitory phenotype observed following shRNA
knockdown. Importantly, BRD4 knockdown suppressed
growth of a multitude of different mouse and human
AML lines, including, but not limited to, those harbor-
ing MLL−fusion oncogenes. BRD4 inhibition, when de-
livered conditionally to established leukemias in vivo,
could also attenuate disease progression. Thus, our RNA
interference (RNAi) screen identified BRD4 as a unique
dependency in AML, which had no prior links to hema-
topoietic cancer pathogenesis.
Convergent studies from the chemistry laboratory
of Dr. James Bradner at the Dana-Farber Cancer Insti-
tute identified a first-in-class small-molecule inhibitor
of BRD4, called JQ1, with demonstrated preclinical ac-
tivity in suppressing growth of BRD4-NUT squamous
cell carcinoma. Through collaborative studies per-
formed with the Bradner laboratory, we observed that
JQ1 also dramatically attenuated progression of the
MLL−fusion leukemia mouse model. Remarkably, JQ1
treatment leads to a phenotype overtly similar to BRD4
knockdown, as revealed by flow cytometry analysis of
cell-surface markers, expression microarrays, and cell
morphology, as well as a broad antileukemia activity in
a collection of different AML lines. Together, these
findings revealed that small-molecule inhibition of
BRD4 is an effective pharmacological strategy in sup-
pressing leukemia progression.
Subsequent mechanistic studies revealed that one of
the most prominent consequences of BRD4 inhibition,
whether with shRNAs or JQ1, was the suppression of
MYC RNA and protein levels. MYC is a well-known
oncogene with an established role in initiation and pro-
gression of a broad variety of cancer types. Remarkably,
exposing cells to JQ1 led to a nearly 50-fold suppression
of MYC expression (see Fig. 1). By ectopically expressing
MYC from an artificial transgene, we demonstrated that
MYC suppression accounts significantly for the antileu-
kemia effects of JQ1 or BRD4 shRNA. Thus, BRD4
provides an opportunity for small-molecule inhibition of
MYC at the level of expression by inhibiting its bromo-
domain function with JQ1.
Ongoing studies in the laboratory are now focused
on identifying other components of the BRD4 pathway
that might be involved in leukemia pathogenesis, as
well as continuing studies on epigenetic inheritance
through mitosis. Clinical trials in leukemia patients
with drug-like derivatives of JQ1 will be initiated
within the next year by Tensha Therapeutics. 
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Figure 1. (A) Western blotting of whole-cell lysates prepared from
MLL-AF9/NrasG12D leukemia cells treated for 48 h with DMSO or
250 nM JQ1.(B) ChIP−qPCR performed in MLL cells with indicated
antibodies and PCR primer locations. (TSS) Transcription start site.
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SCIENCES DEAN’S REPORT
The Watson School of Biological Sciences (WSBS) continues to be one
of the most successful Ph.D. programs in the United States. Our time
to graduation is ~3 years faster than the national average, the publica-
tion record of our students is outstanding, and the success of our
alumni is remarkable.  
Dr. Keisha John has been promoted to Associate Director for Re-
cruitment and Undergraduate Research at the WSBS. Keisha is an
alumna of the WSBS graduate and URP (Undergradate Research Pro-
gram) programs. An invaluable member of “Team Watson,” working
closely with Dawn, Alyson, and Kim, she has been coordinating all vis-
iting students at the Laboratory and is heavily involved in recruitment
for our graduate and undergraduate programs. One of Keisha’s new responsibilities is the administration
of the URP, and together with URP Director Professor Zachary Lippman, she has created a fantastic 
environment of science and fun over the summer. 
Faculty Changes
One new faculty member joined the Watson School in 2011: Christopher Vakoc. Chris, an Assistant
Professor, first came to Cold Spring Harbor Laboratory (CSHL) in 2008 as a Cold Spring Harbor
Fellow and was promoted to the WSBS faculty this year. His work focuses on how chromatin reg-
ulatory pathways participate in the pathogenesis of cancer. As a fellow, Chris has already participated
in School activities as a course lecturer, examiner on qualifying exams, and thesis committee member.
We look forward to his growing participation as a core member of the faculty.
The Eighth WSBS Graduation
On May 1, we celebrated the Watson School’s eighth graduation ceremony. Two students, Amy
Rappaport and Claudio Scuoppo, both from the Entering Class of 2006, were awarded the Ph.D.
degree. Jiahao Huang from the Entering Class of 2008 was awarded a Masters degree, but did not
attend the ceremony. Honorary degrees were bestowed upon Dr. James Simons and Dr. James Lup-
ski. Dr. Simons is the former Chairman of the Mathematics Department at Stony Brook University
and current Board Chair of Renaissance Technologies LLC. He is credited with the discovery and
application of certain geometric measurements used in theoretical physics, particularly string theory,
known as the Chern−Simons Invariants. Dr. Simons and his wife also manage the Simons Founda-
tion, whose philanthropic activities include the establishment of an institute for research in math-
ematics and theoretical physics and a major research initiative on the causes of autism. He was
honored as a scholar and tireless advocate of education, mathematics, and scientific research. Dr.
James Lupski was an Undergraduate Research Participant (URP) at CSHL in the laboratory of Dr.
Ahmad Bukhari during the summers of 1978 and 1979 and is currently a Professor at the Baylor
College of Medicine. He is an accomplished scientist who has earned national distinction for his
groundbreaking work in “genomic disorders,” a term he coined. Nearly two decades ago, he iden-
tified the chromosome 17p12 duplication in the nerve disorder, Charcot−Marie−Tooth syndrome
type 1A (CMT1A), a disease he himself is afflicted with. He was honored as a medical practitioner
Team Watson: (Left to right) Keisha John, Dawn Meehan,
Kim Geer, Leemor Joshua-Tor, and Alyson Kass-Eisler
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and pioneering researcher, who has earned distinction as one of the premier researchers of genomic
disorders of our time. Dr. Lupski also delivered a heartfelt and inspiring commencement address. 
As with each graduation, we extended a special welcome to the family members and friends of
our students who attend the ceremony. Among these special guests were Claudio’s family members
who traveled from Italy to take part in this special event.
Teaching Award
At this year’s graduation, Michael Schatz was presented with the sixth annual Winship
Herr Faculty Teaching Award named in honor of the School’s founding dean. Michael
was an instructor in our brand-new Specialized Disciplines course in Quantitative Bi-
ology. He was chosen by the students for this award, based on his enthusiasm, excel-
lence, and creativity in teaching. The winner of this award is nominated and voted on
by the students. Below is some of what the students had to say about Michael:
Michael Schatz showed the utmost patience with students trying to learn extremely
challenging material. He used cleverly thought-out analogies to explain complicated
concepts rather easily and he was an engaging lecturer who was able to extend his pas-
sion and enthusiasm for the subject to the students. 
Admissions 2011
The School received 256 applications for the 2011/2012 academic year and is deeply indebted to its
Admissions Committee, which reviewed, interviewed, and selected candidates for our doctoral pro-
gram. The Admissions Committee for the 2011 entering class comprised Gregory Hannon (chair),
Mickey Atwal, Leemor Joshua-Tor, Adam Kepecs, Adrian R. Krainer, Zachary Lippman, W. Richard
McCombie, Stephen Shea, Nicholas Tonks, and Linda Van Aelst—a truly remarkable team!
2011 graduates: (Left to right) Honorary degree recipient James Simons, WSBS Dean Leemor Joshua-Tor,
Amy Rappaport, Claudio Scuoppo, CSHL Board of Trustees Chair Jamie Nicholls, CSHL President Bruce
Stillman, honorary degree recipient James Lupski
Michael Schatz
2011 WSBS DOCTORAL DEGREE RECIPIENTS
                               Thesis                         Academic                   
Student                   advisor                       mentor                        Current position
Patrick Finigan         Robert Martienssen      Senthil K.                     Postdoctoral fellow with Dr. Robert Martienssen, 
                                                                     Muthuswamy             CSHL
Amy Rappaport        Scott Lowe                   Marja Timmermans       Postdoctoral fellow with Dr. Leisa Johnson, 
                                                                                                           Genentech, San Francisco, California
Frederick Rollins      Gregory Hannon          Jan. A. Witkowski          Postgraduate student with Dr. Gregory Hannon,
                                                                                                           CSHL
Claudio Scuoppo      Scott Lowe                   Gregory Hannon           Postdoctoral fellow with Dr. Riccardo Dalla-Favera, 
                                                                                                           Columbia University, New York
2011 THESIS DISSERTATION DEFENSES
ENTERING CLASS OF 2005
Patrick Finigan, July 15, 2011
The origin of novel phenotypic variation in Arabidopsis
allopolyploids.
Thesis Examining Committee
Chair:                              Zachary Lippman 
Research mentor:            Robert Martienssen
Academic mentor:           Senthil K. Muthuswamy 
Committee member:       David Jackson
Committee member:       Doreen Ware
Committee member:       Eric Richards, Thompson Institute 
                                      for Plant Research
External examiner:          Craig Pikaard, Indiana University 
Frederick Rollins, July 6, 2011
The genetics and epigenetics of erlotinib resistance in non-small-
cell lung cancer. 
Thesis Examining Committee
Chair:                              Raffaella Sordella 
Research mentor:            Gregory Hannon 
Academic mentor:           Jan A. Witkowski 
Committee member:       Scott Lowe
Committee member:       Scott Powers
External examiner:          Charles L. Sawyers,Memorial 
                                       Sloan-Kettering Cancer Center
ENTERING CLASS OF 2006
Amy Rappaport, March 17, 2011
Dissecting tumor suppressor and tumor maintenance genes in
poor prognosis AML. 
Thesis Examining Committee
Chair:                              Gregory Hannon
Research mentor:            Scott Lowe
Academic mentor:           Marja Timmermans
Committee member:       Bruce Stillman
Committee member:       Lloyd Trotman
Committee member:       Jan A. Witkowski
External examiner:          Kevin M. Shannon, University of 
                                       California, San Francisco 
Claudio Scuoppo, March 21, 2011
Architectural models of tumor suppression in lymphoma.
Thesis Examining Committee
Chair:                              Senthil K. Muthuswamy  
Research mentor:            Scott Lowe
Academic mentor:           Gregory Hannon  
Committee member:       Scott Powers
Committee member:       Lloyd Trotman
Committee member:       Raffaella Sordella
External examiner:          Carol Prives, Columbia University
ENTERING CLASS OF 2007
Wang Zhenxun, December 13, 2011
The mechanism and manipulation of PK-M alternative splicing.
Thesis Examining Committee
Chair:                              Leemor Joshua-Tor
Research mentor:            Adrian R. Krainer
Academic mentor:           Terri Grodzicker
Committee member:       Gregory Hannon
Committee member:       Darryl Papin
External examiner:          Brenton R. Gravely, University of 
                                       Connecticut Health Center 
Dean’s Report      243
244
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Student Academic mentor Research mentor Thesis research 
ENTERING CLASS OF 2006
Eyal Gruntman Josh Dubnau Glenn Turner Olfactory perception in Drosophila.
Elisabeth Sloan Livingston Fellow
ENTERING CLASS OF 2007
Megan Bodnar Nicholas Tonks David L. Spector The nuclear choreography of chromatin 
Starr Centennial Scholar dynamics, gene expression, and gene repression
in embryonic stem cells.
Ralph Burgess Bruce Stillman Gregory Hannon Recombination hot spots: Characterizing fine-
Starr Centennial Scholar scale variation in the frequency of meiotic 
recombination across the mammalian genome.
Joseph Calarco David Jackson Robert Martienssen Transposable element (TE) regulation in the 
NSERC Scholar flowering plant A. thaliana.
David H. Koch Fellow
Saya Ebbesen David J. Stewart Scott Lowe In vivo identification and characterization of 
NIH Predoctoral Trainee (ARRA) novel tumor suppressors relevant to human 
Starr Centennial Scholar breast cancer.
Paloma Guzzardo Adrian R. Krainer Gregory Hannon Dissecting the piRNA pathway in the 
Leslie C. Quick, Jr. Fellow Drosophila ovarian somatic sheet.
NIH Predoctoral Trainee
William Randolph Hearst Student
Kyle Honegger John R. Inglis Glenn Turner Neuronal and circuit mechanisms creating 
Crick-Clay Fellow sparse odor representations in the mushroom 
NIH Predoctoral Trainee body of Drosophila. 
Marek Kudla David Jackson Gregory Hannon CLIP method as a way of direct readout of 
George A. and Marjorie H. Anderson microRNA target sites.
Fellow
Hassana Oyibo Hiro Furukawa Anthony Zador Reconstruction of connectivity of neurons by 
Farish-Gerry Fellow reading of oligonucleotide labels (ROC-N-ROL).
William Randolph Hearst Student
Michael Pautler Robert Lucito David Jackson The RAMOSA pathway and inflorescence 
NSERC Scholar branching in maize.
William R. Miller Fellow
Maria Pineda Adrian R. Krainer Raffaella Sordella Mechanism of “addiction” to receptor tyrosine 
William Randolph Hearst Student kinases in non-small-cell lung carcinoma.
CSHL Women’s Partnership for
Science Student
Yevgeniy Plavskin Jan A. Witkowski Marja Timmermans The evolution of the miR390-dependent 
Alfred Hershey Fellow tasiRNA pathway and its function in bryophyte
NIH Predoctoral Trainee development.
Joshua Sanders Bruce Stillman Adam Kepecs Trans-regional coordination of activity in the 
Edward and Martha Gerry Fellow mouse brain.
Zhenxun Wang Terri Grodzicker Adrian R. Krainer Alternative splicing of pyruvate kinase M in 
A*STAR Fellow tumorigenesis.
Thesis defense: December 2011
Petr Znamenskiy Terri Grodzicker Anthony Zador Pathways for attention and action in the 
David and Fanny Luke Fellow auditory system.
ENTERING CLASS OF 2008
Philippe Batut Alexander Gann Thomas Gingeras Transposons and evolution of transcriptional 
Florence Gould Fellow regulation in the Drosophila clade.
Mitchell Bekritsky W. Richard McCombie Michael Wigler High-throughput microsatellite genotyping.
Starr Centennial Scholar
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Student Academic mentor Research mentor Thesis research 
Dario Bressan Z. Josh Huang Gregory Hannon A genomic approach toward the eludication of
Robert and Teresa Lindsay Fellow connectivity patterns at cellular resolution in 
complex neural networks.
Melanie Eckersley-Maslin Gregory Hannon David L. Spector Making the choice: Mechanistic insights into 
Genentech Foundation Fellow random autosomal monoallelic expression in 
mammalian cells.
Sang Geol Koh Glenn Turner Anthony Zador Attention-dependent information routing in the 
George A. and Marjorie H. Anderson mouse auditory cortex.
Fellow
Katie Liberatore Adrian R. Krainer Zachary Lippman Inflorescence development and heterosis.
Starr Centennial Scholar 
National Science Foundation 
Predoctoral Fellow
Ozlem Mert John R. Inglis Scott Lowe Characterization of the role of E2F7 in onco-
George A. and Marjorie H. Anderson gene-induced senescence and tumorigenesis.
Fellow
Elizabeth Nakasone Alea A. Mills Mikala Egeblad Understanding the effects of cytotoxic 
William Randolph Hearst Fellow chemotherapeutics on the innate immune 
Leslie C. Quick, Jr. Fellow response.
Zinaida Perova Linda Van Aelst Bo Li The role of medial prefrontal cortex in 
Charles A. Dana Fellow behavioral depression.
Felix Schlesinger Gregory Hannon Thomas Gingeras Classification of novel transcription start sites.
Crick-Clay Fellow
Nilgun Tasdemir Josh Dubnau Scott Lowe Investigating the molecular overlaps between 
Robert and Teresa Lindsay Fellow II epigenetic reprogramming and transformation.
Elvin Wagenblast Jan A. Witkowski Gregory Hannon Role of stem/progenitor cells in mammary 
Starr Centennial Scholar gland and breast tumors.
Boehringer Ingelheim Fellow
Susann Weissmueller Raffaella Sordella Scott Lowe In vivo identification and characterization of 
Annette Kade Fellow tumor suppressor genes in hepatocellular 
carcinoma.
ENTERING CLASS OF 2009
Stephane Castel Lloyd Trotman Robert Martienssen RNAi-mediated heterochromatin in S. pombe.
Cashin Fellow 
NSERC Scholar
Kristen Delevich Stephen Shea Bo Li Elucidating the role of Disrupted-in-Schizo-
NIH Predoctoral Trainee phrenia-1 in development of prefrontal cortical 
circuits.
Silvia Fenoglio Linda Van Aelst Gregory Hannon RNAi screening to identify putative thera- 
Elisabeth Sloan Livingston Fellow peutic targets for the treatment of pancreatic 
cancer.
Wee Siong Goh Hiro Furukawa Gregory Hannon Determining piRNA primary biogenesis, and 
A*STAR Fellow MIWI and late piRNA function in mice using 
Delbrück Fellow C. elegans as a model system for genetic screening.
Ian Peikon Mickey Atwal Anthony Zador Reverse engineering the brain.
Dr. John and Consuelo Phelan Student
Kaja Wasik Jan A. Witkowski Gregory Hannon A screen for novel components of the piRNA
George A. and Marjorie H. Anderson pathway in D. melanogaster.
Fellow
Cinthya Zepeda Mendoza Thomas Gingeras David L. Spector Analysis of higher-order chromatin organization
Gonzalo Rio Arronte Fellow at the mouse syntenic region of human 1p36 
upon genomic copy-number changes.
Entering Class of 2011
On August 29, 2011, the Watson School opened its doors for the 13th time to welcome yet another new
class. This year, 10 students joined the School: Robert Aboukhalil, Brittany Cazakoff, Maria Joaquina
Delas Vives, Anja Hohmann, Justus Kebschull, Fred Marbach, Onyekachi Odoemene, Sophie Thomain,
Charles Underwood, and Taekyung (Daniel) Yun. Fred and Sophie were visiting Master’s students in
Florin Albeanu and Robert Martienssen’s laboratories, respectively, in 2010. Robert was a participant in
the School’s Undergraduate Research Program in 2010 under the mentorship of Mickey Atwal.
Academic Mentoring
The Watson School takes great pride in the level of mentoring that it offers its students. One of
the very special aspects in this regard is our two-tiered mentoring approach whereby each student
receives an academic mentor as well as a research mentor. Because WSBS students select a research
mentor only in June right before their qualifying exam, it is the unique responsibility of the aca-
demic mentor to monitor students—and offer advice—during the intensive coursework of the
first term, during their rotations, and to help them identify a suitable research mentor. They then
follow them throughout their doctoral experience, often serving as important advocates for the
students. Entering students select by mutual agreement a member of the research or nonresearch
faculty to serve as an academic mentor. This program continues to receive much support from the
faculty who volunteer to be academic mentors, and it has rightfully become a vital ingredient in
our success. The following are this year’s new Academic Mentors for the Entering Class of 2011: 
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Student Academic mentor Research mentor Thesis research 
ENTERING CLASS OF 2010
Arkarup Bandyopadhyay Zachary Lippman Florin Albeanu Identity and intensity encoding of odors in 
Goldberg Lindsay Fellow rodents.
Proposal defense: January 2012
Colleen Carlston Alexander Gann Christopher Hammell Identification and characterization of noise-
John and Amy Phelan Student suppressor genes that act via microRNAs in 
Proposal defense: January 2012 C. elegans larval development.
Matthew Koh Bo Li Florin Albeanu Roles of olfactory bulb inhibitory microcir-
George A. and Marjorie Anderson Fellow cuits in shaping the temporal response proper-
Proposal defense: January 2012 ties of mitral cells.
Lisa Krug Stephen Shea Josh Dubnau Mechanisms of transposon regulation in the 
NIH Predoctoral Trainee central nervous system.
Proposal defense: January 2012
John Sheppard Josh Dubnau Anne Churchland Neural mechanisms of multisensory decision-
Bristol Myers Squibb/NIH Predoctoral Trainee making.
Proposal defense: January 2012
Jack Walleshauser Christopher Hammell Leemor Joshua-Tor Structural basis for TUT4 uridylation of pre-
Barbara McClintock/NIH Predoctoral Trainee let-7/lin28 complex.
Proposal defense: January 2012
STUDENT MENTOR
Robert Aboukhalil Josh Dubnau
Brittany Cazakoff Christopher Hammell
Maria Joaquina Delas Vives Nicholas Tonks
Anja Hohmann John Inglis
Justus Kebschull Marja Timmermans
STUDENT MENTOR
Fred Marbach Josh Dubnau
Onyekachi Odoemene Stephen Shea
Sophie Thomain Zachary Lippman
Charles Underwood Alex Gann
Taekyung (Daniel) Yun Raffaella Sordella
ENTERING CLASS OF 2011
Robert Aboukhalil,McGill University; Cold Spring Harbor Laboratory
Summer Undergraduate Research Program (2010); Technophilic
Magazine: Publication of the Year (2010); CS Games 2009 and
2010: Member of McGill team that ranked second in North Ameri-
can programming competition (2009, 2010); McGill Faculty of Sci-
ence Student Research Ambassador (2009); CAE Scholarship in
Engineering Excellence (2009); Louis C. Ho Scholarship in Engi-
neering (2008); McGill University Dean’s Honour List (2008);
Canada-wide Science Fair (2007)
Academic Mentor: Josh Dubnau
Brittany Cazakoff, University of Saskatchewan; Marine Biological Lab,
Woods Hole, MA: Neural Systems and Behavior Course (2010);
University of Saskatchewan Graduate Scholarship (2010); Orange
Benevolent Society Scholarship (2010); Natural Sciences and Engi-
neering Research Council of Canada (NSERC); Alexander Graham
Bell Canada Graduate Scholarship (2009); Governor General’s Sil-
ver Medal (2009) 
Academic Mentor: Christopher Hammell
Maria Joaquina Delas Vives, Universidad Politecnica de Valencia;
Erasmus Placement Scholarship: German; Cancer Research Center
(DKFZ): Heidelberg, Germany (2010); Spanish National Research
Council Grant: Centro de  Biología Molecular “Severo Ochoa”
(CBMSO). Madrid, Spain (2009); Spanish Ministry of Science
Grant Recipient (2009); Valencia iGEM Team: Gold Medal (2008,
2009); Experimental Science in Pablo de Olavide  University: Oral
Presentation 2nd Prize (2008)
Academic Mentor: Nicholas Tonks
Anja Hohmann, University of Cambridge; B.A. and M.Sci. Awarded:
University of Cambridge (2011); Cambridge iGEM Team: Finalist,
“Best Wiki” and  Gold Medal Awarded (2010); Hal Dixon Trust
Research Grant (2010); The George Mallory Prize: University of
Cambridge (2009); David Hendersen Memorial Trust Fund Travel
Grant (2008); Cambridge European Trust Bursary (2007−2011) 
Academic Mentor: John R. Inglis
Justus Kebschull, University of Cambridge; B.A. and M.Sci. Awarded:
University of Cambridge (2011); German Society for Periodontol-
ogy Travel Award (2010); Trinity College Summer Research Stu-
dentship (2010); Senior Scholarship, Trinity College (2009, 2010);
University of Cambridge/Massachusetts Institute of Technology Ex-
change (2009–2010); Junior Scholarship, Trinity College (2008)
Academic Mentor: Marja Timmermans
Fred Marbach, Swiss Federal Institute of Technology (EPFL); M.S.
Awarded: Swiss Federal Institute of Technology (EPFL) (2010)
Academic Mentor: Josh Dubnau
Onyekachi Odoemene, The George Washington University; M.S.
Awarded: Purdue University (2011); Honorable Mention, NSF
Graduate Research Fellowship (2010); Carl Storm Travel Fellow-
ship (2010); Purdue University Doctoral Fellowship (2009);
Deans List: The George Washington University (2005–2009);
Coulter Foundation Summer Research Grant (Summer 2007);
George Gamow Research Fellowship (2006–2007); Howard
Hughes Summer Research Scholar (Summer 2006)
Academic Mentor: Stephen Shea
Sophie Thomain, Ecole Normale Superieure; M.S. Awarded: Ecole
Normale Superieure (2011); Amgen Foundation Scholarship:
University of Cambridge (Summer 2009)
Academic Mentor: Zachary Lippman
Charles Underwood, University of Oxford; Academic Merit Schol-
arship: St Anne’s College, University of Oxford (2008–2011);
Summer Studentships: Cancer Research UK (2010), Amgen
Foundation (2009); Ludwig-Maximilians-University of  Munich
(2009); BP Ultimate Field Trip Challenge Finalist (2010);
Travel Grant: St. Anne’s College, University of Oxford (2009)
Academic Mentor: Alexander A.F. Gann
Taekyung Yun, The Johns Hopkins University; M.A. Awarded: Co-
lumbia University (2010)
Academic Mentor: Raffaella Sordella
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2011 entering class: (Front row, left to right) Anja Hohmann, Brittany Cazakoff, Sophie
Thomain, Joaquina Delas Vives. (Back row, left to right) Fred Marbach, Robert Aboukhalil,
Daniel Yun, Charles Underwood, Justus Kebschull, Kachi Odoemene
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The Fall Term Curriculum
Our faculty continues to do an outstanding job of developing and delivering the curriculum. We are
extremely grateful for their considerable time and effort in maintaining the high-quality coursework
that we strive to provide. The Curriculum Development and Integration Committee (CDIC)—Adrian
Krainer (chair), David Jackson, Leemor Joshua-Tor, Nicholas Tonks, and Glenn Turner—continues to
carefully monitor and develop the curriculum. In addition to the outstanding course instructors and
guest lecturers from within the Laboratory, our courses also continue to attract an impressive array of
guest lecturers from other institutions.
Recruiting Efforts
Recruitment for the graduate program’s 2011 class and our URP 2011 was once again managed by
Ms. Dawn Pologruto, the School’s Director for Admissions and Student Affairs. As in years past,
Dawn, our faculty, and our students traveled the length and breadth of the country representing
CSHL and WSBS. They were joined by Keisha John who did most of the traveling this year, making
special recruitment visits aimed at enhancing diversity. Keisha also stepped in to oversee the last
two interview weekends when Dawn went out on maternity leave in February. The table beginning
on the next page details recruitment fairs and conferences in which we have participated, together
with the names of faculty, students, and administrators who represented WSBS on these occasions.
To further raise awareness of our programs, we also mailed more than 15,000 letters to colleges and
universities in the United States and abroad.
Interinstitutional Academic Interactions
WSBS students account for approximately half of the total graduate students here at CSHL. The
other half of the students are visiting graduate students from other universities who have decided
to conduct some or all of their thesis research in CSHL faculty members’ laboratories. A large per-
centage of students are from Stony Brook University (SBU), via a program established between
CSHL and SBU more than 30 years ago. Over the years, we have also established relationships
with institutions around the world, thereby enabling their students to conduct research here at
CSHL. Currently, we have visiting students from institutions in Germany, France, Mexico, and
India to name a few. Keisha John serves as the visiting student liaison in the WSBS. In this capacity,
she is the onsite contact person for the students, and she maintains relationships with administra-
tions from their home institutions. These students are fully integrated into the CSHL community
and receive all the necessary assistance as they navigate the complexities of performing doctoral re-
search away from their home institutions. The following students, listed in the box below, joined
us this year. 
Graduate Student Symposium
Each year, the students participate in three Graduate Student Symposia held at the Laboratory’s
Genome Research Center in Woodbury: one each in January, May, and October. Each Symposium
consisted of five sessions where all of the senior students gave 15-minute talks. Coffee breaks, lunch,
and a wine and cheese reception at the end of the day rounded out the program and provided op-
portunities for more informal interactions. The Graduate Student Symposium is open to the entire
Laboratory community, and as in previous years, all in attendance found the Symposia to be very
worthwhile. We are grateful to the two student chairs of the Symposium, Dong-Woo Hwang (SBU)
and Mitchell Bekritsky (WSBS) and to Keisha John for providing School oversight.
2011 WATSON SCHOOL OF BIOLOGICAL SCIENCES RECRUITMENT SCHEDULE
Event                                                            Location                                      Date                        WSBS attendees/titles
American Association of Cancer Research Orlando, Florida April 2–6 CSHL Meetings and Courses and Press 
Annual Meeting personnel attended with WSBS 
information for distribution
New York Institute of  Technology New York Institute April 7 Keisha John, Associate Director of 
Career and Internship Fair of Technology Recruitment and Undergraduate 
Research
Experimental Biology Annual Meeting Washington, D.C. April 9–13 CSHL Meetings and Courses and Press 
personnel attended with WSBS 
information for distribution
American Society for Microbiology New Orleans, Louisiana May 20–24 CSHL Meetings and Courses and Press 
Annual Meeting personnel attended with WSBS 
information for distribution
International RNA Society Meeting Kyoto, Japan June 14–18 CSHL Meetings and Courses and Press 
personnel attended with WSBS 
information for distribution
International Society for Stem Cell Toronto, Canada June 15−18 CSHL Meetings and Courses and Press
Research Meeting personnel attended with WSBS 
information for distribution
New York City College of Technology Cold Spring Harbor Laboratory July 14 Kristen Delevich, Graduate Student
NSF STEP Program Visit Dawn Pologruto
University of Medicine and Dentistry, New Cold Spring Harbor Laboratory July 15 Michael Pautler, Graduate Student
Jersey: Summer Internship Program Visit Dawn Pologruto
LaGuardia Community College Visit Cold Spring Harbor Laboratory July 25 Hassana Oyibo, Graduate Student
American Society of Plant Biologists Minneapolis, Minnesota August 8–11 CSHL Meetings and Courses and Press 
Annual Meeting personnel attended with WSBS
information for distribution
Brookhaven National Laboratory: Graduate Brookhaven National Laboratory August 10 Keisha John
School Fair and Undergraduate Research 
Program Symposium
Williams College: Information Session Williams College September 16 Keisha John
University of Maryland, Baltimore County: University of Maryland, September 19 Keisha John  
Meyerhoff Scholarship Program and Baltimore County
MARC Program Visit
Cornell University: Information Session Cornell University September 20 Ian Peikon, Graduate Student
Kaja Wasik, Graduate Student
The Johns Hopkins University: Information The Johns Hopkins University September 20 Keisha John
Session
Massachusetts Institute of Technology Massachusetts Institute of September 21 Dawn Pologruto
Career Fair Technology
Cornell University: Graduate and Cornell University September 21 Ian Peikon
Professional School Day Kaja Wasik
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NEW STUDENTS FROM SHARED GRADUATE PROGRAMS
Student                                                  CSHL research mentor                       Affiliation and program
Michelle Falerio                                           Adam Kepecs                                              Universitat Pompeu Fabra, Biomedicine, Spain
Zhen Gong                                                  Partha Mitra                                              Stony Brook, Biomedical Engineering
Priyanka Gupta                                           Florin Albeanu                                           National Centre for Biological Sciences, Neuroscience, India
Hyun-Yong Jeon                                          Adrian Krainer                                           Stony Brook, Molecular and Cellular Biology
Sean M. Kelly                                              Z. Josh Huang                                           Stony Brook, Medical Scientists Training Program
Ha Yan Lee                                                  Michael Schatz                                           Stony Brook, Computer Science
Ioana A. Rus                                                Nick Tonks                                                Stony Brook, Genetics
Siwei Zhang                                                 Nick Tonks                                                Stony Brook, Microbiology
2011 WATSON SCHOOL OF BIOLOGICAL SCIENCES RECRUITMENT SCHEDULE (continued)
Event                                                            Location                                      Date                        WSBS attendees/titles
Morgan State University: MBRS-RISE Morgan State University September 21 Keisha John
Program: Graduate Career Workshop
and Information Session
Hunter College Minority Access for Hunter College September 21 Kristen Delevich
Research Careers (MARC) Program: Stephen Shea, Assistant Professor
Information Session
University of Maryland, Eastern Shore University of Maryland, September 22 Keisha John
MARC Program: Information Session Eastern Shore
Howard University: Information Session Howard University September 22 Keisha John
Massachusetts Institute of Technology: Massachusetts Institute of September 23 Dawn Pologruto
Information Session Technology
University of Maryland, College Park: University of Maryland, September 23 Keisha John
Information Session College Park
Big 10+ Graduate School Fair Purdue University September 26 Colleen Carlston, Graduate Student
Duke University: Information Session Duke University September 27 Stephen Shea
University of California, Santa Cruz University of California, September 28 Keisha John
MARC Program: Information Session Santa Cruz
The Johns Hopkins University Career Fair The Johns Hopkins University September 28 Hassana Oyibo, Graduate Student
University of California, San Diego University of California, October 3 Keisha John
MARC Program: Information Session San Diego
University of California, Berkeley: University of California, October 5 Keisha John
Graduate School Fair Berkeley
Stanford University: Information Session Stanford University October 5 Keisha John
Xavier University: Research Talk and Xavier University October 6 Alea Mills, Professor
MARC Program Information Session
Princeton University: Information Session Princeton University October 6 Keisha John
Northwestern University: Information Session Northwestern University October 7 Petr Znamenskiy, Graduate Student
Princeton University Graduate and Princeton University October 7 Keisha John
Professional School Fair
University of New Mexico: Information University of New Mexico October 7 Katie Liberatore, Graduate Student
Session
Brooklyn College of CUNY MARC and  Brooklyn College of CUNY October 11 Keisha John
RISE Program Information Session
International Congress of Human Montreal, Canada October 11–15 CSHL Meetings and Courses and Press 
Genetics Meeting personnel attended with WSBS 
information for distribution
St. John’s University: Information Session Cold Spring Harbor Laboratory October 12 Zina Perova, Graduate Student
and Campus Visit Dawn Pologruto
Morehouse College: Information Session Morehouse College October 14 Keisha John 
Wellesley College: Information Session Wellesley College October 14 Anne Churchland, Assistant Professor
Conference of Research Experiences for Arlington, Virginia October 16–17 Keisha John
Undergraduate Student Scholarship
Stanford University: Graduate School Fair Stanford University October 17 David Simpson, WSBS Alumni
SUNY, Old Westbury: Information Session SUNY, Old Westbury October 18 Keisha John
California Institute of Technology California Institute of Technology October 19 Katie Liberatore
Career Fair
Queens College, City University of New Queens College, City University October 19 Keisha John
York: MARC-USTAR Program of New York
Information Session
Emory University Graduate School Fair Emory University October 20 Wee Siong Goh, Graduate Student
Yale University: Information Session Yale University October 20 Keisha John
Harvard University: Information Session Harvard University October 21 Keisha John
Barry University MARC Program: Barry University October 21 Maria Pineda, Graduate Student
Information Session
State University of New York, Farmingdale: Cold Spring Harbor Laboratory October 21 Dawn Pologruto
Information Session and Campus Visit Hassana Oyibo
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2011 WATSON SCHOOL OF BIOLOGICAL SCIENCES RECRUITMENT SCHEDULE  (continued)
Event                                                            Location                                      Date                        WSBS attendees/titles
University of Pennsylvania: Information University of Pennsylvania October 24 Dawn Pologruto
Session
Mount St. Mary’s College MARC Program: Mount St. Mary’s College October 24 Keisha John
Information Session
University of California, Irvine MARC University of California, Irvine October 25 Keisha John
and RISE Programs: Information Session
University of California, Davis BUSP University of California, Davis October 25 Keisha John
Program: Information Session
University of California, Los Angeles University of California, Los October 26 Keisha John
Graduate School Fair Angeles
Society for Advancement of Chicanos and San Jose, California October 27−29 Melanie Eckersley-Maslin, Graduate 
Native Americans in Science (SACNAS) Student
Keisha John
Adrian Krainer, Professor
California Forum for Diversity in Graduate University of San Francisco October 29 Keisha John
Education: Graduate School Fair
Brown University: Information Session Brown University October 31 Keisha John
University of Puerto Rico, Rio Piedras University of Puerto Rico, Rio November 2 Paloma Guzzardo, Graduate Student
MARC Program: Information Session Piedras
Hofstra University: Information Session Hofstra University November 2 Keisha John
Rutgers University: Graduate and Professional Rutgers University November 2 Saya Ebbesen, Graduate Student
School Day
North Carolina Central University RISE North Carolina Central November 3 Keisha John
Program: Information Session University
Truman State University: Information Session Truman State University November 4 Keisha John
“What Can You Be With a Ph.D.?” Career New York University November 5–6 Information sent for distribution
Convention
Washington University, St. Louis: Information Washington University, St. Louis November 8 Keisha John
Session
Annual Biomedical Research Conference St. Louis, Missouri November 9–12 Arkarup Bandyopadhyay, Graduate 
for Minority Students (ABRCMS) Student
Colleen Carlston
Christopher Hammell, Assistant
Professor
Brittany Haugen, URP 2011
Keisha John
Sigma Xi Annual Conference and Research Raleigh, North Carolina November 10–12 Maria Pineda
Symposium
Society for Neuroscience Annual Meeting Washington, D.C. November 12–16 CSHL Meetings and Courses and Press 
personnel attended with WSBS 
information for distribution
Hunter College Graduate and Professional Hunter College November 15 Joseph Calarco, Graduate Student
School Fair Keisha John
Columbia University: Information Session Columbia University November 15 Keisha John
City College of New York, York College CUNY, York College November 16 Keisha John
Career and Graduate School Fair
Queensborough Community College, City Queensborough Community November 16 Information sent for distribution
College of New York: Internship Fair College
George Washington University: Information George Washington University November 16 Keisha John
Session
Hampton University MARC Program: Hampton University November 17 Keisha John
Information Session
American Society for Cell Biology Annual Denver, Colorado December 3–7 CSHL Meetings and Courses and Press
Meeting personnel attended with WSBS 
information for distribution
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Graduate Student and Postdoctoral Fellow Departures
With each year come not only new arrivals, but also departures. The following graduate students
and postdoctoral fellows departed from the Laboratory during 2011:
Postdoctoral Fellows
Benoit Boivin Ingrid Ibarra Yuntao Mao Marlies Rossmann
Maia Chanrion Douglas Johnston Sundarmurthy Pandurangan Man-Hung Eric Tang
Sung Wook Chi Lolahon Kadiri Smitha Reddy Milos Tanurdzic
Yu-Chen Chien Kannan Krishnamurthy Francesc Roca Xianfeng Xu
Alexander Goldschmidt Jayant Kulkarni Adam Rosebrock Miguel Zaratiegui Biurrun
Graduate Students
Sihem Cheloufi Yu Fu Mark Orcholski Yang Yang
Carrie Clandaniel Lin Guang Prem Premsrirut Jianping Zhang
Noelle Cutter Aftabul Haque Amy Rappaport Rui Zhao
Christof Fellmann Wen Huang Claudio Scuoppo
Xin Feng Matthew Lazarus Rahul Sinha
Oliver Fregoso Zhijie Liu Elena Tonin
Executive Committee 
The School’s Executive Committee, in its monthly meetings, provides year-round direction for the
School and its students through its invaluable policy recommendations. I thank all of the faculty
members who served on the Executive Committee through 2011: Mickey Atwal, David Stewart,
Adrian Krainer, Alea Mills, David Spector, and Linda Van Aelst. Alea Mills completed her second
term in December 2011. During her tenure, she contributed tremendously to the committee. There
was also turnover among the student representatives as SBU representative Matthew Camiolo was
replaced by Deblina Chatterjee, and Mitchell Bekritsky replaced WSBS representative Katie Liber-
atore. We are thankful for Matthew and Katie who were very insightful and served as wonderful
mouthpieces for their colleagues.  
Special Events: The Gavin Borden Fellow
The annual Gavin Borden Visiting Fellow (so named after the energetic and charismatic publisher
of Molecular Biology of the Cell, who died of cancer in 1991) brings to CSHL an eminent researcher
and educator to give the Gavin Borden Lecture, which is dedicated to the graduate students at the
Laboratory. Nobel laureate Dr. Sydney Brenner, from the Janelia Farm Research Campus of the
Howard Hughes Medical Institute and the Salk Institute, was this year’s Gavin Borden Fellow. His
lecture “Reading the human genome” was well accepted and provoked many questions from the
audience. In addition, the students joined Dr. Brenner during a roundtable lunch and discussion
where he shared stories from “A Life in Science.”
The Watson School Continues to Benefit from Generous Benefactors
We are extremely grateful for the generous donors, whose one-time gifts or continued support made
our 2011 programs possible, including The Banbury Fund, Bristol-Myers Squibb Corporation, Mr.
and Mrs. Richard M. Cashin, Mr. and Mrs. Landon Clay, Lester Crown, The Dana Foundation,
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WSBS GRADUATES IN FACULTY AND SENIOR POSITIONS
Name                               Current position
François Bolduc                  Assistant Professor, University of Alberta, Canada 
Darren Burgess                   Assistant Editor, Nature Reviews Cancer and Nature Reviews Genetics, UK
Amy Caudy                        Assistant Professor, University of Toronto, Canada 
Catherine Cormier             Scientific Liaison, Arizona State University
Yaniv Erlich                        Whitehead Fellow, Whitehead Institute
Rebecca Ewald                    Project Manager, Roche Diagnostics, Inc.
Elena Ezhkova                    Assistant Professor, Mount Sinai School of Medicine
Ira Hall                               Assistant Professor, University of Virginia School of Medicine 
Christopher Harvey            Assistant Professor, Harvard University
Keisha John                        Associate Director, Recruitment and Undergraduate Research, WSBS
Zachary Lippman               Assistant Professor, Cold Spring Harbor Laboratory 
Marco Mangone                 Assistant Professor, Arizona State University
Patrick Paddison                 Assistant Member, Fred Hutchinson Cancer Research Center 
Emiliano Rial-Verde           Engagement Manager, McKinsey & Co., Inc., Geneva, Switzerland
Ji-Joon Song                       Assistant Professor, Korea Advanced Institute of Science and Technology (KAIST), South Korea 
Niraj Tolia                          Assistant Professor, School of Medicine at Washington University, St. Louis 
Wei Wei                              Assistant Professor, University of Chicago
The Samuel Freeman Charitable Trust, The William Stamps Farish Fund, The Genentech Founda-
tion, Mr. and Mrs. Alan Goldberg, Florence Gould Foundation, William Randolph Hearst Foun-
dation, Annette Kade Charitable Trust, Mr. David H. Koch, Mr. and Mrs. Robert D. Lindsay and
Family, Mr. and Mrs. David Luke III, Mr. and Mrs. William R. Miller, OSI Pharmaceuticals Foun-
dation, Estate of Edward L. Palmer, Mr. and Mrs. John C. Phelan, The Quick Family, Estate of
Elisabeth Sloan Livingston, Universidad Nacional Autonoma de Mexico, and The Roy J. Zuckerberg
Family Foundation.
We are also very fortunate to hold a National Research Service Award Predoctoral Training Grant
from the National Institutes of Health, National Institute of General Medical Sciences. The School
submitted a competitive renewal of this award in September 2011.
Student Achievements
The WSBS students continue to impress us all with their accomplishments. They published their
research findings in prestigious international journals—more than 190 to date—and obtained fel-
lowships to pursue their research interests. In addition, our current students and alumni (listed
below) have been successful in receiving prestigious awards and fellowships. 
• WSBS student Maria Joaquina Delas Vives was awarded a La Caixa Fellowship.
• WSBS student Elizabeth Nakasone was selected to attend the AACR’s Translational Cancer Re-
search for Basic Scientists Workshop.
• WSBS graduate Oliver Tam was awarded a Long-Term Fellowship from the Human Frontier
Science Program.
• WSBS graduate Christopher Harvey received a Burroughs-Wellcome Fund Career Award at the
Scientific Interface.
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2011 WSBS STUDENT (CURRENT OR PREVIOUS) PUBLICATIONS
Calarco JP, Martienssen RA. 2011. Genome reprogramming and small interfering RNA in the Arabidopsis germline. Curr Opin
Genet Dev 21: 134–139. Review.
Chien Y,* Scuoppo C,* Wang X, Fang X, Balgley B, Bolden JE, Premsrirut P, Luo W, Chicas A, Lee CS, Kogan SC, Lowe SW.
2011. Control of the senescence-associated secretory phenotype by NF-kB promotes senescence and enhances chemosensitivity.
Genes Dev 25: 2125–2136.
Clark MB, Amaral PP, Schlesinger FJ, Dinger ME, Taft RJ, Rinn JL, Ponting CP, Stadler PF, Morris KV, Morillon A, Rozowsky
JS, Gerstein MB, Wahlestedt C, Hayashizaki Y, Carninci P, Gingeras TR, Mattick JS. 2011. The reality of pervasive transcrip-
tion. PLoS Biol 9: e1000625. Review.
Fellmann C, Zuber J, McJunkin K, Chang K, Malone CD, Dickins RA, Xu Q, Hengartner MO, Elledge SJ, Hannon GJ, Lowe
SW. 2011. Functional identification of optimized RNAi triggers using a massively parallel sensor assay. Mol Cell 41: 733–
746.
Honegger KS, Campbell RA, Turner GC. 2011. Cellular-resolution population imaging reveals robust sparse coding in the
Drosophilamushroom body. J Neurosci 31: 11772−11785.
Jiang L,* Schlesinger F,* Davis CA, ZhangY, Li R, Salit M, Gingeras TR, Oliver B. 2011. Synthetic spike-in standards for RNA-
seq experiments. Genome Res 21: 1543−1551.
Kopec CD, Bowers AC, Pai S, Brody CD. 2011. Semi-automated atlas-based analysis of brain histological sections. J Neurosci
Methods 196: 12–19. 
Leung A, Cajigas I, Jia P, Ezhkova E, Brickner JH, Zhao Z, Geng F, Tansey WP. 2011. Histone H2B ubiquitylation and H3 lysine
4 methylation prevent ectopic silencing of euchromatic loci important for the cellular response to heat. Mol Biol Cell 22:
2741−2753.
McJunkin K, Mazurek A, Premsrirut PK, Zuber J, Dow LE, Simon J, Stillman B, Lowe SW. 2011. Reversible suppression of an
essential gene in adult mice using transgenic RNA interference. Proc Natl Acad Sci 17: 7113−7118.
Pai S, Erlich JC, Kopec C, Brody C. 2011. Minimal impairment in a rat model of duration discrimination following excitotoxic
lesions of primary auditory and prefrontal cortices. Front Syst Neurosci 5: 74.
Premsrirut PK, Dow LE, Kim SY, Camiolo M, Malone CD, Miething C, Scuoppo C, Zuber J, Dickins RA, Kogan SC, Shroyer
KR, Sordella R., Hannon GJ, Lowe SW. 2011. A rapid and scalable system for studying gene function in mice using conditional
RNA interference. Cell 145: 145–158.
Rangan P, Malone CD, Navarro C, Newbold SP, Hayes PS, Sachidanandam R, Hannon GJ, Lehmann R. 2011. piRNA production
requires heterochromatin formation in Drosophila. Curr Biol 21: 1373−1379. 
Simpson DR, Yu M, Zheng S, Zhao Z, Muthuswamy SK, Tansey WP. 2011. Epithelial cell organization suppresses myc function
by attenuating myc expression. Cancer Res 71: 3822−3830. 
Wasik KA, Rebbeck CA. 2011. Keystone symposia 40th season: microRNAs and noncoding RNAs in cancer. Cancer Res 71:
6102–6105. Review.
Zamparini AL, Davis MY, Malone CD, Vieira E, Zavadil J, Sachidanandam R, Hannon GJ, Lehmann R. 2011. Vreteno, a gonad-
specific protein, is essential for germline development and primary piRNA biogenesis in Drosophila. Development 138:
4039−4050. 
Zaratiegui M, Castel SE, Irvine DV, Kloc A, Ren J, Li F, de Castro E, Marín L, Chang AY, Goto D, Cande WZ, Antequera F, Ar-
cangioli B, Martienssen RA. 2011. RNAi promotes heterochromatic silencing through replication-coupled release of RNA
Pol II. Nature 479: 135–138.
Zuber J,* Rappaport AR,* Luo W, Wang E, Chen C, Vaseva AV, Shi J, Weissmueller S, Taylor MJ, Weissenboeck M, Graeber
TG, Kogan SC, Vakoc CR,  Lowe SW. 2011. An integrated approach to dissecting oncogene addiction implicates a Myb-co-
ordinated self-renewal program as essential for leukemia maintenance. Genes Dev 25: 1628−1640.
Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, Magoon D, Qi J, Blatt K, Wunderlich M, Taylor MJ, Johns C,
Chicas A, Mulloy JC, Kogan SC, Brown P, Valent P, Bradner JE, Lowe SW, Vakoc CR. 2011. RNAi screen identifies Brd4 as
a therapeutic target in acute myeloid leukaemia. Nature 478: 524–528.
*These authors contributed equally to the work.
Watson School student.
• Former URP John Calarco was awarded the prestigious Harold M. Weintraub International
Award for Graduate Studies. He was also named a “Top 30 under 30” by Forbes Magazine.
• WSBS graduate Elizabeth Murchison was one of Genome Technology Magazine’s Young Investi-
gators of the Year for 2011 for her research on “Cancer in the Wilderness.” She also gave a lecture
at the TEDGlobal conference in Edinburgh in 2011.
Mentoring Award for Greg Hannon
It was an honor to nominate my colleague, Gregory Hannon, for the prestigious 2011 Geoffrey
Marshall Mentoring Award, which he received in April from the Northeastern Association of Grad-
uate Schools. The award recognizes a mentor’s outstanding support of graduate students from course
completion through research and placement. The achievements of Greg’s trainees have been uni-
formly outstanding. Four of his students completed their Ph.D. degrees in less than 4 years and two
were recipients of the prestigious Harold M. Weintraub Graduate Student Award. 
Alumni in Faculty and Senior Positions
To date, 49 students have received their Ph.D. degree from the WSBS. Of these graduates, 11 cur-
rently hold tenure-track faculty positions and two hold independent research positions. Twenty-
seven of our former students are pursuing postdoctoral research and seven of our alumni completed
their postdoctoral studies and have moved on to positions in administration, education, industry,
management consulting, and journal editing. We are so proud of them all!
WSBS Family Events
Finally, I am pleased to announce that this was a great year for the WSBS students and administration
as we celebrated some wonderful personal occasions. On January 30, just as the first recruitment
weekend of 2011 was ending, Dawn Pologruto and her husband Tom welcomed a son, John Robert.
Three students from the Entering Class of 2007 were married this year. On May 21, Maria Luisa
Pineda Montoya married her fiancé Alvaro Echeverri Monsalve in Cartagena de Indias, Colombia.
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Alvaro and Maria John Robert Pologruto
On July 27, Eugene Plavskin married Alexandra Tsybeskov, and on September 21, Marek Kudla
married Manuela Trzebinska. Also in July, Ozlem Mert, from the Entering Class of 2007, married
Cem Aksoy in their native Turkey. On July 1, Eyal Gruntman, from the Entering Class of 2006,
and his wife Neomi, along with big brothers Jonathan and Eli, welcomed daughter Ella to their
family. Our congratulations and best wishes to all of them.
Leemor Joshua-Tor
Professor and Dean
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Alexandra and Eugene
Ozlem and Cem Ella Gruntman
Manuela and Marek
SPRING CURRICULUM
Topics in Biology
ARRANGED BY Leemor Joshua-Tor, Alyson Kass-Eisler, and Jan A. Witkowski
FUNDED IN PART BY The Daniel E. Koshland, Jr. Visiting Lectureship; The David Pall Visiting Lectureship;
The Fairchild Martindale Visiting Lectureship; The Lucy and Mark Ptashne Visiting 
Lectureship; The Michel David-Weill Visiting Lectureship
Each year, one or a team of invited instructors offer 7-day courses at the Banbury Conference Center
to explore specialized topics outside the expertise of the CSHL faculty. These courses include morn-
ing or evening lectures as well as afternoon sessions during which students read assigned papers.
These intensive courses are modeled on the CSHL Lecture Courses held each summer at the Ban-
bury Conference Center. In spring 2011, there were two such courses: Physical biology of the cell
and Immunology.
Physical Biology of the Cell
Attended by the entering classes of 2007 and 2008
INSTRUCTOR Rob Phillips, California Institute of Technology
VISITING LECTURERS Daniel Fisher, Stanford University
Hernan Garcia, Princeton University
Thomas Gregor, Princeton University
Greg Huber, University of Connecticut
Justin Kinney, Cold Spring Harbor Laboratory
William Klug, University of California, Los Angeles
Jané Kondev, Brandeis University
Sanjoy Mahajan, Franklin W. Olin College of Engineering
TEACHING FELLOW James Boedicker, California Institute of Technology
The aim of this course was to provide a hands-on experience in the use of quantitative models as a
way to view biological problems. The instructors began with “order of magnitude biology,” showing
how simple estimates can be exploited in biology. They demonstrated how to construct simple mod-
els of a variety of different biological problems, primarily using the tools of statistical mechanics.
One of the key themes of the course was to show how physical biology unites and organizes topics
in a fundamentally different way, often revealing that topics that are nearby in physical biology
seem unrelated when viewed from the vantage point of molecular or cell biology. The students were
guided from start to finish on several modeling case studies. The course ran from Saturday, March
6 to Friday, March 11.
257
258 Watson School of Biological Sciences
Immunology
Attended by the entering classes of 2009 and 2010
INSTRUCTOR Hidde Ploegh, Whitehead Institute
GUEST LECTURER Juan Lafaille, New York University
TEACHING FELLOWS Kevin Bohnam, Harvard University
Deepali Malhotra, Harvard University
Immunology is an interdisciplinary field that focuses on understanding the mechanisms by which
multicellular organisms defend themselves against external threats of microbial aggression and internal
threats associated with genetic instability and cellular transformation. The course focused on the
unique elements of the innate immune system and the adaptive immune system. Innate immunity
defends against microbes by recognizing evolutionarily conserved molecular patterns. The adaptive
immune system has enormous flexibility in molecular recognition, but can also target self to cause
autoimmune diseases. The course ran from Sunday to Saturday, March 27−April 2. 
Physical Biology of the Cell course participants: (Left to right) Thomas Gregor, Jané Kondev, Sanjoy Mahajan, Hernan Garcia, Leemor
Joshua-Tor, James Boedicker, Nilgun Tasdemir, Ashutosh Agrawal, Ralph Burgess, Zhenxun Wang, Eugene Plavskin, Josh Sanders, Paloma
Guzzardo, Maria Pineda, Susann Weissmueller, Michael Pautler, Kaja Wasik, Ozlem Mert, Joe Calarco, Beth Nakason, Zina Perova,
Dario Bressan, Kyle Honegger, Justin Kinney, Bill Klug, Mitchell Bekritsky, Rob Phillips, Carrie Clendaniel, Philippe Batut, Elvin Garcia,
Katie Liberatore, Marek Kudla, Greg Huber, Sang-Geol Koh
Immunology course participants: (Left to right) Lisa Krug, Nilgun Tasdemir, Wee Siong Goh, Nihan Kara, Arkarup Bandyopadhyay, Hidde
Ploegh, Kevin Bonham (kneeling), Kristen Delevich, Colleen Carlston, Kaja Wasik, Beth Nakasone, Ozlem Mert, Ian Peikon, Cinthya
Zepeda-Mendoza, Felix Schlesinger, Deepali Malhotra, John Sheppard, Juan Lafaille, Justin Kinney, Jack Walleshauser, Matthew Koh
Teaching Experience at the DNA Learning Center
DIRECTOR David A. Micklos
INSTRUCTORS Amanda McBrien Elna Gottlieb
Jennifer Galasso (Lead) Erin McKechnie
Jermel Watkins
As science plays an increasing role in society, there is also an increasing need for biologists to educate
nonscientists of all ages about biology. The Watson School of Biological Sciences doctoral program
offers its students unique teaching experiences through the Laboratory’s DNA Learning Center,
where students teach laboratory courses to high school and middle school students. From these
teaching experiences, they learn how to communicate with nonbiologists and to inspire and educate
creative young minds. The teaching module entailed pairs of students teaching one morning or af-
ternoon a week for 12 weeks. In the initial weeks, the DNA Learning Center instructors taught the
Watson School students the didactic process—it was not until the fifth week that the graduate stu-
dents taught on their own. At the end of the 12 weeks, the students were very excited about their
teaching experience.  
Laboratory Rotations
The most important element of a doctoral education is learning to perform independent research
that leads to a unique contribution to human knowledge. After the fall course term, students par-
ticipate in laboratory rotations. These rotations provide students and faculty the opportunity to get
to know each other and to explore possibilities for doctoral thesis research. At the end of each rota-
tion, students make short presentations of their studies to the other students and their rotation ad-
visors. These talks give students an opportunity to share their laboratory experiences and to learn
how to give a scientific presentation. With this latter goal in mind, in addition to the research men-
tors, the instructors of the Scientific Exposition and Ethics core course and members of the School’s
Executive Committee attend the talks and give individual feedback to students on their presenta-
tions. This year, 15 WSBS faculty members served as rotation mentors, some mentoring more than
one student.
ROTATION MENTORS Florin Albeanu Christopher Hammell Zachary Lippman
Mickey Atwal Gregory Hannon Stephen Shea
Anne Churchland Z. Josh Huang Nicholas Tonks
Josh Dubnau Leemor Joshua-Tor Glenn Turner
Hiro Furukawa Adam Kepecs Anthony Zador
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CORE COURSES
The Leslie C. Quick, Jr. Core Course on Scientific 
Reasoning and Logic
INSTRUCTORS Gregory Hannon (Lead) Bo Li
Alexander Gann Zachary Lippman
Leemor Joshua-Tor Nicholas Tonks
GUEST LECTURERS Josh Dubnau Robert Martienssen
Hiro Furukawa Senthil Muthuswamy
Christopher Hammell Christopher Vakoc
Alexei Koulakov Linda Van Aelst
The SRL core course was revamped last year with regard to content and instructor participation.
This year, only one module changed, with Bo Li joining the team. Each module of the course has
been designed to cover a different general theme and proceeds with the goal of considering an open,
still unanswered, scientific question. In addition, the first two modules of the course were combined
into one longer module so that an integrated theme could be tackled using two different approaches:
molecular biology and structural biology. 
A fundamental aspect of earning the Ph.D. degree is training in the pursuit of knowledge. In
this core course, which forms the heart of the curriculum, students (1) acquire a broad base of knowl-
edge about the biological sciences, (2) learn the scientific method, and (3) learn how to think crit-
ically. The beginning of the course is divided into four to five modules, each of which has a different
general theme, and proceeds with the goal of considering an open, still unanswered, scientific ques-
tion. For each module, students read an assigned set of research articles (generally four articles), and
at the end of the module, they provide written answers to a problem set that guides them through
several of the articles.  
Twice weekly, students attend lectures related to the module’s topic that included concepts and
fundamental information, as well as experimental methods. During each week, the students meet
among themselves to discuss the assigned papers not covered by the problem set. Each week, students
also spent an evening discussing the assigned articles with faculty. In the final part of the course,
students participated in a mock study section in which real National Institutes of Health, R01 grants
were reviewed and critiqued. This allowed the students to evaluate the questions before the answers
are known, evaluate routes toward discovery before knowing where they will end, and make critical
judgments about how to proceed in the face of an uncertain outcome. 
The module topics for this course were as follows:
Topic Instructor(s)
Mechanism and Structure of Gene Regulation Alex Gann
Leemor Joshua-Tor
The Brain: Wiring, Plasticity, and Maladaptation Bo Li
Developmental Genetics and Morphological Diversity Zachary Lippman
Signal Transduction and the Search for Novel Therapeutics Nicholas Tonks
Study Section Gregory Hannon
The Darrell Core Course on Scientific Exposition and Ethics 
INSTRUCTORS David J. Stewart (Lead)
Alea A. Mills 
Arne Stenlund
TEACHING ASSISTANTS Christina Chen
Aman Husbands
GUEST LECTURERS Diane Esposito 
Jan A. Witkowski
VISITING LECTURERS Olga Akselrod, The Innocence Project
Keith Baggerly, University of Texas, M.D. Anderson Cancer Center
Michael Beilski, The Center for Biotechnology
Robert Charrow, Greenberg Traurig, LLC
Avner Hershlag, North Shore University Hospital 
Amy Harmon, The New York Times
Boyana Konforti, Editor, Nature Structural & Molecular Biology
Tung-Tien (Henry) Sun, New York University
The Scientific Exposition and Ethics (SEE) core course 2011 was taught by the same instructor
team as last year, with David Stewart taking the lead role, joined by Alea Mills and Arne Stenlund.
This year, two CSHL postdoctoral fellows, Christina Chen and Aman Husbands, participated in
the course as teaching assistants. As usual, the course hosted expert guest lecturers who covered
topics including scientific presentations, the editorial review process, the ethical and legal responsi-
bilities of scientists, DNA profiling and postconviction appeals, and reproductive genetics.
This core course offered instruction in the fundamental elements of scientific exposition—writing
skills and public speaking—and ethics. The ability to communicate effectively and to appreciate
the intricacies of ethical issues are essential skills for biologists; both subjects were taught in a series
of example-based lectures and discussion groups. Writing skills included the fundamentals of modern
scientific English and the organization and preparation of papers, research abstracts, and grant ap-
plications. Oral presentation skills were taught by instructors with different modes of presentation.
Together with instructors, students critiqued formal seminar presentations at the Laboratory. In-
struction and discussions about ethics included the ethical implications of biological discovery for
society as well as the nature and boundaries of ethical behavior of scientists and their rights and re-
sponsibilities. A primary objective of the course was that students consider exposition and ethics
integral aspects of scientific research.
Research Topics
ORGANIZERS Kimberley Geer 
Alyson Kass-Eisler
This core course provided students with an in-depth introduction to the fields of research that the
Laboratory scientists investigate. Students and faculty attended a weekly Research Topics seminar,
at which faculty members and CSHL fellows presented their current research topics and methods
of investigation each Wednesday evening over dinner. The students learned how to approach im-
portant problems in biology. These seminars, together with the annual fall Laboratory In-House
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Symposium, provided students with a basis for selecting laboratories in which to do rotations. The
weekly speakers are listed below:
Florin Albeanu David Jackson Partha Mitra Lloyd Trotman
Gurinder (Mickey) Atwal Leemor Joshua-Tor Pavel Osten Glenn Turner
Anne Churchland Adam Kepecs Darryl Pappin Christopher Vakoc
Josh Dubnau Alexei Koulakov Michael Schatz Linda Van Aelst
Mikala Egeblad Adrian R. Krainer Stephen Shea Doreen Ware
Grigori Enikolopov Alexander Krasnitz Raffaella Sordella Michael Wigler
Hiro Furukawa Bo Li David L. Spector Anthony Zador
Thomas Gingeras Zachary Lippman Arne Stenlund Hongwu Zheng
Christopher Hammell Robert Martienssen Bruce Stillman Yi Zhong
Gregory Hannon W. Richard McCombie Marja Timmermans
Z. Josh Huang Alea A. Mills Nicholas Tonks
Specialized Disciplines Courses
In 2010, the School developed two new courses in the areas of statistics, programming, bioinfor-
matics, and theoretical modeling and analysis. One of these courses, the Specialized Disciplines
course in Quantitative Biology, was developed by Mickey Atwal and cotaught by Michael Schatz to
provide students with the tools to interpret large, complex data sets and to use statistical methodology
in their research. With the addition of this course, the students in the entering class of 2011 took a
total of four Specialized Disciplines courses this fall. The other three Specialized Disciplines courses
are Cellular Structure and Function, Genetics and Genomics, and Systems Neuroscience. Cellular Structure
and Function was again taught by lead instructor Linda van Aelst and Raffaella Sordella, but it ran
as a week-long intensive course when the students first arrived. Josh Dubnau led Genetics and Ge-
nomics, and he was joined again by Thomas Gingeras. Anthony Zador, Adam Kepecs, and Glenn
Turner taught the Systems Neuroscience course. 
Cellular Structure and Function
INSTRUCTORS Linda Van Aelst (Lead)
Raffaella Sordella
GUEST LECTURERS Darryl Pappin
David L. Spector
Bruce Stillman
VISITING LECTURERS Aron Jaffe, Novartis
Alexey Khodjakov, Wadsworth Laboratory
Sandy Simon, The Rockefeller University
Marc Symons, The Feinstein Institute for Medical Research
With the complete genome sequence available for many organisms, there is now an increasing em-
phasis on understanding the function of the gene products. This understanding requires an increasing
appreciation of the structure and function of the cell as well as dynamic associations within the cell.
This course provided a basic overview of the structural and functional organization of cells with par-
ticular emphasis on cellular compartmentalization and communication. Topics of focus included
the  cytoskeleton, cell adhesion and signaling, membrane transport, gene expression, and nuclear
organization. In addition, the course provided insight into the basic toolbox of the cell biologist of
the 21st century.
Genetics and Genomics
INSTRUCTORS Josh Dubnau (Lead)
Thomas Gingeras
GUEST LECTURERS Christopher Hammell
Marja Timmermans
This course placed modern human genetics and genomics into the context of classical organismal
genetics. History, perspective, and technique were described around four levels of analysis: naturally
occurring variation, genome evolution, genetic screens, and gene epistasis. How do gene mutations
help to define biological processes? How are more complex traits genetically dissected into simpler
(underlying) components? What concepts and techniques are used to organize genes into pathways
and networks? How are genes mapped, cloned, and engineered to identify functional domains of
proteins? What gene variation exists in natural populations? What are the functional consequences
of gene variation? How is it detected? How are genomes organized and coordinately regulated? How
can genomic information be cataloged, organized, and mined? These questions and concepts were
fleshed out using examples from the literature.
Quantitative Biology 
INSTRUCTORS Mickey Atwal (Lead)
Michael Schatz
GUEST INSTRUCTORS Justin Kinney (CSHL Fellow)
Alexander Krasnitz
With the advent of high-throughput technologies in biology, it has become necessary for biological
researchers to be able to analyze and interpret high-dimensional data and frame hypotheses mathe-
matically. To this end, this course aims to equip the students with basic training in modern statistical
methods. It is hoped that by the end of the course the students will be able to not only answer many
of the simple statistical questions that arise in data analyses, but also be familiar with the more complex
techniques used by fellow computational biologists. Topics to be covered include error fluctuations,
calculating the significance of an experimental result, Bayesian inference, information theory, power
calculations, dimensional reduction, and DNA sequence analyses. In addition, this course will intro-
duce mathematical modeling, and this will be motivated by the classic examples in quantitative biology
such as the Delbruck−Luria experiment, Hopfield’s kinetic proofreading, and Kimura’s neutral theory
of population genetics.
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Systems Neuroscience
INSTRUCTORS Anthony Zador (Lead)
Adam Kepecs
Glenn Turner
GUEST INSTRUCTORS Florin Albeanu
Anne Churchland
Alexei Koulakov
Stephen Shea
This course provided an overview of key aspects of neuroscience. The emphasis was on spanning
levels: How can we go from molecules through cells and circuits to behavior? The three main com-
ponents of the class are lectures, problem sets, and a final project in which students identify and
present a neuroscience paper that spans levels, for example, from the molecular to the synaptic or
the circuit level to the behavioral. 
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Watson students Maria Joaquina Delas Vives and Fred Marbach
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POSTDOCTORAL PROGRAM
PROGRAM DIRECTOR Nicholas Tonks
PROGRAM ADMINISTRATOR Alyson Kass-Eisler
Cold Spring Harbor Laboratory (CSHL) is proud of its rich tradition in postdoctoral education
and has a deep commitment to the postdoctoral experience. CSHL has long been recognized as a
place for nurturing young scientists, with postdoctoral researchers being an integral part of the dis-
covery process. Current fields of research expertise include genetics; molecular, cellular, and struc-
tural biology; neuroscience; cancer; plant biology; genomics; and quantitative biology. The
postdoctoral community at CSHL is diverse and international, arriving at the Laboratory with
many different backgrounds and with needs that change during the course of the postdoctoral years.
The Postdoctoral Program Office works closely with the fellows and the Laboratory’s administration
to coordinate and organize educational and career development activities. Dr. Alyson Kass-Eisler,
the Postdoctoral Program Officer, and Dr. Nicholas Tonks, the Scientific Director of the Postdoc-
toral Program, provide day-to-day support for the postdoctoral program, which is overseen by the
Dean of the Watson School, Dr. Leemor Joshua-Tor.
A New Postdoctoral Liaison Committee
In January 2011, Bruce Stillman held his annual Town Hall meeting with postdocs. One suggestion
that came from the meeting was the establishment of a Postdoctoral Liaison Committee (PDLC),
an elected group of postdocs who would help share information and ideas between the adminis-
tration and the postdoctoral community. The six members elected to serve the first 1-year term
on the PDLC are Kate Creasey, Santiago Jaramillo, Keerthi Krishnan, Dawid Nowak, Kate Revill,
and Milos Tanurdzic. The PDLC has been hard at work. Its members have completed two inform-
ative surveys of issues affecting postdocs, which they have shared with the administration, and are
busy organizing a postdoctoral retreat. The PDLC also submitted a response to the Biomedical
Workforce Committee, a group established by the National Institutes of Health (NIH) Director
to examine the future of the biomedical research workforce in the United States, on behalf of the
CSHL postdocs. 
Career Development Programs 
The postdocs themselves have been very active in organizing career development lectures and work-
shops this year. A group of postdocs known as the IDP (or Individual Development Plan) group
organized a five-part series called “Conversations with Faculty.” In this series, CSHL faculty and
administration gave the postdocs career insights in an informal and interpersonal format. The lec-
turers included Anne Churchland and Hongwu Zheng, two new faculty members who shared their
experiences in applying for and getting an academic position; Stephen Shea and Glenn Turner, who
talked about the challenges and joys of making the postdoc-to-faculty transition, setting up a lab,
and surviving the first year as an Assistant Professor; Raffaella Sordella and Tony Zador, who spoke
as senior faculty members and shared their insights from being members of faculty search commit-
tees; Sydney Gary and Charla Lambert, who discussed careers for life science Ph.D.s outside of ac-
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ademia (science education and science administration); and Vlad Drozdoff and Darryl Pappin, who
talked about technology transfer and intellectual property law careers.
To assist postdocs with the common “What do you do?” question, on March 14, the Watson
School hosted Dr. Bob Tillman, Director of Faculty Development at Columbia University Medical
Center, who gave a seminar on “Short talks that make big impressions: Promoting yourself and your
science informally.” 
The IDP group also hosted an extremely well-received workshop on preparing for the Chalk
Talk—an integral part of the academic job search. In the workshop, senior postdoctoral fellow
Agustin Chicas presented his Chalk Talk to the group, which was moderated by faculty members
Adrian Krainer, David Spector, and Nicholas Tonks. 
The Bioscience Enterprise Club 
The Bioscience Enterprise Club (BEC)—postdocs and students most interested in nonacademic
careers—has recently formed. Members are in the process of organizing a great lineup of speakers
for 2012. Their first seminar took place on October 5 and featured Tom Ippolito and Michael Bielski
from the Fundamentals of the Bioscience Industry Program (FOBIP). In addition to teaching the
FOBIP, Tom Ippolito is the Vice President of Regulatory Affairs/QA for Chembio Diagnostics, and
Michael Bielski is the Assistant Director for Science & Technology Commercialization at the Center
for Biotechnology and practices Intellectual Property Law at the law firm of Mayer, Ross & Hagen.
Tom and Mike discussed careers in Regulatory Affairs and Intellectual Property Law and also dis-
cussed the Fundamentals of the Bioscience Industry Program.
Webinars
Through the Lab’s Human Resources department, the postdocs have had access to free jobseeker
webinars hosted by the Higher Education Research Consortium. The 2011 webinars included “The
campus visit,” “Expanding your career networks,” and “Targeting your cover letter for faculty and
nonfaculty positions.” 
Merck Ambassador Program
CSHL has been a member of a special ambassador recruitment program from Merck Research
Laboratories (MRL) since 2005. This program provides the postdoctoral fellows and students at
CSHL an inside connection to a scientist working at MRL. As a result of this program, Dr. Maarten
Hoek, a postdoctoral fellow from Dr. Bruce Stillman’s laboratory, was hired as a Research Scientist
in 2007, and Dr. Zuo Zhang, a postdoctoral fellow from Dr. Adrian Krainer’s laboratory, joined
MRL as a Research Scientist in January 2009. Dr. Li visited the Laboratory again on May 24 to
talk about what it is like to work in a pharmaceutical company. Jing also gave a talk on his current
research titled, “Applying genomic platforms to generate unbiased responder and treatment hy-
potheses for oncology translational research” to give the fellows a feel for the type of research being
done in industry.
In-House Symposium Poster Prize
Six years ago, the School initiated a prize for the best poster by a postdoctoral fellow and the best
poster by a graduate student at the Laboratory’s annual In-House Symposium. Each “prize” is given
in the form of an educational grant of $500. In addition to providing a forum for the postdoctoral
fellows to show off their research, and potentially win a prize, it gives the entire scientific community
a chance to come together and share ideas beyond the walls of their individual laboratories. It has
been a great success for both the presenters and the Laboratory community as a whole. Fifteen
posters were presented for the postdoctoral prize, which was won by Tim Kees, a postdoctoral fellow
in Mikala Egeblad’s laboratory.
Teaching Opportunities at the Watson School
During the past couple of years, we have increasingly widened the role of postdoctoral fellows in
the curricular activities of the School. Our fellows have been involved in preparing our students for
the challenging Fall Term curriculum by working as one-on-one tutors during the summer. Through-
out the Fall Term, postdoctoral fellows serve as tutors for all aspects of the curriculum, providing
one-on-one tutoring and group tutoring and participating in discussion sessions. In 2007, the Sci-
entific Exposition and Ethics course took further advantage of the expertise of our postdoctoral
community by hiring two fellows as teaching assistants (TAs). These two fellows became an integral
part of the course by providing their expertise in discussions, editing students’ writing work, and
critiquing oral presentations. This format was highly successful and was used again in fall 2011.
Aman Husbands, a postdoctoral fellow from Marja Timmerman’s laboratory, and Cristina Chen,
from Chris Hammell’s laboratory, were this year’s TAs.
Demystifying Science
A new program called “Demystifying Science” has enlisted postdoctoral fellows to bring their ex-
pertise and teaching interests to the educationally diverse staff of the Laboratory. In these sessions
geared toward a general audience, postdocs have talked about “Why haven’t we cured cancer yet?”
presented by Emma Vernersson-Lindahl; “Sensing the world: Insights from neuroscience” by
Katharine Borges; “How plants defend themselves from viruses” by Aman Husbands; “Demystifying
desire: How do we study the brain?” by Keerthi Krishnan; “Fighting cancer with tiny tools: Research
from the Lowe lab” by Kiki Liu; and “How do we see the invisible?: Research from the Joshua-Tor
lab” by Jon Ipsaro.
Professor for a Day
Another new program, in which postdocs have a major role, was designed by the CSHL Meetings
and Courses program to communicate science to the broader public. “Professor for a Day” shows
area high school students the inside story on scientific meetings and poster sessions. Postdocs have
also contributed to the CSHL Meetings and Courses newsletter by writing short summaries of meet-
ings or courses they have attended on campus. 
New York Academy of Science: Science Alliance
Since 2003, all postdoctoral fellows and graduate students at the Laboratory have been enrolled in a
special initiative of the New York Academy of Science (NYAS), the Science Alliance. The Science
Alliance for graduate students and postdoctoral fellows is a consortium of universities, teaching hos-
pitals, and independent research facilities in the New York City metro area that have formed a part-
nership with NYAS. The aim of the Alliance is to provide career and professional development
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monitoring for postdoctoral fellows and graduate students in science and engineering through a series
of live events and a dedicated web portal. In addition, the Science Alliance gives graduate students
and postdoctoral fellows the opportunity to network with their peers across institutions and with key
leaders in academia and industry. This year, the Science Alliance meetings and workshops included
“From idea to IPO: The technology venture course,” “Thinking about teaching: Myths and realities
of becoming an educator,” “Bargaining for success: Mastering the science of negotiation,” “Leadership
and personal success through self-awareness and emotional intelligence,” “From scientist to CSO: A
business and industry prep course,” and “Making the leap: A nonacademic career planning and job
search boot camp.” In addition, the biennial “What can you be with a Ph.D.?” was held on November
5th and 6th at New York University. Supported by a New York City regional consortium of colleges
and universities, including CSHL, this 2-day preeminent career convention features exhibitors, in-
dustry representatives, symposia on options, and trends in career paths.
Scientific Societies
Scientific societies play a large part in shaping science, as well as the career development of its mem-
bers. Lloyd Trotman, a CSHL faculty member and a member of the American Society for Cell Bi-
ology (ASCB), held a roundtable discussion on behalf of the ASCB to provide feedback from junior
faculty and postdocs about how they think about and what they want from the Society. A similar
session was led by CSHL postdoc Christos Noustos, an Ambassador to the American Society for
Plant Biologists.
Cancer Gene Discovery Training Program
In 2011, the Laboratory received a training grant from the NIH. The primary goal of the Cancer
Gene Discovery and Cancer Biology Postdoctoral Training Program is to prepare the next generation
of cancer biologists to pursue independent research that integrates cancer gene discovery with func-
tional biology to facilitate the development of novel cancer therapeutic, diagnostic, and/or preventive
strategies. 
Responsible Conduct of Research Course
An Ethics Course, which provided training in the Responsible Conduct of Research, was held this
spring. The three-part course included sessions on “Use of biohazardous materials,” “Human subjects
and materials,” “The ethical use of animals in research,” “Roles and responsibilities associated with
research funding,” “Financial conflict of interest,” and “Whistleblower policies,” as well as a mod-
erated presentation of the interactive video from the NIH, Office of Scientific Integrity, titled, “The
lab: Avoiding research misconduct.”
Grant Writing Workshop
On December 6th and 7th, the Office of Sponsored Programs, the Development Department, and the
Postdoc Program Office held a very popular course on Grant Writing. The sessions included “Intro-
duction to grants and external funding,” “The grant application,” “Protecting human research
subjects/writing an IACUC,” “The grant abstract/public summary: Dos, don’ts, and examples,” “Peer
review panel discussion,” “Effective writing skills,” “Fellowships, career development awards, and re-
sources for postdocs,” and a “Fellowship discussion panel” featuring postdocs Olga Anczukow-Camarda,
Jonathan Ipsaro, and Keerthi Krishnan, who all currently hold competitive individual fellowships. 
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Success!
Finally, a most important measure of our postdoctoral program’s success is the ability of postdoctoral
fellows to secure positions at the end of their training. In 2011, the Laboratory’s departing post-
doctoral fellows went on to positions at the Institute of Molecular Pathology (IMP), Austria;
Nanyang Technological University, Singapore; Novartis and Rutgers University, both in New Jersey;
the University of Queensland, Australia; and the University of Toronto, Canada.
Postdoctoral Program      269
270
UNDERGRADUATE RESEARCH PROGRAM
PROGRAM DIRECTOR Zachary Lippman
PROGRAM ADMINISTRATOR Keisha John
Established more than 50 years ago, the CSHL Undergraduate Research Program (URP) plays a
major part in providing and setting the standard for meaningful hands-on undergraduate research
training in biology. The ten-week program begins the first week of June. During the first week, the
students are oriented to the campus, and they receive a guided historical tour of campus and a tour
of all facilities and resources available to them, ensuring a smooth transition into the Laboratory
community and research. The URPs work, live, eat, and play among CSHL scientists, and they
have a very busy academic and social calendar throughout the remaining 9 weeks of the summer.
The students receive training in Scientific Research, Science Communication, Career Preparation,
Bioinformatics, and Computational Biology, all while interacting socially with fellow program par-
ticipants and members of the CSHL community at large in formal and informal activities. Some
of these activities in 2011 were a pizza dinner with Dr. and Mrs. Watson, dinner with Dr. and Mrs.
Stillman, BBQ and pool parties, volleyball games, designing the URP T-shirt, competing in the
annual Scavenger Hunt, and the ever-famous URP vs. PI volleyball match.
The students’ scientific development is the most important component of the program. Therefore,
in the beginning of the summer, the URPs write an abstract and present a talk on their proposed re-
search. The URP participants work alongside scientists and become increasingly independent
throughout the summer. Concluding the program in August, the URPs prepare a final report and
The URPs have dinner with Dr. Watson.
Paul Baranay, University of Notre Dame
Advisor: Dr. Michael Schatz
Sponsor: University of Notre Dame Scholar
Metassembler: A secret weapon for winning Assemblathon 2.
Tumas Beinortas, Cambridge University, England
Advisor: Dr. Lloyd Trotman
Sponsor: Emanuel Ax Fellow
Characterization of signature gene expression in Pten-loss-
associated senescence, PlCS.
Lital Chartarifsky, Hebrew University of Jerusalem, Israel
Advisor: Dr. Adrian Krainer
Sponsor: Burroughs Wellcome Fellow
The alternative splicing factor SRSF6: A proto-oncogene?
Sai Chen, Life Science, Peking University, China
Advisor: Dr. Greg Hannon
Sponsor: Dr. Gregory Hannon Fellow
Preexperiments for optimized sensor assay.
Zachary Collins, George Washington University
Advisor: Dr. Partha Mitra
Sponsor: Hazen Fellow
Alterations in GABAergic neuroanatomy in autism spectrum
disorder mouse models.
Thomas Dowling, Georgetown University
Advisor: Dr. Greg Hannon
Sponsor: Steamboat Foundation Scholar
Improving the signal-to-noise ratio of HITS-CLIP.
Katharine Dusenbury,Williams College
Advisor: Dr. Darryl Pappin
Sponsor: Dorcus Cummings Scholar
In vitro translation and mutational modification of Grifola
frondosa metalloendopeptidase. 
Claire Edgcumbe, University of British Columbia, Canada
Advisor: Dr. Bo Li 
Sponsor: William Shakespeare Fellow
ErbB4’s effect on the morphology of somatostatin cell in the
thalamic reticular nucleus.
Thomas Erskine, Florida State University
Advisor: Dr. Alexi Koulakov
Sponsor: 30th Anniversary URP Scholar
Modeling the human brain: A mathematical approach.
Gregory Fitzgerald, Queens College
Advisor: Dr. Pavel Osten
Sponsor: 30th Anniversary URP Scholar
Anterograde tracing of the infralimbic cortex in Ng3 R451C 
and wild-type mice.
Ann-Desdemonia Fowajuh, University of Maryland Eastern
Shore
Advisor: Dr. Grisha Enikolopov
Sponsor: William Townsend Porter Foundation Scholar
The molecular mechanism of NO and its role in cilia function.
Hannah Gendelman, Amherst College
Advisor: Dr. Glenn Turner 
Sponsor: Von Stade Fellow
Light as a remote controller of the proboscis extension response in
Drosophila.
Victoria Hanna, University of California, Irvine
Advisor: Dr. Marja Timermanns
Sponsor: National Science Foundation Scholar
microRNA mobility.
Brittany Haugen, Florida Institute of Technology
Advisor: Dr. Alea Mills 
Sponsor: National Science Foundation Scholar
Investigating p63 isoforms in mouse models mimicking EEC
syndrome.
Valentina Ignatova, St. Petersburg State University, Russia
Advisor: Dr. Alex Krasnitz 
Sponsor: Robert H.P. Olney Fellow
Knowledge-based derivation of markers and subtypes in cancer.
Allison Kolbe, Ohio Wesleyan University
Advisor: Dr. David Jackson
Sponsor: National Science Foundation Scholar
Determination of phyllotaxy in maize by redox regulation of
transcription factors.
Andrew Lawson, Cambridge University, England
Advisor: Dr. Leemor Joshua-Tor
Sponsor: Former URP Fund Scholar
Role of PIWI proteins in planarian regeneration. The structure
and function of human mitochondrial CCA-adding enzyme.
Mitchell Leibowitz, University of Virginia
Advisor: Dr. Richard D. McCombie
Sponsor: National Science Foundation Scholar
Third-generation sequencing as a high-throughput diagnostic tool.
Chengyu Liu, University of Wisconsin, Madison
Advisor: Dr. Mickey Atwal 
Sponsor: Garfield Fellow
Cancer biomarkers investigation in human array CGH data in
learning and memory through reward learning in 
D. melanogaster.
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present their results in a 15-minute talk at the URP Symposium. As in previous years, the program
directors and faculty mentors were highly impressed with the accomplishments of the URP students.
The following 28 students, selected from 727 applicants, took part in the 2011 program:
Monica Manglani, Lafayette College
Advisor: Dr. Steve Shea 
Sponsor: Libby Fellow
Role of neuronal inhibition in vocal communication.
Kelly Mulfaul, Trinity College Dublin, Ireland
Advisor: Dr. Bruce Stillman
Sponsor: Trinity College Fellow
Role of CMG helicase in nucleosome disassembly.
Benjamin Perrella, Hunter College
Advisor: Dr. Yi Zhong
Sponsor: Hunter College Scholar
Role of the NF1 gene.
Kristian Saied, University of Puerto Rico
Advisor: Dr. Josh Dubnau
Sponsor: H. Bentley Glass Fellow
Ago2 protein as the protector against R2 retrotransposons in
Drosophila brain.
Sarah Shareef, Harvard University
Advisor: Dr. Chris Vakoc
Sponsor: Alfred L. Goldberg Fellow
SMARCA4: A potential therapeutic target for acute myeloid
leukemia.
Burak Tepe, Bogazici University, Turkey
Advisor: Dr. Adam Kepecs
Sponsor: Joan Redmond Read Fellow
Role of cholinergic neurons in regulating attention.
Anne Turberfield, Cambridge University, England
Advisor: Dr. Chris Hammell 
Sponsor: James D. Watson Fellow
Systematic RNAi screen to identify developmental regulators of
microRNA activity. 
Jeanette Wat, Rice University
Advisor: Dr. Scott Powers
Sponsor: James D. Watson Fellow
Oncogene dependency in HCC.
Kevin Wu, University of California, San Diego
Advisor: Dr. Doreen Ware
Sponsor: National Science Foundation Scholar
De novo transcriptome assembly and analysis of RNA-seq data
from maize and sorghum in the cloud.
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2011−2012 CSHL Partners for the Future: (Seated, left to right) Angad Anand, Annalise Grammerstorf, Connie Long, Justin Levine.
(Standing, left to right) Holly Flores, Alexandra Marshall, Andrew Ku, Sean Culkin, Beverly Chen, Charles Bill, Daniel Sikavi, Madi-
son Bondy, Joseph Nolan, Dr. David Jackson. (Not pictured) Japbani Nanda, Billy Smith
PARTNERS FOR THE FUTURE
PROGRAM DIRECTOR David Jackson
PROGRAM ADMINISTRATOR Elizabeth Soldatic 
The Partners for the Future Program, established by Dr. James Watson in 1990, provides an op-
portunity for talented Long Island high school students to gain hands-on experience in biomedical
research at Cold Spring Harbor Laboratory (CSHL). This highly competitive program is open to
Long Island high school students in their junior year. Each high school science chairperson may
nominate up to three students. The top candidates are interviewed by CSHL scientists and up to
15 top students are chosen to participate in the program. Students selected for the program are
paired with a scientist mentor and spend a minimum of 10 hours per week, September through
March of their senior year, conducting original research. At the conclusion, the students present
their projects to an enthusiastic audience of the students, scientific mentors and colleagues, CSHL
administrators, parents, and teachers. Although the students learn a great deal about modern biology
and state-of-the-art research techniques, the main advantage of the program is that they are exposed
to day-to-day life in a lab. Interacting with scientists and support staff, the students learn to define
and pursue a research goal while solving problems that may occur along the way. The 2011−2012
Partners for the Future listed below were chosen from among 39 nominations:
Partner High School CSHL Mentor Laboratory
Angad Anand Cold Spring Harbor Tony Zador Santiago Jaramillo
Charles Bill Cold Spring Harbor Zach Lippman Ke Jiang
Madison Bondy South Side Josh Huang Jiangteng Lu
Beverly Chen Syosset Doreen Ware Lifang Zhang
Sean Culkin South Side Marja Timmermans Kate Petsch
Holly Flores Huntington Senthil Muthuswamy Mike Feigen
Annalise Grammerstorf Harborfields Yi Zhong Yichun Shuai
Andrew Ku Huntington Adam Kepecs Hyun Jae Pi
Justin Levine Friends Academy James Hicks Jim Hicks
Connie Long Half Hollow Hills East Adrian Krainer Yimin Hua
Alexandra Marshall North Shore David Jackson David Jackson
Japbani Nanda W.T. Clarke Robert Martienssen Benjamin Roche
Joseph Nolan Harborfields Alea Mills Assaf Vestin
Daniel Sikavi Roslyn Mikala Egeblad Jae-Hyun Park
Billy Smith Cold Spring Harbor Adam Kepecs Sachin Ranade

MEETINGS AND COURSES
ACADEMIC AFFAIRS
The Meetings and Courses program attracts scientists from all over the world to communicate,
learn, and critique the latest ideas and approaches in the biological sciences. The program consists
of advanced laboratory and lecture courses as well as large meetings and biotechnology conferences
that are held almost year `round. More than 9000 scientists ranging from graduate students and
postdoctoral fellows to senior faculty come from ’round the world to attend these events at Cold
Spring Harbor, and ~2700 scientists participated in our new program in Asia. 
In 2011, the 30 laboratory and lecture courses that were held at the Laboratory attracted more
than 1330 participants (including teaching faculty, students, and technicians). These courses covered
a diverse array of topics in molecular biology, neurobiology, structural studies, and bioinformatics.
The primary aim of the courses remains to teach students the latest advances that can be immediately
applied to their own research. Courses are always being evaluated and updated to include the latest
concepts and approaches. Increasingly, many courses feature a strong computational component as
biology grows ever more interdisciplinary, incorporating methodologies from computer science,
physics, and mathematics. 
Instructors, course assistants, and course lecturers come from universities, medical schools, re-
search institutes, and companies around the world to teach at Cold Spring Harbor. It is their excel-
lence and dedication that make the course program work so well. We would especially like to thank
Drs. Mark Alkema, Tracy Andacht, Heather Broihier, James Bruce, Vincent Carey, David Feather-
stone, Nace Golding, Eric Lambie, Andrew Link, Eric Miska, Matthew Nolan, Alison North, Samara
Reck-Peterson, Jeffrey Strathern, Scott Thompson, Jim Tisdall, and John Tyson, who all retired this
year after many years of service. 
Grants from a variety of sources support the courses. The core support provided through the re-
cently renewed grant from the Howard Hughes Medical Institute remains critical to our course pro-
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gram. The courses are further supported by multiple awards from the National Institutes of Health
(NIH) and the National Science Foundation (NSF), and additional support for individual courses
is provided by various foundations and other sources. The courses also depend on equipment and
reagents that are loaned or donated by a large number of companies. These are invaluable for making
it possible to keep up with the latest technologies.
The Laboratory held 29 academic meetings this year, which brought together more than 7800
scientists worldwide to discuss their latest research. The Symposium this year focused on metabolism
and disease, highlighting the emerging integration of molecular biology with the classical biochem-
istry of energy utilization in the cell. The Symposium attracted almost 300 participants including
notable biologists such as Mike Brown, Ron Evans, Joe Goldstein, Lenny Guarente, Cynthia
Kenyon, Steven McKnight, David Sabatini, Bruce Spiegelman, Craig Thompson, Eileen White,
and Douglas Wallace. 
Cold Spring Harbor Laboratory meetings are unique in assembling a program with very few in-
vited speakers. Instead, meeting organizers are encouraged to select talks from abstracts that are sub-
mitted on the basis of scientific merit, ensuring that the latest findings are presented and that young
scientists have the chance to describe their work. The annual meetings on The Biology of Genomes,
Retroviruses, and Neurobiology of Drosophila were all oversubscribed, and many others attracted
strong or record attendances. New meetings were launched on Stem Cell Engineering and Cell-
Based Therapies and The Biology of Cancer: Microenvironment, Metastasis, and Therapeutics, and
the biennial Eukaryotic mRNA Processing meeting began with an earthquake and ended with hur-
ricane Irene! Many of these meetings have become essential for those in the field and are held on a
biannual basis. Partial support for individual meetings is provided by grants from NIH, NSF, foun-
dations, and companies. Core support for the meetings program is provided by the Laboratory’s
Corporate Sponsor Program.
The development of the Cold Spring Harbor Asia program, as a wholly owned affiliate of Cold
Spring Harbor Laboratory in Suzhou, China, continued with 13 scientific meetings and one Sum-
mer School held throughout the year. The Cold Spring Harbor Asia Symposium focused on syn-
thetic biology and highlighted exciting work from around the world, ongoing in this burgeoning
field.
The Meetings and Courses program staff comprises a lean team of talented professionals, many
of whom wear multiple “hats,” who handle the complexities of database design, programming, web
and multimedia design, educational grants management, marketing and recruitment, conference
and course administration, audiovisual services, and other activities. Two new staff members, Dr.
Charla Lambert and Brad Frey, joined the team in early 2011 to fill new positions as program man-
ager, science and training, and marketing associate, respectively. 
Terri Grodzicker
Dean
Academic Affairs
David Stewart
Executive Director
Meetings and Courses Program
76TH COLD SPRING HARBOR LABORATORY 
SYMPOSIUM ON QUANTITATIVE BIOLOGY
Metabolism and Disease
June 1–6 291 Participants
ARRANGED BY Bruce Stillman,Terri Grodzicker, and David Stewart
Cold Spring Harbor Laboratory
Cold Spring Harbor Laboratory selected the theme of Metabo-
lism and Disease for the historic 76th Symposium in the series.
The decision to focus the 2011 Symposium on this topic reflects
the growing convergence of lines of research in fields ranging
from cancer biology to aging, demonstrating that key metabolic
pathways regulate energy homeostasis in cells, organs, and whole
organisms and that many human diseases share profound dys-
function in metabolism at a molecular level. Previous Symposia
that have been devoted in all or in part to metabolism and its
dysfunction include Biological Oxidations (1939), The Mam-
malian Fetus: Physiological Aspects of Development (1954),
Cellular Regulatory Mechanisms (1961), The Cardiovascular
System (2002), and Clocks and Rhythms (2007).
A key theme of early 20th-century investigation, cellular bio-
energetics, yielded a vast body of biochemical knowledge about
key energy transformation processes such as oxidative phosphor-
ylation and glycosylation. In contrast, the molecular biology rev-
olution of the last half century has focused largely on how cells
and organisms process information stored in nucleic acid and
how these mechanisms are regulated during fundamental
processes such as cell division and development or adapt and re-
spond to external conditions. Tremendous light has been shed
on processes such as DNA replication, transcription, RNA processing, and protein translation, and
more recently on signaling cascades, developmental lineages, and disease progression (e.g., oncoge-
nesis). Much of this work has been done with little regard for the metabolic state of the cell, which
could be safely ignored while the reductionist approach yielded such powerful results. But energy
consumption at the cellular and organismal level is once again becoming a major theme of modern
research, because imbalances in these processes are increasingly understood to be major contributory
factors in many diseases that significantly impact society, including obesity, cardiovascular disease,
diabetes, metabolic disorders, and cancer. Moreover, energy homeostasis appears to have a significant
impact on the aging process itself. 
The Symposium aimed to integrate a very broad field of investigative effort, bringing together
advances in our understanding of energy intake, consumption, and storage (diet, exercise, and fat),
oxygen regulation and hypoxia, circadian rhythms, and life span/aging. The Symposium explored
metabolism at the molecular (gene expression, posttranslational modifications, protein turnover,
cofactors and integrators, hormones, and signals), organellar (mitochondria), cellular, organ system
(cardiovascular, bone), and organismal (timing and life span) scales. Diseases impacted by metabolic
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imbalance or dysregulation that were covered in detail included diabetes, obesity, metabolic syn-
dromes, and cancer. New and emerging technologies were presented for simultaneous monitoring
of hundreds of metabolites that allow for sophisticated sampling of the metabolic state of cells. 
In arranging this Symposium, the organizers were dependent on the guidance of a broad cadre
of advisors including Drs. Ron Evans, Lenny Guarente, David Sabatini, Bruce Spiegelman, Craig
Thompson, Eileen White, and Douglas Wallace. Opening night speakers included Douglas Wallace,
Ron Evans, Cynthia Kenyon, and Craig Thompson.
Nobel laureates Joe Goldstein and Mike Brown jointly
presented the Reginald Harris Lecture on “Surviving
Starvation: Essential Role of the Ghrelin-Growth Hor-
mone Axis.” Cynthia Kenyon delivered a compelling
Dorcas Cummings Lecture on “The Deadly Sweet
Tooth” to Laboratory friends, neighbors, and Sympo-
sium participants in advance of the annual dinner parties.
Steven McKnight concluded the meeting with a master-
ful and thought-provoking summary. 
This Symposium was attended by almost 300 scien-
tists from more than 20 countries, and the program in-
cluded 62 invited presentations and 131 poster presen-
tations. To disseminate the latest results and discussion
of the Symposium to a wider audience, attendees were
able to share many of the Symposium talks with their colleagues who were unable to attend using
the Leading Strand video archive, and interviews by Emilie Marcus, Nicola McCarthy, Miranda
Robertson, Richard Sever, and Jan Witkowski with leading experts in the field were arranged during
the Symposium and distributed as free video from the Cold Spring Harbor Symposium interviews
website.
Funds to support this meeting were obtained from the National Institute of General Medical
Sciences, the Eunice Kennedy Shriver National Institute of Child Health and Human Development,
the National Institute of Diabetes and Digestive and Kidney Diseases, and the National Institute
on Aging, all branches of the National Institutes of Health; Amgen; and Seahorse Biosciences. Fi-
nancial support from the corporate sponsors of our meetings program is essential for these Symposia
to remain a success and we are most grateful for their continued support. 
B. Stillman, R. Evans, J. Goldstein
C. Kenyon, D. Mangelsdorf
PROGRAM
Introduction
B. Stillman, Cold Spring Harbor Laboratory
Fat, Exercise, and Rhythms
Chairperson: B. Kahn, Beth Israel Deaconess Medical Center,
Harvard Medical School, Boston, Massachusetts
Insulin Resistance and Sensitivity
Chairperson: J. Goldstein, University of Texas Southwestern
Medical Center, Dallas
Life Span, Aging, and Cancer
Chairperson: J. Brugge, Harvard Medical School, Boston,
Massachusetts
Regulation and Dysregulation of Metabolism
Chairperson: D. Sabatini, Whitehead Institute, Cambridge,
Massachusetts
Reginald B. Harris Lecture: Surviving Starvation: Essential
Role of the Ghrelin−Growth Hormone Axis
M.S. Brown and J.L. Goldstein, University of Texas
Southwestern Medical Center, Dallas
Signaling and Gene Regulation
Chairperson: D. Botstein, Princeton University, New Jersey
Environment and Sensing
Chairperson: K. Vousden, Beatson Institute for Cancer Research,
Glasgow, United Kingdom
Dorcas Cummings Lecture: The Deadly Sweet Tooth
C. Kenyon, University of California, San Francisco
Metabolic Reprogramming
Chairperson: J. Yuan, Harvard Medical School, Boston,
Massachusetts
Clocks and Intermediary Metabolism
Chairperson: S. McKnight, University of Texas Southwestern
Medical Center, Dallas
Metabolism and Cancer
Chairperson: E. White, Rutgers University, The Cancer Institute
of New Jersey, New Brunswick
Autophagy, Timing, and Small RNAs
Chairperson: T. Mak, Ontario Cancer Institute, Toronto, Canada
Summary
S. McKnight, University of Texas Southwestern Medical Center
N. Sonenberg, D. Spector
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MEETINGS
Systems Biology: Networks
March 22–26 154 Participants 
ARRANGED BY Patrick Aloy, Institute for Research in Biomedicine
Trey Ideker, University of California
Marian Walhout, University of Massachusetts Medical School
Biological interaction networks have been in the scientific
limelight for more than a decade. Increasingly, the concept
of network biology and its various applications are becom-
ing more commonplace in the community. Recent years
have seen networks move from pretty pictures with limited
application to solid concepts that are increasingly used to
understand the fundamentals of biology. These networks
span multiple scales of space and time, from networks of
interacting atoms, which influence protein structure, to
networks of genes and proteins with direct implication in
complex disease processes. As in previous editions, this
conference gathered together many of the leading minds
in the world of cell networks and systems biology to sum-
marize the most promising recent advances and discuss how future developments will unfold. 
This year, we had a 5-day program organized into four main topics: gene regulatory networks, pro-
tein−protein interaction networks, signaling networks, and, for the first time, single-cell networks. The
program opened with the first of three Keynote Addresses from Anne-Claude Gavin on the organiza-
tion of the cell machinery of the small bug Mycoplasma genitalium and the application of affinity pu-
rification methods to chart systematically novel types of biological networks between proteins and
small molecules, lipids, or metabolites. In the following days, the program continued with 20 invited
presentations and 28 short talks selected from posters, all of them of outstanding quality, covering
many aspects of network and systems biology, from the development of novel methodologies to chart
interactions with spatiotemporal resolution to several biomedical applications. However, arguably, the
best-received contributions, which also triggered very lively discussions, were those where the use of
network biology shed light on key biological processes or questioned classical textbook knowledge.
The accepted posters were divided into two groups and displayed on Wednesday and Thursday
evenings, in a very relaxed atmosphere during wine and cheese mixers. On Friday evening, we had the
pleasure to attend the second Keynote Address from James Collins, who gave us an exceptional overview
of the current state of synthetic biology and discussed the key role that networks have in the develop-
ment of models. The evening ended with the traditional lobster banquet and drinks. The full program
concluded on Saturday with our third Keynote delivered by James Fowler and with a session devoted
to signaling networks, with a particular emphasis on biomedical implications and applications, and a
lively discussion on the future of network biology and how the meeting should evolve to incorporate
novel developments.
This meeting was funded in part by the National Cancer Institute, a branch of the National In-
stitutes of Health.
T. Ideker, P. Aloy, M. Walhout
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PROGRAM
Keynote Address 
A.-C. Gavin, EMBL-Heidelberg
Gene Regulatory Networks I
Chairperson: B. van Steensel, Netherlands Cancer Institute,
Amsterdam
Single Cell Networks
Chairperson: A. Califano, Columbia University, New York
Protein−Protein Interaction Networks I
Chairperson: S. Michnick, Université de Montréal, Canada
Signaling Networks I
Chairperson: I. Stagljar, University of Toronto, Canada
A. Ergun, D. FurmanF. Holstege, O. Bahcall
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Gene Regulatory Networks II
Chairperson: T. Hughes, University of Toronto, Canada
Protein−Protein Interaction Networks II
Chairperson: A. Keating, Massachusetts Institute of Technology,
Cambridge
Keynote Address
J. Collins, Boston University, Massachusetts
Signaling Networks II
Chairperson: C. Myers, University of Minnesota, Minneapolis
Keynote Address
J. Fowler, University of California, San Diego
Computational Cell Biology
March 29–April 1 111 Participants
ARRANGED BY Galit Lahav, Harvard Medical School
Leslie Loew, University of Connecticut Health Center 
Wallace Marshall, University of California, San Francisco
John Tyson, Virginia Polytechnic Institute and State University
The year 2011 was an exciting one for this meeting. The successful format of previous CSHL meetings
was maintained, and three new sessions were added. Each session was chaired by an established leader
in the field who gave a talk, followed by shorter talks chosen from abstracts. All chairs were actively
involved in nominating abstracts for oral presentations. Many
talks combined both experimental and computational work,
showing the power and synergy between the two approaches and
providing evidence that the field is going in the right direction.
The quality of the poster session was also very high. 
The meeting opened with a Keynote Address by Tobias
Meyer, who talked about the use of single-cell analysis and
mathematical models to understand complex signaling systems
such as chemotaxis and collective cell migration. His talk was
followed by a new session—Beyond Imaging: Modeling and In-
ference from Microscopy Data—chaired by G. Danuser, who
presented a unique approach for studying signal transductions
through measurements of cell fluctuations in basal conditions
and showed how it can shed light on even well-studied systems
such as cytoskeleton regulation. D. Lauffenberger opened the
second day with an exciting talk about the use of multivariant computational modeling to extract
tissue level variation. The second session that morning was also new for this meeting—Noise and
Homeostasis, chaired by J. Hasty, who presented new ideas on how to build genetic circuits to un-
derstand homeostatic control in cells under both static and oscillatory modes. Each of these sessions
was followed by a number of short talks chosen from abstracts. 
Denis Bray gave an inspirational second Keynote Address about the past and future of compu-
tational cell biology and the main challenges in the field. His talk was followed by a session on syn-
thetic biology, which was again new for this meeting. It was chaired by P. Silver, who claimed that
“biology is the technology of this century” and gave a stimulating talk about design and use of living
devices to perform specific tasks such as carbon fixation. 
The third day, J. Lederer presented results on modeling of calcium signaling in cardiac cells. E.
Munro then addressed the interplay between small-scale biochemical activities of cytoskeletal pro-
teins and large-scale mechanical properties and motility of whole cells. In the afternoon, we were
treated to a session on New Tools and Software, chaired by I. Moraru. The afternoon poster session
covered a broad range of exciting topics, ranging from modeling bacterial motility to the develop-
ment of new computational architectures based on field programmable gate arrays for biological
network simulations. One important theme that emerged in several posters is the growing emphasis
on studying gene regulation in the frequency domain. 
The Modeling Cells in Cancer and Development session was met with significant enthusiasm
and contained several fascinating reports, including the use of extended time-lapse automated mi-
croscopy to quantitatively analyze quiescence in cells, the role of cell lineage and feedbacks in con-
G. Lahav, S. Rafelski
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trolling growth and rate of cell divisions of stem cells and tu-
mors, and the use of developing lung as a model to study the
connection between epithelial tube shape and cell division. 
A special feature of this meeting was a lively improvisational
workshop for scientists led by R. Holmes, who used improvisa-
tional theater exercises and games to allow people to get to know
one another and build a social context for conversations across
disciplines and academic positions. 
The meeting was supported by a grant from the National
Science Foundation (NSF) as well as additional contributions
from various companies and will continue on its biennial sched-
ule (March/April 2013). More money has to be applied for fur-
ther meetings. NSF representative Richard Rodewald showed
enthusiasm for continued support of the meetings and con-
firmed that the topic of this meeting is a priority for the NSF.
PROGRAM
Keynote Address: Local Signals at the Leading Edge Control Directional Migration
T. Meyer, Stanford University, California
Beyond Imaging: Modeling and Inference from Microscopy
Data
Chairperson: G. Danuser, Harvard Medical School, Boston,
Massachusetts
Signal Processing and Decision Making
Chairperson: D. Lauffenberger, Massachusetts Institute of Tech-
nology, Cambridge
Noise and Homeostasis
Chairperson: J. Hasty, University of California, San Diego
Keynote Address: Bacterial Chemotaxis and Beyond
D. Bray, University of Cambridge, United Kingdom
Synthetic Biology
Chairperson: P. Silver, Harvard Medical School, Boston, Massa-
chusetts
Cell Physiology
Chairperson:W. Jonathan Lederer, University of Maryland, Bal-
timore
Cell Mechanics: Shape, Motility, and Cytoskeleton
Chairperson: E. Munro, University of Chicago, Illinois
New Tools and Software
Chairperson: I. Moraru, University of Connecticut Health 
Center, Farmington
Improvisational Workshop for Scientists
Chairperson: R. Holmes, University of Connecticut Health 
Center, Farmington
Modeling Cells in Cancer and Development
Chairperson: V. Quaranta, Vanderbilt University, Nashville, Ten-
nessee
A. Shirinifard, E. Spanjaard
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F. Naef, J. Tyson
Stem Cell Engineering and Cell-Based Therapies
April 7–10 109 Participants
ARRANGED BY Rudolf Jaenisch,Whitehead Institute/Massachusetts Institute of Technology
Michel Sadelain,Memorial Sloan-Kettering Cancer Center
Amy Wagers, Harvard University
The derivation of human pluripotent stem cells, their differentia-
tion, and their genetic modification offer tantalizing prospects for
future cell therapies and regenerative medicine. This meeting fo-
cused on recent advances in our understanding of pluripotency
and cancer stem cells; cell differentiation into mesodermal, endo-
dermal, and neural fates; and emerging technologies for safe and
accurate genetic engineering of stem cells, myocardium, and T
lymphocytes. Most of the presented research focused on human
cells, albeit not exclusively, and included clinical trial presentations.
Irving Weissman opened the meeting by summarizing stem
cell hierarchy in the hematopoietic system and its relationship
to leukemia stem cells, extending the discussion to self-renewal
and survival strategies found in malignant cell types. Jacob Han-
nah reported on the conversion between epiblastic and ground-
state stem cells. Konrad Hochedlinger discussed the biology of Sox2 in normal cells, tumors, and
somatic cell reprogramming.
G. Keller explained how early in vitro patterning conditions determine cell fate decisions between
mesodermal lineages, and H. Mikkola pinpointed the interplay between hematopoietic and myo-
cardial fates controlled by Scl/Tal1. D. Srivastava and K. Chien went on to present alternate ap-
proaches for generating cardiomyocytes, based on either trans-differentiation or directed differenti-
ation from newly defined human progenitor cells.
I. Verma discussed the pros and cons of in vivo gene therapy versus potential stem-cell-based ap-
proaches for the treatment of liver diseases, a theme later addressed by D. Williams, who discussed the
regulatory hurdles one must overcome to translate novel stem cell therapies based on his experience with
severe combined immunodeficiency. F.H. Gage discussed the intriguing potential of induced pluripotent
R. Cottle, I. Fernandez V. Sumramnian, J. Muffat
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stem cells to tackle complex neurodevelopmental disorders and how
to possibly investigate behavioral anomalies, and other speakers dis-
cussed progress toward cell-based therapies for Parkinson’s disease. 
Emerging technologies for stem cell engineering were covered in
depth, with ample discussion of bacterial artificial chromosomes, tar-
geted nucleases including zinc finger nucleases, homing endonucle-
ases, and TALE nucleases, and adenoviral- and adeno-associated
virus-mediated homologous recombination. E. Papapetrou articu-
lated the concept of genomic safe harbors, and K. Chien and C. June
presented work on RNA transfection to engineer cells avoiding DNA
integration. Exciting clinical results utilizing genetically modified T
cells to treat HIV/AIDS or leukemia were also presented by C. June,
and R. Brentjens, and Y. Shi presented intriguing preliminary data
on the use of mesenchymal stem cells to alleviate hepatic cirrhosis.
This meeting was funded in part by Fluidigm and Molecular
Devices.
PROGRAM
A.R. Migliaccio, Y. Shi
D. Cohen, F. Stewart
Keynote Address: Normal and Neoplastic Stem Cells
I.L. Weissman, Stanford University, California
Pluripotent and Cancer Stem Cells
Chairperson: R. Jaenisch, Whitehead Institute/Massachusetts In-
stitute of Technololgy, Cambridge
Differentiation I: Mesodermal Lineages
Chairperson: A. Wagers, Harvard University, Cambridge, 
Massachusetts
Differentiation II: Endodermal Lineages
Chairperson: I. Verma, The Salk Institute, La Jolla, California
Stem Cell Engineering
Chairperson:M. Sadelain, Memorial Sloan-Kettering Cancer
Center, New York
Differentiation III: Neuroectodermal Lineages
Chairperson: P. Aubourg, INSERM and University Paris
Descartes, France
Keynote Address: Studying the Cellular and Molecular Basis
of Neurodevelopmental Disease with iPS Cells
F.H. Gage, The Salk Institute for Biological Studies, La Jolla,
California
Immune Engineering and Mesenchymal Stem Cells
Chairperson: C. June, University of Pennsylvania, Philadelphia
Special Lecture: Driving Pluripotent Stem Cells toward a Ven-
triculogenic Fate: Epigenetic and Modifed RNA Pathways
H. Mikkola, G. Keller
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Synapses: From Molecules to Circuits and Behavior
April 12–16 327 Participants
ARRANGED BY Hollis Cline, The Scripps Research Institute
Richard Huganir, Johns Hopkins University School of Medicine/HHMI
Thomas Sudhof, Stanford University School of Medicine/HHMI
The brain consists of a vast network of excitable cells (neurons) that
conduct electrical impulses and communicate with one another via
specialized junctions (synapses). Information is processed and stored
in the nervous system through patterns of electrical activity and via
changes in the strength and structure of synapses. All aspects of ner-
vous system function, including perception, cognition, and action,
depend on proper information processing by synapses. As master reg-
ulators of neuronal excitability and synaptic communication, ion
channels and receptors lie at the heart of neurobiology. In recent
years, the molecular and cell biological analysis of neuronal ion chan-
nels and receptors has revolutionized our understanding of the basic
mechanisms that control electrical signaling and synaptic function
in the nervous system. The convergence of advances in biochemistry,
molecular genetics, microscopic imaging, and electrophysiology has
made synaptic biology one of the most exciting and rapidly growing
fields in neuroscience. Increasingly, scientists are moving to in vivo systems to investigate the synaptic
basis of behavior in living animals via the genetic engineering of channels, receptors, and other
synaptic proteins in mice and other model organisms.
The entire field is poised for further breakthroughs that will not only illuminate basic workings
of the brain but also shed light on neurological and psychiatric diseases that stem from abnormal
neuronal excitability and synaptic dysfunction. Indeed, genetic association studies already point to
genes for synaptic structure and function as being involved in neuropsychiatric illnesses, in particular
autism. Future advances will be facilitated by cross-fertilization of ideas and technologies between
scientists studying channels, receptors, and synapses at all levels, in diverse organisms and using dif-
ferent methodological approaches. 
R. Kaletsky, J. Schulke J. Jakkamsetti, K. Spilker
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This fourth meeting was very successful, bringing together nearly 200 participants from the
United States, Europe, and Asia in an atmosphere of social and scientific exchange. Presenters dis-
cussed a wide range of topics emphasizing the basic physiology of synapses, neurons, and circuits as
well as pathophysiological aspects of nervous system functions. More than 50 attendees were selected
to give oral presentations of their work. The two poster sessions were sites of active discussion of
data and concepts. Outstanding plenary lectures were given by Reinhard Jahn and Mark Bear.
The overall response to the meeting was extremely positive, continuing to cement the reputation
of this Cold Spring Harbor conference in the field. Attendees enjoyed the breadth of subjects covered
and the chance to interact with investigators in related but distinct fields. The unusual opportunity
for junior investigators (including postdocs and students) to present their own work was welcomed. 
The meeting was supported with funds from the National Institute on Drug Abuse and the Na-
tional Institute of Mental Health, branches of the National Institutes of Health.
PROGRAM
W. Hung, M. Zhen
Synapse Development
Chairpersons: A. Majewska, University of Rochester, New York;
L. Mei, Medical College of Georgia, Augusta
Ion Channels, Receptors, and Transporters
Chairpersons: K. Roche, NINDS/National Institutes of Health,
Bethesda, Maryland; E. Perozo, University of Chicago, Illinois
Keynote Address: Exocytosis of Synaptic Vesicles: A
Molecular View 
R. Jahn, Max-Planck Institute for Biophysical Chemistry
Synaptic Function and Plasticity
Chairpersons: B. Sabatini, Harvard Medical School, Boston,
Massachusetts; P. Worley, Johns Hopkins University School of
Medicine, Baltimore, Maryland
Optogenetics: From Molecules to Behavior
Chairpersons: A. Bonci, National Institute on Drug Abuse,
Baltimore, Maryland; A. Kreitzer, J. David Gladstone
Institutes, University of California, San Francisco
Imaging Neuronal Circuits
Chairpersons: J. Wang, University of California, San Diego; C.
Gilbert, The Rockefeller University, New York
Keynote Address
M. Bear, HHMI/Massachusetts Institute of Technology
Neuronal and Circuit Plasticity
Chairpersons: S. du Lac, The Salk Institute, La Jolla, California;
M. Scanziani, University of California, San Diego
Behavioral Plasticity
Chairpersons: J. LeDoux, New York University, New York;
Y. Dudai, Weizmann Institute of Science, Rehovot, Israel
Diseases of Synapses and Circuits
Chairpersons: L. Monteggia, University of Texas Southwestern
Medical Center, Dallas; H. Song, Johns Hopkins University,
Baltimore, Maryland
O. Steward, A.M. Craig
288 Meetings
The Biology of Cancer: Microenvironment, Metastasis,
and Therapeutics
April 26–30 340 Participants
ARRANGED BY Senthil Muthuswamy, Ontario Cancer Institute
Kornelia Polyak, Dana Farber Cancer Institute
David Tuveson, Cambridge Research Institute
Cancer is now recognized as an abnormal organ where multiple signals and cell types cooperate during
cancer initiation and metastatic progression. Significant progress is being made on identifying and
characterizing different cell types, understanding the mechanisms by which these
cell types interact with one another, developing ways to image the changes in a
tumor, and exploring therapeutic opportunities that take into account the non-
cancer cells. Thus, there is an emergence of a need for an integrative approach for
controlling cancer. This meeting brought together biochemists studying cell me-
tabolism; physicists, developing ways to image cells; immunologists, developing
ways to harness the immune system; cell biologists, identifying new ways to stop
the growth of tumors; and mouse modelers, developing models to study human
cancers. Including Keynote Speaker Charles Sawyers, several prominent cancer re-
searchers who are pioneers and thought leaders in their fields presented and partic-
ipated in the meeting. In addition, we held two panel discussions including “Will
personalized cancer medicine (PCM) work? Will xenograft or GEM mouse models
help us address the issue,” and another on the topic of “Stemness versus plasticity:
What drives and maintains cancer?” Both panel discussions were provocative and an effective means
to communicate the expert views and elicit audience participation. The meeting, as a whole, was re-
ceived very well and the participants enjoyed both the diversity and the depth of topics covered.
This meeting was funded in part by the National Cancer Institute, a branch of the National In-
stitutes of Health; Astellas; Applied BioPhysics; and Molecular Devices.
PROGRAM
Integrated Discovery Platforms and Personalized Medicine
Chairperson: D. Epstein, OSI Pharmaceuticals, Farmingdale,
New York
Keynote Address
C. Sawyers, HHMI/Memorial Sloan-Kettering Cancer Center
Modeling Cancer in Mice: Xenograft and Genetically
Engineered Models
Chairpersons: S. Lowe, Cold Spring Harbor Laboratory, New
York; B. Neel, Ontario Cancer Institute, Toronto, Canada
Panel Discussion/Debate: Will Personalized Cancer Medicine
Work andWill Xenograft or GEM Mouse Models Help Us
Address the Issue?
Moderators: D. Tuveson; D. Epstein
Panelists: C. Sawyers, B. Neel, G. Evans, L. Chin, 
S. Lowe, J. Jonkers, T. Mak, L. Coussens
S. Muthuswamy
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Genetics and Biology of Tumor Cell Architecture
Chairpersons: I. Macara, McGill University, Montreal, Canada;
V. Vasioukhin, Fred Hutchinson Cancer Research Center,
Seattle, Washington
Tumor Heterogeneity and Cancer Cell Plasticity
Chairpersons: S. Morrison, HHMI/University of Michigan, Ann
Arbor; R. Weinberg, Whitehead Institute, Cambridge,
Massachusetts
Panel Discussion/Debate: Stemness Versus Plasticity: What
Drives and Maintains Cancer?
Moderators: N. Polyak, S. Muthuswamy
Panelists: S. Morrison, J. Dick, R. Weinberg, 
A. Ashworth, J. Watson
Tumor Immunology
Chairpersons:D. Fearon, University of Cambridge, United
Kingdom; P. Ohashi, Ontario Cancer Institute, Toronto, Canada
Tumor-Stroma Interactions: Inflammation
Chairpersons:M. Bissell, Lawrence Berkeley National
Laboratory, Berkeley, California; V. Weaver, University of
California, San Francisco
D. Feron, C. Caroll, K. Brindle, G. Evan
Cancer Cell Metabolism
Chairpersons: T. Mak, Ontario Cancer Institute, Toronto; C.V.
Dang, Johns Hopkins University School of Medicine,
Baltimore, Maryland
Molecular Imaging and Targeted Drug Delivery
Chairperson:M.C. Simon, University of Pennsylvania,
Philadelphia
Panel discussion
290 Meetings
Telomeres and Telomerase
May 3–7 307 Participants
ARRANGED BY Titia de Lange, The Rockefeller University
Roger Reddel, Children’s Medical Research Institute 
Dorothy Shippen, Texas A&M University
Virginia Zakian, Princeton University
This conference consisted of eight sessions of talks and two
poster sessions. As in 1999, 2001, 2003, 2005, 2007, and
2009, the format was to invite two chairs per session, who were
a mix of established scientists in the field and younger scientists
who had already made their mark by publishing as independ-
ent investigators. Many session chairs gave a scientific (12 min)
presentation. The rest of the presentations (also 12 min) were
chosen from submitted abstracts, allowing as many presenta-
tions as possible. These presentations were primarily given by
graduate students and postdoctoral fellows. Attendance ex-
ceeded 300 participants, a high fraction of whom presented
the 150 posters and 80 talks.
The talks and posters covered many aspects of telomere and
telomerase biology, including telomerase structure, enzymol-
ogy, and regulation; telomere length regulation; protection and processing of chromosome ends; the
consequences of telomere dysfunction; diseases associated with short telomeres; telomerase-independent
telomere maintenance; telomeric RNA; and effects of telomere dysfunction on mitochondria.
The scientific content was very high throughout the conference in both the talks and the posters.
A large body of unpublished data was presented and extensively discussed in an open fashion. Formal
and informal discussions were lively and informative. The conference was judged to be highly suc-
cessful based on verbal and email communications to the organizers. There is strong enthusiasm for
another meeting on the same topic in 2013.
This meeting was funded in part by the National Institute on Aging, a branch of the National
Institutes of Health.
D. Shippen, R. Reddel, T. de Lange, V. Zakian
T. Cech, B. Stillman N. Wesolowska, M. Mefford
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PROGRAM
Chairpersons: P. Baumann, Stowers Institute for Medical
Research, Kansas City, Missouri; C. Greider, Johns Hopkins
University, Baltimore, Maryland
Telomerase Biochemistry and Regulation
Chairpersons: E. Blackburn, University of California, San
Francisco; S. Artandi, Stanford University School of Medicine,
California
Telomeric Proteins
Chairpersons: V. Lundblad, Salk Institute for Biological Studies,
La Jolla, California; S. Smith, Skirball Institute, New York
University, New York
Consequences of Telomere Dysfunction
Chairpersons:M. Longhese, Università di Milano-Bicocca, Italy;
J. Shay, University of Texas Southwestern Medical Center,
Dallas
CST and the Telomeric Overhang
Chairpersons: T. Cech, HHMI/University of Colorado, Boulder;
F. Ishikawa, Kyoto University, Japan
ALT and Telomere Recombination
Chairpersons: T. Cech, HHMI/University of Colorado, Boulder;
F. Ishikawa, Kyoto University, Japan
Telomeres and Disease
Chairpersons: S. Chang, Yale University, New Haven,
Connecticut;M. Lei, University of Michigan, Ann Arbor
Telomere Proteins and Telomere Structure
Chairpersons: P. Lansdorp, BC Cancer Research Centre,
Vancouver, Canada; J. Lingner, École Polytechnique Fédérale 
de Lausanne, Switzerland
Telomeric RNA
Chairpersons: D. Wuttke, University of Colorado, Boulder; M.
Bessler, Children's Hospital of Philadelphia, Pennsylvania
Telomeres and Mitochondria
Chairpersons: D. Wuttke, University of Colorado, Boulder;M.
Bessler, Children’s Hospital of Philadelphia, Pennsylvania
J. Shay, M. Tarsounas
M. Rubtsova
292 Meetings
Honey Bee Genomics and Biology
May 8–10 105 Participants
ARRANGED BY Christina Grozinger, Penn State University
Uli Mueller, Saarland University
Robert Page, Arizona State University
This meeting was well attended by researchers representing 15
countries. The conference began with keynote presentations by
Hugh Robertson, Andrew Feinberg, and Martin Beye. These
speakers, respectively, discussed comparative genomic approaches
to the honey bee chemosensory system, including comparisons
to six newly sequenced ant genomes; the role of DNA methyla-
tion in regulating honey bee worker behavioral plasticity; and an
elegant molecular and evolutionary analysis of the sex determi-
nation pathway in honey bees. The scientific sessions and their
chairpersons are listed on the following page. The poster session
included 41 additional presentations of these topics as well. The
conference was preceded by a National Science Foundation
(NSF)-supported workshop on the “Development of Functional
Genetic Tools in Honey Bees,” which included several presenta-
tions and discussions of the utility of RNA interference (RNAi), cell culture, and other approaches to
dissecting the genetic underpinnings of behavior, physiology, and development in bees. During the
wrap-up session, there was considerable enthusiasm for the conference—several participants felt this
was the best conference that they had attended since the 2007 meeting—and plans were developed to
expand the conference to include other social insects with sequenced genomes.
This meeting was funded in part by the University of Illinois; the National Science Foundation;
and DNAFORM.
C. Grozinger, U. Mueller
G. Thompson, A. Camiletti A. Mushegian
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PROGRAM
Plenary Lectures
H.M. Robertson, University of Illinois, Urbana-Champaign
A.P. Feinberg, Johns Hopkins University School of Medicine
M. Beye, Heinrich-Heine University, Dusseldorf, Germany
Epigenetics and Genomics
Chairpersons: S. Yi, Georgia Institute of Technology, Atlanta;
G. Hunt, Purdue University, West Lafayette, Indiana
Neurobiology and Behavior
Chairpersons: D. Eisenhardt, Freie Universität Berlin, Germany;
R. Scheiner, Universität Potsdam, Germany
Physiology and Development
Chairpersons: G. Amdam, Arizona State University, Tempe; G.
Bloch, Hebrew University of Jerusalem, Israel
Immunity and Host−Parasite Interactions
Chairpersons: J. Evans, USDA-ARS, Beltsville, Maryland; E.
Genersch, Länderinstitut für Bienenkunde, Hohen Neuendorf,
Germany
Population Genetics, Evolutionary, and Comparative
Genomics
Chairpersons: C. Whitfield, University of Illinois, Urbana-
Champaign; J. Gadau, Arizona State University, Tempe
Plenary Lecture: The Blind Men and the Elephant: Genes,
Neurons, and the Brain
G.E. Robinson, University of Illinois, Urbana-Champaign
K. Thle, C. Narraway M. Beye, O. Rueppell
294 Meetings
The Biology of Genomes
May 10–14 550 Participants
ARRANGED BY Susan Celniker, Lawrence Berkeley National Laboratory
Andrew Clark, Cornell University
Joel Hirschhorn, The Broad Institute of Harvard/Massachusetts Institute of Technology
Chris Ponting, UK Medical Research Council, University of Oxford
This annual meeting marked the 24th annual gathering of genome scientists at Cold Spring Harbor
Laboratory. Just over 550 people from around the world attended the meeting, with more than 350
abstracts presented describing a broad array of topics relating
to the production, analysis, and interpretation of genomes
from diverse organisms. The meeting built on the remarkable
progress in the sequencing, functional annotation, and analy-
sis of genomes from many human individuals, “model organ-
isms,” other animals, plants, microbiomes, and prokaryotes.
Many investigators reported on their application of the most
recent generation of DNA sequencing technologies to deter-
mine sequence variants within populations that convey dif-
ferences in molecular function and organismal phenotype and
in susceptibility to disease, including cancer and complex dis-
ease. The new data are also providing important insights into
functional genomic elements and population structure for hu-
mans and other species. Several investigators reported impor-
tant differences in cell-type-specific transcriptome maps and epigenomic profiles. Newly sequenced
primate, lizard, and rodent genomes were also announced.
There were numerous reports on progress in using the sequencing technologies, with mounting
expectation for further advances as these continue to be applied widely. The Keynote Addresses
were delivered by Andrew Feinberg and Susan Lindquist. The ELSI (Ethical, Legal, and Social Im-
plications) panel was moderated by Pilar Ossorio, and the topical area of discussion was the “Ethical,
B. Korberg, B. Dorshorst
C. Ponting, J. Hirschhorn, S. Celniker, A. Clark
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Legal, and Social Issues in Genetics and Genomics Research with Indigenous People.”
This meeting was funded in part by the National Human Genome Research Institute, a branch
of the National Institutes of Health; Agilent Technologies; BioNanomatrix; Complete Genomics;
DNAFORM; EdgeBio; Epigentek; Gene Link; Illumina; Innopsys; Molecular Devices; NimbleGen;
and 454 Life Sciences, a Roche company.
PROGRAM
High-Throughput Genomics and Genetics
Chairpersons: K. Gunsalus, New York University; J. Lieb,
University of North Carolina, Chapel Hill
Genetics of Complex Traits
Chairpersons: C.A. Kong, deCODE Genetics, Reykjavik, Iceland;
P. Visscher, Queensland Institute of Medical Research,
Brisbane, Australia
Functional and Cancer Genomics
Chairpersons: J. Stamatoyannopoulos, University of Washington,
Seattle; G. Getz, Broad Institute of MIT and Harvard,
Cambridge, Massachusetts
Computational Genomics
Chairpersons: R. Bonneau, New York University; K. Makova,
Pennsylvania State University, University Park
ELSI Panel and Discussion: Ethical, Legal, and Social Issues
in Genetics and Genomics Research with Indigenous
People
Moderator: P.N. Ossorio, University of Wisconsin
Panelists: H. Soodyall, University of the Witwatersrand
M.L. Tano, International Institute for Indigenous
Research Management
L.T. Arbour, University of British Columbia
R.J. Whitener, University of Washington
Keynote Address
A. Feinberg, Johns Hopkins University School of Medicine
Evolutionary Genomics
Chairpersons: A. McLysaght, University of Dublin-Trinity
College, Ireland; D. Stern, HHMI/Princeton University, New
Jersey
Population Genomic Variation
Chairpersons: D. Reich, Harvard Medical School, Boston,
Massachusetts; G. Coop, University of California, Davis
Keynote Address
S. Lindquist, Whitehead Institute for Biomedical Research
Genetics and Genomics of Nonhuman Species
Chairpersons: B. Andrews, University of Toronto, Canada; Y.
Gilad, University of Chicago, Illinois
E. Nickerson, D. Ware F. Casals, D. Comas
D. Schwartz, R. Meyers
296 Meetings
The Ubiquitin Family
May 17−20 313 Participants
ARRANGED BY J. Wade Harper, Harvard Medical School
Ronald Hay, University of Dundee
Ron Kopito, Stanford University
Brenda Schulman, Memphis, Tennessee
This fifth meeting reprises the successful inauguration of this series in 2003. It focused on ubiquitin,
a group of structurally related “ubiquitin-like” proteins, and their roles in regulation of various cel-
lular processes. Major questions in the field include how specificity in ubiquitin and ubiquitin-like
protein conjugation reactions is maintained and the molecular mechanisms that are used to control
the specificity of ubiquitin chain linkages. These questions
are being elegantly addressed using structural biology, sophis-
ticated kinetic studies, systematic library screening, and pro-
teomics technologies by an increasing number of investigators
in the field. In addition, important advances continue to be
made in understanding how ubiquitin and its family mem-
bers contribute to the operation of diverse cellular pathways
and how these functions are perturbed in diseases ranging
from viral infections to cancers. Exciting progress is also being
made in the development of small-molecule inhibitors of a
range of enzymes involved in ubiquitin and ubiquitin-like
protein pathways.
The meeting attracted more than 310 scientists who en-
gaged in lively discussions concerning the roles of ubiquitin
in protein turnover; the structure and mechanism of a large multisubunit protease called the protea-
some, which catalyzes the degradation of ubiquitinated proteins; and the involvement of ubiquitin
quality control mechanisms used by cells to eliminate otherwise toxic misfolded proteins. There is
also a growing understanding of nonproteolytic roles of ubiquitin and ubiquitin-like proteins. A wide
array of experimental systems, including fungi, plants, and mammals, were used to probe functions
R. Hay, J.W. Harper, R. Kopito, B. Schulman
C. Dahlberg R. Hjerpe, D. Xirodimas, Y. Thomas R. Milkereit
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of ubiquitin and ubiquitin-like proteins in diverse physiological
processes ranging from control of stem cell division, DNA repair,
and pathways associated with diseases such as neurological disor-
ders and cancers. Other highlights of the meeting this year con-
cerned progress on the use of mass spectrometry to both define
the ubiquitin and SUMO-modified proteomes and understand
how these vary in cellular responses to different signals. Significant
advances were also reported in terms of the structures and mech-
anisms of enzymes that function in ubiquitin conjugation and de-
conjugation, with the emerging understanding of how enzyme
modification, such as by acetylation and phosphorylation, influ-
ences conjugation and deconjugation activities. Fascinating new
structural mechanisms were reported that explain how different
types of ubiquitin chains, and ubiquitin-like protein modifications—and their dynamic properties—
impart new functionalities to target proteins. Finally, mechanism and physiology converged in several
presentations describing exciting new ways in which small molecules can target the ubiquitin pro-
teasome at virtually every level of the pathway. In summary, this meeting has continued to be a uni-
fying forum that helps us to understand the regulatory mechanisms by which ubiquitin and
ubiquitin-like proteins function, their ever-growing roles in cellular physiology and disease, and the
development of therapeutics targeting the ubiquitin family.
This meeting was funded in part by the National Cancer Institute and the National Institute of
Child Health and Human Development, branches of the National Institutes of Health; Boston
Biochem; Millenium Pharmaceuticals; Novartis; and Ubiquigent.
PROGRAM
Conjugation, Removal, and Recognition of Ubiquitin and
Ubiquitin-Like Proteins I
Chairpersons: C. Lima, Memorial Sloan-Kettering Institute, New
York; R. Klevit, University of Washington, Seattle
Keynote Address
R. Deshaies, California Institute of Technology
Conjugation, Removal, and Recognition of Ubiquitin and
Ubiquitin-Like Proteins II
Chairpersons: N. Zheng, University of Washington, Seattle; D.
Morgan, University of California, San Francisco
Substrate Targeting and Degradation
Chairpersons: D. Finley, Harvard Medical School, Boston,
Massachusetts;M. Hochstrasser, Yale University, New Haven,
Connecticut
UBLs in Signaling I: Receptors, Plasma Membrane/
Endosomal Trafficking
Chairpersons: S. Urbe, University of Liverpool, United Kingdom;
A. Smogorzewska, The Rockefeller University, New York
Quality Control
Chairpersons: R. Hampton, University of California, San Diego;
I. Dikic, Goethe University Medical School, Frankfurt,
Germany
Nuclear Functions of UBLs
Chairpersons: C. Wolberger, HHMI/Johns Hopkins University
School of Medicine, Baltimore, Maryland; F. Melchior,
ZMBH, Heidelberg, Germany
Regulation of Intracellular Pathways
Chairpersons:M. Tyers, Mount Sinai Hospital, Toronto, Canada;
M. Rape, University of California, Berkeley
Keynote Address
V. Dixit, Genentech, Inc.
UBLs in Signaling II: Intracellular Communication and
Regulation of Organismal Biology
Chairpersons: A. Bonni, Harvard Medical School, Boston,
Massachusetts,M.G. Mascucci, Karolinska Institute,
Stockholm, Sweden
I.F. Melandri, J. Yin, K. Kluge
298 Meetings
Retroviruses
May 23−28 428 Participants
ARRANGED BY Henry Levin, National Institute of Health
Eric Poeschla,Mayo Clinic College of Medicine
This 36th annual meeting had all of the characteristics that have long made it the most important
one for retrovirologists: the presence of the field’s top scientists along with many students and young
investigators, presentations of cutting-edge unpublished data, exuberant poster sessions, and the
announcement of at least one landmark discovery.
The participants, representing 20 countries and six continents, gave 125 oral and 187 poster
presentations. Following tradition, the 10 oral and three poster sessions focused on unpublished,
basic research on retrovirus replication and on cellular factors exploited by viruses or deployed by
hosts in defense. Lentiviruses, most prominently HIV-1, took center stage, but all seven genera were
represented. Innate (intrinsic) immunity mechanisms, most notably restriction factors, were a strong
theme, and the revelation of a new one, SAMHD1, garnered particular attention.
N. Laguette and K. Hrecka presented the SAMHD1 data, thereby identifying the long-sought tar-
get of Vpx. These findings updated the theme featured on the meeting book cover: Sensors and Sensing
in Innate Antiviral Immunity. Vpx, present in some simian lentiviruses and HIV-2,
enables myeloid cell infection. Fittingly, the Andy Kaplan Prize was awarded to N.
Manel for his 2010 work showing that Vpx allows infection of human dendritic cells
(DCs), whereupon a DC sensor that triggers a type I interferon response is activated.
The current meeting papers showed that Vpx does this by loading the restriction factor
SAMHD1 onto the CRL4/DCAF1 E3 ubiquitin ligase, triggering its degradation.
A second focus of attention was XMRV, a g retrovirus recently implicated in a
human disease (prostate cancer) and syndrome (chronic fatigue). Here, though, a se-
ries of talks presented compelling evidence that XMRV is, in fact, not a human
pathogen. Rather, it arose quite recently, in the laboratory, by recombination between
two endogenous murine precursors when human prostate cancer cell xenografts were
passaged in mice (Cingöz, Hué, Paprotka). It is not detected in well-defined American
and German cohorts subjected to properly controlled, sensitive assays (Hohn, Ikeda).
Antibodies raised by injection of human-cell-produced virus into rabbits, previously
thought to be XMRV-specific and hence of use in probing human tissue for this
virus, were shown to instead cross-react with unknown human proteins (Ikeda). At
the close of the session, moderator G. Towers ably summarized the field and explained
how the totality of present evidence does not support involvement in human illness.
The poster sessions were intensively attended and a prize for the highest impact poster, the Dan
Wolf Memorial prize, followed. It was awarded to T. Schaller for work on a role for RanBP2/Nup358
in nuclear import of HIV-1.
The invited Keynote Speakers were Robert F. Siliciano, who spoke on “Quantitative analysis of
the efficacy of antiretroviral drugs and HIV eradication strategies,” which illuminated fundamental
and sometimes counterintuitive kinetic aspects of drug action and implications for proviral eradi-
cation, and Steven J. Elledge, who spoke on “Genetic approaches to virus function,” which consid-
ered the promise of recent genome-wide screens for understanding RNA viruses and extension of
such screens to identify antiviral drugs.
Some further highlights included multiple presentations on Tetherin, including a Tetherin knock-
out mouse and evidence for enhancement of cell-to-cell spread of FIV by Tetherin; demonstration
that cellular CBFβ is an HIV Vif cofactor required for APOBEC3G degradation; characterization
P. Jolicoeur
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of TREX1 exonuclease targeting cytosolic HIV-1 DNA; several genome and proteome screens that
examined host factors including those involved in interferon response gene repertoires; reports on
roles in uncoating and PIC trafficking for various nucleoporins, TNP03, CPSF6, and microtubule-
associated proteins; evidence for cold inactivation as a significant HIV-1 Env property; studies of
SUMO-interacting motifs in TRIM5α and sumoylation of integrase; characterization of the as-
sembly of a hexagonal TRIM5α lattice on HIV-1 capsid; determination of a role for reverse tran-
scription in facilitating uncoating; studies of assembly in macrophages and other cells; evidence that
HIV-1 can replicate in ferret cells if receptors are provided; and studies of base-excision repair pro-
teins in integration, regulation of foamy virus Gag nuclear localization, and protease activation by
viral RNA. Many other noteworthy advances are not listed here due to space constraints.
This meeting was funded in part by the National Institute of Allergy and Infectious Diseases, a
branch of the National Institutes of Health.
PROGRAM
Env in Entry, Assembly, and Cell-to-Cell Transmission
Chairpersons:M. Johnson, University of Missouri, Columbia; D.
McDonald, Case Western Reserve University, Cleveland, Ohio
To the Nucleus I: Uncoating, Trim, Vpx/Myeloid
Chairpersons: Z. Ambrose, University of Pittsburgh,
Pennsylvania; N. Yan, University of Texas Southwestern
Medical Center, Dallas
To the Nucleus II: Nuclear Import, Host Factors
Chairpersons: E. Bacharach, Tel Aviv University, Israel; C.
Aiken, Vanderbilt University, Nashville, Tennessee
Keynote Address: Quantitative Analysis of the Efficacy of
Antiretroviral Drugs and HIV Eradication Strategies
R. Siliciano, HHMI/Johns Hopkins University School of
Medicine
APOBEC, Genome/Proteome Screens
Chairpersons: R. Harris, University of Minnesota, Minneapolis;
A. Brass, Ragon Institute of MGH/MIT/Harvard University,
Charlestown, Massachusetts
Integration
Chairpersons:M. Kvaratskhelia, Ohio State University, Columbus;
G. Maertens, Imperial College London, United Kingdom
Reverse Transcriptase, RNA, and Encapsidation
Chairpersons: L. Parent, Pennsylvania State University College of
Medicine, Hershey; B. Wöhrl, University of Bayreuth, Germany
Assembly I
Chairpersons: D. Lindemann, Technische Universität Dresden,
Germany; E. Freed, NCI-Frederick, Maryland
Keynote Address: Genetics Approaches to Virus Function
S. Elledge, Harvard Medical School
Assembly II: Tetherin
Chairpersons: D. Evans, Harvard Medical School, Boston,
Massachusetts; A. Ono, University of Michigan Medical
School, Ann Arbor
XMRV, Transcription
Chairpersons: G. Towers, University College London, United
Kingdom; L. Weinberger, University of California, San Diego
Pathogenesis and More
Chairpersons: S. Barr, University of Western Ontario, London,
Canada; K. Strebel, NIAID/National Institutes of Health,
Bethesda
K. Strebel, H. Hofmann V. KewalRamani, S. Hughes
300 Meetings
Single-Cell Analysis
July 22−24 110 Participants
ARRANGED BY James Eberwine, University of Pennsylvania Medical School 
Xiaoliang Sunney Xie, Harvard University
The goal of this second workshop was to bring together investigators who work with single cells
using different experimental paradigms to discuss the progress that is being made. Nearly 112 sci-
entists convened for 31 talks and 22 posters. There was a panoply
of cell types discussed including bacteria, algae, plants, C. elegans,
and mammalian cells. The range of techniques used to investigate
single-cell biology that were discussed included single-cell dis-
section and transcriptomics, single-cell genomic DNA sequenc-
ing, proteomics, and metabolomics, all at single-cell resolution.
A common theme from many of the talks and posters was indi-
vidual cell-to-cell variability in mRNA abundances, DNA se-
quence, and protein expression. An important component of the
meeting was discussion of various imaging modalities, including
single-molecule-resolution optics using PALM and STORM
methodologies. The importance of, and necessity for, microfab-
rication and nanotechnology was highlighted in several talks.
With the large amount of data generated for any particular cell
and the large number of cells that constitute a multicellular organism, the discipline of computa-
tional biology as an organizing and analytical component of single-cell biology was featured in nearly
every presentation. The continued analysis of single-cell biology will undoubtedly lead to a better
understanding of disease states, better production of biofuels, and insight into evolutionary me-
chanics that is unachievable using pooled cells. 
This meeting was funded in part by Applied Biosystems, Fluidigm, Illumina, Molecular Devices,
Olympus, the University of Pennsylvania, and Carl Zeiss, Inc.
PROGRAM
Single-Cell Analyses: Genomes
Chairperson: J. Eberwine, University of Pennsylvania Medical
School, Philadelphia
Keynote Address
X. Zhuang, Harvard University
Single-Cell Analyses: Transcriptomics
Chairperson: X.S. Xie, Harvard University, Cambridge,
Massachusetts
J. Eberwine, X.S. Xie
Single-Cell Analyses: Proteomics
Chairperson: S. Fraser, California Institute of Technology,
Pasadena
Single-Cell Analyses: Imaging
Chairperson: J. Sweedler, University of Illinois, Urbana-Champaign
Single-Cell Analyses: Modeling
Chairperson: L. Cai, California Institute of Technology, Pasadena
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Yeast Cell Biology
August 16−20 219 Participants
ARRANGED BY Kerry Bloom, University of North Carolina, Chapel Hill
Martha Cyert, Stanford University
Lois Weisman, University of Michigan
This was the 14th biannual international meeting devoted to diverse aspects of cell biology in yeasts.
Studies of these simple eukaryotes continue to generate key insights into fundamental, conserved
aspects of cell function. The meeting highlighted the combined use of mathematical modeling and
quantitative imaging of fluorescently labeled proteins in live cells
to understand complex biological processes such as cytokinesis
and endocytosis. T. Pollard’s and R. Li’s labs (using S. pombe and
S. cerevisiae, respectively) are constructing detailed mechanistic
models that explain the dynamic behavior of actin and myosin
during the assembly and contraction of the cytokinetic ring.
Stunning progress in this area is a testament to the enduring
power of yeast as an experimental organism for cell biology.M.
Kaksonen’s lab used fluorescence cross-correlation spectroscopy
to measure precise protein concentrations and interactions in
vivo for key components of endocytosis. J. Skotheim, a mathe-
matician recently recruited to cell biology, used single-cell analy-
ses to quantitatively describe mating-factor-induced cell cycle
arrest. Studies such as these elucidate macroscopic cell behaviors
at a mechanistic level and are revealing that common regulatory
principles underlie diverse biological responses. Quantitative live-cell imaging at a systems level was
discussed by B. Andrews, who determined a “subcellular flux network” for ~3000 green fluorescent
protein (GFP)-labeled yeast proteins that describes how each protein changes in abundance or lo-
calization under several different conditions and offers biologists an integrated, dynamic view of
protein function within the cell.
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M. Cyert, K. Bloom, L. Weisman
J. Johnson, M. Lord B. Andre, P. Lungdahl
Regulation of protein function by posttranslational modifications was a major topic at the con-
ference. The Gasser lab showed that protein sumoylation causes tethering of telomeres to the nuclear
envelope and that short telomeres dissociate from the nuclear envelope when they are elongating.
Thus, telomere anchoring, mediated by sumoylation, may regulate telomerase activity, and similar
observations in C. elegans suggest that this mechanism is conserved. The growing role of acetylation
in modifying protein function was highlighted (Baetz and Strich labs) and insights into the recog-
nition of protein targets by kinases and phosphatases were presented (Pryciak, Weiss, Turk, Stuart,
and Cyert labs).
Other topics included chromosome instability and its consequences in yeast and cancer cells. In-
hibition of Hsp90 increases chromosome loss (R. Li’s lab), and the resulting aneuploidy facilitates
the rapid acquisition of novel traits, including resistance to several drugs. Aneuploid yeast strains
also have high levels of genomic instability due to increased chromosome loss and recombination
and impaired DNA-damage repair (Amon lab). Thus, by analogy, changes in the karyotype of
human cells may profoundly influence the evolution of cancer cells. Mutations in the yeast mRNA
processing machinery also result in chromosome instability and DNA damage that may be caused
by persistence of RNA:DNA hybrids (Hieter lab). These studies suggest new insights into human
leukemias, in which similar mutations occur. 
This intensely enjoyable conference united scientists from disparate areas of cell biology who
share common organism-specific approaches. As always, this cross-fertilization revealed surprising
new connections between well-studied processes and will stimulate the next generation of advances
in cell biology.
This meeting was funded in part by the National Institute of General Medical Sciences, a branch
of the National Institutes of Health; the National Science Foundation; CellASIC; and Molecular
Devices.
PROGRAM
Membranes and Lipids
Chairpersons: M. Hochstrasser, Yale University, New Haven,
Connecticut; A. Spang, Max-Planck Society, Tübingen,
Germany
Chromosomes and Mitosis
Chairpersons: P. Hieter, University of British Columbia,
Vancouver; A. Amon, Massachusetts Institute of Technology,
Cambridge
Cell Cycle and Growth
Chairpersons: D. Botstein, Princeton University, New Jersey;
D. Pellman, Dana-Farber Cancer Institute, Boston,
Massachusetts
Membrane Trafficking
Chairpersons: Y. Ohsumi, Okazaki National Research Institutes,
Japan;M. Munson, University of Massachusetts Medical
School, Worcester
Informal Discussion on Funding for Yeast Research
Led by S. Sazar, National Science Foundation
Nucleus and Cytoplasmic Organelles
Chairpersons: S. Wente, Vanderbilt University Medical Center,
Nashville, Tennessee; K. Cunningham, Johns Hopkins
University, Baltimore, Maryland
Signaling Networks
Chairpersons: J. Weissman, HHMI/University of California, 
San Francisco; R. Li, Stowers Institute for Medical Research,
Kansas City, Missouri
Genomes and Gene Expression
Chairpersons: B. Andrews, University of Toronto, Canada;
J. Haber, Brandeis University, Waltham, Massachusetts
Polarity and Cytokinesis
Chairpersons: T. Pollard, Yale University, New Haven,
Connecticut; F. Verde, University of Miami, Florida
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Eukaroytic mRNA Processing
August 23–27 371 Participants
ARRANGED BY Tom Blumenthal, University of Colorado
Kristen Lynch, University of Pennsylvania
Karla Neugebauer,MPI-CBG
This eighth meeting presented and discussed recent developments in mRNA metabolism. As in the
past, the regulation of alternative pre-mRNA splicing was a focus, as was the mechanism of spliceo-
some assembly and catalysis. Additional areas included mRNA
3¢-end formation, mRNA decay, mRNA trafficking, and the
coupling of RNA processing to transcription and export. Ad-
ditional sessions covered genome-wide approaches to under-
standing RNA-mediated gene regulation and, for the first
time, the control of microRNA (miRNA) biogenesis and
mechanisms of RNA interference (RNAi).
In the splicing mechanisms session, several talks described
new structural data on RNA recognition within the spliceo-
some or the overall conformation of the catalytic complex.
Other results provided important new results on the role of
metal ions in catalysis and the function of DEAH-box heli-
cases in driving conformational changes during the catalytic
cycle. The recognition of the branch point by the U2 small
nuclear ribonucleoprotein (snRNP) and of exon sequences
adjacent to the 5¢ splice site was also described. Finally, a talk presented new examples of trans-splic-
ing in Drosophila as identified by new deep-sequencing methods.
Several presentations on 3¢-end formation focused on links between polyadenylation and tran-
scription and quality control. Progress was described in characterizing the processing of the 3¢ ends
of histone mRNAs. Other talks examined the biogenesis and function of miRNAs. The regulation
of miRNAs by poly(ADP-ribose) and by cell-specific cofactors was described. Effects on miRNA
processing in the nucleus by the spliceosome and heterogeneous nuclear RNPs (hnRNPs) were pre-
sented, as were the roles of partner proteins in determining the specificity of Dicer processing in
the cytoplasm.
Talks in the RNA movement and RNA/protein interactions session examined a variety of impor-
tant RNA-binding factors. Presentations described the different modes of recognition used to bind
RNA. The coupling of export factor assembly to the disassembly of the 3¢ processing complex and
the coupling of poly(A)-binding and 3¢-untranslated region (3¢ UTR)-binding factors to RNA ex-
port were discussed, as were mechanisms for the nuclear retention of RNA. The targeting and lo-
calization of mRNAs in the Drosophila embryo and to the endoplasmic reticulum (ER) and
mitochondria, and the role of splicing in these processes, were also examined. 
In splicing regulation, there has been significant progress in deciphering the detailed regulatory
mechanisms as well as the biological roles of particular factors and splice variants. Biochemical and
yeast genetic approaches have identified specific points in the spliceosome assembly pathway af-
fected by particular factors. Multiple talks presented new data on the autoregulation of splicing
factors and the regulation of splicing during cellular differentiation. Another active area was the
examination of roles for splicing regulation in human disease and the development of splicing-tar-
geted therapeutics.
K. Lynch, K. Neugebauer, T. Blumenthal
304
In the RNA decay session, the nonsense-mediated decay pathway was a particular focus including
work on its global regulation, its coupling to translation and to splicing via the exon junction com-
plex, and the remodeling or recycling of NMD factors during decay. New studies of nuclear and
viral pathways of mRNA decay were also presented, covering both the known nuclear exosome path-
way and a new pathway.
The major theme in the session on genome-wide approaches was regulatory networks. Newly
refined array methods, new high-density sequencing methods, and the wider dissemination of
methods for measuring genome-wide RNA binding by proteins were all evident. Combining these
methods with RNAi approaches is allowing networks of processing events controlled by particular
proteins or during particular developmental or physiological events to be assessed. Computational
approaches to predicting regulation were also presented.
This meeting was funded in part by the National Cancer Institute and the National Institute of
Child Health and Human Development, branches of the National Institutes of Health, and by the
National Science Foundation. The Laboratory would in addition like to thank the RNA Society for
its support of this meeting. 
PROGRAM
Global Analysis: RNA Processing/Global Analysis:
RNPomics
Chairpersons: L. Chasin, Columbia University, New York; J.
Sanford, University of California, Santa Cruz
Spliceosome Assembly/Spliceosome Function
Chairpersons: J. Staley, University of Chicago, Illinois; D. Brow,
University of Wisconsin, Madison
3¢-End Processing/Translation
Chairpersons: J. Wilusz, Colorado State University, Fort Collins;
G. Carmichael, University of Connecticut Health Center,
Farmington
RNAi and miRNAs/ncRNAs
Chairpersons: A. Pasquinelli, University of California, San
Diego; N. Kim, Seoul National University, Korea
Molecular Interactions during RNA Processing/Regulation
of RNA Processing
Chairpersons: C. Kielkopf, University of Rochester, New York;
K. Hertel, University of California, Irvine
Cotranscriptional Pre-mRNA Processing I/
Cotranscriptional Pre-mRNA Processing II
Chairpersons: D. Bentley, University of Colorado School of Medicine,
Aurora; J. Beggs, University of Edinburgh, United Kingdom
Nuclear RNA Degradation/Cytoplasmic RNA Surveillance
and Localization
Chairpersons: D. Tollervey, University of Edinburgh, United
Kingdom; A. Ephrussi, EMBL, Heidelberg, Germany
Splicing Regulatory Mechanisms/Biological Function
of RNA Processing
Chairpersons: C. Smith, University of Cambridge, United King-
dom; T. Cooper, Baylor College of Medicine, Houston, Texas
E. Lund, J. Caceres
M. Umemura K. Hartmuth
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Mechanisms of Eukaryotic Transcription
Aug. 30–Sept. 3 386 Participants
ARRANGED BY Stephen Buratowski, Harvard Medical School
Steven Hahn, Fred Hutchinson Cancer Research Center
Katherine Jones, The Salk Institute for Biological Studies
Regulation of gene transcription has a central role in the growth and development of eukaryotic
organisms. Transcriptional responses occur as a consequence of cell signaling, environmental stresses,
and developmental cues. The field of transcription encompasses a
broad range of study from structural biology to developmental bi-
ology. This 12th meeting appropriately covered many aspects of
the field and brought together a diverse group of scientists. It con-
sisted of eight plenary sessions, three poster sessions, and two break-
out sessions. 
The meeting began with a new session—“Transcription control
of cell fate”—that described mechanisms controlling stem cell iden-
tity and key developmental decisions. Described in other sessions
were studies at the forefront of understanding the mechanisms used
for transcription initiation by all three eukaryotic and the archaeal
RNA polymerases; mechanisms regulating the targeting and activity
of factors, in addition to systems biology approaches for understand-
ing how gene networks are coordinated to direct complex biological
processes; and new studies on the many fascinating ways in which modulation of chromatin can con-
tribute to gene control. Another session showed the importance of regulating polymerase elongation
and the many mechanisms that contribute to this process, and yet another presented the latest findings
on conserved coactivator complexes including their structure, function, and interaction with activation
domains. The elongation theme continued and was primarily focused on cotranscriptional events,
such as nucleosome modification and remodeling, that are linked to elongation. A final session de-
scribed transcription defects directly causing human disease, drugs targeting key transcription com-
ponents, and the role of noncoding RNAs that regulate transcription in unexpected ways. 
S. Buratowski, S. Hahn, K. Jones
A. Bataile, C. Jeronimo, F. Robert E. Rosonina
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Interspersed with these oral presentations were the three poster sessions, where a wide variety of
the latest transcriptional research was presented. New for the meeting was the inclusion of two
breakout sessions that were specifically requested by meeting participants as a way to supplement
the oral and poster sessions and to give an opportunity for junior scientists to present their work.
From discussions with attendees of these sessions, they were a great success. It is hoped that they
will be continued at the next meeting on topics yet to be determined. This meeting was very well
received by the participants and will occur again in 2013. 
The meeting was funded in part by a grant from the National Science Foundation.
PROGRAM
Transcription Control of Cell Fate
Chairperson: B. Cairns, University of Utah, Salt Lake City
Initiation and Promoter Escape
Chairperson: J. Goodrich, University of Colorado, Boulder
Regulation of Transcription Factor Activity and Specificity
Chairperson:M. Levine, University of California, Berkeley
Chromatin
Chairperson: C. Wolberger, HHMI/Johns Hopkins University
School of Medicine, Baltimore, Maryland
Elongation Mechanisms
Chairperson: K. Luger, HHMI/Colorado State University, Fort
Collins
Coactivators
Chairperson:M. Timmers, UMC Utrecht, the Netherlands
Elongation and Coupled Events
Chairperson: I. Grummt, German Cancer Research Center,
Heidelberg
Metabolism and Disease/Noncoding RNAs
Chairperson: S. Mango, Harvard University, 
Cambridge, Massachusetts
A. Cheung, F. MartinezD. Singer, C.M. Chiang
M. Levine, K. Struhl
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Eukaryotic DNA Replication and Genome Maintenance
September 6–10 335 Participants
ARRANGED BY Stephen Bell, HHMI/Massachusetts Institute of Technology
Joachim Li, University of California, San Francisco
Johannes Walter, Harvard Medical School
This 12th biannual meeting reflected the remarkable progress that has been made in the past 2
years and served an important role in bringing together researchers studying eukaryotic DNA repli-
cation, repair, and their cell cycle control. As in the past, the
meeting brought together an international cadre of researchers
who presented exciting new advances upholding the tradition
that this is the most important meeting in the DNA replication
field. A total of 331 investigators participated in the 10 scientific
sessions, with 262 platform and poster presentations. The eight
platform sessions were marked by spirited and enthusiastic ex-
changes of new results. The poster sessions were of very high
quality and were overcrowded with interested attendees delving
into the presented findings.
Sessions at the meeting included novel approaches to under-
standing DNA replication; origin selection and helicase loading;
responses to replication stress and damaged DNA; origin activa-
tion and replication timing; chromatin, cancer, and development;
replisome function; and cell cycle control and connections. The presentations illustrated the growing
power of biochemical reconstitution and single-molecule analysis in dissecting the mechanisms of
cellular DNA replication initiation and repair. Genome-wide and replication-fork-specific assays
showed new promise for understanding the mysterious determinants for origin selection in metazoan
cells. The important influences of replication protein abundance, chromosome folding, chromatin
structure in the determination of origin activation, and replication fork function were reported. In
addition, the presentations illustrated our increasing understanding of the close coordination be-
tween the DNA repair and cell cycle checkpoints and DNA replication initiation and elongation. 
Essential funding for the meeting was provided by the National Cancer Institute, a branch of
the National Institutes of Health, and the National Science Foundation.
S. Bell, J. Walter, J. Li
E. Leo A.M. Mass, R. Muller, K. Gilljam, J. Kusic
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PROGRAM
New Aproaches and Views of Replication
Chairpersons: D. MacAlpine, Duke University Medical Center,
Durham, North Carolina; D. Sherratt, University of Oxford,
United Kingdom
Origin Selection and Pre-RC Assembly
Chairpersons: J. Blow, University of Dundee, United Kingdom;
M. Debatisse, Institut Curie-CNRS-UPMC, Paris, France
Response to Replication Stress and Damage
Chairpersons: K. Cimprich, Stanford University, California; A.
Carr, University of Sussex, Brighton, United Kingdom
Origin Activation and Timing
Chairpersons: J. Berger, University of California, Berkeley; J.
Diffley, Cancer Research UK London Research Institute,
South Mimms
R. Müller
D. Sherratt, J. Blow A. Schwacha, G. Kapler
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Chromatin, Cancer, and Development
Chairpersons: N. Francis, Harvard University, Cambridge,
Massachusetts;M. Jasin, Memorial Sloan-Kettering Cancer
Center, New York
Replisome Activities and Functions
Chairpersons: M. Botchan, University of California, Berkeley; E.
Fanning, Vanderbilt University, Nashville, Tennessee
Cell Cycle Control and Connections
Chairpersons: J. Cook, University of North Carolina, Chapel
Hill; B. Stillman, Cold Spring Harbor Laboratory
Postreplicative Repair and Lesion Bypass
Chairpersons: H. Ulrich, Cancer Research UK London Research
Institute, South Mimms; G. Walker, Massachusetts Institute
of Technology, Cambridge
Microbial Pathogenesis and Host Response
September 13−17 277 Participants
ARRANGED BY Andrew Camilli, Tufts University School of Medicine
Brendan Cormack, Johns Hopkins University School of Medicine
Lalita Ramakrishnan, University of Washington
Despite advances in modern health care, infectious diseases continue to be major causes of human
morbidity and mortality. The evolution of microbial pathogens with humans has resulted in complex
interactions that impact the struggle between the infectious invader and the susceptible host. In-
creased understanding of these interactions with the goal of developing new therapeutics and pre-
ventive strategies requires collaborative and interdisciplinary scientific approaches. This meeting
brought together a diverse group of international scientists who approach the study of bacterial and
fungal pathogens from a broad range of perspectives. Investigators from the disciplines of molecular
microbiology, eukaryotic cell biology, immunology, and genomics, representing academia, industry,
and the public health sector, shared recent findings concerning microbial and host aspects of infec-
tious diseases.
The meeting focused on bacterial and fungal pathogens and the host response and defense to
these invading microbes. Oral sessions were topic-based and included studies of multiple and diverse
organisms. Areas covered included the microbial−host interaction surface, regulation of virulence
gene expression, microbial metabolism and physiology, innate immune signaling, immune evasion
strategies, evolution of virulence, evolution of the host immune response, and microbial genomics.
Speakers for each session were a mixture of established leaders in the field and young investigators;
40% of the speakers, including postdoctoral fellows and graduate students, were chosen from sub-
mitted abstracts. Dr. Ralph Isberg, an internationally recognized leader in microbial pathogenesis,
presented the Keynote Address on how adaptation of Legionella pneumophila to survival in diverse
amoebae has shaped the evolution of the pathogen and trained it to survive in alveolar macrophages
in humans. 
The informal atmosphere combined with the broad perspectives of the meeting participants re-
sulted in a free flow of novel and refreshing ideas on pathogenesis, with the atmosphere of a small
meeting. Active questioning and discussion, which followed all oral presentations, was also evident
A. Huerta-Saquero, S. Hernandez, J. Santander, I. Ferlenghi O. Shannon
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throughout the poster sessions and continued during a wine and cheese reception and other social
gatherings. We strongly encouraged submission of abstracts by junior researchers in the field, and
many young investigators were in attendance. Some of these interactions have already produced
fruitful scientific collaborations.
This meeting was partially supported by funds from the National Institute of Allergy and Infec-
tious Diseases, a branch of the National Institutes of Health.
PROGRAM
Microbial Structures
Chairperson: S. Hultgren, Washington University School of
Medicine, St. Louis, Missouri
Virulence Regulation
Chairperson: W. Bishai, Johns Hopkins University School of
Medicine/K-RITH, Baltimore, Maryland
Signaling: Host and Microbe
Chairperson: T. Koehler, University of Texas, Houston Medical
School
Intracellular Lifestyles
Chairperson: K. Kuchler, Medical University Vienna, Austria
The Cell Envelope and Beyond
Chairperson: T. Silhavy, Princeton University, New Jersey
Immunity
Chairperson: D. Littman, HHMI/New York University School of
Medicine
Keynote Address: Legionella, a Pathogen and a Generalist
R.R. Isberg, Tufts University School of Medicine
Evolution: Host and Pathogen
Chairperson: J. Ernst, New York University School of Medicine
T. Costa, P. Paracuellos A. Camilli, P. Sundstrom, J. Slauch
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Stem Cell Biology
September 20−24 190 Participants
ARRANGED BY Konrad Hochedlinger,Massachusetts General Hospital 
Brigid Hogan, Duke University Medical Center
Allan Spradling, HHMI/Carnegie Institution
This second meeting followed the same basic format that distinguished it 2 years ago. Structurally,
this involved relatively short talks of 20−25 minutes in length, followed by at least 5 minutes of
discussion. Often, the discussion was very lively and lasted 10
minutes or more. Nonetheless, the sessions stayed largely on time
because the number of speakers was limited to about six. The
meeting differed from many others on this topic in a number of
ways. The focus was very much on the molecular and develop-
mental biology of tissue stem cells in vivo and the molecular con-
trols of cell differentiation and dedifferentiation. In contrast,
there were few descriptive presentations that had not yet yielded
mechanistic insights. In addition, insights from a wide range of
relevant systems were presented, including three talks on plants
and one on lamprey development. The best-characterized tissue
stem cells in a range of organisms were discussed from the per-
spectives of their molecular regulation and cell biological mech-
anisms. Key subject areas of the meeting were the stem cell niche,
asymmetric cell division, stem cell differentiation, reversion to the stem cell state, tissue repair, re-
generation and reprogramming, epigenetics of stem cells, and pluripotency. Talks contained a sub-
stantial fraction of unpublished material, and several findings were presented for the first time. The
novelty of the work was reflected by the increased attendance by journal representatives. The Keynote
Address by Elaine Fuchs was a major highlight and was discussed actively for more than 25 minutes,
before participants were asked to clear the hall. Informal feedback suggested that the participants
were extremely positive about the value of the experience. Speaker comments included “I have been
A. Spradling, B. Hogan, K. Hochedlinger
Poster session
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learning a lot,” “this is the best meeting I have been to all year,” and “I’m so glad that you included
talks from such a diversity of systems.” While echoing these sentiments, students and postdocs were
also extremely pleased by the accessibility of speakers and the depth with which they were able to
discuss relevant issues both after the talks and during the two poster sessions. “I learned more from
the discussion than from the talks.” “I just spent 30 minutes discussing my project with Elaine
Fuchs!” 
This meeting was funded in part by Fluidigm and Molecular Devices.
Y. Fung, T. Yamaguchi
PROGRAM
Stem Cell Niches I
Chairperson: A. Spradling, HHMI/Carnegie Institution,
Baltimore, Maryland
Asymmetric Cell Division
Chairperson: A. Brand, University of Cambridge, United
Kingdom
Stem Cell Niches II
Chairperson: B. Ohlstein, Columbia University Medical Center,
New York
Transcriptional and Epigenetic Control of Stem Cell
Differentiation and Reversion
Chairperson: K. Hochedlinger, Harvard Medical School, Boston,
Massachusetts
Tissue Repair, Regeneration, and Reprogramming
Chairperson: B. Hogan, Duke University Medical Center,
Durham, North Carolina
Metabolism and Noncoding RNAs in Stem Cell 
Regulation
Chairperson: E. Fuchs, HHMI/University of California, San
Francisco
Keynote Address: Skin Stem Cells in Normal Homeostasis,
Wound Repair, and Cancer
E. Fuchs, HHMI/The Rockefeller University, New York
Pluripotency and Epigenetics
Chairperson: Y. Yamashita, University of Michigan, Ann Arbor
Q. Lu, J. Wen, M. Qiu Y. Yamashita
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Personal Genomes
Sept. 30–Oct. 2 180 Participants
ARRANGED BY Paul Flicek, European Bioinformatics Institute
James Lupski, Baylor College of Medicine
Elaine Mardis,Washington University School of Medicine
This fourth meeting focused on clinical genome sequencing, the genetic basis of phenotypes, and
return of results in the context of continued advances in DNA sequencing technology and its ap-
plication to clinical medicine. The meeting featured a combination of talks and posters and included
three specifically chosen Keynote talks and an Ethics Panel discussion that directly addressed the
issue of return of results from personal genome studies and incidental findings. The critical success
and timeliness of the meeting are indicative of the fact that the field is changing and the participation
of an increased number of attendees from clinical disciplines is apparent. To address these changes
and the new-found audience, the collective decision was taken to attempt to merge this meeting
with the Pharmogenomics and Personalized Medicine meeting that took place during the same
weekend in Hinxton, United Kingdom, and hold the combined meeting under the title “Personal
Genomes and Medical Genomics.”
This meeting was funded in part by BioNanoMatrix, Complete Genomics, Illumina, and Oxford
Nanopore Technologies.
PROGRAM
Personal Cancer Genomics
Chairpersons: E. Mardis, Washington University School of
Medicine, St. Louis, Missouri; J. Ivanovich, Washington
University, St. Louis, Missouri
Keynote Address: Cancer Whole-Genome Analysis: Discovery
and Clinical Application
E. Mardis, Washington University School of Medicine, St. Louis,
Missouri
Medically Actionable Genomics
Chairpersons: A. Butte, Stanford University School of Medicine,
California; D. Dimmock, Medical College of Wisconsin,
Milwaukee
Personal Genomes
Chairpersons: K. Burns, Johns Hopkins University School of
Medicine, Baltimore, Maryland;M. Kayser, Erasmus MC
University Medical Center, Rotterdam, The Netherlands
F. De la Vega, T. Smith R. Gibbs, J. O’DanielT. Hambuch, G. Lyon
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Keynote Address
D. Valle, Johns Hopkins University School of Medicine
Ethics Panel
Moderator: J. Lupski, Baylor College of Medicine, Houston, 
Texas
Panelists: E. Clayton, Vanderbilt University; L. Dressler, 
University of North Carolina, Chapel Hill; B. 
Eliasen, Ministry of Health, Faroe Islands; H. 
Tabor, University of Washington, Seattle
Panel Discussion: Return of Results
Rare Diseases?
Chairpersons: S. Kingsmore, Children’s Mercy Hospital, Kansas
City, Missouri; P. Flicek, European Bioinformatics Institute,
Hinxton, United Kingdom
Keynote Address: Signs of Change: Personal Genomes as a
Commodity
R.A. Gibbs, Baylor College of Medicine Human Genome
Sequencing Center
Clinical Implementation of Personal Genomics
Chairpersons:M. Boguski, Harvard Medical School, Boston,
Massachusetts; H. Valantine, Stanford University, California
D. Mittleman, M. Ronaghi M. Skipper, D. Bentley
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Neurobiology of Drosophila
October 3–7 481 Participants
ARRANGED BY Nancy Bonini, HHMI/University of Pennsylvania
Claude Desplan, New York University
As in previous years, the goal of this meeting was to foster communication of ideas, techniques, and
new discoveries within the field of Drosophila neurobiology. The meeting was structured with platform
and poster presentations by a variety of researchers including graduate students,
postdoctoral fellows, and junior and senior faculty. The topics for the platform
sessions were chosen to reflect the areas of Drosophila neurobiology in which cut-
ting-edge advances are being made: neuronal cell development, neural circuits
and function, simple and complex behaviors, sensory systems, synaptic trans-
mission, and the evolution of neural systems. A small number of abstracts sub-
mitted in each of these areas were selected by the respective session chairs and
the meeting organizers for platform presentations, and the rest were presented
as posters. The research reported used a wide range of techniques, including ge-
netic, molecular, cellular, biochemical, physiological, and behavioral approaches
to basic questions of nervous system development and function. Among the high-
lights of the meeting were the creative ways in which researchers are using
Drosophila to understand the molecular and cellular underpinnings of many dif-
ferent physiological and pathological processes. Focal points in the meeting were
the Keynote Address by Rüdiger Wehner and the Benzer Lecture by Yuh-Nung
Jan. Rüdiger Wehner, a classic figure in insect behavior, described on the first
evening his major work on navigation by desert ants and the amazing ability of
this insect to find its way without any landmark, simply using the sun as a compass and counting
steps for distance. Yuh-Nung Jan, a prominent leader in the field of Drosophila neurobiology, gave
an historical perspective on Drosophila behavior and his many contributions, starting with his work
with Seymour Benzer. In addition, the meeting included reports of important advances in the devel-
opment of the nervous system, the perception of external stimuli—in particular olfactory cues, of
the fly—and the design of new technology. A significant shift was clear, where many of the talks con-
A. Pisso, S. Birman
K. O’Connor, J.T. Littleton P. Haynes, W. Huetteroth
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cerned circuits and behavior, rather than development and studies of sensory systems. Cory Root,
from Jing W. Wang’s lab at the University of California, San Diego, presented the Elkins Plenary
Lecture. He described his Ph.D. work on olfactory gain control. The environment of the meeting al-
lowed many opportunities for informal discussions among all participants. The high quality of the
presentations, the development of novel techniques, and the exciting new directions of Drosophila
research toward circuits and behavior demonstrate the vitality of this area. Discussions led to cross-
fostering of ideas, which was valuable to everyone in the field.
This meeting was funded in part by the National Institute of Neurological Disorders and Stroke
and the Eunice Kennedy Shriver National Institute for Child Health and Human Development,
branches of the National Institutes of Health, and by the National Science Foundation.
PROGRAM
Sensory Systems
Chairperson: T. Clandinin, Stanford University, California
Keynote Address: Beyond Drosophila: Maps in Insect Minds?
R. Wehner, University of Zürich, Switzerland
Behavior, Brain Function, and Its Evolution
Chairperson: K. Scott, University of California, Berkeley
Neural Circuit: Development, Evolution, and Function
Chairperson:M. Murthy, Princeton University, New Jersey
Elkins Memorial Lecture: The Pursuit of Food and Sex: A
Study of Olfactory Gain Control
C. Root, Columbia University, New York
Neurological Disease Models and Cellular Mechanisms
Chairperson:M. Fortini, Thomas Jefferson University,
Philadelphia, Pennsylvania
Brain Development and Function
Chairperson: J. Kumar, Indiana University, Bloomington
Seymour Benzer Lecture: Control of Dendrite
Morphogenesis and Plasticity
Y.-N. Jan, University of California, San Francisco
Synaptic Transmission, Development, and Plasticity
Chairperson: K. Ito, University of Tokyo
Neural Development and Evolution
Chairperson: I. Salecker, National Insitute of Medical Research,
London, United Kingdom
Technological Innovations and Applications
Chairperson: R. Mann, Columbia University, New York
Poster session I. Jein, C. Organisti
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Cell Death
October 11–15 266 Participants
ARRANGED BY Douglas Green, St. Jude Children’s Research Hospital
J. Marie Hardwick, Johns Hopkins University
Scott Lowe,Memorial Sloan-Kettering Cancer Center
The ninth Cold Spring Harbor meeting on cell death was held
Tuesday, October 11, through Saturday, October 15. The meet-
ing opened with a keynote presentation from Gerard Evan, who
discussed the use of innovative mouse models to understand the
role of the MYC oncoprotein in normal tissue homeostasis and
cancer. Work from his laboratory clearly highlights the addiction
of cancer cells to MYC, whether this is an initiating oncogene
or a “client” of other oncogenes such as RAS. MYC inhibition
in a variety of cancer models rapidly led to sustained cancer re-
gressions, thereby validating anti-MYC therapies as potentially
very effective. In addition to the keynote lecture, there were ap-
proximately 60 oral presentations in seven sessions loosely struc-
tured around Bcl-2 proteins, Cell Death and Senescence in
Cancer, Computational Systems and Approaches, Nonapoptotic
Cell Death, Targets and Therapies, New Mechanisms and Components, Mitochondrial Dynamics
and Function, and Metabolic Control of Cell Death. Speakers from around the globe included high-
profile investigators who were both invited speakers/chairs and abstract presenters. Among these were
session chairs David Andrews, Eric Baehrecke, Barbara Conradt, Adi Kimchi, Sally Kornbluth, An-
thony Letai, Jennifer Lippincott-Schwartz, Seamus Martin, Huseyin Mehmet, Peter Sorger, Andreas
Strasser, Eileen White, Hao Wu, and Junying Yuan, who presented new unpublished data pertaining
to a variety of timely topics ranging from new insights into basic apoptotic mechanisms to the iden-
tification and preclinical development of new cell death therapies. Beyond this, the meeting was no-
table for including talks on new approaches in cell death research (for example, computational
J.M. Hardwick, S. Lowe, D. Green
C. Crehton, R. Screaton, D. Miller V. Hindle, C. Bertram, P. Wagner, X. Lowman
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Keynote Session
Chairpersons: S. Lowe, Memorial Sloan-Kettering Cancer Center,
New York; J.M. Hardwick, Johns Hopkins University,
Baltimore, Maryland
Keynote Address: Finding the Optimal Targets for Effective
Cancer Therapy
G.I. Evan, University of Cambridge, United Kingdom
BCL-2 Proteins
Chairpersons: D. Andrews, McMaster University, Hamilton,
Canada; A. Letai, Dana-Farber Cancer Institute, Boston,
Massachusetts
Cell Death and Senescence in Cancer
Chairpersons: J. Lippincott-Schwartz, National Institutes of
Health, Bethesda, Maryland; H. Mehmet, Merck and Co.,
Rahway, New Jersey
Computational and Systems Approaches
Chairpersons: P. Sorger, Harvard Medical School, Boston,
Massachusetts; A. Kimchi, Weizmann Institute of Science,
Rehovot, Israel
Nonapoptotic Cell Death
Chairpersons: J. Yuan, Harvard Medical School, Boston,
Massachusetts; E. Baehrecke, University of Massachusetts
Medical School, Worcester
Targets and Therapies
Chairpersons: A. Strasser, Walter & Eliza Hall Institute of
Medical Research, Parkville, Australia; E. White, Rutgers
University/The Cancer Institute of New Jersey, New
Brunswick
New Mechanisms and Components
Chairpersons: H. Walczak, Imperial College, London, United
Kingdom; H. Wu, Weill Cornell Medical College, New York
Mitochondrial Dynamics and Function
Chairpersons: D. Green, St. Jude Children’s Research Hospital,
Memphis, Tennessee; B. Conradt, Ludwig-Maximilians-
Universität München, Germany
Metabolic Control of Cell Death
Chairpersons: S. Kornbluth, Duke University School of
Medicine, Durham, North Carolina; S. Martin, Trinity
College Dublin, Ireland
H. Walensky, M. Giam K. Biachi, P. Meier
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methods and functional genomics) and for the large number of presentations related to autophagy
and alternative cell death mechanisms. The meeting also had two poster sessions and experimented
with a morning poster session format for one of the days. The latter was well attended and considered
a success. Finally, Doug Green gave a short address in memory of Jurg Tschopp, a leader in the cell
death field who passed away earlier this year.  Altogether, much exciting science was presented and
the oral sessions were accompanied by lively debate. Although it is clear that the cell death field is
burgeoning into many new directions, it is equally apparent that there remain many unanswered
questions concerning how cell processes are coordinated and their relevance to disease. Based on the
meeting’s success and the perceived continuing importance of the field, the meeting will continue in
fall 2013 with Scott Lowe, Doug Green, and Sally Kornbluth as organizers.
PROGRAM
Protein Data Bank 40th Anniversary Conference
October 28–30 240 Participants
ORGANIZED BY Helen Berman, RCSB PDB, Rutgers University
Stephen K. Burley, Eli Lilly & Co.
Gerard Kleywegt, PDBe, EMBL-EBI, United Kingdom
John Markley, BMRB, University of Wisconsin
Haruki Nakamura, DBj, Osaka University, Japan
A special conference to celebrate the 40th anniversary of the Protein Data Bank (PDB) started at
Cold Spring Harbor Laboratory by members attending the X-Ray Methods in Structural Biology
course. Several Nobel laureates were in attendance and a Keynote Address was given by Johann
Deisenhofer.
The PDB is a repository for the three-dimensional structural data of large biological molecules,
such as proteins and nucleic acids (see also crystallographic database). The data, typically obtained
by X-ray crystallography or nuclear magnetic resonance (NMR) spectroscopy and submitted by bi-
ologists and biochemists from around the world, are freely accessible on the Internet via the websites
of its member organizations (PDBe, PDBj, and RCSB). The PDB is overseen by an organization
called the Worldwide Protein Data Bank (wwPDB). The PDB is a key resource in areas of structural
biology such as structural genomics. Most major scientific journals, and some funding agencies,
such as the National Institutes of Health (NIH) in the United States, now require scientists to
submit their structure data to the PDB. If the contents of the PDB are thought of as primary data,
there are hundreds of derived (i.e., secondary) databases that categorize the data differently. For ex-
ample, both SCOP and CATH categorize structures according to type of structure and assumed
evolutionary relations; GO categorizes structures based on genes. 
Session I 
M. Rossmann, Purdue University, West Lafayette, 
Indiana
S. Burley, Eli Lilly & Co., San Diego, California
Session II
J. Thornton, Wellcome Trust/EBI, Cambridge, United Kingdom
D. Baker, University of Washington, Seattle
A. Sali, University of California, San Francisco 
L. Tan, J. Young S. Bliven, A. Chakrabarty
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Session III
J. Richardson, Duke University, Durham, North Carolina
A. Bax, DHHS, NIDDK, LCP, National Institutes of Health,
Bethesda, Maryland
A. Brunger, HHMI/Stanford University, Stanford, California
Session IV
C. Arrowsmith, University of Toronto, Canada
S. Taylor, University of California, San Diego
Session V
S. Wakatsuki, Structural Biology Research Center, Photon Factory,
Japan
R. Henderson, MRC Laboratory of Molecular Biology, United
Kingdom
W. Chiu, Baylor College of Medicine, Houston, Texas
A. Gronenborn, University of Pittsburgh, Pennsylvania
J. Deisenhofer, University of Texas Southwestern Medical 
Center, Dallas
Session VI
K. Wüthrich, The Scripps Research Institute, La Jolla, 
California
M. Hong, Iowa State University, Ames
W. Hendrickson, Columbia University, New York
Session VII
D. Searls, Independent Consultant, North Wales, 
Pennsylvania
A. McPherson, J. Deisenhofer W. Hendrickson, R. Henderson R. Feldman, P. Moore
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Genome Informatics
November 1−5 302 Participants
ARRANGED BY Inanc Birol, BC Cancer Agency
Jennifer Harrow,Wellcome Trust Sanger Institute
James Taylor, Emory University
This 11th conference was held this year at Cold Spring Harbor Laboratory. The conference series
continues to demonstrate a robust attendance, both from the United States and from abroad. It at-
tracted 302 registrants, presenting more than 200 abstracts, and
offered a snapshot of the latest developments in the field. There
were 11 invited talks and one Keynote Address. The remaining
37 talks were all selected for presentation by session chairs from
openly submitted abstracts.
This year, abstracts represented a shifting balance from tool
development to applications. Yet the community still agrees that
the growth in the capacity of sequencing outpaces the improve-
ments on the informatics side, and there is a continued need to
develop scalable analysis tools, with a special emphasis on the
reproducibility of their results. The sessions, along with their
chairpersons, are listed below.
The Keynote Address, delivered by Dr. Evan E. Eichler, took
place before the reception and was the topic of many lively dis-
cussions. He challenged researchers to go after the difficult problems in the field and not just con-
centrate on easy targets. He made his case around structural variations in the repetitive regions of
human genomes from diverse populations and primate genomes.
It was encouraging to note that the relative student attendance experienced a peak this year, with
19% of the total registrants. It demonstrates that the field is still growing and attracting new talent
across the board.
This meeting was funded in part by the National Human Genome Research Institute, a branch
of the National Institutes of Health.
J. Harrow, I. Birol, J. Taylor
G. Rätsch, K. Tang S. Kumari, D. Fisk
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PROGRAM
Transcriptomics, Alternative Splicing, and Gene Predictions
Chairpersons: G. Rätsch, Max-Planck Society, Tübingen,
Germany; S. Jones, BC Cancer Agency, Vancouver, Canada
Sequencing Pipelines and Assembly
Chairpersons: Z. Ning, Wellcome Trust Sanger Institute,
Hinxton, United Kingdom;M. Schatz, Cold Spring Harbor
Laboratory
Databases, Data Mining, Visualization, and Curation
Chairpersons: A. Bateman, Wellcome Trust Sanger Institute,
Hinxton, United Kingdom; T. Wang, Washington University,
St. Louis, Missouri
Population and Personal Genomics
Chairpersons: L. Ding, Washington University School of
Medicine, St. Louis, Missouri; S.C. Sahinalp, Simon Fraser
University, Burnaby, Canada
Epigenomics and Noncoding Genomes
Chairpersons: A. Milosavljevic, Baylor College of Medicine,
Houston, Texas; J. Rinn, Broad Institute of MIT and
Harvard University, Cambridge, Massachusetts
Keynote Address: Genome Structural Variation Discovery
and Genotyping
E.E. Eichler, HHMI/University of Washington
Comparative and Evolutionary Genomics
Chairpersons:M. Kellis, Massachusetts Institute of Technology,
Cambridge; S. Batzoglou, Stanford University, California
I. Barol, G. Rätsch S. Goldstein, S. Pepke
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Harnessing Immunity to Prevent and Treat Disease
November 16–19 132 Participants
ARRANGED BY Bali Pulendran, Emory University
Robert Seder, Vaccine Research Center, NIAID/NIH
Susan Swain, University of Massachusetts Medical School
This meeting covered a broad spectrum of new insights into how the immune system can prevent
and treat diseases. This included extensive discussion of strategies to improve T-cell and innate im-
munity, especially in response to vaccines, with an emphasis on new findings, regulation of innate
responses and antigen presentation, and how T cells transition to memory cells with long-lived pro-
tective protential. 
Stressing the dangers of overexuberant immune responses, the Keynote speaker, Michael Old-
stone, introduced the meeting by detailing how antagonists of sphingosine-1 phosphate receptor
signaling, involved in lymphocyte motility and migration, could blunt the cytokine storm induced
by pathogenic influenza virus infection. B. Rouse later suggested that galectins have an important
anti-inflammatory role. The next and several later sessions highlighted the many strategies by which
memory T cells protect and how the multiple subsets contribute (S. Swain), as well as the transcrip-
tional regulation of T-cell memory formation in mouse (S. Kaech) and humans (R. Sekaly), pro-
viding a deeper understanding of T-cell memory. In related sessions, D. Littman and Y. Belkaid
detailed how commensal organisms could profoundly regulate the balance of T-cell subsets in the
gut and how the regulatory T cells keep them in check, and L. Hooper discussed how microbiota
and host are spatially separated. Several additional talks pointed to organ-specific aspects of immu-
nity (D. Masopust, M. Bogunovic, K. Hofmeyer, S. Turley, and S. Swain).
A major theme was that specific dendritic cells can regulate T cells (B. Pulendran, B. Edelson,
and S. Turley), and a discussion of how to develop vaccine approaches to exploit this (R. Seder and
A. Hill) was well received. B. Pulendran discussed how the yellow fever vaccine induces the integrated
stress response in dendritic cells, thus programming them to induce CD8 T cells. R. Seder discussed
the multiple mechanisms by which adjuvants stimulate innate immune receptors, such as Toll-like
receptors, to mediate protective immunity against vaccines.
Another theme was the growing recognition that metabolism has a very important role in how
immune cells function. E. Pearce discussed metabolic changes in T cells as they differentiate and
how these impact their function. In his Keynote talk, Craig Thompson proposed that starvation of
cells led to their shedding of all activities except retaining a set of microRNAs that would indicate
their identity if they should be rescued. 
Welcome: S. Swain, University of Massachusetts Medical School,
Worcester, and R. Seder, Vaccine Research Center, NIAID/NIH
Introduction to Keynote: R. Seder, Vaccine Research Center,
NIAID/NIH
Keynote Address: Endothelial Cell-Mediated Modulation of
Cytokine Storm during Influenza Infection
M. Oldstone, Scripps Research Institute
Decision Making in Memory Cell Differentiation
Chairperson: S. Swain, University of Massachusetts Medical
School, Worcester
Innate Programming of Adaptive Immunity I
Chairpersons: E. Pearce, Trudeau Institute, Saranac Lake, New
York; D. Lewis, Stanford University School of Medicine,
California
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Innate Programming of Adaptive Immunity II
Chairpersons: L. Haynes, Trudeau Institute, Saranac Lake, New
York; A. Hill, Wellcome Trust Centre for Human Genomics,
Oxford, United Kingdom
Organ-Specific Immunity
Chairpersons: S. Turley, Dana-Farber Cancer Institute, Boston,
Massachusetts; Y. Belkaid, NIAID, National Institutes of
Health, Bethesda, Maryland
Microbe-Immune Interactions
Chairpersons: L. Hooper, University of Texas Southwestern
Medical Center, Dallas; D. Littman, HHMI/New York
University School of Medicine, New York 
Introduction to Keynote: S. Swain, University of Massachusetts
Medical School, Worcester
Keynote Address: How Do Cells Remember?
C. Thompson, Memorial Sloan-Kettering Cancer Center, New
York
The Journey Within: Human Immunology
Chairpersons: A. Lanzavecchia, Institute for Research in
Biomedicine, Bellinzona, Switzerland;M. Davis,
HHMI/Stanford University School of Medicine, California
Harnessing Immunity to Prevent and Treat Disease     325
Plant Genomes and Biotechnology: From Genes to Networks
Nov. 30–Dec. 3 140 Participants
ARRANGED BY Mary-Lou Guerinot, Dartmouth College
Todd Mockler, Oregon State University
Detlef Weigel,Max-Planck Institute for Developmental Biology
The theme of the meeting, “Genes, networks, and applications,” highlighted the move from un-
derstanding the function of individual genes to the analysis of larger functional networks, and it
highlighted ways in which this knowledge has increasingly prac-
tical applications. The latter is not limited to breeding, but is
also useful for ecological research. The expertise of the three
coorganizers spanned the major areas of the meeting, from trans-
lational genomics (M.-L. Guerinot, Dartmouth, and S. Briggs,
University of California, San Diego) to natural genetic diversity
(D. Weigel, Max-Planck Institute for Developmental Biology).
Following the tradition of the meeting, the two Keynote Ad-
dresses, by Andrew Clark (Cornell) on comparative genomics in
Drosophila and Aviv Regev (Broad Institute/MIT) on regulatory
network analysis in yeasts and mammals, provided exciting in-
sights into current work outside of plants. 
A special highlight of the meeting was the first session cele-
brating the recently finished maize genome sequence. V. Walbot
(Stanford) and P. Schnable (Iowa State) demonstrated how maize
geneticists are already benefitting from this achievement. Maize
is also notable for being the first crop in which breeders and farmers made extensive use of the het-
erosis phenomenon, in which hybrid progeny outperform its inbred parents. L. Rieseberg (University
of British Columbia), D. Zamir (Hebrew University), D. Weigel, and R. Martienssen (CSHL) pre-
sented very different approaches to studying and exploiting genetic and epigenetic effects in hy-
brids.
We are currently witnessing a revolution in DNA sequencing ability, as sequencing capacity at
the same cost has been increasing severalfold annually over the past 3 years. J. Ecker (Salk Institute),
T. Mockler, M.-L. Guerinot, D. Weigel
D. Caldwell, B. Meyers K. Creasey, A. Sullivan S. Hogenout, D. Weigel
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B. Gaut (University of California, Irvine), and R. Kahmann (Max-Planck Institute for Terrestrial
Microbiology) discussed excellent examples of the impact that these new technologies have on plant
sciences.
Until recently, the major limitation in connecting genotype with phenotype was the acquisition
of genotype information, be it by typing individual DNA markers or sequencing complete genomes.
With sequencing prices dropping rapidly, and no end in sight, this is completely changing, and the
major bottleneck now is high-throughput phenotyping. Innovative approaches to this problem were
showcased in the talks by P. Benfey (Duke), N. Raikhel (University of California, Riverside), and
M.-L. Guerinot. Of course, the genotyping and phenotyping information needs to be captured and
interpreted in an integrated fashion. D. Ware (CSHL), J. Carrington (Oregon State), L. Willmitzer
(Max-Planck Institute for Molecular Plant Physiology), and T. Mitchell-Olds (Duke) demonstrated
different approaches to solving this problem. The ultimate challenge then is to combine these data
and to construct genetic, cellular, and physical networks as discussed by J. Traas (ENS Lyon), E.
Meyerowitz (Caltech), A. Millar (Edinburgh University), and G. Coruzzi (New York University).
The last area is the focus of the National Science Foundation (NSF)-funded iPlant initiative, which
was discussed following the network/models session in the context of presenting the results of a
workshop that had been held at the Banbury Center under the auspices of the NSF and several in-
ternational funding agencies.
As mentioned above, not only are advances in plant biology impacting plant breeding, but they
are also important for understanding evolutionary and ecological processes in general, as was dis-
cussed by J. Bergelson (University of Chicago) and M. Yano (NIAS Tsukuba). Finally, in addition
to the invited presenters mentioned by name, each session featured shorter talks drawn from sub-
mitted abstracts. Those not selected had a chance to present their work in a poster session.
Although the meeting was smaller than in previous years, attendees were all very happy about
the high caliber of talks and many mentioned that the speaker lists had made this program partic-
ularly attractive. Apart from the current funding climate allowing fewer scientists to attend confer-
ences, this conference was held between the Plant and Animal Genome Meeting in San Diego in
January and the Annual Maize Meeting the following week, and these were likely factors that reduced
the number of potential attendees.
The meeting was supported by a grant from the NSF and a gift from Dow Agrosciences.
PROGRAM
Introduction to Keynote:M.-L. Guerinot, Dartmouth
Keynote Address
O. Leyser, University of Cambridge
Phenomics
Chairperson: T. Mockler, Oregon State University, Corvallis
Next-Generation Evolutionary Biology
Chairperson: M. Nordborg, Gregor Mendel Institute, Vienna,
Austria
Next-Generation Plant Breeding
Chairperson: N. Sinha, University of California, Davis
New Plant Genomes and Models
Chairperson: U. Kraemer, Ruhr University Bochum, 
Germany
OMICS Integration
Chairperson: T. Michael, Monsanto, Chesterfield, Missouri
Next-Generation Plant−Pathogen Interactions
Chairperson: B. Meyers, University of Delaware, Newark
Discussion of Current Major Funding Initiatives
Discussion Leader: B. Meyers, University of Delaware, Newark
Introduction to Keynote: D. Weigel, Max-Planck Institute for
Developmental Biology
Keynote Address: Insect Resistance for the Long Haul: Les-
sons from a Native Plant
I.T. Baldwin, Max-Planck Institute for Chemical Ecology
Next-Generation Cell Biology
Chairperson: S. Brady, University of California, Davis
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RNA and Oligonucleotide Therapeutics
December 4–7 71 Participants
ARRANGED BY Ryszard Kole, AVI BioPharma
Adrian Krainer, Cold Spring Harbor Laboratory
Bruce Sullenger, Duke University
This was the first Cold Spring Harbor conference on RNA and Oligonucleotide Therapeutics. The
meeting was focused on clinical trials and development of oligonucleotides as drugs, but it brought
together top scientists from academia and industry interested in a variety of RNA-based therapeutics,
not only oligonucleotides. The theme “From the Bench to the Bedside” made it unique among CSHL
meeting series. Covered approaches ranged from antisense oligonucleotides and aptamers through
modulation of splicing, targeting expanded triplet repeats and immunostimulation, to small interfering
RNAs (siRNAs) and microRNAs (miRNAs) as potential drugs and targets. The all-important issue of
RNA therapeutics delivery by a variety of methods was also covered. The applications of these varied
technologies included rare diseases, cancer, cardiovascular diseases, and bacterial and viral infections.
The participants came from 11 companies and universities and research institutions from the
United States and abroad. The seven scientific sessions featured 37 platform talks and 20 posters and
included 90 registered attendees. Animated and insightful exchanges during the sessions continued
throughout. A number of participants expressed interest in attending this conference next year. 
B. Sullenger, R. Kole, A. Krainer
K. Ryan, D. Seth, Y. Jin, E. Wickstrom B. Meade, S. Dowdy, H.L. Grimes
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PROGRAM
Splice Switching Oligos I
Chairperson: A. Krainer, Cold Spring Harbor Laboratory
Splice Switching Oligos II
Chairperson: S. Wilton, University of Western Australia, Perth,
Australia
Aptamers
Chairperson: P. Giangrande, University of Iowa, Iowa City
Delivery
Chairperson: R. Juliano, University of North Carolina, Chapel
Hill
Antisense and Antagomirs
Chairperson: B. Monia, Isis Pharmaceuticals, Carlsbad,
California
siRNA/miRNA and Emerging Technologies
Chairperson: A. Khvorova, RXi Pharmaceuticals, Worcester,
Massachusetts
L. Hao, L. Jin, A. Oguro
V. Franciscis, P. Giangrande
S. Yilmaz, E. Petra
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Rat Genomics and Models
December 7–10 134 Participants
ARRANGED BY Edwin Cuppen, Hubrecht Institute, the Netherlands
Michael Gould, University of Wisconsin, Madison
Norbert Hubner,Max Delbruck Centrum for Molecular Medicine
Anne Kwitek-Black, University of Iowa
This seventh winter biotechnology conference has been held biannually since 1999 at Cold Spring
Harbor Laboratory. It is the first in the United States to focus exclusively on the unique physiological
and genetic relevance of the rat as a model organism for biomedical research into the molecular origins
of human diseases. A complementary meeting outside of the
United States is held in alternating years, with the most recent
meetings being held in Kyoto (2010), Hinxton, UK (2008),
Melbourne, Australia (2006), and Kyoto, Japan (2004). Drs.
Cuppen, Hubner, Kwitek-Black, and Gould served as conference
organizers. The primary goals of this meeting were to (1) pro-
mote interactions between biomedical researchers who utilize rat
models in the study of physiology, pathophysiology, toxicology,
immunology, neuroscience, and oncology and (2) provide an in-
terface between the research community and the various public
and commercial entities that support biomedical research in
which rat models are used.
The meeting was organized into oral presentations by invited
speakers; speakers were selected following evaluation of submit-
ted abstracts, poster sessions, and workshops. The Keynote Address was presented by Dr. Qi-Long
Ying. The remaining 56 oral presentations were organized into six sessions based on diseases or tech-
nologies, and these sessions and their chairpersons are listed on the next page. 
Besides the general interactive poster session, where 32 abstracts were presented, and the active
participation of 25 young researchers/graduate students, Dr. M. Shimano coordinated a workshop/
poster session with 11 abstracts devoted to resources and genomic tools. 
N. Hubner, A. Kwitek-Black, M. Gould, E. Cuppen
J. Coletti, J.A. Landgraf, N. Seiler C.J. Ma, A. Kwitek S. Tobias
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Genomics, Systems Biology, and Resources
Chairpersons: V. Guryev, Hubrecht Institute, Utrecht, the
Netherlands; K. Worley, Baylor College of Medicine,
Houston, Texas
Cardiovascular Diseases I
Chairpersons: S. Cook, MRC Clinical Sciences Centre, London,
United Kingdom; B. Joe, Medical College of Ohio, Toledo
Manipulating the Rat Genome
Chairpersons: Q.-L. Ying, University of Southern California, Los
Angeles; Z. Izsvak, Max-Delbrück-Centre, Berlin, Germany
Keynote Address: Progress in Making Gene Knockout Rats
Using ES-Cell-Based Gene-Targeting Technologies
Q.-L. Ying, University of Southern California, Los Angeles
Tumor Biology
Chairpersons: J. Shull, University of Wisconsin, Madison; B.
Smits, University of Wisconsin, Madison
It is clear that this conference serves an important role in meeting the needs of those in the bio-
medical research community who use rat models in genetics and genomics-based research. The or-
ganizers and attendees expressed high enthusiasm for continuing the present biannual meeting
format at Cold Spring Harbor Laboratory and other sites in the intervening years.
PROGRAM
Neuroscience and Behavior
Chairperson: E. Cuppen, Hubrecht Institute, Utrecht, the
Netherlands
Resources Poster/Demo Session
Cardiovascular Diseases II
Chairpersons: A. Kwitek-Black, University of Iowa, Iowa City;
N. Hubner, Max Delbrück Centre for Molecular Medicine,
Berlin, Germany
Metabolism and Inflammation
Chairpersons: M. Pravenec, Academy of Sciences of the Czech
Republic, Prague; T. Aitman, MRC Clinical Sciences Centre,
London, United Kingdom
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ADJUNCT MEETINGS
National Institutes of Health New Investigator Regional
Conference
March 14 312 Participants 
HOSTED BY Cold Spring Harbor Laboratory, Office of Sponsored Research
This special 1-day meeting was specifically designed to educate new investigators on topics such as
The Future of Biomedical Research; New and Early-Stage Investigators (an NIH Perspective); and
Funding Opportunities, Fostering Success with speakers such as Harold Varmus, Griffin Rodgers,
Thomas Insel, Susan Shurin, Sally Rockey, Cheryl Kitt, Samuel Stanley, Jr., and Bruce Stillman.
Participants were able to meet in small groups with NIH directors and other NIH representatives
(NCI, NIMH, NIAID, NHLBI, NIDDK). An afternoon panel discussion featured “Dos and Don’ts
for New Investigators.”
Support for this conference was provided by the Alfred P. Sloan Foundation.
PROGRAM
The future of biomedical research and the fate of new 
investigators
B. Stillman, Cold Spring Harbor Laboratory
New and early-stage investigators: An NIH perspective
S. Rockey, NIH Office Extramural Research
Funding Opportunities and Challenges for New 
Investigators 
     T. Insel, National Institute of Mental Health
     G. Rodgers, National Institute of Diabetes and 
Digestive and Kidney Diseases
     S. Shurin, National Heart Lung and Blood 
Institute
     H. Varmus, National Cancer Institute
The Peer Review Process: From Application to Funding
of a New Investigator
     C.I. Kitt, NIH Center for Scientific Review
NIH Peer Review Dos and Don’ts for New Investigators
     K. Collins, University of California, Berkeley
     H. Yeh, Dartmouth University
     S. Hammes, University of Rochester
     S. Stanley, Jr., Stony Brook University
Fostering the Success of New Investigators
S. Rockey, NIH Office of Extramural Research
Closing Remarks 
332
New York Structural Biology Group Summer Session
August 1 274 Participants 
ORGANIZED BY David Cowburn, Albert Einstein College of Medicine
David Eliezer,Weill Medical College of Cornell University
Hao Wu,Weill Medical College of Cornell University
This 1-day discussion group provided a forum for structural biology in the New York area. The
speakers and their presentations are listed below. 
This meeting was cosponsored by the National Science Foundation (NSF) Research Coordina-
tion Network. Other sponsors included Bristol-Myers Squibb, GE Healthcare, Nature Structural
& Molecular Biology, Gatan, GenScript, TTP Labtech, Rigaku FEI Company, Cell Press, ImClone
Systems, Inc., JEOL, Varian Roche, Bruker Biospin, and Wyatt Technology.
PROGRAM
Structures of the bacterial ribosome in classical and hybrid
states of tRNA binding
S. Blanchard, Weill Cornell Medical College
Coupling RNAi to heterochromatin: Insights into the struc-
ture of the RITS complex
T. Schalch, Cold Spring Harbor Laboratory
Tracing a killer’s path: Structural insights into the activation
pathway of pro-apoptotic BAX
E. Gavathiotis, Albert Einstein College of Medicine
Tracking death domain complex assembly with NMR
P. Driscoll, MRC National Institute for Medical Research,
London
Multiscale simulation of cadherin-mediated cell adhesion
Y. Wu, Columbia University
Structural studies of human GABA(B) receptor.
Q. Fan, Columbia University
Using SPR to study interactions of membrane proteins
B. Lang, GE Healthcare
Structural biology of the human cancer protein interaction
network
G. Montelione, Rutgers University
DNMT1 and maintenance DNA methylation.
J. Song, Memorial Sloan-Kettering Medical Institute
Signal transduction in RAGE: Structural biology of the 
receptor for advanced glycation end products
A. Shekhtman, SUNY, Albany
Conserved RNA recognition element identifies ZBP1-
operated posttranscriptional regulatory networks
V. Patel, Albert Einstein College of Medicine
Structural analysis of SLAC1-family anion channel 
activity
W. Hendrickson, Columbia University
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POSTGRADUATE COURSES
The Postgraduate Courses program at Cold Spring Harbor Laboratory is aimed at meeting the special
need for training in interdisciplinary subjects that are either so new or so specialized that universities
do not adequately teach them. Our aim is to provide intensive study in the most recent developments
and techniques in these subjects and to prepare students to enter directly into research in a particular
area. To ensure up-to-date coverage of current research work, we bring together course faculty from
many laboratories around the world and supplement this staff with a series of seminar speakers.
Workshop on Leading Bioscience
February 18–21
ARRANGED BY C. Cohen, Newton, Massachusetts
D. Kennedy, Cambridge, Massachusetts
Bioscience now dominates the academic sciences, and the 21st century is often heralded as the cen-
tury in which the life sciences and biotechnologies will have their greatest impact on society. Life
science expertise is now relevant in disciplines from the environment to energy, from psychology to
forensics. Many biologists seek research careers in academia or industry, whereas others explore more
varied careers in education, publishing, business, or law. Few life scientists experience formal lead-
ership training to facilitate their development as future leaders in their chosen profession. The first
in a series of intensive workshops focusing on Leadership in Biosciences emphasized learning by
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PARTICIPANTS
Akakura, S., Ph.D., Roswell Park Cancer Institute, Buffalo,
New York
Bethke, A., Ph.D., Boyce Thompson Institute/Cornell
University, Ithaca, New York
Chi, H., Ph.D., St. Jude Children’s Research Hospital,
Memphis, Tennessee
Du, Y.-C.N., Ph.D., Weill Cornell Medical College, New York
Flames, N., Ph.D., Columbia University, New York
Fuchs, S., Ph.D., University of North Carolina, Chapel Hill,
North Carolina
Hjerling Leffler, J., Ph.D., New York University Medical
School, New York
Huss, W., Ph.D., Roswell Park Cancer Institute, Buffalo, New
York
Kadiri, L., Ph.D., Cold Spring Harbor Laboratory
Madzima, T., Ph.D., Florida State University, Tallahassee
Manjarrez Orduno, N., Ph.D., The Feinstein Institute,
Manhasset, New York
Neher, S., Ph.D., University of North Carolina, Chapel Hill
Oh, S.W., Ph.D., Allen Institute for Brain Science, Seattle,
Washington
Petrella, L., Ph.D., University of California, Santa Cruz
Premsriut, P., Ph.D., Cold Spring Harbor Laboratory
Salvador Esteban, B., Ph.D., University of San Francisco,
California
Schwertassek, U., Ph.D., Cold Spring Harbor Laboratory
Smith, B., Ph.D., Arizona State University, Tempe
Truscott, M., Ph.D., University of Illinois, Chicago
Ubeda, C., Postdoc, Memorial Sloan-Kettering Institute, New
York
Wheeler, T., Ph.D., University of Rochester, New York
Wood, D., Harvard Medical School/BIDMC, Boston,
Massachusetts
Zhang, J., Ph.D., University of Alabama, Birmingham
SEMINARS
Khan, Z., The Rockefeller University, New York: Strategy and
evaluation.
Miller, K., Brown University, Providence, Rhode Island:
Science in the public eye.
doing and involved role playing, giving and receiving feedback, and group problem-solving.  Much
of the learning was peer-to-peer.  It was an intensive 3 1/2-day event where almost 30 participants
learned to develop the skills to lead and interact effectively with others in both one-on-one and
group settings. 
This workshop was generously supported with funds provided by American Express Philan-
thropy.
Protein Purification and Characterization
April 6−19
INSTRUCTORS R. Burgess, University of Wisconsin, Madison
A. Courey, University of California, Los Angeles
S.-H. Lin, M.D. Anderson Cancer Center/University of Texas, Houston
M. Marr, Brandeis University, Waltham, Massachusetts
ASSISTANTS J. Cao, University of California, Los Angeles
M. Chambers, University of California, Los Angeles
R. Chumanov, University of Wisconsin, Madison
A. Esch, University of Wisconsin, Madison
P. Kuhn, University of Wisconsin, Madison
P. Kwong, University of California, Los Angeles
Y.-U. Lee, M.D. Anderson Cancer Center, University of Texas, Houston, Texas
X. Li, M.D. Anderson Cancer Center/University of Texas, Houston, Texas
C. Olson, Brandeis University, Waltham, Massachusetts 
K. Pennington, Brandeis University, Waltham, Massachusetts 
A. Ponce, University of California, Los Angeles
N. Thompson, University of Wisconsin, Madison
This course was for scientists who were not familiar with techniques of protein isolation and char-
acterization. It is a rigorous program that included laboratory work all day and a lecture with dis-
cussion session every evening. Each student became familiar with each of the major techniques in
protein purification by actually performing four separate isolations including (1) a regulatory protein
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PARTICIPANTS
Charles, R., M.D, Massachusetts General Hospital, 
Boston
Hawwari, A., Ph.D., King Faisal Specialist Hospital &
Research Center, Riyadh
Hevener, K., Ph.D., University of Illinois at Chicago
Keeler, A., B.S., University of Iowa, Iowa City
Lyssenko, N., Ph.D., Children’s Hospital of Philadelphia,
Pennsylvania 
Marada, S., Ph.D., St. Jude Children’s Research Hospital,
Memphis, Tennessee
Mochalkin, I., Ph.D., EMD Serono Research Institute,
Billerica, Massachusetts
from muscle tissue, (2) a sequence-specific, DNA-binding protein, (3) a recombinant protein over-
expressed in Escherichia coli, and (4) a membrane-bound receptor. A variety of bulk fractionation,
electrophoretic, and chromatographic techniques included precipitation by salts, pH, and ionic
polymers; ion exchange, gel filtration, hydrophobic interaction, and reverse-phase chromatography;
lectin affinity, ligand affinity, oligonucleotide affinity, and immunoaffinity chromatography; poly-
acrylamide gel electrophoresis and electroblotting; and high-performance liquid chromatography.
Procedures were presented for solubilizing proteins from inclusion bodies and refolding them into
active monomeric forms. Methods of protein characterization were utilized including immunological
and biochemical assays, peptide mapping, amino acid analysis, protein sequencing, and mass spec-
trometry. Emphasis was placed on strategies of protein purification and characterization. Guest lec-
turers discussed protein structure, modification of proteins, methodologies for protein purification
and characterization, and applications of protein biochemistry to cell and molecular biology broadly
and to cancer research in particular.
This course was supported with funds provided by the National Cancer Institute. 
Morgan, J., B.S., Stanford Research USD, Sioux Falls, South
Dakota
Patterson, K., Ph.D., The University of Texas at Austin
Skeie, J., Ph.D., University of Iowa, Iowa City
Stutz, A., M.Sc., University of Massachusetts Medical School,
Worcester
Termathe, M., M.A., Max-Planck Institute for Molecular
Biomedicine, Munster
Tia, S., B.S., University of California, Berkeley 
Wang, P., B.A., Harvard University, Boston, Massachusetts
Yu, Y., Ph.D., Cold Spring Harbor Laboratory
Zhang, S., B.S., University of Pennsylvania, Philadelphia
SEMINARS
Burgess, R., University of Wisconsin, Madison: Welcome and
introduction to course. Introduction to protein purification.
Protein purification in the mid-60s: RNA polymerase and
sigma factor. Rapid isolation of weakly binding proteins with
the IFAST system.
Chumanov, R., University of Wisconsin, Madison/Promega:
Halo tag and purification of CARM1.
Courey, A., University of California, Los Angeles: System-wide
analyses of Groucho and SUMO in Drosophila development.
Lin, S.-H., MD Anderson Cancer Center, Houston, Texas:
Cell adhesion molecules and prostate cancer metastasis.
Marr, M., Brandeis University, Waltham, Massachusetts:
Transcriptional and translational cellular responses to 
stress.
Thompson, N., University of Wisconsin, Madison: MAbs and
immunoaffinity chromatography in cancer research.
Cell and Developmental Biology of Xenopus
April 8−19
INSTRUCTORS A. Sater, University of Houston, Texas
G. Thomsen, Stony Brook University, New York
ASSISTANTS B. Dzamba, University of Virginia, Charlottesville
T. Nakayama, University of Virginia, Charlottesville
K. Pfister, University of Virginia, Charlottesville
Xenopus is a leading vertebrate model for the study of gene function in development. The combi-
nation of lineage analysis, gene-knockout strategies, experimental manipulation of the embryo, and
genomic/bioinformatic techniques makes it ideal for studies on the molecular control of embryo
patterning, morphogenesis. and organogenesis. The course combined intensive laboratory training
with daily lectures from recognized experts in the field. Students learned both emerging technologies
and classical techniques to study gene function in Xenopus development. An important element was
the informal interaction between students and course faculty.
Technologies covered included oocyte and embryos, analysis of limb and tail regeneration in tad-
poles, time-lapse imaging of morphogenesis, gain- and loss-of-function analyses using mRNAs and
antisense oligos, whole-mount in situ hybridization, immunocytochemistry, microsurgery, and ge-
nomic/bioinformatic techniques, preparation of transgenic embryos, and use of Xenopus tropicalis
for genetic analyses. This course was designed for those new to the Xenopus field, as well as for those
wanting a refresher course in the emerging technologies. The course was open to investigators from
all countries.
This course was supported with funds provided by the National Institute of Child Health and
Human Development, the National Science Foundation, and the Howard Hughes Medical Institute. 
338
Cell and Developmental Biology of Xenopus 339
PARTICIPANTS
Alvarado Kristensson, A., Ph.D., Lund University, Malmoe,
Sweden
Chernet, B., B.S., Tufts University, Medford, Massachusetts
Feric, M., B.S., Princeton University, New Jersey
Getwan, M., Dipl., Institute of Zoology, Stuttgart, Germany
Hatch, V., B.Sc. University of East Anglia, Norwich, United
Kingdom
Ioannou, A., B.S., University of Cyprus, Nicosia
Pai, Vaibhav, V., Ph.D., Tufts University, Medford, Massa-
chusetts
Sedzinski, J., M.A., Max-Planck Institute, Dresden, Germany
Strobl, A.-C., M.S., National Institute of Medical Research,
London, United Kingdom
Travis, S., Ph.D., University of Iowa, Iowa City
Wang, W.-L., Ph.D., Albert Einstein College, Bronx, New York
Watson, A., B.A., MRC National Institute for Medical
Research, London, United Kingdom
Wylie, L., B.S., University of Cambridge, United Kingdom
Yim, D., B.Sc., Duke-NUS Graduate Medical
School/TUMCB, Singapore
Zimmerman, L., Ph.D., National Institute for Medical
Research, London, United Kingdom
SEMINARS
Gilchrist, M., National Institutes for Medical Research,
London, United Kingdom: Xenopus: genomes, genomics, and
computational biology. Workshop: Online resources for
Xenopus gene expression data.
Gingeras, T., Cold Spring Harbor Laboratory: Biological
lessons learned about the human and fly transcriptomes from
the looking at the numbers.
Grainger, R., University of Virginia, Charlottesville:
Workshop. Genomic approaches to enhancer identification.
Analysis of eye formation in Xenopus: Model system for
studies of determination and organogenesis.
Houston, D., University of Iowa, Iowa City: Symmetry
breaking in the Xenopus egg-localized RNAs set the stage.
Keller, R., University of Virginia, Charlottesville:
Morphogenesis.
Khokha, M., Yale University School of Medicine, New Haven,
Connecticut: Introduction to X. tropicalis and using Xenopus
to study human disease genes.
Kroll, K., Washington University School of Medicine, St.
Louis, Missouri: Epigenetic regulation of early cell-fate
acquisition.
Lin, K., University of Minnesota, Minneapolis: Cellular and
molecular mechanisms of appendage regeneration in Xenopus
laevis.
Lowe, S., Cold Spring Harbor Laboratory: Identifying tumor
suppressor and tumor maintenance genes using mouse
models and RNAi.
Nakayama, T., University of Virginia, Charlottesville:
Approaches for manipulating gene expression in Xenopus.
Sater, A., University of Houston, Texas: Xenopus as a model
system: History and prospects.
Thomsen, G., Stony Brook University, New York: The
Xenopus Organizer.
Wallingford, J., University of Texas, Austin: The awesome
power of live imaging in Xenopus.
Workshop on Autism Spectrum Disorders
June 8−15
INSTRUCTORS D. Geschwind, University of California, Los Angeles
P. Levitt, University of Southern California, Los Angeles
S. Spence, Children’s Hospital, Boston, Massachusetts
ASSISTANT K. Aldinger, University of Southern California, Los Angeles
Autism spectrum disorders (ASDs) are developmental disorders with complex phenotypes defined by
a triad of symptoms that include disrupted social abilities, verbal and nonverbal communication skills,
and restricted interests with repetitive behaviors. Both neurological and medical conditions often
occur in the disorder. The underlying etiology remains a mystery, but ASD is one of the most highly
heritable of neuropsychiatric disorders. This workshop examined dimensions of ASD on various levels,
including sessions on characteristics of the clinical syndrome, the neuropathology, imaging, and cog-
nitive neuroscience studies that implicate circuits and systems involved in ASD, the current state of
findings from human genetics, concepts regarding the developmental neurobiological basis, the use
of experimental models, and current etiological theories and hypotheses of ASD. 
In addition to hearing about the most recent research in these areas, we explored and debated
controversial topics and challenges to basic assumptions in the field. An exceptional faculty with
diverse interests brought the most up-to-date results and theories to the students, making this work-
shop a valuable resource for young researchers starting out in this fast-moving and expansive field.
Not only did it help them build the foundation for their future research, but it also introduced them
to many potential collaborators working to understand ASD from different disciplines. The work-
shop had hands-on exercises to complement the featured intense lecture sessions.
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PARTICIPANTS
Acharya, V., M.D., Penn State University, Hershey 
Aida, T., Ph.D., Tokyo Medical and Dental University, Japan
Atbasoglu, E.C., Ankara University, Turkey
Aykan, S., B.S., Ankara University, Turkey
Bangash, M.A., B.S., Johns Hopkins School of Medicine,
Baltimore, Maryland
Belgard, T., B.S., National Institutes of Health, Bethesda,
Maryland
Carrulo, M.P., Ph.D., Children’s Hospital, Boston & Harvard
University, Boston, Massachusetts
Glavis-Bloom, C., Ph.D., SRI International, Menlo Park,
California
Gordon, I., Yale University, New Haven, Connecticut
Grubb, M., B.S., New York University, New York
Jung, J.-Y., Ph.D., Harvard Medical School, Cambridge,
Massachusetts
Lippman Bell, J., Ph.D., Children’s Hospital, Boston/Harvard
University, Boston, Massachusetts
Liu, X., B.S., The University of Tokyo, Japan
Lucchina, L., B.S., IFIBYNE-CONICENT, Buenos Aires,
Argentina
McEvoy, K., B.S., University of California, Los Angeles
Mehta, S., B.S., University of California, Los Angeles
Nakai, N., B.S., Hiroshima University, Japan
Raznahan, A., Ph.D., National Institutes of Mental Health,
NIH, Bethesda, Maryland
Soke, G.N., B.S., University of Colorado/JFK Partners,
Denver
SEMINARS
Biederer, T., Yale University, New Haven, Connecticut:
Synaptic differentiation and autism spectrum disorders.
Geschwind, D. University of California, Los Angeles:
Introduction to human genetics and findings in ASDs.
Genomics/gene expression. Molecular models of ASD in
humans.
Hensch,T., Harvard University, Boston, Massachusetts:
Critical periods/plasticity mechanisms.
Kasari, C., University of California, Los Angeles: Treatments
overview.
Levitt, P., University of Southern California, Los Angles:
Mammalian animal models. Neuroanatomical systems
implicated in ASD and neuropathology.
Martinez, F., University of Arizona, Tucson: Environmental
contributions: Asthma as a model.
McPartland, J., Yale University, New Haven, Connecticut:
Neurocognition and face processing mechanisms.
McPartland, J. and Pelfrey, K., Yale University, New Haven,
Connecticut: Introduction to imaging and ERP.
Newschaffer, C., Drexel University, Philadelphia,
Pennsylvania: Epidemiology of ASD: Are rates really rising—
Can we even tell?
Pardo-Villamizar, C., Johns Hopkins University School of
Medicine, Baltimore, Maryland: Neuroimmunology.
Pelfrey, K., Yale University, New Haven, Connecticut:
Neuroimaging findings in ASD.
Rapin, I., Albert Einstein School of Medicine, Bronx, New
York: Autism’s odyssey—1943−2011.
Sahin, M., Children’s Hospital, Boston, Massachusetts:
Translational trials: Rapamycin in tuberous sclerosis
complex.
Spence, S., Children’s Hospital, Boston, Massachusetts:
Clinical assessments (clinical videos, student excercises: 
ADI-R, ADOS, SRS). Medical models/comorbidities.
Endophenotypes, language delay, epilepsy/regression, OFC.
Stone, W., University of Washington, Seattle: Clinical
presentation, core features. ASD measures, broader
phenotypes, phenotypic variability, outcomes.
Suomi, S., NICHD, National Institutes of Health, Bethesda,
Maryland: Evolutionary perspectives on social behavior.
Szyf, M., McGill University, Montreal, Canada: Epigenetics.
Wall, D., Harvard University, Cambridge, Massachusetts:
Genomic tools exercises: Bioformalities, database access, data
gathering and uses.
Advanced Bacterial Genetics
June 8–28
INSTRUCTORS D. Hughes, Uppsala University, Sweden
B. Lazazzera, University of California, Los Angeles
F. Yildiz, University of California, Santa Cruz
ASSISTANTS J. Bergman, Uppsala University, Sweden
S. Hoover, University of California, Los Angeles
N. Shikuma, University of California, Santa Cruz
This course presented logic and method used in the genetic dissection of complex biological processes
in diverse bacteria. Laboratory methods included classical mutagenesis using transposons, mutator
strains, and chemical mutagens; recombineering with single- and double-stranded DNA; detection
of gene expression changes using various reporter genes; the mapping of mutations using genetic
and physical techniques; modern approaches to the generation and analysis of targeted gene dis-
ruptions and fusions using polymerase chain reaction (PCR) and cloning methods; epitope insertion
mutagenesis; site-directed mutagenesis; and fluorescence microscopy. Key components of the course
were the use of sophisticated genetic methods in the analysis of model bacterial (including Escherichia
coli, Salmonella, Bacillus subtilis, and Vibrio cholerae) and the use of the wealth of new genomic se-
quence information to motivate these methods. 
Invited lecturers presented various genetic approaches to study bacterial mechanisms of metab-
olism, development, and pathogenesis. 
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PARTICIPANTS
Anderson, E., B.S., Whitehead, Institute/MIT, Cambridge,
Massachusetts
Ballok, A., B.S., Dartmouth Medical School, Hanover, New
Hampshire
Cenens, W., B.Sc., KuLeuven, Heverlee, Belgium
Currie, D., B.S., Dartmouth College MCB Program, Hanover,
New Hampshire
Engstrom, A., M.Sc., Swedish Institute for Infectious Disease
Control, Solna, Sweden
Hatosy, S., University of California, Irvine
Hsin, J., Ph.D., Stanford University, California
Jochumsen, N., B.S., Technical University of Denmark, Kgs.
Lynbgy, Denmark
Kubik, T., B.Sc., The Rockefeller University, New York
Mathis, R., M.S., ETH Zurich, Duebendorf, Switzerland
Moolman, M., M.Sc., Delft University of Technology, Delft,
The Netherlands
Neupane, M., D.V.M., Michigan State University, Lansing
Rivera, A., Ph.D., University of Illinois, Urbana-Champaign
Schiessl, K., Dipl., Eawag, Dubendorf, Switzerland
Zhang, H., Ph.D., University of Central Florida, Orlando
Ziegler, S., Dipl., Albert-Ludwigs University, Freiburg,
Germany
SEMINARS
DiRita, V., University of Michigan Medical School, Ann Arbor:
Genetic approaches for discovering genes and uncovering
mechanisms in Vibrio cholera and Campylobacter jejuni.
Ibba, M., Ohio State University, Columbus: Aminoacyl-tRNA
synthetases and translation quality control.
Levin, P., Washington University, St. Louis, Missouri: A
nucleotide sugar coordinates cell size with carbon availability
in divergent model organisms.
Maloy, S., San Diego State University, California: Plasticity of
the bacterial genome.
Matic, I., INSERM, Paris, France: Modulation of mutation
rates in bacteria.
Sawitzske, J., National Cancer Institute, Frederick, Maryland:
Optimization of oligo recombination and an update on the
molecular mechanisms.
Visick, K., Loyola University Medical Center, Maywood,
Illinois: Use of genetics to dissect the complex regulatory
pathway controlling biofilm formation and colonization by
Vibrio fischeri.
Winkler, M., Indiana University, Bloomington: Cell wall
biosynthesis and antibiotic stress responses in pneumococcal
growth and virulence.
Ion Channel Physiology
June 8–28
INSTRUCTORS N. Golding, The University of Texas, Austin
P. Kammermeier, University of Rochester Medical Center, New York
M. Nolan, University of Edinburgh, United Kingdom
ASSISTANTS C. Bladen, University of Calgary, Alberta, Canada
A. Fink, Columbia University, New York
A. Graves, Northwestern University, Evanston, Illinois
K. Hansen, Emory University School of Medicine, Atlanta, Georgia
L. Kelly, The Rockefeller University, New York
V. Lu, NIH/NIAAA/LMP, Rockville, Maryland
K. Ogden, Emory University, Atlanta, Georgia
M. Roberts, The University of Texas at Austin
C. Schoonover, Columbia University, New York
The primary goal of this course was to investigate, through lectures and laboratory work, the prop-
erties of ion channels that allow neurons to carry out their unique physiological functions in a variety
of neural systems. Areas of particular interest included channels that (1) are activated by neurotrans-
mitter at central and peripheral synapses, (2) are activated by voltage changes in axons and dendrites,
(3) respond to neuromodulators with changes in functional properties, or (4) are developmentally
required and regulated by light. The research interests of guest lecturers reflected these areas of em-
phasis.
The laboratory component of the course introduced students to electrophysiological approaches
for the study of ion channels in their native environments. Hands-on exercises included patch-clamp
recording of ion channel activity in acutely isolated or cultured cells or neurons in brain slice prepa-
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Abraira, V., Ph.D., Johns Hopkins Medical Institute,
Baltimore, Maryland
Agosto, M., Ph.D., Baylor College of Medicine, Houston, Texas
Buffington, S., B.S., Baylor College of Medicine, Houston, Texas
Che, Y., B.S., University of Connecticut, Storrs
Christianson, J., Ph.D., University of Colorado, Boulder
Hennessey, J., B.A., Duke University, Durham, North
Carolina
rations. Different recording configurations were used (e.g., whole-cell, cell-free, and nucleated
patches) to examine macroscopic or single-channel activity. Similarly, various methods of ligand
and drug application were demonstrated. The advantages and disadvantages of each method, prepa-
ration, and recording technique were considered in relation to the specific scientific questions being
asked. Admissions priority was given to students and postdocs with a demonstrated interest, specific
plans, and a supportive environment to apply these techniques to a defined problem. 
This course was supported by the Howard Hughes Medical Institute.
PARTICIPANTS
Kirkby, L., M.Physicology, University of California, Berkeley
Nagaraja, C., BEME, Uppsala University, Sweden
Rosen, Z., B.A., Columbia University, New York
Sitaraman, D., Ph.D., Yale University, New Haven,
Connecticut
Stempel, V., B.Sc., Charite Berlin, Germany
Wang, G., B.S., Boston University, Massachusetts
SEMINARS
Brenowitz, S., NIDCD/National Institutes of Health,
Bethesda, Maryland: EPSCs.
Brown, D., University College London, United Kingdom:
Evening research lecture.
Clark, B., University College London, United Kingdom:
Sodium channels.
Colecraft, H., Columbia University, New York: Calcium
channels.
Deisseroth, K., Stanford University, California: Channel
engineering 1.
Du Lac, S., The Salk Institute, La Jolla, California: Intrinsic
plasticity, microcircuits.
Farrant, M., University College London, United Kingdom:
Synapses, GABA/IPSCs.
Kramer, R., University of California, Berkeley: Channel
engineering 2.
Larsoon, P., University of Miami, Florida: Potassium channels.
Schwartz, K., National Institutes of Health, Bethesda,
Maryland: Voltage-gated ion channels.”
Sjostrom, J., University College London, United Kingdom:
Plasticity.
Spruston, N., Northwestern University, Evanston, Illinois:
Synaptic integration and dendrites.”
Traynelis, S., Emory University, Atlanta, Georgia: Ligand-
gated channels; glutamate receptors.
Tsien, R., Stanford University Medical Center, California
Molecular Embryology of the Mouse
June 8–28
INSTRUCTORS K. Hadjantonakis, Memorial Sloan-Kettering Cancer Center, New York
J. Rivera-Perez, University of Massachusetts Medical School, Worcester
CO-INSTRUCTORS R. Johnson, MD Anderson Cancer Center, Houston, Texas
X. Sun, University of Wisconsin, Madison
ASSOCIATE
CO-INSTRUCTOR D. Escalante-Alcalde, Institute of Cellular Physiology-UNAM, Mexico
ASSISTANTS E. Domyan, University of Wisconsin, Madison
J. Herriges, University of Wisconsin, Madison
T. Huang, University Medical School, Worcester, Massachusetts
S. Munoz-Descalzo, University of Cambridge, Cambridge, United Kingdom
Y. Yoon, University of Massachusetts Medical School, Worcester
This intensive laboratory and lecture course was designed for biologists interested in applying their
expertise to the study of mouse development. Lectures provided the conceptual basis for contem-
porary research in mouse stem cell biology, embryogenesis, and organogenesis, whereas laboratory
practicals provided extensive hands-on introductions to mouse stem cell and embryo analysis. Ex-
perimental techniques covered included in vitro culture and manipulation of pre- and postimplan-
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PARTICIPANTS
Buecker, C., M.Sc., Stanford School of Medicine, California
Carrera, I.-M., Ph.D., Ebiotec Foundation, La Coruna, 
Spain
Chojnowski, J., Ph.D., University of Georgia, Athens
Cinalli, R., B.S., New York University School of Medicine,
New York
Colaneri, A., Ph.D., National Institute of Environmental
Health Sciences, RTP, North Carolina 
Davis, F., Ph.D., Northeastern University, Boston,
Massachusetts
Gundry, R., Ph.D., Medical College of Wisconsin, Milwaukee
tation embryos, embryo transfer, culture and derivation and genetic manipulation of embryonic
stem (ES) cells, production of chimeras by embryo aggregation and by ES cell injection, and trans-
genesis by pronuclear microinjection. In addition, this year’s practicals featured increased emphasis
on phenotypic analysis of mutants, including techniques of histology, in situ hybridization, im-
munohistochemistry, skeletal preparation, organ culture, and tissue recombination. The course also
introduced the generation of iPS cells (induced pluripotent cells) and time-lapse microscopy of early
gastrulation embryos and organ cultures (eye, kidney and gut).
This course was supported with funds provided by the National Cancer Institute.
Hannibal, R., Ph.D., Stanford University, California
Huang, A., Ph.D., Shriners Hospital for Children Research
Center, Portland, Oregon
Menshykau, D., M.S., ETH Zurich, Basel, Switzerland
Norville, J., Ph.D., Massachusetts Institute of Technology,
Cambridge
O’Brien, K., Ph.D., Cornell University, Ithaca, New York
Ouspenskaia, T., B.S., The Rockefeller University, New York
Steidl, C., M.D., British Columbia Cancer Agency, Vancouver,
Canada
SEMINARS
Behringer, R., The University of Texas/MD Anderson Cancer
Center, Houston: Transgenesis.
Capel, B., Duke University Medical Center, Durham, North
Carolina: Germ cells and development.
Foley, A., Weill Cornell Medical College, New York: Cardio-
vascular development.
Hadjantonakis, K., Memorial Sloan-Kettering Cancer Center,
New York: Mouse embryo imaging: Confocal approaches.
Johnson, R., Anderson Cancer Center, Houston, Texas:
Somitogenesis. Liver development and hippo signaling.
Joyner, A., Memorial Sloan-Kettering Cancer Center, New
York: Patterning and genetic fate mapping approaches:
Application in the nervous system.
Justice, M., Baylor College of Medicine, Houston, Texas: ENU
mutagenesis.
Lovell-Badge, R., MRC National Institute for Medical
Research, London, United Kingdom: Sex determination.
Magnuson, T., University of North Carolina, Chapel Hill:
Epigenetics.
McMahon, A., Harvard University, Cambridge, Massachu-
setts: Kidney development.
Mills, A., Cold Spring Harbor Laboratory: Chromosome
engineering.
Nagy, A., Samuel Lunenfeld Research Institute, Toronto,
Ontario, Canada: iPS cells.
Pevny, L., University of North Carolina, Chapel Hill:
Retinogenesis and eye development.
Rivera-Perez, J., University of Massachusetts Medical School,
Worcester: Early postimplantation development: Morpho-
genesis and cell lineage.
Robertson, E., University of Oxford, United Kingdom:
Signaling in the early postimplantation embryo and axial
development.
Rossant, J., The Hospital for Sick Children, Toronto, Ontario,
Canada: Early cell lineages, embryo-derived stem cells, and
chimeras.
Shen, M., Columbia University Medical Center, New York:
Prostate development, stem cells, and cancer.
Solter, D., Institute of Medical Biology, Singapore: Historical
overview of the mouse as a model system. Preimplantation
development.
Soriano, P., Mt. Sinai School of Medicine, New York: Gene
targeting, gene traps and recombinases: Theory and
applications. 
Sun, X., University of Wisconsin, Madison: Limb develop-
ment. Lung development.
Sussel, L., Columbia University, New York: Pancreas develop-
ment.
Tam, P., Children’s Medical Research Institute, Westmead,
Sydney, Australia: Gastrulation and establishment of the
germ layers.
Trainor, P., Stowers Institute for Medical Research, Kansas
City, Missouri: Craniofacial development and the neural
crest.
Turnbull, D., New York University Medical Center, New York:
Mouse embryo imaging: Ultrasound and MRI.
Proteomics
June 13–28
INSTRUCTORS T. Andacht, Centers for Disease Control and Prevention, Atlanta, Georgia
J. Bruce, University of Washington, Seattle
A. Link, Vanderbilt University School of Medicine, Nashville, Tennessee
D. Pappin, Cold Spring Harbor Laboratory
CO-INSTRUCTOR M. Cilia, USDA-ARS, Ithaca, New York
ASSISTANTS S. DeBlasio, Cold Spring Harbor Laboratory
B. King, Cornell University, Ithaca, New York
C. Ruse, Cold Spring Harbor Laboratory
P. Samir, Vanderbilt University, Nashville, Tennessee
B. Weindorf, Cold Spring Harbor Laboratory
C. Zheng, University of Washington, Seattle
This intensive laboratory and lecture course focused on cutting-edge proteomic approaches and
technologies. Students gained practical experience purifying and identifying protein complexes and
posttranslational modifications. In a section focused on quantitative whole-proteome analyses or
top-down proteomics, students gained hands-on experience using two-dimensional gel electrophore-
sis and mass spectrometry analysis. Students used differential in-gel electrophoresis (DIGE) for gel-
based protein quantification. Differentially expressed proteins were recognized by statistical methods
using advanced gel analysis software and identified using MALDI mass spectrometry. For shotgun
proteomic analysis sections or bottom-up proteomics, students used label-free and covalent isotopic-
labeling quantitative approaches to differentially profile changes in protein complexes and whole
proteomes. Students were trained in high-sensitivity microcapillary liquid chromatography coupled
with nanospray-ESI and tandem mass spectrometry analysis. Students learned both single-dimension
and multidimensional separation methods. In a section focused on targeted proteomics, students
learned to analyze and process shotgun proteomic data for the development of SRM/MRM assays
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Bangasser, D., Ph.D., The Children’s Hospital of Philadelphia,
Pennsylvania
Hinton, S., Ph.D., College of William and Mary, Williams-
burg, Virginia
Mancewicz Arslanoglu, J., M.S., Metropolitan Museum of Art,
New York
Mesrobian, H., M.S., Medical College of Wisconsin,
Milwaukee
Messner, D., Ph.D., Bastyr University, Kenmore, Washington
Morgenstern, D., B.Sc., University of Queensland, St. Lucia,
Australia
Poulsen, L., Ph.D., Technical University of Denmark, Kgs.
Lyngby, Denmark
Ralston, K., Ph.D., University of Virginia, Charlottesville
that accurately identify and quantify targeted proteins. Students designed transitions for selected
peptides and performed SRM/MRM mass spectrometry assays. They learned to process and interpret
the acquired data to measure changing quantities of targeted proteins in a variety of biological sam-
ples. For all sections of the course, a strong emphasis was placed on data analysis. A series of outside
lecturers discussed various proteomics topics including imaging by mass spectrometry, de novo se-
quence analysis, advanced mass spectrometry methods, protein arrays, and functional proteomics.
The aim of the course was to provide each student with the fundamental knowledge and hands-on
experience necessary for performing and analyzing proteomic experiments. The overall goal was to
train students to identify new opportunities and applications for proteomic approaches in their bi-
ological research.
This course is supported with funds provided by the National Cancer Institute.
PARTICIPANTS
Rowland, S., B.S., University of Maryland/IMET, Baltimore,
Maryland
Silva, G., M.S., New York University, New York
Singh, R., M.Sc., Florida State University, Tallahassee 
Slavoff, S., Ph.D., Harvard University, Cambridge,
Massachusetts
Subramanian, V., Ph.D., Whitehead Institute, Cambridge,
Massachusetts
Taka, E., Ph.D., Florida A&M University, Tallahassee
Taylor, H., Ph.D., Meharry Medical College, Nashville,
Tennessee
Waldron, L., B.S., University of North Carolina, Chapel Hill
Zhou, S., Ph.D., Tennessee State University, Nashville
SEMINARS
Andacht, T., Centers for Disease Control and Prevention,
Atlanta, Georgia: Fundamentals of 2-D DIGE for top-down
proteome analysis.
Beckett, P., General Electric, Piscataway, New Jersey:
Application of Decyder software to analyze and interpret 
2-D DIGE for top-down proteome analysis.
Bruce, J., University of Washington, Seattle: Fundamentals of
mass spectrometry for proteomics.
Bulman, A. Bruker Daltonics, Billerica, Massachusetts:
Introduction and application of MALDI-TOF/TOF 
mass spectrometry in proteomics.
Chait, B., The Rockefeller University, New York: Proteomics
analysis of proteins complexes and protein machines: Viral
infections and nuclear pore complex.
Chaurand, P., University of Montreal, Canada: Tissue imaging
and profiling by mass spectrometry.
Clauser, K., Broad Institute of MIT/Harvard, Cambridge,
Massachusetts: Manual de novo peptide MS/MS
interpretation for evaluating database search results.
Cristea, I., Princeton University, New Jersey: A proteomics
perspective of the dynamic interplay between oncogenic
viruses and hosts.
Eng, J., University of Washington, Seattle: MS/MS sequence
database searching and downstream analysis.
Friedman, D., Vanderbilt University, Nashville, Tennessee:
Variation and experimental design for proteomic analyses,
Variation and experimental design for proteomic analyses:
2D-DIGE and LC-MS/MS proteomics.
Hunt, D., University of Virginia, Charlottesville: Application
electron transfer dissociation for the analysis of peptides and
posttranslation moc. Identification of cancer therapeutics
derived from dysregulated signal transduction pathways.
Kellie, J., Northwestern University, Evanston, Illinois:
Methods and applications for top down proteomics. Top-
down analysis of mass spectrometry from intact and
fragmented proteins.
Link, A., Vanderbilt University, Nashville, Tennessee:
Introduction and overview of the 2011 Cold Spring Harbor
Laboratory Proteomics Course.
Pappin, D., Cold Spring Harbor Laboratory: Fundamentals of
mass spectrometry to identify peptides and proteins.
Fundamentals of quantitative mass spectrometry for
proteomics.
Smolka, M., Cornell University, Ithaca, New York:
Investigating cell signaling networks with quantitative
proteomics.
Workshop on Pancreatic Cancer
June 16–June 22
INSTRUCTORS D. Bar-Sagi, New York University Medical Center, New York
A. Maitra, Johns Hopkins University School of Medicine, Baltimore, Maryland
D. Tuveson, Cambridge Research Institute, United Kingdom
ASSISTANT K. Olive, Columbia University, New York
Pancreatic cancer is one of the deadliest cancers: Tumors are often diagnosed at advanced stages of
the disease and metastasize rapidly. This 1-week discussion course provided a comprehensive
overview of clinical and biological aspects of pancreatic cancer with special emphasis on disease di-
agnosis and management, molecular pathways involved in tumor development and progression,
mechanism-based therapeutic strategies, advanced research tools, and ethical concerns. Attendees
were able to interact with senior investigators on a one-to-one basis in an informal environment.
Nonfaculty students were eligible for partial stipends, depending on stated need. Applications were
invited from medical and graduate students, postdoctoral fellows, and faculty. 
PARTICIPANTS
Aizenberg, R., B.S., Pancreatic Cancer Action Network,
Manhattan Beach, California
Bednar, F., Ph.D., University of Michigan, Ann Arbor
Collins, M., B.S., University of Michigan, Ann Arbor
Court, H., Ph.D., New York University Medical Center, New
York
DelGiorno, K., B.S., SUNY Stony Brook, New York
Drosos, Y., Ph.D., St. Jude Children’s Research Hospital,
Memphis, Tennessee
Goni, E., B.S., University Vita-Salute San Raffaele, Milano,
Italy
Holland, A., B.S., Monash University, Clayton, Australia
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Holmstrom, S., Ph.D., University of Texas Southwestern,
Dallas
Huang, L., Ph.D., Ontario Cancer Institute, University of
Toronto, Canada
Ludwig, M., B.S., University of Alabama at Birmingham 
Morris I.V., J., B.S., University of California, San
FranciscoPiciucchi, M., M.D., Sapienza University II
Medical School, Rome, Italy
Roy, I., B.S., Medical College of Wisconsin, Milwaukee
Schmerr, M., Ph.D., Cleveland Clinic, Ohio
Solar, M., B.S., Hospital Clinic/IDIBAPS, Barcelona, Spain 
Tsai, S., M.D., Medical College of Wisconsin, Milwaukee
Wang, M., Ph.D., University of Texas Southwestern Medical
Center, Dallas
Westphalen, C., Ph.D., Columbia University Medical Center,
New York
SEMINARS
Bar-Sagi, D., New York University Medical Center, New York:
Pathways.
Der, C., University of North Carolina, Chapel Hill: Target
identification.
Garrett-Mayer, E., Medical University of South Carolina,
Clarkson: Clinical trial design.
Goggins, M., Johns Hopkins Medical School, Baltimore,
Maryland: Molecular genetics.
Hahn, W., Dana Farber Cancer Institute/Harvard Medical
School, Boston, Massachusetts: Target identification.
Hebrok, M., University of California, San Francisco:
Pathways.
Hollingsworth, M., University of Nebraska Medical Center,
Omaha: Resources and career development.
Kelly, K., University of Virginia, Charlottesville: Imaging new
modalities: Mouse.
Kindler, H., University of Chicago Medical Center, Illinois:
Clinical trial design.
Longnecker, D., Dartmouth Medical School, Hanover, New
Hampshire: Anatomy and physiology.
Maitra, A., Johns Hopkins University School of Medicine,
Baltimore, Maryland: Histopathology.
Megibow, A., New York University, New York: Diagnosis and
imaging II.
Olive, K., Columbia University, New York: Microenviron-
ment: Nonimmune.
Pandey, A., Johns Hopkins Medical School, Baltimore,
Maryland: Omics: Proteomics.
Pollack, J., Stanford University, California: Molecular genetics.
Simeone, D., University of Michigan Medical Center, Ann
Arbor: Diagnosis and imaging I.
Spalholz, B., National Cancer Institute, Rockville, Maryland:
Resources and career development.
Tempero, M., University of California, San Francisco:
Cachexia and pain.
Tuveson, D., Cambridge Research Institute, United Kingdom:
Mouse models.
Van der Heiden, M., Massachusetts Institute of Technology,
Cambridge: Omics: Metabolomics.
Vonderheide, R., University of Pennsylvania, Philadelphia:
Microenvironment: Immune.
Wu, A., University of California, Los Angeles: Imaging new
modalities: Human.
Welch, J., National Institutes of Health, Baltimore, Maryland:
Clinical trial design.
Molecular Neurology and Neuropathology
June 27–July 3
INSTRUCTORS M. Cookson, National Institute on Aging/NIH, Baltimore, Maryland 
B. Davidson, University of Iowa College of Medicine, ,[Need city]
H. Orr, University of Minnesota, Minneapolis
This intensive 1-week discussion course offered successful applicants a unique opportunity to learn
the latest concepts and methodologies associated with the study of human neurological disorders
such as Alzheimer’s, Parkinson’s, and epilepsy. Participants discussed in detail the strengths and
weaknesses of the accumulated experimental evidence underlying our current understanding of these
diseases. Fundamental questions, such as how and why particular neurons die in certain disorders,
were discussed in the context of identifying the best experimental approaches to finding answers,
whether through the use of transgenic and/or lesion-induced mouse models, functional brain and/or
cellular imaging, gain-/loss-of-function molecular and viral approaches, cellular transplantation, or
a combination of these approaches. The course examined why many of these disorders share appar-
ently common features such as protein aggregation, specific vulnerability of certain classes of neuron,
and long incubation period and discussed to what extent these features reflect common pathological
mechanisms. The course further explored how the underlying mechanisms in these disparate disor-
ders may be targeted for potential diagnostic and therapeutic gain. Extended seminars and discussion
by a wide range of leading investigators further illuminated developments in this rapidly moving
field. Participation in the course provided an essential conceptual and methodological framework
for anyone intending to pursue rigorous research.
The course was held at the Laboratory’s Banbury Conference Center located on the north shore
of Long Island. All participants stayed within walking distance of the Center, close to a tennis court,
pool, and private beach. Participants were encouraged to arrive in the afternoon of June 26 for an
evening start.
This course was supported with funds provided by the Howard Hughes Medical Institute.
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SEMINARS
Cookson, M., NIH/National Institute on Aging, Baltimore,
Maryland: Parkinson’s disease.
Darnell, J., The Rockefeller University, New York: Special
lecture.
Davidson, B., University of Iowa, Ames: Lysosmal diseases.
Duff, K., Colombia University, New York: Alzheimer’s disease.
Iadecola, C., Weill Cornell Medical Center, New York: Stroke.
McNamara, J., Duke University Medical Center, Durham,
North Carolina: Epilepsy. 
Morris, H., Cardiff University, United Kingdom: Neurological
aspects.
PARTICIPANTS
Chua, J., B.S., University of Michigan, Ann Arbor
Gogliotti, R., B.S., Northwestern University, Chicago, Illinois 
Hauser, D., B.S., NIH/National Institutes on Aging,
Bethesda, Maryland 
Henderson, M., Ph.D., National Institute on Drug Abuse,
Baltimore, Maryland
Hill, J., B.S., University of Texas Medical School at Houston,
Houston 
Ingram, M., B.S., University of Minnesota, Minneapolis
Jorgensen, N., B.S., University of Copenhagen, Copenhagen,
Denmark
Kay, V., B.S., University London College Institute of
Neurology, United Kingdom
Korff, A., Ph.D., St. Jude Children’s Research Hospital,
Memphis, Tennessee
Nelson, D., Baylor College of Medicine, Houston, Texas:
Fragile X and associated syndromes.
Orr, H., University of Minnesota, Minneapolis: Spinocere-
bellar ataxia.
Rademakers, R., Mayo Clinic College of Medicine, Jackson-
ville, Florida: Front temporal dementia.
Rothstein, J., Johns Hopkins University School of Medicine,
Baltimore, Maryland: Amyotrophic lateral sclerosis.
Warren, S., Emory University School of Medicine, Atlanta,
Georgia: Schizophrenia.
Machamer, J., Ph.D., Johns Hopkins University, Baltimore,
Maryland 
Neuhuber, B., B.S., National Institutes of Health, North
Bethesda, Maryland
Peelaerts, W., B.S., Laboratory for Neurobiology and Gene
Therapy, Leuven, Belgium
Pradhan, S., B.S., Stanford University, California
Sassi, C., M.D., NIH/National Institutes on Aging/University
College London, Bethesda, Maryland
Van der Kant, R., B.S., Netherlands Cancer Institute,
Amsterdam, The Netherlands 
VanGilder, R., Ph.D., West Virginia University, Morgantown
Vannini, E., B.S., Scuola Normale Superiore, C.N.R., Pisa,
Italy
Computational Cell Biology
July 1−21
INSTRUCTORS L. Loew, University of Connecticut Health Center, Farmington
G. Smith, College of William and Mary, Williamsburg, Virginia
J. Tyson, VirginiaTech, Blacksburg
ASSISTANTS A. Ahmet, Colgate University, Hamilton, New York
S.-A. Brown, University of Connecticut Health Center, Farmington
C. Chen, Virginia Tech, Blacksburg
M. LaMar, The College of William and Mary, Williamsburg, Virginia
C. Oguz, Virginia Tech, Blacksburg
O. Walch, The College of William and Mary, Williamsburg, Virginia
Computational cell biology is the field of study that applies the mathematics of dynamical systems
together with computer simulation techniques to the study of cellular processes. The field encompasses
several topics that have been studied long enough to be well established in their own right, such as
calcium signaling, molecular motors and cell motility, the cell cycle, and gene expression during de-
velopment. In addition to providing a recognizable larger community for topics such as these, this
course provided a base for the development of newer areas of inquiry, for example, the dynamics of
intracellular second-messenger signaling, of programmed cell death, of mitotic chromosome move-
ments, and of synthetic gene networks. Unlike computational genomics or bioinformatics, compu-
tational cell biology is focused on simulation of the molecular machinery (genes–proteins–metabo-
lites) that underlie the physiological behavior (input-output characteristics) of living cells.
This 3-week course incorporated a series of didactic lectures on the mathematics of dynamical
systems, computational simulation techniques, cell biology, and molecular biology. Practicing the-
oreticians and experimentalists rotated in for 1−3-day visits during the course to give lectures and
interact with the students. Midway through the course, students selected an area for independent
study, and the focus of the last week of the course was largely on these projects, supplemented by
continued visiting lecturers.
This course was supported with funds provided by the National Science Foundation.
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SEMINARS
Albert, R., Penn State University, University Park: Discrete
dynamic modeling of signal transduction networks.
Blackwell, A., George Mason University Krasnow Institute,
Fairfax, Virginia: Neuronal signaling.
Blackwell, A., George Mason University Krasnow Institute,
Fairfax, Virginia; Keener, J., University of Utah, Salt Lake
City; Smith, G., The College of William and Mary,
Williamsburg, Virginia; Moraru, I., University of Connecticut
Health Center, Farmington; and Schaff, J., University of
Connecticut Health Center, Farmington: Exercises.
Edelstein-Keshet, L., University of British Columbia,
Vancouver: Building up a model from the group up. A case
study using a simple epidemic model.
Faeder, J., University of Pittsburgh, Pennsylvania: Rule-based
modeling.
Hasty, J., University of California, San Diego, La Jolla: Gene
networks.
Hucka, M., California Institute of Technology, Pasadena:
SMBL, model databases, and translation.
Iyengar, R., Mount Sinai School of Medicine, New York:
Signaling models.
Keener, J., University of Utah, Salt Lake City: Cardiac
physiology.
Keener, J., University of Utah, Salt Lake City, and Smith, G.,
The College of William and Mary, Williamsburg, Virginia:
NeuroRD/Cardiac models/Stochastic models.
LaMar, D., and  Day, S., The College of William and Mary,
Williamsburg, Virginia: Network topology/chemical reaction
network theory.
Lechleiter, J., University of Texas Health Sciences Center, San
Antonio: Calcium signaling.
Loew, L., University of Connecticut Health Center,
Farmington: Model building w/VCell; VCell and ODEs.
Ma’ayan, A., Mt. Sinai School of Medicine, New York:
Network analysis in systems biology.
Mendes, P., University of Manchester, United Kingdom:
Copasi and parameter estimation.
Moraru, I., and Loew, L., University of Connecticut Health
Center, Farmington: VCell and ODEs.
Moraru, I., and Schaff, J., University of Connecticut Health
Center, Farmington: VCell stochastic and spatial modeling.
Phair, R., Integrative Bioinformatics, Los Altos, California:
Molecular cell biology and ODEs, fluorescent proteins, and
tracer kinetics.
Schaff, J., and Loew, L., University of Connecticut Health
Center, Farmington: VCell and PDEs; actin dendritic
nucleation.
Schaff, J., Loew, L., and Moraru, I., University of Connecticut
Health Center, Farmington: VCell spatial exercises.
Sherman, A., National Institutes of Health, Bethesda,
Maryland: Modeling calcium dynamics.
Smith, G., The College of William and Mary, Williamsburg,
Virginia: Cellular biophysics and ODEs. Random walks and
diffusion. Stochastic modeling.
Terman, D., Ohio State University, Columbus: Dynamical
systems. Introduction to XPP. Waves. XPP exercises.
Tyson, J., Virginia Tech, Blacksburg: How cells
compute/network motifs and functional modules. Temporal
organization of the cell cycle/design principles of biochemical
oscilliators. XPP exercises.
Wellman, H., Mathworks, Natick, Massachusetts: Matlab.
Wolf, V., Saarland University, Germany: Stochastic modeling
of biochemical networks.
You, L., Duke University, Durham, North Carolina: Modeling
and experimental analysis of mammalian cell cycle entry.
Programming bacteria.
O’Donoghue, D., B.Sc., University College London, United
Kingdom
Parker, K., B.S., Moss Landing Marine Labs, Los Altos,
California
Paulson, J., B.S., University of Maryland, College Park
Qin, H., Ph.D., Spelman College, Atlanta, Georgia
Song, J., Ph.D., New Mexico State University, Las Cruces
Sun, G., B.S., Johns Hopkins University, Baltimore, Maryland
Troaca-Luchici., L.-A., B.Eng., King’s College London, United
Kingdom
Wang, X., B.S., The College of William and Mary, Williams-
burg, Virginia
PARTICIPANTS
Bush, A., M.Sc., Universidad de Buenos Aires, Argentina
Carta, A., M.S., INRIA, Sophia Antipolis Cedex, France
Gao, M., B.S., Vanderbilt University, Nashville, Tennessee
Gomez, J., B.S., University of Iowa, Iowa City
Grzenda, A., Mayo Clinic, Rochester, Minnesota
Jones, Z., B.S., Middle Tennessee State University,
Murfreesboro
Joshi, A., M.Tech, Intelligent Systems Research Centre,
University of Ulster, Londonderry, United Kingdom
Kuhn, H., B.S., Harvard University, Boston, Massachusetts
Lu, Z., B.S., University of Texas Health Science Center, San
Antonio
Marchchenko, O., B.A., University of Connecticut Health
Center, Farmington
Frontiers and Techniques in Plant Science
July 1−21
INSTRUCTORS S. Harmer, University of California, Davis
R. Last, Michigan State University, E. Lansing
J. Maloof, University of California, Davis
ASSISTANTS Y. (Polly) Hsu, University of California, Davis
J. Kim, Michigan State University, E. Lansing
O. Wilkins, Boston, Massachusetts
This course provided an intensive overview of topics in plant physiology, biochemistry, and devel-
opment, focusing on genomic, analytical, computational, and other high-throughput approaches
to understanding plant biology. It emphasized recent results from model organisms including Ara-
bidopsis, maize, and tomato, as well as a variety of other plants, and provided an introduction to
current methods used in basic and applied plant biology. It was designed for scientists with some
experience in molecular techniques or in plant biology who wish to work with plants using the latest
molecular, genomic, and computational technologies. The course consisted of a vigorous lecture se-
ries, a hands-on laboratory, and informal discussions. The instructors and a stellar group of invited
speakers, acknowledged leaders in their fields, presented up-to-the-moment research on a wide range
of topics in plant research.
These seminars included plant evolution, morphology, and anatomy; various topics in plant de-
velopment (including development of meristems, gametophytes, and roots); light perception and
photomorphogenesis; cell wall biosynthesis and biofuels, function, and perception of hormones;
small RNAs; biotic and abiotic interactions; and applications addressing current agronomic prob-
lems. Lectures describing bioinformatics tools available to the plant community and the resources
provided by plant genome projects were also included. Speakers provided expert overviews of their
fields, followed by in-depth discussions of their own work. The laboratory sessions provided exposure
to cutting-edge techniques currently used in plant research. These included studies of plant devel-
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DeVries, A., B.S., University of California, Riverside
Diaz, J., B.S., University of California, Riverside
Dorn, K., B.S., University of Minnesota, St. Paul
Hillmer, R., S.M., University of Minnesota, St. Paul
Jorgensen, M.E., University of Copenhagen, Denmark
Katifori, E., Ph.D., The Rockefeller University, New York
Lee, I., Ph.D., Yonsei University, Seoul, South Korea
Norville, J., Ph.D., Massachusetts Institute of Technology,
Cambridge
Ricigliano, V., B.A., St. Johns University, Queens, New York
opment and genome evolution, transient gene expression, applications of fluorescent proteins, au-
tomated phenotyping, analysis of polysomal mRNA, analysis of global gene expression data (mi-
croarray and short-read sequencing), construction of genetic networks, and metabolome analysis.
Students were introduced to leading computational environments and programs including R, Bio-
conductor, and ImageJ. The course also included several short workshops on important themes in
plant research.
This course was supported with funds provided by the National Science Foundation.
PARTICIPANTS
Rogers, E., B.S., University of Illinois, Chicago
Sanabria, N., Ph.D., University of Johannesburg, South Africa
Sanchez, P., Ph.D., The University of Arizona, Tucson
Seidl-Adams, I., Ph.D., The Pennsylvania State University,
University Park
Sparks, E., B.S., Vanderbilt University, Nashville, Tennessee
Weaver, J., B.S., Northwestern University, Boston, Massa-
chusetts
Weng, J., B.A., Dartmouth, Hanover, New Hampshire
SEMINARS
Bailey-Serres, J., University of California, Riverside: Plant
stress responses.
Beachy, R., Donald Danforth Plant Science Center, St. Louis,
Missouri: Opportunities and challenges in basic and applied
plant biology and agriculture.
Bomblies, K., Harvard University, Cambridge, Massachusetts:
Speciation.
Brady, S., University of California, Davis: Root growth and
development. 
Brutnell, T., Boyce Thompson Institute, Ithaca, New York:
Plastids.
Harmer, S., University of California, Davis: Circadian
rhythms.
Hollick, J., University of California, Berkeley: Maize 
genetics.
Jackson, D., Cold Spring Harbor Laboratory: Shoot
development.
Kellogg, E., University of Missouri, St. Louis: Phylogenetics.
Sequence analysis and phylogeny reconstruction.
Kuhlemeier, C., University of Bern, Switzerland: Phyllotaxis.
Juntawong, P., University of California, Riverside: Quanti-
tative PCR.
Last, R., Michigan State University, E. Lansing: Secondary
metabolites.
Maloof, J., University of California, Davis: Quantitative
genetics. QTL analysis.
Mayfield, S., University of California, San Diego, La Jolla:
Algal biofuels.
McSteen, P., University of Missouri, Columbia: Auxiliary
meristems.
Miller, N., University of Wisconsin, Madison: Phenotyping
using machine vision.
Montgomery, B., Michigan State University, E. Lansing: Light
signaling.
Nemhauser, J., University of Washington, Seattle: Hormone
signaling.
Poethig, S., University of Pennsylvania, Philadelphia:
Introduction to plant anatomical development.
Preuss, S., Monsanto Company, Chesterfield, Missouri: Stress
responses.
Roossnick, M., Noble Foundation, Oklahoma: Plant/virus
interactions.
Schilmiller, A., Michigan State University, E. Lansing: Analysis
of plant volatiles.
Shiu, S.-H., Michigan State University, E. Lansing: Genome
evolution.
Spalding, E., University of Wisconsin, Madison: Plant growth.
Timmerman, M., Cold Spring Harbor Laboratory: RNA
interference.
Walling, L., University of California, Riverside: Plant/pest
interactions.
Wang, L., Boyce Thompson Institute, Ithaca, New York:
RNA-Seq.
Zheng, N., University of Washington, Seattle: F-box signaling.
Neurobiology of Drosophila
July 1−21
INSTRUCTORS H. Broihier, Case Western Reserve University, Cleveland, Ohio
D. Featherstone, University of Illinois, Chicago
A. Rothenfluh, University of Texas Southwestern Medical Center, Dallas
ASSISTANTS T. Fergestad, University of Wisconsin, Madison
R. James, Case Western Reserve University, Cleveland, Ohio
O. Khorramshahi, FU Berlin, Germany
E. Knoche, Charite Berlin, Germany
S. Ojelade, University of Texas Southwestern Medical Center, Dallas 
D. Owald, Charite Berlin, Germany
This laboratory/lecture course was intended for researchers at all levels from beginning graduate
students through established primary investigators who want to use Drosophila as an experimental
system for nervous system investigation. The 3-week course was divided into the study of develop-
ment, physiology/function, and behavior. Daily seminars introduced students to a variety of research
topics and developed those topics by including recent experimental contributions and outstanding
questions in the field. Guest lecturers brought original preparations for viewing and discussion and
direct laboratory exercises and experiments in their area of interest. The course provided students
with hands-on experience using a variety of experimental preparations that were used in the inves-
tigation of current neurobiological questions. The lectures and laboratories focused on both the de-
velopment of the nervous system and its role in controlling larval and adult behaviors. In addition
to an exposure to the molecular genetic approaches available in Drosophila, students learned a variety
of techniques including embryo in situ hybridization, labeling of identified neurons, electrophysi-
ology (intracellular recording and patch clamping), optical imaging of neuronal activity, and the
analysis of larval and adult behavior. Collectively, the course provided a comprehensive and practical
introduction to modern experimental methods for studying the Drosophila nervous system. 
This course was supported with funds provided by the National Institute of Mental Health, the
National Institute of Neurological Disorders and Stroke, and the Howard Hughes Medical Institute.
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SEMINARS
Allada, R., Northwestern University, Evanston, Illinois:
Circadian rhythms and sleep.
Benton, R., University of Lausanne, Switzerland: Olfaction.
Broihier, H., Case Western University, Cleveland, Ohio: Axon
pathfinding.
Broihier, H., Case Western University, Cleveland, Ohio, and
Lee, C.-H., NICHD/National Institutes of Health,
Bethesda, Maryland: Genetic screens.
DiAntonio, A., Washington University, Seattle: The axonal
injury response lessons from flies and mice.
Dubnau, J., Cold Spring Harbor Laboratory: Learning and
memory.
Featherstone, D., University of Illinois, Chicago: Ephys
introduction.
Freeman, M., University of Massachusetts, Worcester: Glia.
Bioinformatics/Web tools.
Galko, M., University of Texas/MD Anderson, Houston:
Nocioception. Neuroanatomy.
Kravitz, E., Harvard Medical School, Boston, Massachusetts:
Aggression.
Lee, C.-H., NICHD/National Institutes of Health, Bethesda,
Maryland: Visual system development.
PARTICIPANTS
Aimon, S., B.S., Institut Curie, Paris, France
Erion, R., B.S., University of Pennsylvania, Philadelphia
Etchegary, J., B.A., Boston University, Massachusetts
Franconville, R., Ph.D., Howard Hughes Medical Institute,
Ashburn, Virginia
Herbert, S., B.A., Champalimaud Neuroscience Programme,
Lisbon, Portugal
Johri, S., M.Sc., University of Utah, Salt Lake City
Kochinke, K., B.S., Radboud University, Nijmegen, The
Netherlands
Levitan, E., University of Pittsburgh, Pennsylvania: Imaging,
peptide release/dense core vesicle trafficking.
Murthy, M., Princeton University, New Jersey: CNS function.
O’Connor-Giles, K., University of Wisconsin, Madison: NMJ
structure and development.
Rolls, M., Penn State University, University Park: Neuronal
cell biology.
Rothenfluh, A., University of Texas Southwestern Medical
Center, Dallas: Drugs.
Ruta, V., Columbia University, New York: CNS functional
organization.
Turner, G., Cold Spring Harbor Laboratory: CNS processing.
Verstreken, P., Katholieke Universiteit Leuven, Belgium:
Imaging; Peptidegric transmission.
Vosshall, L., The Rockefeller University, New York: Feeding.
White, B., NIMH/National Institutes of Health, Bethesda,
Maryland: Tools for neuronal function and circuitry.
Zhang, B., University of Oklahoma, Norman: Genetic
techniques/FINGR.
Martelli, C., Ph.D., Yale University, New Haven, 
Connecticut
Mishra, B., Ph.D., University of Michigan, Ann Arbor
Piccioli, Z., Ph.D., Massachusetts Institute of Technology,
Cambridge 
Velazquez, U.-N., Ph.D., University of California, San
Francisco
Wang, Q.-P., Ph.D., Garvan Institute of Medical Research,
Darlinghurst, Australia
Allegra, M., B.S., Scuola Normale Superiore di Pisa, Italy
Barone, I., B.S., CNR Neuroscience Institute, Pisa, Italy
Davis, Z., B.S., University of California Neuroscience
Graduate Group, Davis
Dillingham, C., B.S., Cardiff University, United Kingdom
Dubis, A., B.S., Medical College of Wisconsin, Milwaukee
Gilbert, M., B.S., University of California, San Diego, La Jolla 
Greenwald, S., B.S., University of Washington, Seattle
Inagaki, M., Ph.D., Osaka University, Toyonaka, Japan
Kiley, C., B.S., University of California, Davis
Kim, E., Ph.D., University of California, San Diego, La Jolla
Lankow, B., B.S., University of California, Davis
Structure Function and Development of the Visual System
July 6–19
INSTRUCTORS B. Chapman, University of California, Davis
W.M. Usrey, University of California, Davis
This lecture/discussion course explored the functional organization and development of the visual
system as revealed by the use of a variety of anatomical, physiological, and behavioral methods. It
was designed for graduate students and more advanced researchers who wish to gain a basic under-
standing of the biological basis for vision and share in the excitement of the latest developments in
this field. Topics included phototransduction and neural processing in the retina; functional archi-
tecture of striate cortex; cellular basis of cortical receptive field properties; anatomy, physiology, and
perceptual significance of parallel pathways; functional parcellation of extrastriate cortex; role of
patterned neuronal activity in the development of central visual pathways; and molecular mecha-
nisms of development and plasticity in the visual system.
PARTICIPANTS
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Lewis, C., B.S., Ernst Strüngmann Institute, Frankfurt am
Main, Germany
Lim, H., Ph.D., Hunter College of the City of New York
University, New York
Reitsma, D., B.S., The Medical College of Wisconsin,
Milwaukee
Short (Hembrook), J., B.S., University of New Hampshire,
Durham
Solomon, S., B.S., University of Sydney, Australia
Stewart, E., B.S., University of Adelaide, Australia
Williams, K., B.S., McMaster University, Hamilton, Canada
SEMINARS
Chapman, B., University of California, Davis: How the visual
system got its stripes.
Chichilnisky, E., Salk Institute, La Jolla, California: Functional
organization of the retina.
Connor, E., Johns Hopkins University, Baltimore, Maryland:
Neural coding of object structure.
Dickson, K., Cell Press, Cambridge, Massachusetts: Career
guidance.
Feldheim, D., University of California, Santa Cruz: Mechan-
isms of topographic mapping.
Feller, M., University of California, Berkeley: Mechanisms 
and development of retinal direction selectivity.
Fitzpatrick, D., Max-Planck Florida Institute, Jupiter: What
maps tell us about the structure, function, and development
of circuits in visual cortex.
Gallant, J., University of California, Berkeley: Representation
of natural scenes and movies: Evidence from neurophysiol-
ogy and fMRI.
Guido, W., Virginia Commonwealth University, Alexandria:
Circuit development in the dorsal lateral geniculate nucleus
of the mouse.
Hirsch, J., University of Southern California, Los Angeles:
Neural circuits for visual processing in thalamus.
Horton, J., University of California, San Francisco: Functional
architecture of striate cortex.
Huberman, A., University of California, San Diego: Genetic
approaches to parsing visual circuit development, function,
and regeneration.
Krauzlis, R., Salk Institute, La Jolla, California: Eye move-
ment: Physiology.
Martin, K., University of Zurich, Switzerland: Visions of
Johanna.
Movshon, A., New York University, New York: Brain
mechanisms of visual motion perception.
Neitz, J., The Medical College of Wisconsin, Milwaukee:
Cones, color vision, and the outer retina.
Nawy, S., Albert Einstein College of Medicine, Bronx, New
York: Synaptic origins of parallel visual pathways in primate.
Sherman, M., University of Chicago, Illinois: Considerations
of thalamocortical and corticothalamic relationships.
Stone, L., NASA Ames Research Center, Moffett Field,
California: Eye movement: Perception and reality. 
Usrey, M., University of California, Davis: Dynamic inter-
actions between thalamus and cortex for visual processing.
Usrey, M. and Chapman, B., University of California, Davis:
The basics. Career guidance.
Wandell, B., Stanford University, Connecticut: Human visual
field maps: Where they are and how they respond. Seeing
words: Cortical responses and white matter pathways.
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Advanced Techniques in Molecular Neuroscience
July 6−21
INSTRUCTORS C. Lai, Indiana University, Bloomington
R. Lansford, California Institute of Technology, Pasadena
ASSOCIATE INSTRUCTORS T. Bell, NDRI Resource, Philadephila, Pennsylvania
L. Fenno, Stanford University, California
K. Haas, University of British Columbia, Vancouver, Canada
TEACHING ASSISTANTS D. Bower, California Institute of Technology, Pasadena 
C. Canaria, California Institute of Technology, Pasadena 
F. Chen, University of Connecticut, Storrs
R. Draft, Harvard University, Cambridge, Massachusetts
M. Girgenti, University of Connecticut, Storrs
L. Gunaydin, Stanford University, California
D. Huss, California Institute of Technology, Pasadena
B. Maher, University of Connecticut, Storrs
E. Munroe, Indiana University, Bloomington
K. Podorski, University of British Columbia, Vancouver, Canada
E. Robinson, Indiana University, Bloomington
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PARTICIPANTS
Ashby, R., Ph.D., Australian National University, Canberra,
Australia
Balu, D., Ph.D., McLean Hospital/Harvard Medical School,
Belmont, Massachusetts
Brosius Lutz, A., Ph.D., Stanford University, California
Chen, Y., Ph.D., Max-Planck Institute for Medical Research,
Heidelberg, Germany
Dougherty, K., Ph.D., Karolinska Institute, Stockholm, Sweden
Fournier, N., Ph.D., Yale University School of Medicine, New
Haven, Connecticut
Fricks-Gleason, A., Ph.D., University of Utah, Salt Lake City
Gao, W.-J., Ph.D., Drexel University College of Medical,
Philadelphia, Pennsylvania
This laboratory and lecture course was designed to provide neuroscientists at all levels with a con-
ceptual and practical understanding of several of the most advanced techniques in molecular neu-
roscience. The course curriculum was divided into three sections: an extensive and up-to-date set of
laboratory exercises, daily lectures covering the theoretical and practical aspects of the various meth-
ods used in the laboratory, and a series of evening research seminars. The informal and interactive
evening lectures were given by leading molecular neuroscientists and served to illustrate the ways in
which the various experimental approaches have been used to advance specific areas of neurobiology.
In this year’s course, the laboratory portion included topics such as an introduction to the design
and use of animal virus vectors in neurobiology; the use of small interfering RNAs (siRNAs) for
regulating the expression of specific genes in neurons; practical exercises in gene delivery systems,
including mammalian cell transfection protocols and single-cell electroporation techniques for tar-
geted gene transfer in vivo; an introduction to overall strategies, use, and design of bacterial artificial
chromosome (BAC) transgenic vectors; multiplex and whole-genome expression analyses using the
most recent DNA microarray technologies (including labeled probe preparation, data analyses, min-
ing, and interpretation); quantitative real-time (RT)-PCR (polymerase chain reaction) analyses from
small numbers of cells (RNA purification, PCR optimization, interpretation of results); single-cell
PCR and cDNA library construction; and methods and application of RNA amplification (aRNA).
Each laboratory module was followed by comprehensive data analyses and interpretation, protocol
troubleshooting, and suggestions for ways to improve or modify the existing technique. Finally,
course participants were introduced to bioinformatics and a wide range of Internet resources available
to molecular neuroscientists.
The course was generously supported by New England BioLabs Inc.; Olympus America Inc.;
Carl Zeiss Inc. along with Bitplane-Andor Technology; Bio-Rad Laboratories; Chroma Technology
Corporation; Coherent Laser; Eppendorf North America; Fotodyne Inc.; Harvard Apparatus Inc.;
Illumina Inc.; Invitrogen Corporation; Leica Microsystems Inc.; Nanodrop Technologies; Narishige
International USA Inc.; PerkinElmer Life; Promega Corporation; Qiagen Inc.; Roche Applied Sci-
ence; Sigma-Aldrich; and Thermo Fisher Scientific. This course was also supported with funds pro-
vided by the National Institute of Mental Health, the National Institute of Neurological Disorders
& Stroke, and the Howard Hughes Medical Institute. 
Godfrey, B., Ph.D., Makerere University College of Health
Sciences, Kampala, Uganda
Gundlfinger, A., Ph.D., Brain Research Institute, University of
Zurich, Switzerland
London, S., Ph.D., University of Illinois, Urbana-Champaign
Morgan, J., Ph.D., University of California, Davis School of
Medicine, Sacramento
Skene, N., Ph.D., University of Cambridge, Hinxton, United
Kingdom
Sitko, A., B.S., Columbia University, New York
Vajn, K., M.D., University of Pittsburgh, Pennsylvania
Whitney, I., B.S., University of California, Santa Barbara
SEMINARS
Barres, B., Stanford University School of Medicine, California:
What do astrocytes do?
Bell, T., University of Pennsylvania, Philadelphia: Single-
neuron mRNA analysis. Optogenetics module. Xenopus
neural transfection module. In utero RNAi module.
Darnell, R., HHMI/The Rockefeller University, New York.
Maps of the RNA world.
DiAntonio, A., Washington University School of Medicine, St.
Louis, Missouri: The axonal injury response: Lessons from
flies and worms.
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Dymecki, S., Harvard Medical School, Boston, Massachusetts:
Decoding the mouse serotonergic system using intersectional
genetics and selective in vivo silencing.
Eberwine, J., University of Pennsylvania Medical School,
Philadelphia: The secret life of a single cell.
Gunaydin, L., Stanford University, California: Single neuron
mRNA analysis. Optogenetics module. Xenopus neural
transfection module.
Haas, K., University of British Columbia, Vancouver, Canada:
Single neuron mRNA analysis. Optogenetics module.
Xenopus neural transfection module.
Lai, C., Indiana University, Bloomington: Cloning and
lentivirus module. BAC recombination module. Neural
imaging module. In utero RNAi module. Lentivirus and
imaging module.
Lansford, R., California Institute of Technology, Pasadena:
Cloning and lentivirus module. BAC recombination module.
Neural imaging module. Cloning and lentivirus module. In
utero RNAi module. Lentivirus and imaging module. In
utero RNAi module.
Lichtman, J., Harvard University, Cambridge, Massachusetts:
Talking about science. Neural imaging module. Cloning and
lentivirus module. BAC recombination module. Lentivirus
and imaging module. In utero RNAi module. Imaging the
connectome.
Lledo, P.-M., Pasteur Institute, Paris, France: Adult-born
neurons and brain plasticity.
Loturco, J., University of Connecticut, Storrs: Neural imaging
module. Cloning and lentivirus module. BAC recombination
module. In utero RNAi module. Single-neuron mRNA
analysis.
Distinguished Alumni Lecture: Storey, K., University of
Dundee College of Life Science, United Kingdom:
Mechanisms regulating neural differentiation.
Circuits and Connectivity in the Vertebrate Brain
July 6−21
INSTRUCTORS P. Mitra, Cold Spring Harbor Laboratory
K. Rockland, RIKEN-MIT Center for Neural Circuits Genetics, Cambridge, Massachusetts
M. Witter, Norwegian University of Science and Technology, Trodheim, Norway
ASSISTANTS S. Mukhopadhyay, Cold Spring Harbor Laboratory
K. O’Reilly, Norwegian University of Science and Technology, Trodheim, Norway
S. Ozen, Stanford University, San Francisco, California
V. Pinskly, Cold Spring Harbor Laboratory
N. Wall, Salk Institute for Biological Studies, La Jolla, California
In comparison with complete reference genomes now available for multiple species, our knowledge
about the neuronal and circuit architecture of vertebrate nervous systems is relatively sparse. How-
ever, this situation is rapidly changing, enabled by technical advances as well as resurgent and wide-
spread interest in the neuroscientific community in mapping out neural circuitry at unprecedented
scales, ranging from the reconstruction of local microcircuits to the mapping of brain-wide meso-
circuits. This circuit architecture naturally and logically complements the molecular architecture as
delineated by the mapping of brain-wide gene expression patterns. Experimental efforts are under
way in multiple species, promising to advance our knowledge of the wiring logic of the vertebrate
brain. This will fundamentally impact our understanding of brain function and evolution and also
have an essential role in understanding pathological changes in circuitry that underlie neurological
and neuropsychiatric disorders. 
This 2-week workshop brought together classical neuroanatomical approaches along with the
new techniques that are enabling a new generation of neuroanatomical research into the circuit and
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PARTICIPANTS
Bienkowski, M., B.S., Center for Neuroscience, University of
Pittsburgh, Pennsylvania
Chung, S., Ph.D., University of California, Berkeley
Dittrich, L., Ph.D., SRI International, Menlo Park, California
Engerer, K., B.S., Medical College of Wisconsin, Milwaukee
Gauthier, J., Ph.D., Princeton University, New Jersey
Karnani, M., Ph.D., University of Cambridge, United
Kingdom
Keeley, P., B.S., University of California, Santa Barbara
Martinez-Molina, N., M.Sc., Instituto de Neurosciencas, San
Juan de Alicante, Spain
Matho, K., B.S., Institut de la Vision, Paris, France
Schreiweis, C., M.A., Max-Planck Institute for Evolutionary
Anthropology, Leipzig, Germany
Viswanathan, S., B.S., HHMI/Janelia Farms Research
Campus, Ashburn, Virginia
Yanik, M., B.S., Massachusetts Institute of Technology,
Cambridge
molecular architecture of the vertebrate brain. The workshop had three main components: classical,
molecular, and computational neuroanatomy. An experimental component of the workshop involved
injection-based tract tracing in the mouse, using classical and viral tracer substances in wild-type
and transgenic mice. Lectures covered classical (tracer injections, sectioning, histochemistry, imaging)
and molecular (genetic engineering of mice as well as viral tracers and optogenetic probing of circuits)
techniques. Material was presented by simultaneous viewing of slides under light microscopy as well
as digital images, including an in-depth orientation to Internet resources. The computational com-
ponent involved hands-on algorithmic analysis and interpretation of digital neuroanatomical data
sets, from both electron microscopy and light microscopy. Species covered included rodents and
human and nonhuman primates, with special lectures on other vertebrate lineages. One lecture ad-
dressed the invertebrate brain.
This meeting was sponsored by Howard Hughes Medical Institute and Cold Spring Harbor Lab-
oratory. 
SEMINARS
Amunts, K., Institute of Neuroscience and Medicine, Juelich,
Germany: Human cerebral cortex: Cytoarchitectonic
parcellation and non-DTI fib tracking.
Barbas, H., Boston University School of Medicine, Massachu-
setts: Sensory pathways and emotion.
Bohland, J., Boston University, Massachusetts: An overview of
image analysis challenges in high-throughput neuroanatomy.
Bota, M., University of Southern California, Los Angeles:
Data and knowledge integration across multiple levels of the
mammalian CNS.
Burkhalter, A., Washington University, St. Louis, Missouri:
Network of mouse visual cortex.
Enquist, L., Princeton University, New Jersey: Transneuronal
spread of a herpes virus infection using PRV to trace neural
circuits.
Grange, P., Cold Spring Harbor Laboratory: Computational
techniques for the analysis of gene-expression atlases.
Hawrylycz, M., Allen Institute for Brain Science, Seattle,
Washington: Computational neuroanatomy of gene
expression.
Helmstaedter, M., Max-Planck Institute for Medical Records,
Heidelberg, Germany: Dense circuits reconstruction from
blockface electron microscopy data.
Huang, J., Cold Spring Harbor Laboratory: Genetic dissection
of GABAergic circuits in cerebral cortex.
Karten, H., University of California, San Diego, LaJolla:
Natural selection is a tinkerer: Evolutionary origins of
neocortex. Conservation of microcircuitry.
Kleinfeld, D., University of California, San Diego, La Jolla:
Feed forward versus cyclic connectivity. The confluence of
reafference and exafference. Basic principles of light micros-
copy.
Lee, J.-H., University of California, Los Angeles: Optogenetic
stimulation and fMRI.
Li, B., Cold Spring Harbor Laboratory: Habenula in psychi-
atric disorders.
Martin, K., University of Zurich, Switzerland: Mapping the
matrix.
Mello, C., Oregon Health and Science University, Portland:
Gene expression in zebra finch.
Mitra, P., Cold Spring Harbor Laboratory: Course introduc-
tion.
Osten, P., Cold Spring Harbor Laboratory: Antomy and c-fos-
based activation mapping by serial two-photon (STP)
tomography.
Peterson, D., Rosalind Franklin University, N. Chicago,
Illinois: Quantitative histology: Introduction to design-based
stereology.
Rockland, K., Masschusetts Institute of Technology/RIKEN
Brain Science Institute, Cambridge: Introduction to
experimental techniques: Axon transport, tracers and
connections.
Rosa, M., Monash University, Victoria, Australia: Toward 
a computational atlas of the cerebral cortex and its connec-
tions.
Safdieh, J., Weill Cornell Medical College, New York: General
organization of the human central and peripheral nervous
system and case studies.
Saper, C., Beth Israel Deaconess Medical Center, Boston,
Massachusetts: Hypothalamic regulation of sleep and
circadian rhythms.
Schiff, N., Cornell University Medical College, New York:
Arousal regulation in intact forebrain.
Sharfman, H., New York University Langone Medical Center,
Orangeburg: Hippocampal anatomy and physiology under
normal and pathological conditions.
Strausfeld, N., University of Arizona, Tucson: Conventional
and neurophylogenetic studies of neural circuits. Part I:
Circuit cracking: The conventional route. Part II: What 600
million years of evolution tells us.
Ugurbil, K., University of Minnesota, Minneapolis: Human
brain imaging, from cortical columns and layers to networks.
Witter, Menno, Norwegian University of Science and
Technology, Trodheim, Norway: Functional neuroanatomy
to study the entorhinal-hippocampal network.
Zaborsky, L., Rutgers University, Newark, New Jersey:
Extracting structural and functional information from large-
and small-scale reconstructions of the basal forebrain
cholinergic system.
Zilles, K., Institute of Neuroscience and Medicine, Juelich,
Germany: Human cerebral cortex: Transmitter receptors,
functional segregation, and hierarchies.
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Biology of Memory
July 21–August 3
INSTRUCTORS C. Alberini, Mt. Sinai School of Medicine, New York
K. Martin, University of California, Los Angeles
J. Raymond, Stanford University, California
ASSISTANTS K. Ramamoorthi, Massachusetts Institute of Technology
J. Rinaldi, Stanford University, California
This lecture course provided an introduction to cellular, molecular, and systems approaches to learn-
ing and memory. It was suited for graduate students and postdoctoral fellows in molecular biology,
neurobiology, and psychology, as well as research workers who are interested in an introduction to
this field. The course covered topics ranging from behavioral considerations of learning and memory
to gene regulation in the nervous system. The lectures provided an intensive coverage of modern
behavioral studies of learning and memory, the cell and molecular biology of neuronal plasticity,
cellular and molecular mechanisms of simple forms of learning and memory, and systems approaches
to learning in vertebrates and humans. Lectures were complemented by exercises in which students
worked in small groups with lecturers to discuss topical issues in learning and memory, evaluated
recent studies, and identified and formulated new research questions and approaches. The course
was thus designed not only to introduce students to the field of learning and memory, but also to
provide an intellectual framework upon which future studies can be built.
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SEMINARS
Alberini, C., Mt. Sinai School of Medicine, New York:
Memory consolidation and reconsolidation.
Byrne, J., University of Texas, Houston Medical School:
Cellular and molecular mechanisms of simple forms of
learning.
Eichenbaum, H., Boston University, Massachusetts: Toward a
neurobiology of declarative memory.
Froemke, R., New York University School of Medicine, New
York: Long-term cortical synaptic plasticity.
Goldman, M., University of California, Davis: Computational
models of short-term memory.
Holland, P., Johns Hopkins University, Baltimore, Maryland:
Learning theory.
Klann, E., New York University, New York: Translational
control in memory and brain disorders.
Martin, K., University of California, Los Angeles: Signaling
between synapse and nucleus during long-lasting synaptic
plasticity.
PARTICIPANTS
Atucha Trevino, E., B.S., University Medical Center,
Groningen, The Netherlands
Carcea, I., B.S., New York University, New York
Gerstner, J., Ph.D., University of Pennsylvania, Philadelphia
Groves-Chapman, J., B.S., University of Georgia, Athens
Karlsson, T., B.S., Karolinska Institute, Stockholm, Sweden
McKinney, R., B.S., Massachusetts Institute of Technology,
Cambridge
Mitakidis, N., B.S., University of Oxford, United Kingdom
Motley, S., B.S., Brigham Young University, Provo, Utah
Mukherjee, S., Ph.D., Florida International University, Miami
Pancrazi, L., B.S., Scuola Normale Superiore, Pisa, Italy
Raymond, J., Stanford University, California: Cerebellum-
dependent learning.
Squire, L., University of California, San Diego/Veterans Affairs
Medical Center, San Diego: The neuroscience of memory in
historical perspective: 1880−2005. Memory systems of the
mammalian brain.
Suzuki, W., New York University, New York: Associative
learning and temporal order memory signals in the monkey
medical temporal lobe.
Suzuki, W., New York University, New York and Jordan, G.,
Handel Group, New York, New York: Leadership seminar.
Silva, A., University of California, Los Angeles: Molecular and
cellular mechanisms of learning and memory.
Waddell, S., University of Massachusetts Medical School,
Worcester: Memory in Drosophila.
Resnik, J., B.S., Weizmann Institute of Science, Rehovot,
Israel
Rueckemann, J., B.S., Boston University, Massachusetts
Salz, D., B.S., Boston University, Massachusetts
Solyst, J., B.S., Emory University, Atlanta, Georgia
Stern, S., B.S., Mt. Sinai School of Medicine, New York
Tiwari, S., B.S., Institute of Psychiatry, King’s College
London, London, United Kingdom
Venkataraman, A., B.S., Texas A&M University, College
Station
Winter, O., B.S., Stanford University, Menlo Park, California
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Eukaryotic Gene Expression
July 26–August 15
INSTRUCTORS J. Espinosa, HHMI/University of Colorado, Boulder
W. Lee Kraus, Cornell University, Ithaca, New York
A. Shilatifard, Stowers Institute for Medical Research, Kansas City, Missouri
D. Taatjes, University of Colorado, Boulder
ASSISTANTS S. Gadad, University of Texas Southwestern Medical Center, Dallas
M. Galbraith, University of Colorado, Boulder
S.-C. Lin, University of Colorado, Boulder
N. Mohaghegh, Stowers Institute for Medical Research, Kansas City, Missouri
M. Sun, Cornell University, Ithaca, New York
This course was designed for students, postdocs, and principal investigators who have recently ven-
tured into the exciting area of gene regulation. The course focused on state-of-the-art strategies and
techniques used in the field. Emphasis was placed on both in vitro and in vivo protein−DNA inter-
actions and on novel methodologies to study gene regulation. Students made nuclear extracts, per-
formed in vitro transcription reactions, and measured RNA levels using primer extension. Charac-
terizations of the DNA-binding properties of site-specific transcription factors were carried out
using electrophoretic mobility shift and DNase I footprinting assays. In addition, students learned
techniques for the assembly and analysis of chromatin in vitro, including transcription assays, chro-
matin footprinting, and chromatin remodeling assays. 
During the past few years, the gene regulation field has developed in vivo approaches to study
gene regulation. Students were exposed to the chromatin immunoprecipitation technique. They
also used RNA interference (RNAi) for specific knock-down experiments in mammalian cells. In
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Andino, B., B.A., Mt. Sinai School of Medicine, New York
Ask, K., M.S., University of Copenhagen, Denmark
Beira, J., M.Sc., University College London/National Institute
Medical Research London, United Kingdom
Benko, S., Parm.D., Mt. Sinai School of Medicine, New York
Bowman, E., B.S., Emory University, Atlanta, Georgia
Chen, M.-W., B.S., Dana-Farber Cancer Institute, Boston,
Massachusetts
Fadul, J., B.S., Huntsman Cancer Institute, Salt Lake City,
Utah
Gu, B., B.S., CNRS UMR 8197–INSERM U1024-ENS,
Paris, France
addition, determining cellular gene expression profiles has been accelerated tremendously by DNA
microarray technology. Students received hands-on training in performing and interpreting results
from DNA microarrays.
Experience with basic recombinant DNA techniques was a prerequisite for admission to this
course. Lectures by the instructors covered the current status of the gene expression field, theoretical
aspects of the methodology, and broader issues regarding strategies for investigating the regulation
of gene expression in eukaryotes. Guest lecturers discussed contemporary problems in eukaryotic
gene regulation and technical approaches to their solution.
This course was supported with funds provided by the National Cancer Institute.
PARTICIPANTS
McPhee, C., Ph.D., Harvard University, Cambridge,
Massachusetts
Moehle, E., B.A., University of California, San Francisco
Nguyen, V., Ph.D., Harvard University, Cambridge,
Massachusetts
Perez-Perri, J., M.S., Instituto Leloir, Ciudad de Buenos Aires,
Argentina
Price, M., B.A., H. Lee Moffitt Cancer Center and Research
Institute, Tampa, Florida
Waldholm, J., M.S., Stockholm University, Sweden
Wat, M., B.S., Baylor College of Medicine, Houston, Texas
Woznicki, J., M.Sc., University College Cork, Ireland
SEMINARS
Berger, S., University of Pennsylvania, Philadelphia: The
complex language of histone posttranslational modification
in genomic regulation.
Conaway, J., Stowers Institute for Medical Research, Kansas
City, Missouri: Mediator.
Espinosa, J., HHMI/University of Colorado at Boulder,
Boulder: Research presentation.
Garrett, A., Stowers Institute for Medical Research, Kansas
City, Missouri: RNA-Req methods.
Gingeras, T., Cold Spring Harbor Laboratory: Lessons learned
from complex genomes.
Jones, K., The Salk Institute for Biological Studies, La Jolla,
California: A role for transcription elongation factors in
gene-specific splicing.
Kingston, R., Massachusetts General Hospital/Harvard
Medical School, Boston: Nucleosome position and
compaction as mechanisms of epigenetic regulation.
Kraus, L., University of Texas Southwestern Medical Center,
Dallas: Research presentation.
Levine, M., University of California, Berkeley: Mechanisms of
transcriptional precision in the Drosophila embryo.
Lis, J., Cornell University, Ithaca, New York: Dynamic interplay
of transcription factors, RNA polymerase II, and chromatin.
Martienssen, R., Cold Spring Harbor Laboratory: RNAi,
heterochromatin, and the clash of the polymerases.
Meyer, B., HHMI/University of California, Berkeley:
Chromosome-wide mechanisms of gene regulation.
Mostoslavsky, R., The Massachusetts General Hospital,
Boston: The histone deacetylase SIRT6 is a master regulator
of glucose homeostasis.
Naar, A., Harvard Medical School, Charlestown, Massachu-
setts: Gene regulatory mechanisms governing cholesterol
and lipid metabolism. 
Pugh, F., Penn State University, University Park: Genome-wide
mapping of chromatin and the transcription machinery at
ultra-high resolution.
Shiekhattar, R., The Wistar Institute, Philadelphia, Pennsyl-
vania: The Yin and Yang of noncoding RNAs.
Shilatifard, A., Stowers Institute for Medical Research, Kansas
City, Missouri: Research presentation.
Struhl, K., Harvard Medical School, Boston, Massachusetts:
Transcription factors, not chromatin, is primarily responsible
for epigenetic inheritance.
Taatjes, D., University of Colorado, Boulder: Research presen-
tation.
Tyler, J., University of Texas/MD Anderson Cancer Center,
Houston: Chromatin assembly and disassembly.
Wang, Y., University of Texas Southwestern Medical Center,
Dallas: Transcriptional regulation of skeletal homeostasis.
Whetstine, J., MCG Cancer Center and Harvard Medical
School, Charlestown, Massachusetts: A glimpse into histone
demethylase function: Novel roles in cell cycle and behavior.
Yamamoto, K., University of California, San Francisco: Com-
binatorial transcriptional regulation: Determinants of speci-
ficity.
Young, R., Whitehead Institute/Massachusetts Institute of
Technology, Cambridge: Transcriptional control of embry-
onic stem cells.
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Imaging Structure and Function in the Nervous System
July 26–August 15
INSTRUCTORS D. DiGregorio, Université Paris 5, France
S. Thompson, University of Maryland School of Medicine, Baltimore
J. Waters, Northwestern University, Chicago, Illinois
ASSISTANTS L. Cathala, Universite Pierre et Marie Curie
S. Cerceo, University of Maryland, Baltimore
A. Nimmerjahn, Salk Institute, La Jolla, California
A. Scimemi, National Institutes of Health, Bethesda, Maryland
A. Shih, University of California, San Diego, La Jolla
Advances in light microscopy, digital image processing, and the development of a variety of powerful
fluorescent probes presented expanding opportunities for investigating the nervous system, from
synaptic spines to networks in the brain. This intensive laboratory and lecture course provided par-
ticipants with the theoretical and practical knowledge to use emerging imaging technologies. The
primary emphasis of the course was on vital light microscopy. Students learned the principles of
light microscopy as well as use of different types of electronic cameras, laser scanning systems, func-
tional fluorophores, delivery techniques, and digital image-processing software. In addition to trans-
mitted light microscopy for viewing cellular motility, the course examined a variety of molecular
probes of cell function, including calcium-sensitive dyes, voltage-sensitive dyes, photo-activated
(“caged”) compounds, and exocytosis tracers. Issues arising in the combination of imaging with
electrophysiological methods were covered. Particular weight was given to multiphoton laser-scan-
ning microscopy and to newly available biological fluorophores, especially green fluorescent protein
(GFP) and its variants. We used a spectrum of neural and cell biological systems, including living
animals, brain slices, and cultured cells. 
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Cho, S., Ph.D., Oregon Health & Science University,
Portland, Oregon
Del Marmol, J., M.S., The Rockefeller University, New York 
Huang, B., B.A., University of California, Los Angeles
Ikeda, K., Ph.D., Australian National University, Canberra,
Australia
Iremonger, K., Ph.D., University of Otago, Dunedin, New
Zealand
Lee, K.H.g, Ph.D., University of California, Los Angeles
Matthews, E., B.S., University Clinic Bonn, Germany
Applicants had a strong background in the neurosciences or in cell biology. In their personal
statements, applicants specify (1) their experience with optical techniques, (2) how they apply optical
methods in their current projects, (3) the microscope systems available to them, and (4) long-term
goals in learning more about optical methods.
This course was supported with funds provided by the National Institute of Mental Health, the
National Institute of Neurological Disorders & Stroke, Howard Hughes Medical Institute, and Co-
herent, Inc.
PARTICIPANTS
Paradiso, K., Ph.D., Rutgers University, Piscataway, New
Jersey
Rompani, S., B.S., Friedrich Miescher Institute for Biomedical
Research, Basel, Switzerland 
Rungta, R., B.S., University of British Columbia, Vancouver,
Canada
Watkins, P., Ph.D., University of Maryland, College Park
Weisz, C., Ph.D., Johns Hopkins University School of
Medicine, Baltimore, Maryland 
SEMINARS
Albeanu, F., Cold Spring Harbor Laboratory: Synaptofluorins
and vesicle imaging.
Blanpied, T., University of Maryland School of Medicine,
Baltimore: PALM/STORM.
Bruchez, M., Carnegie Mellon University, Pittsburgh,
Pennsylvania: New and future indicators.
Deisseroth, K., Stanford University, California: Optogenetics.
Denk, W., Max-Planck Institute for Medical Research, Heidel-
berg, Germany: Extended 2P imaging and block-face EM.
DiGregorio, D., Universite Paris 5, Paris, France: SLMs/
holography.
Dittman, J., Weill Cornell Medical College, New York:
Photoactivatable XFPs.
Eggeling, C., Max-Planck Institute for Biophysical Chemistry,
Gottingen, Germany: STED and FCS.
Engert, F., Harvard University, Cambridge, Massachusetts:
Shot noise. Image J and Fiji.
George, N., Olympus America, Inc., Center Valley, Pennsyl-
vania: BX51 optics.
Griesbeck, O., Max-Planck Institute of Neurobiology,
Martinsried, Germany: XFPs.
Huebener, M., Max-Planck Institute of Neurobiology,
Martinsried, Germany: Intrinsic imaging.
Kilborn, K., Intelligent Imaging Innovations, Inc., Santa
Monica, California: Deconvolution.
Lanni, F., Carnegie-Mellon University, Pittsburgh, Pennsyl-
vania: Basic microscopy.
Moomaw, L. (Butch) and Pritchard, K., Hamamastu Photonic
Systems, Spring Branch, Texas: Cameras and PMTs. 2P
microscopy.
Nimmerjahn, A., Salk Institute, La Jolla, California: Organic
calcium indicators: bulk loading.
Petreka, D., HHMI/Columbia University, New York: VSDs.
Shih, A., University of California, San Diego, La Jolla:
Imaging blood flow.
Szulczewski, M., Prairie Technology, Middleton, Wisconsin:
Confocal microscopy.
Thompson, S., University of Maryland School of Medicine,
Baltimore: Flash photolysis.
Tsai, P., University of California, San Diego, La Jolla: Optics
bench lab exercises—Basics Koehler. Scanning and
fluorescence. Optics bench lab exercises—Scanning—Optics
bench lab exercises—Confocal.
Tyler, W., Arizona State University, Tempe: Ultrasound imag-
ing and stimulation.
Vogel, S., NIAAA/DICBR, National Institutes of Health,
Bethesda, Maryland: FRET and FLIM.
Waters, J., Northwestern University, Chicago, Illinois: Week
One Recap. Organic calcium indicators. Home-brew
microscope including laser safety.
Weninger, K., North Carolina State University, Raleigh:
Single-molecule FRET.
Wilbrecht, L., University of California, Emeryville: GFP
applications, spine morphology.
Witkowsi, J., Banbury Center, Cold Spring Harbor Labora-
tory: Ethics.
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Yeast Genetics and Genomics
July 26–August 15
INSTRUCTORS S. Jaspersen, Stowers Institute for Medical Research, Kansas City, Missouri
J. Smith, University of Virginia Health System, Charlottesville
J. Strathern, National Cancer Institute, Frederick, Maryland
ASSISTANTS J. Avena, University of Colorado, Boulder
J. Johnson, University of Virginia Health Systems, Charlottesville
C. Smoyer, Stowers Institute, Kansas City, Missouri
This was a modern, state-of-the-art laboratory course designed to teach the students the full reper-
toire of genetic approaches needed to dissect complex problems in the yeast Saccharomyces cerevisiae.
Combinations of classical genetic approaches were emphasized, including the isolation and charac-
terization of mutants, tetrad analysis, complementation, and mitotic recombination. Molecular ge-
netic techniques, including various types of yeast transformation, gene replacement with plasmids
and polymerase chain reaction (PCR), construction and analysis of gene fusions, and generation of
mutations in cloned genes, were also emphasized. Students used classical and molecular approaches
to gain experience in identifying and interpreting various kinds of genetic interactions including
suppression and synthetic lethality. Students were immersed in yeast genomics and performed and
interpreted experiments with DNA arrays. Students gained first-hand experience in modern cyto-
logical approaches such as epitope tagging and imaging yeast cells using indirect immunofluores-
cence, green fluorescent protein (GFP)–protein fusions, and a variety of fluorescent indicators for
various subcellular organelles. Lectures on fundamental aspects of yeast genetics were presented
along with seminars given by outside speakers on topics of current interest. 
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PARTICIPANTS
Burke, M., Ph.D., University of California, Irvine
Diaz-Mejia, J., Ph.D., University of Toronto, Canada
Goyal, S., Ph.D., Princeton University, New Jersey
Herrera, C., Ph.D., MRC Imperial College, London, United
Kingdom
Jaeger, P., Ph.D., University of California, San Diego, La Jolla
Kilfoil, M., Ph.D., University of Massachusetts, Amherst
Kokina, A., M.Sc., University of Latvia, Riga, Latvia
Larkin, A., Ph.D., Harvard Medical School, Boston,
Massachusetts
Malmgren Hill, S., M.S., Gothenburg University, Goteborg,
Sweden
Miermont, A., M.S., Laboratoire Matieres et Systems
Complexes, Paris, France
Mikheyev, A., Ph.D., Okinawa Institute of Science and
Technology, Kunigami-gun, Japan
Nazeer, F., Ph.D., Tufts University School of Medicine,
Boston, Massachusetts
Pena, M., Ph.D., University of North Carolina, Chapel Hill
Ranjan, N., Ph.D., ETH Zurich, Switzerland
Reichelt, P., B.Sc, Max-Planck Institute of Biochemistry,
Martinsried/Planegg, Germany
Seeber, A., BSc., Friedrich Miescher Institute for Biomedical
Research, Basel, Switzerland
SEMINARS
Botstein, D., Princeton University, New Jersey: Experimental
evolution studies with yeast. Coordination of growth rate,
stress response, and metabolic activity in yeast.
Burke, D., University of Virginia, Charlottesville: Mitotic
regulation by two checkpoints in yeast.
Costanzo, M., Saccharomyces Genome Database. Stanford,
California: Harnessing the awesome power of yeast with the
Saccharomyces genome database.
Errede, B., University of North Carolina, Chapel Hill: Kinase
control of yeast cell fate.
Gartenberg, M., Robert Wood Johnson Medical School,
Piscataway, New Jersey: Sir2 ties transcriptional silencing to
sister chromatid cohesion.
Gottschling, D., Fred Hutchinson Cancer Research Center,
Seattle, Washington: Organelle deterioration with age: The
limits of an interconnected system.
Hartman IV, J., University of Alabama, Birmingham:
Measuring yeast gene interactions: Technology development
and application to human disease.
Johnson, M., Washington University, St. Louis, Missouri:
Feasting, fasting, and fermenting: Glucose sensing and
signaling by yeasts.
Rine, J., University of Berkeley, California: Yeast models of
human disease.
Rothstein, R., Columbia University, New York: Yeast
combination.
Weiss, E., Northwestern University, Evanston, Illinois:
Defining information flow in signaling systems: Or, the
power of letter words.
Wickner, R., National Institutes of Diabetes and Digestive and
Kidney Diseases, Bethesda, Maryland: Cytoplasmic
inheritance.
This course was supported with funds provided by National Human Genome Research Institute
and the Howard Hughes Medical Institute.
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Arboleda, V., B.A., University of California, Los Angeles
Bunyavanich, S., M.D., Brigham & Women’s Hospital,
Harvard Medical School, Boston, Massachusetts
Busse, D., Dipl., Max-Delbruck Centre for Molecular
Medicine, Berlin, Germany
Cheng, W.-C., Ph.D., University of Maryland School of
Medicine, Baltimore
Gabel, H., Ph.D., Harvard Medical School, Boston,
Massachusetts
Goranskaya, D., M.S., Karolinska Institutet, Stockholm,
Sweden
Gregg, C., B.S., Harvard University, Cambridge,
Massachusetts
Majithia, A., M.D., Massachusetts General Hospital, Boston 
Malik, A., B.S., Harvard Medical School, Boston,
Massachusetts
Meyer-Schaller, N., Ph.D., University of Basel, Switzerland
Pascuzzi, P., Ph.D., North Carolina State University, Raleigh
Peterson, K., Ph.D., Harvard University, Cambridge,
Massachusetts
Simam, J., B.A., KEMRI/Wellcome Trust Research Pro-
gramme, Kilifi, Kenya
Tripathi, V., Ph.D., The University of the West Indies, St.
Augustine, Trinidad and Tobago
Statistical Analysis for Genomic Data
August 2−15
INSTRUCTORS N. Altman, Penn State University, University Park
H. Bussemaker, Columbia University, New York
V. Carey, Harvard University, Boston, Massachusetts
M. Reimers, Virginia Commonwealth University, Richmond
ASSISTANT T. Guennel, Virginia Commonwealth University, Richmond
High-throughput genomics assays have become pervasive in modern biological research. To properly
interpret these data, experimental and computational biologists need to have a firm grasp of statistical
methodology. This course was designed to build competence in quantitative methods for the analysis
of high-throughput molecular biology data.
This course was supported with funds provided by the National Cancer Institute.
PARTICIPANTS
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SEMINARS
Altman, N., Penn State University, University Park and Huber,
W., EMBL, Heidelberg, Germany: RNA-Seq data analysis.
Introduction to course. Experimental design. Differential
expression.
Altman, N., Penn State University, University Park and
Reimers, M., Virginia Commonwealth University School of
Medicine, Richmond: Two-way tables, basic clustering.
Bussemaker, H., Columbia University, New York: Linear
models II. Representations of DNA-binding specificity. GO
scoring. Motif discovery. Linear models I.
Carey, V., Harvard University, Boston, Massachusetts: eQTL
mapping using R/bioconductor.
Culhane, A., Dana Farber Cancer Institute/Harvard, Cam-
bridge, Massachusetts: Reproducible research and cancer.
Davis, S., National Institutes of Health, Bethesda, Maryland:
Integrative epigenomics I. Integrative epigenomics II.
Elemento, O., Weill Cornell Medical College, New York:
Basics of high-throughput sequencing 1. ChIP-Seq analysis.
Three-dimensional chromatin structure revealed by 
high-C-Seq.
Futcher, B., Stony Brook University, New York: Lessons
learned from a successful microarray experiment.
Hansen, K., Johns Hopkins University, Baltimore, Maryland:
DNA methylation at high resolution.
Horvath, S., University of California, Los Angeles: Classifi-
cation. Coexpression networks. 
Hughes, T., University of Toronto, Canada: The landscape 
of sequence speciality for DNA-binding proteins.
Lieb, J., University of North Carolina, Chapel Hill: Research
seminar.
Lucito, R., Cold Spring Harbor Laboratory: Methylation and
copy-number information identify tumor suppressors.
Reimers, M., Virginia Commonwealth University School of
Medicine, Richmond: Precourse for students new to R
workshop. Microarrays preprocessing. Basics of bioconductor
infrastructure.
Storey, J., Princeton University, New Jersey: Controlling
systematic cryptic variation in EQTL studies.
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Cellular Biology of Addiction
August 9–15
INSTRUCTORS A. Bonci, National Institute on Drug Abuse, Baltimore, Maryland
C. Evans, University of California, Los Angeles
M. Von Zastrow, University of California, San Francisco 
ASSISTANTS A. Taylor, University of California, Los Angeles
P. Dhara, National Institute on Drug Abuse, Baltimore, Maryland 
TECH M.M. Sanchez, Pompeu Fabra University, Spain
Drug addiction is the most costly neuropsychiatric disorder faced by our nation. Acute and repeated
exposure to drugs produces neuroadaptation and long-term memory of the experience, but the cellular
and molecular processes involved are only partially understood. The primary objective of this workshop
was to provide an intense dialog on the fundamentals, state-of-the-art advances, and major gaps in the
cell and molecular biology of drug addiction. Targeted to new or experienced investigators, the work-
shop combined formal presentations and informal discussions to convey the merits and excitement of
cellular and molecular approaches to drug addiction research. With the advent of genomics and pro-
teomics, an extraordinary opportunity now exists to develop comprehensive models of neuroadaptive
processes fundamental to addiction, withdrawal, craving, and relapse to drug use and to brain function,
in general. A range of disciplines and topics were represented, including noninvasive brain imaging to
identify drug targets and adaptive processes; neuroadaptative processes at the molecular and cellular
level; neural networks and their modulation; the relevance of genotype to susceptibility and drug re-
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PARTICIPANTS
Akins, C., Ph.D., University of Kentucky, Lexington
Bray, J., Ph.D., The Scripps Research Institute, La Jolla,
California
Cahill, C., Ph.D., Queen’s University, Kingston, Canada
Calu, D., Ph.D., National Institute on Drug Abuse, Baltimore,
Maryland
Dias, C., B.S., Mt. Sinai School of Medicine, New York
Giardino, W., B.S., Oregon Health and Science University,
Portland
Gillaman, A., Ph.D., University of Pittsburgh Medical Center,
Pennsylvania
Gipson, C., B.S., Medical University of South Carolina,
Charleston
Guris, D., M.D., University of Chicago Medical Center, Illinois
Mahajan, S., B.S., State University of New York, Buffalo
sponse; tolerance and adaptation at the cellular level; and approaches to exploiting the daunting volume
generated by neuroinformatics. This workshop provided an integrated view of current and novel re-
search on neuroadaptive responses to addiction, fostered discussion on collaboration and integration,
and provided critical information needed to construct a model of addiction as a disease and identify
novel molecular targets for biological treatments. Beyond the plane of scientific endeavor, the infor-
mation is vital for formulating public policy and for enlightening the public about the neurobiological
consequences of drug use and addiction. The workshop was designed to generate interest in this level
of analysis, open conduits for collaborations, and present novel routes to investigating the neurobiology
of addictive drugs.
Marchant, N., B.S., National Institute on Drug Abuse,
Baltimore, Maryland 
Michaelides, M., Ph.D., Mt. Sinai School of Medicine, New
York
Moeller, S., Ph.D., Brookhaven National Laboratory, Upton,
New York
Munoz, M., B.S., Salk Institute, La Jolla, California 
Nordenankar, K., Ph.D., Uppsala University, Uppsala, Sweden
Shinday, N., B.S., New England Primate Research Center,
Southborough, Massachusetts 
Tacelosky, D., B.S., Penn State College of Medicine, Hershey
Trigo, J., Ph.D., Pompeu Fabra University, Barcelona, Spain
Wu, J., Ph.D., Northwestern University, Chicago, Illinois 
Yang, K., Ph.D., Baylor College of Medicine, Houston, Texas
SEMINARS
Chavkin, C., University of Washington, Seattle: Kappa opioid
signaling mechanisms control addiction risk.
Edwards, R., University of California, San Francisco: The
transport of neurotransmitters into synaptic vesicles.
Evans, C., University of California, Los Angeles and M. Von
Zastrow, University of California, San Francisco: Course overview.
Course conclusions/general discussion. Insights to drug
action from the perspective of receptor cell biology.
Goldman, D., NIAAA/LNG/National Institutes of Health,
Baltimore, Maryland: From genes to addition: Genome
searches for the functional variation underlying heritability.
Heberlein, U., University of California, San Francisco: Genetic
model organisms in addiction research: Focus on inverte-
brates.
Kalivas, P., Medical University of South Carolina, Charleston:
Searching for the holy grail of addiction.
Kenny, P., The Scripps Research Institute, San Diego, Califor-
nia: Noncoding RNAs and addiction.
Kieffer, B., Institut Genetique et de Biologie Moleculaire et
Cellulaire, France: Genetic mouse models for opioid receptor
function and regulation.
Kreek, M.J., The Rockefeller University, New York: Endor-
phins, stress responsivity, gene polymorphisms, and specific
addictions: Bidirectional translational research.
Mackie, K., Indiana University, Bloomington: Cannabinoids.
Nairn, A., Yale University School of Medicine, New Haven,
Connecticut: Beyond the dopamine receptor: Signal trans-
duction mechanisms and psychostimulant action.
Nestler, E., Mount Sinai School of Medicine, New York:
Transcriptional and epigenetic mechanisms of addiction.
O’Brien, C., University of Pennsylvania, Philadelphia:
Translating basic addiction into new treatments.
Palmiter, R., HHMI/University of Washington, Seattle:
Dompamine and glutamate signaling in the basal ganglia.
Picciotto, M., Yale University, New Haven, Connecticut:
Molecular basis of nicotine addiction.
Pollock, J., NIDA/U.S. Department of Health and Human
Services/National Institutes of Health, Baltimore, Maryland:
An overview of the genetics program at NIDA.
Schoenbaum, G., University of Maryland, Baltimore: The role
of the orbitofrontal cortex in addiction.
Skolnick, P., NIDA/National Institutes of Health, Baltimore,
Maryland: Developing medications to treat SUDs: Why
haven’t we been more successful?
Volkow, N., NIDA/National Institutes of Health, Baltimore,
Maryland: The addicted human brain.
Wightman, R.M., University of North Carolina, Chapel Hill:
Dopamine neurotransmission during reward-based behaviors.
Witten, I., Stanford University, California: Optogenetic dissec-
tion of reward circuitry.
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Programming for Biology
October 17−November 1
INSTRUCTORS S. Prochnick, DOE–Joint Genome Institute/University of California, Berkeley
J. Tisdall, DuPont Experimental Station, Wilmington, Delaware
CO-INSTRUCTOR S. Robb, University of California, Riverside
ASSISTANTS J.-M. Chia, Cold Spring Harbor Laboratory
E. Lee, Lawrence Berkeley National Laboratory, California
D. Messina, Stockholm University, Stockholm, Sweden
E. Ross, HHMI/Stowers Institute for Medical Research, Kansas City, Missouri
S. Rynearson, University of Utah, Salt Lake City
A. Wolf, Harvard University, Boston, Massachusetts
A computer is already an indispensable tool for database searches, but the use of web-based tools
alone is not enough for today’s biologist who needs to access and work with data from myriad sources
in disparate formats. This need will become ever more important as new technologies increase the
already exponential rate at which biological data are generated. Designed for students and researchers
with little or no prior programming experience, this 2-week course gave biologists the bioinformatics
skills necessary to exploit this abundance of biological data. 
The course was based around the Perl scripting language, because of its ease of learning and its
incredible wealth of ready-built code modules (e.g., bioperl) designed to solve common biological
problems. Starting with introductory coding, and continuing with a survey of available biological
libraries and practical topics in bioinformatics, students learned how to construct and run powerful
and extensible analysis pipelines in a straightforward manner. The course combined formal lectures
with hands-on sessions in which students worked to solve problem sets covering common scenarios
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PARTICIPANTS
Cooper, L., Ph.D., Oregon State University, Corvallis
Bacanamwo, M., Ph.D., Morehouse School of Medicine,
Atlanta, Georgia
Buchanan, C., B.S., Vanderbilt University, Nashville, Tennessee
Ciarlariello, D., Ph.D., The Ohio State University, Columbus
Danielsson, F., M.Sc., Royal Institute of Technology, Solna,
Sweden
Dutil, J., Ph.D., Ponce School of Medicine, Ponce, Pennsylvania
Hetrick, K., M.S., Johns Hopkins University, Baltimore,
Maryland
Jetty, S., Ph.D., The University of Arizona, Tucson
Joseph, V., Ph.D., Memorial Sloan-Kettering Cancer Center,
New York
Kocher, S., B.S., Harvard University, Cambridge, Massachusetts
Marca, L.R.T., M.Sc., Leipzig University, Germany
in the acquisition, validation, integration, analysis, and visualization of biological data. For their
final projects, which ran during the second week of the course, students posed problems using their
own data and worked with one another and the faculty to solve them. Final projects formed the
basis of publications as well as public biological websites (see, e.g., http://bio.perl.org/wiki/Deob-
fuscator).
The prerequisite for the course was a basic knowledge of UNIX. Lectures and problem sets cov-
ering this background material were available online from previous years and students are able to
study this material before starting the course. Note that the primary focus of this course was to pro-
vide students with practical programming experience, rather than to present a detailed description
of the algorithms used in computational biology. For the latter, we recommend the Computational
Genomics course.
This course was supported by the National Human Genome Research Institute.
Pasternak, J., Ph.D., University of Alberta, Edmonton, Canada
Plouviez, S., Ph.D., Duke University Marine Laboratory,
Beaufort, North Carolina
Smyth, D., Ph.D., New York University, New York
Thatcher, S., Ph.D., University of Delaware, Newark
Triant, D., Ph.D., University of Virginia, Charlottesville
Tschopp, P., Ph.D., Harvard Medical School, Boston,
Massachusetts
Wright, H., Ph.D., University of Wright, Liverpool, United
Kingdom
Yue Cui, J., Ph.D., University of Kansas Medical Center,
Kansas City
Zhang, B., Ph.D., Cold Spring Harbor Laboratory
Zhang, Z., Ph.D., University of Massachusetts Medical
School, Worcester
SEMINARS
Cain, S., Ontario Institute for Cancer Research, Medina,
Ohio: Grows. 
Chia, J.-M., Cold Spring Harbor Laboratory: Mysql/db/dbi.
Hide, W., Harvard University, Boston, Massachusetts: NGS1.
Pearson, W., University of Virginia, Charlottesville: Blast I.
Blast II.
Prochnik, S., DOE-Joint Genome Institute, Walnut Creek,
California: Perl piplines.
Robb, S., University of California, Riverside: Bioperl.
Tisdall, J., Dupont Experimental Station, Wilmington,
Delaware: Scientific computing.
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X-Ray Methods in Structural Biology
October 17–November 1
INSTRUCTORS W. Furey, V.A. Medical Center/University of Pittsburgh, Pennsylvania
G. Gilliland, Centorcor R&D, Inc., Radnor, Pennsylvania
A. McPherson, University of California, Irvine
J. Pflugrath, Rigaku Americas Corporation, The Woodlands, Texas
ASSISTANT L. Koharudin, University of Pittsburgh School of Medicine, Pennsylvania
Crystallography and X-ray diffraction yield a wealth of structural information unobtainable through
other methods. This intensified laboratory/computational course focused on the major techniques
used to determine the three-dimensional structures of macromolecules. It was designed for scientists
with a working knowledge of protein structure and function, but who were new to macromolecular
crystallography. Topics covered included basic diffraction theory, crystallization (proteins, nucleic
acids, and complexes), crystal characterization, X-ray sources and optics, synchrotrons, crystal freez-
ing, data collection, data reduction, multiple isomorphous replacement, multiwavelength anomalous
diffraction, molecular replacement, solvent flattening, noncrystallographic symmetry averaging,
electron density interpretation, molecular graphics, structure refinement, structure validation, co-
ordinate deposition, and structure presentation. Participants learned through extensive hands-on
experiments. One or more proteins were crystallized and the structure(s) determined by several
methods, in parallel with lectures on the theory and informal discussions behind the techniques.
Applicants were familiar with the creation and editing of simple text files on Linux workstations
using a screen-based editor (either vi or emacs).
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SEMINARS
Adams, P., Lawrence Berkeley Laboratory, California: Structure
refinement.
Cohen, A., Stanford Linear Accelerator Center, California:
Remote synchrotron data collection.
Emsley, P., University of Glasgow, Oxford, United Kingdom:
Model-building tools in coot.
Furey, W., V.A. Medical Center/University of Pittsburgh,
Pennsylvania: Anomalous data collection consideration.
Patterson group therapy. Solvent flattening/phase combina-
tion. Noncrystallographic symmetry averaging. MAD
phasing: A classical approach. Solving structures with BnP.
Gilliland, G., Centorcor Inc., Radnor, Pennsylvania: Welcome
and introduction. Course overview: The structure determi-
nation of biological macromolecules. Maximizing crystal-
lization success through seeding.
Holton, J., University of California, San Francisco: Tips and
tricks for improving diffraction.
Kleywegt, G., University of Uppsala, Sweden: Just because it’s
in Nature, doesn’t mean it’s true… (macromolecular struc-
ture validation).
McPherson, A., University of California, Irvine: Crystallization
of macromolecules I. Crystallization of macromolecules II.
Symmetry, periodicity, unit cells, space groups, miller planes,
and lattices. Waves, vectors, and complex numbers. Funda-
mental diffraction relationships and Bragg’s law. Diffraction
patterns, reciprocal space, and Ewald’s sphere. Fourier
PARTICIPANTS
Alam, S., Ph.D., University of Utah, Salt Lake City
Arai, H., B.S., University of California, Irvine
Bojja, R.S., Ph.D., Fox Chase Cancer Center, Philadelphia,
Pennsylvania
Burkinshaw, B., B.S., University of British Columbia,
Vancouver, Canada
Charlton, L., Ph.D., University of Pittsburgh, Pennsylvania
Gore, S., Ph.D., EMBL-EBI, Cambridge, United Kingdom
Hevener, K., Ph.D., University of Tennessee, Chicago, Illinois
Inada, H., Ph.D., Harvard University, Cambridge, Massa-
chusetts
transforms and the electron density equation. Patterson
methods. Crystal growth mechanisms.
Pflugrath, J., Rigaku Americas Corporation, The Woodlands,
Texas: Data collection: Design and setup. Cryocrystallo-
graphy. HKL2000 tutorial. Scaling and merging synchrotron
data.
Ready, R., University of Cambridge, United Kingdom: Using
SAD data in phaser. Molecular replacement: New structures
from old.
Richardson, J., Duke University Medical Center, Durham,
North Carolina: Structure presentation.
Richardson, J. and Richardson, D., Duke University Medical
Center, Durham, North Carolina: Detection and repair of
model errors using MolProbity.
Sweet, R., Brookhaven National Laboratory, Upton, New
York: A slightly different view of fundamental crystal-
lography. X-ray sources and optics.
Terwilliger, T., Los Alamos National Laboratory, New Mexico:
Automated structure solution and model-building.
Tronrud, D., Oregon State University, Corvalis: Macromolecu-
lar refinement I. Macromolecular refinement II. Difference
electron density maps.
Westbrook, J., Rutgers University, Piscataway, New Jersey:
Automating PDB deposition.
Yeh, J., University of Pittsburgh, School of Medicine, Pennsyl-
vania: Approaches for membrane protein crystallization.
Jeffers, S., Ph.D., Institut Pasteur, Paris, France
Lee, C.-H., M.S., Oregon Health & Science University,
Portland
Masoudi, A., B.S., Duke University School of Medicine,
Durham, North Carolina
Neher, S., Ph.D., University of North Carolina, Chapel Hill
Nylander, A., B.S., Umea University, Umea, Sweden
Sevryugina, Y., Ph.D., International Institute of Nano and
Molecular Medicine, Columbia, Missouri
Stampfer, S., B.A., Tufts University, Boston, Massachusetts
Wagner, J., B.S., University of Kentucky, Lexington
This course was supported with funds provided by the National Cancer Institute and the Howard
Hughes Medical Institute.
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Quantitative Imaging: From Cells to Molecules
October 24–November 6
INSTRUCTORS B. Huang, University of California, San Francisco
M. Krummel, University of California, San Francisco
A. North, The Rockefeller University, New York
S. Reck-Peterson, Harvard Medical School, Boston, Massachusetts
J. Waters, Harvard Medical School, Boston, Massachusetts
T. Wittmann, University of California, San Francisco
ASSISTANTS D. Kamiyama, University of California, San Francisco
H. Pemble, University of California, San Francisco
L. Piedmont, Nikon Imaging Center at Harvard Medical School, Boston, Massachusetts
W. Qiu, Harvard Medical School, Boston, Massachusetts
J. Rosenberg, Harvard Medical School, Boston, Massachusetts 
S. Stehbens, University of California, San Francisco
K. Thomas, The Rockefeller University, New York
J. Wong, University of California, San Francisco
This course focused on advanced quantitative fluorescence microscopy techniques used for imaging
a range of biological specimens, from cells to single molecules. The course was designed for cell and
molecular biologists with little or no microscopy experience who wish to begin utilizing microscopy
in their own research. Students gained a theoretical understanding of, and hands-on experience
with, state-of-the-art equipment used in quantitative fluorescence microscopy, including laser-scan-
ning and spinning-disk confocal microscopy, deconvolution methods, total internal fluorescence
microscopy (TIRF), superresolution methods (structured illumination, STORM, and PALM), and
digital image processing and analysis. Students learned how to design and implement a wide range
of imaging experiments using these techniques. Students used the techniques to address specific
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PARTICIPANTS
Auld, D., Ph.D., Novartis Institutes for Biomedical Research,
Cambridge, Massachusetts
Beck, J., Dipl., ETH Zurich, Switzerland
Didier, R., B.S., Florida State University College of Medicine,
Tallahassee
Gonzalez E., M., B.A., Genentech, South San Francisco,
California 
Hoepker, A., Ph.D., Stanford Medical School & HHMI,
California
Hombach-Klonis, S., Ph.D., University of Manitoba,
Winnipeg, Canada
Johnson, J., Ph.D., Washington University School of
Medicine, St. Louis, Missouri
quantitative questions and then discussed the results as a group, learning to troubleshoot the com-
mon problems that occur in the course of a quantitative imaging experiment. Among the lectures
presented were microscopy basics, CCD cameras, confocal microscopy, multiphoton microscopy,
deconvolution, TIRF, single-molecule imaging, imaging ratio-metric “biosensors” (including FRET),
and superresolution techniques. Students also learned specimen preparation for microscopy, includ-
ing fixation and immunofluorescence in tissue culture cells, choosing fluorescent proteins, and work-
ing with live samples requiring environmental control.
This course was supported with funds provided by the National Cancer Institute.
Lambert, T., Ph.D., Washington State University, Pullman
McClelland, A., Ph.D., Harvard University, Cambridge,
Massachusetts
Palacio, S., B.S., Institute of Neurobiology, MSC, University
of Puerto Rico, San Juan
Park, H.-O., Ph.D., Ohio State University, Columbus
Paul, A., Ph.D., Cold Spring Harbor Laboratory
Rogers,K., Ph.D., Harvard University, Cambridge, Massachu-
setts
Sims, C., Ph.D., Harvard University, Boston, Massachusetts
Verver, D., M.Sc., Academic Medical Center Amsterdam, The
Netherlands
Wheeler, T., B.S., University of Rochester, New York
SEMINARS
Goodwin, P., Applied Precision Inc., Issaquah, Washington:
Deconvolution.
Huang, B., University of California, San Francisco: Super-
resolution microscopy: STORM/PALM. Superresolution
microscopy: Structured illumination. Molecular complexes
under the STORM.
Khodjakov, A., Wadsworth Center, Albany, New York: Mitosis
in 3D: Spatial constraints and facilitating mechanisms in
spindle assembly.
Krummel, M., University of California, San Francisco: Prin-
ciples, benefits, and applications of multiphoton microscopy.
Visualization of immune responses in peripheral tissues.
North, A., The Rockefeller University, New York: Objective
lenses. Fluorescence microscopy. Sample preparation for
fluorescence microscopy. Live-cell imaging.
Reck-Peterson, S., Harvard Medical School, Boston, Massa-
chusetts: TIRF and single-molecule imaging. The mecha-
nism and regulation of molecular motors.
Waters, J., Harvard Medical School, Boston, Massachusetts:
Microscopy basics. Transmitted light microscopy. Digital
cameras. Digital imaging. Ratio imaging and FRET.
Wittmann, T., University of California, San Francisco: Con-
focal microscopy. How microtubule + TIP proteins shape cell
function. Live confocal, FRAP, and photoactivation.
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Advanced Sequencing Technologies and Applications
November 8–21
INSTRUCTORS E. Mardis,Washington University School of Medicine, St. Louis, Missouri
G. Marth, Boston College, Chestnut Hill, Massachusetts
W.R. McCombie, Cold Spring Harbor Laboratory
A. Quinlan, University of Virginia, Charlottesville
M. Zody, Broad Institute, Cambridge, Massachusetts
ASSISTANTS A. Farrell, Boston College, Chestnut Hill, Massachusetts
M. Griffith,Washington University School of Medicine, St. Louis, Missouri
M. Kramer, Cold Spring Harbor Laboratory
V. Magrini,Washington University School of Medicine, St. Louis, Missouri
S. McGrath,Washington University School of Medicine, St. Louis, Missouri
J. Walker,Washington University School of Medicine, St. Louis, Missouri
During the last decade, large-scale DNA sequencing has markedly impacted the practice of modern
biology and is beginning to affect the practice of medicine. With the recent introduction of several
advanced sequencing technologies, costs and timelines have been reduced by orders of magnitude,
moving investigators to conceptualize and perform sequencing-based projects that heretofore were
prohibitive. Furthermore, the application of these technologies to answer questions previously not
experimentally approachable is broadening their impact and application.
This intensive 2-week course explored applications of next-generation sequencing technologies,
with a focus on commercially available methods. Students were instructed in the detailed operation
of several revolutionary sequencing platforms, including sample preparation procedures, general
data handling through pipelines, and in-depth data analysis. A diverse range of biological questions
were explored including DNA resequencing of human genomic regions (using cancer samples as a
test case), de novo DNA sequencing of bacterial genomes, and the use of these technologies in study-
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PARTICIPANTS
Bennett, L., Ph.D., Baylor Research Institute, Dallas, Texas
Cox, L., B.S., New York University, New York
De, S., Ph.D., Dana Farber Cancer Institute, Boston,
Massachusetts
de las Nieves Perigones Borderias, M., Ph.D., Children’s
Hospital of Philadelphia, Pennsylvania
Hanna, M., M.S., Dana Farber Cancer Institute, Boston,
Massachusetts
Jacobsen, M., Ph.D., University of Copenhagen, Frederiksberg
C., Denmark
Johansson, I., M.S., Lund University, Sweden
Lindsay, C., Ph.D., University of Pennsylvania, Philadelphia
Maree, H., Ph.D., Agricultural Research Council, Stellen-
bosch, South Africa
ing small RNAs, among others. Guest lecturers highlighted their own applications of these revolu-
tionary technologies. 
We encouraged applicants from a diversity of scientific backgrounds including molecular evolu-
tion, development, neuroscience, cancer, plant biology, and microbiology.
This meeting was sponsored by Applied Biosystems, Illumina, and 454 Life Sciences.
Murtaza, M., M.B., B.S., Cancer Research UK, Cambridge,
United Kingdom
Pirooznia, M., Ph.D., Johns Hopkins University, Baltimore,
Maryland
Pratap, S., Ph.D., Meharry Medical College, Nashville,
Tennessee
Rozenzhak, S., Ph.D., University of California, San Diego,
California
Trompouki, E., Ph.D., Children’s Hospital Boston, Boston,
Massachusetts
Williams, A., B.S., Princeton University, New Jersey
Williams, S., Ph.D., University of Virginia, Charlottesville
SEMINARS
Fiume, M., University of Toronto, Canada: Lecture and
tutorial on Savant software package. 
Griffith, M., BC Cancer Agency, Vancouver, Canada: RNA-
Seq lecture and tutorial. 
Hall, I. and Quinlan, A., University of Virginia, Charlottes-
ville: Structural variant detection.
Hannon, G., Cold Spring Harbor Laboratory: Whole-genome
methylation.
Hicks, J., Cold Spring Harbor Laboratory: Sequencing from 
a single human cell.
Mardis, E., Washington University School of Medicine, 
St. Louis, Missouri: Next-generation cancer genomics.
Nekrutenko, A., Penn State University. University Park:
Galaxy ChIP-Seq and metagenomics.
Robinson, J., Broad Institute, Cambridge, Massachusetts: 
The IGV viewer. 
Stoops, K., Oxford Nanopore, United Kingdom, Oxford:
Nanopore.
Yandell, M., University of Utah. Salt Lake City: The VAAST
software tool. Lecture and tutorial.
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C. elegans
November 8–21
INSTRUCTORS M. Alkema, University of Massachusetts Medical School, Worcester
E. Lambie, LMU—Martinsried, Planegg-Martinsried, Bayern, Germany
E. Miska, University of Cambridge, United Kingdom
ASSISTANTS D. King, Cold Spring Harbor Laboratory
J. Pirri, University of Massachusetts Medical School, Worcester
S. Rolland, Ludwig Maximilian University, Munich, Germany
A. Sapetschnig, University of Cambridge, United Kingdom
This course was designed to familiarize investigators with C. elegans as an experimental system, with
an emphasis on both classical genetic analysis and reverse genetic approaches. A major goal was to
teach students how to successfully exploit the information generated by the C. elegans genome proj-
ect. The course was suited both for those who have current training in molecular biology and some
knowledge of genetics, but no experience with C. elegans, and for students with some prior worm
experience who wished to expand their repertoire of expertise. The following topics were covered
both in the laboratory and by lectures from experts in the field: worm pushing, C. elegans databases
and worm bioinformatics, anatomy and development, forward genetics, chemical and transposon
mutagenesis, generation of transgenic animals, expression pattern analysis, reverse genetics, con-
struction and screening of deletion libraries, and RNA inactivation. The course was designed to im-
part sufficient training to students in the most important attributes of the C. elegans system to enable
them to embark on their own research projects after returning to their home institutions.
This course was supported with funds provided by the National Institute of Child Health and
Human Development. 
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Alkema, M., University of Massachusetts Medical School,
Worcester: The neuroethology of C. elegans escape behavior.
Ambros, V., University of Massachusetts Medical School,
Worcester: microRNAs and developmental timing in C.
elegans.
Antebi, A., Baylor College of Medicine, Houston, Texas: The
neuroethology of C. elegans escape behavior.
Cutter, A., University of Toronto, Ontario, Canada: The
genetic basis of evolutionary change in Nematoda.
Greenstein, D., University of Minnesota, Nashville: Signaling
for sex in C. elegans.
Hall, D., Albert Einstein College of Medicine, Bronx, New
York: Introduction on C. elegans anatomy. Modern EM
methods for nematode.
PARTICIPANTS
Arczewska, K., Ph.D., The Biotechnology Centre of Oslo,
Norway
Bonilla, A., B.S., Dartmouth College, Hanover, New Hamp-
shire
Hernando, G., B.S., National Research Council of Argentina,
Bahia Blanca, Argentina
Huelgas Morales, G., Ph.D., Instituto de Fisiologia Cellular,
UNAM, Mexico City, Mexico
Ly, K., B.Sc., University of Auckland, New Zealand
Maia, A., B.S., University Medical Center Utrecht, The
Netherlands
Martell, J., B.S., Boston College, Chestnut Hill, Massachusetts
Pieczynski, J., Ph.D., University of Alabama, Birmingham
Jorgensen, E., University of Utah, Salt Lake City: Engineering
the genome with the Mos transposon.
Lambie, E., LMU-Martinsried, Planegg-Martinsried, Bayern,
Germany: Forward and reverse genetic analyses of TRPM
channel function in C. elegans.
Miska, E., University of Cambridge, United Kingdom: The
complex life of small RNA.
Rockman, M., New York University, New York: Natural
genetic variation as a research tool.
Schnabel, R., Institut fuer Genetik, Braunschweig, Germany:
A practical approach to multichannel 4D microscopy:
Phainothea and pattern formation by cell focusing in the 
C. elegans embryo.
Walhout, M., University of Massachusetts, Worcester: Gene
regulatory networks.
Reymann, A.-C., Ph.D., CEA Grenoble, France
Riehs-Kearnan, N., M.S., University of California, San
Francisco
Sarkies, P., M.B., MRC Laboratory for Molecular Biology,
Cambridge, United Kingdom
Shibata, Y., Ph.D., Northwestern University, Evanston, Illinois
Stuart, R., Ph.D., Marquette University, Milwaukee, Wiscon-
sin
Vergara, S., Ph.D., University of Massachusetts Medical
School, Worcester
Visscher, M., M.S., University of Medical Center Utrecht, The
Netherlands
Wook Jung, K., B.S., Stanford University, California
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Computational and Comparative Genomics
November 9−15
INSTRUCTORS W. Pearson, University of Virginia, Charlottesville
L. Stubbs, University of Illinois, Urbana
ASSISTANT L. Mills, University of Virginia, Charlottesville
This course presented a comprehensive overview of the theory and practice of computational meth-
ods for the identification and characterization of functional elements from DNA sequence data.
The course focused on approaches for extracting the maximum amount of information from protein
and DNA sequence similarity through sequence database searches, statistical analysis, and multiple
sequence alignment. Additional topics included the following: 
• Alignment and analysis of “next-gen” sequencing data, with applications from metagenomic,
RNA-Seq, and CHiP-Seq experiments.
• The Galaxy environment for high-throughput analysis.
• Regulatory element and motif identification from conserved signals in aligned and unaligned
sequences.
• Integration of genetic and sequence information in biological databases.
• The ENSEMBL genome browser and BioMart.
The course combined lectures with hands-on exercises; students were encouraged to pose chal-
lenging sequence analysis problems using their own data. The course was designed for biologists
seeking advanced training in biological sequence and genome analysis, computational biology core
resource directors and staff, and for individuals in other disciplines (e.g., computer science) who
wished to survey current research problems in biological sequence analysis. Advanced programming
skills were not required. 
The primary focus of this course was the theory and practice of algorithms in computational bi-
ology, with the goals of using current methods more effectively for biological discovery and devel-
oping new algorithms. Students more interested in the practical aspects of software development
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Aitken, K., Ph.D., CSIRO, St. Lucia, Australia
Belleau, P., M.S., CHUL Research Center, Quebec, Canada
Borhan, H., Ph.D., AAFC, Saskatoon, Canada
Borstrom, E., M.S., Science for Life Laboratory, Solna, Sweden
Coykendall, K., Ph.D., USGS-Leetown Science Center,
Kearneysville, West Virginia
Creasey, K., Ph.D., Cold Spring Harbor Laboratory
Fu, Q., M.S., Max-Planck Institute for Evolutionary
Anthropology, Leipzig, Germany
Garg, G., B.Sc., Technical University of Denmark, Kongenss.
Lyngby, Denmark
Koroteev, M., Ph.D., Okinawa Institute of Science and
Technology, Onnason, Japan
Lu, W., B.S., Indiana University School of Medicine,
Indianapolis
are encouraged to apply to the course on Programming for Biology. Students who would like in-
depth training in the analysis of next-generation sequencing data (e.g., SNP calling and the detection
of structural variants) are urged to apply to the course on Advanced Sequencing Technologies and
Applications for next year.
This course was supported by the National Human Genome Research Institute.
PARTICIPANTS
Ntziachristos, P., B.Sc., HHMI/New York University School 
of Medicine, New York
Oza, J., B.S., Robert Wood Johnson Medical School, New
Brunswick, New Jersey
Pearl, S., B.S., University of Georgia, Athens
Potdar, A., M.S., CWRU/Cleveland Clinic, Cleveland, Ohio
Rubio Garcia, A., B.Sc., Technical University of Denmark,
Denmark
Stafford, G., Ph.D., The Jackson Laboratory, Bar Harbor,
Maine
Stevison, L., Ph.D., University of California, San Francisco
Sweigart, A., Ph.D., University of Georgia, Athens
Yang, Y., Ph.D., The University of Texas/MD Anderson
Cancer Center, Smithville
Zhou, C., B.Sc., University of Alberta, Canada
SEMINARS
Mackey, A., University of Virginia, Charlottesville: Signaling
for sex in C. elegans.
Overduin, B., EMBL–European Bioinformatics Institute,
Cambridge, United Kingdom: The ENSEMBL database 
of genomes I. Ensembl/Biomart.
Quellette, F., Ontario Institute for Cancer Research, Toronto,
Canada: Databases for computational biology. Pathway
databases.
Smith, A., University School of California, Los Angeles:
Functional elements II: Epigenomics.
Stubbs, L., University of Illinois, Urbana and Smith, A.,
University School of California, Los Angeles: Identifying
functional elements I.
Stubbs, L., University of Illinois, Urbana: Next-gen biology:
Chromatin and transcription factor maps.
Taylor, J., Emory University, Atlanta, Georgia: Galaxy for
high-throughput analysis.
White, O., University of Maryland School of Medicine,
Baltimore: Introduction to metagenomics.
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The Genome Access Course
April 19−20, November 29−30
TRAINERS G. Howell, The Jackson Laboratory
B. King, Mount Desert Island Biological Laboratories
C. Lambert, Cold Spring Harbor Laboratory
This course is an intensive 2-day introduction to bioinformatics that was held twice in 2011 and trained
almost 70 participants in total. The core of the course was designed to cover the manipulation and
analysis of sequence information. The course was broken into modules designed to give a broad overview
of a given topic, with ample time for examples chosen by the instructors. Each module included three
parts, consisting of a discussion of theory and methods, coverage of software and web resources, and
use of selected tools with examples (including those supplied by the students). The modular design al-
lowed the instructors to tailor the presentation to the interests of the students. Modules included Elec-
tronic Sequence Information; Pairwise Sequence Comparisons; Multiple Sequence Alignments; Gene
Prediction; Genome Analysis; Sequence Variation; Protein Classification and Structural Analysis; Pro-
teomics; and Phylogenetic Analysis. Applications to the course were open to all on a first-come-first-
served basis, subject to basic eligibility requirements. The course was held at the Laboratory’s Genome
Research Center at Woodbury, located seven miles south of the main Laboratory campus. Each student
was provided with a PC laptop with wireless modem for the duration of the course. Students were en-
couraged to supply problem sets and sequences of interest to the trainers for possible incorporation as
examples in the modules. Materials were made available on the web, and students continued to ask
questions of the trainers as they applied what they had learned in their individual endeavors.
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November 29−30
Agshe, D., Harvard University, Cambridge, Massachusetts
Alvarez, D., Harvard Medical School, Boston, Massachusetts
Bekdash, R., Rutgers University, New Brunswick, New Jersey
Breton, T., University of New Hampshire, Durham
Cai, Y., Cold Spring Harbor Laboratory, New York
Chau, J., University of Connecticut, Manchester
Cong, L., New York Presbyterian Hospital/Weill Medical
Center, New York
Congdon, C.B., University of Southern Maine, Portland
Demeure, M., Translational Genomics Research Institute,
Scottsdale, Arizona
Everett, L., University of Michigan, Ann Arbor
Fendler, B., Cold Spring Harbor Laboratory, New York
Guha, U., Medical Oncology Branch, NCI, Bethesda,
Maryland
Hall, L., Harvard Medical School, NEPRC, Southborough,
Massachusetts
Harbour, K., USDA, Maricopa, Arizona
Ho, J., Forage Genetics International, Madison, Wisconsin
Hu, H., SUNY Upstate Medical University, Syracuse, New
York
Imumorin, I., Cornell University, Ithaca, New York
April 19−20
Burns, C., Washington & Jefferson College, Washington,
Pensylvania
Cheng, S., Brigham & Women’s Hospital, Cambridge,
Massachusetts
Ge, H., Peking University, Beijing, China
Hersch, J., Whitehead Institute, Cambridge, Massachusetts
Hultman, K., Northwestern University, Evanston, Illinois
Justiniano, E., University of Puerto Rico, Mayaguez
Mitra, D., Harvard Medical School/Massachusetts General
Hospital, Charlestown
Moragoda, L., Henry Ford Community College, Dearborn,
Michigan
Podur, J., York University, Toronto, Canada
Robb, E., Brock University, St. Catherine’s, Canada
Root, P., Henry Ford Community College, Dearborn,
Michigan
Ko, G.P., Seoul National University, South Korea
Kothera, L., Centers for Disease Control and Prevention, Fort
Collins, Colorado
Lee, H.-A., Boyce Thompson Institute for Plant Research,
Ithaca, New York
Lenz, P., University of Hawaii at Manoa, Honolulu
Maglic, D., Wake Forest University School of Medicine,
Winston-Salem, North Carolina
Morgan, J., Harvard Medical School, NEPRC, Southborough,
Massachusetts
Ni, E., Regeneron Pharmaceuticals Inc., Tarrytown, New York
Nicolette, P., Columbia University, New York
Slabodnick, M., University of California, San Francisco
Stanek, T., Thomas Jefferson University, Philadelphia,
Pennsylvania
Stueve T., Mount Sinai School of Medicine, New York
Tembe, W., TGen, Translational Genomics Institute, Phoenix,
Arizona
Tombert, K., University of Michigan, Ann Arbor
Werling, D., University of California, Los Angeles
Zhang, S., University of Texas/MD Anderson Cancer Center,
Houston
Shaikhibra, Z., University Hospital, Faculty of Medicine,
Bonn, Germany
Solomon, R., Cold Spring Harbor Laboratory, New York
Stepaniak, J., Henry Ford Community College, Dearborn,
Michigan
Tang, J., Metabolix, Cambridge, Massachusetts
Wang, V., Massachusetts General Hospital, Boston, Massa-
chusetts
Webster, K., Brown University, Providence, Rhode Island
Wray, L., Children’s Hospital of Philadelphia, Pennsylvania
Wulf, H., Bartlesville, Oklahoma
Wulf, K., Bartlesville, Oklahoma
Xenopoulos, P., Memorial Sloan-Kettering Cancer Center,
New York
Yoon, H.J., VA Loma Linda HealthCare, Irvine, California
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394 Postgraduate Courses
The Laboratory acknowledges the generosity of the following companies who loaned equipment and reagents
to the various courses: 
454 Life Sciences
Accuri Cytometers Inc.
Agilent Technologies Inc.
Andor Technology
Applied Biosystems
Applied Precision
Art Robbins Institute
Astro-Med Inc.
BD Biosciences
Berthold Technologies USA,
LLC
Bio-Rad Laboratories
Bitplane
Bruker Daltonics Inc.
Caliper Life Sciences
Carl Zeiss Inc.
Chroma Technology
Corporation
Coherent Laser
ConOptics
CoolLED
Corning Inc.
Covaris, Inc.
CrystaLaser
Dagan Corporation
Doric Lenses
Drummond Scientific
Company
Eppendorf North America
Fotodyne Inc.
GE Healthcare
Hamamatsu Photonic
Systems
Hamilton Thorne Biosciences
Hampton Research
Harvard Apparatus Inc.
Heka
Illumina Inc.
Intelligent Imaging
Innovations Inc.
Invitrogen
Jackson Immunoresearch
Laboratories
James A. Hill Instrument
Services
Kinetic Systems Inc.
Kopf Instruments
Leica Microsystems Inc.
Life Technologies
LI-COR
Luigs & Neumann
Millipore Corporation
Molecular Devices
Nalge Nunc International
Nanodrop Technologies
Narishige International USA
Inc.
Nasco
NeoBiosystems
New England Biolabs Inc.
Nikon Inc.
Olympus America Inc.
PerkinElmer Life and
Analytical Sciences
Photometrics
Prairie Technologies
Qiagen Inc.
Q-Imaging Inc.
Roche Applied Science
Roche Nimblegen
Scientifica Ltd.
SciGene
Semba Biosciences, Inc.
Shimadzu Scientific
Instruments, Inc.
Singer Instruments
Spectra-Physics Lasers Inc.
Stanford Photonics
Stanford Research Systems
Stoelting Co.
Stratagene
Sutter Instruments
Tecan US, Inc.
The Lonza Group, Ltd.
Thermo Fisher Scientific
Tokai Hit Co., Ltd.
VDS Vosskuhler GmbH
Warner Instruments
Waters Corporation
World Precision Instruments
Zeitz-Instrumente Vertriebs
GmbH 
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SEMINARS
INVITED SPEAKER PROGRAM
Each year, Cold Spring Harbor Laboratory invites speakers from outside the institution to present
their findings. These weekly seminars keep the CSHL staff current on the latest scientific developments
and broaden their perspectives. Graduate students and postdoctoral fellows meet with the seminar
speakers for lunch immediately after the seminar, allowing an opportunity for the exchange of ideas
in an informal setting. 
Title Host
January
Dr. David Scadden, Massachusetts Niche-induced oncogenesis. Grisha Enikolopov
General Hospital, Harvard University
Dr. Jeffrey Engelman, Massachusetts General Targeted therapies. Lloyd Trotman
Hospital Cancer Center/Harvard Medical
School
Dr. David Stern, Princeton University How a complex enhancer contributes to phenotypic Leemor Joshua-Tor
robustness and morphological evolution.
Dr. Douglas Green, St. Jude Children’s Hospital Metabolic reprogramming in activated T lymphocytes. Richard Sever
February 
Dr. Frederick DeSauvage, Genentech, Inc. Targeting the hedgehog pathway in cancer: From bench Scott Powers
to clinic.  
Dr. Daniel Geschwind, University of California, Autism: A model for integration of genomics, genetics, Pavel Osten
Los Angeles and neurobiology in complex neurodevelopmental 
disorders.
Dr. Randall Johnson, Moores Cancer Center, The physiology of hypoxic response: The yin and yang Mikala Egeblad
University of California, San Diego Medical of HIF-1 and HIF-2.
Center
Dr. Gabriele Bergers, University of California, Feedback control of the microenvironment in tumor Mikala Egeblad
San Francisco progression and resistance.
March
Dr. Frederick “Fritz” Roth, University of Bar-code fusion genetics, entangled mate sequencing, Ivan Iossifov
Toronto and green monsters.
Dr. Arnold Kriegstein, University of California, Neural stem and progenitor cells in human cortical Josh Huang
San Francisco development.
Dr. Nicholas Proudfoot, University of Oxford Gene punctuation in eukaryotes: Gene loops, R-loops, Leemor Joshua-Tor
and noncoding RNA.
Dr. Christopher Miller, Brandeis University Puzzles of molecular recognition in a virtual proton pump. Hiro Furukawa
Dr. Wolf Reik, Babraham Institute, UK Epigenetic reprogramming in mammalian development. Rob Martienssen
April 
Dr. Gero Miesenböck, University of Oxford Lighting up the brain. Josh Dubnau
Dr. Peter Walter, University of California, The unfolded protein response in health and disease. Adrian Krainer
San Francisco
Dr. Steven F. Dowdy, University of California The road to therapeutic RNAi: Tackling the siRNA Adrian Krainer
School of Medicine, San Diego delivery gorilla.
Dr. Kornelia Polyak, Harvard Medical School Diversity in breast cancer: Relevance and therapeutic Mikala Egeblad
and Dana Farber Cancer Institute implications.
October
Dr. Robert Full, University of California, Neuromechanical systems biology: Gripping geckos, Katie Liberatore 
Berkeley crashing cockroaches, and galloping ghost crabs. and Matt Camiolo
Dr. James Allison, Memorial Sloan-Kettering Immune checkpoint blockade in cancer therapy: New Lloyd Trotman
Cancer Center insights and opportunities.
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Title Host
October (continued)
Dr. Massimo Scanziani, University of  Addressing cortical processing by perturbing the activity Bo Li
California, San Diego of individual layers.
November
Dr. Douglas Green, St. Jude Children’s ER−mitochondrial interactions in apoptosis: A “greasy” Richard Sever
Research Hospital road to ruin.
Dr. Allan Bradley, The Wellcome Trust Sanger Genetics in stem cells: From gene discovery to therapy. Alea Mills
Institute, United Kingdom
December
Dr. Bob Darnell, The Rockefeller University Maps of the RNA world. Adrian Krainer
IN-HOUSE SEMINAR PROGRAM
Cold Spring Harbor Laboratory’s In-House Seminars were initiated to provide a semiformal avenue
for communication among the various research groups at the Laboratory. The seminars also afford
a necessary opportunity for the graduate students and postgraduate staff to develop their skills in
organizing, presenting, and defending their research.
January Title
Yuntao “Steve” Mao (Spector Lab) Direct visualization of the cotranscriptional assembly of a nuclear body by 
noncoding RNAs.
Bo Li Excitatory synapse and psychiatric disorders.
Christopher Hammell Developmental regulation of microRNA activity.
February
Agustin Chicas (Lowe Lab) The RB-binding proteins JARID1A/JARID1B link the RB tumor sup-
pressor to epigenetic reprogramming during cellular senescence.
Hiro Furukawa Structural dissection of NMDA receptor pharmacology.
Darryl Pappin New proteomics technologies.
March
Jer-Ming Chia (Ware Lab) Navigating the maze: Tracing the genetic architecture of traits in a fluid genome.
Thomas Schlach (Joshua-Tor Lab) Coupling RNAi to heterochromatin: Insights into the structure of the RITS 
complex.
Adam Kepecs Decisions, uncertainty, and the brain: Neural circuit mechanisms underlying
cognition.
April
Anne Churchland Putting the pieces together: How neural systems integrate information across 
time and sensory modalities.
Hongwu Zheng Understanding glioma pathogenesis.
Benjamin Boettner (Van Aelst Lab) Rap1 signaling at a critical junction to cell−cell adhesion.
October
Navasona Krishnan (Tonks Lab) Something smells in signal transduction.
Glenn Turner Reading the mind of a fly: Neural coding in the Drosophila mushroom body.
Mickey Atwal Cancer: A quantitative story of stress, sex, and evolution.
November
Lloyd Trotman Principles of tumor suppression: Translating cancer genetics into biology.
Stephen Shea Neural circuitry for social communication in mice.
Shipra Das (Krainer Lab) Mechanisms of splicing misregulation in cancer and senescence.
December
Michael Schatz Applications of micro-, mega-, and meta-assembly.
BANBURY CENTER

It was another busy year for the Banbury Center. The Center was used for 34 events with a total of
686 participants. There were 24 science-related meetings, together with six lecture courses run by
the Meetings and Courses Program and two Watson School Topics in Biology courses. Of the 686
participants, 511 were from the United States (from 35 different states) and 96 from Europe (16
different countries). The truly international character of the Center’s program is shown by the fact
that participants came from a total of 25 countries worldwide. 
Banbury Center fosters and promotes research by providing a venue for meetings other than
those dealing with scientific topics, for example, by providing training for young scientists and
physicians at the beginnings of their careers. The National Institute of Mental Health held its third
“Brain Camp” for young physicians, to introduce them to the latest basic research relevant to their
work. The Boehringer Ingelheim Fonds returned with its fellows drawn from Europe and North
America for a “Communicating Science” workshop. The fellows are subjected to a rigorous training
in writing skills, presentation of graphic information, and preparing and delivering a scientific talk,
so that they can excel in these skills as well as their research. For the first time, we held a “Leadership
in Bioscience” workshop. David Stewart received funding from the American Express Foundation
under its Leadership Program for a short course where participants were to be instructed in things
scientists must be able to do—in addition to their research—to succeed. The first course was held
in 2011, organized by Carl Cohen, coauthor of Lab Dynamics: Management Skills for Scientists, pub-
lished by Cold Spring Harbor Laboratory Press. The course drew participants from institutes
throughout the United States.
We also promote research by hosting meetings where a small number of members of groups or
associations come together to discuss policy affecting their work. There were four such examples
this year. The National Cancer Institute (NCI) established a network of biobanks to act as clearing
houses to collect and supply biopsies, DNA, and cell cultures to researchers. In June, representatives
of the NCI biobanks came to Banbury to review the effectiveness and discuss the future of the pro-
gram. Discussions were guided by Laurence Baker (University of Michigan Cancer Center) and
Scott Lowe (CSHL), with input from Harold Varmus, Director of NCI.
We have held several meetings on chronic fatigue syndrome and this year we were delighted to
host the Scientific Advisory Board of the Chronic Fatigue and Immune Dysfunction Syndrome
(CFIDS) Association. During the past few years, CFS research has received high-profile media at-
tention, for example, over the claim (now discredited) that the XMR virus is a cause of CFS. This
has generated both increased interest and unprecedented opportunities for progress. The goals of the
meeting were for the Scientific Advisory Board to provide guidance on research strategies to encourage
innovative research focused on early detection, objective diagnosis, and effective treatment. 
This group also included a meeting of the editorial board of the Federation of Biochemical So-
cieties (FEBS) journal. Banbury Center provided a quiet haven for the board to meet with the jour-
nal’s staff and discuss the performance and future direction of the journal.
Finally, representatives of the Epigenomics of Plants International Consortium (EPIC), funded
by the National Science Foundation (NSF), came to Banbury in November. The Consortium was
established to coordinate and promote research on deciphering the plant epigenome. Participants
discussed intellectual questions, transformative methodologies, and infrastructure needs required
to do this, as well as the means to engage funding agencies and the international research community
as a whole.
BANBURY CENTER
EXECUTIVE DIRECTOR’S REPORT
399
400 Banbury Center
The broad sweep of scientific topics of Banbury Center meetings changes from year to year. One
year, it may be neuroscience and psychiatric disorders, and another year, it may be human genetic
disorders. This year, the focus was on cancer, in particular on treatments for cancer. The first meeting,
Curing Melanoma and Other Cancers by Targeted Therapies, was organized by Joseph Schlessinger
(Yale University) and Jim Watson. It could not have been held at a more auspicious moment. In
the course of the meeting, Jim Allison (Memorial Sloan-Kettering Cancer Center) learned that the
Food and Drug Administration (FDA) had approved a monoclonal antibody therapy for metastatic
melanoma that had been developed based on his work. 
The second cancer meeting was Metformin and Neoplasia. Metformin is an antidiabetic drug used
to treat type II diabetes. It is the most widely prescribed antidiabetic in the world. Remarkably, epi-
demiological studies have shown that patients taking metformin have a lower risk of developing can-
cer. The mechanism(s) underlying this anticancer effect is far from clear and was a focal point of the
presentations and discussions at the meeting. Metformin has an added interest in the context of “re-
purposing” drugs. It is argued that drugs such as metformin, which have been given to hundreds of
millions of people and whose safety is established, should be fast-tracked for approval for other uses.
As long ago as 1995, Stan Prusiner organized the first Banbury Center meeting on prions. At
that time, there were many controversial issues about the nature, replication, and species specificity
of these misfolded proteins. Prion-like particles became immensely important to the population of
the United Kingdom in 1990 when patients were found suffering from what was called variant
Creutzfeldt–Jakob disease. The cause of the disease was demonstrated to be meat contaminated with
neural material from cattle suffering with bovine spongiform encephalopathy. As a result, a large
proportion of the United Kingdom population had been exposed, leading to almost 200 deaths.
Misfolded proteins are found in other disorders (for example, Alzheimer’s disease), and there is
recent evidence that Alzheimer’s disease amyloidosis can be transmitted to primates. That these dis-
orders might be transmissible has important implications for public health, and the time was clearly
right for a critical review of the data on transmission of the amyloidoses, the mechanisms involved,
and the implications for human health.
Another area in which Banbury Center has long had an interest is the genetics of psychiatric dis-
orders. In the early 1990s, we held several meetings reporting on the progress of finding genes in-
volved in these disorders using the only tool then available, linkage analysis. A later incarnation of
this approach, genome-wide association studies, has found many locations associated with psychiatric
disorders, but the significance of these remains unknown. Now, new high-throughput DNA se-
quencing techniques have made, or are about to make, it possible to sequence the whole exomes
and genomes of large numbers of individuals. This will provide opportunities to develop new gene-
hunting strategies for complex genetic disorders. Our meeting brought together experts to critically
assess current strategies and to outline how genome-scale sequencing can be used most effectively
and efficiently.
The Cold Spring Harbor Laboratory Corporate Sponsor Program is a mainstay of the Banbury
Center program, providing funding each year for a small number of meetings. We are very grateful
to members of the Program for their support and happy when they wish to use Banbury Center for
a meeting of their own choice. In 2011, both Astellas-OSI Pharmaceuticals and Sanofi-Aventis came
to Banbury.
The Banbury Center could not operate at its high level without the hard work of many people.
The Center is especially fortunate to have Janice Tozzo and Susanne Igneri ensuring that the meetings
run smoothly, and Basia Polakowski making sure that participants are welcome in Robertson House.
Sonny Leute, Fredy Vasquez, and Joseph McCoy look after the grounds, dealing with vast amounts
of leaves in the fall and, this year, vast amounts of snow in the winter. Jon Parsons is indefatigable
in handling audio-visual requirements, and Connie Brukin enlivens this report with her photo-
graphs. Culinary Services feeds our participants and Housekeeping copes admirably with the rapid
turnover of guests.
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It is now 35 years since the garage of the Robertsons’ estate was converted into the Conference
Room, and for the first time in that period, the room is undergoing a complete renovation. It is
long overdue. In particular, the original wiring was not designed to take the load imposed by all of
the computers that participants bring or the demands of modern projectors and copying machines.
We will also upgrade all of the ethernet cabling and generally bring the facility into the 21st century.
The building has been emptied and turned over to the electricians, carpenters, and painters—and
we look forward to hosting meetings for the next 35 years!
Jan Witkowski
Executive Director
Renovations, 1976Garage
402
BANBURY CENTER MEETINGS
Leadership in Bioscience Workshop
February 18−21
FUNDED BY          The American Express Foundation 
ARRANGED BY      C. Cohen, Science Management Associates, Newton, Massachusetts
                               D. Kennedy, WorkLab, LLC, New York
A scientist running a laboratory is essentially running a business, small to begin with but likely to
get larger with time. And so, scientists need to develop skills akin to those needed to run a business:
identifying and resolving conflicts, dealing with difficult people, leading effective and productive
meetings, and communicating effectively within the laboratory and with the outside world. These
skills, if acquired at all, are usually learned haphazardly, after the fact. How much better to learn
them systematically and in advance of needing them! So, David Stewart, Executive Director of the
Meetings and Courses Program, applied to the American Express Foundation for funding from the
Foundation’s Leadership Program. He was successful and the “Leadership in Bioscience Workshop”
was the result.
SESSION 1:Who We Are
Participants read their 50−100-word “Who I am and what I hope
to get from this workshop” aloud to the entire group. They
revealed to the group what they would be if they were not
scientists.
SESSION 2: Introduction: What Is Leadership and What
Makes a Great Scientist/Leader? 
Part 1. Small groups proposed attributes of leadership
especially in a scientific context, and they discussed examples
of effective and ineffective leadership based on their own
experience and observations.
Part 2. Small groups reported to the entire group. The goal
was to develop attributes of excellent leaders to serve as a
reference point for the rest of the conference. 
SESSION 3: Difficult Conversations and Interactions
Participants explored the types of situations that scientists find
difficult as they transition into leadership positions and
received a practical toolkit to use in those situations.
• Learning to listen and to seek out underlying interests 
• Fundamental tools for negotiating difficult conversations 
• Dealing with difficult people
SESSION 4: Keynote Speaker: Zia Khan, Vice President,
Strategy and Evaluation, Rockefeller Foundation, New York
SESSION 5: Case Studies
Attendees were instructed to bring a one-page case study
describing a difficult management situation or leadership
challenge that they have faced or are facing. 
Part 1. In small groups, each attendee read their case aloud. A
structured discussion guide was provided to elicit comments,
discussion, and suggestions from the group in the context of
the work already done in the workshop. Each small group
selected one case that best illustrated a key leadership challenge
for presentation in summary to the entire group.
Part 2. Each small group made a 1-minute summary of its
selected case to the large group, which then chose just one or
more cases to discuss in the large group. Large groups’ ideas/
suggestions/approaches were compared with those of the small
group. A discussion of leadership characteristics was tied in
from Session 1. 
SESSION 6: Group Dynamics and Meetings
• How to run/lead meetings 
• How to structure and encourage open discussion, ensuring
participation 
• How to deal with silence and nonparticipants 
• How to recognize and manage impediments to effective
group problem solving 
SESSION 7: Projecting Leadership 
Volunteers were selected to deliver a “pitch” about their institu-
tion, department, or group. The large group provided feedback
in the context of what was learned so far in the workshop.
SESSION 8: Science in the Public Eye 
Facilitator: K.R. Miller, Brown University, Providence, Rhode
Island 
SESSION 9: Concluding Group Discussion 
What did we learn? What did we not learn that we would have
liked to learn? 
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M. Le Beau, University of Chicago, Illinois: Commonly
deleted intervals in human leukemias with del 5q/7q.
R. Bergerson, University of Chicago, Illinois: Characterization
of candidate haploinsufficient genes on chromosome 5.
A. Stoddart, University of Chicago, Illinois: Characterization
of the genetic pathways leading to t-MN with a del 5q.
J. Wong, University of California, San Francisco: Modeling 7q
deletions in the mouse.
S. Lowe, Cold Spring Harbor Laboratory: Is MLL3 a 7q tumor
suppressor?
H. Liu, University of Chicago Hospital, Illinois: Targeting
PI3K/mTOR and MEK pathways in AML.
E. Diaz-Flores, University of California, San Francisco:
Biochemical profiling of primary leukemias using
phosphoflow cytometry.
Z. Zhao, Cold Spring Harbor Laboratory: Ras feedback
signaling in leukemogenesis and therapy response. 
S. Rathe, University of Minnesota, Minneapolis: This, that,
and the other thing.
E. Dolan, University of Chicago, Illinois: Pharmacogenetics of
Ara-C.
OPENING SESSION
J. Zuber, Cold Spring Harbor Laboratory: Leukemia maintenance genes.
SESSION 1: Genetics and Biology of 5q/7q Deletions
SESSION 2: Signaling in AML
SESSION 3: Therapy in AML
SESSION 4: Lymphoid Malignancies
M. Dail, University of California, San Francisco: Response and
resistance to PI3K inhibition in T-lineage leukemia. 
C. Scuoppo, Cold Spring Harbor Laboratory: New tumor
suppressor networks in lymphoma. 
C. Miething, Cold Spring Harbor Laboratory: Biology of
PTEN in lymphoma. 
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SCOR Retreat 
March 15−17 
FUNDED BY The Leukemia & Lymphoma Society
ARRANGED BY S. Lowe, Cold Spring Harbor Laboratory, New York
SCOR (Specialized Center of Research) is a program of the Leukemia & Lymphoma Society. The
cornerstone of the SCOR program is its collaborative structure: Every recipient works with a cross-
disciplinary team of leading researchers from their own and other universities and medical institu-
tions. In this case, researchers from Cold Spring Harbor Laboratory collaborate with researchers at
the Universities of Minnesota, California (San Francisco), and Chicago. This meeting provided an
opportunity for those involved to present their data and to interact with one another in person.
The Third NIMH-Sponsored Brain Camp
March 18–21 
FUNDED BY National Institute of Mental Health
ARRANGED BY M. Akil, National Institute of Mental Health, Bethesda, Maryland
T. Insel, National Institute of Mental Health, Bethesda, Maryland 
For the third year, the Banbury Center was very pleased to host the NIMH-sponsored
“Brain Camp.” The goal of the Brain Camp is to identify areas of neuroscience that
are of interest and relevance to psychiatrists and to communicate these to a small
group of outstanding psychiatry residents and research fellows. Some of the most dis-
tinguished and thoughtful neuroscientists in the country took part in the meeting.
The outcome of this meeting will be the start of a neuroscience curriculum that can
eventually be shared with psychiatry training programs around the country.
Introduction and Charge: T. Insel, National Institute of Mental Health, Bethesda, Maryland 
P. Sklar, Mount Sinai School of Medicine, New York: Toward
understanding schizophrenia and bipolar disorder genetics.
J. Gordon, Columbia University, New York: So you’ve cloned
the gene... Now what?
Special Lecture: E. Kandel, Columbia University, New York: Mice, Men, and Mental Illness:
Animal Models of Mental Disorders.
SESSION 1: Genetics and Genomics
M. Akil
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SESSION 2: Developmental Neurobiology
P. Shaw, National Institute of Mental Health, Bethesda,
Maryland: In for the long haul: Using longitudinal
neuroimaging to understand attention-deficit/hyperactivity
disorder.
J. Huang, Cold Spring Harbor Laboratory: Toward a genetic
dissection of GABAergic circuits in cerebral cortex:
Chandeliers light up the path from genes to cognition.
T. Bale, University of Pennsylvania, Philadelphia: Epigenetics
in neurodevelopment: Gene × environment × development
× sex. 
SESSION 3: Cognitive Neuroscience 
C. Carter, University of California, Davis, Sacramento, and A.
MacDonald, III, University of Minnesota, Minneapolis:
Circuits and symptoms: The cognitive neuroscience of
executive control in health and disease. 
SESSION 4: Social Neuroscience
K. Pelphrey, Yale University, New Haven, Connecticut: Neural
signatures of autism. 
T. Insel, National Institute of Mental Health, Bethesda, Mary-
land: Social neuroscience: A new basic science for psychiatry.
Round Table Discussion with All Speakers: Future Directions
in Neuroscience and Psychiatry
SESSION 5: Circuits and Microcircuits
B. Rosen, Massachusetts General Hospital, Charlestown:
Multimodal functional neuroimaging.
K. Hong Wang, National Institute of Mental Health, Bethesda,
Maryland: Illuminating the functional organization and
plasticity of cortical microcircuits.
K. Pelphrey, L. Sjulson E. Kandel
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Curing Melanoma and Other Cancers by Targeted Therapies
March 22−25   
FUNDED BY Hazen Polsky Foundation and the Melanoma Research Alliance
ARRANGED BY J. Schlessinger, Yale University School of Medicine, New Haven, Connecticut
J.D. Watson, Cold Spring Harbor Laboratory, New York
A wealth of genetic and biochemical analyses combined with novel ap-
proaches for drug discovery is offering, for the first time, hope for effective
new therapies for untreatable cancers such as melanoma. The goal of the
meeting was to present new data about targeted therapies that have been
recently developed for the treatment of melanoma and other cancers. Ge-
netic and biochemical studies describing novel targets and new approaches
for targeted therapies were also described. Finally, molecular mechanisms
underlying drug resistance that operate in patients treated with targeted
therapies and new approaches for overcoming this problem were reviewed.
Welcoming Remarks: J.A. Witkowski, Banbury Center, Cold Spring Harbor Laboratory, New York
Introductory Remarks: J.D. Watson, Cold Spring Harbor Laboratory, New York
SESSION 1: Genetic and Molecular Basis for Melanoma
Chairperson: M. Herlyn, The Wistar Institute, Philadelphia, Pennsylvania
M. Herlyn, The Wistar Institute, Philadelphia, Pennsylvania:
Tumor heterogeneity and the consequences of therapy.
D.E. Fisher, Massachusetts General Hospital, Boston: BRAF-
MAPK targets the melanocytic master transcriptional regu-
lator MITF: Targeted therapy and lineage differentiation.
R. Halaban, Yale University School of Medicine, New Haven,
Connecticut: Insights from sequencing the melanoma tran-
scriptome and exome.
T. Wiesner, Memorial Sloan-Kettering Cancer Center, New
York: Germline mutations in BAP1 predispose to melano-
cytic tumors.
S. Topalian, J. Watson
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SESSION 2: Signaling Pathways and Targeted Therapies in Melanoma
Chairperson: J. Schlessinger, Yale University School of Medicine, New Haven, Connecticut
G. Bollag, Plexxikon, Berkeley, California: Discovery of kinase
inhibitors for melanoma.
M.J. Weber, University of Virginia, Charlottesville: Compensa-
tory signaling: A mechanism of resistance and a guide to
combination therapy.
N. Rosen, Memorial Sloan-Kettering Cancer Center, New
York: Resistance to ERK inhibition: Pharmacologic and bi-
ologic issues. 
R. Marais, Institute of Cancer Research, London, England:
Targeting BRAF in melanoma: Synthetic lethality as an ap-
proach to treating cells expressing BRAF and other onco-
genes.
SESSION 3: Resistance Mechanisms in Melanoma and Other Cancers
Chairperson: B. Stillman, Cold Spring Harbor Laboratory, New York
D.A. Tuveson, CRUK Cambridge Research Institute, Cam-
bridge, United Kingdom: Stromal barriers in pancreatic
cancer medicine.
R. Lo, University of California, Los Angeles: Overcoming ac-
quired resistance to BRAF inhibitors.
L.A. Garraway, Dana-Farber Cancer Institute, Boston, Massa-
chusetts: Systematic characterization of resistance to RAF
inhibition in melanoma.
P.D. Nisen, GlaxoSmithKline, Collegeville, Pennsylvania: A
multifaceted approach to melanoma therapy: BRAF, MEK,
MAGE3, and PD-1.
SESSION 4: Epigenetic Pathways in Melanoma and Other Cancers
Chairperson: C.J. Sherr, St. Jude Children’s Research Hospital, Memphis, Tennessee
E. Bernstein, Mount Sinai School of Medicine, New York: Un-
raveling the melanoma epigenome.
J.E. Bradner, Dana-Farber Cancer Institute, Boston, Massachu-
setts: Direct inhibition of epigenetic reader proteins in 
cancer therapy.
C. Vakoc, Cold Spring Harbor Laboratory: RNAi screening to
identify epigenetic vulnerabilities in acute myeloid
leukemia.
SESSION 5: Immunotherapies for Melanoma Treatments
Chairperson: J.P. Allison, Memorial-Sloan Kettering Cancer Center, New York
J.P. Allison, Memorial-Sloan Kettering Cancer Center, New
York: Immune checkpoint blockade in melanoma therapy.
S. Topalian, Johns Hopkins University School of Medicine,
Baltimore, Maryland: Targeting immunological pathways:
B7-H1/PD-1 blockade in cancer.
T.F. Gajewski, University of Chicago, Illinois: Regulation of
antitumor immunity at the tumor microenvironment.
SESSION 6: Differentiation, Stem Cells, and EMT
Chairperson: H. Varmus, National Cancer Institute, Bethesda, Maryland
K. Struhl, Harvard Medical School, Boston, Massachusetts:
Metformin-based combinatorial therapy: New xenograft
data on melanoma cell lines. 
R. Nusse, Stanford University Medical Center, California:
WNT signaling and stem cell control.
R. Kalluri, Beth Israel Deaconess Medical Center, Boston,
Massachusetts: Hypoxia-induced epithelial to mesenchy-
mal transition and metastasis.
SESSION 7: Perspectives on Melanoma, Biomarkers, and Targeted Therapies
Chairperson: D.M. Epstein, Astellas−OSI Oncology, Inc., Farmingdale, New York
I. Mellman, Genentech, S. San Francisco, California: The
practical empiricist’s guide to developing targeted cancer
therapies.
D.M. Epstein, Astellas−OSI Oncology, Inc., Farmingdale,
New York: Dual IGF-1R blockade in cancer therapy.
J.E. Darnell, The Rockefeller University, New York: STAT 3:
Why we must learn to inhibit it and new ideas that might
work.
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SESSION 8: Animal Models and Melanoma: What Can We Learn?
Chairperson: D.A. Tuveson, CRUK Cambridge Research Institute, Cambridge, United Kingdom
M. McMahon, University of California, San Francisco: Mod-
eling the effects of pathway-targeted therapeutics in geneti-
cally engineered mouse models of cancer.
M. Bosenberg, Yale University School of Medicine, New
Haven, Connecticut: Optimizing mouse models of
melanoma for preclinical testing. 
L. Dow, Cold Spring Harbor Laboratory: Using inducible
RNAi in vivo to investigate the role of Wnt signaling in
melanoma progression.
SESSION 9: Fighting Mesenchymal Cancers
Chairperson: J. Schlessinger, Yale University School of Medicine, New Haven, Connecticut
G.F. Vande Woude, Van Andel Institute, Grand Rapids,
Michigan: Targeting c-MET in cancer.
G. Demetri, Dana-Farber Cancer Institute, Boston, Massachu-
setts: Parsing pathogenetic pathways to accelerate drug devel-
opment: Universal lessons from GIST and other sarcomas.
R. Sordella, Cold Spring Harbor Laboratory: Intrinsic and ex-
trinsic regulation of metastatic spread of NSCLC.
Closing Remarks and Discussion: J. Schlessinger, Yale Univer-
sity School of Medicine, New Haven, Connecticut
L. Garraway, R. Nusse, H. Varmus J. Schlessinger
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Neuronal Response Variability and Cortical Computation
April 3−6  
FUNDED BY The Swartz Foundation and the Gatsby Charitable Foundation
ARRANGED BY L. Abbott, Columbia University, New York
J. Reynolds, Salk Institute for Biological Studies, La Jolla, California
It is becoming increasingly clear that neuronal response variability, in particular low-frequency re-
sponse correlations, have a profound impact on how populations of neurons encode information
and provide an important window into neural circuit function. The goal of the meeting was to bring
together experimentalists and theorists seeking to understand neuronal response variability and its
implications for cortical computation and to provide a more unified way to think about variability
and correlations. Participants examined such questions as Is variability “noise” or is it a signature of
important computations that we have yet to understand? How do neural circuits distinguish intrinsic
variability in the neural signal from the stimulus-induced variability? How can we best exploit our
ability to measure variability and correlations to maximize what we learn about neural circuits?
Welcoming Remarks: J.A. Witkowski, Banbury Center, Cold Spring Harbor Laboratory, New York
Introductory Remarks: Why Are We Here? L. Abbott, Columbia University, New York
SESSION 1: Correlations in Data and Models
Chairperson: L. Abbott, Columbia University, New York
A. Kohn, Albert Einstein College of Medicine, Bronx, New
York: Signal propagation between V1 and V2.
M. Smith, University of Pittsburgh, Pennsylvania: Structure of
neuronal correlation: Depth, distance, and dynamics.
A. Tolias, Baylor College of Medicine, Houston, Texas:
Structure of network activity in the neocortex.
A. Renart, Champalimaud Centre for the Unknown, Lisbon,
Portugal: Temporal correlations in recurrent neural networks
with balanced excitation and inhibition.
J. Curtis, Salk Institute for Biological Studies, La Jolla,
California: Changes in neuronal gain modulate neuronal
synchronization and correlation.
M. Cohen, Harvard Medical School, Boston, Massachusetts:
Using the variability of neuronal populations to compare
spatial and feature attention.
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M. Churchland, Stanford University, California: Stimulus
onset quenches neural variability: A widespread cortical
phenomenon.
K. Rajan, Princeton University, New Jersey: Stimulus-
dependent suppression of chaos in recurrent neural networks.
E. Anderson, Salk Institute for Biological Studies, La Jolla.
California: Burstiness and attentional modulation in V4.
T. Pasternak, University of Rochester, New York: Trial−trial
variability of cortical neurons reveals the nature of their
engagement in a visual discrimination task.
K. Shenoy, Stanford University, California: Toward a single-
trial understanding of motor preparation and variability.
SESSION 3: Decisions and Choice Probability
Chairperson: T. Pasternak, University of Rochester, New York
J. de la Rocha, IDIBAPS, Barcelona, Spain: A model for choice
probability: Disambiguating whether response variability
biases the decision or vice versa.
A. Fontanini, SUNY Stony Brook, New York: Effects of
anticipatory cues on gustatory processing in actively 
sensing rats.
X.-J Wang, Yale University School of Medicine, New Haven,
Connecticut: A reservoir of time constants for memory traces
in cortical neurons.
M. Shadlen, University of Washington, Howard Hughes
Medical Institute, Seattle: Variance as a signature of neural
computations during decision making.
D. Ringach, University of California, Los Angeles: Coding by
population variance.
SESSION 4: Variability and Correlations in Coding and Circuits
Chairperson: X.-J. Wang, Yale University School of Medicine, New Haven, Connecticut
B. Averbeck, National Institutes of Health, Bethesda, Maryland:
Noise correlations and information encoding and decoding.
K. Padmanabhan, Carnegie Mellon University, Pittsburgh,
Pennsylvania: Intrinsic biophysical diversity neuronal firing
while increasing information content.
M. Corbetta, Washington University School of Medicine, St.
SESSION 2: Effects of Stimuli and Attention on Variability and Correlations
Chairperson: H. Sompolinsky, the Hebrew University, Jerusalem, Israel
Louis, Missouri: Bold signal noise and behavior.
N. Brunel, Université Paris Descartes, France: Response of
networks of excitatory and inhibitory neurons to time-
dependent inputs.
H. Sompolinsky, the Hebrew University, Jerusalem, Israel:
Sensory processing in random cortical networks.
SESSION 5: Variability and Correlation in Visual Processing
Chairperson: J. Reynolds, Salk Institute for Biological Studies, La Jolla, California
Y. Fregnac, CNRS UNIC, Gif sur Yvette, France: Contextual
dependency of signal reliability and noise in V1 during
sensory processing/adaption of the simple or complex
receptive fields to visual statistics. 
L. Osborne, University of Chicago, Illinois: Variability in
smooth pursuit eye movements and its origin in the brain:
Information coding of visual motion in cortical area MT in
single units and populations.
V. Dragoi, University of Texas, Houston Medical Center:
Correlated variability in laminar cortical circuits.
W. Geisler, University of Texas, Austin: Optimal receptive fields
for natural tasks: Efficiency, redundancy, and neural noise.
Closing Remarks and Discussion: J. Reynolds, Salk Institute for Biological Studies, La Jolla, California
V. Dragoi
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Lyme Disease in the Proteomics–Genomics Era
April 10−13 
FUNDED BY Time for Lyme, Inc.
ARRANGED BY B. Budowle, University of North Texas Health Science, Fort Worth
S. Schutzer, UMDNJ−New Jersey Medical School, Newark
We are now in the proteogenomic era, characterized by a revolution in
high-throughput technologies, most notably in DNA sequencing and pro-
tein identification. These new technologies not only do more faster, they
enable us to think about doing things differently, to exploit their power
to devise new strategies. The goals of this meeting were to explore how
new technologies might be used in conjunction with existing techniques,
to develop new diagnostic strategies, to forecast promising future tests,
and to identify the problems that need to be overcome including support-
ing biorepositories. Participants included not only those with experience
in lyme disease but also a number of individuals whose expertise in pro-
teomics, genomics, and other areas can help move the field forward.
Welcoming Remarks: J.A. Witkowski, Banbury Center, Cold Spring Harbor
Laboratory, New York
What Do We Hope to Accomplish Here?   S. Schutzer, UMDNJ–New Jersey Medical School, Newark
SESSION 1: Overview Talks
Chairperson: S. Schutzer, UMDNJ–New Jersey Medical School, Newark
A.C. Steere, Massachusetts General Hospital, Boston:
Evolution of lyme disease in the United States covering the
clinical spectrum of lyme.
M.E. Schriefer, Centers for Disease Control and Prevention,
Ft. Collins, Colorado: Current state of lyme disease
laboratory tests and immediate future hopes.
B. Budowle, University of North Texas Health Science, Fort
Worth: Things to keep in mind throughout the conference:
What if we did have a promising technique, can it be made
into a good test and what would be the elements of a good
and bad test?
S. Schutzer, A. Hassett
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SESSION 2: Animal Models 
Chairperson: S. Schutzer, UMDNJ–New Jersey Medical School, Newark
S.W. Barthold, University of California, Davis: Role of animal
models in the future.
D. Ecker, Ibis Biosciences, Inc., Carlsbad, California: Rapid
detection of the microbe when culturing is challenging. 
P. Chain, Los Alamos National Laboratory, New Mexico:
What can we deliver on a large scale?
S. Casjens, University of Utah School of Medicine, Salt Lake City:
What has it delivered for lyme disease; is it a game changer?
M. Eshoo, Ibis Biosciences, Inc., Carlsbad, California:
Technological methods: Whole-genome amplification in  host
and vector background. Microbes are unknown.
SESSION 4: Genomics and Proteomics
Chairperson: A.C. Steere, Massachusetts General Hospital, Boston
R.W. McCombie, Cold Spring Harbor Laboratory: What are
genomics and sequencing able to deliver in general?
S. Salzberg, University of Maryland, College Park:
Bioinformatics of complex genetic data.
T.E. Angel, Pacific Northwest National Laboratory, Richland,
Washington: What are integrated strategies to be incor-
porated into mass spectrometry and protein fractionation?
How to maximize the strengths and overcome the 
challenges.
General Discussion: S. Schutzer, UMDNJ−New Jersey
Medical School, Newark, and T.E. Angel, Pacific Northwest
National Laboratory, Richland, Washington
B. Luft, SUNY Stony Brook, New York: Protein arrays I.
P. Felgner, University of California, Irvine: Protein arrays II.
M. Eshoo, Ibis Biosciences, Inc., Carlsbad, California: Can we
identify multiple species and genotypes in ticks and humans?
SESSION 5: Issues for Assay Use and Interpretation on Broad Scale
Chairperson: B. Budowle, University of North Texas Health Science, Fort Worth
M. Lewinski, University of California, Los Angeles: Use in a
large clinical laboratory, gold standards, technological and
regulatory hurdles.
J. Aucott, Johns Hopkins at Greenspring Station, Lutherville,
Maryland: Role of the immune system as a barometer.
SESSION 6: Strategies for Analysis of Genetic Data and Specimen Banks
Chairperson: S. Schutzer, UMDNJ−New Jersey Medical School, Newark
S. Schutzer, UMDNJ−New Jersey Medical School, Newark:
Can compartmental genomics and proteomics be used to
diagnose a disease and distinguish it from others?
R. Chakraborty, University of North Texas Health Science,
Fort Worth: Real-life examples: Getting the right specimens
for repository and errors if you fail to do so.
J.S. Fowler, Brookhaven National Laboratory, Upton, New
York: PT scan and other methodologies to detect
neurological disease.
SESSION 7: Tracking Infection in Animals and Man
Chairperson: S. Schutzer, UMDNJ−New Jersey Medical School, Newark
M. Rusckowski, University of Massachusetts Medical School,
Worcester: Can we track the infection as it moves
throughout the body? 
P. Fox, Animal Medical Center, New York: The dog as a sentinel.
S. Hojvat, Center for Devices and Radiological Health,
Rockville, Maryland: Path to FDA clearance.
SESSION 8: Biorepositories and How to Maintain Them and Ensure Their Integrity
Chairperson: A. Hassett, University of Michigan Health System, Ann Arbor
S. Miller, National Museum of Natural History, Washington,
D.C.: Past repositories at Smithsonian and future ones for
biodefense. Distinctions and defining the purpose.
B. Budowle, University of North Texas Health Science, Fort
Worth: Experience with human genetic and microbial
repositories.
Closing Remarks and Discussion: S. Schutzer,
UMDNJ−New Jersey Medical School, Newark, and 
B. Budowle, University of North Texas Health Science, 
Fort Worth
SESSION 3: Genomic Strategies for Detection and Diagnosis of the Microbe
Chairperson: B. Budowle, University of North Texas Health Science, Fort Worth
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Communicating Science
April 29–May 5 
FUNDED BY Boehringer Ingelheim Fonds Foundation for Basic Research in Medicine
ARRANGED BY A. Hoffmann, Boehringer Ingelheim Fonds, Heidesheim, Germany
C. Walther, Boehringer Ingelheim Fonds, Heidesheim, Germany
The Boehringer Ingelheim Fonds has an international program of support for Ph.D. fellowships. It
first brought its fellows to the Banbury Center for their annual North American retreat in 2005. It
has been a great pleasure to have them return and their 2011 stay at Banbury was the fourth occasion
they have been here. At Banbury, they receive intensive instruction in matters such as giving pre-
sentations and writing papers, topics usually learned by default (and often poorly) during graduate
research.
Opening Remarks: C. Walther, Boehringer Ingelheim Fonds, Heidesheim, Germany
SPEAKERS
Chairperson: R. Berwick, Massachusetts Institute of Technology, Cambridge
W. Wells, Global Alliance for TB Drug Development, New York: Writing techniques and how to structure papers.
First writing assignment.
B. Tansey, Vanderbilt University Medical Center, Nashville, Tennessee: Presentation of graphic information and how
to prepare and deliver a scientific talk.
J. Hudspeth, The Rockefeller University, New York: What makes success in science?
SPECIAL LECTURES
M. Huse, Memorial Sloan-Kettering Cancer Research Institute, New York: Using photoactivation to study
cytoskeletal dynamics in lymphocyte activation and inhibition. 
S. Webb, National Association of Science Writers, New York: Science in the media. 
K. Ris-Vicari, Katie Ris-Vicari Graphic Design, New York, and M. Hansen, Nature Publishing Group, New York:
How to design figures. 
C. Walther, Boehringer Ingelheim Fonds, Heidesheim, Germany: All about BIF. 
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Antibiotic Resistance: Past, Present, Future
May 15−18 
FUNDED BY Oliver Grace Fund
ARRANGED BY J. Davies, University of British Columbia, Vancouver, Canada
S. Levy, Tufts University School of Medicine, Boston, Massachusetts
J.H. Miller, University of California, Los Angeles
J.D. Watson, Cold Spring Harbor Laboratory, New York
Antibiotics (together with vaccines) are biomedical research’s
greatest contribution to human health. But the introduction
of antibiotics in the early 1940s was accompanied by the de-
velopment of antibiotic resistance. Initially, resistance occurred
by mutation (usually during the course of therapy), but in the
1950s, transmissible resistance was identified. In more recent
times, this threat has been magnified because of the emergence
of multidrug-resistant clinical strains coupled with the paucity
of efforts to find and develop new antibiotics. There is even
talk of a return to the pre-antibiotic era. The pharmaceutical
industry has tried to keep up with bacterial evolution, but in
vain. The need for novel antibiotics and methods of suppres-
sing resistance has never been greater, and this Banbury con-
ference addressed these needs. Participants examined the
history of the emergence of antibiotic resistance and the strategies that have been pursued to combat
it. This historical background provided a context for discussion of current practical approaches to
restoring effective antimicrobial therapy and paths that may prove to be promising in the future.
Welcoming Remarks: J.A. Witkowski, Banbury Center, Cold Spring Harbor Laboratory, New York
Introductory Remarks: J.H. Miller, University of California, Los Angeles
S. Levy, J. Miller, J. Davis
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SESSION 1: Defining the Parameters
Chairperson: J. Davies, University of British Columbia, Vancouver, Canada
J. Davies, University of British Columbia, Vancouver, Canada: A
brief history of coevolution of antibiotics and their resistance.
J.H. Miller, University of California, Los Angeles: Antibiotic
sensitivities as codrug targets; some consequences of low
amounts of antibiotics.
B. Kreiswirth, UMDNJ, Newark, New Jersey: The challenges
of XDR-TB.
SESSION 2: Ecological Considerations
Chairperson: G. Wright, McMaster University, Hamilton, Canada
W. Witte, Robert Koch Institute, Wernigerode, Germany:
Spread of livestock-associated MRSA and the risk posed
to humans.
G.A. Jacoby, Lahey Clinic, Burlington, Massachusetts:
Plasmid-mediated quinolone resistance.
G. Wright, McMaster University, Hamilton, Canada: Origins
and ecology of resistance: Inhibition of resistance
mechanisms.
G. Dantas, Washington University in St. Louis School of
Medicine, St. Louis, Missouri: Antibiotic resistome of the
commensal microbiota.
R. Kishony, Harvard Medical School, Boston, Massachusetts:
The ecology of antibiotic resistance.
A. Tomasz, The Rockefeller University, New York: From
resistance gene to the resistant phenotype.
P. Courvalin, Institut Pasteur, Paris, France: Successful
resistance determinants are selectively neutral.
C. Thomas, University of Birmingham, United Kingdom:
Role of the second eukaryotic-like, isoleucyl tRNA
synthetases in a variety of bacteria as a source of resistance
to mupirocin and related antibiotics.
SESSION 3: Decline and Fall of b-Lactams 
Chairperson: K. Bush, Indiana University, Bloomington
K. Bush, Indiana University, Bloomington: b-Lactamase
evolution: Current issues of carbapenemases.
S. Mobashery, University of Notre Dame, Indiana: Molecular
mechanism of resistance to b-lactam antibiotics in
methicillin-resistance in Staphylococcus aureus.
P. Tulkens, Université Catholique de Louvain, Bruxelles,
Belgium: Efflux transporters: Impact of patient treatment
and role in decreased susceptibility of sparsely used or non-
used antibiotics.
O. Lomovskaya, Mpex Pharmaceuticals, San Diego,
California: Use of efflux inhibitors as a strategy to overcome
and reduce resistance.
H. Zgurskaya, University of Oklahoma, Norman: The
assembly and mechanism of multidrug efflux pumps in
gram-negative bacteria. 
SESSION 4: Biology and Discovery
Chairperson: K. Lewis, Northeastern University, Boston, Massachusetts
K. Lewis, Northeastern University, Boston, Massachusetts:
Tolerance, resistance, and opportunities for antibiotic
discovery.
B. Eisenstein, Cubist Pharmaceuticals, Lexington,
Massachusetts: The antibiotic pipeline: Where it is, what
needs fixing.
L. Piddock, University of Birmingham, United Kingdom:
Barriers to overcome to get from drug discovery to new
antibiotics in patients.
T.R. Walsh, Cardiff University, United Kingdom: The
similarities between global antibiotic resistance and global
warming: When two worlds collide.
M. Mulvey, National Microbiology Laboratory, Manitoba,
Canada: Antimicrobial resistance in Canada.
S. Projan, Medimmune, Gaithersburg, Maryland:
Immunoprophylaxis for the prevention of bacterial
infections, better than a cure.
SESSION 5:What Is Next? 
Chairperson: S. Levy, Tufts University, Boston, Massachusetts
P. Huovinen, University of Turku, Finland: Targeted use of
antibiotics: Rapid diagnostics and human microbiota.
S. Levy, Tufts University, Boston, Massachusetts: Circum-
venting antibiotic resistance: Prevention, not treatment.
E. Kutter, Evergreen State College, Olympia, Washington:
Bacteriophages as natural, self-replicating, and self-limiting
antimicrobials.
S. Lerner, Wayne State University, Detroit, Michigan:
Educating the community about the problem of antibiotic
resistance.
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NSF Workshop: The Future of Plant Genome Sequencing
and Analysis 
May 18−20 
FUNDED BY National Science Foundation
ARRANGED BY W.R. McCombie, Cold Spring Harbor Laboratory, New York
M.C. Schatz, Cold Spring Harbor Laboratory, New York
J.A. Witkowski, Banbury Center, Cold Spring Harbor Laboratory, New York
In just the past few years, sequencing instrument capabilities have increased more
than 1000-fold and are likely to continue to increase about fivefold each year
for the next several years. However, analysis methods have not improved nearly
as much during the same time period and a variety of technical limitations of
these new instruments make it even more difficult to carry out whole-genome
sequencing of novel genomes (de novo sequencing). The goals of this meeting
were to assess the current state of de novo sequencing, predict what can be ex-
pected to develop in the near future, and determine how these exciting tech-
nologies could be used to carry out de novo sequencing of entire complex plant
genomes.
Welcoming Remarks: J.A. Witkowski, Banbury Center, Cold Spring Harbor Laboratory, 
New York
Challenges and Opportunities in Plant Genomics: Goals of the Meeting: W.R. McCombie,
Cold Spring Harbor Laboratory, New York
W.R. McCombie
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SESSION 1: Defining the Challenges
Chairperson: W.R. McCombie, Cold Spring Harbor Laboratory, New York
K. Devos, University of Georgia, Athens: The challenges of
complex genomes.
D. Neale, University of California, Davis: The nature of the
size and complexity of the conifer genome.
R. Ming, University of Illinois, Urbana: Assembly of papaya
sex chromosomes.
J. Mudge, National Center for Genome Resources, Santa Fe,
New Mexico: Integration of alternative data types.
D. Main, Washington State University, Pullman: Plant
community databases: The stewards of knowledge.
J. Romero-Severson, University of Notre Dame, Indiana:
Nonmodel, highly heterozygous, outcrossing disomic
polyploids with large genomes.
General Discussion and Listing of Key Points
SESSION 2: Technologies
Chairperson: T. Michael, Monsanto Company, Chesterfield, Missouri
D. Schwartz, University of Wisconsin, Madison: Optical
mapping and nanocoding systems for genome assembly and
analysis.
H. Cao, BioNanomatrix, Inc., Philadelphia, Pennsylvania:
High-throughput single-molecule-level imaging of the linear
genome for assembly with nanochannel rays.
S. Turner, Pacific Biosciences, Inc., Menlo Park, California:
Application of SMRT sequencing to assembly problems.
Discussion and Listing of Key Points
T. Michael, Monsanto Company, Chesterfield, Missouri:
Building tools, pipelines, and processes to utilize long, single-
molecule PacBio reads to assemble plant genomes.
A. Zimin, University of Maryland, College Park, Maryland:
Efficient assembly of large genomes from short reads.
M. Schatz, Cold Spring Harbor Laboratory: Computational
challenges of plant genome assembly.
I. Birol, British Columbia Cancer Research Centre, Vancouver,
Canada: Haploid assembly of diploid genomes.
M. Caccamo, Genome Analysis Centre, Norwich, United
Kingdom: Assembly of large genomes with cortex.
S. DesChamps, DuPont Experimental Station, Wilmington,
Delaware: Local and global de novo assemblies in complex
crop genomes.
S. Gnerre, Broad Institute, Cambridge, Massachusetts:
Assembling large and small genomes with ALLPATHS-LG.
P. Kersey, European Bioinformatics Institute, Cambridge,
United Kingdom: Squeezing through the bottlenecks:
Strategies for assembling large genomes.
K. Mockaitis, Indiana University, Bloomington: Using
transcriptome data to facilitate genome assembly.
T. Tatusova, National Center for Biotechnology, Bethesda,
Maryland: NCBI efforts to support assembly submissions.
General Discussion and Listing of Key Points
Summary Discussion and Future Developments
SESSION 3: Assembly
Chairperson: M.C. Schatz, Cold Spring Harbor Laboratory, New York
K. Mockaitis
D. Schwartz
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Future of Biomarker Discovery and Biobanks in Cancer Diagnosis,
Prognosis, and Therapy
June 23−24 
FUNDED BY SWOG
ARRANGED BY L. Baker, University of Michigan, Ann Arbor
S. Lowe, Cold Spring Harbor Laboratory, New York
The availability of suitable biomarkers to identify appropriate patient
populations and tissue-specific drug activation indices is crucial for
maximizing the efficacy of many existing and developing therapies
and for trial design for drug development. In turn, the successful iden-
tification and validation of new biomarkers requires the availability
of biospecimens for clinical research. Patient specimens obtained from
clinical trials sponsored by NCI-designated cooperative groups such
as SWOG provide an incredibly rich source of tissue for the advance-
ment of cancer research, biomarker discovery, and patient care. This
meeting examined the optimization of biospecimen repositories as
well as the cutting-edge approaches and technologies that may be
brought to bear on biomarker discovery.
Welcoming Remarks: J.A. Witkowski, Banbury Center, Cold Spring Harbor Laboratory, New York
Meeting Expectations and Goals: S. Lowe, Cold Spring Harbor Laboratory, New York
Cooperative Overview and Challenges: L. Baker, University of Michigan, Ann Arbor
R. Sordella, S. Powers, S. Lowe
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SESSION 1: Improving Therapy through Analysis of Clinical
Specimens
Chairpersons: H. Varmus, National Cancer Institute,
Bethesda, Maryland, and R. Fisher, University of Rochester,
New York
A. Types of Scientific Questions that Can Be Addressed 
with Biobank Tissues
T. Tlsty, University of California, San Francisco: Stratifying
DCIS biopsies for risk of future tumor formation.
R. Levine, Memorial Sloan-Kettering Cancer Center, New
York: Use of clinical trial leukemia samples to gain novel
insights into AML pathogenesis.
P. Kantoff, Dana-Farber Cancer Institute, Boston, Massachu-
setts: Genetic variants in antioxidant pathways and risk of
prostate cancer.
R. Sordella, Cold Spring Harbor Laboratory: Intrinsic and
extrinsic mechanisms of erlotinib resistance.
B. On the Horizon: New Technologies and Approaches
J. Hicks, Cold Spring Harbor Laboratory: Biomarkers from
sequencing, copy number, and single cells.
S. Powers, Cold Spring Harbor Laboratory: Using genomics 
to develop biomarkers for hepatocellular carcinoma.
A. Van Oudenaarden, Massachusetts Institute of Technology,
Cambridge: Single-cell transcript counting in tissue.
L. Wickerham, NSABP Foundation, Pittsburgh, Pennsylvania:
Case study.
SESSION 2: How Are We Doing? 
Chairperson: T. Tlsty, University of California, San Francisco 
A. Lessons from the Cooperatives and Overview of
Repositories
S. Hamilton, University of Texas MD Anderson Cancer
Center, Houston: The ECOG experience and next-gen
clinical trials.
P. Febbo, University of California, San Francisco: Lessons from
the cooperative groups and overview of repositories: Cancer
and leukemia group B.
W. Franklin, University of Colorado School of Medicine,
Aurora: Best practices in cooperative group biobanks: What
we have and what we need.
B. Overview of Committees and Selection Process: Who Gets
Tissues and How
C. Hoban, SWOG, Ann Arbor, Michigan: Life cycle of
biospecimen use in SWOG: Promoting access and overview
of distribution process.
C. Ways Cooperative Groups and BioBank Tissue Inform
Scientific and Medical Advance
R. Comis, Eastern Cooperative Oncology Group, Philadel-
phia, Pennsylvania: Role of the cooperative groups in the
translational cancer research continuum.
R. Fisher, University of Rochester, New York: LLMPP: A
consortium designed to develop a new molecular
understanding of lymphoma resulting in targeted
therapeutic initiatives.
SESSION 3: Biomarker Discovery Beyond the Cooperative
Groups: What Can We Learn?
Chairpersons: P. Febbo, University of California, San
Francisco, and S. Hamilton, University of Texas MD
Anderson Cancer Center, Houston
N. Rosen, Memorial Sloan-Kettering Cancer Center, New
York: Dynamic markers of tumor adaptation to therapy.
J. Derry, Sage Bionetworks, Seattle, Washington: The need 
for sharing data and models.
SESSION 4: Banking Strategies that Facilitate Biomarker
Discovery
Chairpersons: N. Rosen, Memorial Sloan-Kettering Cancer
Center, New York, and P. Kantoff, Dana-Farber Cancer
Institute, Boston, Massachusetts
K. Shaw, National Cancer Institute, Bethesda, Maryland:
Banking.
W. McCaskill-Stevens, National Cancer Institute, Bethesda,
Maryland: Banking of biospecimens from clinical trials:
Lessons, challenges, and future opportunities.
N. Ramirez, Nationwide Children’s Hospital, Columbus,
Ohio: COG and GOG biospecimen resources: More than
“tissue bank.”
J.-G. Foster, Nationwide Children’s Hospital, Columbus,
Ohio: Hand in hand: Centralized reference laboratory
testing and optimization of cooperative group banking.
S. Paik, NSABP Foundation, Pittsburgh, Pennsylvania: Why
great science often fails to become good clinical tests:
Development of predictive test for adjuvant Trastuzumab
using archived tumor blocks from NSABP trial B-31.
General Discussion: Banking Strategies that Facilitate
Biomarker Discovery
Moderator: L. Baker, University of Michigan, Ann Arbor
SESSION 5:Meeting Wrapup: Framing the Future
Chairperson: Scott Lowe, Cold Spring Harbor Laboratory,
New York
Discussion
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Translation of Cellular and Molecular Mechanisms of Aging
to Geriatric Disorders
September 11–13 
FUNDED BY The Therapeutic Strategic Unit of Aging–Sanofi US
ARRANGED BY B. Baron, Sanofi-Aventis, Bridgewater, New Jersey
C. Marta, Sanofi-Aventis, Bridgewater, New Jersey
E. Tamer, Sanofi-Aventis, Bridgewater, New Jersey
The Center and the Laboratory are indebted to members of the CSHL Corporate Sponsor Program,
and we are pleased when members of the Program make use of the benefits of the Program. One of
these is to hold meetings at Banbury on a topic of their own choosing, and we were happy to wel-
come members of the Sanofi Therapeutic Strategic Unit of Aging. The meeting brought together
key experts with Sanofi scientists to critically evaluate two areas with major implications for aging:
(1) the contribution of mitochondrial dysfunction and oxidative stress to aging and its associated
disorders and (2) the impact of aging on the immune system and immunosenescence. The focus
was on connecting clinical observations to underlying mechanisms, using this knowledge to compare
the relevance of potential interventions, and predicting the most appropriate patient populations
and outcome parameters.
Welcoming Remarks: J.A. Witkowski, Banbury Center, Cold Spring Harbor Laboratory, New York
Keynote Address: Translating Novel Scientific Findings in Aging into Therapies for Geriatric Practice
  R. Hodes, National Institute on Aging, Bethesda, Maryland
OPENING SESSION: From Biology of Aging to Treatment of Aging Disorders
Chairperson: R. Belder, Sanofi-Aventis, Bridgewater, New Jersey
Introduction of TSU-Aging Strategy and Therapeutic Goals 
Opening Remarks: R. Belder, Sanofi-Aventis, Bridgewater, New Jersey
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SESSION 1:Mitochondrial Dysfunction, Oxidative Stress, and Translational Interventions
Chairperson: S. Kahn, Gencia Biotechnology, Charlottesville, Virginia 
G. Gibson, Weill Medical College, White Plains, New York:
The brain’s use of glucose and calcium is abnormal in
Alzheimer’s disease. Why? Does it matter? Can we do
anything about it?
R. De Cabo, Biomedical Research Center, NIH, Baltimore,
Maryland: Dietary manipulations for healthy aging.
V. Bohr, National Institutes of Health, Baltimore, Maryland:
Nuclear and mitochondrial DNA repair defects in aging.
S. Melov, Buck Institute for Research on Aging, Novato,
California: A murine mitochondrial model for age-related
cardiovascular disease.
Special Lecture
P. Shiels, University of Glasgow, United Kingdom: Cellular and molecular basis of the diseases of aging.
SESSION 1 (continued):Mitochondrial Dysfunction, Oxidative Stress, and Translational Interventions
Chairperson: M. Flint Beal, Cornell University, New York
J.M. Cook-Mills, Northwestern University, Chicago, Illinois:
Vitamin E isoforms differentially regulate inflammation.
G.S. Shadel, Yale University School of Medicine, New Haven,
Connecticut: Regulation of life span by adaptive
mitochondrial ROS signaling.
D. Wallace, University of Pennsylvania, Philadelphia: The
mitochondrial bioenergetic origin of complex diseases.
SESSION 2: Immunosenescence: Alterations in the Functional and Regenerative Capacity of the Immune
System during Immunosenescence. Lessons Learned from Translational Studies
Chairperson: D. Unutmaz, New York University School of Medicine, New York
G. Pawelec, University of Tübingen Clinical School,
Germany: Models and mechanisms of human
immunosenescence.
California: Receptor threshold calibration in T cells:
Implications for T-cell homeostasis and responses with age.
H. Geiger, Cincinnati Children’s Hospital Medical Center,
Ohio: DC42 activity regulates hematopoietic stem-cell aging
and rejuvenation.
B. Grubeck-Loebenstein, Austrian Academy of Sciences,
Innsbruck, Austria: Age-related changes in the CD8 T-cell
pool and their consequences.
SESSION 2 (continued): Immunosenescence: Alterations in the Functional and Regenerative Capacity of the
Immune System during Immunosenescence. Lessons Learned from Translational Studies
Chairperson: G. Pawelec, University of Tübingen Clinical School, Germany
D. Unutmaz, New York University, New York: Does chronic
inflammation accelerate immunosenescence?
L. Haynes, Trudeau Institute, Saranac Lake, New York: How
aging impacts CD4 T cells.
J. Goronzy, Stanford University School of Medicine,
D. Wallace M. Beal
Scientific and Technological Barriers to Global Real-Time Risk
Assessment of Vector-Borne Infections
September 18−21 
FUNDED BY Defense Threat Reduction Agency, Department of Defense
ARRANGED BY D. Barnard, Agricultural Research Service, USDA, Gainesville, Florida
R. Breeze, Global Security Directorate, Lawrence Livermore National Laboratory, Livermore, California
D. Fish, Yale University, New Haven, Connecticut
A. Rudolph, Chemical and Biological Defense Directorate, Defense Threat Reduction Agency, Fort 
Belvoir, Virginia
In 1991, the Banbury Center held its first meeting on lyme disease, then a
newly emerging disease. From that first meeting has developed a series of meet-
ings on newly emerging diseases and the threat that they pose to world health.
New pathogens emerge regularly in many regions of the world, and they are
often zoonotic, making the jump from a wild or domestic animal reservoir or
an arthropod vector to humans. This meeting, supported by the U.S. Depart-
ment of Defense—which has long focused on protecting the health of its
forces deployed overseas from numerous infectious diseases not indigenous to
the United States—examined what is being done and what could be done to
detect such diseases. Questions discussed included What data are available
from existing and evolving vector-borne disease surveillance and risk assess-
ment activities and how might these data be enhanced? How might data be
generated in low-resource countries, mega cities, and remote regions without
long-term and costly investments in human and physical capital? What do we
need to know about the ecology of the microbes, vectors, and hosts, including
microbial variants that provide early indications of disease activity?
Welcoming Remarks: J.A. Witkowski, Banbury Center, Cold Spring Harbor Laboratory, New York
Introductory Remarks: A. Rudolph, Chemical and Biological Defense Directorate, Fort Belvoir, Virginia
SESSION 1: A World of Vector-Borne Threats
Chairperson: R. Breeze, Global Security Directorate, Lawrence Livermore National Laboratory, California
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C. Phillips, Texas Tech University, Lubbock: Global disease
surveillance, emergent disease preparedness, and national
security.
W. Reisen, University of California, Davis: Arbovirus
surveillance in California.
D. Fish, Yale University, New Haven, Connecticut: Disease
emergence: Lessons from ticks.
G. Glass, Johns Hopkins University, Baltimore, Maryland:
Observations on some challenges of finding what you are
looking for.
P. Daszak and W. Karesh, EcoHealth Alliance, New York:
Predicting the origins and spread of vector-borne diseases.
M. Kilpatrick, University of California, Santa Cruz: A
mathematical framework and research plan for predicting
which vector-borne pathogens could cause epidemics in
North America.
D. Impoinvil, University of Liverpool, United Kingdom:
QWeCI and LUCINDA.
D. Knowles, USDA Agricultural Research Service, Pullman,
Washington: Determinants contributing to the reemergence
of a foreign animal tick-borne infection in the U.S.
T. Myers, Armed Forces Health Sciences Center, Silver Spring,
Maryland: The Global Emerging Infections Surveillance and
Response System (GEISS).
R. Jarman, Walter Reed Army Institute of Research, Silver
Spring, Maryland: Pathogen and disease surveillance: Lessons
from dengue cohort studies in northern Thailand.
K. Gage, Centers for Disease Control and Prevention, Fort
Collins, Colorado: Selection of sites to evaluate newly
developed techniques for assessing global risks of vector-
borne infections.
Somalia Scenario and Conference Discussion (Part 1)
D. Barnard, USDA Agricultural Research Service, Gainesville,
Florida: Detection systems for dipteran vectors. 
Discussion led by W. Reisen, University of California, Davis
R. Baker, Texas Tech University, Lubbock: The significance of
knowing mammalian reservoir species.
T. Briese, Columbia University, New York: Strategies for
comprehensive pathogen surveillance and discovery.
I. Lipkin, Columbia University, New York: Microbe hunting.
P. Naraghi-Arani, Lawrence Livermore National Laboratory,
California: Novel detection technologies applicable to vector-
borne disease surveillance.
M. Eshoo, IBIS Biosciences, Carlsbad, California: The use of
PCR/ESI-MS to detect known and novel vector-borne
pathogens.
SESSION 2: Technologies and Technology Gaps 
Chairperson: E. Van Gieson, Chemical and Biological Defense Directorate, Fort Belvoir, Virginia
SESSION 3: The Virtual World
Chairperson: B. Knols, Soper Strategies, Amsterdam, the Netherlands
J. Brownstein, Harvard University, Cambridge, Massachusetts:
HealthMap: Harvesting informal sources for public health
surveillance. 
L. Eisen, Colorado State University, Fort Collins: Data
management system/decision support system for surveillance
and control of vectors and vector-borne diseases.
J. Richardson, Walter Reed Army Institute of Research, Silver
Spring, Maryland: Vector map.
B. Knols, Soper Strategies, Amsterdam, the Netherlands:
Malariaworld.
Somalia Scenario and Conference Discussion (Part 2)
SESSION 4: Dynamic Spatial Risk Maps
Chairperson: D. Fish, Yale University, New Haven, Connecticut
A. Tatem, University of Florida, Gainesville: Mapping and
modeling population and vector-borne infection movements
in resource-poor settings.
C. Lord, University of Florida, Gainesville: Scale in models of
vector-borne diseases.
B. Blumenthal, Columbia University, New York: Real-time
provision of climate analysis for vectoral environment
evaluation. 
M. Thomson, Columbia University, New York: Climate
information for the prediction and prevention of vector-
borne diseases. 
N. Nurthen, Chemical and Biological Defense Directorate,
Fort Belvoir, Virginia: Data sharing/access issues for global
real-time risk assessment of vector-borne infections.
Somalia Scenario and Conference Discussion (Part 3)
Strategic Research Initiative for CFS
September 25−27 
FUNDED BY CFIDS Association of America
ARRANGED BY K.K. McCleary, CFIDS Association of America, Charlotte, North Carolina
S. Vernon, CFIDS Association of America, Charlotte, North Carolina
Banbury Center has held several meetings on chronic fatigue syndrome and related dis-
orders and the Center was pleased to be the site for the inaugural meeting of the Scien-
tific Advisory Board (SAB) of the CFIDS Association of America. During the past few
years, CFS research has received high-profile media attention, generating both increased
interest and unprecedented opportunities for progress. The Association was looking to
its new SAB for guidance on research strategy to encourage innovative research focused
on early detection, objective diagnosis, and effective treatment. Banbury takes great
pride in the role the Center has had in helping foster research on CFS.
Welcoming Remarks: J.A. Witkowski, Banbury Center, Cold Spring Harbor Laboratory, New York
Introductory Remarks: S. Vernon, CFIDS Association of America, Charlotte, North Carolina
K.K. McCleary, CFIDS Association of America, Charlotte, North 
Carolina: 25 Years of Service: Where the CFIDS Association Stands Today
SESSION 1: Background on the Association and CFS
Chairpersons: R. Silverman, Learner Research Institute, Cleveland, Ohio, and R. Dodd,
American Red Cross, Holland Laboratory, Rockville, Maryland 
A. Lesser, CFIDS Association of America, San Francisco,
California: From advocacy to research.
A. Divine, Boulder, Colorado, J. Spotila, King of Prussia,
Pennsylvania, and P. Venetucci, Park Ridge, Illinois: Illness
narratives.
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S. Vernon, CFIDS Association of America, Charlotte, North
Carolina: What’s in a name?
L. Bateman, The Fatigue Consultation Clinic, Salt Lake City,
Utah: A clinical perspective of CFS.
N. Klimas, University of Miami School of Medicine, Florida:
Plausible causes/triggers of CFS (as we know it today).
G. Broderick, University of Alberta, Edmonton, Canada: A
system biology perspective of CFS.
V. Racaniello, Columbia University Medical Center, New
York: Lessons learned from XMRV.
K. MoranB. Allshouse, L. Bateman
SESSION 2: Transforming CFS Research
Chairpersons: K. Moran, Integrated Strategy, LLC, Greenwood Village, Colorado, and P. DeStefano,
McDermott Will & Emery, Menlo Park, California
S. Vernon, CFIDS Association of America, Charlotte, North
Carolina, and K.K. McCleary, CFIDS Association of
America, Charlotte, North Carolina: Strategic and promising
areas of research.
E. Aslakson, Centers for Disease Control and Prevention,
Atlanta, Georgia: Biomarker hit lists and hypothesis
generation.
I. Biaggioni, Vanderbilt University School of Medicine,
Nashville, Tennessee: Common platforms for progress.
D. Papanicolaou, Merck Research Laboratories, Kenilworth,
New Jersey: Piquing the interest of the pharmaceutical
industry.
R. Bromley, Redwood City, California: Not-for-profit research
organization successes and failures.
B. Raidt, River Forest, Illinois, and P. Venetucci, CFIDS
Association of America, Park Ridge, Illinois: Weaving CFS
into the social and medical fabric.
SESSION 3: Transforming Research with the Help of the SAB
Chairperson: K. Frick, CFIDS Association of America, San Francisco, California
R. Bromley, Redwood City, California: Strategic issues: What
is next? Strategic governance for research support organiza-
tions.
FEBS Journal Editorial Board Meeting
September 30–October 2
FUNDED BY FEBS Journal, John Wiley & Sons, Ltd., New York
ARRANGED BY N. Tonks, Cold Spring Harbor Laboratory, New York
V. Wilkinson, FEBS Journal, Cambridge, United Kingdom
The Banbury Center takes a broad perspective on its mission to promote biomedical research. We
have, for example, held meetings to discuss scientific fraud, funding for research, and open access
journals. This meeting provided an opportunity for the editorial board of the FEBS Journal to meet
with the journal’s staff and discuss the performance and future direction of the journal.
Editorial Office Statistics and Update
V. Johnson and D. Nicholson, Wiley-Blackwell, Oxford,
United Kingdom: Wiley-Blackwell presentation and
structured brainstorming session.
Editorial Board Meeting
R. Apweiler, European Bioinformatics Institute, Cambridge,
United Kingdom
M. Hall, University of Basel, Switzerland
J. Hardy, University College, London, United Kingdom
D. Michele, University of Michigan, Ann Arbor
P. Munoz-Canoves, University Pompeu Fabra, Barcelona,
Spain
R. Perham, University of Cambridge, United Kingdom
N. Scrutton, The University of Manchester, United Kingdom
N. Tonks, Cold Spring Harbor Laboratory, New York
A. Wlodawer, National Cancer Institute, Bethesda, Maryland
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J.-M. Chia, Cold Spring Harbor Laboratory: HapMap II.
J. Lu and M. Regulski, Cold Spring Harbor Laboratory:
Progress on epigenetic variation profiling. 
V. Llaca, DuPont Experimental Station, Wilmington, Dela-
ware: The maize methylome pipeline.
M. Dotto, Cold Spring Harbor Laboratory: Small RNAs in lbl1
mutants: Genome-wide search for ta-siRNA loci in maize.
F. Van Ex, Cold Spring Harbor Laboratory: Alternate
regulation of RNAi components as an epigenetic basis for
apomixis.
A. Eveland, Cold Spring Harbor Laboratory: Systems
approaches in maize inflorescence architecture.
SESSION 1: Genomics and Epigenomics
Chairperson: A. Rafalski, DuPont Experimental Station, Wilmington, Delaware
SESSION 2: Mechanisms of Reproductive Development
Chairperson: D. Jackson, Cold Spring Harbor Laboratory, New York
Dosage, Epigenetics, and the Biology of Hybridization and Hybrids
October 10−13  
FUNDED BY Cold Spring Harbor Laboratory/Pioneer DuPont Joint Collaborative Project
ARRANGED BY Z. Lippman, Cold Spring Harbor Laboratory, New York
R. Martienssen, Cold Spring Harbor Laboratory, New York
R. Williams, DuPont Experimental Station, Wilmington, Delaware
Each year, members of the Cold Spring Harbor−Pioneer DuPont Joint Collaborative Group meet
to review the progress of the collaboration. In addition, a small number of researchers not part of
the collaboration come to the meeting for discussion of an important topic related to the work of
the collaboration. This year, the topic dealt with the molecular biology of hybridization, exploring
the roles of gene expression in phenotypic variation—with a particular emphasis on changes not
easily explained by simple nucleotide changes (for example, chromosome structure, genome or-
ganization, epigenetics, and regulatory RNA). These mechanisms are likely to have effects on plant
development, response to stress, heterosis, and evolution.
Welcoming Remarks: J.A. Witkowski, Banbury Center, Cold Spring Harbor Laboratory, New York
Introductory Remarks: Z. Lippman, Cold Spring Harbor Laboratory, New York
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C. MacAlister, Cold Spring Harbor Laboratory: Control of
meristem formation and homeostasis at the transition to
flowering in tomato: Role of terminating flower and
fasciated flower.
J. Habben, Pioneer Hi-Bred International, Inc., Johnston,
Iowa: Testing of maize transgenics for drought tolerance.
B. Il Je, Cold Spring Harbor Laboratory: New players in maize
fasciated pathways and seed row number.
T. Michael
D. Jackson, Cold Spring Harbor Laboratory: A new pathway
for meristem maintenance in maize: Uniting fasciated and
abphyl phenotypes.
B. Li, DuPont Experimental Station, Wilmington, Delaware:
Cloning of maize mutant genes involved in reproductive
development.
S. Lawit, Pioneer Hi-Bred International, Johnston, Iowa: Paths
toward self-reproducing hybrids.
SESSION 3: Dosage, Development, and Hybridization
Chairperson: Z. Lippman, Cold Spring Harbor Laboratory, New York
Z. Lippman, Cold Spring Harbor Laboratory: Dynamics of
meristem maturation and the evolution of inflorescence
architecture.
O. Danilevskaya, Pioneer Hi-Bred International, Johnston,
Iowa: Functional analysis of the PEBP gene family from
maize.
O. Loudet, INRA, Versailles, France: Natural variation for
growth and allelic incompatibilities in Arabidopsis thaliana.
M. Tanurdzic, Cold Spring Harbor Laboratory: RNAi and
inheritance of epigenetic states in plant interspecific hybrids.
L. Comai, University of California, Davis: Dosage-dependent
interspecific incompatibility in Arabidopsis.
M. Freeling, University of California, Berkeley: Ancient
epigenetic origins of genome dominance following
paleopolyploidies, and gene regulatory consequences.
SESSION 4: Epigenetics 
Chairperson: R. Martienssen, Cold Spring Harbor Laboratory, New York
R. Martienssen, Cold Spring Harbor Laboratory: Hetero-
chromatin, small RNA, and the epigenetic control of
gametogenesis.
M. Timmermans, Cold Spring Harbor Laboratory: Generation
of robust development patterns by opposing gradients of
mobile small RNAs.
J. Birchler, University of Missouri, Columbia: Studies at the
intersection of ploidy and heterosis.
SESSION 5: Tackling Genomics and Phenomics
Chairperson: R. Williams, DuPont Experimental Station, Wilmington, Delaware
R. Mosher, University of Arizona, Tucson: Pol IV-dependent
siRNAs in Arabidopsis seeds.
J. Reinders, DuPont Experimental Station, Wilmington,
Delaware: Dynamic retroelement transmission rates during
sexual reproduction of Arabidopsis.
M. Hudson, University of Illinois, Urbana: The genetics and
effects of small RNA expression in Arabidopsis and maize
hybrids.
M. Schatz, Cold Spring Harbor Laboratory: Challenges and
solutions for plant genome assembly.
K. Creasey, Cold Spring Harbor Laboratory: Epigenetically
activated small RNA mediates transgenerational phenotypes
in Arabidopsis.
M. Frank, Pioneer Hi-Bred International, Johnston, Iowa:
NUE screens: A chimeric approach.
C. Lu, DuPont Experimental Station, Wilmington, Delaware:
Forward genetic screens in drought discovery.
S. Pasternak, J. Stein, and A. Olson, Cold Spring Harbor
Laboratory: What up with wheat? Progress on wheat genome
sequencing.
D. Ware M. Freeling
Genotype to Phenotype: Deriving Biological Knowledge 
from Large Genomic Data Sets
October 16−19  
FUNDED BY Cold Spring Harbor Laboratory Corporate Sponsor Program
ARRANGED BY T. Michael, Monsanto Company, Chesterfield, Missouri
P. Schnable, Iowa State University, Ames
In the past few years, sequencing instrument capabilities have increased more than 1000-fold and
are likely to continue to increase about fivefold each year for the next several years. However, analysis
methods have not improved nearly as much during the same time period, and a variety of technical
limitations of these new instruments make it even more difficult to carry out whole-genome se-
quencing of novel genomes (de novo sequencing). The goals of this meeting were to assess the current
state of de novo sequencing, predict what can be expected to develop in the near future, and deter-
mine how these exciting technologies could be used to carry out de novo sequencing of entire com-
plex plant genomes.
Welcoming Remarks: J.A. Witkowski, Banbury Center, Cold Spring Harbor Laboratory, New York 
Goals and Structure of Meeting: T. Michael, Monsanto Company, Chesterfield, Missouri, and
P. Schnable, Iowa State University, Ames
SESSION 1
R. Reiter, Monsanto Company, St. Louis, Missouri: Large
breeding data sets.
E. Spalding, University of Wisconsin, Madison: Phenotyping
in the laboratory.
T. Harkins, Life Technologies, Carlsbad, California: Future of
next-gen sequencing technologies.
L. Comai, University of California, Davis: Sexual
incompatability in a genomic context.
R. Flavell, Ceres, Inc., Thousand Oaks, California: Bold ideas
for energy crops.
D. Fischoff, Monsanto Company, St. Louis, Missouri: Future
opportunities in biotech breeding.
General Discussion and Focus Challenge
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SESSION 3
Moderators: T. Michael, Monsanto Company, Chesterfield,
Missouri, and P. Schnable, Iowa State University, Ames
General Discussion and Focus Challenge
SESSION 4 
Introduction and Day 1 Summary: T. Michael, Monsanto
Company, Chesterfield, Missouri
R. Last, Michigan State University, Lansing: Metabolomics.
P. Benfey, Duke Institute for Genome Sciences and Policy,
Durham, North Carolina: Transcriptomics.
R. Martienssen, Cold Spring Harbor Laboratory:
Epigenomics.
S. Briggs, University of California, San Diego: Proteomics.
I. Baxter, U.S. Department of Agriculture, St. Louis, Missouri:
Ionomics.
T. Altmann, Leibniz Institute of Plant Genetics and Crop
Plant Research, Gatersleben, Germany: Phenomics.
General Discussion and Focus Challenge
SESSION 5 
E. Buckler, Cornell University, Ithaca, New York: Genotype to
phenotype in cross-pollinated crops.
N. Springer, University of Minnesota, St. Paul: Methylation
variation.
P. Schnable, Iowa State University, Ames: Structural variation.
N. Stein, Leibniz Institute of Plant Genetics and Crop Plant
Research, Gatersleben, Germany: Genotype to phenotype in
self-pollinated crops.
O. Loudet, INRA Versailles, France: Natural variation.
D. Klieberstein, University of California, Davis: Statistical
quantitative genetics.
SESSION 6
Moderators: T. Michael, Monsanto Company, Chesterfield, Missouri, and P. Schnable, Iowa State University, Ames
S. Jackson, University of Georgia, Athens: Economically
important crop genomes.
W.R. McCombie, Cold Spring Harbor Laboratory: Strategies
for next-gen sequencing.
T. Mockler, Oregon State University, Corvallis: Genome
features.
SESSION 2
M. Schatz, Cold Spring Harbor Laboratory: Novel genome
assembly strategies.
T. Michael, Monsanto Company, Chesterfield, Missouri:
Novel genomes. 
A. Paterson, University of Georgia, Athens: Comparative
genomics.
General Discussion and Focus Challenge
SESSION 7
Introduction and Day 2 Summary: P. Schnable, Iowa State
University, Ames
V. Walbot, Stanford University, California: Studying
development in a genomic context.
S. Goff, University of Arizona, Tucson: Model-based
approaches to molecular breeding.
J. Bennetzen, University of Georgia, Athens: Interactions
between plant genotypes and soil microflora.
M. Timmermans, Cold Spring Harbor Laboratory: Small
RNAs regulating shoot meristem function.
SESSION 8
Moderators: T. Michael, Monsanto Company, Chesterfield, Missouri, and P. Schnable, Iowa State University, Ames
General Discussion and Focus Challenge
Metformin and Neoplasia
October 30−November 2
FUNDED BY Oliver Grace Cancer Fund
ARRANGED BY M. Pollak, McGill University, Montreal, Canada
C. Thompson, Memorial Sloan-Kettering Cancer Center, New York
Metformin is widely prescribed for type II diabetes, and it is known to be a safe and effective agent for
this condition. Recent retrospective epidemiologic data suggest that use of metformin or related
biguanides is associated with substantially reduced cancer incidence and/or improved cancer outcomes.
Furthermore, these compounds have been shown to reduce tumor growth in several in vivo models
and to reduce tumor formation in carcinogenesis assays. Participants at this meeting reviewed and crit-
ically assessed the most recent results in the field and discussed the many proposed mechanisms of
action. The question of potential clinical applications for treatment or prevention was also considered,
and gaps in knowledge such as how to optimize pharmacokinetics, identification of predictive biomark-
ers to select patients who may benefit, and the definition of rational combinations were considered.
Welcoming Remarks: J.A. Witkowski, Banbury Center, Cold Spring Harbor Laboratory, New York
Introductory Remarks: M. Pollak, McGill University, Montreal, Canada, and
C. Thompson, Memorial Sloan-Kettering Cancer Center, New York
SESSION 1
History
C. Bailey, Aston University, Birmingham, United Kingdom:
History of biguanides and development of metformin as an
antidiabetic.
Pharmaco-Epidemiology
J. Johnson, University of Alberta, Edmonton, Canada: Epidemi-
ologic evidence for an influence of metformin on neoplasia.
Cancer Models
P. Dennis, National Cancer Institute, Bethesda, Maryland:
Metformin as a chemopreventive agent in mouse models of
cancer.
M. Martin, Institute of Cancer Research, London, United
Kingdom: Investigating the potential for metformin as an
antimelanoma agent.
B. Zheng, Columbia University, New York: Cross-talk between
LKB1-AMPK and BRAF signaling pathways and its impli-
cation for melanoma therapy.
D. Sabatini, Whitehead Institute for Biomedical Research,
Cambridge, Massachusetts: Nutrient sensing by the mTOR
pathway.
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SESSION 2: Cancer Models
K. Struhl, Harvard Medical School, Boston, Massachusetts:
Metformin selectively kills cancer stem cells and acts
together with chemotherapy to prolong remission.
F. Bost, INSERM U895, University of Nice Sophia-Antipolis,
France: The multiple biological actions of metformin on
cancer cells.
M. Schwab, Dr. Margarete Fischer-Bosch-Institute of Clinical
Pharmacology, Stuttgart, and University Tübingen, Germany:
Pharmacokinetics and pharmacogenomics of metformin.
Mechanistic Aspects I: Mitochondria
B. Guigas, Leiden University Medical Center, the Netherlands:
Role of mitochondria in the mechanism of action of
metformin.
M. Vander Heiden, Dana-Farber Cancer Institute, Boston,
Massachusetts: Metabolic pathway regulation in cancer.
M. Haigis, Harvard Medical School, Boston, Massachusetts:
Role of sirtuins in metabolism.
D. Shackelford, University of California, Los Angeles:
Phenformin as a cancer therapeutic.
G. Hardie, University of Dundee, United Kingdom: AMPK:A
target for metformin that is down-regulated in cancer cells
and during viral infection.
G. Rocha, Universidade Estadula de Campinas, Sao Paulo,
Brazil: Metformin and chemotherapy.
A. Selvaraj, University of Cincinnati, Ohio: Metformin and
TOR pathway.
N. Sonenberg, McGill University, Montreal, Canada:
Metformin alters the translatome.
I. Topisirovic, McGill University, Montreal, Canada: Effects of
biguanides and mTOR inhibitors on protein synthesis and
energy metabolism.
C.L. Walker, MD Anderson Cancer Center, Smithville, Texas,
and J. Pouyssegur, University of Nice, France: Targeting
lactic acid export of glycolytic tumors. Best anticancer
benefit: Metformin or AMPK block?
F. Wondisford, Johns Hopkins University, Baltimore,
Maryland: Molecular mechanism of metformin action.
B. Viollet, Institut Cochin Université Paris Descartes,
France: Metformin actions in the liver to inhibit gluco-
neogenesis: Insights to possible mechanisms relevant to
oncology.
M. Driscoll, Rutgers University, Piscataway, New Jersey:
Metformin engages pathways that promote healthy aging in
C. elegans.
M. Pollak, McGill University, Montreal, Canada: Metformin
can influence tumor growth as an indirect consequence of
actions on the liver.
G. Hardie, University of Dundee, United Kingdom:
Relationship between ATM and metformin action.
Early Clues from the Clinic
G. Hardie, University of Dundee, United Kingdom: Results
of biomarker trial in breast cancer.
S. Jiralerspong, Baylor College of Medicine, Houston, Texas:
Clinical evidence regarding metformin antineoplastic
activity.
Novel Aspects
G. Ferbeyre, University of Montreal, Canada: Metformin
reduces DNA damage and mutations due to endogenous
reactive oxygen species.
R. Jones, McGill University, Montreal, Canada: Metformin
effects on immunity of possible relevance to oncology.
Repurposing Drugs
A. So, Duke University, Durham, North Carolina:
Repurposing drugs: Policy challenges and economic
prospects.
SESSION 4: Mechanistic Aspects II: Cellular Physiology (continued)
SESSION 5: Early Clues from the Clinic
SESSION 3:Mechanistic Aspects II: Cellular Physiology
Concluding Remarks and General Discussion: M. Pollak, McGill University, Canada, and C. Thompson,
Memorial Sloan-Kettering Cancer Center, New York 
Workshop: The Future of the Epigenomics of Plants
International Consortium 
November 2–4
FUNDED BY Epigenomics of Plants International Consortium
ARRANGED BY R. Martienssen, Cold Spring Harbor Laboratory, New York
C. Pikaard, Indiana University, Bloomington
D. Wagner, University of Pennsylvania, Philadelphia
Plant research is leading the way in many areas of epigenomics, and the Epigenomics of Plants In-
ternational Consortium (EPIC) is a National Science Foundation (NSF)-funded research coordi-
nation initiative to form an international consortium to decipher the plant epigenome. It has been
clear for many years that epigenetic interactions with the environment shape the plant body plan
during development and control growth and survival responses of these sessile organisms. As a result,
plants have a sophisticated epigenomic “toolkit” that modulates genome accessibility. Deciphering
the plant epigenome is a large task and will be most effectively achieved via an internationally co-
ordinated effort. This conference discussed the intellectual questions, transformative methodologies,
and infrastructure needs required to achieve this goal, as well as the means to engage funding agencies
and the international research community as a whole.
Welcoming Remarks: J.A. Witkowski, Banbury Center, Cold Spring Harbor Laboratory, New York
Overview of EPIC: D. Wagner, University of Pennsylvania, Philadelphia: Our mandate, relevance to recent 
U.S. Plant Science Summit and 10-year goals, EPIC’s accomplishments to date, 
challenges ahead.
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SESSION 1: Defining the Mission
Concurrent meeting of breakout groups led by C. Pikaard (Group A) and D. Wagner (Group B)
conditions (e.g., developmental, environmental, and genetic)
to be analyzed. Report of breakout group A and full group
discussion.
Report of breakout group B and full group discussion.
Group A: Data sets and tools needed.
Group B: Data collection (coordination, standards, and
analysis), data storage, data display, and availability.
Report of breakout group A and full group discussion.
Report of breakout group B and full group discussion.
L. Dennis E. Richards, C. Pikaard V. Chandler
SESSION 2: Obtaining, Storing, and Displaying the Data
Concurrent meeting of breakout groups led by C. Pikaard (Group A) and R. Martienssen (Group B)
SESSION 3: Plan of Action 
Concurrent meeting of breakout groups led by D. Wagner (Group A) and R. Martienssen (Group B)
Group A: Engaging the community.
Group B: Governance structure for an international EPIC
consortium. 
Report of breakout group A.
Report of breakout group B.
Full group discussion of the White paper draft: Contents,
authors. 
Next steps for EPIC, future meetings, and engaging the
funding agencies for an international cooperative effort.
Group A: Potential grand challenges, gaps in our
understanding or capabilities, long- and short-term goals. 
Group B: Epigenetic modifications to be examined, what
“reference epigenomes” are needed, model systems vs. crops,
D. Levens, National Cancer Institute, Bethesda, Maryland:
How a simplified model of Myc function requires and
explains the complexity of the c-Myc promoter.
J. Bradner, Dana-Farber Cancer Institute, Boston, Massa-
chusetts: Chemical inhibition of Myc expression and
function.
Myc and the Pathway to Cancer
November 6–9
FUNDED BY Cold Spring Harbor Laboratory Corporate Sponsor Program
ARRANGED BY C. Dang, University of Pennsylvania, Philadelphia
R. Eisenman, Fred Hutchinson Cancer Research Center, Seattle, Washington
Myc was discovered 30 years ago and was recognized as being a key player in cancer development.
Although a great deal has been learned about Myc interactions and functions, we still lack a detailed
understanding of how Myc activity influences normal versus cancer cell behavior. Specific topics cov-
ered at this meeting included the regulation of myc gene transcription, the role of Myc in normal and
tumor stem cells, transcriptional and nontranscriptional activities of Myc, and functions of the ex-
tended Myc network (including Mlx and Mondo proteins). Participants included experts on cancer
models who provided perspective concerning potential roles of Myc in different tumor systems. The
meeting explored ways through which myc, as a pivotal oncogene in human cancers and its associated
pathways, can provide targets for the development of therapies.
Welcoming Remarks: J.A. Witkowski, Banbury Center, Cold Spring Harbor Laboratory, New York
Introductory Remarks: R. Eisenman, Fred Hutchinson Cancer Research Center, Seattle, Washington
SESSION 1: Myc Transcriptional Activities
Chairperson: C. Dang, University of Pennsylvania, Philadelphia
R. Young, Whitehead Institute, Boston, Massachusetts:
Control of gene expression by c-Myc.
S. Hann, Vanderbilt University, Nashville, Tennessee: ARF
inhibition of c-Myc transcriptional domain ubiquitylation
controls c-Myc-mediated apoptosis.
M. Cole, Dartmouth University, Lebanon, New Hampshire: A
new mechanism for Myc-mediated repression.
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SESSION 2: Regulation of Myc Abundance
Chairperson: S. Hann, Vanderbilt University, Nashville, Tennessee
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SESSION 3:Myc Regulation of Cell Physiology
Chairperson: L. Penn, University of Toronto, Ontario, Canada
G. McArthur, Peter MacCallum Cancer Centre, East
Melbourne, Victoria, Australia: Inhibition of RNA
polymerase I as a therapeutic strategy for cancer-specific
activation of p53 in Myc-driven malignancy.
L. Johnston, Columbia University, New York: Myc, p53, and
metabolism: A Drosophila model for premalignancy.
C. Dang, University of Pennsylvania, Philadelphia: Regulation
of cancer cell metabolism by Myc and therapeutic targets.
D. Ayer, University of Utah, Salt Lake City: Nutrient sensing
by MondoA:M1x complexes.
SESSION 3 (continued):Myc Regulation of Cell Physiology
Chairperson: M. Cole, Dartmouth University, Lebanon, New Hampshire
S. McMahon, Thomas Jefferson University, Philadelphia, Penn-
sylvania: Control of the survival/apoptosis decision by Myc. 
B. Amati, Italian Institute of Technology, Milan: Targeting the
ATR-Chk1 pathway in Myc-induced lymphoma.
S. Dalton, University of Georgia, Athens: Myc in pluripotency
and reprogramming.
Pathogenetic pathways and treatment strategies from a
Burkitt lymphoma genome project.
M. Henriksson, Karolinska Institutet, Stockholm, Sweden:
MYCN and neuroblastoma differentiation.
D. Felsher, Stanford University, California: Multiscale
modeling of Myc-associated oncogene addiction.
SESSION 5: Tumorigenesis and Therapeutic Approaches
Chairperson: M. Roussel, St. Jude Children’s Research Hospital, Memphis, Tennessee
L. Penn, University of Toronto, Ontario, Canada: Strategies to
target Myc as an effective anticancer therapeutic: Under-
standing posttranslational modifications as a point of Myc
regulation.
M. Eilers, University of Würzburg, Germany: Synthetic lethal
interactions with deregulated Myc or genome-wide analyses
of Myc and miz1-binding sites
M. Ptashne, Memorial Sloan-Kettering Cancer Center, New
York: Epigenetic switches are easier to construct in eukary-
otes than in prokaryotes.
SESSION 4:Myc-Regulated Targets and Pathways
Chairperson: C. Sherr, St. Jude Children’s Research Hospital, Memphis, Tennessee
J. Sedivy, Brown University, Providence, Rhode Island: Role of
Myc in aging: The best of two worlds.
S. Lowe, Memorial Sloan-Kettering Cancer Center, New York:
Characterizing tumor maintenance genes using mouse
models and RNAi.
L. Staudt, National Cancer Institute, Bethesda, Maryland:
SESSION 5 (continued): Tumorigenesis and Therapeutic Approaches
Chairperson: M. Eilers, University of Würzburg, Germany
T. Look, Dana-Farber Cancer Institute, Massachusetts: Apop-
totic response in MycN-overexpressing sympathoadrenal cells
is blocked by activated ALK, leading to neuroblastoma.
C. Grandori, Fred Hutchinson Cancer Research Center,
Seattle, Washington: Identification of therapeutic targets for
Myc-driven cancers by functional genomics. 
R. Eisenman, Fred Hutchinson Cancer Research Center,
Seattle, Washington: A point mutation in Myc generates a
tumor-prone phenotype.
M. Roussel, St. Jude Children’s Research Hospital, Memphis,
Tennessee: Myc proteins in pediatric medulloblastoma.
C. Vakoc, Cold Spring Harbor Laboratory: RNAi screening to
identify epigenetic vulnerabilities in acute myeloid leukemia.
R. Sears, Oregon Health & Science University, Portland:
Phosphorylation and proline isomerization events that
regulate c-Myc DNA binding, oncogenetic activity, and
protein stability.
W. Tansey, Vanderbilt University, Nashville, Tennessee:
Regulation of Myc by the ubiquitin-proteasome system.
J. Freedman, GlaxoSmithKline, Collegeville, Pennsylvania:
Regulation of Myc through bromodomain modulation
(ready for patient testing).
Concluding Remarks and General Discussion: R. Eisenman, Fred Hutchinson Cancer Research Center, Seattle,
Washington, and C. Dang, University of Pennsylvania, Philadelphia
Transmissible Amyloidoses
November 29–December 2 
FUNDED BY Cold Spring Harbor Laboratory Corporate Sponsor Program
ARRANGED BY J. Collinge, University College London, United Kingdom
D. Goldgaber, SUNY Stony Brook, New York
After succeeding in demonstrating the transmission of kuru and
Creutzfeldt−Jakob disease (CJD) in the late 1960s, Carleton Gajdusek
suspected that other late-onset diseases of the brain might also be trans-
missible. In the 1970s, he inoculated hundreds of animals with brain tis-
sues of patients with Alzheimer’s disease, multiple sclerosis, Parkinson’s
disease, and other diseases and kept them under observation for many
years, some of them for decades. Using the same criteria that worked for
kuru and CJD, namely, clinical symptoms and gross pathological changes
in the brain, he found not a single case of transmission. In the 1990s,
however, data began to accumulate that Alzheimer’s disease amyloidosis
can be transmitted to primates, and transmission of b-amyloid to trans-
genic mice was demonstrated. The time was clearly right for a critical re-
view of the data on transmission of the amyloidoses, the mechanisms
involved, and the implications for human health.
Welcoming Remarks: J.A. Witkowski, Banbury Center, Cold Spring Harbor Laboratory, New York
Introductory Remarks: D. Goldgaber, SUNY Stony Brook, New York
SESSION 1:Mammalian and Yeast Prions and Their Properties
Chairperson: J. Collinge, University College London, United Kingdom
J. Collinge, University College London, United Kingdom:
Mammalian prion propagation, strains, and transmission
barriers.
B. Caughey, NIAID Rocky Mountain Laboratories, Hamilton,
Montana: Structure and detection of prions.
I. Vorberg, Deutsches Zentrum für Neurodegenerative Erkran-
kugen, Bonn, Germany: Propagation of yeast prions in
mam- malian cells.
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R. Wickner, National Institute of Diabetes and Digestive and
Kidney Diseases, Bethesda, Maryland: Yeast prion disease
amyloid structure can explain prion strains.
C. Weissmann, Scripps Research Institute, Jupiter, Florida:
Mutation of prions.
D. Goldgaber, J. Collinge
J. Buxbaum, C. Weissmann D. Eisenberg, I. Vorberg
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SESSION 2:Mechanisms of Protein Misfolding/Aggregation and Structure of Amyloids
Chairperson: A. Horwich, Yale University School of Medicine, New Haven, Connecticut
R. Tycko, National Institute of Diabetes and Digestive and
Kidney Diseases, Bethesda, Maryland: In vitro vs. in vivo b-
amyloid fibril structures: Propagation of amyloid structures
in vitro.
D. Eisenberg, University of California, Los Angeles: Are
structural polymorphisms the basis of prion strains?
R. Morimoto, Northwestern University, Evanston, Illinois:
Transmission of protein aggregates in C. elegans.
SESSION 3: Alzheimer’s Disease and Tauopathies
Chairperson: D. Goldgaber, SUNY Stony Brook, New York
D. Goldgaber, SUNY Stony Brook, New York: Historical
perspective and review of archived NIH primate transmission
series.
A. Nicoll, UCL Institute of Neurology, London, United
Kingdom: Review of archived attempted transmission of
Alzheimer pathology to transgenic mice.
L. Walker, Emory University, Atlanta, Georgia: Seeded in-
duction of b-amyloid deposition in transgenic rodents.
M. Jucker, University of Tübingen, Germany: Characterization
of b-amyloid-inducing seed.
M. Goedert, MRC Laboratory of Molecular Biology,
Cambridge, United Kingdom: Prion-like properties of
assembled tau.
C. Soto, University of Texas Medical School, Houston:
Transmission of Alzheimer’s disease and type-2 diabetes.
M. Diamond, Washington University, St. Louis, Missouri:
Propagation of protein misfolding in neurodegenerative
diseases.
General Discussion
SESSION 4: Cellular Spread and Pathogenesis: Prion-Like Mechanisms
Chairperson: J. Buxbaum, Scripps Research Institute, La Jolla, California
A. Bertolotti, MRC Laboratory of Molecular Biology,
Cambridge, United Kingdom: Prion-like propagation of
mutant SOD1 misfolding.
S.-J. Lee, Konkuk University, Seoul, Korea: Transmission of
synucleinopathies and neuroinflammation via extracellular
a-synuclein.
K. Luk, University of Pennsylvania School of Medicine,
Philadelphia: a-Synuclein transmission in synucleinopathies.
T. Outeiro, University Medizin Göttingen, Germany: Intra-
and extracellular effects of a-synuclein oligomers: Implica-
tions for transmission.
General Discussion
SESSION 5: Transmissibility of Other Amyloidoses 
Chairperson: D. Eisenberg, University of California, Los Angeles
J. Watts, University of California, San Francisco:
Bioluminescence imaging of induced protein deposition in
transgenic mice.
J. Buxbaum, Scripps Research Institute, La Jolla, California:
Amyloid−amyloid interactions.
K. Higuchi, Shinshu University School of Medicine,
Matsumoto, Japan: Transmission of amyloidoses in mouse
and cheetah: Implications in human systemic amyloidoses.
P. Westermark, Uppsala University, Sweden: Transmission of
systemic amyloidosis/dissemination of deposits in systemic
amyloidoses.
General Discussion
L. Walker, M. Jucker
Evolution of Neural Circuits and Behavior
December 7−9 
FUNDED BY Marie Robertson Memorial Fund
ARRANGED BY K. Honegger, Cold Spring Harbor Laboratory, New York 
S. Shea, Cold Spring Harbor Laboratory, New York
Nervous systems have evolved under unique sets of selective pressures driving adaptive
changes, and thus, their structure and function reflect the organism’s environment. The
ultimate expression of these forces on the brain is diversity of behavior. Empirical studies
of the interaction among environment, neural processing, and behavior have largely
consisted of neuroethological, comparative, and molecular genetic approaches. Partic-
ipants in this meeting discussed how the synthesis of these complementary approaches
might enrich our understanding of nervous system function and further aid in the in-
terpretation of experimental findings across animal phyla.
Welcoming Remarks: J.A. Witkowski, Banbury Center, Cold Spring Harbor Laboratory, 
New York
Introductory Remarks: K. Honegger, Cold Spring Harbor Laboratory, New York
SESSION 1: Fundamental Constraints of the Evolution of Neural Circuits
Chairperson: D. Chklovskii, Janelia Farm/HHMI, Ashburn, Virginia
S. Grant, University of Edinburgh, United Kingdom: Synapse
evolution.
D. Chklovskii, Janelia Farm/HHMI, Ashburn, Virginia: Do
more neurons make you smarter? A sensory processing
perspective.
J. Niven, University of Cambridge, United Kingdom:
Energetic and biophysical constraints on neural circuits.
P. Katz, Georgia State University, Atlanta: Homology and
homoplasy in neural circuits underlying behavior.
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D. Chklovskii
M. Hale H. Zakon
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D. Stern, Howard Hughes Medical Institute, Ashburn,
Virginia: Tools and approaches for studying the evolutionary
genetics of behavior in closely related Drosophila species.
J. Huang, Cold Spring Harbor Laboratory: Chandelier cell: An
entry point to cortical circuit organization, assembly, and
evolution.
J. Dubnau, Cold Spring Harbor Laboratory: A microRNA−
dopamine receptor genetic module in distinct neural circuits
for olfactory arousal and olfactory memory.
SESSION 3: Comparative Neuroanatomy
Chairperson: H. Karten, University of California, San Diego
S. Farris, West Virginia University, Morgantown: Evolution of
structural and functional novelty in insect mushroom bodies.
C. Ragsdale, University of Chicago, Illinois: Sensory, motor,
and memory circuitries in the octopus CNS.
M. Hale, University of Chicago, Illinois: Biomechanical and
neural analysis of the evolution of motor systems.
SESSION 2:Molecular Genetics and the Evolution of Neural
Circuits
Chairperson: J. Dubnau, Cold Spring Harbor Laboratory,
New York
H. Karten, University of California, San Diego: Cells, circuits,
and systems: Natural selection and conservation among
amniotes.
SESSION 4: Comparative Physiology
Chairperson: H. Zakon, University of Texas, Austin
E. Fortune, Johns Hopkins University, Baltimore, Maryland:
Evolution of neural circuits for cooperative behaviors.
N. Sawtell, Columbia University, New York: Mechanisms for
predicting sensory events in cerebellum-like circuits.
H. Zakon, University of Texas, Austin: Electric fish are green:
Conserving energy and recycling ion channels.
D. Soares, University of Maryland, College Park: Sensory
specialization and adaptation in cavefishes.
D. Kelley, Columbia University, New York: Evolution of songs
and their neural circuits in Xenopus.
C. Fernando, University of Sussex, Brighton, United
Kingdom: Darwinian neurodynamics.
General Discussion and Summary: S. Shea, Cold Spring
Harbor Laboratory, New York
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Psychiatric Genomics
December 11−14 
FUNDED BY The Stanley Research Foundation
ARRANGED BY W.R. McCombie, Cold Spring Harbor Laboratory, New York
M. Owen, Cardiff University, United Kingdom
The first Banbury Center meeting on molecular human genetics was held in 1982 at a time when
restriction-fragment-length polymorphisms (RFLPs) linked to human genetic diseases were first
being sought and a complete human gene had yet to be sequenced. How times have changed! And
yet it is still difficult to find the genes underlying psychiatric and other complex disorders. However,
new high-throughput DNA sequencing techniques have made, or are about to make, it possible to
sequence the whole exomes and genomes of large numbers of individuals. This will provide oppor-
tunities to develop new gene-hunting strategies for complex genetic disorders. This meeting brought
together experts to critically assess current strategies and to outline how genome-scale sequencing
can be used most effectively and efficiently.
Welcoming Remarks: J.A. Witkowski, Banbury Center, Cold Spring Harbor Laboratory, New York
Introductory Remarks: W.R. McCombie, Cold Spring Harbor Laboratory, New York
SESSION 1: Common Variants
Chairperson: D. Goldstein, Duke University, Durham, North Carolina
O. Andreassen, Oslo University Hospital, Norway: LD-based
annotation enrichment reveals new schizophrenia genes.
P. Gejman, North Shore University Health System−Research
Institute, Evanston, Illinois: Genome-wide gene expression
study of a schizophrenia GWAS data set.
S. Leal, Baylor College of Medicine, Houston, Texas:
Quantifying missing heritability and estimating genetic
effects for complex traits due to rare variants.
M. Noethen, University of Bonn, Germany: NCAN in psychi-
atric disorders: From genetic association to mouse model.
A. Corvin, St. James Hospital, Dublin, Ireland: Schizophrenia
redefined: The promise of genomics.
M. Daly, Massachusetts General Hospital, Boston: Autism
sequencing? 
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SESSION 2: Phenotype
Chairperson: D. Goldstein, Duke University, Durham, North Carolina
K. Kendler, Virginia Commonwealth University, Richmond:
Genetics and psychiatric nosology in the genomics era. 
D. Blackwood, University of Edinburgh, United Kingdom:
Phenotypic spectrum of DISC1 variation.
M. Owen, Cardiff University, United Kingdom: Rethinking
psychiatric phenotypes.
K. Mitchell, Trinity College, Dublin, United Kingdom: Rare
mutations, oligogenic interactions, and endophenotypes.
P. Thomson, University of Edinburgh Centre for Molecular
Medicine, United Kingdom: Next-generation sequencing of
the DISC1 (disrupted in schizophrenia 1) locus.
SESSION 3: Rare Variants
Chairperson: W.R. McCombie, Cold Spring Harbor Laboratory, New York
W. Byerley, University of California, San Francisco: Whole-
genome sequencing of multiplex bipolar pedigrees.
C.T. Caskey, Baylor College of Medicine, Houston, Texas:
Whole-genome sequencing of families with multiple affected
individuals with schizophrenia.
E. Eichler, University of Washington, Seattle: New mutations
and autism.
D. Goldstein, Duke University, Durham, North Carolina:
Finding schizophrenia risk factors in sequence data.
M.-C. King, University of Washington School of Medicine,
Seattle: Discovering the (many) genes responsible for
schizophrenia: Strategies based on genomic sequencing.
J. Lupski, Baylor College of Medicine, Houston, Texas:
Reciprocal CNV, mirror image phenotypes, and neuro-
psychiatric traits.
S. McCarroll, Harvard Medical School, Boston, Massachu-
setts: What constitutes sufficient evidence that a gene is
actually related to schizophrenia?
F. McMahon, National Institute of Mental Health, Bethesda,
Maryland: Sequencing members of virtual pedigrees drawn
from inbred founder populations.
M. O’Donovan, Cardiff University School of Medicine,
United Kingdom: Synaptic genes and de novo mutations.
A. Need, Duke University, Durham, North Carolina: Next-
generation sequencing of 170 schizophrenia patients.
A. Palotie, Wellcome Trust Sanger Institute, Cambridge,
United Kingdom: Identification of low-frequency variants in
the neurodevelopmental studies of the UK10K project.
J. Potash, University of Iowa, Iowa City: Whole-exome
sequencing in bipolar disorder.
S. Purcell, Massachusetts General Hospital, Boston: Exome
sequencing in schizophrenia.
G.A. Rouleau, CHU Sainte-Justine, Montreal, Canada: De
novo mutations in psychiatric diseases.
M. Wigler, Cold Spring Harbor Laboratory: Role of de novo
mutation in autism.
SESSION 4:What’s Next?
Chairperson: M. Owen, Cardiff University, United Kingdom
F. Henn, Cold Spring Harbor Laboratory: Problems, circuits,
genes, and models: An agnostic’s thoughts on psychiatric
genetics.
T. Lehner, National Institute of Mental Health, Bethesda,
Maryland: The neuropsychiatric disease consortium.
W.R. McCombie, Cold Spring Harbor Laboratory: Case
controls or family studies, and where we have to go next to
understand rare variants.
D. Weinberger, National Institute of Mental Health, Bethesda,
Maryland: From gene to brain circuits and back.
Y. Berstein M.C. King C.T. Caskey
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On December 23rd, our effort in computer BioMedia
was recognized with the Science Magazine Prize for On-
line Resources in Education. The prize essay, “Lessons
from a Science Education Portal,” gave us an opportunity
to look back on our success in the world of online pub-
lishing. When we launched the DNA Learning Center
(DNALC) website (www.dnalc.org) in 1996, we could
not foresee that it would become an Internet portal with
21 websites, a YouTube channel, and smartphone/tablet
apps that reached 7.45 million visitors in 2011. The evo-
lution of our online efforts and the challenges we faced
along the way provide four lessons for science organiza-
tions that want to build modern learning resources.
Lesson 1: Make Content More Visible to Search Engines. After a decade of continuous growth, vis-
itation to our websites mysteriously declined in 2007. During that period, the number of active
websites had increased 10-fold, to more than 100 million. In an exponentially crowded web, Google
and other search engines had become the de facto arbiters of web visitation. Search engines create
an index of the information at a site to scan for search term matches. A “robot” or “spider” visits a
website periodically to rebuild its index. Our downturn came as Google changed its search algo-
rithms and we lost “attention” of its robots. 
We therefore embarked on an ambitious program to redesign our websites to increase “visibility”
to search engines, a process called search engine optimization (SEO). This included directing robots
to rich keywords and detailed descriptions of all content, especially animations and videos that can-
not be indexed themselves. We also “freshened” content with blogs and newsfeeds. The SEO
makeover of dnalc.org nearly doubled average monthly visits from search engine robots, resulting
in a 25% increase in visitation in 2010. Continued attention to SEO is keeping us on an upward
trajectory.
Lesson 2: Disaggregate and Flow Content through Multiple Channels. Everyone likes a good story,
but students and teachers most often turn to the Internet for answers to specific questions or to il-
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lustrate key points. These are much harder to find when deeply embedded within a website. Thus,
we disaggregated our websites into searchable content “atoms” that can be accessed individually.
Greatly aided by our participation in the National Science Digital Library, we have cataloged more
than 5300 animations, videos, photos, and illustrations. Eight of 10 visits to dnalc.org now arrive
at a content atom identified by an Internet search, often with links to related DNALC items. Mov-
ing content to YouTube and smartphone apps generated new audiences for DNALC multimedia,
contributing 15% of total Internet visits in 2011. Views of 190 high-quality animations and videos
on our YouTube channel increased 150% to 693,917. 3D Brain, an app adapted from the Genes to
Cognition (G2C) Online website, was downloaded 440,073 times, and the new Gene Screen app was
downloaded 4888 times.
Lesson 3: Try to Answer the Difficult Question. Every educator and multimedia developer is faced
from time to time with the following difficult question from a board member or funding agency:
“This program is very nice, but can you prove it actually helps students to learn?” In recent years,
Congress has asked the same question of the educational grant portfolios of the National Science
Foundation (NSF) and National Institutes of Health (NIH). This has led to increasing pressure on
principal investigators to go beyond anecdotal reports of teacher satisfaction with new resources to
sophisticated studies of how those resources impact students in the classroom. 
We accepted this charge in 2011, conducting classroom experiments with 662 high school and
college students to see if the DNALC’s G2C Online and Inside Cancer websites improve science
learning. To control for differences between teachers and students, we used a crossover repeated-mea-
sures design in which each student participated as both an experimental and control subject, using
a DNA website to learn one topic and using lectures, textbooks, or other websites to learn another
topic. Strikingly, scores on quizzes given after each topic were significantly higher when students used
G2C Online (81% vs. 70%) and Inside Cancer (85% vs. 73%). Thus, we now have a practical and
supportable answer to that difficult question: An engaging website can potentially increase student
learning by about one letter grade!
Lesson 4: Help Distribute Cybertools and Data to a Broader Audience. Science takes place on a con-
tinuum between research and education. Traditionally, access to limited data kept most good science
far to the research end of the spectrum. Now, the ready availability of nearly unlimited data from high-
throughput DNA sequencers—plus powerful bioinformatics analyses from shared servers—promises
to unify the research-education continuum into a single endeavor. For the first time in the history of
science, students and teachers can work with the same data, at the same time, and with the same tools
as elite-level researchers. We have devoted considerable effort to developing educational resources to help
students generate, share, and analyze the same genome data as scientists.
In 1998, we developed the first cyberexperiment to allow students to analyze a short DNA se-
quence from their own genome, along with the first DNA database and bioinformatics interface for
education (BioServers). Our interest in community workspaces and bioinformatics culminated in our
involvement in the iPlant Collaborative, a project to develop a cyberinfrastructure for plant science
research. As educational outreach for this project, we are developing a parallel bioinformatics work-
flow, DNA Subway (www.dnasubway.org), for genome analysis and comparison. These projects
begin to push bioinformatics mid spectrum, where the battle for advanced cyberliteracy must take
place. Here, we all must work hard to make bioinformatics workflows accessible to the legions of
bright biologists who are not computer scientists and who do not know one down the hall.
A Trio of New BioMedia Projects
We partnered with the Victor Center for the Prevention of Jewish Genetic Diseases, at Einstein
Healthcare Network, to produce a new iPhone and iPad app, Gene Screen. The animated app aims
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to help people understand that (1) the prevalence of re-
cessive genetic diseases varies among different popula-
tion groups and (2) healthy members of at-risk groups
should consider being screened to see if they are carriers
of a disease gene. Interactive Punnett squares update this
classic way to calculate how traits are passed from par-
ents to children, and a “slot machine” spins to show car-
rier frequencies of 19 genetic diseases in Jewish com-
munities versus the general population. An interactive
ancestry map highlights recessive genetic diseases that
are more common in certain regions of the world. Al-
though the app was specifically designed to alert people to genetic screening, precollege science
teachers and students will appreciate this fun way to learn basic genetics.
The Spinal Muscular Atrophy (SMA) Foundation has long supported CSHL researcher Adrian
Krainer’s work on RNA splicing and molecular approaches to SMA therapies. To coincide with the
first clinical trials of a drug based on Dr. Krainer’s methods, we developed the Internet microsite
Learn About SMA as a resource for patients, families, and researchers, funded by the SMA Founda-
tion. A major aim is to explain how emerging therapies attempt to “turn up” production of an es-
sential muscle protein by correcting or compensating for an error in RNA splicing. Interviews with
patients and clinicians are complemented by interviews with researchers, including CSHL alumni
Philip Sharp and Richard Roberts, who shared the Nobel Prize for the discovery of RNA splicing.
Animations illustrate the physiological and molecular genetic basis of SMA and emerging thera-
pies. A detailed three-dimensional animation of the mechanism of RNA splicing was produced by
Drew Berry, a 2010 McArthur Fellow with whom we collaborated on the award-winning DNA In-
teractive website and the PBS television series “DNA.”
As outreach for an NSF research project on maize growth, with CSHL researcher Marja Tim-
mermans and Cornell researcher Mike Scanlon, we completed development of Weed to Wonder. This
“e-book” tells the story of how human ingenuity transformed a common Mexican weed (teosinte) into
a modern food wonder (maize). Using state-of-the-art software, we created a flexible, National Geo-
graphic-style magazine that can be ported as an Internet microsite, tablet-enabled application, or
printable PDF. The tablet application shows off the real power of the technology, where pages advance
by “swiping” and videos automatically expand to play full screen. The work takes readers on a jour-
ney from the domestication of maize in Mexico to the development of modern hybrids, genome se-
quencing, transposons, and direct genetic modification and biofortification. The history of maize
research is brought to life through reconstructions of George Shull’s and Barbara McClintock’s work
at Cold Spring Harbor Laboratory, rare photographs, and links to original publications and artifacts. 
As part of the project, we filmed a time-lapse video of the life cycle of maize plants—from emerg-
ing cotyledons to harvest, during a period of 105 days. With help from Peter Bommert, Tim Mul-
ligan, and the CSHL facilities staff, we installed a minigarden of six plants on the DNALC roof
and automatically recorded numerous clips per day on two video cameras installed behind a Plexi-
glas screen. The plants weathered the early onset of Hurricane Irene, but they were brought inside
for the worst of it. Once the hurricane was past, video capture continued using battery packs for sev-
eral days until power was restored to the DNALC.
Urban Barcode Project
The Urban Barcode Project (UBP) is a science competition to support independent, open-ended in-
vestigations using DNA barcoding by New York City (NYC) high school students. Supported by
an 18-month grant from the Alfred P. Sloan Foundation, we aim to show that we can quickly de-
velop an infrastructure to support large-scale dissemination of student DNA barcoding in NYC and
other sites around the world as outreach for the International Barcode of Life Project (iBOL).
In 2011, we completed development of a robust protocol to extract, amplify, and sequence DNA
barcodes from many plant, fungal, and animal species. The experiment is supported by a dedicated
Internet microsite, www.DNAbarcoding101.org, which includes online and downloadable lab pro-
tocols, detailed teacher preparation materials, video podcasts (“vodcasts”), animations, and a news
feed. In 2012, the experiment will be published in the DNALC’s forthcoming lab/text Genome Sci-
ence (by CSHL Press) and as a stand-alone kit marketed by the Carolina Biological Supply Com-
pany. DNA sequencing is provided at $3.00 per read by GENEWIZ, with results automatically
uploaded to DNA Subway. 
In addition to this research infrastructure, we also built a UBP website to support all aspects of the
project (www.urbanbarcodeproject.org), including vodcasts on barcoding and student projects, guide-
lines for proposal preparation, and management tools for tracking student projects from submission
to completion. During the first 6 months of the year, we engaged in a blitz of promotion, with targeted
e-mails to 10,500 NYC teachers and administrators, superintendents, principals, and teachers in NYC
public and private high schools, 21,500 e-copies of the DNALC’s BioBulletin, and posters and
brochures delivered to 150 high schools and 25 universities. Nearly 800 high school teachers, admin-
istrators, and researchers attended 19 information sessions, and 128 teachers and mentors attended 18
workshops for training on the DNA barcoding experiment. These 6-hour workshops dovetailed with
our existing Howard Hughes Medical Institute (HHMI) teacher-training program.
Our advertising, recruitment, and training strategies worked. After careful review, we accepted 102
of 118 project proposals, meeting our goal of involving 100 teams in the first year of the project. The
teams comprise 304 students (including 26% Latino or African American) from 31 public and nine
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private schools across the five bor-
oughs of NYC. Teams are men-
tored by 36 high school teachers,
four graduate students, two post-
doctoral fellows, and six univer-
sity professors. Projects examine
biodiversity in parks and public
areas (42%), species traded in eth-
nic markets (28%), food fraud
(17%), exotic and invasive species
(8%), and public health and dis-
ease vectors (5%). To assist with
collecting specimens, we coordi-
nated permits and activities with
the New York State (NYS) De-
partment of Environmental Conservation and Department of Parks and Recreation. Participating
teams have free access to equipment and reagents needed to isolate DNA and amplify the barcode re-
gion from their samples. They may check out an equipment footlocker for use at their own school or
attend Open Lab sessions at Harlem DNA Lab and Genspace, a nonprofit citizen science center in
Brooklyn. All students have access to a DNALC staff member or trained mentor. Teams will present
their study results in poster sessions held in spring 2012. A jury of experts in biodiversity, conserva-
tion biology, DNA barcoding technology, and science education will select the top teams based on proj-
ect originality, creativity, relevance, thoroughness, and scientific merit. Finalists will give oral
presentations at a symposium, where teams winning the $10,000 grand prize and $10,000 in runner-
up prizes will be announced.
iPlant Collaborative
The most obvious driver of plant research is the race to develop higher-yielding plants to feed a bur-
geoning world population. Aside from more human mouths to feed—world population hit 7 bil-
lion in October 2011—there are also more livestock to feed. Increasing wealth in developing
countries means that more people can afford Western diets where more calories come from meat
raised on grain. Global climate change adds new urgency to this age-old problem, and genome sci-
entists are joining forces with plant breeders to help crop plants adapt to regional changes in rain-
fall and temperature. 
The iPlant Collaborative is a major NSF project to develop a computer infrastructure to help plant
scientists increase global food production in the face of climate change. A consortium of the University
of Arizona, University of Texas at Austin, and CSHL, iPlant focuses on building computer tools and
services to solve two “Grand Challenges” in plant research: Genotype to Phenotype aims to predict how
genes and the environment work together to influence plant traits, and Tree of Life works to build a
phylogenetic tree that represents the evolutionary relationships of all species of plants. Both efforts
are made possible by new technologies, such as next-generation DNA sequencing, which can produce
an amount of data equivalent to the human genome in less than a week. 
During the year, iPlant launched three major legs of its cyberinfrastructure: (1) Discovery Envi-
ronment is a customizable workspace for a variety of data analyses, (2) Data Store is a secure place to
make large-scale user data available to iPlant analysis tools, and (3) Atmosphere is a personal, cus-
tomizable computing cloud to run analyses and share projects. With the maturation of the iPlant
cyberinfrastructure, education, outreach, and training (EOT) is becoming a primary concern of all
iPlant staff and collaborators.
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As leader of the EOT effort, the DNALC lends its expertise in organizing workshops, develop-
ing training materials, and building websites and interfaces. During the first half of the year, the
DNALC’s BioMedia Group redesigned the iPlant website to streamline navigation and better con-
vey the project’s goals and progress. Vodcasts provide overviews and guided tutorials to acquaint
scientists with iPlant’s many tools and services. The improved website was relaunched in July with
remarkable results: Visits increased 64% July–December 2011 (21,881) compared to the same pe-
riod in 2010 (13,331). 
We continued to evolve DNA Subway as the educational analog of the Discovery Environment. DNA
Subway is an intuitive bioinformatics platform based on the metaphor of a subway line. Most effort
focused on development of the Blue Line for DNA barcode and phylogenetics analyses. The Blue Line
includes a number of new web applications that heretofore could only be purchased as stand-alone
desktop software. An electropherogram viewer allows users to visualize the peaks that determine DNA
sequence “reads,” and a DNA barcode viewer makes it easy to see patterns of single-nucleotide poly-
morphisms (SNPs) between aligned DNA sequences. A consensus builder and editor helps users max-
imize data from forward and reverse reads. Automatic links to Google images, Wikipedia, and the
Encyclopedia of Life provide context to DNA sequence search (BLAST) results. Phylogenetic trees
are constructed using both neighboring joining and maximum likelihood methods. Toward the end
of 2011, the team began working with the NIH National Center
for Biotechnology Information (NCBI) to develop a pipeline for
users to submit novel barcode sequences to GenBank. 
DNALC staff introduced DNA Subway and barcode analysis
to more than 300 high school and college educators at workshops
conducted at nine locations across the United States. An addi-
tional 222 educators learned about DNA Subway at short courses
and demonstrations at meetings of the American Society of Plant
Biologists (ASPB), Botanical Society of America, National Asso-
ciation of Biology Teachers (NABT), National Science Teachers
Association (NSTA), iPlant Collaborative, and USDA Plant and
Animal Genome Research Program.
Howard Hughes Medical Institute 
Virtually all students in NYC receive instruction in genetics and biotechnology at two key points
in their education: in 8th grade as part of the NYC Scope and Sequence for Science and in 9th–10th
grade in the NYS Regents course, Living Environment. Many teachers in the middle grades do not
have sufficient training and have very few resources for providing hands-on, inquiry-based labs to
make genetics and biotechnology content interesting and relevant for students. Thus, the objective
of the HHMI project is to train teachers to use a set of six targeted labs that cover key concepts and
techniques within the NYC and NYS curricula: variability and inheritance, DNA structure and iso-
lation, bacterial transformation, protein isolation, DNA analysis and forensics, and analysis of human
DNA variations by polymerase chain reaction (PCR).
In 2011, 146 science teachers attended HHMI workshops at the Harlem DNA Lab: 128 teach-
ers participated in 44 1-day workshops, and an additional 18 highly qualified teachers participated
in the 2-week Leadership Symposium. More than three-quarters of the trainees were within our pri-
mary audience of 8th–10th-grade teachers. Notably, nearly half of the workshop participants were
African American or Hispanic (48%), although these groups comprise only 14% of teachers na-
tionwide (U.S. Census Bureau, 2011 Statistical Abstract). 
Evaluating pre- and postworkshop surveys of 2011 participants revealed significant knowledge
gains for all workshops (pretest mean score 74% ± 16 vs. posttest 81% ± 14; t
56 = 5.535, P < 0.001).
Follow-up surveys showed that of the 2009 and 2010 program participants, 81% had improved
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confidence in teaching labs, and a majority had implemented at least one of the targeted labs (59%)
or used the DNALC’s online teaching resources (61%) during the last 12 months.
Support of in-class instruction became a crucial focus in 2011. Through a grant from the Richard
Lounsbery Foundation, we developed 15 biotechnology footlockers that contain all of the equipment
and expendable supplies needed to teach each targeted lab. It took us a little time to figure out why
footlocker use was slow in 2010; logistically, there was no way for teachers to get the bulky kits to
their schools by public transport and many could not afford the modest restocking fee. Thus, we now
use unrestricted funds from the Dana Foundation to pay for restocking and FedEx shipping. A
DNALC instructor is also available to help set up the equipment and co-teach the lab activities in
school. As a result, footlocker use doubled in 2011, with 2567 students participating in experiments
at their schools, 60% of whom were African American or Hispanic.
HHMI program participants are supported by dedicated online resources for each targeted lab.
Each Lab Center is a virtual classroom set, into which a DNALC staff member enters to make a video
introduction. By clicking on various objects on the whiteboard and desk, users can access (1) interac-
tive and PDF versions of the experimental protocol, (2) follow-up activities, (3) scientist interviews,
(4) animations, and (5) selected links to related Internet resources. Lab Center content was devel-
oped and reviewed by six HHMI Teacher Fellows, who are seasoned educators from the New York
metropolitan area.
In 2011, we developed the pilot New York Stories, a series of vodcasts to highlight research done
at New York institutions related to each of the target labs. The pilot production was led by HHMI
Teacher Fellow Kathleen Rucker and science teacher David Conneely of Brooklyn International
High School. A six-student production team developed a rough script/storyline for bacterial trans-
formation. In parallel with a BioMedia videographer, the students filmed themselves with Flip cam-
eras as they performed a transformation experiment at school and then traveled to Columbia
University to interview Nobel laureate Dr. Martin Chalfie. Stop-motion animations and intercut-
ting low- and high-resolution footage contributed to an edgy production with an MTV feel.
New National Science Foundation Training Program
Careers in biotechnology increasingly demand a genome-wide perspective that requires students to
move comfortably between in vitro experiments at the lab bench and in silico experiments on the
computer. In the spring, the DNALC was awarded a grant from the NSF Advanced Technological
Education (ATE) Program to help community college faculty move students toward this synthesis.
In collaboration with the National Advanced Technological Education Center for Biotechnology
(Bio-Link), we presented Genomic Approaches in Biosciences workshops that provided the scientific
foundation for biotechnology careers in the genome age. The program focuses on four key tech-
nologies—PCR, DNA sequencing, RNA interference (RNAi), and bioinformatics—in three eu-
karyotic systems: humans, plants, and Caenorhabditis elegans (roundworm). Each experiment/
bioinformatics module can be integrated into existing courses, provide the basis for new courses, or
serve as the foundation for student research projects. 
During its 3-year term, the program will reach 288 biotechnology faculty at week-long workshops
conducted at 12 community colleges nationwide. In spring, we convened a board of 12 faculty ad-
visors who are involved in all aspects of the program: determining the workshop curriculum, host-
ing and co-instructing workshops, providing follow-up participant support, and evaluating the
program. In the summer, 88 educators participated in workshops conducted in four locations: Gwin-
nett Technical College (Lawrenceville, Georgia), Madison Area Technical College (Madison, Wis-
consin), Shoreline Community College (Shoreline, Washington), and Universidad del Turabo
(Gurabo, Puerto Rico). Postworkshop surveys of participants showed gains in concept knowledge
and teaching confidence, particularly for DNA barcoding, RNAi, and bioinformatics, and 82%
said they would implement the materials in their teaching.
The ATE program makes use of two DNA sequencing projects developed by the DNALC. DNA
barcoding, developed for the iPlant Collaborative and the Urban Barcode Project, is described above.
Human mitochondrial DNA sequencing, developed in 1998, allows students to examine a variable
DNA sequence from their own genome. Using a kit developed with our collaborator, Carolina Bio-
logical Supply Company, students isolate DNA from cheek cells, amplify part of the mitochondrial
control region, and send their samples for DNA sequencing. With kits donated by Applied Biosys-
tems, the DNALC provided free DNA sequencing from 1998 through 2010. 
Anticipating increased demand for sequencing from three grant-supported programs, we calcu-
lated that the cost of commercial sequencing had declined so much by 2011 that it was less than our
costs to have a college intern do the lab work! Thus, we contracted with GENEWIZ to provide
DNA sequences for the DNALC and affiliated schools for $3.00 each. This had the effect of im-
proving sequence quality and reducing turnaround time from 2 weeks to 2 days. Under this new par-
adigm, a record number of sequences were uploaded to DNALC databases. A total of 8436 student
samples (7073 mitochondrial control region sequences and 1363 DNA barcodes) were submitted
from 110 high schools and 67 colleges and universities.
Nationwide Teacher-Training Programs
For more than 25 years, the DNALC has provided cutting-edge lab and computer training for ed-
ucators at sites around the world. In 2011, 457 high school and college faculty participated in work-
shops conducted at 19 sites across the United States. These were in addition to the 273 NYC teachers
trained with support from HHMI and the Sloan Foundation, where 40% of participants were mi-
norities underrepresented in science (African Americans and Hispanics). Overall, underrepresented
minorities composed 27% of 730 educators trained at 76 workshops (1–10 days). An additional
1400 people attended seminars or short workshops at professional meetings, including ASPB, iBOL,
NABT, NSTA, International C. elegansMeeting, and Plant and Animal Genomes. (For a complete
list of training activities and host sites, see the table at the back of this report, “2011 Workshops,
Meetings, and Collaborations.”)
In addition to the student experimental studies highlighted in the introduction, we were interested
in learning the effects of three teacher-training programs that concluded in 2011: Silencing Genomes,
Genes to Cognition (G2C) Online, and Inside Cancer. In each case, faculty were surveyed at three time
points: preworkshop, postworkshop, and 9−18 months later. This added to more than 20 years of lon-
gitudinal DNALC studies tracking the effects of workshop training on classroom teaching behaviors.
Silencing Genomes, funded by the NSF Course Curriculum and Laboratory Improvement (CCLI)
Program, introduced faculty to the Nobel-Prize-winning technology of RNAi. The 5-day work-
shops clearly had their intended effect of increasing hands-on lab experience. Before the workshop,
only 6% of participants had done labs, but 12–18 months later, 71% had done at least one lab. Re-
markably, 20% of educators had students develop custom RNAi vectors, and 43% had students do
complementary bioinformatics exercises. Respondents reported doing the new labs with 3926 stu-
dents and providing classroom lectures on RNAi to 10,053. There was also a marked “train-the-train-
ers” effect, with workshop participants providing labs to 156 other instructors and lectures to 392
faculty. To support classroom implementation, the DNALC built a collection of C. elegans strains
and Escherichia coli RNAi feeding strains, which are available free of charge through the Silencing
Genomes website. A formatted e-mail allows educators to request strains for specific dates. Since
launching the service in August 2007, we have filled orders for more than 2800 strains, which ed-
ucators reported using with more than 16,000 students.
Likewise, the majority of participants in 1-day workshops on G2C Online and Inside Cancer re-
ported improved understanding and use of the multimedia materials to scaffold instruction in a va-
riety of classes.
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G2C Online Inside Cancer
Reported good to very great improvement in
Understanding of topic 88% 54%
How to teach the topic 90% 61%
Had used website with one or more classes since workshop 86% 97%
Classes in which materials were implemented
General biology 42% 50%
Honors/AP biology 19% 33%
Genetics/Biotechnology 14% 27%
Anatomy and physiology 14% 20%
General/AP psychology 19% N/A
How website was used
As a source of information 70% 82%
As a source of new teaching materials 63% 64%
To read scientific articles 52% 55%
For student projects 48% 37%
To teach directly in the classroom 39% 45%
Dolan and DNALC West Student Programs
This year, we served 25,836 student participants in both in-school instruction programs and field
trips to the Dolan and West facilities. Participation of 2800 students from underserved Long Island
and Queens school districts was sponsored by grants from Bank of America and the National Grid
Foundation. This included our continuing collaboration with Brentwood Union Free School Dis-
trict, where we provided genetic engineering labs for 6th–8th grade classes participating in the first
district-wide science fair. The entire world was inspired when Samantha Garvey, a former partici-
pant in DNALC labs at Brentwood, overcame homelessness to become a semifinalist in the Intel Sci-
ence Competition.
The summer workshop season was record-breaking in every sense. Topping the previous record
from 2009, more than 1000 students participated in 44 week-long camps held at six locations on
Long Island and NYC: Dolan DNALC, DNALC West, Stony Brook University, Chapin School, and
Trinity School. Among the summer campers were 19
students from Beijing No. 166 High School, the first
specialized school of life sciences in the Chinese cap-
ital. The students spent three weeks at the DNALC,
progressing from classical genetics, to bacterial
cloning, to human and plant genomics. The summer
study culminated in a book signing and Q&A session
with CSHL’s own Nobel laureate, James Watson, and
a field trip to the Human Origins exhibit at the
American Museum of Natural History. Anticipating
a growing exchange program with Beijing 166 and
other schools in China, we proceeded with plans to
develop a fourth teaching lab at the Dolan DNALC.
We struggled to save the last week of summer camps in the aftermath of a visit by Hurricane
Irene, which took out power for more than 350,000 homes and businesses on Long Island. The
Monday following the storm, we returned to find power off, the basement flooded, and more than
50 families arriving with camp registrants. After meeting parents at the curb and communicating a
Executive Director’s Report      455
Students, teachers, and administrators from Beijing No. 166
pose with DNALC staff.
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hurried plan, we spent the rest of the day moving three labs’ worth of equipment and supplies to
teaching spaces on the CSHL campus. By Tuesday morning, all was in place to restart the camps,
with greeters directing parents to locations in Beckman and Delbrück labs, and 95% of registered
campers turning up.
Monthly Saturday DNA! sessions drew 219 participants, with parents and grandparents joining
their children to learn about superbugs, dinosaurs, and mitochondrial DNA. The annual Great Mo-
ments in DNA Science seminar series drew 162 top Long Island high school students for presenta-
tions on current biological research. CSHL researcher Dr. Andrea Eveland explained how she
combines classical genetics with cutting-edge technologies to understand the molecular mechanisms
that control flowering in maize. Dr. Damon Love, a postdoctoral researcher at Weill Cornell Med-
ical College, discussed how RNAi can potentially silence genes involved in the progression of liver
cancer. Dr. Benoit Boivin from the Tonks lab at CSHL explained how cell physiology is affected
when oxygen reacts with a class of enzymes called protein tyrosine phosphatases.
Harlem DNA Lab
With continued core support from the Dana Foundation and student scholarship funding from the
William Townsend Porter Foundation, in 2011 the Harlem DNA Lab hosted 1849 NYC public and pri-
vate school students, 60% of whom were either African American or Hispanic. We also provided in-
tensive enrichment to students from two schools housed with us in the John S. Roberts (JSR)
Educational Complex: 12th graders from the Coalition School for Social Justice participated in three
biotechnology laboratories, and 6th–8th graders from MS45 enjoyed three introductory genetics labo-
ratories. In the spring, we participated in the World
Science Festival, hosting children at an outdoor DNA
extraction booth in Washington Square Park. Harlem
DNA Lab also became the focal point for our Urban
Barcode Project, hosting information and training ses-
sions for educators and providing kits and Open Lab
days for teams to conduct their experiments. 
The Charter Membership Program continued in
2011 with Chapin School and Trinity School. The
program provides intensive support to independent
schools wishing to develop a sequenced program of ac-
celerated science opportunities for students and teach-
ers. Each school receives customized instruction that
includes professional development for science teach-
ers, field trips to DNALC facilities, in-school lab vis-
its, and on-site summer camps taught by DNALC
instructors. As a result of this successful partnership,
we worked with Chapin School’s Head of School, Patricia Hayot, to develop an extensive program of
DNA camps for students from NYC independent schools to be held at Chapin in summer 2012.
Although we have managed to stay afloat against a current of change within the NYC public
school system, the continued devolvement of the Department of Education (DOE) is a source of
unease. The JSR Educational Complex is emblematic of continued reorganization and adminis-
trative shuffling within the DOE, with two schools phased out and two new schools phased in
during our tenancy. Student discipline and security are recurring concerns. HHMI support has
helped us prove that a small, focused science institution can indeed have a substantial impact on
a megalithic school system. However, at this point, it seems imperative that we establish a stand-
alone facility in Manhattan, where we can continue to expand teacher and student opportunities
to participate in the gene age. 
Visitors to our booth at the World Science Festival view
cells and extract DNA.
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Partnerships and Graduate Training
We continued our partnership with Cold Spring Harbor High School (CSHHS) to offer Molecular
and Genomic Biology. This college-level course is scheduled during the last two class periods and is
co-instructed by DNALC staff members and CSHHS biology and research teacher Jaak Raudsepp.
The course emphasizes hands-on experimentation, critical thinking, and independent projects across
a range of biological systems. The sixth class started in the fall with a unit on gene function in the
roundworm C. elegans. CSHL Watson School of Biological Sciences (WSBS) graduate student
Colleen Carlston helped the CSHHS students set up a genetic screen that identified three new genes
that affect RNAi function. The class then moved on to projects using DNA barcoding to identify
wild plants and animals, pets, and food products from grocery stores. 
A project on three-dimensional protein modeling was conducted in collaboration with the Cen-
ter for Science and Mathematics Education (CESAME) at Stony Brook University. The students
used data from primary research papers to identify important parts of proteins involved in the cell
cycle and drugs that interact with them. They then used three-dimensional modeling software to
highlight key atoms involved in molecular interactions. The modified structure files were sent to 
CESAME, where detailed atomic resolution models of the proteins were manufactured on a state-
of-the-art prototyping three-dimensional printer. This machine is essentially a laser printer that lay-
ers droplets of polymer resin in three dimensions to build a detailed molecular model. Students will
present their models and explanatory posters at the May 2012 CSHL meeting, The Cell Cycle. (A
highlight of last year’s course was students’ poster presentations at the CSHL Biology of Cancermeet-
ing, where the audience included Nobel laureate Robert Weinberg.)
As part of our expanding collaboration with CESAME, Multimedia and Evaluation Manager
Amy Nisselle, Ph.D., was appointed an adjunct faculty member at Stony Brook University. Calling
on her academic background in public health, education, and medical research, Amy coadvises 
CESAME doctoral program candidates on thesis projects. Two candidates are helping to evaluate
the NSF ATE Genomic Approaches in Biosciences program: DNALC Teacher Fellow Caren Gough is
investigating the program’s impact on teachers’ pedagogical beliefs and practices, and Robin Torn-
abene is examining its socioscientific effects. Jaak Raudsepp of CSHHS is tracking the long-term ca-
reer trajectories of CSHL Partners for the Future alumni.
In our collaboration with the WSBS, graduate students engage in a 3-month rotation in science
instruction. Pairs of students work with a seasoned DNALC instructor to master the presentation
of genetics labs to middle and high school students. During the first phase of training, student teams
observe the DNALC instructor in the classroom and organize a lesson plan that integrates their
own perspectives. The second phase is coteaching, during which graduate students instruct the lab
portion of the class. DNALC instructors provide constructive critique in preparation of the third
and final phase: independent teaching. After completion of both middle and high school teaching
rotations, WSBS students deliver three additional lessons to demonstrate mastery of instruction and
classroom management skills, which are useful for teaching at any level.
We applied our expertise in graduate education to a collaboration with the New York Academy
of Sciences (NYAS). One of the oldest scientific institutions in the United States, the NYAS is now
based in the new World Trade Center. The DNALC provided 6 hours of lab instructional training
to 100 graduate students and teachers who serve as NYAS mentors in after-school programs for
NYC students in grades K–12. The mentors learned to deliver several popular DNALC labs, in-
cluding the DNA Extraction from Banana and Baggie Cell Model. 
We also continued our long-term collaboration with the Singapore Ministry of Education, host-
ing six Singaporean teachers for 2-week attachments. In July, high school biology teachers Ms. Leo
Minyin and Mr. Yang Wenjun participated in HHMI Leadership training at the Harlem DNA Lab.
In November, primary teachers Mrs. Thia Woon Ling, Ms. Eileen Chin, Mdm. Wee Shu Yi, and
Mr. Azman bin Mohammed Dali participated in student labs and small workshop sessions focused
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on Fun with DNA and World of Enzymes curricula. All teachers are required to author formal lesson
plans and share new teaching methods with teachers at their home schools. 
Staff and Interns
The year 2011 saw a number of significant staff changes, with bittersweet partings and promises of
new challenges. Uwe Hilgert wound up 10 years’ service to the DNALC and CSHL when he re-
turned to the University of Arizona to become director of outreach
for the Bio5 Institute. Reared on a riverboat in Germany, Uwe re-
ceived a Ph.D. from the Max Planck Institute for Plant Breeding in
Cologne and then conducted postdoctoral research at the Univer-
sity of Arizona. Uwe started at the DNALC in 2000 as a high school
instructor, then quickly developed the DNALC’s bioinformatics ca-
pability under an HHMI grant. As Assistant Director, beginning in
2005, Uwe assumed responsibility for all of the DNALC’s profes-
sional development activities, which each year involved planning
several dozen events around the country. After a year’s special as-
signment as Assistant Dean of the WSBS, where he helped ease tran-
sition to new leadership, Uwe returned to the DNALC in 2008 to
spearhead the outreach component of the iPlant Collaborative. His
attention to detail and ability to carry out complex planning was
critical during a period when DNALC’s teacher training increased
fivefold. Although he will be greatly missed, we continue to collaborate on a weekly basis.
Ileana Rios left her position as Harlem DNA Labmanager for a teaching position at the prestigious
Trinity School, where her son is a student. Ileana was the perfect person to initiate our effort to bring
high-level science to underrepresented students in NYC. She was born and attended elementary
school only blocks away from our facility in Harlem, received a bachelor’s degree in biology from
Barnard College and Ph.D. in molecular biology from City University of New York (CUNY). Her
background and work at Harlem DNA Lab will come in handy as she develops a molecular genetics
elective at Trinity and as several teams of her students participate in the Urban Barcode Project. 
Under normal circumstances, the loss of two key staff would have been traumatic, but we were
lucky to have two fantastic replacements waiting in the wings. Uwe’s loss was compensated by a re-
ciprocal move back to CSHL by Sheldon McKay, who had moved from Lincoln Stein’s lab to the
iPlant Collaborative at the University of Arizona. Sheldon brings high-level bioinformatics exper-
tise to the DNALC. Sheldon has bachelor’s and master’s degrees in genetics from the University of
British Columbia and a Ph.D. in evolutionary genetics from Simon Fraser University. His first task
will be to build Green Line for our DNA Subway; this workflow will provide a simple interface to
analyze RNA data sets from next-generation sequencers. 
New Harlem DNA LabManager Melissa Lee has an undergraduate degree in biology from Johns
Hopkins and a master’s degree in science education from CUNY. Her work experience includes
managing a molecular genetics lab at New York University and, for the last several years, teaching
at Marie Curie Science High School in the Bronx. As a student growing up in the Bronx, Melissa’s
interest in genetics was sparked when she attended a DNA Science course taught by the DNALC at
the AMNH.
At the same time, we recruited Oscar Pineda-Catalan as Urban Barcode Project Manager. A na-
tive of Mexico City, Oscar has an undergraduate degree in biomedical basic research and a master’s
degree in urban studies from the University of Mexico. Teaching biology, human anatomy, and
physiology in a Mexico City high school inspired him to pursue a career encompassing both scien-
tific research and education. Under a Fulbright Fellowship, he completed a Ph.D. in ecology and
conservation biology at Columbia University, where his thesis examined threatened turtles of the
Uwe Hilgert and Sheldon McKay
Amazon River in Ecuador. George Amato graciously
allowed him to keep an office at the Sackler Institute
for Comparative Genomics at the AMNH, where he
most recently did postdoctoral research. This signif-
icantly strengthened our collaboration with this im-
portant institution.
Our outreach effort was further bolstered with
two incredible staff members from Europe. A native
of Austria, Dr. Christine Marizzi divides her time be-
tween the Harlem DNA Lab and DNALC West,
where she is the new Lab Manager. After receiving a
Ph.D. in genetics from the University of Vienna,
Christine developed youth education programs with
wienXtra and was an instructor at Vienna Open Lab, a long-term licensee of DNALC intellectual
property. Dr. Alexandra Manaia is working on the UBP in fulfillment of the final phase of a Ful-
bright Fellowship and master’s degree in international education development at Columbia Uni-
versity. After receiving a Ph.D. in developmental biology from Paris 7 University, she worked as
science education officer at the European Molecular Biological Laboratory in Heidelberg, where
Dave Micklos met her when working as an advisor to a Europe-wide teaching training program.
The DNALC bid farewell to middle school instructor Jennifer Aiello in 2011. Jen started at the
DNALC as a high school intern in 2002 and worked her way up to instructor after completing a
bachelor’s degree in forensic science in 2009 from Long Island University. In November, Jen ac-
cepted a position with the NYC Police Department to pursue a career in criminalistics and foren-
sics. We also said goodbye to videographer Todd Rocheford, who will use his experience developing
New York Stories and UBP videos in his new consultancy. 
Our internship program continued to draw some of Long Island’s most talented high school and
college students, engaging them in science research and providing practical laboratory experience.
Our new high school interns were Kathryn Bellissimo (Walt Whitman), Cyril Danielkutty (Har-
borfields), Alexa DeAngelis (St. Anthony’s), Frieda Haerter, Julie Hemphill, Eun Sung Suh (John
Glenn), Paras Patel (Half Hollow Hills East), Anna Saum (home schooled), and Gianna Torre (Wan-
tagh). The new hires joined a dedicated group of returning interns: Jack Greenfield (Oyster Bay),
Devika Gupta (Farmingdale), Jueng Woen Kim (Hauppauge), and Young Joon Suh (John Glenn).
During the summer, we welcomed four new interns to assist with DNALC West camps: Eliana and
Juliet Jacobson (Hebrew Academy of Nassau County), James Polke (Regis), and Aman Sharma (Her-
ricks). We bid farewell to a number of high school interns as they left for their freshman year at col-
lege: Laura Bergsten (Dartmouth), George Economou, Lindsay Hochberg, David Streitman (Cor-
nell), Max Vaysman (SUNY Geneseo), and Pamela Wax (Northwestern). 
College interns supervise high school students, assist with summer camps, and work on special-
ized projects, including fulfilling faculty requests for RNAi targeting vectors. Returning college in-
terns in 2011 were David Dopfel, Lina-Mari Varghese (Stony Brook University), Katherine Villalon
(John Jay University), and Sara Weinclaw (University of Maryland). City-dwellers Arielle Scardino
(City College of New York) and Sulaiman Usman (New York Institute of Technology) assist at
Harlem DNA Lab and with the UBP.
Many DNALC interns are involved in independent research projects and compete in state and na-
tional science competitions: Alexa DeAngelis studied visual and spatial short-term memory loss, Young
Joon Suh studied bioremediation of oil spills using cyanobacteria, Eun Sung Suh studied effects of an-
tibiotics on C. elegans, Katherine Villalon used random amplified polymorphic DNA (RAPD) to de-
tect genomic instability in lung cancer, and David Dopfel examined longevity genes in C. elegans.
We also welcomed two BioMedia college interns in 2011. Mara Smith is completing a degree in
neuroscience and science journalism at Brown University. Under a Royce Fellowship, she assisted
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Oscar Pineda-Catalan, Melissa Lee, Alexandra Manaia,
and Christine Marizzi
with the development of the Learn About SMA Internet microsite. Anne Burlet-Parendel returned
to CSHL in 2011 after studying neural stem cells in the Grisha Lab as part of her master’s in genetics,
University Denis Diderot, Paris, in 2010. In preparation for starting a master’s in science commu-
nication at the University Louis Pasteur in Strasbourg, Anne assisted with several projects and in-
ventoried DNALC lab instructional assets. 
Expert Advisors and Corporate Support
The DNALC benefits from a Corporate Advisory Board (CAB) that focuses on fundraising from
the Long Island business community. Under the guidance of development staff member Karen Orzel
since 2005, the CAB golf outing and annual fund have contributed more than $200,000 per year
to DNALC operations. Also during that time, CAB members Laurie Landau, Eddie Chernoff, Peter
and Dori Tilles, Pall Corporation, and OSI Pharmaceuticals provided major endowment gifts.
Over the years, the CAB has operated in parallel with the CSHL Association. This group of
“friends of the Lab” has raised annual funds for CSHL since the 1920s. To unify local fundraising
and foster a greater sense of common purpose, the CAB and CSHL Association annual funds were
merged in 2011. Although the two organizations will continue to be managed by separate boards,
the unrestricted funds they raise will support both the research and education missions of CSHL.
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January 15 HHMI Professional Development, Detecting Genetically Modified Organisms Workshop, Harlem DNA Lab
January 15–19 Plant and Animal Genome XIX Conference, Town and Country Convention Center, “DNA Subway: The Fast 
Track to Gene Annotation,” San Diego, California
January 21–22 NSF iPlant Collaborative Professional Development, Genomics in EducationWorkshop, Florida A&M 
University, Tallahassee, Florida
January 22 Graduate Student Training for STEM Mentoring Program, New York Academy of Science, New York
Saturday DNA! “Mitochondrial DNA—Mom’s Legacy,” DNALC
January 26–28 NSF 2011 Course, Curriculum, and Laboratory Improvement—Transforming Undergraduate Education in 
Science (CCLI-TUES) Conference, Washington, D.C.
January 29 Graduate Student Training for STEM Mentoring Program, New York Academy of Science, New York
February 4 Site visit by Christine Marizzi, Max F. Perutz Laboratories, Vienna, Austria
HHMI Professional Development, DNA Structure and IsolationWorkshop, Harlem DNA Lab
February 5 HHMI Professional Development, DNA Structure and IsolationWorkshop, Harlem DNA Lab
February 8 Site visit by Wang Lei, Zhu Yan, and Li Zhenghua, Beijing No. 166 High School, Beijing, China
February 12 HHMI Professional Development Discovering the Urban EnvironmentWorkshop, New York Academy of Science, 
New York
February 18–20 Science Without Borders, The American Association for the Advancement of Science Meeting, “Search Engine 
Optimization to Increase Audiences for Online Science Education,” Washington, D.C.
February 25–26 NSF iPlant Collaborative Professional Development, Genomics in EducationWorkshop, University of Arizona, Tucson
February 26 Saturday DNA! “Dino DNA!,” DNALC
HHMI Professional Development, Variability and InheritanceWorkshop, Harlem DNA Lab
March 8 Site visit by Father James Williams and John Westerman, Chaminade High School, Mineola, New York
March 8–9 NSF iPlant Collaborative Professional Development, Genomics in EducationWorkshop, City College of San 
Francisco, California
March 11–12 National Science Teachers Association 2011 National Conference on Science Education, “Barcoding Plants,” 
“Frontiers in Genomics,” “RNAi/CBSC,” “DNA Subway,” “Iceman,” “Lab Center,” and “CSI,” San Francisco,
California
March 12 HHMI Professional Development, DNA Transformation and Protein IsolationWorkshop, Harlem DNA Lab
Urban Barcode Project Information Session, New York Academy of Sciences, New York
March 19 Urban Barcode Project Information Session, Harlem DNA Lab
March 21–24 Joint Genome Institute User Meeting, Walnut Creek, California
March 25 HHMI Professional Development, DNA Analysis and ForensicsWorkshop, Harlem DNA Lab
March 26 HHMI Professional Development, DNA Analysis and ForensicsWorkshop, Harlem DNA Lab
Saturday DNA! “Recovering the Romanovs,” DNALC
Urban Barcode Project Information Session, The Rockefeller University, New York
April 2 Urban Barcode Project Training Session, Harlem DNA Lab
Urban Barcode Project Information Session, SCONYC Conference, Stuyvesant High School, New York
April 8 HHMI Professional Development, PCR and Human DNA Variation, Part 1Workshop, Harlem DNA Lab
April 9 HHMI Professional Development, PCR and Human DNA Variation, Part 1Workshop, Harlem DNA Lab
Urban Barcode Project Information Session, American Museum of Natural History, New York
April 15–16 NSF iPlant Collaborative Professional Development, Genomics in EducationWorkshop, North Carolina A&T 
State University, Greensboro
April 16 Saturday DNA! “Milky Menace,” DNALC
April 27 Urban Barcode Project Training Session, Harlem DNA Lab
April 30 Urban Barcode Project Training Session, Harlem DNA Lab
April 30–May 3 NSF ATE Genomic Approaches in Biosciences, Advisory Board Meeting, CSHL
May 5 Great Moments in DNA Science Honors Seminar: “Sowing the Next-Generation ‘Green Revolution’: Genetics 
and Genomics of Maize Development,” Andrea Eveland, CSHL, DNALC
May 6 HHMI Professional Development, PCR and Human DNA Variation, Part 2Workshop, Harlem DNA Lab
May 6–7 NSF iPlant Collaborative Professional Development, Genomics in EducationWorkshop, Bowie State University, 
Maryland
May 7 HHMI Professional Development, PCR and Human DNA Variation, Part 2Workshop, Harlem DNA Lab
May 8–12 National Institutes of Health Science Education Partnership Award Principal Investigators Conference, 
“Nationwide Dissemination of Inside Cancer,” Seattle, Washington
May 10 Site visit by Leo Brizuela and Jim Lynch, Agilent, Santa Clara, California
Great Moments in DNA Science Honors Seminar, “A Gene Silencing Approach to Control the Development of 
Liver Cancer Cells,” Damon Love, Weill Cornell College of Medicine, New York, DNALC
May 12 Site visit by Leo Brizuela, Agilent, Santa Clara, California 
Urban Barcode Project Information Session, New York Academy of Sciences, New York
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May 14 Urban Barcode Project Training Session, Harlem DNA Lab
May 18 Science Coordinators Network Meeting, Dowling College, Oakdale, New York
May 21 Saturday DNA! “Personalized Medicine,” DNALC
May 26 Great Moments in DNA Science Honors Seminar, “How Much Is too Much? Tracking Down Oxygen-Dependent 
Modifications in Normal and Diseased Cells,” Benoit Boivin, CSHL, DNALC
June 4 Urban Barcode Project Training Session, Harlem DNA Lab
June 4–5 World Science Festival, “Harlem DNA Lab,” and “DNA Subway,” New York
June 6–10 Teacher Professional Development Workshop, The Chapin School, New York
June 7 18th Annual Golf Outing, Piping Rock Club, Locust Valley, New York
June 10 NSF Shoot Apical Meristem Meeting, CSHL
June 10–11 NSF iPlant Collaborative Professional Development, Genomics in EducationWorkshop, Canisius College, 
Buffalo, New York
June 11 Urban Barcode Project Training Session, Genspace, Brooklyn, New York
June 13–17 DNA ScienceWorkshop, Trinity School, New York
Fun with DNAWorkshop, The Chapin School, New York
Fun with DNAWorkshop, Trinity School, New York
Human GenomicsWorkshop, The Chapin School, New York
World of EnzymesWorkshop, The Chapin School, New York
June 16 Site visit by Gregory Crawford, University of Notre Dame, Indiana
June 18 Saturday DNA! “Express Yourself!” DNALC
June 20–24 NSF ATE Professional Development, Genomic Approaches in BiosciencesWorkshop, Gwinnett Technical College, 
Lawrenceville, Georgia
June 22–26 18th International C. elegansMeeting, University of California, Los Angeles
June 27–July 1 World Conference on Educational Multimedia, “Novel Networked Navigation: A Case Study of a Genetics 
Education Internet Site,” Lisbon, Portugal
NSF ATE Professional Development, Genomic Approaches in BiosciencesWorkshop, Shoreline Community 
College, Washington
DNA ScienceWorkshop, DNALC
Fun with DNAWorkshop, DNALC
Fun with DNAWorkshop, DNALC West
World of EnzymesWorkshop, DNALC
July 1 Urban Barcode Project Training Session, Harlem DNA Lab
July 5–8 Fun with DNAWorkshop, DNALC
Green GenesWorkshop, DNALC
Plant GenomicsWorkshop, DNALC
World of EnzymesWorkshop, DNALC West
July 5 HHMI Professional Development, DNA Structure and IsolationWorkshop, Harlem DNA Lab
July 6 HHMI Professional Development, Variability and InheritanceWorkshop, Harlem DNA Lab
July 7 HHMI Professional Development, DNA Transformation and Protein IsolationWorkshop, Harlem DNA Lab
July 7–8 NSF iPlant Collaborative Professional Development, Genomics in EducationWorkshop, Washington University, 
St. Louis, Missouri
July 8 HHMI Professional Development, DNA Analysis and ForensicsWorkshop, Harlem DNA Lab
July 9–10 Botanical Society of America, “DNA Subway,” and “DNA Barcoding,” St. Louis, Missouri
July 11–15 DNA ScienceWorkshop, DNALC
DNA ScienceWorkshop, DNALC West
Human GenomicsWorkshop, Central Islip
Human GenomicsWorkshop, DNALC
World of EnzymesWorkshop, DNALC
July 11 HHMI Professional Development, DNA Transformation and Protein IsolationWorkshop, Harlem DNA Lab
July 12 HHMI Professional Development, DNA Analysis and ForensicsWorkshop, Harlem DNA Lab
July 13 HHMI Professional Development, PCR and Human DNA Variation, Part 1Workshop, Harlem DNA Lab
July 14 HHMI Professional Development, PCR and Human DNA Variation, Part 2Workshop, Harlem DNA Lab
July 15 HHMI Professional Development and Urban Barcoding Project Training Session, “DNA Barcoding,” Harlem 
DNA Lab
July 18–22 Fun with DNAWorkshop, DNALC
Green GenesWorkshop, DNALC
Green GenesWorkshop, DNALC West
Silencing GenomesWorkshop, DNALC
July 18–29 HHMI Professional Development, Leadership Symposium, Harlem DNA Lab
July 25–29 NSF Professional Development, Silencing GenomesWorkshop, DNALC
Forensic DetectivesWorkshop, DNALC
Genetic HorizonsWorkshop, DNALC West
July 25–Aug. 12 Introduction to Genetics and Biochemistry, DNA Science, and Genome ScienceWorkshops, Beijing No. 166 High 
School, DNALC
July 26 Learn About Spinal Muscular Atrophy interviews with Phil Sharp, Massachusetts Institute of Technology, 
Cambridge, and Richard Roberts, New England BioLabs Inc., Ipswich, Massachusetts
July 29 HHMI Professional Development and Urban Barcoding Project Training Session, “DNA Barcoding,” Harlem 
DNA Lab
August 1–5 Fun with DNAWorkshop, DNALC West
Green GenesWorkshop, DNALC
World of EnzymesWorkshop, DNALC
August 1 HHMI Professional Development, DNA Structure and IsolationWorkshop, Harlem DNA Lab
August 2 HHMI Professional Development, Variability and InheritanceWorkshop, Harlem DNA Lab
August 3 HHMI Professional Development, DNA Transformation and Protein IsolationWorkshop, Harlem DNA Lab
August 4 HHMI Professional Development, DNA Analysis and ForensicsWorkshop, Harlem DNA Lab
August 5 HHMI Professional Development, PCR and Human DNA Variation, Part 1Workshop, Harlem DNA Lab
Urban Barcode Project Training Session, New York Hall of Science, Queens, New York 
August 8 HHMI Professional Development, DNA Transformation and Protein IsolationWorkshop, Harlem DNA Lab
American Society of Plant Biologists Annual Conference, “DNA Subway,” Minneapolis, Minnesota
August 8–12 NSF ATE Professional Development, Genomic Approaches in BiosciencesWorkshop, Universidad del Turabo, 
Gurabo, Puerto Rico
Genetic HorizonsWorkshop, DNALC
World of EnzymesWorkshop, DNALC
World of EnzymesWorkshop, DNALC West
August 9 HHMI Professional Development, DNA Analysis and ForensicsWorkshop, Harlem DNA Lab
August 10 HHMI Professional Development, PCR and Human DNA Variation, Part 1Workshop, Harlem DNA Lab
August 11 HHMI Professional Development, PCR and Human DNA Variation, Part 2Workshop, Harlem DNA Lab
August 12 HHMI Professional Development, DNA BarcodingWorkshop, Harlem DNA Lab
Urban Barcode Project Training Session, Harlem DNA Lab
Learn About Spinal Muscular Atrophy interviews with Darryl De Vivo, Columbia Medical Center, and SMA 
patients and families, New York
August 15–19 NSF ATE Professional Development, Genomic Approaches in BiosciencesWorkshop, Madison Area Technical 
College, Wisconsin
DNA ScienceWorkshop, DNALC
DNA ScienceWorkshop, Stony Brook University, New York
DNA ScienceWorkshop, DNALC West
Fun with DNAWorkshop, DNALC
Green GenesWorkshop, DNALC
August 16 Urban Barcode Project Training Session, Harlem DNA Lab
August 19 Site visit by Maryann Martone, Spinal Muscular Atrophy Foundation, New York
August 22–26 DNA ScienceWorkshop, DNALC
Fun with DNAWorkshop, DNALC
Genome ScienceWorkshop, Stony Brook University, New York
Human GenomicsWorkshop, DNALC
Human GenomicsWorkshop, DNALC West
August 23 Urban Barcode Project Training Session, Genspace, Brooklyn, New York
August 26 Site visit by Pat Hayot, Michael Maloy, and Jill Hirsch, The Chapin School, New York
Aug. 29–Sept. 2 DNA ScienceWorkshop, DNALC
Green GenesWorkshop, DNALC
Green GenesWorkshop, DNALC West
World of EnzymesWorkshop, DNALC
September 1 Urban Barcode Project Information Session, New York Botanical Garden, Bronx, New York
September 7 Urban Barcode Project Information Session, Richard Gilder Graduate School, American Museum of Natural 
History, New York
September 16 Urban Barcode Project Information Session, Trinity High School, New York
September 17 Urban Barcode Project Promotion at Maker Faire, New York Hall of Science, Queens, New York
Graduate Student Training for STEM Mentoring Program, New York Academy of Science, New York
September 19 Urban Barcode Project Training Session, Harlem DNA Lab
September 21 Urban Barcode Project Information Session, The Gateway Institute, New York
Urban Barcode Project Information Session, Brooklyn Bridge Park, Brooklyn New York
September 23 Urban Barcode Project Information Session, American Museum of Natural History, New York
September 26 Urban Barcode Project Training Session, Harlem DNA Lab
September 26–28 Site visit by Tony Chiovitti, Gene Technology Access Centre, Melbourne, Australia
September 28 Urban Barcode Project Information Session, Trinity High School, New York
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October 1 Urban Barcode Project Training Session, Harlem DNA Lab
October 3 Site visit by James Bono, Buck Koonce, and Camille Bibeau, Lawrence Livermore National Laboratory, 
Livermore, California
October 5 Urban Barcode Project Information Session, The River Project, New York University, New York
October 6 Pandora “Town Hall” Discussion and Reception, DNALC
Urban Barcode Project Information Session, Columbia Secondary School for Mathematics, Science and 
Engineering, New York
October 7 Site visit by Kim Kerns and Katya Lanfant, Cablevision, New York
October 8 Urban Barcode Project Training Session, Harlem DNA Lab
October 11–12 NSF iPlant Collaborative Professional Development, Genomics in EducationWorkshop, University of California, 
Riverside
October 12 Saturday DNA! “Superbugs Uncovered,” DNALC
Urban Barcode Project Information Session, Graduate Center, City University of New York, New York
October 12–15 NABT Professional Development Conference, “DNA Barcoding in Your Classroom,” “Silencing Genomes,” 
“RNAi/CSBC,” “DNA Subway,” “DNA Barcoding,” and “Evaluation of Biology Teaching Resources,” 
Anaheim, California
October 14 Urban Barcode Project Information Session, The Urban Assembly, New York
HHMI Professional Development, Variability and InheritanceWorkshop, Harlem DNA Lab
October 15 HHMI Professional Development, Variability and InheritanceWorkshop, Harlem DNA Lab
October 21 HHMI Professional Development, DNA Transformation and Protein IsolationWorkshop, Harlem DNA Lab
October 22 HHMI Professional Development, DNA Transformation and Protein IsolationWorkshop, Harlem DNA Lab
October 24 Site visit by Ania Wieczorek, University of Hawaii, Manoa, Hawaii
October 25 Site visit by Mathias Schmitt, ARTE, Strasbourg Cedex, France
October 26–28 NSF ATE Principal Investigators Conference, “Developing Leaders in Biosciences,” Washington, D.C.
October 27 Urban Barcode Project Information Session, Brooklyn Technical High School, Brooklyn, New York
October 28–29 NSF iPlant Collaborative Professional Development, Genomics in EducationWorkshop, Arnold Arboretum of 
Harvard University, Roslindale, Massachusetts
November 1 Urban Barcode Project Information Session, Department of Education, New York
November 3–4 Site visit by Shannon Oliver, iPlant Collaborative, Tucson, Arizona
November 5 Urban Barcode Project Training Session, Genspace, Brooklyn, New York
November 8 HHMI Professional Development, DNA Structure and IsolationWorkshop, Harlem DNA Lab
HHMI Professional Development, DNA Structure and IsolationWorkshop, Genspace, Brooklyn, New York
November 10 Criminal Courts Bar Association of Nassau County, DNA Analysis and ForensicsWorkshop, Reception, and 
“DNA—Nothing to Fear,” Eric Carita, Forensic DNA Consultant, DNALC
November 11 Urban Barcode Project Training Session, Harlem DNA Lab
November 11–12 NSF iPlant Collaborative Professional Development, Genomics in EducationWorkshop, University of Lone Star 
College, Kingwood, Texas
November 12 Saturday DNA! “Gram-tastic!” DNALC
November 14 Urban Barcode Project Information Session, Benjamin C. Cardozo High School, New York
November 15–16 NSF iPlant Collaborative Professional Development, Tools and ServicesWorkshop, National Evolutionary 
Synthesis Center, Durham, North Carolina
November 16 Site visit by Siobhan McKenna, Agilent, Santa Clara, California
Learn About Spinal Muscular Atrophy interview with Charlotte Sumner,The Johns Hopkins Hospital, 
Baltimore, Maryland
November 17–18 National Human Genome Research Institute (NHGRI) Genomic Literacy Workshop, “Limited Effects and 
Genome Education in the Digital Age,” Rockville, Maryland
November 18 HHMI Professional Development, DNA Analysis and ForensicsWorkshop, Harlem DNA Lab
November 19 HHMI Professional Development, DNA Analysis and ForensicsWorkshop, Harlem DNA Lab
Nov. 28–Dec. 10 Singapore Primary Teachers Attachment, DNALC
November 30 NSF iPlant Collaborative Professional Development, Tools and ServicesWorkshop, CSHL
Nov. 30–Dec. 2 International Barcode of Life Conference, “Urban Barcode Project: A Scalable Infrastructure for IBOL Outreach,” 
Oaks Embassy, Adelaide, Australia
December 1 Site visit by Suzana Dobre, Mircea Miclea, and Roxana Vitan, Romanian-American Foundation, Bucharest, Romania
December 8 Site visit by Amanda Dubrowski, Bard College, Annandale on Hudson, New York
December 9 HHMI Professional Development, PCR and Human DNA Variation, Part 1Workshop, Harlem DNA Lab
December 10 Saturday DNA! “Mendelian Inheritance,” DNALC 
HHMI Professional Development, PCR and Human DNA Variation, Part 1Workshop, Harlem DNA Lab
December 14 Site visit by Alex Wolfe, Second Nature Toys, New York
Sites of Major Faculty Workshops 1985–2011
Key: Middle School High School College
ALABAMA University of Alabama, Tuscaloosa 1987–1990
ALASKA University of Alaska, Fairbanks 1996
ARIZONA Arizona State University, Tempe 2009
Tuba City High School 1988
University of Arizona, Tucson 2011
ARKANSAS Henderson State University, Arkadelphia 1992
CALIFORNIA California State University, Dominguez Hills 2009
California State University, Fullerton 2000
California Institute of Technology, Pasadena 2007
Canada College, Redwood City 1997
City College of San Francisco 2006 
City College of San Francisco 2011
Contra Costa County Office of Education, Pleasant Hill 2002, 2009
Foothill College, Los Altos Hills 1997
Harbor-UCLA Research & Education Institute, Torrance 2003
Laney College, Oakland 1999
Los Angeles Biomedical Research Institute (LA Biomed), Torrance 2006
Lutheran University, Thousand Oaks 1999
Oxnard Community College, Oxnard 2009
Pasadena City College 2010
Pierce College, Los Angeles 1998
Salk Institute for Biological Studies, La Jolla 2001, 2008
San Francisco State University 1991
San Jose State University 2005
Santa Clara University, Santa Clara 2010
University of California, Berkeley 2010
University of California, Davis 1986
University of California, Northridge 1993
University of California, Riverside 2011
COLORADO Aspen Science Center 2006
Colorado College, Colorado Springs 1994, 2007
United States Air Force Academy, Colorado Springs 1995
University of Colorado, Denver 1998, 2009–2010
CONNECTICUT Choate Rosemary Hall, Wallingford 1987
DISTRICT OF COLUMBIA Howard University, Washington 1992, 1996, 2009–2010
FLORIDA Armwood Senior High School, Tampa 1991
Florida Agricultural & Mechanical University, Tallahassee 2007–2008 
Florida Agricultural & Mechanical University, Tallahassee 2011
North Miami Beach Senior High School 1991
University of Miami School of Medicine 2000
University of Western Florida, Pensacola 1991
GEORGIA Fernbank Science Center, Atlanta 1989, 2007
Gwinnett Technical College, Lawrenceville 2011
Morehouse College, Atlanta 1991, 1996–1997
Spelman College, Atlanta 2010
HAWAII Kamehameha Secondary School, Honolulu 1990
ILLINOIS Argonne National Laboratory, Argonne 1986–1987
iBIO Institute/Harold Washington College, Chicago 2010
Illinois Institute of Technology, Chicago 2009
University of Chicago 1992, 1997, 2010
INDIANA Butler University, Indianapolis 1987
IDAHO University of Idaho, Moscow 1994
IOWA Drake University, Des Moines 1987
KANSAS University of Kansas, Lawrence 1995
KENTUCKY Murray State University, Murray 1988
University of Kentucky, Lexington 1992
Sites of Major Faculty Workshops 1985–2011 465
466 DNA Learning Center
Western Kentucky University, Bowling Green 1992
LOUISIANA Bossier Parish Community College, Bossier City 2009
Jefferson Parish Public Schools, Harvey 1990
John McDonogh High School, New Orleans 1993
MAINE Bates College, Lewiston 1995
Foundation for Blood Research, Scarborough 2002
MARYLAND Annapolis Senior High School 1989
Bowie State University, Bowie 2011
Frederick Cancer Research Center, Frederick 1995
McDonogh School, Baltimore 1988
Montgomery County Public Schools, Rockville 1990–1992
National Center for Biotechnology Information, Bethesda 2002
St. John’s College, Annapolis 1991
University of Maryland, School of Medicine, Baltimore 1999
MASSACHUSETTS Arnold Arboretum of Harvard University, Roslindale 2011
Beverly High School 1986
Biogen Idec, Cambridge 2002, 2010
Boston University 1994, 1996
CityLab, Boston University School of Medicine 1997
Dover-Sherborn High School, Dover 1989
Randolph High School, Randolph 1988
The Winsor School, Boston 1987
Whitehead Institute for Biomedical Research, Cambridge 2002
MICHIGAN Athens High School, Troy 1989
MINNESOTA Minneapolis Community and Technical College 2009
University of Minnesota, St. Paul 2005
University of Minnesota, St. Paul 2010
MISSISSIPPI Mississippi School for Math & Science, Columbus 1990–1991
Rust College, Holly Springs 2006–2008, 2010
MISSOURI St. Louis Science Center 2008–2010
Stowers Institute for Medical Research, Kansas City 2002, 2008
Washington University, St. Louis 1989, 1997, 2011
NEVADA University of Nevada, Reno 1992
NEW HAMPSHIRE Great Bay Community College, Portsmouth 2009
New Hampshire Community Technical College, Portsmouth 1999
St. Paul’s School, Concord 1986–1987
NEW JERSEY Coriell Institute for Medical Research, Camden 2003
Raritan Valley Community College, Somerville 2009
NEW MEXICO Bio-Link Southwest Regional Meeting, Albuquerque 2008
NEW YORK Albany High School 1987
American Museum of Natural History, New York 2007
Bronx High School of Science 1987
Canisius College, Buffalo 2007 
Canisius College, Buffalo 2011
Cold Spring Harbor High School 1985, 1987
Columbia University, New York 1993
Cornell University, Ithaca 2005
DeWitt Middle School, Ithaca 1991, 1993
DNA Learning Center West, Lake Success 2005
Dolan DNA Learning Center, Cold Spring Harbor 1988–1995, 2001–
2004, 2006–2009
Dolan DNA Learning Center, Cold Spring Harbor 1990, 1992, 1995, 
2000–2011
Dolan DNA Learning Center, Cold Spring Harbor 1990–1992
Fostertown School, Newburgh 1991
Harlem DNA Lab, East Harlem 2008–2009, 2011
Huntington High School 1986
Irvington High School 1986
John Jay College of Criminal Justice, New York 2009
Junior High School 263, Brooklyn 1991
Lindenhurst Junior High School 1991
Mount Sinai School of Medicine, New York 1997
New York City Department of Education 2007
New York Institute of Technology, New York 2006
New York Institute of Technology, New York 2006
Orchard Park Junior High School 1991
Plainview−Old Bethpage Middle School 1991
State University of New York, Purchase 1989
State University of New York, Stony Brook 1987–1990
Stuyvesant High School, New York 1998–1999
The Rockefeller University, New York 2003
The Rockefeller University, New York 2010
Titusville Middle School, Poughkeepsie 1991, 1993
Trudeau Institute, Saranac Lake 2001
Union College, Schenectady 2004
United States Military Academy, West Point 1996
Wheatley School, Old Westbury 1985
NORTH CAROLINA CIIT Center for Health Research, Triangle Park 2003
North Carolina Agricultural & Technical State University, Greensboro 2006–2007, 2009–
2011
North Carolina School of Science, Durham 1987
OHIO Case Western Reserve University, Cleveland 1990
Cleveland Clinic 1987
Langston University, Langston 2008
North Westerville High School 1990
OKLAHOMA Oklahoma City Community College 2000
Oklahoma City Community College 2006–2007, 2010
Oklahoma Medical Research Foundation, Oklahoma City 2001
Oklahoma School of Science and Math, Oklahoma City 1994
Tulsa Community College 2009
OREGON Kaiser Permanente−Center for Health Research, Portland 2003
PENNSYLVANIA Duquesne University, Pittsburgh 1988
Germantown Academy 1988
Kimmel Cancer Center, Philadelphia 2008
RHODE ISLAND Botanical Society of America, Providence 2010
SOUTH CAROLINA Clemson University 2004
Medical University of South Carolina, Charleston 1988
University of South Carolina, Columbia 1988
TENNESSEE NABT Professional Development Conference, Memphis 2008
TEXAS Austin Community College-Rio Grande Campus 2000
Austin Community College-Eastview Campus 2007–2009
Houston Community College Northwest 2009–2010
J.J. Pearce High School, Richardson 1990
Langham Creek High School, Houston 1991
University of Lone Star College, Kingwood 2011
Midland College 2008
Southwest Foundation for Biomedical Research, San Antonio 2002
Taft High School, San Antonio 1991
Texas A&M, AG Research and Extension Center, Weslaco 2007
Trinity University, San Antonio 1994
University of Texas, Austin 1999, 2004, 2010
University of Texas, Brownsville 2010
UTAH University of Utah, Salt Lake City 1993
University of Utah, Salt Lake City 1998, 2000
Utah Valley State College, Orem 2007
VERMONT University of Vermont, Burlington 1989
VIRGINIA Eastern Mennonite University, Harrisonburg 1996
Jefferson School of Science, Alexandria 1987
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Mathematics and Science Center, Richmond 1990
Mills Godwin Specialty Center, Richmond 1998
Virginia Polytechnic Institute and State University, Blacksburg 2005, 2008–2009
WASHINGTON Fred Hutchinson Cancer Research Center, Seattle 1999, 2001, 2008
Shoreline Community College, Shoreline 2011
University of Washington, Seattle 1993, 1998, 2010
WEST VIRGINIA Bethany College, Bethany 1989
WISCONSIN Blood Center of Southeastern Wisconsin, Milwaukee 2003
Madison Area Technical College 1999, 2009, 2011
Marquette University, Milwaukee 1986–1987
University of Wisconsin, Madison 1988–1989
University of Wisconsin, Madison 2004
WYOMING University of Wyoming, Laramie 1991
PUERTO RICO Universidad del Turabo, Gurabo, Puerto Rico 2011
University of Puerto Rico, Mayaguez 1992
University of Puerto Rico, Mayaguez 1992
University of Puerto Rico, Rio Piedras 1993
University of Puerto Rico, Rio Piedras 1994
AUSTRALIA Walter and Eliza Hall Institute and University of Melbourne 1996
AUSTRIA Vienna Open Lab 2007
CANADA Red River Community College, Winnipeg, Manitoba 1989
CHINA Ho Yu College, Hong Kong 2009
GERMANY Urania Science Center, Berlin 2008
ITALY International Institute of Genetics and Biophysics, Naples 1996
Porto Conte Research and Training Laboratories, Alghero 1993
MEXICO ASPB Plant Biology, Merida 2008
PANAMA University of Panama, Panama City 1994
RUSSIA Shemyakin Institute of Bioorganic Chemistry, Moscow 1991
SINGAPORE National Institute of Education 2001–2005
SWEDEN Kristineberg Marine Research Station, Fiskebackskil 1995
Uppsala University 2000
THE NETHERLANDS International Chromosome Conference, Amsterdam 2007
COLD SPRING HARBOR
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Serials
Genes & Development, Vol. 25 (www.genesdev.org)
Genome Research, Vol. 21 (www.genome.org)
Learning & Memory, Vol. 18 (www.learnmem.org)
RNA, Vol. 17 (www.rnajournal.org)
Cold Spring Harbor Symposia on Quantitative Biology, Vol. 75: 
Nuclear Organization and Function, edited by Terri Grodzicker,
David Spector, and Bruce Stillman
Cold Spring Harbor Protocols (www.cshprotocols.org)
Cold Spring Harbor Perspectives in Biology 
(www.cshperspectives.org)
Cold Spring Harbor Perspectives in Medicine 
(www.perspectivesinmedicine.org)
Laboratory Manuals
Imaging in Neuroscience: A Laboratory Manual,
edited by Fritjof Helmchen and Arthur Konnerth; Series 
Editor Rafael Yuste
Textbooks
An Introduction to Animal Behavior: An Integrative Approach, 
by Michael J. Ryan and Walter Wilcynski
Yeast Intermediary Metabolism, by Dan G. Fraenkel
Monographs (Topic Collections from
Perspectives in Biology and Perspectives
in Medicine)
The Biology of Lipids: Trafficking, Regulation, and Function, 
edited by Kai Simons
The Mammary Gland as an Experimental Model, edited by 
Mina J. Bissell, Kornelia Polyak, and Jeffrey M. Rosen
Germ Cells, edited by Paolo Sassone-Corsi, Margaret T. Fuller, 
and Robert Braun
The Golgi, edited by Graham Warren and James Rothman
Calcium Signaling, edited by Martin D. Bootman, Michael J.
Berridge, James W. Putney, and H. Llewelyn Roderick
Protein Homeostasis, edited by Richard I. Morimoto, Dennis J.
Selkoe, and Jeffery W. Kelly
Extracellular Matrix Biology, edited by Richard O. Hynes 
and Kenneth M. Yamada
Angiogenesis: Biology and Pathology, edited by Michael Klagsbrun
and Patricia A. D’Amore
The Biology of Alzheimer Disease, edited by Dennis J. Selkoe, 
Eckhard Mandelkow, and David M. Holtzman
HIV: From Biology to Prevention and Treatment, edited by 
Frederic D. Bushman, Gary J. Nabel, and Ronald Swanstrom
History
Mutation: The History of an Idea from Darwin to Genomics, 
by Elof Axel Carlson
RNA: Life’s Indispensable Molecule, by James Darnell
Science and Society
Incurable: A Life After Diagnosis, by Charles Harris
Other
CSHL Annual Report 2010, Yearbook Edition
CSHL Annual Report 2010, Executive Summary
Banbury Center Annual Report 2010
Watson School of Biological Sciences Annual Report 2010
Online Book
Guide to the Human Genome, by Stewart Scherer (www.cshlp.org)
E-books (Kindle editions)
The Honest Look, by Jennifer L. Rohn
Sydney Brenner: A Biography, by Errol F. Friedberg
Imaging: A Laboratory Manual, edited by Rafael Yuste
At the Helm: Leading Your Laboratory, Second Edition,
by Kathy Barker
At the Bench: A Laboratory Navigator, Updated Edition, 
by Kathy Barker
Websites
Cold Spring Harbor Monograph Archive
(www.cshmonographs.org) 
Cold Spring Harbor Symposium on Quantitative Biology Archive
(symposium.cshlp.org)
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The publications of Cold Spring Harbor Laboratory Press are used and valued throughout the world,
a reminder that the Laboratory has a special place in the landscape of international science. Nowhere
else combines research excellence with professional education of the nature and quality that Cold
Spring Harbor offers. The research and review journals, handbooks, manuals, monographs, histories,
biographies, and textbooks of the Press are a vital part of how the Laboratory connects with the
worldwide scientific community. Our goal is to identify important research, technologies, and sci-
entists; to amplify their effectiveness by selecting, aggregating, and curating information research
communities can use; and to deliver that information when, where, and how the communities want
it. By successfully achieving these goals, the Press makes a substantial financial contribution to the
Laboratory. In 2011, that contribution exceeded $1.4 million, the largest the Press has ever made.
The major drivers of this success were the continued subscription growth among our journals, both
mature and start-up titles, and the cost-cutting measures that were implemented at the end of 2010.
During the year, research articles published by the Press’ seven scientific journals were downloaded
more than 8.8 million times, more than 2100 electronic journal subscriptions were fulfilled at aca-
demic institutions in 160 countries (including all leading American universities), and 39,600 copies
of print books were shipped. This reach is complemented by interest from foreign publishers in
translating certain books into languages such as Chinese, Japanese, Arabic, and, most recently, Viet-
namese.
As measured by impact factor, the best-known metric of worth, all of our journals advanced in
2011. Genes & Development and Genome Research continue to occupy the first tier of genetics,
biotechnology, and developmental biology journals, and of the 8000 most important science journals
published in the world, they are within the top 1.2%. All of the journals exceeded financial expec-
tation and Cold Spring Harbor Protocols, in its fifth year, had a particularly remarkable increase in
subscriptions. A new journal, Cold Spring Harbor Perspectives in Medicine, was launched on schedule
in September, with papers on AIDS, Alzheimer’s disease, and Parkinson’s syndrome. This new on-
line-only review journal will have a wide scope, ranging from the molecular and cellular basis of
disease to translational medicine and emerging therapeutic strategies.
Seventeen new books were published during the year, bringing the number of available titles to
more than 150. James Darnell’s book, RNA: Life’s Indispensable Molecule, published in July to critical
acclaim, was named one of the 25 Outstanding Academic Titles for 2011 by Choicemagazine. Elof
Carlson’s Mutation: From Darwinian Fluctuations to Comparative Genomics was also warmly received
by reviewers. The best-selling titles of the year were the classic handbooks At the Bench and At the
Helm, the iconic manual Molecular Cloning, and the magisterial history of molecular biology The
Eighth Day of Creation by Horace Freeland Judson, whose passing at the age of 80 during the year
we noted with great sadness. Our mission to deliver scientific information when, where, and how
it is needed is being profoundly altered by changes in distribution channels. Laboratory protocols
and topic-specific review articles are two types of content for which the Press has been renowned.
Five years ago, that content was delivered only in printed books. Now, it comes also in the much
more usable form of online-only subscription-based review journals made possible by the reputation
of those print books and the strategies used in creating them. So the same content types now have
an additional means of delivery and a different, more robust business model—but the same excep-
tional quality. Print book sales have declined but our journal subscriptions, particularly for review
journals, are rising. We are adapting our strategy, our technology, and our staffing structure to take
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account of this digital evolution. E-books and device apps are being explored. All Press journals
online are now optimized for reading on mobile phones and tablet devices. Although so far, as read-
ers, scientists are not abandoning the familiar and substituting with these new media formats, these
are still early days. More than 6000 people are now following our journals on Twitter, a dramatic
increase in a year. It is an exhilarating time to be engaged in scientific communication and Cold
Spring Harbor Laboratory Press is committed to maintaining its reputation and effectiveness in the
rapidly changing world of digital information.
Staff
During the year, we said farewell to David Crotty, Antonella Caiazza, Victor Manchiso, and Ann
Smith. A particularly notable event in May was the retirement of Bill Keen from his position as 
Finance Director, a position he had occupied with great effectiveness for 10 years. For the previous
30 years, however, Bill had been the Laboratory’s Comptroller, the most senior position in the in-
stitution’s financial management. He served in this role during a period of extraordinary growth in
the size and complexity of the Laboratory, and his calm and good humor in managing CSHL’s in-
ternal affairs as well as its engagement with the wider financial world were much appreciated by
the Laboratory’s leadership and Board of Trustees at the time. Replacing his vital contribution to
the management of the Press was a formidable challenge. However, we were fortunate to be able to
recruit Stephen Nussbaum to join us in April, bringing with him an impressive degree of experience
gained in senior positions in New York publishing, most recently at Oxford University Press. His
credentials also include a CUNY teaching position in accountancy. Steve has quickly become in-
dispensable to our operations. We also welcomed Michael Henigman, Diane Schubach, Richard
Abreu, and Matthew D’Amico. In March, Richard Sever was promoted to assistant director of the
Press, a newly created position in which he will assist in the strategic management of the organization
while continuing his editorial activities for the Perspectives and Protocols journals and the books pro-
gram. Since he joined us 3 years ago, Richard’s energy, productivity, and ideas have helped us make
significant improvements in output and internal efficiency, and it is a pleasure to have his talents
in this expanded role.
A complete list of staff members of the Press at the end of December 2011 is printed elsewhere
in this volume. Publishing is a team-based activity, reliant on the effective meshing of groups of
people with a variety of skills. The Press is fortunate to have able and dedicated individuals in all
its departments. But I am particularly grateful to my hard-working and unfailingly cheerful assistant
Mala Mazzullo and to the talented individuals who have leadership roles in the activities of the
Press: Jan Argentine, Alex Gann, Terri Grodzicker, Wayne Manos, Stephen Nussbaum, Richard
Sever, Marcie Siconolfi, Hillary Sussman, Linda Sussman, and Denise Weiss.
John R. Inglis
Executive Director
and Publisher
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FINANCIAL STATEMENTS
CONSOLIDATED BALANCE SHEET
December 31, 2011
(with comparative financial information as of December 31, 2010)
  2011 2010
Assets:
Cash and cash equivalents $       58,055,329 60,766,362 
Grants receivable 5,733,104 7,725,659 
Contributions receivable, net 163,144,645 104,272,591 
Publications inventory 3,292,898 3,555,193 
Investments 269,786,326 276,424,730 
Restricted use assets 2,882,590 2,580,471 
Other assets 15,027,787 9,922,097 
Land, buildings and equipment, net 241,828,796 238,777,879 
Total assets $     759,751,475 704,024,982 
Liabilities and net assets:
Liabilities:
Accounts payable and accrued expenses $       11,135,584 9,195,850 
Deferred revenue 5,467,566 8,210,668 
Interest rate swap 37,726,697 16,439,159 
Bonds payable 97,200,000 97,200,000 
Total liabilities 151,529,847 131,045,677 
Net assets:
Unrestricted 205,967,407 227,854,292 
Temporarily restricted 298,351,339 242,589,902 
Permanently restricted 103,902,882 102,535,111 
Total net assets 608,221,628 572,979,305 
Total liabilities and net assets $     759,751,475 704,024,982  
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CONSOLIDATED STATEMENT OF ACTIVITIES
Year ended December 31, 2011
(with summarized financial information for the year ended December 31, 2010)
                                                                                                      Temporarily       Permanently              2011                    2010
                                                                        Unrestricted            Restricted          Restricted                Total                     Total
Revenue and other support:
Public support–contributions and 
nonfederal grant awards $      19,694,851 92,621,395  1,367,771 113,684,017 45,420,328 
Federal grant awards 34,490,267 –    –   34,490,267 35,405,944 
Indirect cost allowances 25,623,148 –   –   25,623,148 25,973,354 
Investment return utilized 13,114,916 9,470,558  –   22,585,474 18,309,184 
Program fees 6,963,110 –   –   6,963,110 6,971,358 
Publications sales 9,848,446 –   –   9,848,446 9,251,441 
Dining services 4,309,694 –   –   4,309,694 4,319,847 
Rooms and apartments 3,345,273 –   –   3,345,273 3,556,328 
Miscellaneous 3,745,958 –   –   3,745,958 2,126,513 
Net assets released from restrictions 36,474,563 (36,474,563) –   – –
Total revenue and other support 157,610,226 65,617,390 1,367,771 224,595,387 151,334,297 
Expenses:
Research 91,848,784 – – 91,848,784 86,810,119 
Educational programs 16,117,941 – – 16,117,941 17,121,875 
Publications 9,323,927 – – 9,323,927 10,877,055 
Banbury Center conferences 1,409,384 – – 1,409,384 1,370,778 
DNA Learning Center programs 1,857,078 – – 1,857,078 1,406,339 
Watson School of Biological Sciences 
programs 3,584,716 – – 3,584,716 3,535,758 
General and administrative 115,596,163 – – 15,596,163 14,746,870 
Dining services 5,717,278 – – 5,717,278 5,137,648 
Total expenses 145,455,271 – – 145,455,271 141,006,442 
Excess of revenue and other support over
expenses 12,154,955 65,617,390 1,367,771 79,140,116 10,327,855 
Other changes in net assets:
Investment (loss) return excluding 
amount utilized (12,754,302) (9,855,953) – (22,610,255) 8,599,598 
Change in fair value of interest rate swap (21,287,538) – – (21,287,538) (4,990,800)
(Decrease) increase in net assets (21,886,885) 55,761,437 1,367,771 35,242,323 13,936,653 
Net assets at beginning of year 227,854,292 242,589,902 102,535,111 572,979,305 559,042,652 
Net assets at end of year $    205,967,407 298,351,339 103,902,882 608,221,628 572,979,305 
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CONSOLIDATED STATEMENT OF CASH FLOWS
Year ended December 31, 2011
(with comparative financial information for the year ended December 31, 2010)
     2011 2010
Cash flows from operating activities:
Increase in net assets $     35,242,324   13,936,653  
Adjustments to reconcile increase in net assets
to net cash (used in) provided by operating activities:
Change in fair value of interest rate swap 21,287,538 4,990,800
Depreciation and amortization 14,697,263 15,443,523 
Net depreciation (appreciation) in fair value of investments 4,173,189 (23,724,939)
Contributions restricted for long-term investment (13,475,213) (1,712,498)
Changes in assets and liabilities:
Grants receivable 1,992,555 (1,525,261)
Contributions receivable, net of financing activities (53,517,765)  11,309,672
Publications inventory 262,295 1,015,085
Other assets (5,008,296) 929,237
Restricted use assets (302,119) (469,381) 
Accounts payable and accrued expenses, net of financing activities 1,835,064 (2,521,650) 
Deferred revenue (2,743,102) 2,570,639 
Net cash provided by operating activities (4,443,733) 20,241,880 
Cash flows from investing activities:
Capital expenditures (17,748,180) (16,429,996)
Proceeds from sales and maturities of investments 33,325,960 36,404,485 
Purchases of investments (30,860,745) (47,508,712)
Net change in investment in employee residences (97,394) (453,121) 
Net cash used in investing activities (15,380,359) (27,987,344)
Cash flows from financing activities:
Contributions restricted for long-term investment 1,600,563 1,109,499 
Contributions restricted for investment in capital 11,874,650 602,999 
(Increase) decrease in contributions receivable (5,354,289) 4,157,922 
Increase (decrease) in accounts payable relating to capital
expenditures 104,669 (3,309,152) 
Net cash provided by financing activities 8,225,593 2,561,268 
Net decrease in cash and cash equivalents (2,711,033) (5,184,196)
Cash and cash equivalents at beginning of year 60,766,362 65,950,558 
Cash and cash equivalents at end of year $     58,055,329   60,766,362 
Supplemental disclosure:
Interest paid $       3,614,370     3,652,690 
Noncash investing and financing activity:
Contributed property $       1,095,000         57,475 
FINANCIAL SUPPORT OF THE LABORATORY
Cold Spring Harbor Laboratory, Banbury Center, and the DNA Learning Center receive a substantial
portion of their funding through grants from the federal government and through grants, capital
gifts, and annual contributions from New York State, private foundations, corporations, and indi-
viduals. The following section summarizes funding that occurred during 2011.
GRANTS January 1–December 31, 2011
COLD SPRING HARBOR LABORATORY
Grantor Program/Principal Investigator Duration of Grant 2011 Funding1
FEDERAL GRANTS
NATIONAL INSTITUTES OF HEALTH
Program Project and Center Support Drs. Hannon/Krainer/Lowe/Spector/Stillman 01/01/07 12/31/12 $   4,592,515  
Dr. Stillman–Cancer Center Core 08/17/11 07/31/16 4,306,037 * 
Cooperative Research Agreement Support2 Drs. Gingeras/Hannon 09/27/07 06/30/12 2,037,906 
Drs. Lowe/Hannon/Hicks/Powers 09/01/09 08/31/14 841,281  
Research Support Dr. Churchland 09/01/10 08/31/13 249,801 
Dr. Dubnau  09/15/09 08/31/14 430,650 
Drs. Enikolopov/Koulakov 09/15/11 08/31/16 437,918 * 
Dr. Furukawa 03/01/10 02/28/15 430,650 
Dr. Hannon  09/01/09 08/31/13 349,602 
Dr. Huang   07/01/11 03/31/16 556,080 * 
Dr. Joshua-Tor 07/01/07 06/30/12 304,484 
Drs. Kepecs/Huang  07/01/11 05/31/16 388,063 * 
Dr. Koulakov 02/01/08 01/31/13 413,424 
Drs. Koulakov/Enikolopov 07/15/10 02/28/14 334,485 
Dr. Li      07/01/10 03/31/15 518,880 
Dr. Martienssen 09/15/11 08/30/15 354,798 * 
Dr. McCombie 07/23/10 02/28/15 1,039,526 
Dr. Mills   12/26/07 11/30/12 351,641 
Dr. Mitra   08/01/10 05/31/13 376,587 
Drs. Mitra/Osten 09/30/09 03/31/14 914,483 
Dr. Muthuswamy 02/01/09 12/31/13 377,711 
Dr. Powers 12/02/06 11/30/12 19,310 
Dr. D. Spector 04/01/11 03/31/15 687,053 * 
Dr. Stenlund 02/01/08 01/31/13 426,344 
Dr. Stillman 06/01/08 05/31/12 638,144 
Dr. Tonks   07/01/10 04/30/15 687,770 
Dr. Tonks   01/11/10 12/31/13 404,432 
Dr. Trotman 04/01/10 01/31/14 240,475 
Dr. Turner  07/15/10 06/30/15 421,080 
Dr. Van Aelst 07/01/08 03/31/13 387,585 
Dr. Van Aelst 01/01/09 12/31/13 350,219 
Dr. Zador 09/18/09 07/31/13 354,339 
Dr. Zador 09/27/10 05/31/15 430,650 
Dr. Zhong 06/01/10 05/31/13 341,040 
1Includes direct and indirect costs
2Cooperative research agreement funding amounts include only CSHL portion of award
*New or competing renewal grants awarded in 2011
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Grantor Program/Principal Investigator Duration of Grant 2011 Funding1
Research Subcontracts
NIH/Allen Institute for Brain Science Dr. Mitra 09/15/09 08/31/13 $      244,200 
Consortium Agreement
NIH/Carnegie Mellon University Dr. Osten 09/15/10 07/31/13 113,100
Consortium Agreement 
NIH/Cornell University Dr. Mitra 04/03/08 01/31/12 20,235 
Consortium Agreement
NIH/Georgia Institute of Technology Dr. D. Spector 09/30/06 07/31/15 292,219 
Consortium Agreement 
NIH/University of California, Berkeley Dr. Gingeras 05/01/07 03/31/12 205,801 
National Laboratory Consortium 
Agreement
NIH/University of California, San Dr. Egeblad 09/01/09 08/31/14 182,652 
Francisco Consortium Agreement
NIH/University of Southern California Dr. Hannon 07/01/10 06/30/14 117,450 
Consortium Agreement
NIH/University of Texas Consortium Dr. Furukawa 09/30/11 05/31/15 51,819 *
Agreement 
NIH/University of Texas Consortium Dr. Krainer 08/01/10 07/31/12 78,839 
Agreement
Fellowship Support Dr. Borges 08/16/09 08/15/12 54,734 
Dr. Ipsaro 09/01/11 08/31/13 48,398 * 
Dr. Jansen 01/01/11 12/31/13 48,398 * 
Institutional Training Program Support Dr. Joshua-Tor, Watson School of Biological 07/01/07 06/30/12 251,640 
Sciences, Predoctoral
Dr. Mills, Postdoctoral 09/01/11 08/31/16 175,032 * 
Course Support Advanced Immunocytochemistry: In Situ 
Hybridization and Live Cell Imaging 09/01/10 08/31/15 100,166 
Advanced Techniques in Molecular Neuroscience 07/01/01 06/30/12 81,866 
Cell and Developmental Biology of Xenopus 04/01/09 03/31/14 56,335 
Cellular Biology of Addiction 03/01/11 02/29/16 79,300 * 
Computational and Comparative Genomics 06/06/91 07/31/13 51,792 
Imaging Structure and Function in the Nervous 07/01/01 06/30/12 77,520 
System
Integrated Data Analysis for High Throughput 09/01/07 04/30/12 81,564 
Biology
Neurobiology of Drosophila 07/01/01 06/30/12 61,508 
Programming for Biology 09/01/09 08/31/14 63,654 
X-Ray Methods in Structural Biology 07/01/07 06/30/12 77,830 
Yeast Genetics and Genomics 09/18/10 06/30/13 53,462 
Meeting Support The Biology of Cancer: Microenvironment, 04/01/11 03/31/12 3,000 *
Metastasis and Therapeutics  
The Biology of Genomes 04/01/08 03/31/13 39,339 
Cell Death 09/14/07 08/31/12 4,000 
Eukaryotic DNA Replication and Genome 09/01/11 08/31/12 6,500 *
Maintenance
Eukaryotic mRNA Processing 06/03/11 05/31/12 4,000 * 
Genome Informatics 08/08/11 07/31/12 30,990 * 
Harnessing Immunity to Prevent and Treat 11/04/11 10/31/12 10,000 *
Disease 
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Grantor Program/Principal Investigator Duration of Grant 2011 Funding1
Metabolism and Disease 05/30/11 04/30/12 $        28,000 * 
Microbial Pathogenesis and Host Response 08/15/11 07/31/12 15,000 * 
Network Biology 04/21/09 02/28/14 5,000 
Neurobiology of Drosophila 09/01/11 08/31/12 15,000 * 
PTEN Pathways and Targets 09/30/11 08/31/12 7,500 * 
Retroviruses 04/15/11 03/31/12 15,000 * 
Synapses: From Molecules to Circuits 04/01/11 01/31/16 20,000 *
and Behavior
The Ubiquitin Family 04/11/07 03/31/12 4,500 
Yeast Cell Biology 06/01/11 05/31/16 5,000 * 
NATIONAL SCIENCE FOUNDATION
Multiple Project Award Support Dr. Jackson 10/01/10 09/30/15 1,071,458 
Drs. McCombie/Martienssen/Ware 08/01/10 07/31/12 999,985 
Research Support Dr. Churchland 08/01/11 07/31/14 43,155 * 
Dr. Jackson 09/01/10 08/31/13 150,000 
Dr. Lippman 09/15/09 08/31/12 172,910 
Dr. Timmermans 08/15/10 07/31/13 150,000 
Research Subcontracts
NSF/Cornell University Consortium Dr. Timmermans 09/01/08 08/31/12 413,998 
Agreement
NSF/North Carolina State University Dr. Martienssen 03/01/11 02/29/16 491,432 * 
Consortium Agreement
NSF/New York University Consortium Drs. McCombie/Martienssen 08/01/10 07/31/14 396,042 
Agreement
NSF/University of Arizona Consortium Dr. Ware 08/15/10 07/31/14 605,604 
Agreement
NSF/University of Arizona Consortium Drs. Ware/Martienssen/Stein 02/01/08 01/31/13 1,774,355 
Agreement 
Facility Upgrade and Renovation Drs. Martienssen Jackson/Lippman/ 10/01/10 09/30/12 497,423 3
Timmermans/Ware
Fellowship Support Dr. Liberatore 06/01/10 05/31/13 40,500 
Undergraduate Training Support Dr. Lippman 03/01/09 02/29/12 72,197 
Course Support Advanced Bacterial Genetics 07/01/09 06/30/14 93,258  
Computational Cell Biology 08/15/11 07/31/12 60,000 *
Frontiers and Techniques in Plant Science 07/01/11 06/30/12 57,000 * 
Meeting Support Computational Cell Biology 03/15/11 02/29/12 20,950 * 
Eukaryotic DNA Replication and Genome 08/01/11 07/31/12 7,000 *
Maintenance 
Eukaryotic mRNA Processing 08/01/11 07/31/12 7,000 * 
The Future of Plant Genome Sequencing 05/01/11 04/30/12 48,840 *
and Analysis
Mechanisms of Eukaryotic Transcription 08/01/11 07/31/12 7,000 * 
Neurobiology of Drosophila 08/15/11 07/31/12 21,220 * 
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Grantor Program/Principal Investigator Duration of Grant 2011 Funding1
Meeting Support (continued) Plant Biology Conference 09/15/11 08/31/12 $        30,000 * 
Yeast Cell Biology 08/01/11 07/31/12 10,528 *
Meeting Subcontracts
NSF/University of Illinois Honey Bee Genomics and Biology 04/01/11 03/31/12 25,000 * 
UNITED STATES DEPARTMENT OF AGRICULTURE
Research Support Dr. Jackson 01/15/11 01/14/15 119,117 * 
Dr. McCombie 09/11/09 09/10/14 268,198 
UNITED STATES DEPARTMENT OF ENERGY
Research Support Dr. Martienssen 09/03/10 09/02/12 797,433 
Research Subcontracts
DOE/Brookhaven National Laboratory Drs. Ware/Schatz 11/29/11 09/30/16 1,050,000 *
UNITED STATES DEPARTMENT OF THE ARMY
Research Support Dr. Hannon 09/01/08 08/31/13 687,346 
Dr. Trotman 08/15/09 08/14/12 88,546 
Drs. Wigler/Hicks/Krasnitz 09/01/11 08/31/12 2,140,000 * 
Dr. Zhong 06/15/10 06/14/13 293,951 
Fellowship Support Dr. Nakasone 01/01/11 12/31/13 43,200 * 
Dr. B. Zhang 03/15/10 03/14/12 62,428 
MISCELLANEOUS SOURCES OF FUNDING
Equipment
The Mary K. Chapman Foundation Dr. McCombie 12/31/10 12/31/11 250,000 * 
Dr. Stillman 12/22/11 12/21/12 450,000 * 
Alan Seligson Dr. Wigler 06/01/11 05/31/12 100,000 * 
Theodore R. and Vada S. Stanley Drs. Watson/McCombie 06/01/11 05/31/14 5,000,000 *
Program Project Support
Pioneer Hi-Bred International, Inc. Drs. Jackson/Lippman/Martienssen/ 07/01/07 06/30/12 1,600,000
Timmermans/Ware
Pfizer Inc. Dr. Stillman 12/31/11 12/31/13 1,600,000 * 
Theodore R. and Vada S. Stanley Drs. Watson/McCombie 07/01/07 06/30/12 5,000,000 
The Simons Foundation/Center Dr. Wigler 09/01/08 08/31/15 1,500,000
for Quantitative Biology
Research Support
Paul G. Allen Family Foundation Dr. Zador 10/01/10 09/30/13 564,900 
Alzheimer’s Association Dr. Furukawa 03/01/10 02/28/12 30,031 
American Cancer Society Dr. Wigler  01/01/11 12/31/11 10,000 * 
Dr. Wigler  01/01/11 08/31/12 70,000 * 
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The A&P Foundation Dr. Egeblad 06/01/11 05/31/12 $        20,000 * 
Babylon Breast Cancer Coalition Inc. Dr. Egeblad 12/30/11 12/29/12 7,100 * 
Breast Cancer Alliance Dr. Egeblad 01/01/10 12/31/11 62,500 
The Breast Cancer Research Foundation Dr. Wigler  10/01/11 09/30/12 225,000 * 
Burroughs Wellcome Fund Dr. Vakoc   09/01/11 08/31/16 95,000 * 
Carnegie Mellon University/Anonymous Dr. Osten   01/01/10 11/30/11 75,000 
The Mary K. Chapman Foundation Dr. Osten   12/31/11 12/30/13 300,000 * 
Mr. and Mrs. Edward Chernoff in Dr. Furukawa 08/15/10 08/14/11 500 
memory of James J. Kehoe
Clear Channel Worldwide (Walk 97.5) Dr. Egeblad 06/01/11 05/31/12 4,500 * 
The Dana Foundation Dr. Li      01/01/09 12/31/11 200,000 
Dr. Li      10/01/09 09/30/12 69,156 
Dart Neuroscience LLC Dr. Dubnau  10/01/11 09/30/12 250,000 * 
The Kathryn W. Davis Foundation Dr. Hannon  01/15/07 01/14/12 986,640 
The Ellison Medical Foundation Dr. Enikolopov 09/09/09 09/08/13 252,000 
Entertainment Industry Foundation Dr. Hannon  11/01/11 10/31/12 250,000 * 
The Eppley Foundation for Research, Inc. Dr. Shea    07/01/11 06/30/12 50,000 * 
Edward P. Evans Foundation Dr. Vakoc   11/01/11 10/31/12 500,000 * 
Charitable Lead Annuity Trust under Dr. Osten 12/29/10 11/30/12 225,000 
the Will of Louis Feil  
Find a Cure Today Long Island Dr. Egeblad 03/01/11 02/29/12 10,000 *
Foundation 
Douglas and Christine Fox Dr. Zhong   12/15/11 12/14/12 1,000 * 
The Joni Gladowsky Breast Cancer Dr. Tonks   10/01/11 09/30/12 35,000 *
Foundation 
Glen Cove C.A.R.E.S., Inc. Dr. Egeblad 02/01/11 01/31/12 10,000 * 
Dr. Sordella 02/01/11 01/31/12 10,000 * 
Good Samaritan, Inc. Dr. Li      06/01/11 05/31/12 75,000 * 
Richard and Mindy Gordon Dr. Egeblad 01/01/11 12/31/11 1,000 * 
The Irving A. Hansen Memorial Dr. Tonks   07/01/11 06/30/12 20,000 *
Foundation 
Jo-Ellen and Ira Hazan Dr. Osten   12/01/11 11/30/12 200,000 * 
Hearts for Cancer Dr. Egeblad 04/01/11 03/31/12 8,473 * 
Howard Hughes Medical Institute– Dr. Martienssen 12/01/11 11/30/16 333,333 *
Gordon and Betty Moore Foundation
The International Human Frontier Dr. Lippman 07/01/09 06/30/12 100,000 
Science Program
Isis Pharmaceuticals, Inc. Dr. Krainer 11/01/11 10/26/13 150,000 * 
Dr. Krainer 06/15/11 06/14/12 50,000  * 
Islip Breast Cancer Coalition Inc. Dr. Tonks   11/15/11 11/14/12 10,000 * 
Sidney Kimmel Foundation for Cancer
Research Dr. Zheng   07/01/11 06/30/13 100,000 * 
F.M. Kirby Foundation, Inc. Dr. Vakoc   09/15/11 09/14/12 100,000 * 
The Susan G. Komen Breast Cancer Dr. Egeblad 04/13/10 04/12/13 150,000 
Foundation, Inc.
Lake Grove Triangle Soccer, Inc. Dr. Vakoc   06/01/11 05/31/12 3,000 * 
The George Link, Jr. Foundation, Inc. Dr. Sordella 12/01/11 11/30/12 50,000 * 
The Long Island 2-Day Walk to Fight Dr. Egeblad 08/15/11 08/14/12 28,000 *
Breast Cancer
The Lustgarten Foundation Drs. Hannon/Lowe 01/01/10 12/31/12 1,042,732 
Drs. Powers/Lowe/Van Aelst 02/01/10 01/31/12 467,921 
The Manhasset Women’s Coalition Dr. Egeblad 01/01/11 12/31/11 100,000 *
Against Breast Cancer, Inc. Dr. Egeblad 07/19/11 07/18/12 1,000 *
Carol Marcincuk Fund Dr. Tonks   01/01/11 12/31/11 7,380 *
In honor of Carissa Maringo Dr. Egeblad 10/01/11 09/30/12 5,000 * 
Financial Support of the Laboratory      481
1Includes direct and indirect costs
*New or competing renewal grants awarded in 2011
Grantor Program/Principal Investigator Duration of Grant 2011 Funding1
Research Support (continued)
The G. Harold and Leila Y. Mathers Dr. Mitra   09/01/10 08/31/13 $       03,919 
Charitable Foundation
Breast Cancer Awareness Day in memory Dr. Wigler  01/01/11 12/31/11 72,305 *
of Elizabeth McFarland
The John Merck Fund Dr. Kepecs  06/01/10 05/31/14 75,000 
Dr. Churchland 06/01/11 05/31/15 75,000 * 
The Melanoma Research Alliance Drs. Hannon/Hammell/Vakoc 08/01/11 07/31/14 200,000 * 
Mirus Bio LLC Dr. Furukawa 10/18/11 10/17/12 5,000 * 
The Don Monti Memorial Research Dr. Lowe 03/01/11 02/29/12 400,000 *
Foundation
Louis Morin Charitable Trust Dr. Joshua-Tor 12/01/11 11/30/12 60,000 * 
MSC Biotarget LLC Dr. Tonks   11/01/09 10/31/11 60,000 
NARSAD    Dr. Li      07/15/11 07/14/13 30,000 * 
Dr. Huang   10/15/11 10/14/12 100,000 * 
New York State Department of Health– Drs. Enikolopov/Koulakov 01/01/09 12/31/11 360,000 
New York Stem Cell Science 
(NYSTEM)
Panera Bread/Doherty Breads, LLC Dr. Egeblad 12/01/11 11/30/12 7,600 * 
The Perkin Fund Dr. Egeblad 01/01/11 12/31/11 75,000 * 
The Pew Charitable Trusts Dr. Hannon  01/01/11 12/31/15 348,074 * 
V. Kann Rasmussen Foundation Dr. Trotman 09/01/07 08/31/12 50,000 
Christina Renna Foundation Inc. Dr. Van Aelst  01/01/11 12/31/11 15,000 * 
Damon Runyon Cancer Research Dr. Sordella 01/01/10 12/31/12 150,000 
Foundation
Diane Emdin Sachs Memorial Fund Dr. Sordella 09/01/11 08/31/12 8,949 * 
Eleanor Schwartz Charitable Foundation Dr. Churchland 07/15/11 07/14/14 200,000 * 
Judi Shesh Memorial Foundation Dr. Egeblad 09/01/11 08/31/12 5,000 * 
Dr. Tonks   09/01/11 08/31/12 5,000 * 
The Simons Foundation Dr. Henn    09/01/10 08/31/12 305,791 
Dr. Henn    09/01/10 08/31/12 602,811 
Dr. Mills   07/01/10 06/30/13 350,000 
Drs. Mitra/Huang/Osten 12/01/11 11/30/14 300,000 * 
Dr. Osten   10/01/11 09/30/13 175,000 * 
Spinal Muscular Atrophy Foundation Dr. Krainer 09/01/11 08/31/12 100,000 * 
Mary F. Smith Family Foundation Dr. Egeblad 12/01/11 11/30/12 5,000 * 
Starr Cancer Consortium Dr. Hannon  08/01/11 07/31/13 216,000 * 
Dr. Hannon  08/01/11 07/31/13 270,000 * 
Drs. Hicks/Wigler 08/01/11 07/31/13 270,000 * 
Drs. Sordella/Pappin 08/01/11 07/31/13 249,301 * 
Drs. Sordella/Van Aelst 08/01/10 07/31/12 669,422 
Dr. Sordella 08/01/11 07/31/13 216,000 * 
Dr. Vakoc   08/01/10 07/31/12 83,750 
Dr. Vakoc   08/01/11 07/31/13 180,000 * 
Swim Across America Dr. Sordella 12/15/11 12/14/14 75,000 * 
U.S.–Israel Binational Agricultural Dr. Krainer 10/01/10 09/30/14 10,000 
Research and Development Fund Dr. Lippman 06/01/10 05/31/13 42,000 
Dr. Zador   10/01/10 09/30/14 13,000 
University Health Network Dr. Muthuswamy 01/01/11 12/31/11 50,000 * 
University of  California, Los Angeles/ Dr. Hannon  10/01/09 09/30/12 414,284 
Entertainment Industry Foundation
The V Foundation Dr. Zheng   11/01/11 10/31/13 100,000 * 
West Islip Breast Cancer Coalition for Dr. Egeblad 11/01/11 10/31/12 10,000 *
Long Island Inc.        
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Whitehall Foundation, Inc.  Dr. Shea    09/01/11 08/31/14 $       75,000 * 
Wild for Zumba Dr. Egeblad 12/01/11 11/30/12 1,013 * 
Ms. Evelyn W. Willard Dr. Churchland 12/21/10 12/20/11 50,000 
The Bradley Zankel Foundation, Inc. Dr. Zheng   07/16/11 07/15/12 15,000 * 
Fellowship Support
American Cancer Society Dr. Feigin 01/01/11 12/31/12 50,000 * 
Dr. Preall 10/01/11 09/30/14 48,000 * 
Australian Government National Health Dr. Bolden 04/01/10 03/31/12 39,155 
and Medical Research Council Dr. Dow 02/01/10 01/31/11 13,640 
Carnegie Institution for Science Dr. Timmermans 08/01/11 07/31/12 27,000 * 
The Jane Coffin Childs Memorial Fund 
for Medical Research Dr. Kuhn 03/29/10 01/31/12 50,500 
CSHL Association Fellowship New Investigator Support 01/01/11 12/31/11 280,000 * 
Fundacion Rafael del Pino (Spain) Dr. Fernandez-Marco 01/01/11 12/31/11 50,000 * 
German Academic Exchange Service Dr. Bergmann 09/01/11 08/31/12 14,900 * 
Genentech Foundation Dr. Joshua-Tor, Watson School of Biological 07/01/09 06/30/12 59,384 
Sciences
The Fred C. Gloeckner Foundation, Inc. J. Calarco 08/01/10 07/31/12 8,100 
Lola Goldring Dr. Stillman 09/01/11 08/31/12 75,000 * 
Lita Annenberg Hazen Foundation Watson School of Biological Sciences 05/01/08 04/30/18 10,000 
Human Frontier Science Program Dr. Canela 05/01/09 04/30/12 53,940 
Dr. Kvitsiani 09/01/08 02/29/12 5,320 
Dr. Skopelitis 04/01/09 03/31/12 53,640 
International Rett Syndrome Foundation Dr. K. Krishnan 10/01/10 09/30/12 50,000 
Annette Kade Charitable Trust Watson School of Biological Sciences 09/01/11 08/31/12 25,000 * 
The Esther A. & Joseph Klingenstein Dr. Shea 07/01/10 06/30/13 50,000 
Fund Inc. Dr. Kepecs 07/01/09 06/30/12 50,000 
Susan G. Komen for the Cure Dr. Anczukow 06/04/09 06/03/12 60,000 
Life Sciences Research Foundation Dr. MacAlister 08/01/11 07/31/14 56,000 * 
Topspin Partners Dr. Premsrirut 01/16/11 02/16/11 41,744 * 
NARSAD Dr. Karakas 01/01/10 12/31/11 30,000 
Dr. Taniguchi 01/01/10 12/31/11 30,000 
Dr. Mirrione 07/15/11 07/14/13 30,000 * 
National Cancer Center Dr. Mao 07/01/10 06/30/12 14,000 
Mr. and Mrs. John C. Phelan Watson School of Biological Sciences 09/01/10 08/31/15 100,000 
Marie Robertson Memorial Fund CSHL Neuroscience Program Support 01/01/11 12/31/11 137,500 * 
Sass Foundation for Medical Research Inc. Dr. Vakoc 11/01/10 10/31/12 161,248 
Lauri Strauss Leukemia Foundation Dr. Vernersson Lindahl 09/01/11 08/31/12 10,000 * 
The Swartz Foundation Dr. Zador 01/01/11 12/31/11 7,500 * 
Drs. Kepecs/Hangya 01/01/11 12/31/11 55,000 * 
Drs. Koulakov/Wei 01/01/11 12/31/11 55,000 * 
Dr. Zador 01/01/11 12/31/11 75,000 * 
U.S.–Israel Binational Agricultural Dr. Galon-Wolfenson 10/01/11 09/30/12 45,000 *
Research and Development Fund
Training Support
Research Foundation of the City Undergraduate Research Program 06/01/11 05/31/12 23,000 * 
University of New York
Steamboat Foundation Undergraduate Research Program 05/01/11 04/30/12 12,000 *
William Townsend Porter Foundation Undergraduate Research Program 04/01/11 03/31/12 12,000 * 
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Course Support
American Express Foundation Leadership in Bioscience 11/01/11 10/31/14 $     75,000 * 
Applied Biosystems Advanced Sequencing Technologies and 07/01/10 06/30/12 30,000 
Applications
Coherent Imaging Structure & Function in the Nervous 04/01/11 03/31/12 2,500 *
System
Howard Hughes Medical Institute Course Support 01/01/07 12/31/11 675,000 
Illumina, Inc. Advanced Sequencing Technologies and 07/01/10 06/30/12 30,000 
Applications
Society for Neuroscience/International Summer Neuroscience Course 07/01/11 06/30/12 16,500 *
Brain Research Organization
Meeting Support
Amgen USA 76th CSHL Symposium: Metabolism and Disease 02/01/11 01/31/12 2,000 * 
Applied Biosystems Single Cell Analysis 04/01/11 03/31/12 5,000 * 
Boston Biochem The Ubiquitin Family 02/01/11 01/31/12 1,000 * 
Bruker AXS Inc. Protein Data Bank 40th Anniversary 12/01/10 11/30/11 1,000 
Bruker Biospin Corporation Protein Data Bank 40th Anniversary 12/01/10 11/30/11 1,000 
Cambridge Isotope Laboratories, Inc. Protein Data Bank 40th Anniversary 12/01/10 11/30/11 1,000 
Chemical Computing Group Inc. Protein Data Bank 40th Anniversary 12/01/10 11/30/11 1,000 
Enzo Life Sciences, Inc. The Ubiquitin Family 02/01/11 01/31/12 2,000 * 
Genentech Inc. The Ubiquitin Family 02/01/11 01/31/12 4,000 * 
Howard Hughes Medical Institute Viruses and Oncogenes: Celebrating Stephen Goff 10/01/11 09/30/12 5,600 * 
Illumina, Inc. Single Cell Analysis 04/01/11 03/31/12 3,900 * 
The March of Dimes Foundation Germ Cells 10/01/10 03/31/11 5,000 
Millennium Pharmaceuticals, Inc. The Ubiquitin Family 06/01/11 05/31/12 10,000 * 
Novartis Pharmaceuticals Corp. The Ubiquitin Family 02/01/11 01/31/12 2,500 * 
OSI Pharmaceuticals, Inc. The Biology of Cancer: Microenvironment, 
Metastasis, and Therapeutics 02/01/11 01/31/12 25,000 * 
Peptide Institute, Inc. Protein Data Bank 40th Anniversary 12/01/10 11/30/11 5,000 
Progenics Pharmaceuticals, Inc. Viruses and Oncogenes: Celebrating Stephen Goff 10/01/11 09/30/12 1,000 * 
Rayonix, L.L.C. Protein Data Bank 40th Anniversary 12/01/10 11/30/11 500 
Rigaku Americas Corporation Protein Data Bank 40th Anniversary 12/01/10 11/30/11 1,000 
Seattle Biomedical Research Institute Protein Data Bank 40th Anniversary 12/01/10 11/30/11 1,000 
SGI Japan, LTD Protein Data Bank 40th Anniversary 12/01/10 11/30/11 3,500 
Toray Industries, Inc. Protein Data Bank 40th Anniversary 12/01/10 11/30/11 2,000 
University of Pennsylvania Single Cell Analysis 04/01/11 03/31/12 5,000 * 
Library Support
The Ellen Brenner Memorial Fund 12/15/11 12/14/12 2,000 * 
National Endowment for the Humanities 02/01/11 07/31/12 6,000 * 
National Historical Publications and 08/01/11 10/31/12 66,361 *
Records Commission
New York State Education Department 07/01/10 06/30/11 3,701 
Wellcome Trust 08/01/11 07/31/13 298,008 * 
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Bay Shore Union Free School District $ 4,800
Bellmore Union Free School District 1,500
Bellmore−Merrick Central High School District 23,800
Bethpage Union Free School District 1,600
East Meadow Union Free School District 4,550
East Williston Union Free School District 2,800
Elwood Union Free School District 3,950
Floral Park−Bellerose Union Free School District 6,500
Friends Academy, Locust Valley 2,800
Garden City Union Free School District 14,975
Half Hollow Hills Central School District 9,150
Hebrew Academy of Five Towns 1,200
Herricks Union Free School District 4,050
Hofstra STEP Program, Hofstra University 1,800
Huntington Union Free School District 4,650
Island Park Union Free School District 2,200
Jericho Union Free School District 8,125
Laurel Hill School, St. James $ 1,200
Lawrence Union Free School District 6,700
Locust Valley Central School District 8,309
Merrick Union Free School District 5,600
MS 447−The Math and Science Exploratory School, NYC 1,500
North Bellmore Union Free School District 1,450
Oceanside Union Free School District 1,500
Rockville Centre Union Free School District 5,400
Smithtown Central School District 1,400
St. Dominic Elementary School, Oyster Bay 4,050
St. Edward the Confessor School, Syosset 2,025
St. Patrick School, Huntington 1,350
Syosset Central School District 32,800
Three Village Central School District 6,000
Trinity Regional School, Northport 1,100
Valley Stream 13 Union Free School District 1,350
Yeshiva Darchei Torah School, Far Rockaway 1,920
The following schools and school districts each contributed $1000 or more for participation in the Genetics as a Model for Whole Learning Program:
North Shore Central School District $ 3,000
North Shore Hebrew Academy High School 1,500
Oceanside Union Free School District 1,500
Oyster Bay−East Norwich Central School District 1,500
Plainedge Union Free School District 1,500
Plainview−Old Bethpage Central School District 1,500
Portledge School 1,500
Port Washington Union Free School District 1,500
Ramaz Upper School 3,000
Roslyn Union Free School District 1,500
Sachem Central School District 1,500
South Huntington Union Free School District 1,500
Syosset Central School District 1,500
West Hempstead Union Free School District 1,500
DNA LEARNING CENTER GRANTS
Duration 2011 
Grantor Program of Grant Funding†
FEDERAL GRANTS
National Institutes of Health Science Education Partnership Award (SEPA): Nationwide 8/08–7/11 $   37,060
Dissemination of Inside Cancer Internet Site
National Science Foundation Course, Curriculum, and Laboratory Instruction (CCLI) Program: 9/07–8/11 44,882
Nationwide Dissemination of RNAi Curriculum
National Science Foundation, Educational Outreach for iPlant: A Cyberinfrastructure for 2/08–1/13 783,255
University of Arizona Plant Sciences
National Science Foundation, Weed to Wonder Internet Site Development: Educational Outreach 9/08–8/11 51,818
Cornell University for Functional Genomics of the Maize Shoot Apical Meristem
National Science Foundation, GEPR: Epigenome Dynamics During DNA Replication 3/11–2/13 68,700
North Carolina State University
National Science Foundation Advanced Technology Education (ATE) Program: Genomic 4/11–3/14 173,883
Approaches in Biosciences
NONFEDERAL GRANTS
Victor Centers for Prevention of Gene Screen iPhone/iPad Application 12/10–12/12 39,150
Jewish Genetic Diseases, Albert
Einstein Healthcare Center/
Marcus Jewish Genetic Disease 
Consortium
Alfred P. Sloan Foundation DNA Barcoding Experiments by New York City High School 1/11–7/12 225,466
Students (Urban Barcode Project)
Hewlett Foundation Genes to Cognition Online Internet Site: Dissemination and Evaluation 10/08–4/11 41,756
Howard Hughes Medical Pre-College Science Education Initiative: NYC Teacher Professional 9/07–8/12 138,875
Institute Development
Dana Foundation Harlem DNA Lab Operating Support 3/09–2/12 124,666
Lounsbery Foundation Biotechnology Footlocker Program at Harlem DNA Lab 11/09–10/11 1,537
William Townsend Porter Scholarships for Minority and Underserved Students at Harlem 3/10–3/11 17,000
Foundation DNA Lab
Bank of America Scholarships for Minority and Underserved Students on Long Island 2011 25,000
National Grid Foundation Scholarships for Minority and Underserved Students in the Brentwood 10/10–10/11 15,000
Union Free School District
Spinal Muscular Atrophy Learn About SMA Internet site 4/11–4/13 131,000
Foundation
Bellmore−Merrick Central High School District $ 1,500
East Meadow Union Free School District 1,500
Elwood Union Free School District 1,500
Garden City Union Free School District 3,000
Green Vale School 1,500
Harborfields Central School District 1,500
Herricks Union Free School District 1,500
Huntington Union Free School District 3,000
Island Trees Union Free School District 1,500
Jericho Union Free School District 3,000
Levittown Union Free School District 1,500
Long Beach City School District 1,500
Manhasset Union Free School District 3,500
Massapequa Union Free School District 1,500
Northport−East Northport Union Free School District 2,000
The following schools and school districts each contributed $1000 or more for participation in the Curriculum Study Program:
†Includes direct and indirect costs
BANBURY CENTER GRANTS
Duration 2011 
Grantor Program of Grant Funding
FEDERAL SUPPORT
Defense Threat Reduction Agency Scientific and Technological Barriers to Global 2011 $ 34,929
Department of Defense Real-Time Risk Assessment of Vector-Borne
Infections
NIH−National Institute of The 3rd Annual NIMH-Sponsored Brain Camp 2011 41,325
Mental Health
National Science Foundation The Future of Plant Genome Sequencing and 2011 34,196
Analysis
NONFEDERAL SUPPORT
Boehringer Ingelheim Fonds Science: Get it across! 2011 65,472
CFIDS Association Strategic Research Initiative for CFS 2011 33,397
Cold Spring Harbor Laboratory Genotype to Phenotype: Deriving Biological 2011 42,051
Corporate Sponsor Program Knowledge from Large Genomic Datasets
Cold Spring Harbor Laboratory Transmissible Amyloidoses 2011 41,078
Corporate Sponsor Program 
Cold Spring Harbor Laboratory Myc and the Pathway to Cancer 2011 45,337
Corporate Sponsor Program
Cold Spring Harbor Laboratory− Dosage, Epigenetics, and the Biology of 2011 51,155
Pioneer/DuPont Collaborative Hybridization and Hybrids
Research Program
Epigenomics of Plants Board Meeting 2011 17,384
International Consortium
FEBS Journal FEBS Journal Editorial Board Meeting 2011 10,020
The Gatsby Charitable Foundation Neuronal Response Variability and Cortical 2011 15,000
Computation
Hazen Polsky Foundation Curing Melanoma and Other Cancers by 2011 50,000
Targeted Therapies
Individual participants The Future of Biomarker Discovery and 2011 2,610
Biobanks in Cancer Diagnosis, Prognosis,
and Therapy
Individual participants Scientific and Technological Barriers to Global 2011 15,665
Real-Time Risk Assessment of Vector-Borne
Infections
John Wiley & Sons Ltd FEBS Journal Editorial Board Meeting 2011 1,695
The Lehrman Institute DNA and the History of Mankind 2011 170,245
Leukemia & Lymphoma Society SCOR Retreat 2011 7,235
Marie Robertson Research Fund Evolution of Neural Circuits and Behavior 2011 20,000
Melanoma Research Alliance Curing Melanoma and Other Cancers by 2011 50,000
Targeted Therapies 
Oliver Grace Fund Antibiotic Resistance: Past, Present, Future 2011 46,970
Oliver Grace Cancer Fund Metformin and Neoplasia 2011 51,121
Sanofi-Aventis TSU-Aging Translation of Cellular and Molecular 2011 44,817
Mechanisms of Aging to Geriatric Disorders
The Swartz Foundation Neuronal Response Variability and Cortical 2011 43,266
Computation
The Stanley Research Foundation Psychiatric Genomics 2011 63,607
SWOG The Future of Biomarker Discovery and 2011 30,943
Biobanks in Cancer Diagnosis, Prognosis
and Therapy
Time for Lyme, Inc. Lyme Disease in the Proteomics-Genomics Era 2011 41,304
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CORPORATE SPONSOR PROGRAM 
FOR MEETINGS SUPPORT
The Corporate Sponsor Program continues to provide critical funding for the vigorous meetings pro-
gram held at Cold Spring Harbor Laboratory, whether at Grace Auditorium on the main Laboratory
campus or at the Banbury Center. Without the strong foundation provided by the Program, we could
neither plan with confidence for the year’s meetings nor introduce new and unusual topics.
We are especially grateful to the companies that joined us in 2011 as the economic difficulties
began to take effect. The year 2012 is going to be especially challenging as the number of companies
shrinks through takeovers, and companies and foundations adopt austerity measures.
The members of the Program receive special privileges in acknowledgment of their contributions.
We waive all on-site fees for eight representatives of the Corporate Sponsors at our meetings. Three
scientists from Sponsors may attend meetings at the Banbury Center, where attendance is otherwise
only by invitation of the organizers. Member companies also receive gratis copies of Cold Spring
Harbor Laboratory Press publications, including the journals Genes & Development, Learning &
Memory, Genome Research, and RNA. 
We acknowledge our Sponsors in all relevant publications, including the books of abstracts given
to each of the 7000 participants who come to the meetings each year. The names of the sponsoring
companies are listed on the poster describing the meetings, and this is mailed to approximately 17,000
scientists throughout the world. In addition, the companies are listed on the Cold Spring Harbor
Laboratory website on the Meetings Office and Banbury Center pages. Members in 2011 were the
following:
FOUNDATION
Hudson-Alpha Institute for Biotechnology
PLANT CORPORATE SPONSORS
Monsanto Company
Pioneer Hi-Bred International, Inc.
CORPORATE SPONSORS
Agilent Technologies, Inc.
AstraZeneca UK Ltd.
BioVentures, Inc.
Bristol-Myers Squibb Company
Genentech, Inc.
GlaxoSmithKline
Life Technologies
New England BioLabs, Inc.
OSI Astellas Pharma US, Inc.
Sanofi-Aventis
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DEVELOPMENT
Cold Spring Harbor Laboratory had a noteworthy year in 2011, with many scientific breakthroughs. In June, we pub-
lished the most comprehensive genetic road map for autism to date. The goal of this work is to design more immediate
and accurate diagnostic tools for autism, which will allow for earlier intervention. In August, using advanced genetic
tools developed at CSHL, we discovered a new target for a very lethal form of leukemia. Collaborating with the Dana
Farber Cancer Institute, we were successful in identifying a drug for this target that will enter clinical trials next year.
Using a similar strategy, CSHL researchers are pinpointing new targets for melanoma, pancreas, breast, and prostate can-
cers. Through these advancements, the Laboratory is moving beyond basic research and is focusing its efforts on developing
therapeutics for cancer and neurological diseases. Dr. David Tuveson—a world-renowned scientist who focuses on pan-
creatic cancer and melanoma—will join the Laboratory in 2012. In collaboration with the Lustgarten Foundation and
Memorial Sloan-Kettering Cancer Center, Dr. Tuveson will be leading CSHL’s program in cancer therapeutics. 
We were deeply saddened by the loss of Honorary Trustee, Double Helix Medal recipient, and Founder of the
Breast Cancer Research Foundation (BCRF), Evelyn Lauder. Through her work at BCRF, Evelyn raised millions of
dollars for breast cancer research and distributed these funds to breast cancer researchers around the world, including
CSHL scientist Mike Wigler. Thanks to BCRF and Evelyn, women and men diagnosed with breast cancer today are
recovering and surviving at much higher rates. The Laboratory also lost Peter Stehli, a longtime friend, supporter,
and former member of the Development Department. Peter’s welcoming and enthusiastic spirit made him an instant
friend to everyone he met, and he will be greatly missed. 
This year, our Double Helix Medals Dinner was a huge success as we honored three remarkable people: Kareem
Abdul-Jabbar, Temple Grandin, and Harold Varmus. In their own unique way, each of the recipients has had a tremen-
dous impact on genetic disease awareness and research. With more than $3 million raised, this event has become an
important source of unrestricted funding for the Laboratory.
I would like to take this opportunity to thank all of our dedicated volunteers and loyal supporters. With your help,
the Laboratory continues to be rated one of the top research institutions in the world, and our researchers are making
significant strides against the devastating diseases that afflict humankind.
Charles V. Prizzi, Vice President for Development
Cold Spring Harbor Laboratory is a nonprofit research and educational institution chartered by the State of New
York. Less than half of the Laboratory’s annual revenues are derived from federal grants and contracts, and thus, it
relies heavily upon support from the private sector: foundations, corporations, and individuals. CSHL takes this
occasion to sincerely thank each and every donor whose generous contributions have made possible the discoveries
we report in this publication. There are a variety of ways to give to the Laboratory:  
Capital and Endowment Campaign Support: Dona-
tions help to secure the financial stability of CSHL and
provide resources to expand the facilities and staff. 
Research Support:Donations in specific areas of research
help to increase the speed at which genetic discoveries are
translated into diagnostic tests and therapeutics.
Annual Fund: Donations provide funding for some of
the most innovative young researchers in science today
and constitute an important investment in ground-
breaking research in cancer, neuroscience, plant biology,
and bioinformatics. 
Science Education:Donations support programs at the
DNA Learning Center and the Watson School of Bio-
logical Sciences, where the next generation learns
about genetics in an exciting and interactive environ-
ment. 
Planned and Estate Gifts: Individuals who inform us
of their intention to make a gift to CSHL from their
estate are invited to become members of The Harbor
Society. Estate gifts help to ensure that CSHL will
continue to pursue its mission for many years to
come.
For additional information, please contact Charlie Prizzi, Vice President for Development, Cold Spring Harbor Laboratory, One Bungtown
Road, Cold Spring Harbor, New York 11724. Phone number: 516-367-6961. E-mail: prizzi@cshl.edu
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President’s Council
An outstanding lecture program this year included talks on addiction’s numerous manifestations, the physical,
emotional, and fiscal toll addiction imposes on individuals and society as a whole, extraordinary advancements in
brain-imaging technologies, and the molecular mechanisms that drive addictive behavior. Lara and Remy Trafelet
hosted our April reception at their beautiful Park Avenue apartment, where CSHL Assistant Professor Anne Church-
land spoke about the role of decision making in addiction.
Former Congressman Patrick Kennedy kicked off the October retreat at the Banbury Conference Center with
a powerful talk about his own struggles with addiction and his advocacy for increased national investment in basic
and translational neuroscience. Guests were moved by an evocative photo exhibit, Expressions of Addiction, by
speaker Howard Shaffer, a Harvard psychiatrist. Co-chairs of this year’s meeting were CSHL Trustee Howard Mor-
gan and Council members Cynthia Stebbins and Steve Wiggins.
President
Dr. Bruce Stillman
Chairpersons
Howard Morgan
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Dr. and Mrs. Lalit Bahl
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Liz Watson, Patrick Kennedy, Jim Watson, Catherine Moraetis, and Greg
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Bruce Stillman, Anne Churchland, and Lara and Remy Trafelet
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Cold Spring Harbor Laboratory Association
With 1200 members, the Cold Spring Harbor Laboratory Association (CSHLA) continues to increase awareness of
CSHL, and this year helped raise nearly $6 million in unrestricted support for the Laboratory. Events and benefits
spearheaded by Directors of the Association included our first Labapalooza fund-raiser featuring local restaurants
and artists and music by Lab researchers; the Double Helix Medals Dinner in New York City; a golf tournament at
Piping Rock Club; Symposium dinner parties; the Women’s Partnership in Science luncheon, and a variety of re-
ceptions and dinners that introduced new friends to the exceptionally talented young scientists at CSHL.
Mary Lindsay, former CSHLA President and Honorary Director, continues to set an example for all with her
participation at many Laboratory events, commitment to CSHL research and education programs, as well as her
interest in the day care center that bears her name. Mary is truly the epitome of what it means to give back to the
institutions you believe in.
Special thanks go to Sandy Tytel, Association President, as she enthusiastically led the Association Directors to
new levels of participation in all aspects.
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Tracey DeMatteis Serko 
Debbie Parmet Sondock
Heather Lane Spehr
James A. Woods
Joseph V. Amella
Hans E.R. Bosch
Michele Munn Celestino
Maria de Lesseps
Nelson DeMille
Charles B. Goodwin, M.D.
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President
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President
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2011 CSHLA Directors
Honorary Directors
Mary D. Lindsay
Anne R. Meier
Cathy Cyphers Soref
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DNA Learning Center Corporate Advisory Board
The Corporate Advisory Board (CAB) continues to be a vital liaison between Cold Spring Harbor
Laboratory (CSHL) and the tristate business community. Established more than 20 years ago, the CAB
continues to be the driving force behind the extremely popular CSHL annual golf outing held in June
at Piping Rock. Special thanks go to Eddie Chernoff, who not only has been the Chairman of the CAB
for more than 10 years, but continues to chair the golf outing as well. On a beautiful June day, over
140 golfers participated in the 18th annual golf tournament, which raised more than $125,000.  
Laurie Landeau, CSHL Trustee and liaison to the Corporate Advisory Board, continues to champion
the efforts of the DNA Learning Center through her quiet but remarkable support and guidance.
Corporate Advisory Board
Chairman: Edward A. Chernoff, Motors & Armatures Inc.
CSHL Trustee Liaison: Laurie Landeau, V.M.D.
Jack O’Donnell, Judy and Barney Fortunato, and Barney Fortunato, Jr. at
CSHL’s 2011 Golf Tournament
CAB member Pat Peterson with colleagues from Daniel Gale
Sotheby’s International Realty at CSHL’s 2011 Golf Tournament
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On November 15, the sixth Double Helix Medals Dinner was held at the Mandarin
Oriental in Manhattan. CSHL Chancellor Emeritus Jim Watson (far left) and President
Bruce Stillman (far right) appear with 2011 Double Helix Medals Dinner honorees
Harold Varmus (middle left), Kareem Abdul-Jabbar (back), and Temple Grandin.
CSHL Vice Chairman Marilyn Simons with her
husband Jim Simons at the 2011 Double Helix
Medals Dinner
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CSHL President Bruce Stillman with Karen
Orzel (left) and Caroline Monti Saladino, Presi-
dent of the Don Monti Memorial Research
Foundation. Photo by Miranda Gatewood;
courtesy of Networking magazine.
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Mr. and Mrs. Robert W. Chasanoff
Jane H. Choate
Mr. and Mrs. David C. Clark
Cosel-Pieper Family Foundation
Rebecca Creavin
Curtis Cushman
Curtis, Mallet-Prevost, Colt & Mosle LLP
Lucy P. Cutting
David and Jamie Deming
Mr. and Mrs. Donald L. Deming
Mr. and Mrs. Jack DiMaio
Dr. and Mrs. Thomas J. Dowling, Jr.
Dr. Lester Dubnick
Patrick Dumas
Lev Dynkin
Brenda Earl
Electronix Systems Central Station Alarms
Enzo Life Sciences
Johnston and Lisa Evans
Donald Eversoll
EVLV Realty, LLC
Dr. and Mrs. Robert J. Feeney
William B. Finneran
G. Fred Fisher
Dr. David Botstein and Dr. Renée Fitts
Brian Fox
Chris and Doug Fox
Mr. and Mrs. Roger Fradin
Kate and John Friedman
E. Maxwell Geddes, Jr.
Cosby W. George
Robert J. Glaser, M.D.
Jessica and Lawrence Glassman
Paula and Pierre A. Gonthier
Mindy and Rich Gordon
Dr. Maurice Green
The Niki and Joe Gregory Charitable
Foundation
Lois Perelson-Gross and Stewart Gross
Mr. and Mrs. William H. Grover
Horace and Amy Hagedorn Fund
Rev. Linda Peyton Hancock
Mr. and Mrs. Gordon S. Hargraves
Albert and Rebecca Haug
Walter H. Haydock
Gil and Sheila Henoch
William A. Herzog
James Hicks, Ph.D.
Lori and Chris Homer–A.L.L. Caring
Foundation
Theodora Hooton
Mr. and Mrs. James B. Hoover
Frederic B. Ingraham
Mr. and Mrs. Fredd Hoff Isaksen
Walter B. James Fund No. 2
Isabel and Jerry Jasinowski
Johnston Family Foundation
Barclay G. Jones
Dr. and Mrs. Joel J. Kassimir
Eli and Cliff Katus
Paul and Lynn Knight
Mr. and Mrs. John L. Kubacki
The Lampert Foundation
Mr. and Mrs. James Large
Isabel B. Leib
Leo Model Foundation
Mr. and Mrs. Robert G. MacLean
Mr. and Mrs. Christopher B. Mailman
Neil T. McGoldrick
Mr. and Mrs. Clarence F. Michalis
Mr. and Mrs. David A. Micklos
Dr. Jeffrey H. Miller
Montebello 2002 Realty Fund
Kathleen Mooney
Mr. and Mrs. Paul Napoli
Richard P. and Faye Nespola Charitable
Foundation
Larry Norton, M.D.
Ruth Nussdorf
Oheka Castle Hotel & Estate
Richard H. Brown and M.J. Otsea
Tracy Dellomo and Clifford Packingham
Rhoda Parmet
Mr. and Mrs. Nicholas B. Paumgarten
Cecile Pickart Student Travel Award
Louise S. Pickart
Mr. and Mrs. Robert A. Pilkington
Mr. and Mrs. Arthur M. Rogers, Jr.
Michele Rosenberg
Mr. and Mrs. Robert Rosenthal
Kirby Veevers and Eric C. Rubenstein
Pamela and Richard Rubinstein 
Foundation
Mr. and Mrs. J. Wright Rumbough, Jr.
Mr. and Mrs. Frank Russo
Mr. and Mrs. Henry E. Salzhauer
Jacquelyn D. Samnick
Mr. and Mrs. Thomas A. Saunders III
Mr. and Mrs. Peter Schiff
Robin and Enrique Senior
Mr. and Mrs. Ian Kendall Wheeler Snow
Mr. and Mrs. James L. Spingarn
Philip Starr
Byam K. Stevens, Jr.
Irwin and Judith Tantleff
Mrs. David S. Taylor
James Childress and Ann Thompson
Pamela M. Thye
Mr. and Mrs. Bart T. Tiernan
Barbara and Donald Tober
Cathleen and Al Trautwig
Betsy Soref Trimble
Mr. and Mrs. Stanley S. Trotman, Jr.
Richard W. Tully–Keystone Electronics
Corporation
Christopher and Doreen Tuohy
Thomas Vandeventer
John Vermylen
Helene Victor
Mr. and Mrs. John A. Werwaiss
Neil Westreich
Wild for Zumba
Lisa & Jeffrey Wilks Family Foundation
Frank Wisner
Marilyn Monter and Wilfried Witthuhn
Mayer Wolf
Wolfensohn Family Foundation
Hans-Jorg Zobel
CSHL Trustee Jim Stone with Honorary Trustee
Mary Lindsay (center) and Henriette Darrell 
at the spring President’s Council reception
Carole Alexander, Fiona Whalley, and Elisa Paone of the Manhasset Women’s Coalition Against
Breast Cancer presented CSHL researcher Dr. Mikala Egeblad (third from left, front row) and mem-
bers of her laboratory with a check to support breast cancer research.
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